

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

FIELD OF THE INVENTION

The present invention is directed to novel 3-pyrimidinyl-4-yl-oxazolidin-2-one compounds, compositions containing these compounds, the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity and in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

BACKGROUND OF THE INVENTION

Isocitrate dehydrogenase (IDH) is a key family of enzymes found in cellular metabolism. They are $\text{NADP}^+ / \text{NAD}^+$ and metal dependent oxidoreductases of the enzyme class EC 1.1.1.42. The wild type proteins catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate generating carbon dioxide and $\text{NADPH} / \text{NADH}$ in the process. They are also known to convert oxalosuccinate into alpha-ketoglutarate. Mutations in IDH1 (cytosolic) and IDH2 (mitochondrial) have been identified in multiple cancer types including, but not limited to, glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia (AML), prostate cancer, thyroid cancer, colon cancer, chondrosarcoma, cholangiocarcinoma, peripheral T-cell lymphoma, and melanoma. (See L. Dang *et al.*, Trends Mol. Med., 2010, 16, 387; T. Shibata *et al.*, Am. J. Pathol., 2011, 178(3), 1395; Gaal *et al.*, J. Clin. Endocrinol. Metab. 2010; Hayden *et al.*, Cell Cycle, 2009; Balss *et al.*, Acta Neuropathol., 2008). The mutations have been found at or near key residues in the active site: G97D, R100, R132, H133Q, and A134D for IDH1, and R140 and R172 for IDH2. (See L. Dang *et al.*, Nature, 2009, 462, 739; L. Sellner *et al.*, Eur. J. Haematol., 2011, 85, 457).

These mutant forms of IDH are shown to have a neomorphic activity (also known as a gain of function activity), reducing alpha-ketoglutarate to 2-hydroxyglutarate (2-HG). (See P.S. Ward *et al.*, Cancer Cell, 2010, 17, 225) In general, production of 2-HG is enantiospecific, resulting in generation of the D-enantiomer (also known as R enantiomer or R-2-HG). Normal cells have low native levels of 2-HG, whereas cells harboring these mutations in IDH1 or IDH2 show significantly elevated levels of 2-HG. High levels of 2-HG have been detected in tumors harboring the mutations. For example, high levels of 2-HG have been detected in the plasma of patients with mutant IDH containing AML. (See S. Gross *et al.*, J. Exp. Med., 2010, 207(2), 339). High levels of 2-HG are highly associated with tumorigenesis.

Mutant IDH2 is also associated with the rare neurometabolic disorder D-2-hydroxyglutaric aciduria type II (D-2-HGA type II). Germline mutations were found at R140 in


IDH2 in 15 pateints having D-2-HGA type II. Patients having this disorder also have consistently increased levels of D-2-HG in their urine, plasma and cerebrospinal fluid. (See Kranendijk, M. *et al.*, Science, 2010, 330, 336). Finally, patients with Ollier Disease and Mafucci Syndrome (two rare disorders that predispose to cartilaginous tumors) have been

5 shown to be somatically mosaic for IDH1 and 2 mutations and exhibit high levels of D-2-HG. (See Amary et al., Nature Genetics , 2011 and Pansuriya et al., Nature Genetics, 2011).

Thus, there is a need for small molecule inhibitors of mutant IDH proteins having a neomorphic activity for the treatment of diseases and disorders associated with these proteins.

SUMMARY OF THE INVENTION

In one aspect, this invention provides for a compound of formula (I)



(I)

or a pharmamceutically acceptable salt thereof wherein R¹, R^{2a}, R^{2b} and R³-R⁷ are defined below.

15 In a second aspect, this invention provides for a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

In a third aspect, this invention provides for the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as an inhibitor of a mutant IDH protein having a

20 neomorphic activity such as reducing alpha-ketoglutarate to 2-hydroxyglutarate (2-HG neomorphic activity). Suitably, this invention provides for the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as an inhibitor of mutant IDH1 having a neomorphic activity, such as 2-HG neomorphic activity, and/or mutant IDH2 having a neomorphic activity, such as 2-HG neomorphic activity. This invention further provides for the

25 use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as an inhibitor of IDH1 having a mutation at residue 97, 100 or 132, for example G97D, R100Q, R132H, R132C, R132S, R132G, R132L, and R132V; and/or an inhibitor of IDH2 having a mutation at residue 140 or 172, for example R172K, R172M, R172S, R172G, and R172W.


In a fourth aspect, this invention provides for a method of treating a disease or disorder associated with a mutant IDH protein having a neomorphic activity comprising administration of an effective amount of a compound according to formula (I), or a pharmaceutically acceptable salt thereof, to a subject in need thereof. In one embodiment, the disease or disorder is a cell proliferation disorder, such as cancer. In another embodiment, the cancer is brain cancer, such as glioma, glioblastoma multiforme, paraganglioma, and supratentorial primordial neuroectodermal tumors (pNET); leukemia, such as acute myeloid leukemia (AML), myelodysplastic syndrome, and chronic myelogenous leukemia (CML); skin cancer, including melanoma; prostate cancer; thyroid cancer; colon cancer; lung cancer; sarcoma, including central chondrosarcoma, central and periosteal chondroma; and fibrosarcoma. In another embodiment the disease or disorder is D-2-hydroxyglutaric aciduria.

In a fifth aspect the invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with another therapeutic agent.

These and other aspects of the present invention are described further in the following detailed description of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a compound of formula (I)



(I)

20

wherein:

R¹ is hydrogen, methyl or ethyl;


R^{2a} is hydrogen, methyl or C₁₋₃ haloalkyl;

R^{2b} is OH, halo, C₁₋₆ alkoxy, C₁₋₃ haloalkyl, NH₂, NH(CH₃) or N(CH₃)₂;

R^3 and R^4 are each independently hydrogen, methyl or ethyl or R^3 and R^4 are joined together forming cyclopropyl, cyclobutyl or oxetanyl;

R^5 and R^6 are each independently hydrogen, deuterium, halo, $-C(O)OCH_3$, C_{1-3} alkyl or C_{1-3} haloalkyl;

5 R^7 is



wherein:

ring A is a 6 membered heteroaryl ring having one to three nitrogen atoms;

10 ring B is a 5 membered heteroaryl ring having one to four heteroatoms each independently selected from the group consisting of N, O and S;

X is N or CH;

each R^8 is independently hydrogen, halo, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy or C_{1-3} haloalkoxy;

15 n is 1 or 2;

R^9 is hydrogen, halo, C_{1-3} haloalkyl, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted 5 or 6 membered heterocyclic, optionally substituted heteroaryl, $-OR^{9a}$, $-SO_2R^{9a}$, $-C(O)NHR^{9a}$, CH_2R^{9b} or $CHCH_3R^{9b}$, provided that when X is N, R^9 is hydrogen, C_{1-3} haloalkyl, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl,

20

optionally substituted aryl, optionally substituted heteroaryl, $-\text{SO}_2\text{R}^{9a}$ or $-\text{C}(\text{O})\text{NHR}^{9a}$,
wherein:

said C_{1-6} alkyl is optionally substituted with one to three substituents each
independently selected from the group consisting of: OH, phenyl and phenoxy,
and

said C_{3-6} cycloalkyl, 5 or 6 membered heterocyclic, aryl and heteroaryl are
each optionally substituted with one to three substituents each independently
selected from the group consisting of: halo, hydroxyl, cyano, $-\text{NRR}$, C_{1-6} alkyl,
 C_{1-6} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

R^{9a} is optionally substituted C_{1-6} alkyl, C_{1-6} haloalkyl, optionally substituted C_{3-6}
cycloalkyl, optionally substituted phenyl, or optionally substituted heterocyclic,
wherein:

said C_{1-6} alkyl is optionally substituted with one C_{3-6} cycloalkyl,

said C_{3-6} cycloalkyl and heterocyclic are each optionally substituted with one
to three substituents each independently selected from the group consisting of:
hydroxyl, CH_2OH , $-\text{NRR}$, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, and C_{1-3} alkoxy,
and

said phenyl is optionally substituted with one to three substituents each
independently selected from the group consisting of: halo, hydroxyl, cyano,
 $-\text{NRR}$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

R^{9b} is optionally substituted C_{3-6} cycloalkyl, optionally substituted phenyl or optionally
substituted heterocyclic,

said C_{3-6} cycloalkyl and heterocyclic are each optionally substituted with one to
four substituents each independently selected from the group consisting of:
hydroxyl, CH_2OH , $-\text{NRR}$, $-\text{NRC}(\text{O})\text{CH}_3$, 4 to 6 membered heterocyclic, cyano,
halo, C_{1-3} alkyl, C_{1-3} haloalkyl, and C_{1-3} alkoxy, and

said phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy; and

each R is independently selected from the group consisting of H, C₁₋₃ alkyl and C₃₋₆ cycloalkyl.

“Alkyl” refers to a monovalent saturated hydrocarbon chain having the specified number of carbon atoms. For example, C₁₋₆ alkyl refers to an alkyl group having from 1 to 6 carbon atoms. Alkyl groups may be optionally substituted with one or more substituents as defined in formula (I). Alkyl groups may be straight or branched. Representative branched alkyl groups have one, two, or three branches. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, sec-butyl, and t-butyl), pentyl (n-pentyl, isopentyl, and neopentyl), and hexyl.

“Alkoxy” refers to any alkyl moiety attached through an oxygen bridge (i.e. a –O-C₁₋₃ alkyl group wherein C₁₋₃ alkyl is as defined herein). Examples of such groups include, but are not limited to, methoxy, ethoxy, and propoxy.

“Aryl” refers to a hydrocarbon ring system having an aromatic ring. Aryl groups are monocyclic ring systems or bicyclic ring systems. Monocyclic aryl ring refers to phenyl. Bicyclic aryl rings refer to naphthyl and to rings wherein phenyl is fused to a C₅₋₇ cycloalkyl or C₅₋₇ cycloalkenyl ring as defined herein. Aryl groups may be optionally substituted with one or more substituents as defined in formula (I).

“Cycloalkyl” refers to a saturated hydrocarbon ring system having the specified number of carbon atoms. Cycloalkyl groups are monocyclic or bicyclic ring systems. For example, C₃₋₆ cycloalkyl refers to a cycloalkyl group having from 3 to 6 carbon atoms. Cycloalkyl groups may be optionally substituted with one or more substituents as defined in formula (I). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

“Cycloalkenyl” refers to an unsaturated hydrocarbon ring system having the specified number of carbon atoms and having a carbon-carbon double bond within the ring. For example, C₅₋₇ cycloalkenyl refers to a cycloalkenyl group having from 5 to 7 carbon atoms. In certain embodiments, cycloalkenyl groups have one carbon-carbon double bond within the ring. In other embodiments, cycloalkenyl groups have more than one carbon-carbon double bond within the ring. Cycloalkenyl rings are not aromatic. Cycloalkenyl groups may be optionally substituted with one or more substituents as defined in formula (I).

“Halo” refers to the halogen radicals fluoro, chloro, bromo, and iodo.

“Haloalkyl” refers to an alkyl group wherein at least one hydrogen atom attached to a carbon atom within the alkyl group is replaced with halo. The number of halo substituents includes, but is not limited to, 1, 2, 3, 4, 5, or 6 substituents. Haloalkyl includes, but is not limited to, monofluoromethyl, difluoroethyl, and trifluoromethyl.

5 “Haloalkoxy” refers to a haloalkyl moiety attached through an oxygen bridge (i.e. a –O–C₁₋₃ haloalkyl group wherein C₁₋₃ haloalkyl is as defined herein). An example of a haloalkoxy group is trifluoromethoxy.

“Heteroaryl” refers to an aromatic ring system containing from 1 to 5 heteroatoms. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms.

10 Heteroaryl groups may be optionally substituted with one or more substituents as defined in formula (I). Heteroaryl groups are monocyclic ring systems or are fused bicyclic ring systems. Monocyclic heteroaryl rings have from 5 to 6 ring atoms. Bicyclic heteroaryl rings have from 8 to 10 member atoms. Bicyclic heteroaryl rings include those ring systems wherein a heteroaryl ring is fused to a phenyl ring. Heteroaryl includes, but is not limited to, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl (including 1,3,4-oxadiazolyl and 1,2,4-oxadiazolyl),

15 thiazolyl, isothiazolyl, thiadiazolyl, furanyl, furanzanyl, thienyl, triazolyl, pyridinyl (including 2-, 3-, and 4-pyridinyl), pyrimidinyl, pyridazinyl, pyrazinyl, trazinyl, tetrazinyl, tetrzolyl, indonyl, isoindolyl, indoliziny, indazolyl, purinyl, quinoliny, isoquinoliny, quinoxaliny, quinazoliny, benzimidazolyl, benzopyranyl, benzopyranyl, benzoxazolyl, benzoisoxazolyl, benzofuranyl,

20 benzothiazolyl, benzothieryl, naphthyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, imidazo[2,1-b][1,3,4]thiadiazolyl and the like.

“Heteroatom” refers to a nitrogen, oxygen, or sulfur atom.

“Heterocyclic” refers to a 3 to 11 membered saturated or unsaturated monocyclic or bicyclic ring containing from 1 to 4 heteroatoms. Heterocyclic ring systems are not aromatic.

25 Heterocyclic groups containing more than one heteroatom may contain different heteroatoms. Heterocyclic includes ring systems wherein a sulfur atom is oxidized to form SO or SO₂. Heterocyclic groups may be optionally substituted with one or more substituents as defined in formula (I). Heterocyclic groups are monocyclic, spiro, or fused or bridged bicyclic ring systems. Monocyclic heterocyclic rings have 3 to 7 ring atoms. Examples of monocyclic

30 heterocyclic groups include oxtanyl, tetrahydrofuranyl, dihydrofuranyl, 1,4-dioxanyl, morpholiny, 1,4-dithianyl, piperazinyl, piperidinyl, 1,3-dioxolanyl, imidazolidinyl, imidazoliny, pyrroliny, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, oxathiolanyl, dithiolanyl, 1,3-dioxanyl, 1,3-dithianyl, oxathianyl, thiomorpholiny, tetrahydro-thiopyran1,1-dioxide, 1,4-diazepanyl, and the like. Fused heterocyclic ring systems have from 8 to 11 ring atoms and include groups

35 wherein a heterocyclic ring is fused to a phenyl ring, a heteroaryl ring or another heterocyclic ring. Examples of fused heterocyclic rings include 2,3-dihydrobenzo[b][1,4]dioxiny, benzo[1,3]dioxyl, octahydro-pyrrolo[1,2-a]pyrazinyl, octahydro-pyrido[1,2-a]pyrazinyl,

octahydro-pyrrolo[3,4-c]pyrrolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazinyl and the like. Examples of bridged heterocyclic groups include 3,8-diaza-bicyclo[3.2.1]octanyl, 3,8-diaza-bicyclo[4.2.0]octanyl and the like. Examples of spiro heterocyclic groups include 4,7-diaza-spiro[2.5]octanyl and the like.

5 “5-6 membered heterocyclic” refers to a heterocyclic group as defined above, having 5 or 6 ring atoms and containing from 1 to 4 heteroatoms.

“Optionally substituted” indicates that a group, such as an alkyl, cycloalkyl, heteroaryl, heterocyclic, phenyl, and benzyl may be unsubstituted or the group may be substituted with one or more substituents as defined in formula (I).

10 “Pharmaceutically acceptable” means a compound which is suitable for pharmaceutical use. Salts and solvates (e.g. hydrates and hydrates of salts) of compounds of the invention which are suitable for use in medicine are those where in the counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the
15 present invention, for example, for use as intermediates in the preparation of other compounds of the invention and their pharmaceutically acceptable salts and solvates.

“Substituted” in reference to a group such as alkyl, phenyl, benzyl, heteroaryl, and heterocyclic, indicates that one or more hydrogen atoms attached to an atom within the group is replaced with a substituent selected from the group of defined substituents. It should be
20 understood that the term “substituted” includes the implicit provision that such substitution be in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound (i.e. one that does not spontaneously undergo transformation, for example, by hydrolysis, rearrangement, cyclization, or elimination and that is sufficiently robust to survive isolation from a reaction mixture). When it is stated that a group
25 may contain one or more substituents, one or more (as appropriate) atoms within the group may be substituted. In addition, a single atom within the group may be substituted with more than one substituent as long as such substitution is accordance with the permitted valence of the atom. Suitable substituents are defined for each substituted or optionally substituted group.

30 The skilled artisan will appreciate that salts, including pharmaceutically acceptable salts, of the compounds according to formula (I) may be prepared. These salts may be prepared *in situ* during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively.

35 Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride,

chlorthiophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen
5 phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.

Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.

Organic acids from which salts can be derived include, for example, acetic acid,
10 propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

Inorganic bases from which salts can be derived include, for example, ammonium salts
15 and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.

Organic bases from which salts can be derived include, for example, primary,
20 secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.

The pharmaceutically acceptable salts of the present invention can be synthesized from
25 a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or
30 in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington's Pharmaceutical Sciences", 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

35 Solvates, including pharmaceutically acceptable solvates, of the compounds of formula (I) may also be prepared. "Solvate" refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the invention may not interfere with the

biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.

5 The compounds of formula (I), including salts and solvates thereof, may exist in crystalline forms, non-crystalline forms, or mixtures thereof. The compound or salt or solvate thereof may also exhibit polymorphism, i.e. the capacity of occurring in different crystalline forms. These different crystalline forms are typically known as "polymorphs". Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other
10 descriptive properties of crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, all of which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or
15 adjusting the conditions used in crystallizing/recrystallizing a compound of formula (I).

 The invention also includes various isomers of the compounds of formula (I). "Isomer" refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With
20 regard to stereoisomers, the compounds of formula (I) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof, unless specifically indicated otherwise. If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a
25 disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.

 Any asymmetric atom (e.g., carbon or the like) of a compound of formula (I) can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric
30 excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in *cis*- (*Z*)- or *trans*- (*E*)- form.

 Accordingly, as used herein a compound of formula (I) can be in the form of one of the
35 possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (*cis* or *trans*) isomers, diastereomers, optical isomers, racemates or mixtures thereof.

Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.

5 Any resulting racemates of final products or intermediates can be resolved into the optical isomers by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical isomers, e.g., by fractional crystallization of a salt formed
10 with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-*O,O'*-*p*-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.

The invention includes unlabeled forms as well as isotopically labeled forms of
15 compounds of formula (I). Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}F , ^{31}P , ^{32}P , ^{35}S , ^{36}Cl ,
20 ^{125}I respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as ^3H and ^{14}C , or those into which non-radioactive isotopes, such as ^2H and ^{13}C are present. Such isotopically labelled compounds are useful in metabolic studies (with ^{14}C), reaction kinetic studies (with, for example ^2H or ^3H), detection or imaging techniques, such as positron emission tomography
25 (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ^{18}F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying
30 Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

Furthermore, substitution with heavier isotopes, particularly deuterium (i.e., ^2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in
35 therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment

factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

10

Representative Embodiments

Various embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide for further embodiments.

15 In one embodiment of the present invention R^1 is hydrogen.

In another embodiment of the present invention R^{2a} is hydrogen or methyl. Suitably R^{2a} is methyl.

In another embodiment of the present invention R^{2b} is OH, fluoro, methoxy, t-butoxy, CHF_2 , CF_3 , NH_2 or $NH(CH_3)$. Suitably R^{2b} is OH, fluoro or NH_2 .

20 In another embodiment of the present invention R^3 and R^4 are each hydrogen.

In another embodiment of the present invention R^5 is hydrogen or halo. Suitably R^5 is hydrogen, fluoro or chloro. More suitably R^5 is hydrogen or fluoro.

In another embodiment of the present invention R^6 is hydrogen, halo, methyl, CH_2F , CHF_2 , or CF_3 . Suitably R^6 is hydrogen, fluoro, chloro, methyl, CH_2F , CHF_2 , or CF_3 . More


25 suitably R^6 is hydrogen or methyl.

In another embodiment of the present invention R^5 is hydrogen and R^6 is hydrogen, halo, methyl, CH_2F , CHF_2 , or CF_3 . Suitably R^5 is hydrogen and R^6 is hydrogen, fluoro, chloro, methyl, CH_2F , CHF_2 , or CF_3 . More suitably R^5 is hydrogen and R^6 is hydrogen or methyl.


30 In another embodiment of the present invention R^6 is hydrogen and R^5 is hydrogen or halo. Suitably R^6 is hydrogen and R^5 is hydrogen, fluoro or chloro. More suitably R^6 is hydrogen and R^5 is hydrogen or fluoro.

In another embodiment R^5 and R^6 are both hydrogen.

In another embodiment R^7 is



In another embodiment R^7 is



In another embodiment R^8 is hydrogen, fluoro, chloro or methyl and n is 1. In another embodiment each R^8 is independently fluoro or chloro and n is 2.

10 In another embodiment R^9 is hydrogen, halo, C_{1-3} haloalkyl, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl. Suitably R^9 is hydrogen, halo, CF_2H , CF_3 , CF_2CH_3 , $C(CH_3)_2F$, C_{1-6} alkyl optionally substituted with one substituent selected from the

group consisting of: OH, phenyl and phenoxy, or C₃₋₆ cycloalkyl optionally substituted with one substituent selected from the group consisting of: cyano, C₁₋₃ alkyl, and C₁₋₃ alkoxy. Suitably R⁹ is hydrogen, halo, CF₂H, CF₃, CF₂CH₃, C(CH₃)₂F, C₁₋₃ alkyl optionally substituted with one substituent selected from the group consisting of: OH, phenyl and phenoxy group, or cyclopropyl optionally substituted with one substituent selected from the group consisting of: cyano, C₁₋₃ alkyl, and C₁₋₃ alkoxy.

In another embodiment R⁹ is phenyl or 2,3-dihydro-1H-indenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, bromo, cyano, methoxy, CH₂OH, C₁₋₄ alkyl, C₁₋₄ haloalkyl and C₁₋₃ haloalkoxy.

10 In another embodiment R⁹ is phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, bromo, cyano, methoxy, CH₂OH, C₁₋₄ alkyl, C₁₋₄ haloalkyl and C₁₋₃ haloalkoxy. Suitably R⁹ is phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, bromo, cyano, methoxy, CH₂OH, C₁₋₄ alkyl, CF₂H, CF₃,
15 C(CH₃)₂CF₃, OCF₃, -OCH₂CF₃, and -OCHF₂. Suitably R⁹ is phenyl substituted in the para position with chloro, fluoro, methyl, cyano, CF₃ or isopropyl. Suitably R⁹ is phenyl substituted in the para position with chloro, CF₃ or isopropyl.

In another embodiment R⁹ is optionally substituted heteroaryl. Suitably R⁹ is optionally substituted pyrazolyl, pyridinyl, indolyl or isoquinolinyl. Suitably R⁹ is pyrazolyl or pyridinyl
20 optionally substituted with one or two substituents each independently selected from the group consisting of halo, C₁₋₆ alkyl and C₁₋₆ haloalkyl, for example, fluoro, methyl and CF₃ or C(CH₃)₂CF₃.

In another embodiment R⁹ is -OR^{9a} wherein R^{9a} is optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, optionally substituted phenyl, or optionally substituted 5 or 6 membered
25 heterocyclic. Suitably R^{9a} is tetrahydrofuranyl, CF₃, CHF₂, CHCF₃, C₁₋₆ alkyl optionally substituted with one cyclopropyl, or phenyl optionally substituted with one halo.

In another embodiment R⁹ is -SO₂R^{9a} wherein R^{9a} is C₁₋₆ alkyl.


In another embodiment R⁹ is -C(O)NHR^{9a} wherein R^{9a} is optionally substituted C₃₋₆ cycloalkyl. Suitably R⁹ is -C(O)NHR^{9a} wherein R^{9a} is cyclopentyl.

30 In another embodiment R⁹ is CH₂R^{9b} wherein R^{9b} is optionally substituted heterocyclic. Suitably R^{9b} is optionally substituted 5 to 6 membered heterocyclic. Suitably


R^{9b} is piperidinyl, piperazinyl or morpholinyl each of which is optionally substituted with one to four substituents each independently selected from the group consisting of: hydroxyl, halo, CH₂OH, -NRR, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and C₁₋₃ alkoxy. Suitably R^{9b} is piperidinyl, piperazinyl or morpholinyl each of which is optionally substituted with one to three substituents each independently selected from the group consisting of: hydroxyl, CH₂OH, fluoro, NH₂, N(CH₃)₂, NHCH₃, methyl, and CF₃.

In another embodiment of the present invention each R is independently selected from the group consisting of: H, C₁₋₃ alkyl.


Another embodiment of the present invention is a compound according to formula (II).



Another embodiment of the present invention is a compound according to formula (III).



Another embodiment of the present invention is a compound according to formula (IV).



(IV) wherein R^{2b} is OH or NH₂. Suitably R^{2b} is

OH. Suitably R^{2b} is NH₂.

Another embodiment of the present invention is a compound according to formula (IV),









5 wherein:

R^{2b} is OH;


R⁵ is hydrogen or fluoro;

R⁶ is hydrogen, chloro, methyl or CH₂F;

R⁷ is



10




R^8 is hydrogen, methyl or fluoro;

n is 1 or 2; and

- 5 R^9 is methylcyclopropyl, isobutoxy, phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, bromo, C_{1-4} alkyl, CF_2H , and CF_3 , or pyridinyl optionally substituted with one or two substituents each independently selected from the group consisting of: methyl, CF_3 and $C(CH_3)_2CF_3$; Suitably R^5 is hydrogen and R^6 is chloro, methyl or CH_2F or R^6 is hydrogen and R^5 is fluoro.
- 10 Suitably R^5 is hydrogen and R^6 are both hydrogen.

Another embodiment of the present invention is a compound according to formula (V).




(V).

Another embodiment of the present invention is a compound according to formula (V)

- 15 wherein:

R^5 is hydrogen or fluoro;

R^6 is hydrogen;



R⁷ is , or ;


R⁸ is hydrogen or methyl;

n is 1; and

R⁹ is phenyl optionally substituted with one chloro.

5

Another embodiment of the present invention is a compound according to formula (VI)




wherein:

R^{2b} is fluoro;

R⁵ is hydrogen or fluoro;

R⁶ is hydrogen;



R⁷ is , or ;

R⁸ is hydrogen or methyl;

n is 1; and

R⁹ is phenyl optionally substituted with one chloro; or a pharmaceutically acceptable salt thereof.

Preferred compounds of the invention include:

- (R)-4-((R)-1-hydroxy(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-onethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(6-(trifluoromethyl)-[2,3'-bipyridin]-6'-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chloro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(3-chloro-5-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-{2-[(R)-1-(3-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-{(S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one;
- (R)-3-(2-{(S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one;

- (R)-3-(5-fluoro-2-(((S)-1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- 5 (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-
- 10 hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- 15 (4R)-3-(5-fluoro-2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-
- 20 hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- 25 (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-(fluoromethyl)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-
- 30 hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- 35 (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

- (R)-3-(2-(((S)-1-(2-(4-(difluoromethyl)phenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl) oxazolidin-2-one;
- 5 (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- 10 (R)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- 15 (R)-3-(2-(((S)-1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
- (R)-3-(6-chloro-2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl) oxazolidin-2-one;
- 20 (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino) pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one;
- 25 (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl) oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2-(4-chlorophenyl) thiazol-5-yl)ethyl)amino) pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(5-(4-chlorophenyl) isoxazol-3-yl)ethyl)amino) pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;
- 30 (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl) amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl) oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl) oxazolidin-2-one;
- 35 (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one;

(S)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one;

5 (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(5-fluoro-2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;

10 (R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one; and

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one.

Certain compounds of the present invention were found to have improved preclinical properties. For example, certain compounds of the present invention were found to have
15 maintained potency against mLDH1 (for example IDH R132H and/or R132C) in biochemical and/or cellular activity assays, while at the same time improving in-vitro absorption, distribution, metabolism and excretion (ADME) properties. For example, certain compounds of the present invention were found to have reduced clearance rates in rat and/or mouse and/or human *in vitro* liver microsomal stability assays. Stability in the presence of liver microsomes is
20 important because it can be predictive of *in-vivo* clearance, and therefore also be predictive of whether or not a compound will have an adequate systemic exposure profile in the human body to effect the desired pharmacological response. Lower clearance rates, *i.e.* the more stable the compound is in the presence of liver microsomes *in vitro*, suggests the compound is more likely to have adequate systemic exposure in humans.

25 General Synthetic Procedures

The compounds of the present invention may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the Schemes given below.


The compounds of formula (I) may be prepared by methods known in the art of organic
30 synthesis as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York
35 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well

as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of formula (I).

Those skilled in the art will recognize if a stereocenter exists in the compounds of formula (I). Accordingly, the present invention includes both possible stereoisomers and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).

The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.


Scheme 1.




wherein R² is CH₂R^{2a}R^{2b}

Non-commercial aminoacids can be prepared following the procedures of Scheme 1. Conversion of ketone **1** to the corresponding imidazolidine-2,4-dione **2** followed by hydrolysis provides aminoacid **3**.

5 Scheme 2.




When aminoalcohol, precursor of oxazolidinone, is not commercially available, it can be prepared from aminoacid **3** following the procedures of Scheme 2. When $\text{R}^3 = \text{R}^4$, protected aminoester **5** is treated with an appropriate Grignard reagent to give protected aminoalcohol **6** which goes through basic or acidic deprotection step. When $\text{R}^3 \neq \text{R}^4$, protected aminoacid **8** is converted into Weinreb amide **9** which is treated with different Grignard reagents sequentially to provide protected aminoalcohol **10**. Either basic or acidic deprotection of **10** gives **11**. Insertion of CO unit into **7** or **11** to provide oxazolidinone **12** is accomplished with several reagents, including (but not limited to) triphosgene, Et_2CO_3 or N,N'-carbonyldiimidazole, as shown in Scheme 2.

5 **Scheme 3.**

wherein R² is CH₂R^{2a}R^{2b}


Oxazolidinone **12** is coupled with dihalogen-pyrimidine **13** in the presence of NaH and
 10 the resulting **14** is treated with primary amine **15** under several different reaction conditions as
 shown in Scheme 3 to provide **16**.

Scheme 4.

15

wherein R² is CH₂R^{2a}R^{2b}

Alternately intermediate **14** can be prepared by coupling the amino alcohol **11** and
 dihalogen-pyrimidine **13** in the presence of a base such as diisopropylethyl amine resulting in
 20 intermediate **17** which can be treated with triphosgene in the presence of a base such as 2,6-
 lutidine resulting in intermediate **14**.

5 **Scheme 5.**

wherein R^2 is $\text{CH}_2\text{R}^2\text{aR}^2\text{b}$

Intermediate **14** can undergo modification of functional groups on R^1 , R^2 , R^3 or R^4 prior to transformation to compound **16** as described in Scheme 3.

Methods of Use

The compounds of the present invention are inhibitors of a mutant IDH protein having a neomorphic activity and are therefore useful in the treatment of diseases or disorders associated with such proteins including, but not limited to, cell proliferation disorders, such as cancer.

Examples of a mutant IDH protein having a neomorphic activity are mutant IDH1 and mutant IDH2. A neomorphic activity associated with mutant IDH1 and mutant IDH2 is the ability to produce 2-hydroxyglutarate (2-HG neomorphic activity), specifically R-2-HG (R-2-HG neomorphic activity). Mutations in IDH1 associated with 2-HG neomorphic activity, specifically R-2-HG neomorphic activity, include mutations at residues 97, 100, and 132, e.g. G97D, R100Q, R132H, R132C, R132S, R132G, R132L, and R132V. Mutations in IDH2 associated with 2-HG neoactivity, specifically R-2-HG neomorphic activity, include mutations at residues 140 and 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, and R172W.

Cell-proliferation disorders associated with a mutant IDH protein having a neomorphic activity include, but are not limited to, cancer. Examples of such cancers include Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; AIDS-
5 Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma, Childhood Cerebellar; Astrocytoma, Childhood Cerebral; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Cerebellar Astrocytoma, Childhood; Brain Tumor, Cerebral
10 Astrocytoma/Malignant Glioma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors, Childhood; Brain Tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenomas/Carcinoids, Childhood; Carcinoid Tumor,
15 Childhood; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Carcinoma of Unknown Primary; Central Nervous System Lymphoma, Primary; Cerebellar Astrocytoma, Childhood; Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Childhood Cancers; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths;
20 Colon Cancer; Colorectal Cancer, Childhood; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma, Childhood; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer, Childhood; Ewing's Family of Tumors; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach)
25 Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma, Childhood Brain Stem; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Hodgkin's
30 Lymphoma, Adult; Hodgkin's Lymphoma, Childhood; Hodgkin's Lymphoma During Pregnancy; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma, Childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Laryngeal Cancer, Childhood; Leukemia, Acute Lymphoblastic, Adult; Leukemia, Acute Lymphoblastic, Childhood; Leukemia, Acute Myeloid, Adult; Leukemia, Acute
35 Myeloid, Childhood; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer, Adult (Primary); Liver Cancer, Childhood (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoblastic

Leukemia, Adult Acute; Lymphoblastic Leukemia, Childhood Acute; Lymphocytic Leukemia, Chronic; Lymphoma, AIDS- Related; Lymphoma, Central Nervous System (Primary); Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin's, Adult; Lymphoma, Hodgkin's, Childhood; Lymphoma, Hodgkin's During Pregnancy; Lymphoma, Non-Hodgkin's, Adult; Lymphoma, Non-Hodgkin's, Childhood; Lymphoma, Non-Hodgkin's During Pregnancy; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma, Adult; Malignant Mesothelioma, Childhood; Malignant Thymoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Nasopharyngeal Cancer, Childhood; Neuroblastoma; Non-Hodgkin's Lymphoma, Adult; Non-Hodgkin's Lymphoma, Childhood; Non-Hodgkin's Lymphoma During Pregnancy; Non-Small Cell Lung Cancer; Oral Cancer, Childhood; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; Osteosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer, Childhood; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Childhood; Pancreatic Cancer, Islet Cell; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer; Pregnancy and Hodgkin's Lymphoma; Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer, Adult; Primary Liver Cancer, Childhood; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Cell Cancer, Childhood; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Salivary Gland Cancer, Childhood; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Rhabdomyosarcoma, Childhood; Sarcoma, Soft Tissue, Adult; Sarcoma, Soft Tissue, Childhood; Sezary Syndrome; Skin Cancer; Skin Cancer, Childhood; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma, Adult; Soft Tissue Sarcoma, Childhood; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Stomach (Gastric) Cancer, Childhood; Supratentorial Primitive Neuroectodermal Tumors, Childhood; T- Cell Lymphoma, Cutaneous; Testicular Cancer; Thymoma, Childhood; Thymoma, Malignant; Thyroid Cancer; Thyroid Cancer, Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Unknown Primary Site, Cancer of, Childhood; Unusual Cancers of

Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma, Childhood; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor.

In another embodiment the cancer associated with a mutant IDH protein having a
5 neomorphic activity is brain cancer, such as astrocytic tumor (e.g., pilocytic astrocytoma, subependymal giant-cell astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma); oligodendroglial tumor (e.g., oligodendroglioma, and anaplastic oligodendroglioma); oligoastrocytic tumor (e.g.,
10 oligoastrocytoma, and anaplastic oligoastrocytoma); ependymoma (e.g., myxopapillary ependymoma, and anaplastic ependymoma); medulloblastoma; primitive neuroectodermal tumor, schwannoma, meningioma, atypical meningioma, anaplastic meningioma; and pituitary adenoma. In another embodiment, the brain cancer is glioma, glioblastoma multiforme, paraganglioma, or supratentorial primordial neuroectodermal tumors (sPNET).

15 In another embodiment the cancer associated with a mutant IDH protein having a neomorphic activity is leukemia, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), myeloproliferative neoplasm (MPN), MDS/MPN including chronic myelomonocytic leukemia, post MDS AML, post MPN AML, post MDS/MPN AML, del(5q)-associated high risk MDS or AML, blast-phase chronic myelogenous
20 leukemia, angioimmunoblastic lymphoma and acute lymphoblastic leukemia.

In another embodiment the cancer associated with a mutant IDH protein having a neomorphic activity is skin cancer, including melanoma.

In another embodiment the cancer associated with a mutant IDH protein having a neomorphic activity is prostate cancer, thyroid cancer, colon cancer, or lung cancer.

25 In another embodiment the cancer associated with a mutant IDH protein having a neomorphic activity is sarcoma, including central chondrosarcoma, central and periosteal chondroma, and fibrosarcoma.

In another embodiment the cancer associated with a mutant IDH protein having a neomorphic activity is cholangiocarcinoma.

30 Another disease or disorder associated with a mutant IDH protein having R-2-HG neomorphic activity is D-2-hydroxyglutaric aciduria.

Another disease or disorder associated with a mutant IDH protein having R-2-HG neomorphic activity is Oller disease and Mafucci syndrome.

As used herein the term "neomorphic activity" refers to a gain of novel activity of a
35 protein that the wild-type protein does not have or does not exhibit to a significant degree. For example, a neomorphic activity associated with a mutant form of IDH1 and IDH2 is the ability to reduce alpha-ketoglutarate to 2-hydroxyglutarate (i.e. 2-HG, specifically R-2-HG). The wild

type form of IDH1 and IDH2 does not have the ability to reduce alpha-ketoglutarate to 2-hydroxyglutarate (i.e. 2-HG, specifically R-2-HG) or if it does have this ability, it does not produce significant (i.e. harmful or disease causing) amounts of 2-HG.

As used herein, the term "subject" refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.

As used herein, the term "therapeutically effective amount" in reference to a compound of the invention means an amount of the compound sufficient to treat the subject's disease or condition, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio) within the scope of sound medical judgment. A therapeutically effective amount of a compound will vary with the particular compound chosen (e.g. consider the potency, efficacy, and half-life of the compound); the route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the subject being treated; the medical history of the subject being treated; the duration of the treatment; the nature of the concurrent therapy; the desired therapeutic effect; and like factors and can be routinely determined by the skilled artisan.

As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treat", "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treat", "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease or disorder.

As used herein, a subject is "in need of" a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.

The compounds of the present invention may be administered by any suitable route including oral and parenteral administration. Parenteral administration is typically by injection or infusion and includes intravenous, intramuscular, and subcutaneous injection or infusion.

The compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the

invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution and half life which can be determined by the skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound of the invention depend on the disease or condition being treated, the severity of the disease or condition, the age and physical condition of the subject being treated, the medical history of the subject being treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual subject's response to the dosing regimen or over time as the individual subject needs change. Typical daily dosages may vary depending upon the particular route of administration chosen. Typical daily dosages for oral administration, to a human weighing approximately 70kg would range from about 5mg to about 500mg of a compound of formula (I).

One embodiment of the present invention provides for a method of treating a disease or disorder associated with a mutant form of IDH having a neomorphic activity comprising administration of a therapeutically effective amount of a compound of formula (I) to a subject in need of treatment thereof. In one embodiment, the disease or disorder associated with a mutant form of IDH having a neomorphic activity is a cell proliferation disorder. In another embodiment, the cell proliferation disorder is cancer. In another embodiment, the cancer is a cancer associated with mutant IDH1 having 2-HG neomorphic activity or mutant IDH2 having 2-HG neomorphic activity. In another embodiment the neomorphic activity is R-2-HG neomorphic activity. In another embodiment the cancer is associated with mutant IDH1 having 2-HG or R-2-HG neomorphic activity having a mutation at residues 97, 100, or 132, such as G97D, R100Q, R132H, R132C, R132S, R132G, R132L, and R132V. In another embodiment the cancer is associated with mutant IDH2 having 2-HG or R-2-HG neomorphic activity having a mutation at residues 140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, and R172W. In another embodiment the cancer is brain cancer, leukemia, skin cancer, prostate cancer, thyroid cancer, colon cancer, lung cancer or sarcoma. In another embodiment the cancer is glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, prostate, thyroid, colon, lung, central chondrosarcoma, central and periosteal chondroma tumors, fibrosarcoma, and cholangiocarcinoma.

Another embodiment of the present invention provides for a method of treating a disease or disorder associated with a mutant form of IDH having R-2-HG neomorphic activity comprising administration of a therapeutically effective amount of a compound according to formula (I) to a subject in need thereof wherein the disease or disorder is D-2-hydroxyglutaric aciduria, Ollier Disease, or Mafucci Syndrome.

Another embodiment of the present invention provides for the use of a compound of formula (I) in therapy. In a further embodiment the therapy is a disease or disorder associated with a mutant form of IDH having a neomorphic activity. In another embodiment the therapy is a cell proliferation disorder associated with a mutant form of IDH having a neomorphic activity.

5 In another embodiment the therapy is cancer. In another embodiment the therapy is a cancer associated with a mutant IDH protein having a neomorphic activity, such as mutant IDH1 having 2-HG neomorphic activity or mutant IDH2 having 2-HG neomorphic activity. In another embodiment the neomorphic activity is R-2-HG neomorphic activity. In another embodiment the cancer is associated with mutant IDH1 having 2-HG or R-2-HG neomorphic activity having
10 a mutation at residues 97, 100, or 132, such as G97D, R100Q, R132H, R132C, R132S, R132G, R132L, and R132V. In another embodiment the cancer is associated with mutant IDH2 having 2-HG or R-2-HG neomorphic activity having a mutation at residue at residues R140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, and R172W. In another embodiment the cancer is brain cancer, leukemia, skin cancer, prostate cancer, thyroid cancer,
15 colon cancer, lung cancer or sarcoma. In another embodiment the cancer is glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, prostate, thyroid, colon, lung, central chondrosarcoma, central and periosteal chondroma tumors, fibrosarcoma, and cholangiocarcinoma.

20 Another embodiment of the present invention provides for the use of a compound of formula (I) in therapy wherein the therapy is D-2-hydroxyglutaric aciduria, Ollier Disease, or Mafucci Syndrome.

Another embodiment of the present invention provides for the use of a compound according to formula (I) in the manufacture of a medicament for the treatment of disease or
25 disorder associated with a mutant form of IDH having a neomorphic activity. In one embodiment the disease or disorder associated with a mutant form of IDH having a neomorphic activity is a cell proliferation disorder. In another embodiment, the cell proliferation disorder is cancer. In another embodiment the cancer is a cancer associated with a mutant IDH protein having a neomorphic activity, such as mutant IDH1 having 2-HG neomorphic
30 activity or mutant IDH2 having 2-HG neomorphic activity. In another embodiment the neomorphic activity is R-2-HG neomorphic activity. In another embodiment the cancer is associated with mutant IDH1 having 2-HG or R-2-HG neomorphic activity having a mutation at residues 97, 100, or 132, such as G97D, R100Q, R132H, R132C, R132S, R132G, R132L, and R132V. In another embodiment the cancer is associated with mutant IDH2 having 2-HG or R-
35 2-HG neomorphic activity having a mutation at residue at residues 140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, and R172W. In another embodiment the cancer is brain cancer, leukemia, skin cancer, prostate cancer, thyroid cancer, colon cancer, lung cancer

or sarcoma. In another embodiment the cancer is glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, prostate, thyroid, colon, lung, central chondrosarcoma, central and periosteal chondroma tumors, fibrosarcoma, and cholangiocarcinoma.

Another embodiment of the present invention provides for the use of a compound according to formula (I) in the manufacture of a medicament for the treatment of disease or disorder associated with a mutant form of IDH having R-2-HG neomorphic activity wherein the disease or disorder is D-2-hydroxyglutaric aciduria, Ollier Disease, or Mafucci Syndrome.

Another embodiment of the present invention provides for a compound of formula (I) for use in therapy. In a further embodiment the therapy is a disease or disorder associated with a mutant form of IDH having a neomorphic activity. In another embodiment the therapy is a cell proliferation disorder associated with a mutant form of IDH having a neomorphic activity. In another embodiment the therapy is cancer. In another embodiment the therapy is a cancer associated with a mutant IDH protein having a neomorphic activity, such as mutant IDH1 having 2-HG neomorphic activity or mutant IDH2 having 2-HG neomorphic activity. In another embodiment the neomorphic activity is R-2-HG neomorphic activity. In another embodiment the cancer is associated with mutant IDH1 having 2-HG or R-2-HG neomorphic activity having a mutation at residues 97, 100, or 132, such as G97D, R100Q, R132H, R132C, R132S, R132G, R132L, and R132V. In another embodiment the cancer is associated with mutant IDH2 having 2-HG or R-2-HG neomorphic activity having a mutation at residue at residues R140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, and R172W. In another embodiment the cancer is brain cancer, leukemia, skin cancer, prostate cancer, thyroid cancer, colon cancer, lung cancer or sarcoma. In another embodiment the cancer is glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, prostate, thyroid, colon, lung, central chondrosarcoma, central and periosteal chondroma tumors, fibrosarcoma, and cholangiocarcinoma.

Another embodiment of the present invention provides for a compound of formula (I) for use in therapy wherein the therapy is D-2-hydroxyglutaric aciduria, Ollier Disease, or Mafucci Syndrome.

Compositions

In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier or excipient.

The pharmaceutical compositions of the invention may be prepared and packaged in bulk form wherein a therapeutically effective amount of a compound of the invention can be

extracted and then given to a subject, such as with powders or syrups. Alternatively, the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form wherein each physically discrete unit contains a therapeutically effective amount of a compound of the invention. When prepared in unit dosage form, the pharmaceutical
5 compositions of the invention typically contain from about 5mg to 500mg of a compound of formula (I).

As used herein the term "pharmaceutically acceptable carrier or excipient" means a pharmaceutically acceptable material, composition or vehicle that, for example, are involved in giving form or consistency to the pharmaceutical composition. Each excipient must be
10 compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a subject and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided. In addition, each excipient must, of course, be of sufficiently high purity to render it pharmaceutically acceptable.

The compound of the invention and the pharmaceutically acceptable carrier or excipient(s) will typically be formulated into a dosage form adapted for administration to the subject by the desired route of administration. For example, dosage forms include those adapted for (1) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; and (2) parenteral
20 administration such as sterile solutions, suspensions, and powders for reconstitution. Suitable pharmaceutically acceptable excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically acceptable excipients may be chosen for a particular function that they may serve in the composition. For example, certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the
25 production of uniform dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound or compounds of the invention, once administered to the subject, from one organ or portion of the body to another organ or another portion of the body.
30 Certain pharmaceutically acceptable excipients may be chosen for their ability to enhance patient compliance.

Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, lubricants, binders, disintegrants, fillers, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers,
35 sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.

Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically acceptable carriers and excipients in appropriate amounts for the use in the invention. In addition, there are a number of resources available to the skilled artisan, which describe pharmaceutically acceptable carriers and excipients and may be useful in selecting suitable pharmaceutically acceptable carriers and excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).

The pharmaceutical compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).

In one aspect, the invention is directed to a solid oral dosage form such as a tablet or capsule comprising a therapeutically effective amount of a compound of the invention and a diluent or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives, (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g. corn starch, potato starch, and pre-gelatinized starch) gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmellose, alginic acid, and sodium carboxymethyl cellulose. The oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The composition can also be prepared to prolong or sustain the release as, for example, by coating or embedding particulate material in polymers, wax, or the like.

The compounds of the invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyranicopolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanacrylates and cross-linked or amphipathic block copolymers of hydrogels.

In another aspect, the invention is directed to a liquid oral dosage form. Oral liquids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given

quantity contains a predetermined amount of a compound of the invention. Syrups can be prepared by dissolving the compound of the invention in a suitably flavored aqueous solution; while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound of the invention in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or other natural sweeteners or saccharin or other artificial sweeteners and the like can also be added.

In another aspect, the invention is directed to parenteral administration. Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

Combinations

The compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent(s). The compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agent(s).

In one embodiment, the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or disorder associated with a mutant form of IDH. Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.

In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.

In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I). In one embodiment, the kit comprises means for separately retaining said compositions, such as a

container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.

The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.

In the combination therapies of the invention, the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic agent may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.

Accordingly, the invention provides the use of a compound of formula (I) for treating a disease or disorder associated with a mutant form of IDH, wherein the medicament is prepared for administration with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or disorder associated with a mutant form of IDH, wherein the medicament is administered with a compound of formula (I).

The invention also provides a compound of formula (I) for use in a method of treating a disease or disorder associated with a mutant form of IDH, wherein the compound of formula (I) is prepared for administration with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or disorder associated with a mutant form of IDH, wherein the other therapeutic agent is prepared for administration with a compound of formula (I). The invention also provides a compound of formula (I) for use in a method of treating a disease or disorder associated with a mutant form of IDH, wherein the compound of formula (I) is administered with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or disorder associated with a mutant form of IDH, wherein the other therapeutic agent is administered with a compound of formula (I).

The invention also provides the use of a compound of formula (I) for treating a disease or disorder associated with a mutant form of IDH, wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or disorder associated with a mutant form of IDH, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I).

In one embodiment, the other therapeutic agent is selected from: vascular endothelial growth factor (VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothened inhibitors, alkylating agents, anti-tumor antibiotics, anti-metabolites, retinoids, and other cytotoxic agents.

Examples of vascular endothelial growth factor (VEGF) receptor inhibitors include, but are not limited to, bevacizumab (sold under the trademark Avastin® by Genentech/Roche), axitinib, (*N*-methyl-2-[[3-[(*E*)-2-pyridin-2-ylethenyl]-1*H*-indazol-6-yl]sulfanyl]benzamide, also known as AG013736, and described in PCT Publication No. WO 01/002369), Brivanib Alaninate ((*S*)-((*R*)-1-(4-(4-Fluoro-2-methyl-1*H*-indol-5-yloxy)-5-methylpyrrolo[2,1-*f*][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-1*H*-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, and described in PCT Publication No. WO 02/066470), pasireotide (also known as SOM230, and described in PCT Publication No. WO 02/010192), and sorafenib (sold under the tradename Nexavar®).

Examples of topoisomerase II inhibitors, include but are not limited to, etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames Toposar®, VePesid® and Etopophos®), and teniposide (also known as VM-26, sold under the tradename Vumon®).

Examples of alkylating agents, include but are not limited to, temozolomide (sold under the tradenames Temodar® and Temodal® by Schering-Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename Cosmegen®), melphalan (also known as L-PAM, L-sarcophycin, and phenylalanine mustard, sold under the tradename Alkeran®), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename Hexalen®), carmustine (sold under the tradename BiCNU®), bendamustine (sold under the tradename Treanda®), busulfan (sold under the tradenames Busulfex® and Myleran®), carboplatin (sold under the tradename Paraplatin®), lomustine (also known as CCNU, sold under the tradename CeeNU®), cisplatin (also known as CDDP, sold under the tradenames Platinol® and Platinol®-AQ), chlorambucil (sold under the tradename Leukeran®), cyclophosphamide (sold under the tradenames Cytoxan® and Neosar®), dacarbazine (also known as DTIC, DIC and imidazole carboxamide, sold under the tradename DTIC-Dome®), altretamine (also known as hexamethylmelamine (HMM) sold under the tradename Hexalen®), ifosfamide (sold under the tradename Ifex®), procarbazine (sold under the tradename Matulane®), mechlorethamine (also known as nitrogen mustard, mustine and mechlorethamine hydrochloride, sold under the tradename Mustargen®), streptozocin (sold under the tradename Zanosar®), thiotepa (also known as thiophosphoamide, TESP and TSPA, and sold under the tradename Thioplex®).

Examples of anti-tumor antibiotics include, but are not limited to, doxorubicin (sold under the tradenames Adriamycin® and Rubex®), bleomycin (sold under the tradename lenoxane®), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and

rubidomycin hydrochloride, sold under the tradename Cerubidine®), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome®), mitoxantrone (also known as DHAD, sold under the tradename Novantrone®), epirubicin (sold under the tradename Ellence™), idarubicin (sold under the tradenames Idamycin®, Idamycin PFS®),
 5 and mitomycin C (sold under the tradename Mutamycin®).

Examples of anti-metabolites include, but are not limited to, claribine (2-chlorodeoxyadenosine, sold under the tradename leustatin®), 5-fluorouracil (sold under the tradename Adrucil®), 6-thioguanine (sold under the tradename Purinethol®), pemetrexed (sold under the tradename Alimta®), cytarabine (also known as arabinosylcytosine (Ara-C), sold
 10 under the tradename Cytosar-U®), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCyt™), decitabine (sold under the tradename Dacogen®), hydroxyurea (sold under the tradenames Hydrea®, Droxia™ and Mylocel™), fludarabine (sold under the tradename Fludara®), floxuridine (sold under the tradename FUDR®), cladribine (also known as 2-chlorodeoxyadenosine (2-CdA) sold under the tradename Leustatin™),
 15 methotrexate (also known as amethopterin, methotrexate sodim (MTX), sold under the tradenames Rheumatrex® and Trexall™), and pentostatin (sold under the tradename Nipent®).

Examples of retinoids include, but are not limited to, alitretinoin (sold under the tradename Panretin®), tretinoin (all-*trans* retinoic acid, also known as ATRA, sold under the
 20 tradename Vesanoid®), Isotretinoin (13-*cis*-retinoic acid, sold under the tradenames Accutane®, Amnesteem®, Claravis®, Clarus®, Decutan®, Isotane®, Izotech®, Oratane®, Isotret®, and Sotret®), and bexarotene (sold under the tradename Targretin®).

Examples of other cytotoxic agents include, but are not limited to, arsenic trioxide (sold under the tradename Trisenox®), asparaginase (also known as L-asparaginase, and Erwinia
 25 L-asparaginase, sold under the tradenames Elspar® and Kidrolase®).

Intermediates and Examples

The following examples are intended to be illustrative only and not limiting in any way. Unless otherwise noted, the following Intermediates and Examples were purified vial silica gel
 30 column chromatograph using RediSep® Rf columns from Teledyne Isco, Inc. Abbreviations used are those conventional in the art or the following:

ACN acetonitrile

BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl

BSA bovine serum albumin

35 C Celsius

d doublet

dd doublet of doublets

- DAST diethylaminosulfur trifluoride
DEAD diethyl azodicarboxylate
DIPEA NN-diisopropylethylamine
DMF N,N-dimethylformamide
- 5 DMSO dimethylsulfoxide
DTT dithiothreitol
EtOAc ethyl acetate
EtOH ethanol
g gram
- 10 h hour(s)
hr hour(s)
HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HPLC high pressure liquid chromatography
- 15 IPA isopropyl alcohol
kg kilogram
L liter
LC liquid chromatography LCMS liquid chromatography and mass spectrometry
MeOH methanol
- 20 MS mass spectrometry
m multiplet
min minutes
mL milliliter(s)
 μ M micromolar
- 25 m/z mass to charge ratio
nm nanometer
nM nanomolar
N normal
NADPH nicotinamide adenine dinucleotide phosphate
- 30 NMP N-methylpyrrolidone
NMR nuclear magnetic resonance
PdCl₂(dppf).CH₂Cl₂ 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane complex
psi pounds per square inch
- 35 rac racemic
Rt retention time
s singlet

sat. saturated
SFC supercritical fluid chromatography
t triplet
tR retention time
5 TCEP tris(2-carboxyethyl)phosphine
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
TLC thin layer chromatography

10

Instrumentation**LCMS:**

Unless otherwise noted, LCMS data (also reported herein as simply MS) were recorded using a Waters System (Acuity UPLC and a Micromass ZQ mass spectrometer; Column: Acuity HSS
15 C18 1.8-micron, 2.1 x 50 mm; gradient: 5-95 % acetonitrile in water with 0.05 % TFA over a 1.8 min period; flow rate 1.2 mL/min; molecular weight range 200-1500; cone Voltage 20 V; column temperature 50 °C). All masses reported are those of the protonated parent ions unless recorded otherwise.

20 High Resolution Mass Spectrometry (HRMS):

HRMS Method A: ESI-MS data were recorded using a Synapt G2 HDMS (TOF mass spectrometer, Waters) with electrospray ionization source. The resolution of the MS system was approximately 15000. Leucine Enkephalin was used as lock mass (internal standards) infused from lock spray probe. The compound was infused into the mass spectrometer by
25 UPLC (Acquity, Waters) from sample probe. The separation was performed on Acquity UPLC BEH C18 1x50 mm column at 0.2 mL/min flow rate with the gradient from 5% to 95% in 3 min. Solvent A was Water with 0.1% Formic Acid and solvent B was Acetonitrile with 0.1% Formic Acid. The mass accuracy of the system has been found to be <5 ppm with lock mass.

30 HRMS Method B: LC-MS/ESI-MS data were recorded on an Acquity G2 Xevo QToF - Rs(FWHM) > 20000 Accuracy < 5 ppm. The separation was performed on Acquity CSH 1.7µm 2.1x50mm - 50°C column Eluent A: Water + 3.75 mM ammonium acetate. Eluent B: Acetonitrile. Gradient: from 2 to 98% B in 4.4 min - flow 1.0 mL/min.


35 HRMS Method C: Same as HRMS method B, except Gradient: from 40 to 98% B in 3.4 min - flow 1.0 mL/min.

HRMS Method D: LC-MS/ESI-MS data were recorded on an Acquity LCTp ToF - $R_s(\text{FWHM}) > 12000 < 5$ ppm. The separation was performed on Acquity BEHC18 $1.7\mu\text{m}$ $2.1 \times 50\text{mm}$ - 50°C column Eluent A: Water + 0.1% Formic Acid + 3.75mM Am acetate. Eluent B: Acetonitrile + 0.04% formic + 3.75 mM Am Acetate + 5% Water. Gradient: from 0.2 to 98% B in 4.4 min -
5 flow 1.0 mL/min.

HRMS methods A, B, C and D are referred to throughout as HRMS(A), HRMS(B), HRMS(C) and HRMS(D) respectively.


10 Intermediates

Intermediate 1: benzyl ((2R)-(3R)-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate



A solution of (S)-2-(((benzyloxy)carbonyl)amino)-(R)-3-(tert-butoxy)butanoic acid
15 dicyclohexylammonium salt (500 mg, 1.0 mmol) in 10 ml of THF and isobutyl chloroformate (167 mg, 1.2 mmol, 1.2 equiv) at -25°C was added N-methylmorpholine (124 mg, 1.2 mmol, 1.2 equiv), the mixture was stirred at same temperature for 10 min and filtered. The filtrate was cooled to -20°C and to it was added NaBH_4 , followed by 2 ml of water immediately afterwards. The reaction mixture was stirred at same temperature for 5 min. then gradually
20 warmed to room temperature for 25 min, poured into water(10ml) and extracted with EA(2x20ml). The combined organic phases were washed with water, brine and dried over Na_2SO_4 . The solvent was removed to yield the desired product as the clear oil. No further purification was required for next step. ^1H NMR (400 MHz, CDCl_3) δ 7.37 – 7.16 (m, 5H), 5.25 (d, $J = 8.0$ Hz, 1H), 5.02 (s, 1H), 4.04 (ddd, $J = 12.0, 8.9, 2.8$ Hz, 1H), 3.92 – 3.75 (m, 1H),
25 3.59 (dddd, $J = 32.3, 14.6, 8.2, 4.3$ Hz, 2H), 1.10 (s, 9H), 1.09 – 1.06 (m, 3H).

Intermediate 2: (R)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one




Method A: A solution of benzyl ((2R)-(3R)-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate (134 mg, 0.45 mmol in 5 mL of THF) was pre-cooled to 0°C) under nitrogen was treated with potassium tert-butoxide (153 mg, 1.4 mmol, 3.0 equiv), it was stirred at same temperature for 2 hours, 5 mL of water was added, it was extracted with EtOAc (2x20mL), the combined organic layers were washed with water, brine, dried over Na₂SO₄, the solvent was removed to yield the desired product as a yellow oil, no further purification was required for next step. ¹H NMR (400 MHz, CDCl₃) δ 6.20 (br s, 1H), 4.33 (t, *J* = 8.7 Hz, 1H), 4.07 (dd, *J* = 8.9, 5.5 Hz, 1H), 3.67 – 3.58 (m, 1H), 3.58 – 3.49 (m, 1H), 1.13 (s, 9H), 1.02 (d, *J* = 6.0 Hz, 3H).

10

Method B: (2R,3R)-2-amino-3-(tert-butoxy)butan-1-ol hydrochloride (19.77 g, 100 mmol) was dissolved in DCM (200mL) at 0°C, and added triethylamine (69.7 ml, 500 mmol). Solution was treated over 90 mins with a solution of triphosgene (12.76 g, 43.0 mmol) in DCM (100mL) [keep the reaction mixture below 5°C]. The reaction mixture was stirred at 0°C for 30mins before allowing to warm to room temperature and stirring overnight. The reaction mixture was treated with aqueous saturated NH₄Cl (200mL), water (50mL) and stirred vigorously at room temperature for 1h. Separated the organics, extracted the aqueous with DCM (500mL), combined the organics and washed them with 1N HCl (3x150mL), and aqueous saturated NH₄Cl, dried (MgSO₄) and concentrated to dryness (careful not to leave under vacuum or heat excessively) to give a pale brown oil. TLC shows mostly product with some small by-product peaks at higher R_f and some baseline materials. Subjected to flash column chromatography on silica with neat heptanes, 20% Et₂O/heptanes, 50% Et₂O/heptanes, neat Et₂O, and 30%EtOAc/Et₂O. TLC : neat ether, stain with cupric ammonium sulfate (heat hard for 1 minute to see the blue product stain); product R_f = 0.34. Product off mostly with neat Et₂O. One of the cleanest single fractions was concentrated to dryness to give 2.02g of a very pale yellow / brown oil which crystallized upon standing. The remainder of the product fractions were combined and concentrated to dryness to give 15.2g as a pale brown oil, which was seeded with crystals of the initial batch to give a pale brown crystalline solid. Overall yield ~90%. ¹H NMR (400 MHz, CDCl₃) δ 5.28 (br s, 1H); 4.44 (t, 1H); 4.13-4.09 (m, 1H); 3.7-3.57 (m, 2H); 1.23 (s, 9H); 1.11 (d, 3H).


30

Intermediate 3: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one

Method A: A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one (86mg, 0.46 mmol) and 2,4-difluoropyrimidine (79 mg, 0.55 mmol, 1.2 equiv) in 3 ml of DMF was cooled to 0°C under N₂ before adding NaH (60%, 28 mg, 0.69 mmol, 1.5 equiv) slowly. The reaction mixture was stirred at 0°C for 45 min., then gradually warmed to room temperature, and stirred at room temperature overnight. The reaction was quenched with 5 ml of water, and extracted with EtOAc (2x10ml). The solvent was removed to yield the crude product. Silica gel column chromatography (ethyl acetate in heptane 10 to 50%) provided the desired product as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (dd, *J* = 5.8, 2.1 Hz, 1H), 8.14 (dd, *J* = 5.8, 3.8 Hz, 1H), 4.85 – 4.63 (m, 2H), 4.56 – 4.30 (m, 2H), 1.26 (s, 9H), 1.05 (d, *J* = 6.5 Hz, 3H).

Method B: A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one (5 g, 26.7 mmol) in DMF (50 mL) was cooled to -5°C under N₂ atmosphere. Internal temperature was monitored and maintained at ca. -5°C during the portionwise addition of 60% NaH (1.602 g, 40.1 mmol) over 5 mins (no appreciable exotherm seen, but effervescence observed and cloudy suspension resulted). Added 2,4-difluoropyrimidine (2.507 mL, 29.4 mmol) dropwise whilst still maintaining the temperature at ca. -5°C. After complete addition the reaction mixture was stirred at this temperature for 15mins before removing the cooling bath and allowing the reaction mixture to warm to room temperature (ca. 27°C internal temp). Left stirring at room temperature for 2h. Workup : [Safety Note: NaF salt present. Do not acidify workup] Quenched the reaction mixture with water (100mL) which resulted in considerable effervescence although minimal increase in temperature. Added EtOAc (75mL) and separated, extracted the aqueous with EtOAc (2x75mL), combined the organics, washed with water (100mL), brine (50mL), dried (MgSO₄) and concentrated to dryness to give crude product as a pale yellow oil [8.33g] which was purified by silica gel chromatography (initial ramp DCM/heptane 5 to 100%, then EtOAc/DCM 0% to 20%, product off with ~5% EtOAc/DCM). Combined and concentrated the pure product fractions to dryness to give a white solid which was placed under high vacuum for 4h. ¹H NMR (400 MHz, CDCl₃) δ 8.5 (dd, 1H), 8.15 (dd, 1H); 4.77-4.66 (m, 2H); 4.53-4.42 (m, 2H); 1.26 (s, 9H); 1.05 (d, 3H). MS *m/z* 284.1 (M+H)⁺.


Intermediate 4: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,5-difluoropyrimidin-4-yl)oxazolidin-2-one



A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one (5 g, 26.7 mmol) in DMF (50 mL) was cooled to -5°C under N₂ atmosphere. Internal temperature was monitored and maintained at ca. -5°C during the portionwise addition of 60% NaH (1.28 g, 32 mmol) over 5 mins (no appreciable exotherm seen, but effervescence observed and cloudy suspension resulted). Added 2,4,5-trifluoropyrimidine (3.76g, 28 mmol) dropwise whilst still maintaining the temperature at ca. -5°C. After complete addition the reaction mixture was stirred at this temperature for 15mins before removing the cooling bath and allowing the rm to warm to room temperature (ca. 27°C internal temp). Left stirring at room temperature for 6h. Sampled reaction mixture and quenched with water, extracted into EtOAc; TLC and LCMS show significant product but remaining oxazolidinone sm. Cooled reaction mixture to 0°C and added an additional portion of trifluoropyrimidine (1.2g, 8.95 mmol), warmed to room temperature and left stirring for 3h at rt. Still faint residual sm seen by TLC of sample, but quenched reaction mixture at this point. Workup : [Safety Note: NaF salt present. Do not acidify workup]

Quenched the reaction mixture with water (100mL) which resulted in considerable effervescence. Added EtOAc (75mL) and separated, extracted the aqueous with EtOAc (2x75mL), combined the organics, washed with water (100mL), brine (50mL), dried (MgSO₄) and concentrated to dryness to give crude product as a pale yellow oil. Crude was purified by silica gel chromatography (initial neat DCM, then ramp to 20% EtOAc/DCM). Pure product fractions were combined and concentrated to dryness to give a colourless oil which was placed under high vacuum. Upon standing the oil converted into a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (dd, *J* = 3, 1 Hz, 1H); 4.73-4.68 (m, 1H); 4.62-4.52 (m, 2H); 4.34-4.28 (m, 1H); 1.20 (s, 9H); 1.11 (d, 3H). MS *m/z* 302.1 (M+H)⁺.


Intermediate 5: (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (1.0 g, 3.35 mmol) in 20 mL of DCM was cooled in an ice bath, and treated with 8.16 mL of TFA. The


mixture was stirred at same temperature for 4 hours, and allowed to warm to room temp and stir 16 h. The reaction was poured into 10 mL water. The DCM was removed in vacuo. The aqueous was basified by slow addition of saturated NaHCO₃ solution, then extracted with (2 x 30 mL) EtOAc. The organics were washed with 30 mL brine, and dried over Na₂SO₄. Filtered and concentrated to give the desired alcohol, (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (0.56 g, 70% yield) as a white solid. HRMS(B) tR = 0.80 min; MS m/z 228.4 (M + H)⁺.

Intermediate 6: (R)-methyl 3-(2-fluoropyrimidin-4-yl)-2-oxooxazolidine-4-carboxylate



A solution of (R)-methyl 2-oxooxazolidine-4-carboxylate (200 mg, 1.4 mmol) and 2,4-fluoropyrimidine (176 mg, 1.5 mmol, 1.1 equiv) in DMF (3 mL) was treated with NaH (60 %, 66.2 mg, 1.2 mmol, 1.2 equiv), then the resulting mixture was stirred at 0°C for 45 minutes, then room temperature for 12 h. The reaction mixture was diluted with EtOAc (20 mL), washed with sat. NH₄Cl (15 mL) and 4% aqueous NaCl (2 x 100 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 10% to 50%) to provide (R)-methyl 3-(2-fluoropyrimidin-4-yl)-2-oxooxazolidine-4-carboxylate (240 mg, white wax solid) in 71% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (dd, J = 5.8, 2.0 Hz, 1H), 8.07 (dd, J = 5.7, 3.7 Hz, 1H), 5.18 (dd, J = 9.4, 3.7 Hz, 1H), 4.68 (t, J = 9.4 Hz, 1H), 4.45 (dd, J = 9.3, 3.7 Hz, 1H), 3.78 (s, 3H).

Intermediate 7 : 2-amino-4,4,4-trifluoro-3-methylbutan-1-ol




To a chilled (0°C) solution of 2-amino-4,4,4-trifluoro-3-methylbutanoic acid (736 mg, 4.30 mmol) in THF (9 mL) was added aluminum (III) lithium hydride (2.26 mL, 9.03 mmol, 4M) dropwise. After addition complete, the reaction was allowed to stir at ambient temperature for 1 hour. Cool to 0°C and quench w/ sat. Na₂SO₄ soln, added EtOAc (50 mL), Na₂SO₄, filtered, conc. *in vacuo* afforded material that was a mixture of the title compound and the starting material

acid in a 3 : 2 ratio which was used crude in the next step. ^1H NMR (400 MHz, CDCl_3) δ 3.71 (dd, $J = 10.7, 3.7$ Hz, 1H), 3.57 (dd, $J = 10.4, 5.2$ Hz, 1H), 3.45 (ddd, $J = 10.7, 8.0, 4.8$ Hz, 2H), 3.28 (ddd, $J = 8.2, 5.3, 2.9$ Hz, 1H), 3.06 (td, $J = 7.3, 3.6$ Hz, 1H), 2.44 – 2.20 (m, 2H), 2.04 – 1.54 (m, 1H), 1.21 – 1.08 (m, 7H). ^{19}F NMR (376 MHz, CDCl_3) δ -68.33 (s), -70.12 (s).

5


Intermediate 8 : 4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one



To a solution of 2-amino-4,4,4-trifluoro-3-methylbutan-1-ol (580 mg, 3.69 mmol) in DCM (13 ml) was added triethylamine (1.132 ml, 8.12 mmol) and added dropwise a solution of triphosgene (329mg, 1.107mmol) in 1 mL in DCM (3 ml) over 10 min.. The reaction mixture was washed with sat. NH_4Cl solution (13 ml) dry, and concentrated in vacuo. Afforded 450 mg (lt yellow solid). Used crude in the next step. ^1H NMR (400 MHz, CDCl_3) δ 5.91 (d, $J = 13.3$ Hz, 1H), 4.61 – 4.34 (m, 1H), 4.22 – 4.00 (m, 2H), 3.05 (q, $J = 7.3$ Hz, 1H), 2.54 – 2.14 (m, 1H), 1.34 (t, $J = 7.3$ Hz, 1H), 1.17 (d, $J = 7.1$ Hz, 2H), 1.09 (d, $J = 7.1$ Hz, 1H). MS 183.0507 m/z .


15

Intermeidate 9 : 3-(2-fluoropyrimidin-4-yl)-4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one



A solution of 4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one (270 mg, 1.474 mmol) and 2,4-difluoropyrimidine (171 mg, 1.474 mmol, 1 eq) in DMF (4 mL) was treated with NaH (60 %, 88 mg, 2.212 mmol, 1.5 eq), then the resulting mixture was stirred at 0°C for 10 minutes, then room temperature for 1 h. The reaction mixture was quenched with sat. Na_2SO_4 (15 mL) diluted with EtOAc (20 mL), washed and 4% aqueous NaCl (3 x 20 mL), dried over Na_2SO_4 , concentrated *in vacuo*. Flash column chromatography (silica, 120 g, 15 m) 5% EtOAc/DCM to provide 3-(2-fluoropyrimidin-4-yl)-4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one (100 mg, white solid). ^1H NMR (400 MHz, CDCl_3) δ 8.55 (dd, $J = 5.8, 2.1$ Hz, 1H), 8.20 (dd, $J = 5.8, 3.7$ Hz, 1H), 5.04 – 4.84 (m, 1H), 4.68 (dd, $J = 9.5, 2.6$ Hz, 1H), 4.54 (t, $J = 9.2$ Hz, 1H), 3.34 (dddd, $J = 13.3, 9.3, 7.1, 3.9, 1.6$ Hz, 1H), 1.29 (d, $J = 7.3$ Hz, 3H). MS 279.0631 m/z .

25

Intermediate 10: (R)-3-(2,6-dichloropyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one**Step 1**

To a round bottom flask was added NaH (0.54 g, 13.5 mmol, 57% dispersion in mineral oil) to a solution of 2,4,6-trichloropyrimidine (1.22 ml, 10.6 mmol) and (R)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one (1.8 g, 9.61 mmol) in DMF (32 mL) at 0 °C (ice bath) under a bubbler. The yellow suspension was then stirred at 0 °C for 15 min and then the ice bath was removed and reaction mixture allowed to stir 1 hr at room temperature. Reaction mixture was diluted with EtOAc and then carefully quenched with brine. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one (2.1 g, 6.28 mmol, 65% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 1.04 (d, J=6.55 Hz, 3 H) 1.26 (s, 9 H) 4.38 - 4.48 (m, 2 H) 4.64 - 4.75 (m, 2 H) 8.22 (s, 1 H). LCMS *m/z* 334.1(M + H)⁺, Rt 1.10 min.

Step 2


To a round bottom flask containing (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one (1 g, 2.99 mmol) was added DCM (7.5 mL) followed by the addition of TFA (7.5 mL). The resulting homogenous reaction mixture allowed to stir 1 hr at room temperature. The volatiles were then removed. Residue dissolved in DCM and neutralized with a saturated solution of NaHCO₃. The phases were partitioned, the aqueous phase extracted with DCM. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated to a white foam of (R)-3-(2,6-dichloropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (737 mg, 2.65 mmol, 89 % yield). ¹H NMR (400 MHz, CDCl₃) δ 1.19 (d, J=6.46 Hz, 3 H) 4.47 (dd, J=9.37, 8.53 Hz, 1 H) 4.55 (quin, J=5.69 Hz, 1 H) 4.63 (dd, J=9.49, 2.79 Hz, 1 H) 4.89 (ddd, J=8.19, 4.96, 2.79 Hz, 1 H) 8.24 (s, 1 H). LCMS *m/z* 278.0 (M + H)⁺, Rt 0.66 min.

Step 3

To a round bottom flask was added (R)-3-(2,6-dichloropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (364 mg, 1.31 mmol) followed by the addition of DCM (10.8 mL). The reaction mixture was then cooled to 0 °C in a (ice/water bath) under nitrogen. To

this cold solution was added tetrafluoroboric acid (0.20 mL, 1.31 mmol, 50% aqueous solution) followed by the addition of trimethylsilyldiazomethane (1.96 mL, 3.93 mmol, 2 M in hexanes) divided into 3 portions added 20 min apart. A second addition of trimethylsilyldiazomethane in hexanes (1.96 mL, 3.93 mmol, 2 M in hexanes) again divided into 3 portions added 20 min
5 apart was added. Reaction mixture was quenched with water and diluted with DCM. Phases partitioned and the aqueous phase extracted with DCM. Organic phases combined and washed with brine, dried (Na_2SO_4), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (R)-3-(2,6-dichloropyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one (119 mg, 0.41 mmol, 31% yield) as a colorless oil which
10 crystallizes upon standing. ^1H NMR (400 MHz, CDCl_3) δ 1.09 (d, $J=6.50$ Hz, 3 H) 3.44 (s, 3 H) 4.09 (qd, $J=6.46, 4.16$ Hz, 1 H) 4.38 - 4.49 (m, 1 H) 4.60 (dd, $J=9.49, 2.84$ Hz, 1 H) 4.99 (ddd, $J=8.50, 3.95, 2.96$ Hz, 1 H) 8.23 (s, 1 H). LCMS m/z 292.0 ($\text{M} + \text{H}$) $^+$, Rt 0.86 min.

Intermediate 11: (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one



15

Step 1

To a round bottom flask containing a stir bar and (2S,3R)-2-((tert-butoxycarbonyl)amino)-3-methoxybutanoic acid (2.5 g, 10.7 mmol) in THF (80 mL) under nitrogen was cooled to $-30\text{ }^\circ\text{C}$ in a dry ice/acetone bath. To this cold solution was added isobutyl chloroformate (1.7 mL, 12.9
20 mmol) followed by the addition of N-methylmorpholine (1.4 mL, 12.9 mmol). Mixture was stirred for 15 min at $-30\text{ }^\circ\text{C}$. N-Methylmorpholine salt develops and was filtered from mixture. Mother liquor was cooled to $-30\text{ }^\circ\text{C}$ where upon sodium borohydride (0.61 g, 16.1 mmol) was added followed by the addition of water (10 mL) immediately afterwards. Reaction mixture allowed to stir for 15 min at $-20\text{ }^\circ\text{C}$ then gradually allowed to warm to room temperature.
25 Reaction mixture was stirred for 30 min at room temperature. Reaction mixture was then diluted with water and extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated to afford tert-butyl ((2R,3R)-1-hydroxy-3-methoxybutan-2-yl)carbamate (2.0 g, 9.1 mmol, 85 % yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 1.18 (d, $J=6.26$ Hz, 3 H) 1.45 (s, 9 H) 3.33 (s, 3 H) 3.55 - 3.84 (m, 4 H).
30 LCMS m/z 220.2 ($\text{M} + \text{H}$) $^+$, Rt 0.57 min.

Step 2

To a round bottom flask containing tert-butyl ((2R,3R)-1-hydroxy-3-methoxybutan-2-yl) (2 g, 9.1 mmol) and stir bar was added DCM (5.0 mL) followed by the addition of TFA (5.0 mL). Resulting reaction mixture allowed to stir 30 min at room temperature. Volatiles were removed to afford (2R,3R)-2-amino-3-methoxybutan-1-ol (2.1 g, 9.0 mmol, 99 % yield) as a TFA salt.

5 Material was used in next step without further purification. LCMS m/z 120.0 ($M + H$)⁺, Rt 0.15 min.

Step 3

To a round bottom flask containing (2R,3R)-2-amino-3-methoxybutan-1-ol (2.1 g, 9.0 mmol)
10 and a stir bar was added acetonitrile (100 mL) followed by the addition of 2,4-dichloropyrimidine (1.34 g, 9.0 mmol) and DIEA (4.7 mL, 27.0 mmol). Resulting reaction mixture allowed to stir 18 hr at room temperature. Volatiles were then removed. Residue was partitioned between EtOAc and water. Aqueous layer extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated to afford
15 (2R,3R)-2-((2-chloropyrimidin-4-yl)amino)-3-methoxybutan-1-ol (1.68 g, 3.63 mmol, 40 % yield) which contains some unreacted 2,4-dichloropyrimidine. LCMS m/z 232.0 ($M + H$)⁺, Rt 0.38 min.

Step 4

20 To a round bottom flask containing (2R,3R)-2-((2-chloropyrimidin-4-yl)amino)-3-methoxybutan-1-ol (1.68 g, 3.63 mmol) and a stir bar under nitrogen was added DCM (18 mL). The resulting reaction mixture cooled to 0 °C in a brine/ice bath. To this cold solution was then added triphosgene (0.59 g, 1.99 mmol) followed by the addition of 2,6-dimethylpyridine (2 mL, 17.0 mmol). Resulting reaction mixture allowed to stir 30 min at 0 °C. The reaction mixture was
25 diluted with DCM and water and allowed to stir 1 hr at room temperature. The phases partitioned and the aqueous phase extracted with DCM. Organic phases were combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (R)-3-(2-chloropyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one (145 mg, 0.56 mmol, 15% yield) as a white crystalline.
30 ¹H NMR (400 MHz, CDCl₃) δ 1.09 (d, J =6.26 Hz, 3 H) 3.45 (s, 3 H) 4.15 (qd, J =6.39, 4.30 Hz, 1 H) 4.39 - 4.47 (m, 1 H) 4.60 (dd, J =9.39, 2.74 Hz, 1 H) 5.02 (dt, J =8.61, 3.52 Hz, 1 H) 8.17 (d, J =5.87 Hz, 1 H) 8.48 (d, J =5.87 Hz, 1 H). LCMS m/z 258.1 ($M + H$)⁺, Rt 0.69 min.


Step 5

35 To a microwe vial with stir bar was added (R)-3-(2-chloropyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one (145 mg, 0.56 mmol), potassium fluoride (327 mg, 5.63 mmol) and DMSO (4 mL). Vial capped and heated to 120 °C in a sand bath for 3 hr. Reaction

mixture was then cooled to room temperature, diluted with water and aqueous mixture extracted with EtOAc. The Organic phases were combined and washed with water, brine, dried (Na_2SO_4), filtered and concentrated to afford a white crystalline of (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one (117 mg, 0.49 mmol, 86 % yield).

5 LCMS m/z 242.1 ($\text{M} + \text{H}$)⁺, Rt 0.63 min.

Intermediate 12: (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-chloropyrimidin-4-yl)oxazolidin-2-one



Step 1

- 10 To a round bottom flask containing a stir bar and (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)butanoic acid (8.55 g, 21.5 mmol) in THF (72 mL) under nitrogen was cooled to -30°C in a dry ice/acetonitrile bath. To this cold solution was added isobutyl chloroformate (3.4 mL, 25.8 mmol) followed by the addition of N-methylmorpholine (2.8 mL, 25.8 mmol). Mixture was stirred for 15 min at -30 °C.
- 15 N-methylmorpholine salt develops and was filtered from mixture. Mother liquor was cooled to -30 °C where upon sodium borohydride (1.22 g, 32.3 mmol) was added followed by the addition of water (25 mL) immediately afterwards. Reaction mixture allowed to stir for 15 min at -20 °C then gradually allowed to warm to room temperature. Reaction mixture was stirred for 30 min at room temperature. Reaction mixture was diluted with water, extracted with EtOAc. Organic
- 20 phases combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated to afford (9H-fluoren-9-yl)methyl ((2R,3S)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate (8.11 g, 21.15 mmol, 98 % yield) as a colorless oil. ¹H NMR (400 MHz, CDCl_3) δ 1.18 (s, 9 H) 1.24 (d, $J=5.87$ Hz, 3 H) 4.11 - 4.26 (m, 2 H) 4.42 (d, $J=7.04$ Hz, 2 H) 5.73 (d, $J=7.43$ Hz, 1 H) 7.29 - 7.35 (m, 2 H) 7.38 - 7.45 (m, 2 H) 7.61 (t, $J=6.06$ Hz, 2 H) 7.78 (d, $J=7.43$ Hz, 2 H).). LCMS
- 25 m/z 384.3 ($\text{M} + \text{H}$)⁺, Rt 0.96 min.

Step 2


- To a round bottom flask with stir bar was added (9H-fluoren-9-yl)methyl ((2R,3S)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate (4.7 g, 12.3 mmol) and acetonitrile (100 mL) followed
- 30 by the addition of piperidine (1.8 mL, 18.4 mmol). The flask was capped and stirred for 18 hr at room temperature. The volatiles were then removed. A white solid develops which contains the amino alcohol product and the fmoc deprotection by products. Solids were redissolved in

acetonitrile (50 ml)(some of the fmoc polymer is insoluble) and 2,4-dichloropyrimidine (5.48 g, 36.8 mmol) and DIEA (2.141 mL, 12.26 mmol) were added. Resulting reaction mixture allowed to stir 18 hr at room temperature. The volatiles were again removed. Reaction mixture was diluted with water and extracted with EtOAc. Organic phases combined, washed
5 with water, brine, dried (Na_2SO_4), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (2R,3S)-3-(tert-butoxy)-2-((2-chloropyrimidin-4-yl)amino)butan-1-ol (1.80 g, 6.58 mmol, 54% yield) as a colorless oil which crystallizes upon standing. LCMS m/z 274.1 ($\text{M} + \text{H}$)⁺, Rt 0.56 min.

10 Step 3

To a round bottom flask containing (2R,3S)-3-(tert-butoxy)-2-((2-chloropyrimidin-4-yl)amino)butan-1-ol (1.8 g, 6.58 mmol) and a stir bar under nitrogen was added DCM (66 ml). The resulting reaction mixture cooled to -70 °C in a dry ice/acetone bath. To this cold solution was added triphosgene (1.07 g, 3.62 mmol) followed by the addition of 2,6-dimethylpyridine
15 (3.6 mL, 30.9 mmol). Resulting reaction mixture allowed to gradually warm to room temperature and stirred for 30 min at room temperature. Reaction mixture diluted with DCM and water and allowed to stir 1 hr at room temperature. The phases were then partitioned and aqueous extracted with DCM. Organics phases combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated onto silica gel. Silica gel column chromatography
20 (EtOAc/Heptane 0 to 100%) provided (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-chloropyrimidin-4-yl)oxazolidin-2-one (1.44 g, 4.80 mmol, 73% yield) as a white crystalline. LCMS m/z 300.1 ($\text{M} + \text{H}$)⁺, Rt 0.91 min.

Intermediate 13: (R)-4-((R)-1-tert-butoxyethyl)-3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one




A solution of (R)-4-((R)-1-tert-butoxyethyl)oxazolidin-2-one (0.830 g, 4.43 mmol) and 2,4,6-trichloropyrimidine (0.894 g, 4.88 mmol, 1.10 equiv) in DMF (15 mL) was treated with NaH (60 %, 0.248 g, 6.21 mmol, 1.40 equiv), then the resulting mixture (yellow) was stirred at room temperature for 1 h. The reaction mixture was diluted with EtOAc (100 mL) and quenched with
30 saturated aqueous NaCl (100 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over Na_2SO_4 ,

filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 0 to 40%) provided (R)-4-((R)-1-tert-butoxyethyl)-3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one (1.0 g, white solid) in 69% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.22 (s, 1H), 4.70 – 4.66 (m, 2H), 4.45 – 4.40 (m, 2H), 1.26 (s, 9H), 1.04 (d, J = 6.6 Hz, 3H); MS m/z 334.0 ($M + H$) $^+$; Rt-1.10 min.


5

Intermediate 14: (R)-4-((R)-1-tert-butoxyethyl)-3-(6-(difluoromethyl)-2-(methylthio)pyrimidin-4-yl)oxazolidin-2-one




A solution of (R)-4-((R)-1-tert-butoxyethyl)oxazolidin-2-one (0.100 g, 0.534 mmol) and 4-chloro-6-(difluoromethyl)-2-(methylthio)pyrimidine (0.124 g, 0.587 mmol, 1.10 equiv) in DMF (2.7 mL) was treated with NaH (60 %, 0.026 g, 0.64 mmol, 1.20 equiv), then the resulting mixture (yellow) was stirred at room temperature for 30 min. The reaction mixture was diluted with EtOAc (20 mL), washed with saturated aqueous NaCl (2 x 20 mL), dried over Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 0 to 40%) provided (R)-4-((R)-1-tert-butoxyethyl)-3-(6-(difluoromethyl)-2-(methylthio)pyrimidin-4-yl)oxazolidin-2-one (0.164 g, white solid) in 85% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.15 (s, 1H), 6.45 (t, J = 54 Hz, 1H), 4.80 – 4.72 (m, 1H), 4.66 (dd, J = 9.4, 3.0 Hz, 1H), 4.49 – 4.34 (m, 2H), 2.58 (s, 3H), 1.25 (s, 9H), 1.02 (d, J = 6.5 Hz, 3H); MS m/z 362.3 ($M + H$) $^+$; Rt-1.09 min.

20 **Intermediate 15:** (R)-4-((R)-1-tert-butoxyethyl)-3-(6-(difluoromethyl)-2-(methylsulfonyl)pyrimidin-4-yl)oxazolidin-2-one



A solution of (*R*)-4-((*R*)-1-*tert*-butoxyethyl)-3-(6-(difluoromethyl)-2-(methylthio)pyrimidin-4-yl)oxazolidin-2-one (0.164 g, 0.454 mmol) in DCM (4.5 mL) was treated with *m*-CPBA (0.244 g, 1.09 mmol, 2.4 equiv) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 4 h. The reaction was carefully quenched with a 1:1 mixture of 1 M aqueous sodium
5 thiosulfate solution and saturated aqueous sodium bicarbonate solution (20 mL). The mixture was extracted with DCM (3 x 20 mL) and the combined organic extracts were washed with saturated aqueous NaCl (20 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 20% to 40%) provided (*R*)-4-((*R*)-1-*tert*-butoxyethyl)-3-(6-(difluoromethyl)-2-(methylsulfonyl)pyrimidin-4-yl)oxazolidin-2-one as a white solid in 82%
10 yield. MS *m/z* 338.1 (*M* + *H* – *tert*-butyl)⁺; Rt-0.87 min.


Intermediate 16: (*R*)-4-((*R*)-1-*tert*-butoxyethyl)-3-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)oxazolidin-2-one



15 A solution of (*R*)-4-((*R*)-1-*tert*-butoxyethyl)oxazolidin-2-one (0.070 g, 0.374 mmol) and 2,4-dichloro-6-(trifluoromethyl)pyrimidine (0.089 g, 0.411 mmol, 1.10 equiv) in DMF (1.3 mL) was treated with NaH (60 %, 0.018 g, 0.45 mmol, 1.20 equiv), then the resulting mixture (yellow) was stirred at room temperature for 60 min. The reaction mixture was diluted with EtOAc (20 mL), washed with saturated aqueous NaCl (2 x 20 mL), dried over Na₂SO₄, filtered and
20 concentrated. Silica gel column chromatography (EtOAc/Heptane 0 to 15%) provided (*R*)-4-((*R*)-1-*tert*-butoxyethyl)-3-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)oxazolidin-2-one (0.116 g, white solid) in 84% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1H), 4.76 (ddd, *J* = 8.5, 4.2, 2.9 Hz, 1H), 4.70 (dd, *J* = 9.5, 2.9 Hz, 1H), 4.50–4.42 (m, 2H), 1.26 (s, 9H), 1.04 (d, *J* = 6.5 Hz, 3H). MS *m/z* 368.1 (*M* + *H*)⁺; Rt-1.10 min.


25

Intermediate 17: (2*R*,3*R*)-3-(*tert*-butoxy)-2-((2-chloro-6-methylpyrimidin-4-yl)amino)butan-1-ol




A solution of (2R,3R)-2-amino-3-(tert-butoxy)butan-1-ol (267 mg, 1.35 mmol, 1.1 equiv), 2,4-dichloro-6-methylpyrimidine (200 mg, 1.23 mmol, 1.0 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.54 mL, 3.1 mmol, 2.5 equiv) in 1,4-dioxane (6 mL) was heated at 75 °C for 4 h. The reaction was cooled to room temperature and concentrated in vacuo. Silica gel column chromatography (EtOAc/Heptane) provided (2R,3R)-3-(tert-butoxy)-2-((2-chloro-6-methylpyrimidin-4-yl)amino)butan-1-ol (86 mg, white solid) in 24% yield. ¹H NMR (400 MHz, CDCl₃) δ 6.17 (s, 1H), 4.02 (m, 2H), 3.79 – 3.64 (m, 2H), 2.30 (s, 3H), 1.22 (s, 9H), 1.18 (d, J = 6.2 Hz, 3H); MS m/z 288.1 (M + H)⁺; Rt-0.59 min.

Intermediate 18: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-methylpyrimidin-4-yl)oxazolidin-2-one




Triphosgene (35 mg, 0.12 mmol, 0.4 equiv) was added to a solution of (2R,3R)-3-(tert-butoxy)-2-((2-chloro-6-methylpyrimidin-4-yl)amino)butan-1-ol (86 mg, 0.30 mmol) in DCM (3 mL) at -78 °C, followed by the dropwise addition of 2,6-lutidine (0.14 mL, 1.2 mmol, 4 equiv). The solution was allowed to warm to room temperature and was then heated at 35 °C for 5 hours. The reaction was then cooled to room temperature and diluted with DCM (30 mL) and saturated aqueous sodium chloride (30 mL). The layers were separated and the organic layer was dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) provided (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-methylpyrimidin-4-yl)oxazolidin-2-one (0.057 g, white solid) in 61% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 4.73 (ddd, J = 8.6, 4.1, 3.0 Hz, 1H), 4.65 (dd, J = 9.4, 2.9 Hz, 1H), 4.48 (m, 1H), 4.41 (m, 1H), 2.52 (s, 3H), 1.26 (s, 9H), 1.03 (d, J = 6.5 Hz, 3H); MS m/z 314.1 (M + H)⁺; Rt-1.02 min.

Intermediate 19: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoro-6-methylpyrimidin-4-yl)oxazolidin-2-one



Potassium fluoride (0.063 g, 1.08 mmol, 10 equiv) was added to a solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-methylpyrimidin-4-yl)oxazolidin-2-one (34 mg, 0.108 mmol) in DMSO (1.1 mL). The suspension was heated at 120 °C for 3 hours and then cooled to room temperature. The reaction was diluted with ethyl acetate (20 mL) and water (20 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (20 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to give crude (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoro-6-methylpyrimidin-4-yl)oxazolidin-2-one, which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, J = 3.8 Hz, 1H), 4.71 (m, 1H), 4.65 (m, 1H), 4.46 (m, 1H), 4.41 (m, 1H), 2.53 (s, 3H), 1.25 (s, 9H), 1.03 (d, J = 6.5 Hz, 3H); MS m/z 298.2 (M + H)⁺; Rt-0.96 min.

Intermediate 20: methyl 6-((R)-4-((R)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)-2-chloropyrimidine-4-carboxylate




Sodium hydride (60% dispersion in mineral oil, 23 mg, 0.58 mmol, 1.2 equiv) was added to a solution of methyl 2,6-dichloropyrimidine-4-carboxylate (100 mg, 0.483 mmol) and (R)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one (90 mg, 0.483 mmol, 1 equiv) in DMF (2.4 mL) at 0 °C. The suspension was stirred at 0 °C for 1 hour, by which time it turned yellow. The reaction was quenched with dilute aqueous sodium chloride (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined extracts were dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) separated the regioisomers and provided methyl 6-

((R)-4-((R)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)-2-chloropyrimidine-4-carboxylate (0.111 g, white solid) in 64% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.79 (s, 1H), 4.76 (m, 1H), 4.69 (dd, J = 9.4, 2.7 Hz, 1H), 4.52 – 4.41 (m, 2H), 4.02 (s, 3H), 1.26 (s, 9H), 1.05 (d, J = 6.6 Hz, 3H). MS m/z 358.2 ($M + H$) $^+$; R_t -1.00 min.

5


Intermediate 21: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-(hydroxymethyl)pyrimidin-4-yl)oxazolidin-2-one



Sodium borohydride (60 mg, 1.59 mmol, 1.4 equiv) was added to a suspension of methyl 6-
10 ((R)-4-((R)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)-2-chloropyrimidine-4-carboxylate (400 mg, 1.12 mmol) in methanol (11.2 mL) at 0 °C. The ice bath was removed and the reaction was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with saturated aqueous sodium chloride (30 mL), dried over
15 Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) provided (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-(hydroxymethyl)pyrimidin-4-yl)oxazolidin-2-one (0.220 g, white solid) in 60% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.18 (s, 1H), 4.77 – 4.72 (m, 3H), 4.66 (dd, J = 9.4, 2.9 Hz, 1H), 4.48 (m, 1H), 4.41 (m, 1H), 2.83 (m, 1H), 1.26 (s, 9H), 1.03 (d, J = 6.6 Hz, 3H). MS m/z 330.1 ($M + H$) $^+$; R_t -0.86 min.


20

Intermediate 22: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-(fluoromethyl)pyrimidin-4-yl)oxazolidin-2-one



N,N-Diethylaminosulfur trifluoride (0.13 mL, 0.98 mmol, 1.5 equiv) was added to a solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-(hydroxymethyl)pyrimidin-4-yl)oxazolidin-2-one (215 mg, 0.652 mmol) in DCM at -78°C . The reaction was stirred at -78°C for 1 hour, then warmed to room temperature and stirred for another hour. Additional N,N-Diethylaminosulfur trifluoride (0.26 mL, 2.0 mmol, 3 equiv) was added and the reaction stirred for another 1 hour. The reaction was quenched with water (50 mL) and extracted with DCM (3 x 25 mL). The combined extracts were washed with saturated aqueous sodium chloride (30 mL), dried over Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) provided (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-(hydroxymethyl)pyrimidin-4-yl)oxazolidin-2-one (0.165 g, white solid) in 76% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 5.40 (d, $J = 44$ Hz, 1H), 4.75 (ddd, $J = 8.6, 4.1, 3.0$ Hz, 1H), 4.67 (dd, $J = 9.4, 2.9$ Hz, 1H), 4.49 (m, 1H), 4.43 (m, 1H), 1.27 (s, 9H), 1.04 (d, $J = 6.5$ Hz, 3H). MS m/z 332.1 ($\text{M} + \text{H}^+$); Rt-1.02 min.



- 15 **Intermediate 23:** (S)-4,6-difluoro-N-(1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)pyrimidin-2-amine



- (S)-1-(1-(4-Fluorophenyl)-1H-pyrazol-4-yl)ethanamine (175 mg, 0.724 mmol) was added to a solution of 2,4,6-trifluoropyrimidine (146 mg, 1.09 mmol, 1.5 equiv) and N-ethyl-N-isopropylpropan-2-amine (0.32 mL, 1.8 mmol, 2.5 equiv) in 1,4-dioxane at room temperature. The mixture was stirred at room temperature for 1 hour and then the reaction was concentrated in vacuo. Silica gel column chromatography (EtOAc/Heptane) provided (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-chloro-6-(hydroxymethyl)pyrimidin-4-yl)oxazolidin-2-one (0.085 g) in 37% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.82 (s, 1H), 7.68 (s, 1H), 7.62 (dd, $J = 8.9, 4.6$ Hz, 1H), 7.18 – 7.11, (m, 2H), 5.80 (t, $J = 1.2$ Hz, 1H), 5.49 (m, 1H), 5.25 (m, 1H), 1.62 (d, $J = 6.8$ Hz, 3H). MS m/z 320.1 ($\text{M} + \text{H}^+$); Rt-0.95 min.

The Intermediates in **Table 1a** were prepared by a method similar to the one described for the preparation of Intermediate 23.

Table 1a.


Intermediate 24	Intermediate 25
	

5

Table 1b. Chemical name, NMR chemical shifts and LCMS signal for each intermediate listed in **Table 1a**.

Intermediate: Name	¹ H NMR (400 MHz, CDCl ₃) δ ppm	LCMS
24: (S)-4,6-difluoro-N-(1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)pyrimidin-2-amine	7.82 (s, 1H), 7.68 (s, 1H), 7.62 (dd, J = 8.9, 4.6 Hz, 1H), 7.18 – 7.11, (m, 2H), 5.80 (t, J = 1.2 Hz, 1H), 5.49 (m, 1H), 5.25 (m, 1H), 1.62 (d, J = 6.8 Hz, 3H).	MS m/z 320.1 (M + H) ⁺ ; Rt-0.95 min
25: (S)-N-(1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)-4,6-difluoropyrimidin-2-amine		MS m/z 336.0 (M + H) ⁺ ; Rt-1.04 min

Intermediate 26: (R)-4-(((tert-butyl)diphenylsilyl)oxy)methyl)oxazolidin-2-one




Imidazole (1.74 g, 25.6 mmol, 2.0 equiv) was added to a solution of (S)-4-((hydroxymethyl)oxazolidin-2-one (1.5 g, 12.8 mmol) and tert-butylchlorodiphenylsilane (3.95 mL, 15.4 mmol, 1.2 equiv) in DCM (43 mL) at room temperature. A white precipitate formed.

- 5 The solution was stirred at room temperature for 16 hours and then diluted with water (50 mL). The layers were separated and the aqueous layer was extracted with DCM (50 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (50 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 20 to 65%) provided (R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)oxazolidin-2-one (3.55 g, sticky colorless oil) in 78% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (m, 4H), 7.50 – 7.38 (m, 6H), 5.31 (m, 1H), 4.44 (t, J = 8.7 Hz, 1H), 4.15 (m, 1H), 4.00 (m, 1H), 3.65 (d, J = 5.5 Hz, 2H), 1.07 (s, 9H). MS *m/z* 356.1 (M + H)⁺; Rt-1.00 min.
- 10

Intermediate 27: (R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one

15




Sodium hydride (34 mg, 0.84 mmol, 1.5 equiv) was carefully added to a solution of (R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)oxazolidin-2-one (200 mg, 0.563 mmol) in DMF (2.8 mL). The mixture was stirred at room temperature for 20 minutes and then 2,4-difluoropyrimidine

- 20 (0.072 mL, 0.84 mmol, 1.5 equiv) was added (bubbling). The yellow suspension was stirred for 10 minutes and the reaction was then carefully quenched with saturated aqueous ammonium chloride (5 mL). Water (20 mL) was added and the mixture was extracted with ethyl acetate (2 x 25 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (20 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 30%) provided (R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (0.185 g, sticky colorless oil) in 73% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.44 (dd, J = 5.8, 2.2 Hz, 1H), 8.12 (dd, J = 5.8, 3.4 Hz, 1H), 7.58 (m, 2H), 7.48 – 7.32 (m, 6H), 7.23 (m, 2H), 4.80 (m, 1H), 4.65 (dd, J = 8.6, 3.0 Hz, 1H), 4.55 (m, 1H),
- 25


4.18 (dd, $J = 11.1, 3.5$ Hz, 1H), 3.83 (dd, $J = 11.1, 2.1$ Hz, 1H), 1.04 (s, 9H). MS m/z 452.3 ($M + H$)⁺; Rt-1.15 min.

5 **Intermediate 28:** (S)-3-(2-fluoropyrimidin-4-yl)-4-(hydroxymethyl)oxazolidin-2-one



A solution of tetrabutylammonium fluoride (1.0 M in THF, 0.44 mL, 0.44 mmol, 1.1 equiv) was added to a solution of (R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (180 mg, 0.40 mmol) in THF (4 mL) at room temperature. The solution was stirred for 1 hour and then diluted with saturated aqueous sodium chloride (30 mL). The mixture was extracted with ethyl acetate (2 x 30 mL) and the combined extracts were dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) provided (S)-3-(2-fluoropyrimidin-4-yl)-4-(hydroxymethyl)oxazolidin-2-one (0.051 g, white solid) in 60% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dd, $J = 5.8, 2.1$ Hz, 1H), 8.19 (dd, $J = 5.8, 3.8$ Hz, 1H), 4.86 (dq, $J = 8.1, 4.0$ Hz, 1H), 4.55 (m, 2H), 4.09 (m, 1H), 3.96 (m, 1H), 2.18 (t, $J = 5.4$ Hz, 1H). MS m/z 214.0 ($M + H$)⁺; Rt-0.37 min.


Intermediate 29: (R)-4-(fluoromethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one



20 Perfluorobutanesulfonyl fluoride (0.18 mL, 0.98 mmol, 4 equiv) was added to a solution of (S)-3-(2-fluoropyrimidin-4-yl)-4-(hydroxymethyl)oxazolidin-2-one (52 mg, 0.24 mmol) in THF (1.2 mL) at room temperature. Triethylamine trihydrofluoride (0.16 mL, 0.98 mmol, 4 equiv) and triethylamine (0.41 mL, 3.0 mmol, 12 equiv) were then added and the solution was stirred at 40 °C for 18 hours. The reaction was then cooled to room temperature and diluted with water

(25 mL). The mixture was extracted with ethyl acetate (2 x 25 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (10 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) provided (R)-4-(fluoromethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (0.021 g, colorless oil) in 40% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.53 (dd, J = 5.7, 2.1 Hz, 1H), 8.18 (dd, J = 5.7, 3.7 Hz, 1H), 5.08 – 4.93 (m, 2H), 4.91 – 4.72 (m, 1H), 4.66 – 4.55 (m, 2H). MS *m/z* 215.9 (M + H)⁺; Rt-0.57 min.

Intermediate 30: (R)-4-((R)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one



Step 1

To a round bottom flask containing a stir bar and (2S,3S)-2-(((benzyloxy)carbonyl)amino)-3-(tert-butoxy)butanoic acid DCHA (10 g, 20.4 mmol) in THF (160 mL) under nitrogen was cooled to -30 °C in a dry ice/acetone bath. To this cold white suspension was added isobutyl chloroformate (3.2 mL, 24.5 mmol) followed by the addition of N-methylmorpholine (2.7 mL, 24.5 mmol). Mixture was stirred for 20 min at -30 °C. A N-Methylmorpholine salt develops and was filtered from mixture. Mother liquor was cooled to -30 °C where upon sodium borohydride (1.16 g, 30.6 mmol) was added followed by the addition of water (20 mL) immediately afterwards. Reaction mixture allowed to stir for 15 min at -20 °C then gradually allowed to warm to room temperature. The reaction mixture was stirred for 30 min at room temperature. The reaction mixture was then diluted with water and extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated to afford benzyl ((2R,3S)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate (5.27 g, 17.8 mmol, 88% yield) as a colorless oil. LCMS *m/z* 296.1 (M + H)⁺, Rt 0.84 min.

Step 2

To a round bottom flask containing benzyl ((2R,3S)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate (5.27 g, 17.8 mmol) was added MeOH (100 mL). Solution was degassed with nitrogen for 15 min at which time palladium on carbon (0.95 g, 0.89 mmol) in MeOH (5 mL) was added. A hydrogen atmosphere was then inserted. Resulting reaction mixture allowed to stir 40 min at room temperature at atmospheric pressure when water (2 mL) was added and once again a hydrogen atmosphere was inserted at atmospheric pressure and the subsequent

reaction mixture allowed to stir 18 hr at room temperature. The reaction mixture was filtered through a pad of celite and concentrated to a brown oil. Oil redissolved in toluene and concentrated to afford (2R,3S)-2-amino-3-(tert-butoxy)butan-1-ol (2.5 g, 15.5 mmol, 87% yield) as a brown oil. LCMS m/z 162.1 ($M + H$)⁺, Rt 0.41 min (Mass ion only, no UV peak).

5

Step 3

To a round bottom flask containing (2R,3S)-2-amino-3-(tert-butoxy)butan-1-ol (1.25 g, 7.75 mmol) and a stir bar was added acetonitrile (50 mL) followed by the addition of 2,4-difluoropyrimidine (0.99 g, 8.53 mmol) and DIEA (4.1 mL, 23.3 mmol). The resulting reaction mixture allowed to stir 1 hr at room temperature. The volatiles were then removed. Residue was partitioned between EtOAc and water. Aqueous layer extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated to a viscous yellow oil of (2R,3S)-3-(tert-butoxy)-2-((2-fluoropyrimidin-4-yl)amino)butan-1-ol (1.5 g, 5.83 mmol, 75% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.14 (s, 9 H) 1.31 (d, $J=6.26$ Hz, 3 H) 3.64 (d, $J=12.91$ Hz, 2 H) 3.86 (br. s., 1 H) 4.26 (d, $J=10.17$ Hz, 1 H) 6.09 (br. s., 1 H) 6.25 (br. s., 1 H) 7.99 (br. s., 1 H). LCMS m/z 258.2 ($M + H$)⁺, Rt 0.62 min

10

15

Step 4

To a round bottom flask containing (2R,3S)-3-(tert-butoxy)-2-((2-fluoropyrimidin-4-yl)amino)butan-1-ol (1.5 g, 5.83 mmol) and a stir bar under nitrogen was added DCM (58 mL). The resulting reaction mixture cooled to -70 °C in a dry ice/acetone bath. To this cold solution was added triphosgene (0.95 g, 3.21 mmol) followed by the addition of 2,6-dimethylpyridine (2.7 mL, 23.3 mmol). The resulting reaction mixture allowed to warm to room temperature and stirred for 1 hr.

20

25

30

The reaction mixture was then diluted with DCM and water and allowed to stir 1 hr at room temperature. The phases were then partitioned and aqueous phase extracted with DCM. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (502 mg, 1.77 mmol, 30% yield) as a white crystalline. LCMS m/z 284.1 ($M + H$)⁺, Rt 0.89 min.

Step 5

To a round bottom flask containing (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (502 mg, 1.77 mmol) was added DCM (4 mL) and TFA (4 mL). Resulting reaction mixture stirred for 1 hr at room temperature. The volatiles were then removed and the residue neutralized with a saturated solution of NaHCO₃. The aqueous mixture was extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and


35

concentrated to a colorless residue of (R)-3-(2-fluoropyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one (382 mg, 1.68 mmol, 95% yield). LCMS m/z 228.1 (M + H)⁺, Rt 0.44 min.

5 Step 6

To a round bottom flask containing a solution of (R)-3-(2-fluoropyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one (348 mg, 1.53 mmol) in THF (5.1 mL) was added perfluorobutanesulfonyl fluoride (0.83 mL, 4.60 mmol) followed by the addition of triethylamine trihydrofluoride (0.75 mL, 4.60 mmol) and triethylamine (1.9 mL, 13.8 mmol). The resulting
10 reaction mixture allowed to stir at room temperature for 6 hr. The reaction mixture was diluted with water and the aqueous mixture was extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 60%) provided a viscous oil of (R)-4-((R)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (125 mg, 0.44 mmol, 28% yield) which
15 crystallizes upon standing. ¹H NMR (400 MHz, CDCl₃) δ 1.34 (dd, J =24.26, 6.65 Hz, 3 H) 4.45 - 4.55 (m, 1 H) 4.61 - 4.68 (m, 1 H) 5.11 (dt, J =7.63, 4.01 Hz, 1 H) 5.30 - 5.52 (m, 1 H) 8.13 - 8.17 (m, 1 H) 8.52 (d, J =5.87 Hz, 1 H). LCMS m/z 230.0 (M + H)⁺, Rt 0.66 min.

Intermediate 31: (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one



20

Step 1

To a round bottom flask containing (2R,3S)-2-amino-3-(tert-butoxy)butan-1-ol (1.25 g, 7.75 mmol) and a stir bar was added acetonitrile (50 mL) followed by the addition of 2,4,5-trifluoropyrimidine (1.04 g, 7.75 mmol) and DIEA (4.1 mL, 23.3 mmol). The resulting reaction
25 mixture allowed to stir 1 hr at room temperature. The volatiles were then removed. Reaction mixture was then partitioned between EtOAc and water. Aqueous layer extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated to a viscous yellow oil of (2R,3S)-3-(tert-butoxy)-2-((2,5-difluoropyrimidin-4-yl)amino)butan-1-ol (1.56 g, 5.67 mmol, 73% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.15 (s, 9 H) 1.32 (d, J =6.26
30 Hz, 3 H) 3.45 (br. s., 1 H) 3.67 (d, J =11.35 Hz, 1 H) 3.85 - 3.92 (m, 1 H) 4.27 (d, J =11.74 Hz, 1 H) 6.29 (d, J =5.48 Hz, 1 H) 7.87 (d, J =2.35 Hz, 1 H). LCMS m/z 276.4 (M + H)⁺, Rt 0.71 min.

Step 2

To a round bottom flask containing (2R,3S)-3-(tert-butoxy)-2-((2,5-difluoropyrimidin-4-yl)amino)butan-1-ol (1.56 g, 5.67 mmol) and a stir bar under nitrogen was added DCM (57 mL). The resulting reaction mixture cooled to -70 °C in a dry ice/acetone bath. To this cold solution
5 was added triphosgene (0.93 g, 3.12 mmol) followed by the addition of 2,6-dimethylpyridine (2.64 mL, 22.7 mmol). The resulting reaction mixture allowed to warm to room temperature and stirred 90 hr at room temperature. The reaction mixture was then diluted with DCM and water and allowed to stir 1 hr at room temperature. The phases were then partitioned and aqueous phase extracted with DCM. Organic phases combined, washed with water, brine, dried
10 (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2,5-difluoropyrimidin-4-yl)oxazolidin-2-one (0.59 g, 1.96 mmol, 35% yield) as a white crystalline. ¹H NMR (400 MHz, CDCl₃) δ 1.03 (s, 9 H) 1.16 (d, *J*=6.65 Hz, 3 H) 4.15 (qd, *J*=6.39, 1.96 Hz, 1 H) 4.43 - 4.52 (m, 1 H) 4.59 - 4.72 (m, 2 H) 8.43 (d, *J*=1.57 Hz, 1 H). LCMS *m/z* 246.0 (– t-butyl fragment) (M +
15 H)⁺, Rt 0.88 min.

Step 3


To a round bottom flask containing (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2,5-difluoropyrimidin-4-yl)oxazolidin-2-one (590 mg, 1.96 mmol) was added DCM (4 mL) and TFA (4 mL). Resulting
20 reaction mixture stirred for 1 hr at room temperature. The volatiles were then removed. Residue neutralized with a saturated solution of NaHCO₃ and aqueous mixture extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated to a colorless residue of (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one (470 mg, 1.917 mmol, 98 % yield). LCMS *m/z* 246.0 (M + H)⁺,
25 Rt 0.41 min.

Step 4

To a round bottom flask containing a solution of (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one (0.47 g, 1.917 mmol) in THF (6.4 mL) was added
30 perfluorobutanesulfonyl fluoride (1.03 mL, 5.75 mmol) followed by the addition of triethylamine trihydrofluoride (0.94 mL, 5.75 mmol) and triethylamine (2.40 mL, 17.3 mmol) resulting reaction mixture allowed to stir at room temperature for 6 hr. The reaction mixture was diluted with water and the aqueous mixture was extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column
35 chromatography (EtOAc/Heptane 0 to 60%) provided a white crystalline of (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one (150 mg, 0.61 mmol, 32 % yield). ¹H NMR (400 MHz, CDCl₃) δ 1.37 (dd, *J*=24.26, 6.26 Hz, 3 H) 4.48 (dd, *J*=9.39, 4.70 Hz, 1 H)

4.63 (t, $J=8.80$ Hz, 1 H) 4.90 - 5.02 (m, 1 H) 5.02 - 5.25 (m, 1 H) 8.50 (s, 1 H). LCMS m/z 248.0 (M + H)⁺, Rt 0.59 min.

5

Intermediate 32:**Step 1**

To a round bottom flask containing (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (2.1 g, 7.41 mmol) was added DCM (18.5 mL) and TFA (18.5 mL). The resulting reaction mixture stirred for 1 hr at room temperature. The volatiles were then removed and the residue neutralized with a saturated solution of NaHCO₃. The aqueous mixture was then extracted with EtOAc. The organic phases were combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated to a colorless residue of (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (1.52 g, 6.69 mmol, 90% yield) which crystallizes upon standing. LCMS m/z 228.0 (M + H)⁺, Rt 0.44 min.

Step 2


To a round bottom flask containing a solution of (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (1.52 g, 6.69 mmol) in THF (22 mL) was added perfluorobutanesulfonyl fluoride (3.6 mL, 20.1 mmol) followed by the addition of triethylamine trihydrofluoride (3.3 mL, 20.1 mmol) and triethylamine (8.4 mL, 60.2 mmol). The resulting reaction mixture allowed to stir at room temperature for 2 hr. The reaction mixture was then diluted with water and the aqueous mixture was extracted with EtOAc. The organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 60%) provided a white crystalline of (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (207 mg, 0.90 mmol, 14% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.44 (dd, $J=23.48$, 6.26 Hz, 3 H) 4.47 - 4.57 (m, 1 H)

4.66 (dd, $J=8.80, 3.33$ Hz, 1 H) 4.71 - 4.86 (m, 1 H) 5.22 - 5.45 (m, 1 H) 8.21 (dd, $J=5.48, 3.91$ Hz, 1 H) 8.52 (dd, $J=5.48, 1.96$ Hz, 1 H). LCMS m/z 230.1 ($M + H$)⁺, Rt 0.63 min.


Alternative method for making Intermediate 32:

- 5 To a cooled (0 °C) solution of 2,4-difluoropyrimidine (160 mg, 1.375 mmol) and (R)-4-((S)-1-fluoroethyl)oxazolidin-2-one (183 mg, 1.375 mmol) in DMF (Volume: 4.6 mL) was added NaH (60% in mineral oil, 66.0 mg, 1.650 mmol). The resulting mixture was stirred at 0 °C for 30 min and at room temperature for 2 hr. Desired product was observed from LC-MS. The mixture was quenched with brine (1 ml). Diluted w/ EtOAc (20 ml) and water (10 ml), and separated
- 10 layers. The organic was extracted with an additional 20 mL EtOAc. The combined organics were washed with brine, dried, and concentrated. Crude was purified through flash column chromatography (10-100% EtOAc/Heptane) to give (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one, 210 mg white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dd, $J = 5.8, 2.1$ Hz, 1H), 8.20 (dd, $J = 5.7, 3.7$ Hz, 1H), 5.33 (dq, $J = 49.5, 6.6, 1.3$ Hz, 1H),
- 15 4.77 (dddd, $J = 26.5, 9.1, 3.4, 1.4$ Hz, 1H), 4.65 (dd, $J = 9.0, 3.4$ Hz, 1H), 4.50 (td, $J = 9.0, 1.3$ Hz, 1H), 1.43 (dd, $J = 23.1, 6.6$ Hz, 3H). MS m/z 230.1 ($M + H$).

Intermediate 33: 4-(2-fluoropropan-2-yl)oxazolidin-2-one




Step 1: Preparation of 2-amino-3-fluoro-3-methylbutan-1-ol




20

- To the solution of LiBH₄ (2M in THF, 7.40 mL, 14.8 mmol) and trimethylchlorosilane (3.78 mL, 29.6 mmol) in THF (7 mL) was added 3-fluoro-D,L-valine (1 g, 7.40 mmol). The resulting mixture was stirred at room temperature for 24 hr. The reaction mixture was quenched with methanol and then concentrated under reduced pressure to give an oily product. The oily
- 25 product was diluted with DCM and 10% aqueous sodium bicarbonate solution and then stirred at room temperature for ~16 hr. The separated organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried over sodium sulfate, filtered off and concentrated under reduced pressure providing 2-amino-3-fluoro-3-methylbutan-1-ol (350 mg) as a solid, which was used without further purification. MS m/z 121.9 ($M + H$)⁺; Rt-0.16 min.


Step 2: Preparation of 4-(2-fluoropropan-2-yl)oxazolidin-2-one

To a solution of N,N'-carbonyldiimidazole (530 mg, 3.27 mmol in THF (5 mL) was added slowly
5 a solution of 2-amino-3-fluoro-3-methylbutan-1-ol (360 mg, 2.97 mmol) in THF (10 mL). The
reaction mixture was stirred at room temperature for 18 hr, was diluted with DCM and stirred
for additional 30 min. The separated organic layer was washed with water and brine, dried
over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was
10 purified by column chromatography [SiO₂, 12 g, EtOAc/heptane = 0/100 to 80/20] to provide 4-
(2-fluoropropan-2-yl)oxazolidin-2-one (150 mg) as a brown solid. MS *m/z* 148.0 (M + H)⁺; Rt-
0.32 min. ¹H NMR (400 Mhz, CDCl₃) δ ppm 6.30 (br. s., 1H), 4.39 - 4.54 (m, 1H), 4.26 (dd, J =
8.9, 5.1 Hz, 1H), 3.84 - 3.99 (m, 1H), 1.29 - 1.45 (m, 6H).


Intermediate 34: 3-(2-chloropyrimidin-4-yl)-4-(2-fluoropropan-2-yl)oxazolidin-2-one

15 To the solution of 2,4-dichloropyrimidine (150 mg, 1.006 mmol) and 4-(2-fluoropropan-2-
yl)oxazolidin-2-one (148 mg, 1.01 mmol) in DMF (4.5 mL), sodium hydride (60%wt.89 mg, 2.21
mmol) was added to give a pale yellow mixture. The mixture was stirred at room temperature
for 2 hr, diluted with EtOAc and stirred for additional 30 min. The separated organic layer was
20 washed with saturated aqueous sodium bicarbonate solution, water and brine. The organic
phase was dried over sodium sulfate, filtered off and concentrated under reduced pressure.
The residue was purified by column chromatography [SiO₂, 12 g, EtOAc/heptane = 0/100 to
80/20] providing 3-(2-chloropyrimidin-4-yl)-4-(2-fluoropropan-2-yl)oxazolidin-2-one (150 mg) as
a brown solid. MS *m/z* 260.1 (M + H)⁺; Rt-0.72 min. ¹H NMR (400 Mhz, CDCl₃) δ ppm 8.51 (d,
25 J = 5.9 Hz, 1H), 8.17 (d, J = 5.9 Hz, 1H), 5.14 (dd, J = 17.4, 8.0 Hz, 1H), 4.66 (d, J = 9.4 Hz,
1H), 4.43 - 4.52 (m, 1H), 1.42 - 1.52 (m, 3H), 1.30 - 1.40 (m, 3H).

Intermediate 35: (S)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one




Step 1: Preparation of (S)-benzyl 3-((tert-butoxycarbonyl)amino)-4-hydroxybutanoate



Reference: V.L. Truong, et al.; *Synlett* **2005**, 8, 1279-1280.

- 5 To a solution of Boc-Asp(OBnzl)-OH (20 g, 61.9 mmol) in DME (60 mL) at -40 °C (dry ice/acetonitrile bath) was added N-methylmorpholine (7.07 mL, 64.3 mmol) over 5 min followed by isobutyl chloroformate (8.53 mL, 64.9 mmol) dropwise over 15 min, keeping the temperature below -10 °C. The mixture was stirred for 30 min (-30 °C to -40 °C). The solids were quickly filtered off and rinsed with DME (60 mL). The clear filtrate was cooled to -35 °C and a solution
- 10 of NaBH₄ (2.93 g, 78 mmol) in 30 mL water was added dropwise maintaining a temperature between -30 °C and -15 °C [Caution: gas development]. Water (332 mL) was added dropwise over 30 min to the white suspension maintaining a temperature below -15 °C. The thick white slurry was filtered, rinsed with water (300 mL). The filtered solid was dissolved in DCM (250 mL). The solution was dried over sodium sulfate, filtered off and concentrated under reduced
- 15 pressure to provide (S)-benzyl 3-((tert-butoxycarbonyl)amino)-4-hydroxybutanoate (16.35 g) as a white solid. MS *m/z* 254.2 (M – *tert*-butyl)⁺; Rt-0.78 min. ¹H NMR (400 Mhz, D₃C(CO)CD₃) δ ppm 7.45 - 7.28 (m, 4 H), 5.92 - 5.80 (m, 1 H), 5.11 (s, 2 H), 4.07 - 3.91 (m, 1 H), 3.67 - 3.48 (m, 2 H), 2.82 - 2.77 (m, 1H), 2.74 - 2.68 (m, 1 H), 2.61 - 2.52 (m, 1 H), 1.39 (s, 9 H).

20 **Step 2: Preparation of (S)-benzyl 2-(2-oxooxazolidin-4-yl)acetate**




Reference: V.L. Truong, et al.; *Synlett* **2005**, 8, 1279-1280.

- To a solution of (S)-benzyl 3-((tert-butoxycarbonyl)amino)-4-hydroxybutanoate (16.3 g, 52.7 mmol) and pyridine (10.65 mL, 132 mmol) in DCE (157 mL) at 0 °C was added p-
- 25 toluenesulfonic anhydride (17.10 g, 52.4 mmol) in two portions over 5 min. The mixture was


stirred for a few minutes, then allowed to warm to room temperature and stirred for 1 hr. The mixture was heated for 6 hr at 92 °C and then allowed to cool to room temperature. The mixture was diluted with DCM (80 mL), washed with 1N aqueous HCl solution (2x 200 mL), brine (200 mL), and saturated aqueous sodium bicarbonate solution (100 mL). The organic layer was dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by column chromatography [SiO₂, 220 g, EtOAc/heptane = 5/95 to 75/25] to provide (S)-benzyl 2-(2-oxooxazolidin-4-yl)acetate (10.0 g) as a white solid. MS *m/z* 236.2 (M + H)⁺; Rt-0.59 min.

10 **Step 3: Preparation of (R)-benzyl 2-((S)-2-oxooxazolidin-4-yl)propanoate**




To a solution of sodium bis(trimethylsilyl)amide (1M in THF; 68.0 mL) under argon atmosphere was added THF (40.4 mL). The mixture was cooled to -78 °C and a solution of (S)-benzyl 2-(2-oxooxazolidin-4-yl)acetate (7.80 g, 33.2 mmol) in THF (85 mL) was added slowly over ~15 min. The mixture was stirred for 1 hr at -78 °C and a solution of iodomethane (4.25 mL, 68.0 mmol) in THF (40.4 mL) was added slowly over ~10 min. The reaction mixture was stirred for 1 hr at -78 °C and ~1 hr at -40 °C. The mixture was quenched with saturated aqueous ammonium chloride solution (~100 mL) and allowed to warm to room temperature. The mixture was extracted with DCM (3x). The combined organic layers were dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by column chromatography [SiO₂, 220 g, EtOAc/heptane] to provide (R)-benzyl 2-((S)-2-oxooxazolidin-4-yl)propanoate (7.47 g) as a colorless oil. MS *m/z* 250.1 (M + H)⁺; Rt-0.65 min. ¹H NMR (400 Mhz, DMSO-d₆) δ ppm 7.85 (s, 1 H), 7.44 - 7.28 (m, 5 H), 5.10 (s, 2 H), 4.36 (t, J = 1.0 Hz, 1 H), 4.11 (dd, J = 5.4, 8.9 Hz, 1 H), 4.06 - 3.98 (m, 1 H), 2.69 (quin, J = 6.9 Hz, 1 H), 1.08 (d, J = 7.1 Hz, 3 H).

Step 4: Preparation of (R)-2-((S)-2-oxooxazolidin-4-yl)propanoic acid




To a solution of (R)-benzyl 2-((S)-2-oxooxazolidin-4-yl)propanoate (1.99 g, 7.98 mmol) in THF (18.7 mL) was added Pd/C (10%wt., Degussa; 0.425 g). The mixture was stirred under hydrogen atmosphere (balloon) at room temperature for 4 hr. The mixture was filtered through a plug of celite and rinsed several times with THF. The filtrate was concentrated under reduced pressure providing (R)-2-((S)-2-oxooxazolidin-4-yl)propanoic acid (1.17 g) as a white solid, which was directly used without further purification. MS m/z 160.0 ($M + H$)⁺; Rt-0.26 min. ¹H NMR (400 Mhz, CD₃OD) δ ppm 4.53 - 4.47 (m, 1 H), 4.26 (dd, $J = 5.7, 9.1$ Hz, 1 H), 4.13 (td, $J = 6.0, 8.8$ Hz, 1 H), 2.69 - 2.61 (m, 1 H), 1.18 (d, $J = 7.2$ Hz, 3 H).

Step 5: Preparation of (R)-N-methoxy-N-methyl-2-((S)-2-oxooxazolidin-4-yl)propanamide




To a mixture of (R)-2-((S)-2-oxooxazolidin-4-yl)propanoic acid (1.1 g, 6.91 mmol) in DCM (20 mL) was added 1-chloro-N,N,2-trimethylprop-1-en-1-amine (1.385 g, 10.37 mmol) at 0 °C. The ice bath was removed and the mixture was stirred for 30 min at ambient temperature. A mixture of N,O-dimethylhydroxylamine (1.011 g, 10.37 mmol) and pyridine (1.677 mL, 20.74 mmol) in DCM (20 mL) was added and stirring was continued for ~1 hr. The mixture was diluted with water (~2 mL) and saturated sodium bicarbonate solution (~2 mL) and stirred for ~15 min. The mixture was diluted with dichloromethane (~30 mL). The separated aqueous layer was extracted with DCM (1x), the organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure providing crude (R)-N-methoxy-N-methyl-2-((S)-2-oxooxazolidin-4-yl)propanamide (2.73 g) as an orange oil which was directly used without further purification. MS m/z 203.1 ($M + H$)⁺; Rt-0.36 min.

Step 6: Preparation of (R)-2-((S)-3-benzyl-2-oxooxazolidin-4-yl)-N-methoxy-N-methylpropanamide



To a mixture of crude (R)-N-methoxy-N-methyl-2-((S)-2-oxooxazolidin-4-yl)propanamide (1.3 g, 6.43 mmol) and (bromomethyl)benzene (1.30 mL, 11.4 mmol) in THF (25 mL) was added slowly sodium hydride (60%wt.; 0.643 g) at 0 °C [Caution: gas development!]. The ice bath
 5 was removed and the mixture was stirred for ~2hr. The mixture were diluted carefully with water and ethyl acetate. The reaction was repeated on the same scale and the mixtures were combined. The aqueous layer was separated and extracted with ethyl acetate (1x). The combined organic layers were dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by column chromatography [SiO₂, 80 g,
 10 EtOAc/heptane = 5/95 to 75/25] to provide (R)-2-((S)-3-benzyl-2-oxooxazolidin-4-yl)-N-methoxy-N-methylpropanamide (1.83 g) as a slightly yellow oil, which contained also N-methoxy-N-methylisobutyramide. MS *m/z* 293.7 (M + H)⁺; Rt-0.64 min.


Step 7: Preparation of (R)-2-((S)-3-benzyl-2-oxooxazolidin-4-yl)propanal



15 To a solution of (R)-2-((S)-3-benzyl-2-oxooxazolidin-4-yl)-N-methoxy-N-methylpropanamide from **Step 6** (1.5 g, 5.13 mmol) in THF (30 mL) was added dropwise DIBAL-H (1M solution in hexane; 11.29 mL) at -78 °C. The mixture was stirred for 90 min at -78 °C, diluted slowly with Rochelle's salt solution (1M solution in water; ~20 mL) and stirred vigorously for ~15 min. The
 20 aqueous layer was separated and extracted with ethyl acetate (3x). The combined organic extracts were washed with saturated sodium bicarbonate solution and brine, filtered through a mixture of celite/silica gel. The filtrate was concentrated under reduced pressure providing crude (R)-2-((S)-3-benzyl-2-oxooxazolidin-4-yl)propanal (1.26 g) as a colorless oil, which was directly used without further purification. MS *m/z* 234.2 (M + H)⁺; Rt-0.60 min.


25

Step 8: Preparation of (S)-3-benzyl-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one




To a solution of (R)-2-((S)-3-benzyl-2-oxooxazolidin-4-yl)propanal (1.26 g, 5.40 mmol) in DCM (13 mL) was added slowly DAST (2.85 mL, 21.6 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred overnight. The mixture was carefully diluted with ice-water. The separated aqueous layer was extracted with DCM (3x). The combined organic layers were dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by column chromatography [SiO₂; 80 g, ethylacetate/heptane] providing (S)-3-benzyl-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (627 mg) as a slightly yellowish oil. MS *m/z* 255.7/257.3 (M + H)⁺; Rt-0.80 min. ¹H NMR (400 Mhz, CD₃OD) δ ppm 7.31 - 7.43 (m, 5 H), 5.86 (dt, J=1.0 Hz, 1 H), 4.70 (d, J=15.3 Hz, 1 H), 4.32 (d, J=7.4 Hz, 2 H), 4.23 (d, J=15.7 Hz, 1 H), 4.06 (td, J=7.4, 2.7 Hz, 1 H), 2.40 - 2.59 (m, 1 H), 0.98 (d, J=7.0 Hz, 3 H).

Step 9: Preparation of (S)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one




15

To liquid ammonia at -50 °C under argon was slowly added a solution of (S)-3-benzyl-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (627 mg) (200 mg, 0.784 mmol) in diethylether (10 mL). Lithium (pellets; 54.4 mg, 7.84 mmol) were added in three portions. The reaction mixture became green then dark greenish blue over ~10 min. The mixture was stirred for additional 15 min and then quenched slowly by the addition of saturated aqueous ammonium chloride solution (3 mL). The mixture was allowed to warm slowly to room temperature. The residue was diluted with diethylether (20 mL) and water (10 mL). The separated aqueous layer was extract with ether (2x 25 mL) and DCM (3x 20 mL). The DCM and ether layers were separately concentrated under reduced pressure. The residues were dissolved in DCM and combined. The organic layer was dried over manesium sulfate, filtered off and concentrated under reduced pressure providing crude (S)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (114 mg) as a colorless solid, which was directly used without further purification. MS *m/z* 166.1 (M + H)⁺; Rt-0.37 min.

Intermediate 36: (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one

To a solution of (S)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (223 mg, 1.35 mmol) and 2,4-difluoropyrimidine (157 mg, 1.35 mmol) in DMF (4.09 mL) was added sodium hydride (60%wt.; 70.2 mg) in three portions at <0 °C (sodium chloride/ice). After the first portion of sodium hydride the mixture was stirred for ~5 min. The remaining two portions of sodium hydride were added over ~5 min and stirring was continued for 30 min. The mixture was diluted with ethylacetate (10 mL), stirred for 5 min and further slowly diluted with brine/water (1/1; 10 mL). The mixture was allowed to warm to 5 °C and poured into a mixture of brine/water (1/1; 20 mL) and ethylacetate (20 mL). The aqueous layer was separated and extracted with ethylacetate (25 mL). The combined organic layers were washed with brine (40 mL), dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by column chromatography [SiO₂, 12 g, EtOAc/heptane] to provide (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (207 mg) as a white solid.


MS *m/z* 262.1 (*M* + *H*)⁺; Rt-0.72 min. ¹H NMR (400 Mhz, CD₃OD) δ ppm 8.55 (dd, *J* = 2.3, 5.8 Hz, 1 H), 8.17 (dd, *J* = 3.8, 5.8 Hz, 1 H), 6.02 (q, *J* = 1.0 Hz, 1 H), 5.17 (td, *J* = 3.1, 8.3 Hz, 1 H), 4.62 - 4.52 (m, 2 H), 3.11 - 2.88 (m, 1 H), 1.05 (dd, *J* = 0.7, 7.2 Hz, 3 H).

Intermediate 37: (S)-3-(2-chloro-5-fluoropyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one

To a solution of (S)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (114 mg, 0.69 mmol) and 2,4-dichloro-5-fluoropyrimidine (115 mg, 0.690 mmol) in DMF (2.26 mL) was added sodium hydride (60%wt.; 35.9 mg) in three portions at <0 °C (sodium chloride/ice). After the first portion of sodium hydride the mixture was stirred for ~5 min. The remaining two portions of sodium hydride were added over ~5 min and stirring was continued for 30 min. The mixture


was diluted with ethylacetate (10 mL), stirred for 5 min and further slowly diluted with brine/water (1/1; 10 mL). The mixture was allowed to warm to 5 °C and poured into a mixture of brine/water (1/1; 10 mL) and ethylacetate (10 mL). The aqueous layer was separated and extracted with ethylacetate (25 mL). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by column chromatography [SiO₂, 12 g, EtOAc/heptane] to provide (S)-3-(2-chloro-5-fluoropyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (134 mg) as a white solid. MS *m/z* 296.1 (M + H)⁺; Rt-0.75 min. ¹H NMR (400 Mhz, CD₃OD) δ ppm 8.69 (d, J = 2.6 Hz, 1 H), 5.99 (q, J = 1.0 Hz, 1 H), 5.17 (ddd, J = 3.5, 7.4, 8.6 Hz, 1 H), 4.69 - 4.50 (m, 2 H), 2.88 - 2.70 (m, 1 H), 1.04 (d, J = 7.1 Hz, 3 H).

Intermediate 38: 2-(1-azidoethyl)-5-(4-chlorophenyl)-4-methyloxazole




Sodium azide (635 mg, 9.760 mmol) and a catalytic amount of 1,4,7,10,13,16-hexaoxacyclooctadecane was added to a solution of 2-(1-chloroethyl)-5-(4-chlorophenyl)-4-methyloxazole (250 mg, 0.976 mmol) in acetonitrile (10 ml) and refluxed at 80°C for 3 hours. The reaction was concentrated *in vacuo*. Flash column chromatography (silica, 40 g) eluting with 0-5% EtOAc/DCM provided the title compound (254 mg, clear oil). HRMS(C) *tR* = 1.52 min; MS *m/z* 262.0621

Intermediate 39: 1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethanamine




SiliaBond®Diphenylphosphine (1500 mg, 1.19 mmol/g) was added to a solution of 2-(1-azidoethyl)-5-(4-chlorophenyl)-4-methyloxazole (366 mg, 1.393 mmol) in anhydrous methanol (15 ml) and shaken for 3 hours. The reaction was filtered and concentrated *in vacuo*. Flash column chromatography (silica, 40 g) eluting with 2-10% MeOH/DCM afforded 160 mg (white solid). HRMS(B) *tR* = 1.73 min; MS *m/z* 236.0716

Intermediate 40: (2S)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-2-(1,3-dioxisoindolin-2-yl)propanamide




A solution of 2-amino-1-(4-chlorophenyl)ethanol (1000 mg, 5.83 mmol) and (S)-2-(1,3-dioxoisindolin-2-yl)propanoic acid (1280 mg, 5.83 mmol) in THF (20 ml) was added N,N'-methanediylidenedicyclohexylamine (1.1 eq, 1322 mg, 6.41 mmol) and allowed to stir at ambient temperature for 12 hours. Concentrate *in vacuo*, dilute w/ EtOAc, filter washing w/ EtOAc, wash w/ water, brine, concentrate *in vacuo*. Used crude directly in the next step. 2 g of white solid. HRMS(B) tR = 1.04 min; MS m/z 373.1

Intermediate 41: (S)-N-(2-(4-chlorophenyl)-2-oxoethyl)-2-(1,3-dioxoisindolin-2-yl)propanamide




1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (3.091 g, 7.29 mmol) was added to a solution of (2S)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-2-(1,3-dioxoisindolin-2-yl)propanamide (2.173 g, 5.83 mmol) in dichloromethane (20 ml) and allowed to stir for 2 hours. Dilute w/ dichloromethane (50 ml), wash w/ a sol'n of sat. sodium bicarbonate and 10% Na₂S₂O₃ solution, dry, concentrate *in vacuo*. 2.162 g (Used directly in the next step without further purification. HRMS(B) tR = 1.24 min; MS m/z 371.2

Intermediate 42: (S)-2-(1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)isoindoline-1,3-dione




Phosphoryl trichloride (1.07 ml, 10.8 mmol) was added to a solution of (S)-N-(2-(4-chlorophenyl)-2-oxoethyl)-2-(1,3-dioxoisindolin-2-yl)propanamide (2.162 g, 5.83 mmol) in toluene and heated at 110°C for 15 hours. Dilute with dichloromethane (50 ml), wash with saturated sodium bicarbonate solution, water, brine, dried and concentrated *in vacuo*. Flash column chromatography (silica, 80 g) eluting with 0-50% EtOAc/DCM afforded the pure product 430 mg (yellow foam). HRMS(B) tR = 1.42 min; MS m/z 353.1

Intermediate 43: (S)-2-(1-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)isoindoline-1,3-dione




To a stirred solution of (Z)-3-chloro-N'-hydroxybenzimidamide (500 mg, 2.93 mmol) and (S)-2-(1,3-dioxoisoindolin-2-yl)propanoic acid (642 mg, 2.93 mmol) was added N,N'-methanediylidenedicyclohexanamine (1.1 eq, 665 mg, 3.22 mmol) and allowed to reflux at 100°C for 12 hours. Concentrate *in vacuo*, dilute w/ EtOAc, filter washing w/ EtOAc, wash w/ water, brine, concentrate *in vacuo*. Flash column chromatography (silica, 40 g) eluting w/ 0-10% EtOAc/DCM afforded 300 mg. HRMS *m/z* 353.0567

10 **Intermediate 44:** (S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethanamine



Hydrazine (0.55 ml, 6.09 mmol) was added to a solution of (S)-2-(1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)isoindoline-1,3-dione (430 mg, 1.219 mmol) in ethanol (15 ml) and heated at 80°C for 13 hours. The reaction was concentrated in *vacuo*. Flash column chromatography (silica, 40 g) eluting with 2-10% MeOH/DCM afforded the desired product (200 mg, yellow oil). ¹H NMR (400 MHz, CDCl₃) δ 7.67 – 7.51 (m, 9H), 7.47 – 7.35 (m, 8H), 7.31 – 7.21 (m, 1H), 4.25 (q, *J* = 6.8 Hz, 4H), 1.97 – 1.66 (m, 15H), 1.63 – 1.48 (m, 2H). HRMS(B) *tR* = 1.49 min; MS *m/z* 222.0560

20 **Intermediate 45:** (Z)-3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzimidamide



To a solution of 3-chloro-4-(trifluoromethoxy)benzonitrile (1.0 g, 4.51 mmol) and hydroxylamine hydrochloride (1.5 eq, 0.47 g, 6.77 mmol) in ethanol (10 ml) was added N-ethyl-N-isopropylpropan-2-amine (1.6 eq, 1.26 ml, 7.22 mmol) and refluxed at 80°C for 12










hours under N₂. Allow to cool to rt. Dilute with EtOAc (25 ml), wash with water (25 ml), brine (25 ml), dry, concentrate *in vacuo* afforded (Z)-3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzimidamide (0.71 g, 62.1%, white solid). Used crude in the next step. HRMS(B) *m/z* 254.0070

5

The intermediates in **Table 2a** were prepared using a method similar to that described for the preparation of **Intermediate 45**

10

Table 2a.

Intermediate 46	Intermediate 47	Intermediate 48
		
Intermediate 49	Intermediate 50	Intermediate 51
		
Intermediate 52	Intermediate 53	Intermediate 54
		
Intermediate 55	Intermediate 56	Intermediate 57












		
Intermediate 58	Intermediate 59	Intermediate 60
		
Intermediate 61	Intermediate 62	Intermediate 63
		
Intermediate 64		
		

Table 2b. Chemical name and analytical data for each intermediate listed in **Table 2a**.


Intermediate: Name	Analytical data
46: (Z)-4-bromo-N'-hydroxy-3-methoxybenzimidamide	HRMS(B) tR = 1.24 min; MS m/z 243.9847.
47: (Z)-4-chloro-N'-hydroxy-3-methylbenzimidamide	HRMS(B) tR = 1.35 min; MS m/z 184.0403
48: (Z)-N'-hydroxy-1,2-dimethyl-1H-indole-4-carboximidamide	HRMS(B) tR = 1.13 min; MS m/z 203.1059

49: (Z)-N'-hydroxy-2-(trifluoromethoxy)benzimidamide	HRMS(B) tR = 1.20 min; MS m/z 220.0460
50: (Z)-2,2-difluoro-N'-hydroxybenzo[d][1,3]dioxole-5-carboximidamide	HRMS(B) tR = 1.33 min; MS m/z 216.0347
51: (Z)-N'-hydroxy-3-(2,2,2-trifluoroethoxy)benzimidamide	HRMS(B) tR = 1.46 min; MS m/z 234.061
52: (Z)-4-chloro-N'-hydroxy-3-(trifluoromethoxy)benzimidamide	HRMS(B) tR = 1.44 min; MS m/z 254.0070
53: (Z)-N'-hydroxyisoquinoline-8-carboximidamide	Anal. RP-HPLC tR = 0.93 min (Gradient: 1 to 30% B in 3.2 min to 98% in 1.95 min. - flow 1 mL/min. Eluent A: Water + 3.75 mM NH ₄ Ac + 0.001% formic acid. Eluent B: ACN. Column: Acquity CSH 1.7µm 2.1x50mm - 50°C.) MS m/z 187.0746
54: (Z)-4-chloro-N'-hydroxy-2-(trifluoromethyl)benzimidamide	HRMS(B) tR = 1.35 min; MS m/z 238.0121
55: (Z)-N'-hydroxy-3-(trifluoromethyl)benzimidamide	HRMS(B) tR = 1.36 min; MS m/z 204.0510
56: (Z)-N'-hydroxy-4-(trifluoromethoxy)benzimidamide	HRMS(B) tR = 1.69 min; MS m/z 220.0460
57: (Z)-4-fluoro-N'-hydroxy-3-(trifluoromethoxy)benzimidamide	HRMS(B) tR = 1.55 min; MS m/z 238.0365
58: (Z)-3-(difluoromethoxy)-N'-hydroxybenzimidamide	HRMS(B) tR = 1.05 min; MS m/z 202.0554
59: (Z)-4-chloro-N'-hydroxy-3-methoxybenzimidamide	HRMS(B) tR = 1.14 min; MS m/z 200.0352
60: (Z)-4-chloro-N'-hydroxy-3-(trifluoromethyl)benzimidamide	HRMS(B) tR = 1.19 min; MS m/z 239.3000 (M+H)
61: (Z)-3-(tert-butyl)-N'-hydroxybenzimidamide	HRMS(B) tR = 1.51 min ; MS m/z 193.1342 (M+H)
62: (Z)-N'-hydroxy-1-methyl-1H-indole-6-carboximidamide	HRMS(B) tR = 1.03 min; MS m/z 190.0883 (M+H)
63: (Z)-N'-hydroxy-2,3-dihydro-1H-indene-5-carboximidamide	HRMS(B) tR = 1.30 min; MS m/z 176.0950

64: 4-chloro-N'-hydroxybenzimidamide

MS m/z 171.0 (M + H)⁺; Rt-0.35 min.**Intermediate 65:** (S)-tert-butyl 1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylcarbamate
















A solution of 4-chloro-N'-hydroxybenzimidamide (1.24 g, 7.27 mmol), (S)-2-(tert-butoxycarbonylamino)propanoic acid (1.38 g, 7.27 mmol, 1.0 equiv), and DCC (1.65 g, 8.00 mmol, 1.1 equiv) in 1,4-dioxane (73 mL) was heated at 100 °C for 18 hours. The reaction was then cooled to room temperature and concentrated *in vacuo*. Silica gel column chromatography (EtOAc/Heptane, 0 to 35%) provided (S)-tert-butyl 1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylcarbamate (1.13 g, white solid) in 48% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8.8 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 5.18 (m, 1H), 1.64 (d, J = 6.8 Hz, 3H), 1.47 (s, 9H).

Intermediate 66 (S)-tert-butyl (1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate

To a stirred solution of (Z)-3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzimidamide (500 mg, 1.964 mmol) and (S)-2-((tert-butoxycarbonyl)amino)propanoic acid (372 mg, 1.964 mmol) was added N,N'-methanediylidenedicyclohexylamine (1.1 eq, 446 mg, 2.160 mmol) and allowed to reflux at 100°C for 12 hours. Concentrate *in vacuo*, dilute w/ EtOAc, filter washing w/ EtOAc, wash w/ water, brine, concentrate *in vacuo*. Flash column chromatography (silica, 80 g) eluting w/ 0-5% EtOAc/DCM afforded 230 mg. HRMS m/z 407.0860

The intermediates in **Table 3a** were prepared using a method similar to that described for the preparation of **Intermediate 66**

Table 3a.

Intermediate 67	Intermediate 68	Intermediate 69
		
Intermediate 70	Intermediate 71	Intermediate 72
		
Intermediate 73	Intermediate 74	Intermediate 75
		
Intermediate 76	Intermediate 77	Intermediate 78
		
Intermediate 79	Intermediate 80	Intermediate 81
		
Intermediate 82	Intermediate 83	Intermediate 84






		
Intermediate 85		
		

Table 3b. Chemical name and analytical data for each intermediate listed in Table 3a.

Intermediate: Name	Analytical data
67: (S)-tert-butyl (1-(3-(4-bromo-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.20 min; MS m/z 397.0637
68: (S)-tert-butyl (1-(3-(4-chloro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.42 min; MS m/z 337.1193
69: (S)-tert-butyl (1-(3-(1,2-dimethyl-1H-indol-4-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.12 min; MS m/z 356.1848
70: (S)-tert-butyl (1-(3-(2-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.12 min; MS m/z 373.1249
71: (S)-tert-butyl(1-(3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.41 min; MS m/z 369.1136
72: (S)-tert-butyl(1-(3-(3-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.33 min; MS m/z 387.1406
73: (S)-tert-butyl (1-(3-(isoquinolin-8-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 0.71 min; MS m/z 340.1535
74: (S)-tert-butyl(1-(3-(4-chloro-2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.35 min; MS m/z 392.1055
75: (S)-tert-butyl (1-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.41 min; MS m/z 357.1300
76: (S)-tert-butyl(1-(3-(4-fluoro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.42 min; MS m/z 392.1302
77: (S)-tert-butyl (1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-	HRMS(C) tR = 1.59 min;

5-yl)ethyl)carbamate	MS m/z 357.1300
78: (S)-tert-butyl (1-(3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.38 min; MS m/z 374.1378 (M+H)
79: (S)-tert-butyl (1-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.69 min; MS m/z 373.1249
80: (S)-tert-butyl (1-(3-(3-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.12 min; MS m/z 355.1344
81: (S)-tert-butyl (1-(3-(4-chloro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.14 min; MS m/z 353.1142
82: (S)-tert-butyl(1-(3-(4-chloro-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.52 min; MS m/z 391.0911
83: (S)-tert-butyl (1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.03 min; MS m/z 342.1692
84: (S)-tert-butyl (1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.62 min; MS m/z 345.2052
85: (S)-tert-butyl (1-(3-(2,3-dihydro-1H-inden-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate	HRMS(C) tR = 1.50 min; MS m/z 329.1740

Intermediate 86: (S)-tert-butyl (1-(5-bromopyridin-2-yl)ethyl)carbamate



- 5 To a solution of (S)-1-(5-bromopyridin-2-yl)ethanamine (300 mg, 1.49 mmol) in DCM (7.5 mL) was added di-tert-butyl dicarbonate (358 mg, 1.64 mmol) and triethylamine (0.31 mL, 2.24 mmol). The solution was stirred for 16 h at room temperature then washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/heptane 0 to 80%) provided a white solid (308 mg, 68.5% yield).
- 10 ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 2.2 Hz, 1H), 7.76 (dd, *J* = 8.3, 2.4 Hz, 1H), 7.16 (d, *J* = 8.3 Hz, 1H), 5.57 - 5.42 (m, 1H), 4.86 - 4.73 (m, 1H), 1.43 (t, *J* = 3.4 Hz, 12H); MS m/z 303.4 (M + H).

The intermediates in Table 4a were prepared using a method similar to that described for the preparation of Intermediate 86

15


Table 4a.

Intermediate 87	Intermediate 88	Intermediate 89
Intermediate 90	Intermediate 91	

Table 4b. Chemical name and analytical data for each intermediate listed in **Table 4a.**

Intermediate: Name	Analytical data
87: (S)-tert-butyl (1-(6-bromopyridin-3-yl)ethyl)carbamate	^1H NMR (400 MHz, CDCl_3) δ 8.33 (d, J = 2.6 Hz, 1H), 7.49 (dd, J = 8.2, 2.5 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 4.88 - 4.69 (m, 2H), 1.45 (d, J = 7.1 Hz, 3H), 1.41 (s, 9H); MS m/z 303.4 (M + H).
88: (S)-tert-butyl (1-(5-bromo-4-methylpyridin-2-yl)ethyl)carbamate	LCMS t_R = 1.31 min; MS m/z 317.0 (M+H)
89: (S)-tert-butyl (1-(5-bromo-6-methylpyridin-2-yl)ethyl)carbamate	LCMS t_R = 1.35 min; MS m/z 317.1 (M+H)
90: (S)-tert-butyl (1-(5-bromo-3-fluoropyridin-2-yl)ethyl)carbamate	LCMS t_R = 1.31 min; MS m/z 319.0 (M+H)
91: (S)-tert-butyl (1-(5-bromo-3-methylpyridin-2-yl)ethyl)carbamate	LCMS t_R = 1.37 min; MS m/z 317.0 (M+H)

Intermediate 92: (S)-tert-butyl (1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)carbamate



In a 5 mL microwave vial a solution of (S)-tert-butyl (1-(5-bromopyridin-2-yl)ethyl)carbamate (60 mg, 0.2 mmol), (4-fluoro-3-methylphenyl)boronic acid (37 mg, 0.24 mmol), Sodium bicarbonate (0.2 mL, 0.4 mmol, 2 M aqueous solution) in Dioxane (2 mL) was bubbled N₂ for 3 min then Cl₂Pd(dppf)CH₂Cl₂ (16 mg, 0.02 mmol) was added. The capped tube was heated to 100°C for 16 h. After cooling the reaction mixture was diluted with EtOAc (10 mL) and washed with water (10 mL). After separation, the aqueous phase was extracted with EtOAc (3 x 10 mL). Combined organics were dried over Na₂SO₄, filtered and concentrated. The crude material was purified through silica gel column chromatography (EtOAc in Heptane 12 to 100%) to give a white solid (66 mg, 80% yield). LCMS t_R = 1.43 min; MS m/z 331.1 (M+H).

The intermediates in Table 5a were prepared using a method similar to that described for the preparation of Intermediate 92

Table 5a.

Intermediate 93	Intermediate 94	Intermediate 95
Intermediate 96	Intermediate 97	Intermediate 98

Intermediate 99	Intermediate 100	Intermediate 101
Intermediate 102	Intermediate 103	Intermediate 104
Intermediate 105		

Table 5b. Chemical name and analytical data for each intermediate listed in **Table 5a**.


Intermediate: Name	Analytical data
93: (S)-tert-butyl (1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethyl)carbamate	LCMS tR = 1.69 min; MS m/z 365.5 (M - H).
94: (S)-tert-butyl (1-(6-(4-fluoro-3-methylphenyl)pyridin-3-yl)ethyl)carbamate	LCMS tR = 1.62 min; MS m/z 329.5 (M - H).
95: (S)-tert-butyl (1-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)ethyl)carbamate	LCMS tR = 1.68 min; MS m/z 365.4 (M - H).

96: (S)-tert-butyl (1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)carbamate	¹ H NMR (400 MHz, CDCl ₃) δ 8.83 (t, <i>J</i> = 3.9 Hz, 2H), 7.92 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 7.87 (d, <i>J</i> = 1.7 Hz, 1H), 7.73 - 7.66 (m, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 1H), 5.59 (d, <i>J</i> = 7.6 Hz, 1H), 4.93 (p, <i>J</i> = 6.9 Hz, 1H), 1.50 (d, <i>J</i> = 7.0 Hz, 3H), 1.45 (s, 9H); MS <i>m/z</i> 368.2 (M + H).
97: (S)-tert-butyl (1-(6'-(trifluoromethyl)-[2,3'-bipyridin]-5-yl)ethyl)carbamate	¹ H NMR (400 MHz, CDCl ₃) δ 9.27 (d, <i>J</i> = 2.1 Hz, 1H), 8.71 (s, 1H), 8.49 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.80 - 7.75 (m, 3H), 4.90 (br s, 1H), 1.52 (d, <i>J</i> = 6.3 Hz, 3H), 1.43 (s, 9H); MS <i>m/z</i> 368.2 (M + H).
98: (S)-tert-butyl (1-(6'-(trifluoromethyl)-[3,3'-bipyridin]-6-yl)ethyl)carbamate	¹ H NMR (400 MHz, CDCl ₃) δ 8.93 (d, <i>J</i> = 2.1 Hz, 1H), 8.79 (d, <i>J</i> = 2.3 Hz, 1H), 8.04 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 7.88 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.80 (d, <i>J</i> = 8.2 Hz, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 1H), 5.60 (d, <i>J</i> = 7.8 Hz, 1H), 4.93 (p, <i>J</i> = 6.9 Hz, 1H), 1.50 (d, <i>J</i> = 6.8 Hz, 3H), 1.44 (s, 9H); MS <i>m/z</i> 368.2 (M + H).
99: (S)-tert-butyl (1-(6-(trifluoromethyl)-[2,3'-bipyridin]-6'-yl)ethyl)carbamate	¹ H NMR (400 MHz, CDCl ₃) δ 9.15 (d, <i>J</i> = 2.3 Hz, 1H), 8.36 (dd, <i>J</i> = 7.8, 2.4 Hz, 1H), 8.01 - 7.89 (m, 2H), 7.66 (dd, <i>J</i> = 7.5, 1.1 Hz, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 1H), 5.69 (d, <i>J</i> = 7.9 Hz, 1H), 4.92 (p, <i>J</i> = 6.9 Hz, 1H), 1.49 (d, <i>J</i> = 6.8 Hz, 3H), 1.45 (s, 9H); MS <i>m/z</i> 368.2 (M + H).
100: (S)-tert-butyl (1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)carbamate	¹ H NMR (400 MHz, CDCl ₃) δ 8.83 (d, <i>J</i> = 4.9 Hz, 1H), 8.36 (s, 1H), 7.66 (s, 1H), 7.51 - 7.42 (m, 1H), 7.21 (s, 1H), 5.60 (d, <i>J</i> = 7.7 Hz, 1H), 4.87 (p, <i>J</i> = 6.9 Hz, 1H), 2.30 (s, 3H), 1.48 (d, <i>J</i> = 6.9 Hz, 3H), 1.45 (s, 9H); MS <i>m/z</i> 326.4 (M + H - 56).
101: (S)-tert-butyl (1-(2-methyl-2'-(trifluoromethyl)-	¹ H NMR (400 MHz, CDCl ₃) δ 8.81 (d, <i>J</i> =

[3,4'-bipyridin]-6-yl)ethyl)carbamate	5.0 Hz, 1H), 7.66 (s, 1H), 7.50 (d, $J = 7.9$ Hz, 1H), 7.47 (dd, $J = 4.9, 1.6$ Hz, 1H), 7.20 (d, $J = 7.8$ Hz, 1H), 5.75 (d, $J = 7.5$ Hz, 1H), 4.86 (p, $J = 6.9$ Hz, 1H), 2.51 (s, 3H), 1.48 (d, $J = 6.9$ Hz, 3H), 1.46 (s, 9H); MS m/z 326.4 ($M + H - 56$).
102: (S)-tert-butyl (1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)carbamate	^1H NMR (400 MHz, CDCl_3) δ 8.85 (d, $J = 5.1$ Hz, 1H), 8.66 (s, 1H), 7.87 – 7.84 (m, 1H), 7.70 – 7.67 (m, 1H), 7.65 (dd, $J = 9.8, 1.9$ Hz, 1H), 5.76 (d, $J = 7.7$ Hz, 1H), 5.31 – 5.23 (m, 1H), 1.47 (d, $J = 6.8$ Hz, 3H), 1.45 (s, 9H); MS m/z 386.1 ($M + H$).
103: (S)-tert-butyl (1-(5-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)carbamate	^1H NMR (400 MHz, CDCl_3) δ 8.81 (d, $J = 5.1$ Hz, 1H), 8.68 (d, $J = 2.2$ Hz, 1H), 7.88 - 7.85 (m, 1H), 7.71 (d, $J = 1.7$ Hz, 1H), 7.68 (dd, $J = 5.0, 1.7$ Hz, 1H), 5.99 (d, $J = 8.2$ Hz, 1H), 5.13 (p, $J = 6.7$ Hz, 1H), 2.48 (s, 3H), 1.45 (s, 9H), 1.42 (d, $J = 6.6$ Hz, 3H); MS m/z 382.2 ($M + H$).
104: 1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethanone	^1H NMR (400 MHz, CDCl_3) δ 9.30 (d, $J = 1.5$ Hz, 1H), 9.11 (d, $J = 1.5$ Hz, 1H), 8.39 (s, 1H), 8.29 (d, $J = 8.0$ Hz, 1H), 7.78 (s, 1H), 7.69 (t, $J = 7.8$ Hz, 1H), 2.76 (s, 3H.); MS m/z 266.9 ($M + H$).
105: 1-(5-(4-fluoro-3-methylphenyl)pyrazin-2-yl)ethanone	^1H NMR (400 MHz, CDCl_3) δ 9.24 (d, $J = 1.5$ Hz, 1H), 9.01 (d, $J = 1.5$ Hz, 1H), 7.97 (dd, $J = 7.3, 1.9$ Hz, 1H), 7.89 (ddd, $J = 7.6, 4.8, 2.3$ Hz, 1H), 7.17 (t, $J = 8.9$ Hz, 1H), 2.74 (s, 3H), 2.39 (d, $J = 2.0$ Hz, 3H); MS m/z 230.9 ($M + H$).


The following intermediates were prepared using a method similar to that described for the preparation of Intermediate 92

- 5 **Intermediate 106:** (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2'-(tert-butyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.67 min; MS m/z 519.3 (M + H).

Intermediate 107: (R)-4-(((R)-1-(tert-butoxy)ethyl)-3-(2-((((S)-1-(2'-(1,1,1-trifluoro-2-methylpropan-2-yl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



¹H NMR (400 MHz, CDCl₃) δ 8.83 (d, *J* = 2.2 Hz, 1H), 8.73 (d, *J* = 5.1 Hz, 1H), 8.23 (d, *J* = 5.6 Hz, 1H), 7.90 (dd, *J* = 8.1, 2.3 Hz, 1H), 7.68 (s, 1H), 7.50 (d, *J* = 5.8 Hz, 1H), 7.47 - 7.41 (m, 2H), 5.34 (p, *J* = 6.9 Hz, 1H), 4.81 - 4.72 (m, 1H), 4.64 (dd, *J* = 9.3, 2.9 Hz, 1H), 4.45 (p, *J* = 6.3 Hz, 1H), 4.36 (t, *J* = 9.0 Hz, 1H), 1.69 (s, 6H), 1.63 (d, *J* = 6.9 Hz, 3H), 1.26 (s, 9H), 1.04 (d, *J* = 6.4 Hz, 3H); MS m/z 573.3 (M + H).

Intermediate 108: (S)-4-(1-(tert-butoxycarbonylamino)ethyl)-2-fluorobenzoic acid



15

To a solution of (S)-4-(1-aminoethyl)-2-fluorobenzoic acid (5 g, 22.76 mmol) in water (66 mL) and THF (66 mL) was added di-tert-butyl dicarbonate (6.95 g, 31.9 mmol) and sodium carbonate (5.74 g, 68.3 mmol). The solution was stirred for 16 h at room temperature then THF was removed under reduced pressure. The aqueous solution was acidified with 1N HCl to pH 3-4 and extracted with EtOAc (3 x 60 mL). Combined organics were dried over Na₂SO₄,


20

filtered and concentrated to give a white solid (1.94 g, 30.1% yield). The crude product was used to next step without further purification.

^1H NMR (400 MHz, MeOD) δ 7.89 (t, J = 7.8 Hz, 1H), 7.20 (dd, J = 8.2, 1.7 Hz, 1H), 7.13 (dd, J = 12.0, 1.6 Hz, 1H), 4.70 (d, J = 7.1 Hz, 1H), 1.47 – 1.35 (m, 12H); MS m/z 282.0 ($M - H$).

5

Intermediate 109: (S)-tert-butyl 1-(3-fluoro-4-(methoxy(methyl)carbamoyl)phenyl)ethylcarbamate




A solution of (S)-4-(1-(tert-butoxycarbonylamino)ethyl)-2-fluorobenzoic acid (1.416 g, 5mmol),
 10 N,O-dimethylhydroxylamine hydrochloride (732 mg, 7.5 mmol), HATU (2.85 g, 7.5 mmol) and
 DIPEA (3.49 mL, 20 mmol) in DMF (25 mL) was stirred at room temperature for 16 h. The
 reaction mixture was diluted with EtOAc and washed with water. After separation, the aqueous
 phase was washed with EtOAc (2 x 75 mL). Combined organics were dried over Na₂SO₄,
 filtered and concentrated. Silica gel column chromatography (EtOAc/heptane 12 to 100%)
 15 provided (S)-tert-butyl 1-(3-fluoro-4-(methoxy(methyl)carbamoyl)phenyl)ethylcarbamate as a
 white solid (1.5 g, 92 % yield).

^1H NMR (400 MHz, CDCl₃) δ 7.40 (t, J = 7.4 Hz, 1H), 7.13 (dd, J = 7.8, 1.6 Hz, 1H), 7.04 (dd, J = 10.7, 1.6 Hz, 1H), 4.80 (br s, 1H), 3.56 (s, 3H), 3.34 (s, 3H), 1.50 – 1.29 (m, 12H); MS m/z 327.1 ($M + H$).

20

Intermediate 110: (S)-tert-butyl 1-(3-fluoro-4-formylphenyl)ethylcarbamate




To a cooled (0 °C) solution of (S)-tert-butyl 1-(3-fluoro-4-(methoxy(methyl)carbamoyl)phenyl)ethylcarbamate (1.175 g, 3.6 mmol) in THF (36 mL) was
 25 added a solution of LAH in THF (1.0 M, 18 mL, 18 mmol) and the resulting mixture was stirred
 at 0 °C for 20 min. The reaction mixture was quenched by addition of a saturated Na₂SO₄

solution until gas evolution ceased. The reaction mixture was extracted with EtOAc (2 x 100 mL). Combined organics were dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/heptane 12 to 100%) provided (S)-tert-butyl 1-(3-fluoro-4-formylphenyl)ethylcarbamate as a white solid (760 mg, 79% yield).

- 5 ¹H NMR (400 MHz, CDCl₃) δ 10.31 (s, 1H), 7.87 – 7.80 (m, 1H), 7.20 (dd, *J* = 8.2, 1.3 Hz, 1H), 7.11 (dd, *J* = 11.5, 1.4 Hz, 1H), 4.80 (br s, 1H), 1.45 (br s, 12H); MS *m/z* 212.1 (*M* - 56 + H).

Intermediate 111: (S)-tert-butyl 1-(3-fluoro-4-((3,3,4-trimethylpiperazin-1-yl)methyl)phenyl)ethylcarbamate




10

A solution of (S)-tert-butyl 1-(3-fluoro-4-formylphenyl)ethylcarbamate (267 mg, 1 mmol) and 1,2,2-trimethylpiperazine dihydrochloride (402 mg, 2 mmol) in THF (5 mL) was stirred at room temperature for 1 h and treated with sodium triacetoxyborohydride (848 mg, 4 mmol). The resulting mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with saturated aqueous solution of NaHCO₃ (15 mL) and extracted with EtOAc (3 x 25 mL). Combined organics were dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (MeOH/CH₂Cl₂ 0 to 10%) provided (S)-tert-butyl 1-(3-fluoro-4-((3,3,4-trimethylpiperazin-1-yl)methyl)phenyl)ethylcarbamate as a white solid (186 mg, 49% yield).

- 15 ¹H NMR (400 MHz, CDCl₃) δ 7.35 (t, *J* = 7.7 Hz, 1H), 7.03 (dd, *J* = 7.9, 1.9 Hz, 1H), 6.95 (dd, *J* = 11.1, 1.8 Hz, 1H), 4.77 (s, 1H), 3.49 (s, 2H), 2.56 (br s, 4H), 2.24 (br s, 5H), 1.42 (br s, 12H), 1.04 (s, 6H); MS *m/z* 380.4 (*M* + H).


Intermediate 112: (S)-tert-butyl 1-(4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorophenyl)ethylcarbamate



25

Following the procedure for intermediate 111: Title compound was prepared from (S)-tert-butyl 1-(3-fluoro-4-formylphenyl)ethylcarbamate and 4,4-difluoropiperidine hydrochloride as a white solid. LCMS tR = 1.63 min; MS m/z 371.5 (M - H).

5 **Intermediate 113:** 1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanone



A cloudy solution of 1-(5-bromopyrimidin-2-yl)ethanone (300 mg, 1.49 mmol), 3-(trifluoromethyl)phenylboronic acid (567 mg, 2.98 mmol), K_3PO_4 (950 mg, 4.48 mmol), DavePhos ligand [2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl] (59 mg, 0.15 mmol), and $Pd(OAc)_2$ (17 mg, 0.075 mmol) in 6 mL toluene was heated at 100°C for 1 h. The mixture was cooled to room temperature, and filtered through Celite. Filter cake was rinsed with 30 mL EtOAc. The filtrate was poured into 20 mL water. Layers were separated, and the aqueous was further extracted with EtOAc (20 mL). Combined organics were washed with water (20mL) and brine (20mL), dried over Na_2SO_4 , filtered and concentrated directly onto silica gel. Column chromatography (10 - 100% EtOAc/heptane) gave 0.26 g 1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanone as tan solid. MS m/z 267.1 (M + H)⁺. ^1H NMR (400 MHz, $CDCl_3$) δ 9.16 (s, 2H), 7.93 – 7.69 (m, 4H), 2.87 (s, 3H).

The intermediates in **Table 6a** were prepared using a method similar to that described for the preparation of **Intermediate 113**

Table 6a.

Intermediate 114	Intermediate 115	Intermediate 116
Intermediate 117	Intermediate 118	Intermediate 119


Intermediate 120	Intermediate 121	Intermediate 122
Intermediate 123	Intermediate 124	

Table 6b. Chemical name and analytical data for each intermediate listed in **Table 6a**, using Anal. RP-HPLC Column = Inertsil C8 Column, 3.0 μ m, 3.0 x 30 mm. Column Temperature =50°C. Eluents =A: Water (5 mM Ammonium formate, 2% ACN); B: ACN. Flow Rate =2 mL/min. Gradient =0 min 5% B; 5% to 95% B in 1.70 min; 0.3 min 95% B; 2.1 min 1%B.)

Intermediate: Name	Analytical data
114: 1-(5-(3,4-dichlorophenyl) pyrimidin-2-yl)ethanone.	Anal. RP-HPLC tR = 1.17 min. MS m/z 266.9 (M + H)+.
115: 1-(5-(4-fluoro-3-(trifluoromethyl)phenyl) pyrimidin-2-yl)ethanone.	Anal. RP-HPLC tR = 1.26 min. MS m/z 285.2 (M + H)+.
116: 1-(5-(4-chloro-3-(trifluoromethyl)phenyl) pyrimidin-2-yl)ethanone.	Anal. RP-HPLC tR = 1.33 min. MS m/z 301.3 (M + H)+.
117:: 1-(5-(5-fluoro-2-methylphenyl) pyrimidin-2-yl)ethanone	Anal. RP-HPLC tR = 1.16 min. MS m/z 231.2 (M + H)+.
118: 1-(5-(4-fluoro-3-methylphenyl) pyrimidin-	¹ H NMR (400 MHz, CDCl ₃) δ 9.09 (s, 2H),

2-yl)ethanone.	7.52 – 7.41 (m, 2H), 7.24 – 7.16 (m, 1H), 2.85 (s, 3H), 2.41 (d, J = 2.0 Hz, 3H). Anal. RP-HPLC tR = 1.20 min. MS m/z 231.0 (M + H)+.
119: 1-(5-(2,3-dichlorophenyl) pyrimidin-2-yl)ethanone	Anal. RP-HPLC tR = 1.15 min. MS m/z 267.9 (M + H)+.
120: 1-(5-(4-fluoro-3-methylphenyl) pyridin-2-yl)ethanone.	¹ H NMR (400 MHz, CDCl ₃) δ 8.88 (dd, J = 2.3, 0.8 Hz, 1H), 8.13 (dd, J = 8.1, 0.8 Hz, 1H), 7.98 (dd, J = 8.1, 2.3 Hz, 1H), 7.50 – 7.39 (m, 2H), 7.21 – 7.12 (m, 1H), 2.78 (s, 3H), 2.42 – 2.36 (m, 3H). Anal. RP-HPLC tR = 1.40 min. MS m/z 230.8 (M + H)+.
121: 1-(5-(2-fluoro-3-(trifluoromethyl)phenyl) pyrimidin-2-yl)ethanone.	Anal. RP-HPLC tR = 1.19 min. MS m/z 285.0 (M + H)+.
122: 1-(5-(4-chloro-3-methylphenyl) pyrimidin-2-yl)ethanone.	Anal. RP-HPLC tR = 1.30 min. MS m/z 247.2 (M + H)+.
123: 1-(5-(3-chloro-5-(trifluoromethyl)phenyl) pyrimidin-2-yl)ethanone.	Anal. RP-HPLC tR = 1.27 min. MS m/z 301.0 (M + H)+.
124: 1-(5-(4-(trifluoromethyl)phenyl) pyrimidin-2-yl)ethanone.	Anal. RP-HPLC tR = 1.22 min. MS m/z 266.8 (M + H)+.


Intermediate 125: (S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethanamine



2,2,2-Trifluoroacetic acid (4 mL, 52 mmol) was added to a solution of (S)-tert-butyl 1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylcarbamate (0.613 g, 1.89 mmol) in DCM (10 mL) at room temperature. The solution was stirred at room temperature for 1 hour and then concentrated in vacuo. The residue was dissolved in chloroform (100 mL) and washed with saturated aqueous sodium bicarbonate (100 mL). The layers were separated and the aqueous layer was extracted with chloroform (3 x 30 mL) and the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give (S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethanamine (500 mg, yellow oil). The material was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, J = 8.7 Hz, 2H), 7.47 (d, J =


8.6 Hz, 2H), 4.37 (q, J = 6.9 Hz, 1H), 1.62 (d, J = 6.9 Hz, 3H). MS m/z 224.0 (M + H)⁺; Rt-0.56 min.

Intermediate 126 (S)-1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine



(S)-tert-butyl (1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate (2.0 g, 4.90 mmol) was treated with 90% TFA/water for 2 hours. Concentrate *in vacuo* and neutralized by passing through a column of MP-carbonate resin (6.0 g, 0.55 mmol/g eluting with MeOH/DCM/MeOH afforded 1.4 g waxy off-white solid. HRMS m/z 307.0335

Intermediate 127 (S)-1-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethanamine



To a stirred solution of (S)-2-(1-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)isoindoline-1,3-dione (100 mg, 0.283 mmol) in ethanol (5 ml) was added methylhydrazine (16 μ L, 0.311 mmol). Stir for 13 hours at 80°C. Concentrate *in vacuo*. Flash column chromatography (silica, 40 g) eluting with dichloromethane afforded 50 mg of desired product. HRMS m/z 224.4 (M + H)

The intermediates in **Table 7a** were prepared using a method similar to that described for the preparation of **Intermediate 126** or **Intermediate 127**

Table 7a.

Intermediate 128	Intermediate 129	Intermediate 130
Intermediate 131	Intermediate 132	Intermediate 133




















		
Intermediate 134	Intermediate 135	Intermediate 136
		
Intermediate 137	Intermediate 138	Intermediate 139
		
Intermediate 140	Intermediate 141	Intermediate 142
		
Intermediate 143	Intermediate 144	Intermediate 145
		
Intermediate 146	Intermediate 147	Intermediate 148
		

Table 7b. Chemical name and analytical data for each intermediate listed in **Table 7a.**

Intermediate: Name	Analytical data
128: (S)-1-(3-(4-bromo-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.88 min; m/z 297.0113
129: (S)-1-(3-(4-chloro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.05 min; m/z 237.0669
130: (S)-1-(3-(1,2-dimethyl-1H-indol-4-yl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.38 min; m/z 256.1324
131: (S)-1-(3-(2-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.92 min; m/z 273.0725
132: (S)-1-(3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.04 min; m/z 269.0612
133: (S)-1-(3-(3-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.02 min; m/z 287.0882
134: (S)-1-(3-(isoquinolin-8-yl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 0.68 min; m/z 240.1011
135: (S)-1-(3-(4-chloro-2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.08 min; m/z 291.0386
136: (S)-1-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.02 min; m/z 257.0776
137: (S)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.01 min; m/z 257.0776
138: (S)-1-(3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.20 min; m/z 274.0 (M+H)
139: (S)-1-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.09 min; m/z 273.0725
140: (S)-1-(3-(4-fluoro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.16 min; m/z 291.0631
141: (S)-1-(3-(isoquinolin-8-yl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 0.71 min; m/z 240.1011
142: (S)-1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.67 min; m/z 242.1168
143: (S)-1-(3-(3-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.74 min; m/z 255.0819
144: (S)-1-(3-(4-chloro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.82 min;

yl)ethanamine	m/z 253.0618
145: (S)-1-(3-(4-chloro-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.26 min; m/z 291.0386
146: (S)-1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 1.67 min; m/z 242.1168
147: (S)-1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.33 min; m/z 246.1552
148: (S)-1-(3-(2,3-dihydro-1H-inden-5-yl)-1,2,4-oxadiazol-5-yl)ethanamine	HRMS(B) tR = 2.02 min; m/z 229.1215

Intermediate 149: 1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanamine.



1-(5-(3-(Trifluoromethyl)phenyl)pyrimidin-2-yl)ethanone (260 mg, 0.977 mmol), NH₄OAc (1.13 g, 14.6 mmol), and NaBH₃CN (245 mg, 3.91 mmol) were taken up in 8 mL 200 proof EtOH, and heated at 120°C for 5 minutes in a microwave apparatus. The mixture was concentrated to remove the EtOH. Crude was taken up in 30 mL water + 25 mL EtOAc. 6N NaOH was added until aqueous pH was ~10. Separated layers, and extracted aqueous with EtOAc (25 mL). The combined organic layer was washed with 25 mL brine and dried with Na₂SO₄. Filtered and concentrated with reduced pressure to give 262 mg crude yellow oil, which was carried forward without further purification. Anal. RP-HPLC tR = 0.90 min. (Column = Inertsil C8 Column, 3.0 μm, 3.0 x 30 mm. Column Temperature = 50°C. Eluents = A: Water (5 mM Ammonium formate, 2% ACN); B: ACN. Flow Rate = 2 mL/min. Gradient = 0 min 5% B; 5% to 95% B in 1.70 min; 0.3 min 95% B; 2.1 min 1%B.) MS m/z 268.1 (M + H)⁺.

The intermediates in **Table 8a** were prepared using a method similar to that described for the preparation of **Intermediate 149**

Table 8a.

Intermediate 150	Intermediate 151	Intermediate 152
------------------	------------------	------------------















		
Intermediate 153	Intermediate 154	Intermediate 155
		
Intermediate 156	Intermediate 157	Intermediate 158
		
Intermediate 159	Intermediate 160	Intermediate 161
		
Intermediate 162		
		

Table 8b. Chemical name and analytical data for each intermediate listed in **Table 8a**.

Intermediate: Name	Analytical data
150: 1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethanamine.	Anal. RP-HPLC tR = 1.09 min; MS m/z 268.4 (M + H)+.
151: 1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanamine.	Anal. RP-HPLC tR = 1.04 min. MS m/z 286.3 (M + H)+.
152: 1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanamine.	Anal. RP-HPLC tR = 1.06 min. MS m/z 302.3 (M + H)+.
153: 1-(5-(5-fluoro-2-methylphenyl)pyrimidin-2-yl)ethanamine	Anal. RP-HPLC tR = 0.79 min. MS m/z 232.0 (M + H)+.
154: 1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethanamine	Anal. RP-HPLC tR = 0.81 min. MS m/z 231.9 (M + H)+.
155: 1-(5-(2,3-dichlorophenyl)pyrimidin-2-yl)ethanamine	Anal. RP-HPLC tR = 1.01 min. MS m/z 269.0 (M + H)+.
156: 1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethanamine	Anal. RP-HPLC tR = 0.92 min. MS m/z 230.9 (M + H)+.
157: 1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanamine.	Anal. RP-HPLC tR = 0.96 min. MS m/z 286.0 (M + H)+.
158: 1-(5-(4-chloro-3-methylphenyl)pyrimidin-2-yl)ethanamine.	Anal. RP-HPLC tR = 0.97 min. MS m/z 247.9 (M + H)+.
159: 1-(5-(3-chloro-5-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanamine.	Anal. RP-HPLC tR = 1.06 min. MS m/z 301.9 (M + H)+.
160: 1-(5-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanamine.	Anal. RP-HPLC tR = 1.02 min. MS m/z 268.2 (M + H)+.
161 : 1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethanamine	LCMS tR = 1.04 min; MS m/z 267.9 (M + H)+.
162: 1-(5-(4-fluoro-3-methylphenyl)pyrazin-2-yl)ethanamine	LCMS tR = 0.91 min; MS m/z 231.9 (M + H)+.


Intermediate 163: 1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethanamine



Step 1: A solution of 1-(5-fluoropyrimidin-2-yl)ethanone (700 mg, 5.0 mmol) and 4-fluorophenol (616 mg, 5.50 mmol) in 6 mL DMF was treated with potassium carbonate (829 mg 6.0 mmol) and heated to 50°C for 3.5 h. The reaction mixture was poured into 20 mL water, and extracted with EtOAc (2 x 20 mL). Organics were washed with 20 mL each water, brine, and dried over Na₂SO₄. Mixture was filtered and concentrated on silica gel. Column chromatography (10 - 100% EtOAc/hept) gave 295 mg (25%) 1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethanone as a white solid used directly in the following step. MS m/z 233.2 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.55 (s, 2H), 7.23 – 7.07 (m, 4H), 2.78 (s, 3H).

Step 2: 1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethanone (290 mg, 1.25 mmol), NH₄OAc (1.9 g, 24.6 mmol), and NaBH₃CN (314 mg, 5.00 mmol) were taken up in 20 mL 200 proof EtOH, and heated at 130 C for 3 minutes in a microwave apparatus. The mixture was concentrated to remove the EtOH. Crude was taken up in 30 ml water + 25 mL EtOAc. 6N NaOH was added until aqueous pH was ~10. Separated layers, and extracted aqueous with EtOAc (25 ml). The combined organic layer was washed with 25 mL brine and dried with Na₂SO₄. Filtered and concentrated with reduced pressure to give 275 mg crude tan oil, which was carried forward without further purification. Major product Anal. RP-HPLC t_R = 1.26 min. (Column = Inertsil C8 Column, 3.0 μm, 3.0 x 30 mm. Column Temperature =50°C. Eluents =A: Water (5 mM Ammonium formate, 2% ACN); B: ACN. Flow Rate =2 mL/min. Gradient =0 min 5% B; 5% to 95% B in 1.70 min; 0.3 min 95% B; 2.1 min 1%B.) MS m/z 234.1 (M + H)+.

Intermediate 164: 1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethanamine



25 Step 1: In a well vented vial, 90% t-butyl nitrite (4.74 mL, 35.8 mmol) and CuCl (2.96 g, 29.9 mmol) were taken up in 30 mL ACN. Over 15 mins, 4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-amine (6.0 g, 19.9 mmol) was added in portions. Gas evolved. The mixture was stirred 30 min at r.t., then warmed to 65 C for another 30 min. The reaction mixture was filtered through Celite. 200 mL Water was added to the filtrate. This
30 was extracted with (2 x 150 mL) EtOAc. Organics were washed with 200 mL brine, and dried over Na₂SO₄. Filtered and concentrated on silica gel. Flash column chromatography (10-50%

EA/hept) gave 3.35 g (52%) 2-chloro-4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazole as a green oil. MS m/z 321.0 ($M + H$)⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.69 (dd, J = 5.1, 0.8 Hz, 1H), 7.52 (dq, J = 1.7, 0.8 Hz, 1H), 7.31 – 7.22 (m, 1H), 2.55 (s, 3H), 1.67 (s, 6H).

5

Step 2: To a solution of 2-chloro-4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazole (3.3 g, 10.3 mmol) and Pd(PPh₃)₂Cl₂ (0.72 g, 1.03 mmol) in 50 mL dioxane under nitrogen, tributyl(1-ethoxyvinyl)stannane (3.82 ml, 11.32 mmol) was added. The mixture was heated to 100 C for 16 h. The reaction was cooled to r.t. and diluted with 25 mL EtOAc. 2M KF

10

(15.4 ml) solution was added and stirred for 1 h. Copious precipitate formed. The reaction was filtered through Celite and chased with EtOAc. The organic layer was rinsed with 60 mL water, and concentrated to give grey solid. Crude solid was dissolved in THF (50 mL) and 1N HCl (20.58 mL) was added. The reaction was stirred at r.t. for 2 h. The mixture was neutralized by addition of 1 N NaOH. THF was removed in vacuo. Extracted aqueous with 2 x 50 mL EtOAc.

15

The organic layers were washed with 50 mL brine, and dried over Na₂SO₄. Filtered and concentrated on silica gel. Flash chromatography using 10-50% EtOAc in heptane gave 1.65 g (49%) 1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethanone as a yellow oil. MS m/z 329.0 ($M + H$)⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.72 (dd, J = 5.2, 0.9 Hz, 1H), 7.60 (dq, J = 1.8, 0.9 Hz, 1H), 7.34 (dd, J = 5.1, 1.6 Hz, 1H), 2.74 (s, 3H), 2.63 (s, 3H),

20

1.69 (s, 6H).


Step 3: 1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethanone ethanone (1.6 g, 4.87 mmol), NH₄OAc (5.6 g, 73.1 mmol), and NaBH₃CN (1.2 g, 19.5 mmol) were taken up in 40 mL 200 proof EtOH, and heated at 130 C for 10 minutes in a sealed tube.

25

The mixture was concentrated to remove the EtOH. Crude was taken up in 50 mL water + 50 mL EtOAc. 6N NaOH was added until aqueous pH was ~9. Separated layers, and extracted aqueous with EtOAc (50 mL). The combined organic layer was washed with 60 mL brine and dried with Na₂SO₄. Filtered and concentrated with reduced pressure to give 1.58 g crude tan oil. This material was taken up in 20 mL dioxane. 2.2 eq HCl (4N in dioxane) was added, and stirred 1 h. Yellow ppt was formed. The suspension was concentrated in vacuo to give 1.97 g 1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethanamine dihydrochloride salt as a yellow-green solid, which was carried forward without further purification. Major product Anal. RP-HPLC t_R = 1.23 min. MS m/z 330.1 ($M + H$)⁺.


30

35 **Intermediate 165:** 4-((S)-1-Amino-ethyl)-piperidine-1-carboxylic acid benzyl ester



Benzyl 4-((1S)-1-(1,1-dimethylethylsulfinamido)ethyl)piperidine-1-carboxylate (1.825 g, 4.98 mmole) was dissolved in dioxane (10 mL) and 4N HCl in dioxane (5 mL, 1.3 eq.) was added. The mixture was stirred for 3 hours at room temperature. The solvents were removed by rotary evaporation to give the title compound as a hydrochloride salt (1.3 g). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.46 (s, 2H), 7.44 – 7.27 (m, 5H), 5.11 (s, 2H), 4.26 (d, *J* = 13.57 Hz, 2H), 3.24 – 3.12 (m, 1H), 2.86 – 2.61 (m, 2H), 1.99 – 1.86 (m, 3H), 1.38 (d, *J* = 6.33 Hz, 3H), 1.34 – 1.23 (m, 2H). HRMS(C) *t*R = 1.87 min; MS *m/z* 263.1760 (M+H)⁺

10 **Intermediate 166:** (S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethanamine



To a solution of (S)-tert-butyl (1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)carbamate (66 mg, 0.47 mmol) in DCM (2 mL) was added TFA (2 mL, 26 mmol) slowly at -78 °C. The reaction was stirred at room temperature for 1 h then concentrated and diluted with DCM (10 mL). The solution was stirred with 3 eq. of MP-carbonate resin (3.28 mmol/g, Biotage) for 1 hr at room temperature. The resin was removed by filtration and washed (2 x 5 mL) with DCM. The filtrate was concentrated and the crude residue was used to next step without further purification. LCMS *t*R = 0.97 min; MS *m/z* 231.1 (M + H).

20 The intermediates in Table 9a were prepared using a method similar to that described for the preparation of Intermediate 166

Table 9a.

Intermediate 167	Intermediate 168	Intermediate 169
------------------	------------------	------------------















		
Intermediate 170	Intermediate 171	Intermediate 172
		
Intermediate 173	Intermediate 174	Intermediate 175
		
Intermediate 176	Intermediate 177	Intermediate 178
		
Intermediate 179		
		


Table 9b. Chemical name and analytical data for each intermediate listed in **Table 9a.**

Intermediate: Name	Analytical data
167: (S)-1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethanamine	LCMS tR = 1.12 min; MS m/z 267.7 (M + H).
168: (S)-1-(6-(4-fluoro-3-methylphenyl)pyridin-3-yl)ethanamine	LCMS tR = 1.05 min; MS m/z 231.4 (M + H).
169: (S)-1-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)ethanamine	LCMS tR = 1.14 min; MS m/z 267.4 (M + H).
170: (S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine	LCMS tR = 0.79 min; MS m/z 268.1 (M + H).
171: (S)-1-(6'-(trifluoromethyl)-[2,3'-bipyridin]-5-yl)ethanamine	LCMS tR = 0.81 min; MS m/z 268.1 (M + H).
172: (S)-1-(6'-(trifluoromethyl)-[3,3'-bipyridin]-6-yl)ethanamine	LCMS tR = 0.81 min; MS m/z 268.1 (M + H).
173: (S)-1-(6-(trifluoromethyl)-[2,3'-bipyridin]-6'-yl)ethanamine	LCMS tR = 0.89 min; MS m/z 268.1 (M + H).
174: (S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine	LCMS tR = 0.85 min; MS m/z 282.1 (M + H).
175: (S)-1-(2-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine	LCMS tR = 0.86 min; MS m/z 282.1 (M + H).
176: (S)-1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine	LCMS tR = 0.88 min; MS m/z 286.1 (M + H).
177: (S)-1-(5-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine	LCMS tR = 0.89 min; MS m/z 282.1 (M + H).
178: (S)-1-(3-fluoro-4-((3,3,4-trimethylpiperazin-1-yl)methyl)phenyl)ethanamine	LCMS tR = 0.29 min; MS m/z 280.2 (M + H).
179: (S)-1-(4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorophenyl)ethanamine	LCMS tR = 0.29 min; MS m/z 273.2 (M + H).

Intermediate 180: (S)-tert-butyl (1-hydrazinyl-1-oxopropan-2-yl)carbamate


A solution of (S)-methyl 2-((tert-butoxycarbonyl)amino)propanoate (1.00 g, 4.92 mmol) and hydrazine (0.23 mL, 1.5 equiv) in THF (8 mL) was heated in a sealed tube at 72 °C for 15 hours. Additional hydrazine (0.23 mL, 1.5 equiv) was added and heating was continued for another 21 hours. The reaction was then cooled to room temperature and concentrated in vacuo to give crude (S)-tert-butyl (1-hydrazinyl-1-oxopropan-2-yl)carbamate (1 g, white solid), which was used without purification. ¹H NMR (400 MHz, CDCl₃) δ 4.20 (m, 1H), 1.44 (s, 9H), 1.36 (d, J = 7.1 Hz, 3H).

Intermediate 181: (S)-tert-butyl (1-(2-(4-chlorobenzoyl)hydrazinyl)-1-oxopropan-2-yl)carbamate



4-Chlorobenzoyl chloride (0.63 mL, 4.92 mmol, 1.0 equiv) was added to a solution of (S)-tert-butyl (1-hydrazinyl-1-oxopropan-2-yl)carbamate (1.0 g, 4.92 mmol) in DCM (25 mL) at 0 °C. A white precipitate formed. The mixture was stirred at 0 °C for 1 hour and the reaction mixture was then concentrated in vacuo to give crude (S)-tert-butyl (1-(2-(4-chlorobenzoyl)hydrazinyl)-1-oxopropan-2-yl)carbamate (1.55 g), which was used without purification. ¹H NMR (400 MHz, CD₃OD) δ 7.85 (d, J = 8.7 Hz, 2H), 7.49 (d, J = 8.7 Hz, 2H), 4.21 (q, J = 7.0 Hz, 1H), 1.45 (s, 9H), 1.41 (d, J = 7.2 Hz, 3H). MS *m/z* 342.1 (M + H)⁺; Rt-0.69 min.


Intermediate 182: (S)-tert-butyl (1-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)ethyl)carbamate



A solution of (S)-tert-butyl (1-(2-(4-chlorobenzoyl)hydrazinyl)-1-oxopropan-2-yl)carbamate (1.0 g, 2.93 mmol) and 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide (1.18 g, 2.93 mmol, 1.0 equiv) in THF (29 mL) was heated at reflux for 2 hours. The reaction wash then cooled to room temperature and filtered through a pad of celite, using THF to wash through. The filtrate was concentrated in vacuo. Silica gel column chromatography (EtOAc/Heptane, 0 to 30%) provided (S)-tert-butyl (1-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)ethyl)carbamate

(0.600 g, light green solid) in 60% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 5.23 (m, 1H), 1.72 (d, J = 6.5 Hz, 3H), 1.48 (s, 9H). MS m/z 340.1 ($\text{M} + \text{H}$) $^+$; Rt-0.99 min.


5 **Intermediate 183:** (S)-1-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)ethanamine



A solution of hydrogen chloride (4.0 M in 1,4-dioxane, 4 mL, 16 mmol, 9 equiv) was added to a solution of (S)-tert-butyl (1-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)ethyl)carbamate (600 mg, 1.77 mmol) in 1,4-dioxane (5 mL) at room temperature. The solution was stirred for 3 hours, by which time a white precipitate had formed. The reaction was concentrated in vacuo to give the hydrochloride salt of (S)-1-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)ethanamine (480 mg, white solid) in 97% yield. The material was used without purification. ^1H NMR (400 MHz, CD_3OD) δ 8.00 (d, J = 8.7 Hz, 2H), 7.58 (d, J = 8.7 Hz, 2H), 5.10 (q, J = 6.9 Hz, 1H), 1.82 (d, J = 6.9 Hz, 3H). MS m/z 240.0 ($\text{M} + \text{H}$) $^+$; Rt-0.54 min.

15


Intermediate 184: (S)-tert-butyl but-3-yn-2-ylcarbamate



A solution of (S)-tert-butyl (1-oxopropan-2-yl)carbamate (500 mg, 2.89 mmol), dimethyl (1-diazo-2-oxopropyl)phosphonate (610 mg, 3.18 mmol, 1.1 equiv), and potassium carbonate (638 mg, 4.62 mmol, 1.6 equiv) in methanol (14.4 mL) was stirred at room temperature for 18 hours. The reaction was then diluted with ethyl acetate (30 mL) and saturated aqueous sodium chloride (40 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (30 mL) and the combined organic extracts were dried over Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (20% EtOAc in Heptane) provided (S)-tert-butyl but-3-yn-2-ylcarbamate (0.258 g, white solid) in 53% yield. ^1H NMR (400 MHz, CDCl_3) δ 4.49 (m, 1H), 2.26 (d, J = 2.2 Hz, 1H), 1.46 (s, 9H), 1.41 (d, J = 6.8 Hz, 3H).


25

Intermediate 185: (S)-tert-butyl (1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)carbamate




A solution of (S)-tert-butyl but-3-yn-2-ylcarbamate (250 mg, 1.48 mmol), 1-azido-4-chlorobenzene (227 mg, 1.48 mmol, 1.0 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.77 mL, 4.43 mmol, 3.0 equiv) in anhydrous acetonitrile (14.8 mL) was stirred at room temperature for 10 min. Copper(I) iodide (563 mg, 2.95 mmol, 2.0 equiv) was then added in portions. The mixture was stirred at room temperature for 30 min. The reaction was quenched with saturated aqueous ammonium chloride (50 mL) and diluted with water (50 mL). The mixture was extracted with ethyl acetate (3 x 30 mL) and the combined organic extracts were washed with water (30 mL), saturated aqueous sodium chloride (30 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc /Heptane) provided (S)-tert-butyl (1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)carbamate (0.428 g, white solid) in 90% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 8.8 Hz, 2H), 5.02 (m, 1H), 1.63 (d, J = 6.8 Hz, 3H), 1.46 (s, 9H). MS *m/z* 323.1 (M + H)⁺; Rt-0.92 min.

15 Intermediate 186: (S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethanamine



A solution of hydrogen chloride (4.0 M in 1,4-dioxane, 3.3 mL, 13.2 mmol, 10 equiv) was added to a solution of (S)-tert-butyl (1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)carbamate (425 mg, 1.32 mmol) in 1,4-dioxane (5 mL) at room temperature. The solution was stirred for 1 hour, by which time a white precipitate had formed. The reaction was concentrated in vacuo to give the hydrochloride salt of (S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethanamine (338 mg, white solid) in 99% yield. The material was used without purification. ¹H NMR (400 MHz, CD₃OD) δ 8.68 (s, 1H), 7.90 (d, J = 9.0 Hz, 2H), 7.63 (d, J = 9.0 Hz, 2H), 4.77 (q, J = 6.9 Hz, 1H), 1.78 (d, J = 6.9 Hz, 3H). MS *m/z* 223.1 (M + H)⁺; Rt-0.50 min.

Intermediate 187: 2-(6-methylpyridin-3-yl)thiazole-5-carbaldehyde

A mixture of 2-bromothiazole-5-carbaldehyde (400 mg, 2.08 mmol), (6-methylpyridin-3-yl)boronic acid (428 mg, 3.12 mmol, 1.5 equiv), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (170 mg, 0.21 mmol, 0.1 equiv) and 2.0 M aqueous sodium carbonate (5.2 mL, 10.4 mmol, 5 equiv) in 1,2-dimethoxyethane (6.9 mL) was heated in a microwave reactor at 110 °C for 20 minutes. The reaction was then diluted with ethyl acetate (50 mL) and water (50 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 25 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (30 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc) provided 2-(6-methylpyridin-3-yl)thiazole-5-carbaldehyde (0.176 g, brown solid) in 41% yield. ¹H NMR (400 MHz, CDCl₃) δ 10.08 (s, 1H), 9.15 (d, J = 2.0 Hz, 1H), 8.47 (s, 1H), 8.19 (dd, J = 8.1, 2.4 Hz, 1H), 7.31 (d, J = 8.3 Hz, 1H), 2.66 (s, 3H). MS *m/z* 205.0 (M + H)⁺; Rt-0.36 min.

The intermediates in **Table 10a** were prepared using a method similar to that described for the preparation of **Intermediate 187**

Table 10a.


Intermediate 188	Intermediate 189	Intermediate 190

Table 10b. Chemical name, NMR chemical shifts and LCMS signal for each intermediate listed in **Table 10a**.


Intermediate: Name	¹ H NMR (400 MHz, CDCl ₃) δ ppm	LCMS

188: 2-(6-methylpyridin-3-yl)thiazole-5-carbaldehyde	10.08 (s, 1H), 9.15 (d, J = 2.0 Hz, 1H), 8.47 (s, 1H), 8.19 (dd, J = 8.1, 2.4 Hz, 1H), 7.31 (d, J = 8.3 Hz, 1H), 2.66 (s, 3H).	MS <i>m/z</i> 205.0 (M + H) ⁺ ; Rt-0.36 min
189: 2-(6-(trifluoromethyl)pyridin-3-yl)thiazole-5-carbaldehyde	10.13 (s, 1H), 9.37 (d, J = 1.6 Hz, 1H), 8.55 (s, 1H), 8.50 (dd, J = 8.2, 2.0 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H)	MS <i>m/z</i> 259.0 (M + H) ⁺ ; Rt-0.74 min
190: 2-(2-(trifluoromethyl)pyridin-4-yl)thiazole-5-carbaldehyde	10.14 (s, 1H), 8.91 (d, J = 5.0 Hz, 1H), 8.57 (d, J = 0.6 Hz, 1H), 8.30 (s, 1H), 8.06 (d, J = 5.1 Hz, 1H)	MS <i>m/z</i> 259.0 (M + H) ⁺ ; Rt-0.76 min

Intermediate 191: 1-(4-chlorophenyl)-4-(1,3-dioxolan-2-yl)-1H-imidazole




A solution of ethane-1,2-diol (0.081 mL, 1.45 mmol, 1.5 equiv), 1-(4-chlorophenyl)-1H-imidazole-4-carbaldehyde (200 mg, 0.968 mmol), and camphorsulfonic acid (45 mg, 0.19 mmol, 0.2 equiv) in toluene (10 mL) was heated at reflux with a Dean-Stark apparatus for 1 hour. The reaction was cooled to room temperature and quenched with saturated aqueous sodium bicarbonate (30 mL). The mixture was extracted with ethyl acetate (30 mL) and the organic layer was dried (Na₂SO₄), filtered, and concentrated in vacuo. Silica gel column chromatography (EtOAc with 7% methanol) provided 1-(4-chlorophenyl)-4-(1,3-dioxolan-2-yl)-1H-imidazole (0.100 g, tan solid) in 41% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (s, 1H), 7.46 (d, J = 8.4 Hz, 2H), 7.36 (s, 1H), 7.33 (d, J = 8.4 Hz, 2H), 5.96 (s, 1H), 4.20 (m, 2H), 4.05 (m, 2H). MS *m/z* 251.0 (M + H)⁺; Rt-0.53 min.

Intermediate 192: 1-(4-chlorophenyl)-4-(1,3-dioxolan-2-yl)-2-methyl-1H-imidazole

A solution of n-butyllithium (1.6 M in hexane, 0.37 mL, 0.60 mmol, 1.5 equiv) was added to a solution of N,N-diisopropylamine (0.085 mL, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) at -78 °C.

- 5 The solution was stirred at -78 °C for 10 min and then a solution of 1-(4-chlorophenyl)-4-(1,3-dioxolan-2-yl)-1H-imidazole (100 mg, 0.40 mmol) in THF (1 mL) was added dropwise. The resulting solution was stirred at -78 °C for 30 min, and then iodomethane (0.042 mL, 0.68 mmol, 1.7 equiv) was added. The solution was allowed to warm to room temperature and then quenched with water (20 mL). The mixture was extracted with ethyl acetate (30 mL) and the
- 10 organic extract was washed with saturated aqueous sodium chloride (15 mL), dried (Na₂SO₄), filtered, and concentrated in vacuo to give crude 1-(4-chlorophenyl)-4-(1,3-dioxolan-2-yl)-2-methyl-1H-imidazole. The material was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.09 (s, 1H), 5.88 (s, 1H), 4.20 (m, 2H), 4.03 (m, 2H), 2.35 (s, 3H). MS *m/z* 265.0 (M + H)⁺; Rt-0.57 min.


15

Intermediate 193: 1-(4-chlorophenyl)-2-methyl-1H-imidazole-4-carbaldehyde

- A solution of 1-(4-chlorophenyl)-4-(1,3-dioxolan-2-yl)-2-methyl-1H-imidazole (1.05 g, 3.97 mmol) and camphorsulfonic acid (92 mg, 0.40 mmol, 0.1 equiv) in THF (26.5 mL) and water
- 20 (13.3 mL) was heated at 60 °C for 1 hour. The reaction was then cooled to room temperature and quenched with saturated aqueous sodium bicarbonate (100 mL). The mixture was extracted with ethyl acetate (100 mL) and the organic layer was washed with saturated aqueous sodium chloride (50 mL), dried (Na₂SO₄), filtered, and concentrated in vacuo. Silica gel column chromatography (EtOAc with 7% methanol) provided 1-(4-chlorophenyl)-2-methyl-
- 25 1H-imidazole-4-carbaldehyde (0.600 g, tan solid) in 69% yield. ¹H NMR (400 MHz, CDCl₃) δ

9.89 (s, 1H), 7.67 (s, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H), 2.40 (s, 3H). MS m/z 221.0 (M + H)⁺; Rt-0.47 min.


Intermediate 194: 1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazole-3-carbaldehyde



5

A mixture of 1H-pyrazole-3-carbaldehyde (0.700 g, 7.29 mmol), 5-bromo-2-(trifluoromethyl)pyridine (2.31 g, 10.2 mmol, 1.4 equiv), cesium carbonate (4.75 g, 14.6 mmol, 2.0 equiv), copper(I) iodide (0.069 g, 0.36 mmol, 0.05 equiv), and (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (0.23 mL, 1.46 mmol, 0.2 equiv) in DMF (9.5 mL) was heated in a sealed reaction vessel at 110 °C for 16 hours. The reaction was then cooled to room temperature and saturated aqueous ammonium chloride (100 mL) was added. The mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (50 mL), dried (Na₂SO₄), filtered, and concentrated in vacuo. Silica gel column chromatography (EtOAc/heptane) provided 1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazole-3-carbaldehyde (0.470 g, brown solid) in 27% yield. ¹H NMR (400 MHz, CDCl₃) δ 10.13 (s, 1H), 9.18 (d, J = 2.1 Hz, 1H), 8.34 (dd, J = 8.7, 2.0 Hz, 1H), 8.12 (m, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 1.8 Hz, 1H). MS m/z 241.9 (M + H)⁺; Rt-0.78 min.

20 **Intermediate 195:** (R,E)-N-((5-(4-chlorophenyl)isoxazol-3-yl)methylene)-2-methylpropane-2-sulfonamide






















A suspension of 5-(4-chlorophenyl)isoxazole-3-carbaldehyde (2.00 g, 9.63 mmol), (R)-2-methylpropane-2-sulfonamide (1.28 g, 10.6 mmol, 1.1 equiv) and anhydrous copper(II) sulfate

(2.31 g, 14.5 mmol, 1.5 equiv) in 1,2-dichloroethane (19 mL) was heated at 55 °C for 2 – 18 hours. The reaction was then cooled to room temperature and filtered through a pad of celite, using 1,2-dichloroethane to wash through. The filtrate was concentrated in vacuo to give crude (R,E)-N-((5-(4-chlorophenyl)isoxazol-3-yl)methylene)-2-methylpropane-2-sulfonamide as a
 5 green solid, which was used without further purification. MS m/z 311.0 (M + H)⁺; Rt-1.11 min.

The intermediates in **Table 11a** were prepared using a method similar to that described for the preparation of **Intermediate 195**

10 **Table 11a.**

Intermediate 196	Intermediate 197	Intermediate 198
		
Intermediate 199	Intermediate 200	Intermediate 201
		
Intermediate 202	Intermediate 203	Intermediate 204
		


Intermediate 205	Intermediate 206	Intermediate 207
		
Intermediate 208	Intermediate 209	Intermediate 210
		
Intermediate 211	Intermediate 212	Intermediate 213
		
Intermediate 214		
		

5 **Table 11b.** Chemical name and analytical data for each intermediate listed in **Table 11a.**

Intermediate: Name	Analytical data
196: (R,E)-N-((5-(4-chlorophenyl)isoxazol-3-yl)methylene)-2-methylpropane-2-sulfinamide	MS <i>m/z</i> 311.0 (M + H) ⁺ ; Rt-1.11 min
197: (R,E)-N-((2-(4-chlorophenyl)thiazol-5-yl)methylene)-2-methylpropane-2-sulfinamide	MS <i>m/z</i> 327.1 (M + H) ⁺ ; Rt-1.13 min
198: (R,E)-2-methyl-N-((5-phenylthiophen-2-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 292.0 (M + H) ⁺ ; Rt-1.05 min
199: (R,E)-2-methyl-N-((5-phenylisoxazol-3-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 277.1 (M + H) ⁺ ; Rt-1.02 min
200: (R,E)-N-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methylene)-2-methylpropane-2-sulfinamide	MS <i>m/z</i> 310.1 (M + H) ⁺ ; Rt-1.00 min
201: (R,E)-N-((5-(4-fluorophenyl)isoxazol-3-yl)methylene)-2-methylpropane-2-sulfinamide	MS <i>m/z</i> 295.1 (M + H) ⁺ ; Rt-1.00 min
202: (R,E)-N-((1-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-methylpropane-2-sulfinamide	MS <i>m/z</i> 294.1 (M + H) ⁺ ; Rt-0.90 min
203: (R,E)-2-methyl-N-((5-(pyridin-2-yl)thiophen-2-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 293.1 (M + H) ⁺ ; Rt-0.85 min
204: (R,E)-2-methyl-N-((5-(morpholinomethyl)isoxazol-3-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 300.1 (M + H) ⁺ ; Rt-0.43 min
205: (R,E)-2-methyl-N-((2-morpholinothiazol-5-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 302.1 (M + H) ⁺ ; Rt-0.69 min
206: (R,E)-2-methyl-N-((2-(pyridin-2-yl)thiazol-5-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 294.2 (M + H) ⁺ ; Rt-0.92 min
207: (R,E)-2-methyl-N-((2-(pyridin-3-yl)thiazol-5-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 294.1 (M + H) ⁺ ; Rt-0.63 min
208: (R,E)-2-methyl-N-((2-(pyridin-4-yl)thiazol-5-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 294.1 (M + H) ⁺ ; Rt-0.55 min
209: (R,E)-N-((2-(4-(difluoromethyl)phenyl)thiazol-5-yl)methylene)-2-methylpropane-2-sulfinamide	MS <i>m/z</i> 342.9 (M + H) ⁺ ; Rt-0.86 min
210: (R,E)-2-methyl-N-((2-(6-methylpyridin-3-	MS <i>m/z</i> 308.1 (M + H) ⁺ ; Rt-0.58 min

yl)thiazol-5-yl)methylene)propane-2-sulfinamide	
211: (R,E)-2-methyl-N-((2-(6-(trifluoromethyl)pyridin-3-yl)thiazol-5-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 362.1 (M + H) ⁺ ; Rt-0.96 min
212: (R,E)-2-methyl-N-((2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 362.1 (M + H) ⁺ ; Rt-0.97 min
213: (R,E)-2-methyl-N-((1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)methylene)propane-2-sulfinamide	MS <i>m/z</i> 345.0 (M + H) ⁺ ; Rt-0.95 min
214: (R,E)-N-((1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfinamide	MS <i>m/z</i> 324.0 (M + H) ⁺ ; Rt-0.62 min










Intermediate 215: (R)-N-((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)-2-methylpropane-2-sulfinamide



- 5 A solution of methylmagnesium bromide (3.0 M in diethyl ether, 12.8 mL, 38.4 mmol, 4 equiv) was added to a solution of (R,E)-N-((5-(4-chlorophenyl)isoxazol-3-yl)methylene)-2-methylpropane-2-sulfinamide (2.98 g, 9.6 mmol) in DCM (96 mL) at 0 °C. The solution became orange, then faded to yellow. The reaction was stirred at 0 °C for 30 min and then carefully quenched with saturated aqueous ammonium chloride (100 mL). The layers were separated
- 10 and the aqueous layer was extracted with DCM (40 mL). The combined organic layers were washed with water (50 mL), saturated aqueous sodium chloride (50 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) provided (R)-N-((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)-2-methylpropane-2-sulfinamide (1.0 g, white solid) in 32% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 6.50 (s, 1H), 4.75 (m, 1H), 3.47 (m, 1H), 1.70 (d, J = 6.8 Hz, 3H), 1.25 (s, 9H). MS *m/z* 327.0
- 15 (M + H)⁺; Rt-0.94 min.

The intermediates in **Table 12a** were prepared using a method similar to that described for the preparation of **Intermediate 215**.

Table 12a.

Intermediate 216	Intermediate 217	Intermediate 218
		
Intermediate 219	Intermediate 220	Intermediate 221
		
Intermediate 222	Intermediate 223	Intermediate 224
		
Intermediate 225	Intermediate 226	Intermediate 227












		
Intermediate 228	Intermediate 229	Intermediate 230
		
Intermediate 231	Intermediate 232	Intermediate 233
		
Intermediate 234	Intermediate 235	
		


Table 12b. Chemical name, NMR chemical shifts and LCMS signal for each intermediate listed in **Table 12a**.

Intermediate: Name	¹ H NMR (400 MHz, CDCl ₃) δ ppm	LCMS
216: (R)-N-((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)-2-methylpropane-2-sulfinamide	7.71 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 6.50 (s, 1H), 4.75 (m, 1H), 3.47 (m, 1H), 1.70 (d, J = 6.8 Hz, 3H), 1.25 (s, 9H).	MS m/z 327.0 (M + H) ⁺ ; Rt-0.94 min
217: (R)-N-((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)-2-methylpropane-2-sulfinamide	CD ₃ OD: 7.88 (d, J = 8.7 Hz, 2H), 7.73 (d, J = 1.0 Hz, 1H), 7.47 (d, J = 8.7 Hz, 2H), 4.83 (m, 1H), 1.71 (d, J = 6.7 Hz, 3H), 1.25 (s, 9H)	MS m/z 343.1 (M + H) ⁺ ; Rt-0.97 min
218: (R)-2-methyl-N-((S)-1-(5-phenylthiophen-2-yl)ethyl)propane-2-sulfinamide	7.58 (d, J = 7.4 Hz, 2H), 7.37 (m, 2H), 7.27 (m, 1H), 7.16 (d, J = 3.7 Hz, 1H), 6.95 (d, J = 3.7 Hz, 1H), 4.84 (m, 1H), 3.42 (m, 1H), 1.70 (d, J = 6.6 Hz, 3H), 1.26 (s, 9H)	MS m/z 308.1 (M + H) ⁺ ; Rt-0.95 min
219: (R)-2-methyl-N-((S)-1-(5-phenylisoxazol-3-yl)ethyl)propane-2-sulfinamide		MS m/z 293.2 (M + H) ⁺ ; Rt-0.85 min
220: (R)-N-((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)-2-methylpropane-2-sulfinamide	7.84 (s, 1H), 7.63 (s, 1H), 7.61 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 4.64 (m, 1H), 3.31 (m, 1H), 1.62 (d, J = 6.7 Hz, 3H), 1.24 (s, 9H)	MS m/z 326.1 (M + H) ⁺ ; Rt-0.89 min
221: (R)-N-((S)-1-(5-(4-fluorophenyl)isoxazol-3-yl)ethyl)-2-methylpropane-2-sulfinamide	7.77 (dd, J = 8.9, 5.2 Hz, 2H), 7.16 (t, J = 8.7 Hz, 2H), 6.46 (s, 1H), 4.77 (m, 1H), 3.47 (d, J = 5.7 Hz, 1H), 1.70 (d, J = 6.8 Hz, 3H), 1.25 (s, 9H)	MS m/z 311.1 (M + H) ⁺ ; Rt-0.85 min
222: (R)-N-((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)-2-methylpropane-2-	7.80 (s, 1H), 7.63 (m, 3H), 7.14 (t, J = 8.5 Hz, 2H), 4.63 (m, 1H),	MS m/z 310.1 (M +

sulfinamide	3.31 (d, J = 5.0 Hz, 1H), 1.62 (d, J = 6.7 Hz, 3H), 1.24 (s, 9H)	H) ⁺ ; Rt-0.79 min
223: (R)-2-methyl-N-((S)-1-(5-(pyridin-2-yl)thiophen-2-yl)ethyl)propane-2-sulfinamide	8.53 - 8.59 (m, 1 H), 7.60 - 7.73 (m, 2 H), 7.43 (d, J=3.7 Hz, 1 H), 7.15 (ddd, J=7.1, 5.0, 1.2 Hz, 1 H), 6.99 (d, J=3.8 Hz, 1 H), 4.84 (quin, J=6.3 Hz, 1 H), 3.43 (d, J=5.5 Hz, 1 H), 1.70 (d, J=6.6 Hz, 3 H), 1.26 (s, 9 H)	MS m/z 309.1 (M + H) ⁺ ; Rt-0.58 min
224: (R)-2-methyl-N-((S)-1-(5-(morpholinomethyl)isoxazol-3-yl)ethyl)propane-2-sulfinamide		MS m/z 316.1 (M + H) ⁺ ; Rt-0.38 min
225: (R)-2-methyl-N-((S)-1-(2-morpholinothiazol-5-yl)ethyl)propane-2-sulfinamide	7.06 (s, 1H), 4.69 (quin, J = 6.1 Hz, 1H), 3.81 (m, 4H), 3.44 (m, 4H), 3.32 (d, J = 4.9 Hz, 1H), 1.60 (d, J = 6.6 Hz, 3H), 1.22 (s, 9H)	
226: (R)-2-methyl-N-((S)-1-(2-(pyridin-2-yl)thiazol-5-yl)ethyl)propane-2-sulfinamide	8.60 (m, 1H), 8.15 (m, 1H), 7.80 (m, 2H), 7.33 (m, 1H), 4.93 (m, 1H), 1.71 (d, J = 6.6 Hz, 3H), 1.25 (s, 9H)	MS m/z 310.0 (M + H) ⁺ ; Rt-0.69 min
227: (R)-2-methyl-N-((S)-1-(2-(pyridin-3-yl)thiazol-5-yl)ethyl)propane-2-sulfinamide	9.11 (m, 1H), 8.65 (m, 1H), 8.23 (m, 1H), 7.75 (m, 1H), 7.38 (m, 1H), 4.90 (m, 1H), 3.50 (m, 1H), 1.71 (d, J = 6.6 Hz, 3H), 1.24 (s, 9H)	MS m/z 310.0 (M + H) ⁺ ; Rt-0.50 min
228: (R)-2-methyl-N-((S)-1-(2-(pyridin-4-yl)thiazol-5-yl)ethyl)propane-2-sulfinamide	8.70 (m, 2H), 7.79 (m, 3H), 4.94 (m, 1H), 1.72 (d, J = 6.6 Hz, 3H)	MS m/z 310.2 (M + H) ⁺ ; Rt-0.46 min
229: (R)-N-((S)-1-(2-(4-(difluoromethyl)phenyl)thiazol-5-yl)ethyl)-2-methylpropane-2-sulfinamide	8.01 (d, J = 8.0 Hz, 2H), 7.74 (s, 1H), 7.59 (d, J = 8.0 Hz, 2H), 6.69 (t, J = 56 Hz, 1H), 4.91 (m, 1H), 3.45 (d, J = 4.7 Hz, 1H),	MS m/z 359.1 (M + H) ⁺ ; Rt-0.89 min

	1.72 (d, J = 6.6 Hz, 3H), 1.25 (s, 9H)	
230: (R)-2-methyl-N-((S)-1-(2-(6-methylpyridin-3-yl)thiazol-5-yl)ethyl)propane-2-sulfinamide	9.01 (d, J = 2.2 Hz, 1H), 8.10 (dd, J = 8.1, 2.3 Hz, 1H), 7.73 (s, 1H), 7.24 (d, J = 8.2 Hz, 1H), 4.91 (m, 1H), 3.46 (d, J = 4.8 Hz, 1H), 2.62 (s, 3H), 1.72 (d, J = 6.6 Hz, 3H), 1.25 (s, 9H)	MS m/z 324.1 (M + H) ⁺ ; Rt-0.49 min
231: (R)-2-methyl-N-((S)-1-(2-(6-(trifluoromethyl)pyridin-3-yl)thiazol-5-yl)ethyl)propane-2-sulfinamide	9.23 (s, 1H), 8.40 (d, J = 8.3 Hz, 1H), 7.82 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 4.95 (m, 1H), 3.49 (d, J = 4.1 Hz, 1H), 1.74 (d, J = 6.6 Hz, 3H), 1.26 (s, 9H)	MS m/z 378.1 (M + H) ⁺ ; Rt-0.84 min
232: (R)-2-methyl-N-((S)-1-(2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)ethyl)propane-2-sulfinamide	8.82 (d, J = 5.0 Hz, 1H), 8.19 (s, 1H), 7.97 (dd, J = 5.0, 1.6 Hz, 1H), 7.85 (s, 1H), 4.95 (m, 1H), 3.49 (d, J = 4.5 Hz, 1H), 1.74 (d, J = 6.6 Hz, 3H), 1.26 (s, 9H)	MS m/z 378.1 (M + H) ⁺ ; Rt-0.85 min
233: (R)-2-methyl-N-((R)-1-(5-(morpholinomethyl)isoxazol-3-yl)ethyl)propane-2-sulfinamide		MS m/z 316.2 (M + H) ⁺ ; Rt-0.43 min
234: (R)-2-methyl-N-((S)-1-(1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)ethyl)propane-2-sulfinamide	9.06 (d, J = 2.3 Hz, 1H), 8.22 (dd, J = 8.6, 1.9 Hz, 1H), 7.98 (dd, J = 2.6, 0.9 Hz, 1H), 7.78 (d, J = 8.6 Hz, 1H), 6.51 (dd, J = 2.5, 0.9 Hz, 1H), 4.76 (m, 1H), 3.48 (d, J = 4.1 Hz, 1H), 1.68 (d, J = 6.8 Hz, 3H), 1.24 (s, 9H)	MS m/z 361.1 (M + H) ⁺ ; Rt-0.85 min
235: (R)-N-((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)-2-methylpropane-2-sulfinamide	7.45 (d, J = 8.6 Hz, 2H), 7.24 (d, J = 8.6 Hz, 2H), 6.87 (s, 1H), 4.54 (m, 1H), 3.48 (d, J = 5.8 Hz, 1H), 2.33 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H), 1.22 (s, 9H)	MS m/z 340.1 (M + H) ⁺ ; Rt-0.64 min

Intermediate 236: (R)-N-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide



Step 1

- 5 To an oven dried round bottom flask with stir bar was added 4-bromo-2-fluorobenzaldehyde (5 g, 24.6 mmol), (R)-2-methylpropane-2-sulfinamide (3.28 g, 27.1 mmol) and DCE (49 mL). To this mixture was then added copper (II) sulfate (5.90 g, 36.9 mmol). Reaction mixture was heated in a preheated oil bath to 55 °C for 18 hours. Reaction mixture was filtered through a pad celite, washing the solids with CH₂Cl₂. The filtrate was concentrated to afford a viscous
- 10 yellow oil of (R,E)-N-(4-bromo-2-fluorobenzylidene)-2-methylpropane-2-sulfinamide (7.73 g, 25.2 mmol, 103 % yield). ¹H NMR (400 MHz, CDCl₃) δ 1.27 (s, 9 H) 7.31 - 7.42 (m, 2 H) 7.87 (t, *J*=7.87 Hz, 1 H) 8.83 (s, 1 H). LCMS *m/z* 307.9 (M + H)⁺, Rt 1.01 min.

Step 2

- 15 To a solution of (R,E)-N-(4-bromo-2-fluorobenzylidene)-2-methylpropane-2-sulfinamide (7.73 g, 25.2 mmol) in CH₂Cl₂ (252 mL), cooled to 0°C (water/ice bath) under nitrogen, was added 3M methyl magnesium bromide (33.7 mL, 101 mmol) in Et₂O. Reaction mixture allowed to stir for 30 min at 0°C, then gradually allowed to warm to room temperature and stirred for 1 hour at room temperature. Reaction mixture was cooled to 0°C then quenched with the slow addition
- 20 of a saturated solution of NH₄Cl. Aqueous mixture extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 40 to 100%) provided (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (4.93 g, 15.3 mmol, 60% yield) as a white crystalline solid. ¹H NMR (400 MHz, CDCl₃) δ 1.20 (s, 9 H) 1.56 (d, *J*=6.70 Hz, 3 H)
- 25 3.34 (br. s., 1 H) 4.77 - 4.87 (m, 1 H) 7.19 - 7.31 (m, 3 H). LCMS *m/z* 324.0 (M + H)⁺, Rt 0.90 min.

Step 3


- To a microwave vial with stir bar was added (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-
- 30 methylpropane-2- (1 g, 3.10 mmol), isopropenyl boronic acid pinacol ester (1.51 mL, 8.07 mmol), DME (8 mL), sodium carbonate (7.76 mL, 15.5 mmol) (2.0 M aq) and PdCl₂(dppf).

CH₂Cl₂ adduct (0.127 g, 0.155 mmol). Vessel was capped and heated by microwave irradiation for 20 min at 100 °C. Reaction mixture was diluted with a saturated solution of NH₄Cl. The aqueous mixture was extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 50 to 100%) provided (R)-N-((S)-1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (830 mg, 2.93 mmol, 94 % yield) as a pale brown crystalline. ¹H NMR (400 MHz, DMSO) δ 1.08 - 1.11 (m, 9 H) 1.47 (d, J=6.80 Hz, 3 H) 2.09 (d, J=0.54 Hz, 3 H) 4.61 - 4.71 (m, 1 H) 5.14 (t, J=1.32 Hz, 1 H) 5.43 (d, J=5.58 Hz, 1 H) 5.49 (s, 1 H) 7.24 - 7.30 (m, 1 H) 7.31 - 7.36 (m, 1 H) 7.41 - 7.47 (m, 1 H). LCMS *m/z* 284.0 (M + H)⁺, Rt 0.93 min.

Step 4

To a round bottom flask containing (R)-N-((S)-1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethyl)-2-methylpropane-2- (0.37 g, 1.31 mmol) in DCE (13 mL) at 0 °C was added under argon diethylzinc (1.0M in hexanes) (13.1 mL, 13.1 mmol) followed by the dropwise addition of chloriodomethane (0.95 mL, 13.1 mmol). Reaction mixture allowed to warm to room temperature and stirred for 1 hour. Reaction mixture was cooled to 0 °C whereupon a second addition of diethylzinc (1.0M in hexanes) (13.1 mL, 13.1 mmol) took place followed by the addition of chloriodomethane (0.95 mL, 13.1 mmol). Reaction mixture allowed to warm to room temperature and stirred 18 hours under argon. Reaction mixture was cooled to 0 °C in a ice bath and to the cold reaction mixture was slowly added a saturated solution of NH₄Cl. The aqueous mixture was extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 20 to 100%) provided a white crystalline of (R)-N-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (89 mg, 0.299 mmol, 22.92 % yield). ¹H NMR (400 MHz, CDCl₃) δ 0.75 - 0.79 (m, 2 H) 0.85 - 0.90 (m, 2 H) 1.20 (s, 9 H) 1.55 (s, 3 H) 1.57 (d, J=6.80 Hz, 1 H) 3.34 (d, J=5.23 Hz, 1 H) 4.75 - 4.85 (m, 1 H) 6.90 (dd, J=12.30, 1.74 Hz, 1 H) 6.97 (dd, J=8.05, 1.78 Hz, 1 H) 7.22 (t, J=7.97 Hz, 1 H). LCMS *m/z* 298.1 (M + H)⁺, Rt 1.01 min.

Intermediate 237: (R)-N-((S)-1-(4-(1-ethoxycyclopropyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide




Step 1

To a microwave vial with stir bar was added (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (500 mg, 1.55 mmol) followed by the addition of tributyl(1-ethoxyvinyl)stannane (1.12 g, 3.10 mmol), triethylamine (0.65 ml, 4.65 mmol) and PdCl₂(dppf). CH₂Cl₂ adduct (63 mg, 0.078 mmol). To the solids was added toluene (10 ml). Vial capped and heated in a preheated sand bath at 100 °C for 1 hour. Reaction mixture was loaded onto silica gel column. Silica gel column chromatography (MeOH/ CH₂Cl₂ 0 to 10% with 1% NH₄OH buffer) provided (R)-N-((S)-1-(4-(1-ethoxycyclopropyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (498 mg, 1.59 mmol, 102 % yield) as a brown viscous oil which crystallizes upon standing. ¹H NMR (400 MHz, CDCl₃) δ 1.20 (s, 9 H) 1.43 (t, *J*=6.97 Hz, 3 H) 1.58 (d, *J*=6.75 Hz, 3 H) 3.35 (d, *J*=4.74 Hz, 1 H) 3.92 (q, *J*=6.96 Hz, 2H) 4.23 (d, *J*=2.79 Hz, 1 H) 4.65 (d, *J*=2.79 Hz, 1 H) 4.79 - 4.89 (m, 1 H) 7.16 - 7.20 (m, 1 H) 7.29 - 7.34 (m, 1 H) 7.39 (dd, *J*=8.07, 1.66 Hz, 1 H).

Step 2

To a round bottom flask containing (R)-N-((S)-1-(4-(1-ethoxycyclopropyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (0.49 g, 1.56 mmol) and chloriodomethane (1.14 mL, 15.6 mmol) in toluene (15 mL) at 0 °C under argon was added diethylzinc (1.0M in hexanes) (15.6 mL, 15.6 mmol). Reaction mixture allowed to warm to room temperature and stirred for 1 hour. Reaction mixture was cooled to 0 °C in an ice bath and to the cold reaction mixture was slowly added a saturated solution of NH₄Cl. The aqueous mixture was extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (MeOH/CH₂Cl₂ 0 to 10%) provided (R)-N-((S)-1-(4-(1-ethoxycyclopropyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (145 mg, 0.44 mmol, 28 % yield) as a viscous brown oil. ¹H NMR (300 MHz, CDCl₃) δ 0.93 - 0.99 (m, 2 H) 1.14 - 1.20 (m, 3 H) 1.21 (s, 9 H) 1.22 - 1.27 (m, 2 H) 1.57 - 1.61 (m, 4 H) 3.35 (d, *J*=4.98 Hz, 1 H) 3.45 (q, *J*=7.07 Hz, 2 H) 4.77 - 4.87 (m, 1 H) 6.98 (dd, *J*=7.58, 1.43 Hz, 3 H) 7.00 - 7.03 (m, 4 H) 7.28 - 7.32 (m, 1 H). LCMS *m/z* 328.1 (M + H)⁺, Rt 0.95 min.

Intermediate 238: (R)-N-((S)-1-(4-(1-cyanocyclopropyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide



Step 1


- 5 To a microwave vial with a stir bar was added (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (300 mg, 0.93 mmol), 4-isoxazoleboronic acid pinacol ester (218 mg, 1.12 mmol), PdCl₂(dppf).CH₂Cl₂ adduct (76 mg, 0.09 mmol), potassium fluoride (2.7 mL, 1.0 M in water, 2.79 mmol) and finally DMSO (9 mL). The reaction mixture was degassed with bubbling nitrogen (3 min) and the vial capped and heated in a preheated oil bath at 130 °C for
- 10 18 hours. The reaction mixture was diluted with a saturated solution of NH₄Cl and extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptanes 40 to 100%) provided (R)-N-((S)-1-(4-(cyanomethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (136 mg, 0.48 mmol, 52 % yield) as a viscous brown oil. ¹H NMR (400 MHz,
- 15 CDCl₃) δ 1.19 (s, 9 H) 1.57 (d, J=6.80 Hz, 3 H) 3.39 (d, J=4.35 Hz, 1 H) 3.74 (s, 2 H) 4.81 - 4.88 (m, 1 H) 7.04 (d, J=10.66 Hz, 1 H) 7.11 (d, J=7.97 Hz, 1 H) 7.38 (t, J=7.73 Hz, 1 H). LCMS *m/z* 283.0 (M + H)⁺, Rt 0.72 min.

Step 2

- 20 To a scintillation vial containing (R)-N-((S)-1-(4-(cyanomethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2- (86 mg, 0.31 mmol) and a stir bar was added toluene (2 mL). To this mixture was then added tetrabutylammonium bromide (19 mg, 0.06 mmol) followed by the addition of NaOH (1.52 ml, 1.0 M (aq), 1.52 mmol) and 1,2-dibromoethane (0.11 ml, 1.22 mmol). Vial capped and reaction mixture was stirred vigorously at room temperature for 18
- 25 hours. Whereupon, 1,2-dibromoethane (0.11 ml, 1.22 mmol) and tetrabutylammonium bromide (19 mg, 0.06 mmol) were added and reaction mixture allowed to stir an additional 18 hours. A third addition of 1,2-dibromoethane (0.11 ml, 1.22 mmol) was added and the reaction mixture heated to 50 °C for an additional 18 hours in a preheated aluminum tray. The reaction mixture was quenched with a saturated solution of NH₄Cl and the aqueous mixture extracted
- 30 with EtOAc. Organics combined and washed twice with water, brine, dried (Na₂SO₄), filtered and concentrated. Crude material was passed through a small plug of silica gel using

10%MeOH:90%DCM to elute product. The solution was concentrated to afford a viscous orange oil of (R)-N-((S)-1-(4-(1-cyanocyclopropyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (23 mg, 0.08 mmol, 24 % yield). ^1H NMR (400 MHz, CDCl_3) δ 1.20 (s, 9 H) 1.38 - 1.44 (m, 2 H) 1.56 (d, $J=6.75$ Hz, 3 H) 1.73 - 1.79 (m, 2 H) 3.37 (d, $J=4.45$ Hz, 1 H) 4.78 - 4.88 (m, 1 H) 6.94 (dd, $J=11.35$, 1.91 Hz, 1 H) 7.09 (dd, $J=8.07$, 1.91 Hz, 1 H) 7.34 (t, $J=7.90$ Hz, 1 H). LCMS m/z 309.2 ($\text{M} + \text{H}$) $^+$, Rt 0.83 min.


Intermediate 239: (R)-N-((S)-1-(2-fluoro-4-isopropylphenyl)ethyl)-2-methylpropane-2-sulfonamide



10

To a round bottom flask containing (R)-N-((S)-1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethyl)-2-methylpropane-2-sulfonamide (204 mg, 0.72 mmol) and a stir bar was added MeOH (7.2 mL). To this solution was added palladium on carbon (77 mg, 10%, 0.07 mmol) in MeOH (1 mL). A hydrogen atmosphere was inserted and the resulting reaction mixture stirred at room temperature for 18 hours, at which time more palladium on carbon was added (300 mg) in MeOH (5 mL). A hydrogen atmosphere was inserted again and the reaction mixture allowed to stir an additional 18 hours at room temperature. The reaction mixture was filtered through a syringe filter and concentrated to afford a light brown viscous oil of (R)-N-((S)-1-(2-fluoro-4-isopropylphenyl)ethyl)-2-methylpropane-2-sulfonamide (149 mg, 0.52 mmol, 73 % yield) which crystallizes upon standing. ^1H NMR (400 MHz, CDCl_3) δ 1.20 (s, 9 H) 1.24 (d, $J=5.87$ Hz, 6 H) 1.58 (d, $J=6.70$ Hz, 3 H) 2.89 (dt, $J=13.79$, 6.90 Hz, 1 H) 3.35 (d, $J=5.04$ Hz, 1 H) 4.76 - 4.85 (m, 1 H) 6.90 (dd, $J=12.03$, 1.52 Hz, 1 H) 6.98 (dd, $J=7.90$, 1.54 Hz, 1 H) 7.24 (t, $J=7.97$ Hz, 1 H). LCMS m/z 286.3 ($\text{M} + \text{H}$) $^+$, Rt 1.01 min.

Intermediate 240: (R)-N-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)-2-methylpropane-2-sulfonamide



25

To a two microwave vials with stir bars were added (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (1.5 g, 4.65 mmol), 1-methyl-4-1H-pyrazoleboronic acid pinacol ester (2.91 g, 13.9 mmol), DME (20 mL), sodium carbonate (11.6 mL, 23.3 mmol, 2.0 M aq) and PdCl₂(dppf).CH₂Cl₂ adduct (190 mg, 0.23 mmol) divided
 5 between the two vials. The vials were capped and heated by microwave irradiation for 20 min at 100 °C respectively. The reaction mixtures combined, diluted with a saturated solution of NH₄Cl and EtOAc. The phases were partitioned and the aqueous phase extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 40 to 100%)
 10 provided a orange crystalline of (R)-N-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)-2-methylpropane-2-sulfonamide (1.07 g, 3.31 mmol, 71 % yield. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.21 (s, 9 H) 1.60 (d, *J*=6.80 Hz, 3 H) 3.36 (d, *J*=4.25 Hz, 1 H) 3.96 (s, 3 H) 4.79 - 4.91 (m, 1 H) 7.13 (dd, *J*=11.69, 1.61 Hz, 1 H) 7.23 (dd, *J*=8.00, 1.64 Hz, 1 H) 7.30 - 7.37 (m, 1 H) 7.60 (s, 1 H) 7.74 (s, 1 H). LCMS *m/z* 324.0 (M + H)⁺, Rt 0.74 min.

15

The Intermediates in Table 13a were prepared by a method similar to the one described for the preparation of Intermediate 240.

Table 13a.

Intermediate 241	Intermediate 242


20

Table 13b. Chemical name, NMR chemical shifts and LCMS signal for each intermediate listed in Table 13.

Intermediate: Name	¹ H NMR (400 MHz) δ ppm	LCMS
241: (R)-2-methyl-N-((S)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)propane-2-sulfonamide		MS <i>m/z</i> 306.0 (M + H) ⁺ , Rt 0.71 min.
242: (R)-N-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)-2-	(DMSO) 1.10 (s, 9 H) 1.47 (d, <i>J</i> =6.75 Hz, 3 H) 4.60 - 4.70 (m, 1 H) 5.41 (d, <i>J</i> =5.48 Hz,	MS <i>m/z</i> 310.0 (M + H) ⁺ , Rt

methylpropane-2-sulfonamide	1 H) 7.38 - 7.44 (m, 3 H) 7.96 (br. s., 1 H) 8.23 (br. s., 1 H) 12.97 (br. s., 1 H)	0.67 min.
-----------------------------	--	-----------

Intermediate 243: (R)-N-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-2-methylpropane-2-sulfonamide



5 Step 1


To a oven dried round bottom flask with stir bar was added 2-fluoro-4-(trifluoromethyl) benzaldehyde (5 g, 26.0 mmol), (R)-2-methylpropane-2-sulfonamide (3.47 g, 28.6 mmol) and DCE (52 mL). To this mixture was then added copper (II) sulfate (6.23 g, 39.0 mmol). The reaction mixture was heated in a preheated oil bath at 55 °C for 18 hours. The reaction mixture was filtered through a pad celite, washing the solids with DCE. The filtrate was concentrated to afford a viscous green oil of (R,E)-N-(2-fluoro-4-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfonamide (7.3 g, 24.7 mmol, 95 % yield). Material was taken onto next step without further purification. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.29 (s, 9 H) 7.44 (d, *J*=10.08 Hz, 1 H) 7.51 (d, *J*=8.27 Hz, 1 H) 8.13 (t, *J*=7.46 Hz, 1 H) 8.92 (s, 1 H). LCMS *m/z* 296.0 (M + H)⁺, Rt 1.02 min.

Step 2

To a solution of (R,E)-N-(2-fluoro-4-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfonamide (7.3 g, 24.7 mmol) in CH₂Cl₂ (247 mL) cooled to 0°C (water/ice bath) under nitrogen, was added 3M methyl magnesium bromide (33 mL, 99 mmol) in Et₂O. Reaction mixture allowed to stir for 30 min at 0°C, then gradually allowed to warm to room temperature and stirred for 1 hour at room temperature. Reaction mixture was cooled to 0°C then quenched with the slow addition of a saturated solution of NH₄Cl. Aqueous mixture extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 40 to 100%) provided (R)-N-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-2-methylpropane-2-sulfonamide (4.68 g, 15.0 mmol, 61% yield) as a white crystalline solid. ¹H NMR (400 MHz, CDCl₃) δ 1.22 (s, 9 H) 1.60 (d, *J*=6.80 Hz, 3 H) 3.38 (d, *J*=4.01 Hz, 1 H) 4.87 - 4.97 (m, 1 H)

7.33 (d, $J=10.32$ Hz, 1 H) 7.39 - 7.45 (m, 1 H) 7.49 - 7.55 (m, 1 H). LCMS m/z 312.0 ($M + H$)⁺, Rt 0.92 min.

Intermediate 244: (S)-tert-butyl 1-(3-chloro-4-(cyclopentylcarbamoyl)phenyl)ethyl carbamate



5

Step 1

To a round bottom flask with stir bar was added 4-((S)-1-aminoethyl-2-chlorobenzoic acid HCl salt (1.05 g, 4.45 mmol) followed by the addition of THF (40 mL). To this solution was added DIEA (1.86 ml, 10.7 mmol). The reaction mixture becomes cloudy white followed by the addition of di-tert-butyl dicarbonate (1.07 g, 4.89 mmol). Resulting reaction mixture allowed to stir for 18 hours at room temperature. At which time the reaction mixture was then heated to 60 °C for 2 hours in a oil bath. Di-tert-butyl dicarbonate (1.07 g, 4.89 mmol) and NMP (20 ml) were then added and the resulting reaction mixture allowed to stir for 2 hours at 60 °C. Volatiles were removed. The resulting oil was diluted with a saturated solution of NH₄Cl and the aqueous mixture extracted with EtOAc. The organic phases combined, washed twice with water, brine, dried (Na₂SO₄), filtered and concentrated to a viscous yellow oil of (S)-4-(1-(tert-butoxycarbonylamino)ethyl)-2-chlorobenzoic acid (2.32 g, 6.19 mmol, 139 % yield) which contains some excess di-tert-butyl dicarbonate and NMP. LCMS m/z 284.9 ($M + H$)⁺(carboxylic acid fragment + CH₃CN adduct), Rt 0.75 min.


20

Step 2

To a round bottom flask with stir bar was added (S)-4-(1-(tert-butoxycarbonylamino)ethyl)-2-chlorobenzoic acid (450 mg, 1.20 mmol), cyclopentylamine (355 μ L, 3.60 mmol), EDC HCl (460 mg, 2.40 mmol), 1-hydroxy-7-aza-benzotriazole (229 mg, 1.68 mmol) and DMF (6 mL). To this mixture was then added DIEA (629 μ L, 3.60 mmol). Reaction mixture was allowed to stir at room temperature for 18 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic phases were combined, washed with twice with water, brine, dried (Na₂SO₄), filtered and concentrated to a brown crystalline of (S)-tert-butyl 1-(3-chloro-4-(cyclopentylcarbamoyl) phenyl)ethylcarbamate (476 mg, 1.17 mmol, 97 % yield). LCMS m/z 367.0 ($M + H$)⁺, Rt 0.90 min.

30

Intermediate 245: (R)-N-((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide



5 Step 1

To a round bottom flask with stir bar was added 4-bromo-2,5-difluorobenzaldehyde (5.3 g, 24.0 mmol), (R)-2-methylpropane-2-sulfinamide (3.2 g, 26.4 mmol) and DCE (80 mL). To this mixture was then added copper (II) sulfate (5.74 g, 36.0 mmol). The reaction mixture was heated in a preheated oil bath at 60 °C for 18 hours. The reaction mixture was filtered through a pad celite, washing the solids with DCE. The filtrate was concentrated to afford a viscous green oil of (R,E)-N-(4-bromo-2,5-difluorobenzylidene)-2-methylpropane-2-sulfinamide (7.2 g, 22.2 mmol, 93 % yield). Material was taken onto next step without further purification. LCMS m/z 326.0 (M + H)⁺, Rt 1.04 min.

15 Step 2

To a solution of (R,E)-N-(4-bromo-2,5-difluorobenzylidene)-2-methylpropane-2-sulfinamide (7.2 g, 22.2 mmol in CH₂Cl₂ (200 mL) cooled to 0°C (water/ice bath) under nitrogen, was added 3M methyl magnesium bromide (29.6 mL, 89 mmol) in Et₂O. Reaction mixture allowed to stir for 5 hours at 0°C then quenched with the slow addition of a saturated solution of NH₄Cl. Aqueous mixture adjusted to pH 8 with HCl (1 N) and extracted with DCM. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 30 to 100%) provided (R)-N-((S)-1-(4-bromo-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (6.86 g, 20.2 mmol, 91% yield) LCMS m/z 342.1 (M + H)⁺, Rt 0.96 min.

25


Step 3

To two microwave vials with stir bars were added (R)-N-((S)-1-(4-bromo-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (500 mg, 1.47 mmol), 1-Methyl-4-1H-pyrazoleboronic acid, pinacol ester (917 mg, 4.41 mmol), DME (6 ml), Na₂CO₃ (3.67 ml, 7.35 mmol) (2.0 M aq) and PdCl₂(dppf).CH₂Cl₂ adduct (60.0 mg, 0.07 mmol) divided evenly between the two vessels. Vessels were capped and heated by microwave irradiation for 20 min at 100 °C. Reaction mixtures were combined, diluted with a saturated solution of NH₄Cl and EtOAc. Phases

30

partitioned. Aqueous phase extracted with EtOAc and organic phases combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 60 to 100%) provided (R)-N-((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (370 mg, 1.08 mmol, 73.7 %
5 yield). ^1H NMR (400 MHz, CDCl_3) δ ppm 1.23 (s, 9 H) 1.57 - 1.60 (m, 3 H) 3.33 (d, $J=4.06$ Hz, 1 H) 3.97 (s, 3 H) 4.79 - 4.88 (m, 1 H) 7.10 (dd, $J=11.20$, 6.06 Hz, 1 H) 7.20 (dd, $J=10.78$, 6.19 Hz, 1 H) 7.76 (d, $J=2.20$ Hz, 1 H) 7.82 (s, 1 H). LCMS m/z 342.1 ($\text{M} + \text{H}$) $^+$, Rt 0.77 min.

Intermediate 246: (S)-N-((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)-2-methylpropane-
10 2-sulfinamide



Step 1

To a mixture of 1H-imidazole-4-carbaldehyde (3.71 g, 38.6 mmol), 1-chloro-4-iodobenzene
15 (13.81 g, 57.9 mmol), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (1.10 g, 7.72 mmol), copper(I) iodide (0.368 g, 1.93 mmol) and cesium carbonate (25.2 g, 77 mmol) was added DMF (50 mL). The reaction was sealed and heated to 110 °C for 18 hours. The reaction mixture was then cooled to room temperature and diluted with a saturated solution of NH_4Cl . A brown solid develops. Solid was collected, washed with water and air dried. Solid material
20 was then dissolved in 10%MeOH:90%DCM solution and dried (Na_2SO_4), filtered and concentrated to afford a dark brown solid 1-(4-chlorophenyl)-1H-imidazole-4-carbaldehyde (8.55 g, 41.4 mmol, 107 % yield). Material as used without further purification. LCMS m/z 207.1 ($\text{M} + \text{H}$) $^+$, Rt 0.58 min.

Step 2


To a suspension of (S)-(-)-tert-Butanesulfinamide (2.35 g, 19.4 mmol) and 1-(4-chlorophenyl)-
1H-imidazole-4-carbaldehyde (4 g, 19.4 mmol) in DCE (39 mL) was added CuSO_4 (4.63 g, 29.0 mmol). The reaction mixture was heated at 60 °C for 18 hours in a oil bath. A dark brown suspension resulted. The reaction mixture was then cooled to room temperature, filtered
30 through a pad of celite, rinsed with DCM. The solution was then concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (S,E)-N-((1-(4-

chlorophenyl)-1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfonamide (1.69 g, 5.45 mmol, 28.2 % yield) as a light brown solid. LCMS m/z 310.0 ($M + H$)⁺, Rt 0.75 min.

Step 3

- 5 To a solution of (S,E)-N-((1-(4-chlorophenyl)-1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfonamide (1.69 g, 5.45 mmol) in DCM (27 mL), cooled to -40°C (acetone/dry ice) under N₂, was added 3M MeMgBr (7.27 mL, 21.8 mmol) in diethyl ether. Reaction mixture allowed to stir for 1 hr at -40 °C. Reaction mixture was quenched with the slow addition of a saturated solution of NH₄Cl and diluted with EtOAc. Phases partitioned, aqueous phase extracted with
- 10 EtOAc and the organic layers combined washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/MeOH:EtOAc 0 to 5%) provided (S)-N-((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)-2-methylpropane-2-sulfonamide (1.11 g, 3.41 mmol, 62 % yield). ¹H NMR (400 MHz, CDCl₃) δ 1.25 (s, 9 H) 1.58 (d, J =6.65 Hz, 3 H) 3.80 (d, J =5.48 Hz, 1 H) 4.59 (quin, J =6.36 Hz, 1 H) 7.26 (s, 1 H) 7.33 (d, J =8.61 Hz, 2 H) 7.41 - 7.47 (m, 2 H) 7.76 (d, J =1.17 Hz, 1 H). LCMS m/z 326.1 ($M + H$)⁺,
- 15 Rt 0.59 min.












Intermediate 247: (S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethanamine














- 20 A solution of hydrochloric acid (4.0 M in 1,4-dioxane, 2.1 mL, 8.2 mmol, 2 equiv) was added to a solution of (R)-N-((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide (1.34 g, 4.1 mmol) in 1,4-dioxane at room temperature. A precipitate formed. The suspension was stirred for 1 hour and then concentrated in vacuo to give the hydrochloride salt of (S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethanamine (1.1 g, light yellow solid), which was used
- 25 without purification. ¹H NMR (400 MHz, CD₃OD) δ 7.87 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.8 Hz, 2H), 6.98 (s, 1H), 4.72 (q, J = 6.9 Hz, 1H), 1.72 (d, J = 7.0 Hz, 3H). MS m/z 223.1 ($M + H$)⁺; Rt-0.59 min.

- The intermediates in **Table 14a** were prepared using a method similar to that described for the
- 30 preparation of **Intermediate 247**.

Table 14a.

Intermediate 248	Intermediate 249	
		
Intermediate 250	Intermediate 251	Intermediate 252
		
Intermediate 253	Intermediate 254	Intermediate 255
		
Intermediate 256	Intermediate 257	Intermediate 258
		
Intermediate 259	Intermediate 260	Intermediate 261

		
Intermediate 262	Intermediate 263	Intermediate 264
		
Intermediate 265	Intermediate 266	
		
Intermediate 267	Intermediate 268	Intermediate 269
		
Intermediate 270	Intermediate 271	Intermediate 272









		
Intermediate 273	Intermediate 274	Intermediate 275
		
Intermediate 276	Intermediate 277	
		

Table 14b. Chemical name, NMR chemical shifts and LCMS signal for each intermediate listed in Table 14a.

Intermediate: Name	¹ H NMR (400 MHz, CD ₃ OD) δ ppm	LCMS
248: (S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethanamine	7.97 (d, J = 8.7 Hz, 2H), 7.94 (s, 1H), 7.52 (d, J = 8.7 Hz, 2H), 4.95 (m, 1H), 1.78 (d, J = 6.8 Hz, 3H)	MS m/z 239.9 (M + H) ⁺ ; Rt-0.59 min
249: (S)-1-(5-phenylthiophen-2-yl)ethanamine	7.29 (dd, J = 8.3, 1.2 Hz, 2H), 7.05 (m, 2H), 6.99 (m, 2H), 6.89 (dd, J = 3.8, 0.6 Hz, 1H), 4.45 (m, 1H), 1.41 (d, J = 6.8 Hz, 3H)	MS m/z 187.1 (M – NH ₂) ⁺ ; Rt-0.59 min
250: (S)-1-(5-phenylisoxazol-3-yl)ethanamine	7.87 (m, 2H), 7.55 (m, 3H), 6.95 (s, 1H), 4.72 (q, J = 6.9 Hz, 1H), 1.73 (d, J = 6.9 Hz, 3H)	MS m/z 189.2 (M + H) ⁺ ; Rt-0.50


		min
251: (S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethanamine	8.43 (s, 1H), 7.87 (s, 1H), 7.78 (d, J = 9.0 Hz, 2H), 7.51 (d, J = 9.0 Hz, 2H), 4.61 (q, J = 6.9 Hz, 1H), 1.72 (d, J = 6.9 Hz, 3H)	MS m/z 223.1 (M + H) ⁺ ; Rt-0.54 min
252: (S)-1-(5-(4-fluorophenyl)isoxazol-3-yl)ethanamine	7.92 (dd, J = 9.0, 5.2 Hz, 2H), 7.30 (t, J = 8.8 Hz, 2H), 6.92 (s, 1H), 4.71 (q, 7.0 Hz, 1H), 1.72 (d, J = 7.0 Hz, 3H)	MS m/z 207.1 (M + H) ⁺ ; Rt-0.51 min
253: (S)-1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethanamine	8.39 (s, 1H), 7.86 (s, 1H), 7.78 (dd, J = 9.2, 4.6 Hz, 2H), 7.25 (dd, J = 9.1, 8.4 Hz, 2H), 4.60 (q, J = 6.9 Hz, 1H), 1.71 (d, J = 6.9 Hz, 3H)	MS m/z 207.1 (M + H) ⁺ ; Rt-0.46 min
254: (S)-1-(5-(pyridin-2-yl)thiophen-2-yl)ethanamine	8.73 - 8.78 (m, 1 H), 8.57 (td, J=8.0, 1.6 Hz, 1 H), 8.31 (d, J=8.3 Hz, 1 H), 8.03 (d, J=4.0 Hz, 1 H), 7.92 (ddd, J=7.5, 6.0, 1.1 Hz, 1 H), 7.50 (dd, J=4.0, 0.6 Hz, 1 H), 4.91 - 4.98 (m, 1 H) 1.80 (d, J=6.8 Hz, 3 H)	MS m/z 206.0 (M + H) ⁺ ; Rt-0.35 min
255: (S)-1-(5-(morpholinomethyl)isoxazol-3-yl)ethanamine	6.97 (s, 1H), 4.72 (m, 3H), 3.96 (m, 4H), 3.38 (m, 4H), 1.70 (d, J = 7.0 Hz, 3H)	MS m/z 212.1 (M + H) ⁺ ; Rt-0.14 min
256: (S)-1-(2-morpholinothiazol-5-yl)ethanamine	7.56 (s, 1H), 4.78 (quin, J = 6.8 Hz, 1H), 3.88 (m, 4H), 3.68 (m, 4H), 1.71 (d, J = 6.9 Hz, 3H)	MS m/z 197.0 (M – NH ₂) ⁺ ; Rt-0.26 min
257: (S)-1-(2-(pyridin-2-yl)thiazol-5-yl)ethanamine	8.68 (m, 1H), 8.30 (m, 1H), 8.17 (m, 1H), 8.09 (m, 1H), 7.66 (m, 1H), 4.99 (q, J = 7.1 Hz, 1H), 1.80 (d, J = 6.9 Hz, 3H)	MS m/z 189.0 (M – NH ₂) ⁺ ; Rt-0.39 min
258: (S)-1-(2-(pyridin-3-yl)thiazol-5-yl)ethanamine	9.49 (d, J = 2.0 Hz, 1H), 9.14 (m, 1H), 8.96 (m, 1H), 8.23 (ddd, J = 8.3, 5.8, 0.7 Hz, 1H),	MS m/z 189.0 (M – NH ₂) ⁺ ; Rt-

	8.17 (d, J = 0.7 Hz, 1H), 5.04 (q, J = 6.9 Hz, 1H), 1.82 (d, J = 6.9 Hz, 3H)	0.25 min
259: (S)-1-(2-(pyridin-4-yl)thiazol-5-yl)ethanamine	8.97 (d, J = 6.9 Hz, 2H), 8.62 (d, J = 6.9 Hz, 2H), 8.29 (d, J = 0.6 Hz, 1H), 5.08 (q, J = 6.8 Hz, 1H), 1.84 (d, J = 6.9 Hz, 3H)	MS m/z 189.0 (M – NH ₂) ⁺ ; Rt-0.24 min
260: (S)-1-(2-(4-(difluoromethyl)phenyl)thiazol-5-yl)ethanamine	8.09 (d, J = 7.7 Hz, 2H), 7.99 (s, 1H), 7.68 (d, J = 7.7 Hz, 2H), 6.84 (t, J = 56 Hz, 1H), 4.96 (m, 1H), 1.78 (d, J = 6.9 Hz, 3H)	MS m/z 256.0 (M + H) ⁺ ; Rt-0.56 min
261: (S)-1-(2-(6-methylpyridin-3-yl)thiazol-5-yl)ethanamine	9.30 (d, J = 2.0 Hz, 1H), 8.98 (dd, J = 8.5, 2.0 Hz, 1H), 8.14 (s, 1H), 8.06 (d, J = 8.5 Hz, 1H), 5.03 (q, J = 6.9 Hz, 1H), 2.87 (s, 3H), 1.82 (d, J = 6.9 Hz, 3H)	MS m/z 220.1 (M + H) ⁺ ; Rt-0.27 min
262: (S)-1-(2-(6-(trifluoromethyl)pyridin-3-yl)thiazol-5-yl)ethanamine	9.31 (d, J = 2.1 Hz, 1H), 8.59 (dd, J = 8.2, 1.7 Hz, 1H), 8.10 (s, 1H), 7.98 (d, J = 8.3 Hz, 1H), 5.01 (q, J = 6.8 Hz, 1H), 1.81 (d, J = 6.8 Hz, 3H)	MS m/z 274.0 (M + H) ⁺ ; Rt-0.51 min
263: (S)-1-(2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)ethanamine	8.87 (d, J = 5.1 Hz, 1H), 8.34 (dd, J = 1.5, 0.7 Hz, 1H), 8.17 (m, 1H), 5.02 (q, J = 6.9 Hz, 1H), 1.82 (d, J = 6.9 Hz, 3H)	MS m/z 274.0 (M + H) ⁺ ; Rt-0.51 min
264: (R)-1-(5-(morpholinomethyl)isoxazol-3-yl)ethanamine	7.01 (s, 1H), 4.74 (m, 3H), 4.00 – 3.86 (br m, 4H), 3.45 – 3.37 (br m, 4H), 1.70 (d, J = 6.9 Hz, 3H)	MS m/z 212.2 (M + H) ⁺ ; Rt-0.14 min
265: (S)-1-(1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)ethanamine	9.29 (d, J = 2.4 Hz, 1H), 8.56 (d, J = 2.6 Hz, 1H), 8.47 (dd, J = 8.6, 2.5 Hz, 1H), 7.98 (d, J = 8.6 Hz, 1H), 6.73 (d, J = 2.6 Hz, 1H), 4.68 (q, J = 7.0 Hz, 1H), 1.72 (d, J = 6.9 Hz, 3H)	MS m/z 257.0 (M + H) ⁺ ; Rt-0.12 min
266: (S)-1-(1-(4-chlorophenyl)-2-methyl-1H-	7.83 (d, J = 0.7 Hz, 1H), 7.72	MS m/z

imidazol-4-yl)ethanamine	(m, 2H), 7.63 (m, 2H), 4.75 (q, J = 7.0 Hz, 1H), 2.63 (s, 3H), 1.79 (d, J = 7.0 Hz, 3H)	236.1 (M + H) ⁺ ; Rt-0.45 min
267: (S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethanamine		MS m/z 194.1 (M + H) ⁺ , Rt 0.60 min.
268: (S)-1-(4-(1-ethoxycyclopropyl)-2-fluorophenyl)ethanamine	(D2O) 0.98 (s, 1 H) 1.03 - 1.08 (m, 2 H) 1.14 (t, J=7.09 Hz, 1 H) 1.25 - 1.30 (m, 2 H) 1.64 (d, J=6.99 Hz, 3 H) 3.45 - 3.59 (m, 2 H) 7.16 (dd, J=5.58, 1.47 Hz, 1 H) 7.17 - 7.21 (m, 1 H) 7.40 - 7.48 (m, 1 H)	MS m/z 224.1 (M + H) ⁺ , Rt 0.56 min.
269: (S)-1-(4-(1-aminoethyl)-3-fluorophenyl)cyclopropanecarbonitrile		MS m/z 205.1 (M + H) ⁺ , Rt 0.44 min.
270: (S)-1-(2-fluoro-4-isopropylphenyl)ethanamine		MS m/z 182.1 (M + H) ⁺ , Rt 0.59 min.
271: (S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethanamine		MS m/z 220.1 (M + H) ⁺ , Rt 0.43 min.
272: (S)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethanamine		MS m/z 185.1 (M + H) ⁺ , Rt 0.41 min.
273: (S)-1-(2-fluoro-4-(1H-pyrazol-4-	(D2O) 1.66 (d, J=6.99 Hz, 3 H)	MS m/z

yl)phenyl)ethanamine	4.76 - 4.82 (m, 1 H) 7.39 - 7.52 (m, 3 H) 8.16 (s, 2 H)	206.1 (M + H) ⁺ , Rt 0.37 min.
274: (S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethanamine	(D ₂ O) 1.67 (d, J=6.94 Hz, 3 H) 4.84 (q, J=6.94 Hz, 1 H) 7.54 - 7.70 (m, 3 H)	MS m/z 208.0 (M + H) ⁺ , Rt 0.51 min.
275: (S)-4-(1-aminoethyl)-2-chloro-N-cyclopentylbenzamide		MS m/z 267.0 (M + H) ⁺ , Rt 0.50 min.
276: (S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethanamine	(D ₂ O) 1.65 (d, J=6.94 Hz, 3 H) 3.53 (q, J=7.11 Hz, 1 H) 3.91 (s, 3 H) 7.28 (dd, J=11.10, 6.26 Hz, 1 H) 7.44 (dd, J=11.18, 6.24 Hz, 1 H) 7.94 (s, 1 H) 8.06 (d, J=1.86 Hz, 1 H)	MS m/z 239.1 (M + H) ⁺ , Rt 0.45 min.
277: (S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethanamine	(D ₂ O) 1.74 (d, J=6.65 Hz, 3 H) 4.76 - 4.85 (m, 1 H) 7.61 (q, J=9.00 Hz, 4 H) 8.00 (s, 1 H) 9.04 (s, 1 H)	MS m/z 222.1 (M + H) ⁺ , Rt 0.44 min.

Intermediate 278: (S)-1-(2-fluoro-4-(2-fluoropropan-2-yl)phenyl)ethanamine



Step 1

- To a round bottom flask containing (R)-N-((S)-1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (1.02 g, 3.60 mmol) was added dioxane (7 mL). To this homogenous solution was then added HCl in Dioxane (1.80 mL, 7.20 mmol, 4 M). Resulting reaction mixture allowed to stir 10 min at room temperature. Volatiles removed. Et₂O was

added and mixture sonicated briefly. Volatiles removed again. Et₂O was added and the solid collected and washed with Et₂O to afford a white HCl salt of (S)-1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethanamine (742 mg, 3.44 mmol, 96 % yield). ¹H NMR (400 MHz, D₂O) δ 1.65 (d, *J*=6.94 Hz, 3 H) 2.12 (s, 3 H) 5.23 (s, 1 H) 5.50 (s, 1 H) 7.37 (d, *J*=13.06 Hz, 1 H) 7.43 (m, 2H).

5 LCMS *m/z* 163.2 (deamino fragment) (M + H)⁺, Rt 0.56 min.

Step 2

To a RBF containing (S)-1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethanamine (742 mg, 3.44 mmol) was added NMP (7 mL). To this solution was then added TEA (959 μl, 6.88 mmol) followed
10 by the addition of Di-*tert*-butyl dicarbonate (976 mg, 4.47 mmol). Resulting reaction mixture allowed to stir 2 hr at room temperature. Reaction mixture was diluted with water and extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptanes 0 to 100%) provided (S)-*tert*-butyl (1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethyl)carbamate (1.28 g,
15 4.58 mmol, 133 % yield) as a white crystalline. ¹H NMR (400 MHz, CDCl₃) δ 1.40 - 1.48 (m, 12 H) 2.12 (d, *J*=0.44 Hz, 3 H) 4.98 (br. s., 2 H) 5.10 - 5.12 (m, 1 H) 5.37 (s, 1 H) 7.11 - 7.16 (m, 1 H) 7.19 - 7.24 (m, 2 H). LCMS *m/z* 163.0 (deamino fragment) (M + H)⁺, Rt 1.13 min.

Step 3

20 To a round bottom flask containing (S)-*tert*-butyl (1-(2-fluoro-4-(prop-1-en-2-yl)phenyl)ethyl)carbamate (1.28 g, 4.58 mmol) was added DCM (23 mL). The homogenous solution was cooled to -70 °C in a acetone/dry ice bath. Ozone (g) was then gently bubbled through the solution for 25 min at which time the solution becomes pale blue in color. Dimethyl sulfide (1.02 mL, 13.8 mmol) was then added to the cold solution and mixture gradually allowed to
25 warm to room temperature and stirred for 30 min. Reaction mixture was diluted with a water. Phases partitioned. Aqueous phase extracted with DCM. Organic phases combined, washed with brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 60%) provided (S)-*tert*-butyl (1-(4-acetyl-2-fluorophenyl)ethyl)carbamate (296 mg, 1.05 mmol, 23 % yield) as a colorless oil that
30 crystallizes upon standing. ¹H NMR (400 MHz, CDCl₃) δ 1.38 - 1.49 (m, 12 H) 2.59 (s, 3 H) 5.01 (br. s., 1 H) 7.40 (t, *J*=7.65 Hz, 1 H) 7.62 (dd, *J*=11.20, 1.57 Hz, 1 H) 7.71 (dd, *J*=7.95, 1.54 Hz, 1 H). LCMS *m/z* 267.1 (carboxylic acid fragment + CH₃CN) (M + H)⁺, Rt 0.89 min.

Step 4

35 To a solution of (S)-*tert*-butyl (1-(4-acetyl-2-fluorophenyl)ethyl)carbamate (296 mg, 1.05 mmol) in DCM (5.2 mL), cooled to 0 °C (water/ice bath) under N₂, was added 3M MeMgBr (1.4 mL, 4.21 mmol) in diethyl ether. Reaction mixture allowed to stir for 5 min at 0 °C. Then gradually

allowed to warm to room temperature and stirred for 30 min at room temperature. Reaction mixture was cooled to 0 °C then quenched with the slow addition of a saturated solution of NH₄Cl and diluted with DCM. Phases partitioned, aqueous phase extracted with DCM and the organic layers combined washed with water, brine, dried (Na₂SO₄), filtered and concentrated to (S)-tert-butyl (1-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)ethyl)carbamate (288 mg, 0.97 mmol, 92 % yield) afford as a colorless oil which slowly crystallizes upon standing. ¹H NMR (400 MHz, CDCl₃) δ 1.39 - 1.48 (m, 12 H) 1.57 (s, 6 H) 7.15 - 7.25 (m, 2 H) 7.31 - 7.36 (m, 1 H).


Step 5

- 10 To a RBF containing (S)-tert-butyl (1-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)ethyl)carbamate (288 mg, 0.97 mmol) was added DCM (5 mL) the resulting colorless solution was cooled to -70 °C in a dry ice/acetone bath. To this cold solution under N₂ was then added DAST (0.26 mL, 1.94 mmol) resulting reaction mixture allowed to stir 1 hr at -70 °C. To the cold solution was added ice and resulting mixture allowed to warm to room temperature.
- 15 Mixture diluted with DCM, phases partitioned and the aqueous phase extracted with DCM. Organic layers combined, washed with brine, dried (Na₂SO₄), filtered and concentrated to onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 50%) provided (S)-tert-butyl (1-(2-fluoro-4-(2-fluoropropan-2-yl)phenyl)ethyl)carbamate (126 mg, 0.42 mmol, 44 % yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 1.39 - 1.49 (m, 12 H) 1.66 (d, J=21.52 Hz, 6 H) 4.97 (br. s., 1 H) 7.04 - 7.12 (m, 2 H) 7.22 - 7.26 (m, 1 H). LCMS *m/z* 285.1 (carboxylic acid fragment + CH₃CN) (M + H)⁺, Rt 1.06 min.
- 20

Step 6

- To a round bottom flask containing (S)-tert-butyl (1-(2-fluoro-4-(2-fluoropropan-2-yl)phenyl)ethyl)carbamate (126 mg, 0.42 mmol) was added HCl in dioxane (2.1 mL, 8.42 mmol). Resulting reaction mixture allowed to stir 1 hr at room temperature. Volatiles were removed. Et₂O was then added and the mixture sonicated briefly. Volatiles were once again removed to afford an HCl salt of (S)-1-(2-fluoro-4-(2-fluoropropan-2-yl)phenyl)ethanamine (104 mg, 0.44 mmol, 105 % yield) as a white solid. ¹H NMR (400 MHz, D₂O) δ 1.59 - 1.80 (m, 9 H) 7.24 - 7.37 (m, 2 H) 7.43 - 7.56 (m, 1 H). LCMS *m/z* 200.1 (M + H)⁺, Rt 0.54 min.
- 25
- 30

Intermediate 279: (S)-2-(4-(1-aminoethyl)-3-fluorophenyl)propan-2-ol



Step 1

To a microwave vial with stir bar was added (R)-N-((S)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (1 g, 3.10 mmol) followed by the addition of tributyl(1-ethoxyvinyl)stannane (2.24 g, 6.21 mmol), TEA (1.3 mL, 9.31 mmol) and PdCl₂(dppf).CH₂Cl₂ adduct (0.127 g, 0.155 mmol). To the solids was then added toluene (10 mL). Vial capped and heated by microwave irradiation at 100 °C for 30 min. To this reaction mixture was added 1 ml of TFA to try to convert vinyl ether to the ketone which was unsuccessful. Resulting reaction mixture allowed to stir 5 min at room temperature. Reaction mixture was then quenched with a saturated solution of NaHCO₃ to pH 8. Aqueous mixture extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 40 to 100%) provided (R)-N-((S)-1-(4-(1-ethoxyvinyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (0.60 g, 1.91 mmol, 62% yield) as a yellow viscous residue. ¹H NMR (400 MHz, CDCl₃) δ 1.20 (s, 9 H) 1.43 (t, J=6.94 Hz, 3 H) 1.56 - 1.63 (m, 5 H) 3.36 (d, J=3.13 Hz, 1 H) 3.92 (q, J=6.96 Hz, 2 H) 4.23 (br. s., 1 H) 4.65 (s, 1 H) 4.79 - 4.91 (m, 1 H) 7.30 (s, 2 H) 7.40 (d, J=8.02 Hz, 1 H).

Step 2

To a round bottom flask containing (R)-N-((S)-1-(4-(1-ethoxyvinyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (600 mg, 1.91 mmol) was added MeOH (19 mL). To this homogenous solution was then added HCl (aq) (3.2 mL, 19.1 mmol, 3 M). Resulting reaction mixture was stirred at room temperature for 30 min. Volatiles were then removed. Residue triturated with Et₂O to provide (S)-1-(4-(1-aminoethyl)-3-fluorophenyl)ethanone (0.43 g, 1.98 mmol, 103 % yield) as a HCl salt. ¹H NMR (400 MHz, D₂O) δ 1.67 (d, J=6.99 Hz, 3 H) 2.64 (s, 3 H) 4.80 - 4.87 (m, 1 H) 7.61 (t, J=7.73 Hz, 1 H) 7.77 (dd, J=11.30, 1.66 Hz, 1 H) 7.87 (dd, J=8.09, 1.64 Hz, 1 H). LCMS *m/z* 182.0 (M + H)⁺, Rt 0.36 min.

Step 3

To a round bottom flask with stir bar was added (S)-1-(4-(1-aminoethyl)-3-fluorophenyl)ethanone (0.43 g, 1.98 mmol) followed by the addition of NMP (9.9 mL). To this solution was then added DIEA (0.83 mL, 4.74 mmol) and Di-tert-butyl dicarbonate (0.95 g, 4.35 mmol). The resulting reaction mixture allowed to stir 2 hr at room temperature. Reaction mixture was diluted with water, extracted with EtOAc. Organic phase washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (S)-tert-butyl 1-(4-acetyl-2-fluorophenyl)ethylcarbamate (369 mg, 1.31 mmol, 66.4 % yield) as a colorless oil which crystallizes upon standing. ¹H NMR (400 MHz, CDCl₃) δ 1.38 - 1.49 (m, 12 H) 2.59 (s, 3 H) 5.01 (br. s., 1 H) 7.40 (t, J=7.65 Hz, 1

H) 7.62 (dd, $J=11.20, 1.57$ Hz, 1 H) 7.71 (dd, $J=7.95, 1.54$ Hz, 1 H). LCMS m/z 267.1 (carboxylic acid fragment + CH_3CN) ($\text{M} + \text{H}$)⁺, Rt 0.89 min.


Step4

- 5 To a solution of (S)-tert-butyl (1-(4-acetyl-2-fluorophenyl)ethyl)carbamate (200 mg, 0.71 mmol) in DCM (7.1 mL), cooled to 0°C (water/ice bath) under N_2 , was added 3M MeMgBr (10.95 mL, 2.84 mmol) in diethyl ether. Reaction mixture allowed to stir for 5 min at 0 °C. Then gradually allowed to warm to room temperature and stirred for 30 min at room temperature. Reaction mixture was cooled to 0 °C then quenched with the slow addition of a saturated solution of
- 10 NH_4Cl and diluted with DCM. Phases partitioned, aqueous phase extracted with DCM and the organic layers combined washed with water, brine, dried (Na_2SO_4), filtered and concentrated to (S)-tert-butyl (1-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)ethyl)carbamate (184 mg, 0.62 mmol, 87 % yield) afford as a colorless oil which slowly crystallizes upon standing. ^1H NMR (400 MHz, CDCl_3) δ 1.39 - 1.48 (m, 12 H) 1.57 (s, 6 H) 7.15 - 7.25 (m, 2 H) 7.31 -
- 15 7.36 (m, 1 H).

Step 5


- To a round bottom flask containing (S)-tert-butyl (1-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)ethyl)carbamate (184 mg, 0.62 mmol) and a stir bar was added dioxane (2 mL). To
- 20 this reaction mixture was then added HCl in dioxane (0.93 ml, 3.71 mmol, 4.0M). Resulting reaction mixture allowed to stir at room temperature for 18 hr. Volatiles were then removed. Residue triturated with Et_2O to afford (S)-2-(4-(1-aminoethyl)-3-fluorophenyl)propan-2-ol (142 mg, 0.61 mmol, 98 % yield) as a HCl salt. ^1H NMR (400 MHz, D_2O) δ 1.53 (s, 6 H) 1.64 (d, $J=7.04$ Hz, 3 H) 3.73 (s, 1 H) 7.28 - 7.37 (m, 2 H) 7.42 - 7.48 (m, 1 H). LCMS m/z 198.1 ($\text{M} +$
- 25 H)⁺, Rt 0.37 min.

Intermediate 280: (R)-N-((S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide



To a mixture of ethyl 2-oxocyclohexanecarboxylate (58.0 mg, 0.341 mmol), (R)-N-((S)-1-(4-bromo-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (580 mg, 1.705 mmol), Cs₂CO₃ (1555 mg, 4.77 mmol), copper(I) iodide (32.5 mg, 0.170 mmol) was added 2,2,2-trifluoroethanol (871 µl, 11.93 mmol). The reaction was sealed and heated at 78 °C for 24 hours. LCMS indicated complete conversion to product. The reaction mixture was then cooled to room temperature and diluted with EtOAc (20mL). The mixture was filtered through a pad of celite and the pad was rinsed with EtOAc (20mL). The organic was washed with water (2x15 mL), dried (Na₂SO₄) and concentrated. The residue was then filtered through a pad of silica gel (30 g) with EtOAc/heptane (1:3) to give crude (R)-N-((S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide (0.601 g). LCMS (B) *m/z* 360.1 (M + H)⁺

Intermediate 281: (S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethanamine



To a solution of (R)-N-((S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide (0.601g, 1.672 mmol) in dioxane (10 ml) was added dropwise HCl (0.836 ml, 3.34 mmol). The reaction was stirred at room temperature for 30 minutes. LCMS indicated complete conversion to product. The reaction mixture was concentrated and DCM (20mL) and saturated NaHCO₃ solution (10mL) was added to the residue. The mixture was stirred for 10 minutes and phases were separated. Aqueous layer was then extracted with DCM (2x10mL), and the combined organic was dried (Na₂SO₄) and concentrated to give crude product. LCMS (B) *m/z* 256.2 (M + H)⁺

The intermediates in **Table 15a** were prepared using a method similar to that described for the preparation of **Intermediate 281**.

Table 15a.





Intermediate 282	Intermediate 283	Intermediate 284
		

Table 15b. Chemical name and analytical data for each intermediate listed in Table 15a.

Intermediate: Name	Analytical data
282: (S)-1-(4-bromo-2,5-difluorophenyl)ethanamine	LCMS m/z (M + H) ⁺ 239.2, RT 0.52 min.
283: (S)-1-(2-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethanamine	LCMS m/z (M + H) ⁺ 238.3, RT 0.57 min.
284: (S)-1-(3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethanamine	LCMS m/z (M + H) ⁺ 238.3, RT 0.58 min.

5


Intermediate 285: (R,E)-N-((1-(4-chlorophenyl)-1H-pyrazol-3-yl)methylene)-2-methylpropane-2-sulfonamide



- 10 To a mixture of 1H-pyrazole-3-carbaldehyde (1.52 g, 15.82 mmol), 1-chloro-4-iodobenzene (5.66 g, 23.73 mmol), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (0.450 g, 3.16 mmol), copper(I) iodide (0.151 g, 0.791 mmol) and K₂CO₃ (4.37 g, 31.6 mmol) was added toluene (20 mL). The reaction was sealed and heated to 110 °C for 18 hours. The reaction mixture was then cooled to room temperature and diluted with water (50mL), and extracted with EtOAc
- 15 (3x30mL). The combined organic was then dried (Na₂SO₄) and concentrated to give crude 1-(4-chlorophenyl)-1H-pyrazole-3-carbaldehyde (1.86 g, 9.0 mmol), to which was added (R)-2-methylpropane-2-sulfonamide (1.20 g, 9.90 mmol), CuSO₄ (2.155 g, 13.50 mmol) and DCE (30


ml). The reaction was sealed, heated at 60 °C for 18 hours. A dark green suspension resulted. The reaction mixture was then cooled to 20°C, filtered through a pad of celite, rinsed with DCM. The solution was then concentrated to give final crude product as a light green oil. The residue was purified via silica gel chromatography (EtOAc/Heptane). LCMS (B) m/z 310.3 (M + H)⁺

Intermediate 286: (R)-N-((R)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide



To a solution of (R,E)-N-((1-(4-chlorophenyl)-1H-pyrazol-3-yl)methylene)-2-methylpropane-2-sulfonamide (2.12 g, 6.84 mmol) in DCM (40 ml) at -40 °C was added methylmagnesium bromide (9.12 ml, 27.4 mmol). The reaction was stirred at -40 °C for 3 hours. The reaction mixture was then quenched with saturated NH₄Cl solution (20mL). The aqueous layer was adjusted to pH=8 with HCl (1M) and extracted with DCM (2x200mL). The combined organic
was dried (Na₂SO₄) and concentrated. The residue was then purified via silica gel chromatography (EtOAc/heptane) to give (R)-N-((R)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide (1.11 g). LCMS (B) m/z 326.3 (M + H)⁺

Intermediate 287: (R)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethanamine




To a solution of (R)-N-((R)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide (0.98 g, 3.01 mmol) in dioxane (10 ml) was added dropwise HCl (1.504 ml, 6.01 mmol). The reaction was stirred at room temperature for 30 minutes. LCMS indicated complete conversion to product. The reaction mixture was concentrated and DCM (20mL) and

saturated NaHCO_3 solution (10mL) was added to the residue. The mixture was stirred for 10 minutes and phases were separated. Aqueous layer was then extracted with DCM (2x10mL), and the combined organic was dried (Na_2SO_4) and concentrated to give product (0.556 g). LCMS (B) m/z 222.2 ($\text{M} + \text{H}$)⁺

5


Intermediate 288: (R)-N-((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide



To a solution of (R,E)-N-((1-(4-chlorophenyl)-1H-pyrazol-3-yl)methylene)-2-methylpropane-2-sulfonamide (2.12 g, 6.84 mmol) in DCM (40 ml) at -40 °C was added methylmagnesium bromide (9.12 ml, 27.4 mmol). The reaction was stirred at -40 °C for 3 hours. The reaction mixture was then quenched with saturated NH_4Cl solution (20mL). The aqueous layer was adjusted to pH=8 with HCl (1M) and extracted with DCM (2x200mL). The combined organic was dried (Na_2SO_4) and concentrated. The residue was then purified via silica gel chromatography (EtOAc/heptane) to give (R)-N-((R)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide (1.01 g). LCMS (B) m/z 326.3 ($\text{M} + \text{H}$)⁺

15

Intermediate 289: (S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethanamine



To a solution of (R)-N-((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide (0.98 g, 3.01 mmol) in dioxane (10 ml) was added dropwise HCl (1.504 ml, 6.01 mmol). The reaction was stirred at room temperature for 30 minutes. LCMS indicated complete conversion to product. The reaction mixture was concentrated and DCM (20mL) and saturated NaHCO_3 solution (10mL) was added to the residue. The mixture was stirred for 10 minutes and phases were separated. Aqueous layer was then extracted with DCM (2x10mL),

25

and the combined organic was dried (Na_2SO_4) and concentrated to give crude product (0.501 g). LCMS (B) m/z 222.2 ($\text{M} + \text{H}$)⁺

The intermediates in **Table 16a** were prepared using a method similar to that described for the
5 preparation of **Intermediate 289**

Table 16a.








Intermediate 290	Intermediate 291	Intermediate 292
		
Intermediate 293	Intermediate 294	Intermediate 295
		

Table 16b. Chemical name and analytical data for each intermediate listed in **Table 16a**.


Intermediate: Name	Analytical data
290: (S)-1-(5-bromo-3-fluoropyridin-2-yl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 219.0, 221.0, RT 0.37 min.
291: (R)-1-(5-bromo-3-fluoropyridin-2-yl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 219.0, 221.0, RT 0.38 min.
292: (S)-1-(5-bromopyridin-2-yl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 201.0, 203.0, RT 0.37 min.
293: (R)-1-(5-bromopyridin-2-yl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 201.0, 203.0, RT 0.40 min.
294: (S)-1-(3,5-dichloropyridin-2-yl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 191.1, RT 0.45 min.
295: (R)-1-(3,5-dichloropyridin-2-yl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 191.1, RT 0.44 min.

Intermediate 296: (R)-N-((S)-1-(2,5-difluoro-4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)ethyl)-2-methylpropane-2-sulfonamide



To a solution of (R)-N-((S)-1-(4-bromo-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (230 mg, 0.676 mmol) in dioxane/H₂O (5mL/1mL) was added sodium 2'-(dicyclohexylphosphino)-2,6-dimethoxy-[1,1'-biphenyl]-3-sulfonate (34.7 mg, 0.068 mmol), (2-(trifluoromethyl)pyridin-4-yl)boronic acid (194 mg, 1.014 mmol), K₂CO₃ (234 mg, 1.690 mmol) followed by Pd₂dba₃ (31.0 mg, 0.034 mmol). The reaction mixture was sealed and heated to 110 °C and stirred for 2 hours. LCMS show complete conversion. The reaction mixture was then cooled to room temperature and diluted with EtOAc (20mL) and water (10mL). The aqueous layer was then extracted with EtOAc (2x20mL). The combined organic was then concentrated. The residue was purified by silica gel chromatography (50% heptane in EtOAc to 10% MeOH in EtOAc) to give product. (0.25 g). LCMS (B) *m/z* 407.6 (M + H)⁺

Intermediate 297: (S)-1-(2,5-difluoro-4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)ethanamine



To a solution of (R)-N-((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)-2-methylpropane-2-sulfonamide (0.98 g, 3.01 mmol) in dioxane (10 ml) was added dropwise HCl (1.504 ml, 6.01 mmol). The reaction was stirred at room temperature for 30 minutes. LCMS indicated complete conversion to product. The reaction mixture was concentrated and DCM (20mL) and saturated NaHCO₃ solution (10mL) was added to the residue. The mixture was stirred for 10 minutes and phases were separated. Aqueous layer was then extracted with DCM (2x10mL),

and the combined organic was dried (Na_2SO_4) and concentrated to give crude product (0.501 g). LCMS (B) m/z 303.2 ($\text{M} + \text{H}$)⁺

The intermediates in **Table 17a** were prepared using a method similar to that described for the
5 preparation of **Intermediate 297**

Table 17a.





Intermediate 298	Intermediate 299	Intermediate 300
		

Table 17b. Chemical name and analytical data for each intermediate listed in **Table 17a**.

Intermediate: Name	Analytical data
298: (S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 249.2, RT 0.34 min.
299: (S)-1-(2,5-difluoro-4-(6-methylpyridin-3-yl)phenyl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 249.1, RT 0.32 min.
300: (S)-1-(2,5-difluoro-4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)ethanamine	LCMS(B) m/z ($\text{M} + \text{H}$) ⁺ 303.2, RT 0.64 min.


10

Intermediate 301: (R)-N-((S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethyl)-2-methylpropane-2-sulfonamide




To a solution of di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[1,1'-biphenyl]-2-yl)phosphine (80 mg, 0.166 mmol) in toluene/dioxane (8mL/2mL) was added Pd₂dba₃ (60 mg, 0.066 mmol). The reaction mixture was sealed and heated to 120 °C and stirred for 5 minutes. The reaction was cooled to room temperature and 4-methyl-1H-imidazole (157 mg, 1.910 mmol), (R)-N-((S)-1-(4-bromo-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (500 mg, 1.470 mmol) and K₃PO₄ (624 mg, 2.94 mmol) was added to the reaction mixture. The reaction was sealed and heated to 120 °C for 2 hours. LCMS show complete conversion. The reaction mixture was then cooled to room temperature and diluted with EtOAc (20mL) and water (10mL). The aqueous layer was then extracted with EtOAc (2x20mL). The combined organic was then concentrated. The residue was purified by silica gel chromatography (50% heptane in EtOAc to 10% MeOH in EtOAc) to give (S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethanamine (500mg). LCMS (B) *m/z* 342.6 (M + H)⁺

Intermediate 302: (S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethanamine



To a solution of (R)-N-((S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (500mg) in MeOH (10 mL) was added dropwise HCl (732 µl, 2.93 mmol). The reaction was stirred at room temperature for 30 minutes. LCMS indicated complete conversion to product. The reaction mixture was concentrated and DCM (20mL) and saturated NaHCO₃ solution (10mL) was added to the residue. The mixture was stirred for 10 minutes and phases were separated. Aqueous layer was then extracted with DCM (2x10mL), and the combined organic was dried (Na₂SO₄) and concentrated to give (S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethanamine (330mg). LCMS (B) *m/z* 238.1 (M + H)⁺

Intermediate 303: (S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride



Step 1: preparation of tert-butyl 4-formyl-1H-imidazole-1-carboxylate

To di-tert-butyl dicarbonate (23.25 g, 107 mmol) and 1H-imidazole-4-carbaldehyde (9.75 g, 101 mmol) in THF (200mL) was added DMAP (100 mg, 0.819 mmol). The reaction was stirred for two hours. The reaction mixture was then diluted with saturated NaHCO₃ solution/EtOAc (100 mL/100 mL). The aqueous was then extracted with EtOAc (2x100mL) and the combined organic was dried (Na₂SO₄) and concentrated to give crude product (19.9 g). LCMS (B) *m/z* 197.2 (M + H)⁺

Step 2: preparation of (S,E)-tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)-1H-imidazole-1-carboxylate

To CuSO₄ (24.28 g, 152 mmol) and tert-butyl 4-formyl-1H-imidazole-1-carboxylate (19.9 g, 101 mmol) in DCE (100mL) was added (S)-2-methylpropane-2-sulfinamide (13.52 g, 112 mmol).

The reaction was heated to 65 °C for 18 hours. The reaction mixture was then cooled to room temperature and filtered through a pad of celite. The pad was rinsed with DCM (200mL) and the filtrate was concentrated. The residue was then run through a pad of silica gel with heptane/EtOAc (3:1) as eluent. The filtrate was concentrated to give crude (S,E)-tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)-1H-imidazole-1-carboxylate (22g). LCMS (B) *m/z* 300.2 (M + H)⁺

Step 3: preparation of (S,E)-N-((1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfinamide

To (S,E)-tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)-1H-imidazole-1-carboxylate (18.61 g, 62.2 mmol) in DCM (250mL) at -70 °C was added dropwise methylmagnesium bromide (83 mL, 249 mmol) in Et₂O. The reaction was stirred at -70 °C for 4 hours. The reaction mixture was then warmed to -40 °C and stirred for one hour. The reaction was then quenched with cautious addition of HCl (1N). Cold bath was removed and while with stirring the aqueous layer was adjusted pH=8. The aqueous layer was separated and extracted with DCM (3x100mL). The combined organic was dried (Na₂SO₄) and concentrated to give crude product as a mixture of tert-butyl 4-((S)-1-((S)-1,1-dimethylethylsulfinamido)ethyl)-1H-

imidazole-1-carboxylate and (S,E)-N-((1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfonamide, to which was added DCM (300mL) at 0 °C and formic acid (100 mL, 2651 mmol). The cold bath was then removed and the reaction was stirred for 2 hours. The reaction mixture was then concentrated under reduced pressure to remove DCM and formic acid. The residue
5 was diluted with DCM (400mL) and washed with saturated Na₂CO₃ aqueous solution (2x200mL). The combined aqueous was extracted with DCM (2x200mL). The combined organic was then dried (Na₂SO₄) and concentrated to give (S,E)-N-((1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfonamide (12.5 g). LCMS (B) *m/z* 216.1 (M + H)⁺

10 Step 4: preparation of (S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride


To a 200mL RBF was added toluene/dioxane (80mL/20mL). The flask was cooled to 0 °C and the mixture of solvents was evacuated under high vacuum for 2 minutes and then recharged with argon. The process was repeated three more times. This solvent was then used for the
15 reaction.

A vial containing di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[1,1'-biphenyl]-2-yl)phosphine (55.8 mg, 0.116 mmol) and Pd₂(dba)₃ (42 mg, 0.046 mmol) was evacuated under high vacuum for 1 minute and then recharged with argon. The process was repeated three
20 more times and the toluene/dioxane solvent (10mL) prepared as above was added followed by the palladium/ligand complex prepared as above was then added to the reaction vial containing the other starting materials. The reaction mixture was sealed and heated to 120 °C and stirred for 5 minutes. The reaction was cooled to room temperature.

A separate reaction vial was charged with (S,E)-N-((1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfonamide (500 mg, 2.322 mmol), 1-bromo-4-fluorobenzene (447 mg, 2.55 mmol) and K₃PO₄ (986 mg, 4.64 mmol). The vial was evacuated under high vacuum for 1 minute and then recharged with argon. The process was repeated three more times and the palladium/ligand complex prepared as above was then added to the reaction vial containing the other starting materials. The reaction was sealed and heated to 120 °C for 18 hours.
30 LCMS show complete conversion. The reaction mixture was then cooled to room temperature and filtered through a pad of celite. The solid was rinsed with EtOAc (30mL). The filtrate was then washed with water (2x20mL). The aqueous layer was then extracted with EtOAc (20mL). The combined organic was then concentrated. The residue was purified via silica gel chromatography (EtOAc/Heptane 70%-100% with 5%MeOH) to give (S)-N-((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)-2-methylpropane-2-sulfonamide. LCMS (B) *m/z* 310.2 (M + H)⁺
35

To the above intermediate product was added MeOH (5mL) and HCl (4M in dioxane, 1mL). The reaction mixture was stirred for one hour and LCMS showed complete conversion, The mixture was then concentrated to give (S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (300 mg). LCMS (B) m/z 206.0 (M + H)⁺

5

Intermediate 304: 5-chloro-6-(1,1-difluoroethyl)nicotinaldehyde**Step 1: Preparation of ethyl 5,6-dichloronicotinate**

To a solution of 5,6-dichloronicotinic acid (20.01 g, 104 mmol) in EtOH (500 mL) at 20 °C was added chlorotrimethylsilane (132 mL, 1042 mmol). The reaction was stirred for 72 hours. The reaction mixture was then concentrated and diluted with EtOAc (500mL), and washed with saturated NaHCO₃ (2x100mL) and brine (100mL). The organic was then dried (Na₂SO₄) and concentrated under reduced pressure to give final crude product (21.25 g). LCMS m/z 220.1 (M + H)⁺, Rt 0.94 min.

15

Step 2: Preparation of ethyl 6-acetyl-5-chloronicotinate

To a suspension of ethyl 5,6-dichloronicotinate (5.26 g, 23.90 mmol) and tetraethylammonium-chloride (11.88 g, 71.7 mmol) in MeCN (50 mL) was added tributyl(1-ethoxyvinyl)stannane (9.50 g, 26.3 mmol) and PdCl₂(PPh₃)₂ (0.671 g, 0.956 mmol). The reaction was sealed, heated at 80 °C for 5 hours. A dark color clear solution resulted. The reaction mixture was then cooled to 20 °C, concentrated and diluted with EtOAc (200mL), and washed with water (50mL) and brine (50mL). The organic was then dried (Na₂SO₄) and concentrated to give crude ethyl 5-chloro-6-(1-ethoxyvinyl)nicotinate. The residue was then dissolved in THF (100mL) and HCl (20mL, 3M in H₂O) was added. The reaction mixture was stirred at 20 °C for 5 hours, and saturated NaHCO₃ solution was added until pH=8. The mixture was then diluted with EtOAc (200mL) and water (50mL). The phases were separated and the aqueous layer was extracted with EtOAc (2x50mL). The combined organics was washed with brine (20mL), dried (Na₂SO₄) and concentrated to afford the desired product (3.56 g). LCMS m/z 228.5 (M + H)⁺, Rt 0.83 min.

30

Step 3: Preparation of ethyl 5-chloro-6-(1,1-difluoroethyl)nicotinate

To a solution of ethyl 6-acetyl-5-chloronicotinate (3.01 g, 13.22 mmol) in CHCl_3 (7 mL) was added DAST (5.20 mL, 39.7 mmol) and ethanol (0.061 g, 1.32 mmol). The reaction was sealed, heated at 60 °C for 24 hours. A dark color clear solution resulted. The reaction mixture was then cooled to 20 °C, and added cautiously with cold concentrated NaHCO_3 aqueous solution (50mL). The aqueous layer was extracted with DCM (2x100mL). The combined organic was then dried (Na_2SO_4) and concentrated. The residue was purified via silica gel flash chromatography (0-20percent EtOAc-Hexanes) to afford the desired product as yellow oil (2.88 g). LCMS m/z 250.1 ($\text{M} + \text{H}$)⁺, Rt 0.99 min.

10 Step 4: Preparation of (5-chloro-6-(1,1-difluoroethyl)pyridin-3-yl)methanol


To a solution of ethyl 5-chloro-6-(1,1-difluoroethyl)nicotinate (2.68 g, 10.74 mmol) in Et_2O (40mL) was added LiBH_4 (0.351 g, 16.10 mmol), followed by dropwise addition of methanol (0.653 mL, 16.10 mmol). The reaction was refluxed at 40 °C for one hour. The reaction mixture was then cooled to 0 °C, and quenched with HCl (1M) until pH=2 for aqueous layer.

15 The phases were separated and the aqueous layer was extracted with DCM (3x50mL). The organic was then dried (Na_2SO_4) and concentrated under reduced pressure to give final crude product (2.12 g). LCMS m/z 208.0 ($\text{M} + \text{H}$)⁺, Rt 0.63 min.

Step 5: Preparation of 5-chloro-6-(1,1-difluoroethyl)nicotinaldehyde

20 To a solution of (5-chloro-6-(1,1-difluoroethyl)pyridin-3-yl)methanol (2.12 g, 10.21 mmol) in DCM (100 ml) was added PCC (3.30 g, 15.32 mmol). The reaction was stirred at 20 °C for 3 hours. A dark color suspension resulted. LCMS showed clean conversion to the product. The reaction mixture was then filtered through a pad of celite, and washed with DCM (200mL). The filtrate was then concentrated to give crude product (1.78 g). LCMS m/z 224.0 ($\text{M} + \text{H}_2\text{O} + \text{H}$)⁺,
25 Rt 0.72 min.

Intermediate 305: 5-chloro-6-(2,2,2-trifluoroethoxy)nicotinaldehyde



Step 1: Preparation of ethyl 5-chloro-6-(2,2,2-trifluoroethoxy)nicotinate

30 To a solution of ethyl 5,6-dichloronicotinate (6.28 g, 28.5 mmol) and 2,2,2-trifluoroethanol (2.71 mL, 37.1 mmol) in THF (90 mL) at -73 °C was added NaHMDS (37.1 mL, 37.1 mmol). The reaction was stirred at -73 °C for 30 minutes, then at 0 °C for 5 hours. The reaction was

quenched with 30 mL saturated NH_4Cl solution. The reaction mixture was then poured into 50 mL brine and phases were separated. The aqueous layer was extracted with DCM (2x100mL). The combined organics were dried (Na_2SO_4) and concentrated. Silica gel chromatography with 100% heptane to 30% EtOAc in heptane provided final product (7.51 g). LCMS m/z 284.1

5 $(\text{M} + \text{H})^+$, Rt 1.07 min.

Step 2: Preparation of (5-chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methanol


To a solution of ethyl 5-chloro-6-(2,2,2-trifluoroethoxy)nicotinate (7.51 g, 26.5 mmol) in Et₂O (200mL) was added LiBH_4 (0.865 g, 39.7 mmol), followed by drop wise addition of methanol
10 (1.611 ml, 39.7 mmol). The reaction was refluxed at 40 °C for one hour. The reaction mixture was then cooled to 0 °C, and quenched with HCl (1M) until pH=2 for aqueous layer. The phases were separated and the aqueous layer was extracted with DCM (3x200mL). The organic was then dried (Na_2SO_4) and concentrated under reduced pressure to give final crude product (6.31 g). LCMS m/z 242.1 $(\text{M} + \text{H})^+$, Rt 0.77 min.

15

Step 3: Preparation of 5-chloro-6-(2,2,2-trifluoroethoxy)nicotinaldehyde

To a solution of (5-chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methanol (4.00 g, 16.56 mmol) in EtOAc (15 mL) was added manganese(IV) oxide (16.93 g, 166 mmol). The reaction was heated with microwave at 120 °C for 30 minutes. The mixture was then filtered through a pad
20 of celite, and rinsed with EtOAc. The filtrate was concentrated to give crude product (3.38 g).

Intermediate 306: (S)-1-(2,3-difluorophenyl)ethanamine



Step 1

25 To a oven dried round bottom flask with stir bar was added 2,3-difluorobenzaldehyde (0.5 g, 3.52 mmol), (R)-2-methylpropane-2-sulfinamide (0.469 g, 3.87 mmol) and DCE (7.04 mL). To this mixture was then added Copper (II) Sulfate (0.842 g, 5.28 mmol). Reaction mixture heated in a preheated oil bath to 55 °C for 24hr. The reaction mixture was filtered through a celite pad washing solids with DCE. Combined filtrate was concentrated to afford a viscous
30 yellow oil of (R,E)-N-(2,3-difluorobenzylidene)-2-methylpropane-2-sulfinamide (0.8007 g, 3.26 mmol, 93 % yield). MS m/z 246.1 $(\text{M} + \text{H})^+$; Rt-0.91 min.

Step 2

To a solution of (R,E)-N-(2,3-difluorobenzylidene)-2-methylpropane-2-sulfinamide (0.800 g, 3.26 mmol) in DCM (32.6 mL), cooled to 0°C (water/icebath) under N₂, was added 3M MeMgBr (4.35 mL, 13.05 mmol) in diethyl ether. Reaction mixture allowed to stir for 30 min at 0 °C. Then gradually allowed to warm to room temperature and stirred for 30min at room temperature. Reaction mixture was cooled to 0 °C then quenched with the slow addition of a saturated solution of NH₄Cl and diluted with EtOAc. Phases partitioned aqueous phase extracted with EtOAc and the organic layers combined washed with water, brine, dried with MgSO₄, filtered and concentrated to afford (R)-N-((S)-1-(2,3-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (0.7868 g, 3.01 mmol, 92 % yield) as yellow solid. MS m/z 262.0 (M + H)⁺; Rt-0.70 min.

Step 3

To a round bottom flask containing (R)-N-((S)-1-(2,3-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (786.8 mg, 3.01 mmol) was added Dioxane (10.000 mL). To this solution was added HCl in dioxane 4.0M (1.505 mL, 6.02 mmol) and the solution was allowed to stir 15 min at room temperature. The reaction mixture was concentrated, dissolved in Et₂O 10 ml, and concentrated again. Et₂O was again added and resulting mixture sonicated and a solid material was filtered and dried to afford (S)-1-(2,3-difluorophenyl)ethanamine (0.4213 g, 2.176 mmol, 72.3 % yield) as a white crystalline HCl salt. ¹H NMR (400 MHz, <d₂o>) δ ppm 1.55 (d, J=6.99 Hz, 3 H) 4.71 (q, J=6.96 Hz, 1 H) 7.10 - 7.26 (m, 3 H); MS m/z 158.0 (M + H)⁺; Rt-0.37 min.

The intermediates in **Table A** were prepared using a method similar to that described for the preparation of **Intermediate 306**

Table 18a.





Intermediate 307	Intermediate 308	Intermediate 309
		

Table 18b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 18a.


Intermediate: Name	Analytical data
307: (S)-1-(3,4-difluorophenyl)ethanamine	¹ H NMR (400 MHz, <cd3od>) δ ppm 1.61 (d, <i>J</i> =6.90 Hz, 3 H) 4.47 (q, <i>J</i> =6.90 Hz, 1 H) 7.25 - 7.30 (m, 1 H) 7.32 - 7.46 (m, 2 H) LCMS <i>m/z</i> 158.1.1 (M + H) ⁺ ; Rt-0.39 min.
308: (S)-1-(2,4-difluorophenyl)ethanamine	¹ H NMR (400 MHz, <cd3od>) δ ppm 1.65 (d, <i>J</i> =1.00 Hz, 3 H) 4.71 (q, <i>J</i> =6.91 Hz, 1 H) 7.05 - 7.15 (m, 2 H) 7.51 - 7.61 (m, 1 H) LCMS <i>m/z</i> 158.1.1 (M + H) ⁺ ; Rt-0.37 min.

5

Intermediate 310: (S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethanamine



Step 1: Preparation 1-(4-bromo-3-fluorophenyl)ethanol




- 10 Methylmagnesium bromide (3M in diethylether, 6.77 mL, 20.31 mmol) was added dropwise over ~15 min to a solution of 4-bromo-3-fluorobenzaldehyde (3.1 g, 15.27 mmol) in THF (50 mL) under argon at a temperature of -60 °C to -50 °C. The ice bath was removed and the reaction mixture was allowed to warm to room temperature and stirred ~20 hr. The reaction mixture was slowly diluted/quenched with saturated aqueous ammonium chloride solution (20

mL) and further diluted with water (10 mL). The separated aqueous layer was extracted with ethyl acetate (2x 40 mL). The combined organic layers were washed with brine (60 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to provide crude 1-(4-bromo-3-fluorophenyl)ethanol as a pale yellow oil, which was directly used without further purification.


LCMS m/z 201.0 ($M - H_2O$)⁺, Rt 0.75 min.

Step 2: Preparation 1-(4-bromo-3-fluorophenyl)ethanone



- 10 To a solution of crude 1-(4-bromo-3-fluorophenyl)ethanol oil (from **Step 1**) in DCM (100 mL) was added pyridinium dichromate (8.96 g, 23.82 mmol). The mixture was stirred overnight at room temperature. To the mixture was added celite, the reaction mixture was filtered through a celite pad and rinsed several times with DCM. The filtrate was concentrated under reduced pressure. The crude material was purified by column chromatography [SiO_2 , 40 g, 15 heptane/ethyl acetate] providing 1-(4-bromo-3-fluorophenyl)ethanone (3.08 g) as a white solid. ^1H NMR (400 Mhz, $CDCl_3$) δ ppm 7.72 - 7.58 (m, 3 H), 2.59 (s, 3 H).


Step 3: Preparation 1-bromo-4-(1,1-difluoroethyl)-2-fluorobenzene



- 20 To a solution of 1-(4-bromo-3-fluorophenyl)ethanone (3.08 g, 14.19 mmol) in chloroform (15 mL) was added DAST (5.62 mL, 42.6 mmol) and ethanol (0.083 mL, 1.42 mmol). The orange solution was heated at 60 °C for 24 hr in a sealed container. The reaction mixture was allowed to cool to ~20 °C and to the mixture was added slowly saturated aqueous sodium bicarbonate solution (75 mL). Stirring was continued until off-gased ceased (~15 min). The separated 25 aqueous layer was diluted with additional saturated aqueous sodium bicarbonate solution (25 mL) and carefully mixed. The basic aqueous layer was extracted with DCM (2x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography [SiO_2 , heptane/ethyl acetate] providing 1-bromo-4-(1,1-difluoroethyl)-2-fluorobenzene (2.1 g) as a slightly cloudy

colorless oil. ^1H NMR (400 MHz, CD_3OD) δ ppm 7.73 (dd, $J = 7.2, 8.1$ Hz, 1 H), 7.40 (dd, $J = 2.0, 9.4$ Hz, 1 H), 7.29 (m, $J = 1.0$ Hz, 1 H), 1.92 (t, $J = 18.4$ Hz, 3 H).


Step 4: Preparation 4-(1,1-difluoroethyl)-2-fluorobenzaldehyde



5

To a solution of 1-bromo-4-(1,1-difluoroethyl)-2-fluorobenzene (2.1 g, 8.79 mmol) in THF (30.3 mL) was added n-butyllithium (1.6M in hexanes, 5.60 mL) over ~20 min at -78°C . The mixture was stirred for 30 min at -78°C and DMF (1.02 mL, 13.18 mmol) was added dropwise over ~4 min. Stirring was continued for 1 hr, the mixture was diluted/quenched with 1N aqueous HCl/MeOH (2/1, 15 mL) and allowed to warm to room temperature. The reaction mixture was diluted further with water (50 mL) and extracted with diethylether (2x 50 mL). The combined organic layers were washed with 1N aqueous sodium hydroxide solution (50 mL) and brine (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography [SiO_2 , 40 g, heptane/ethyl acetate] providing 4-(1,1-difluoroethyl)-2-fluorobenzaldehyde (699 mg) as a dark yellow, volatile oil, which was contaminated with 1-bromo-4-(1,1-difluoroethyl)-2-fluorobenzene. ^1H NMR (400 Mhz, CDCl_3) δ ppm 10.40 (s, 1 H), 7.95 (t, $J = 7.4$ Hz, 1 H), 7.39 - 7.47 (m, 2 H), 7.35 (d, $J = 10.6$ Hz, 1 H), 1.94 (t, $J = 18.2$ Hz, 4 H) 7.73 (dd, $J = 7.2, 8.1$ Hz, 1 H).


20 **Step 5: Preparation (R,E)-N-(4-(1,1-difluoroethyl)-2-fluorobenzylidene)-2-methylpropane-2-sulfonamide**



To a mixture of 4-(1,1-difluoroethyl)-2-fluorobenzaldehyde (693 mg, from **Step 4**) and (R)-2-methylpropane-2-sulfonamide (513 mg, 4.24 mmol) in DCE (12.9 mL) was added copper(II) sulfate (882 mg, 5.52 mmol). The reaction mixture was placed in a pre-heated oil bath (55°C) and heated for ~2 d. The mixture was allowed to cool to room temperature, filtered through a pad of celite and rinsed with DCE. The combined filtrates were concentrated under reduced pressure. The residue was purified by column chromatography [SiO_2 , 24 g, heptane/ethyl


acetate] providing (R,E)-N-(4-(1,1-difluoroethyl)-2-fluorobenzylidene)-2-methylpropane-2-sulfonamide (497 mg) as a yellow oil. LCMS m/z 292.1 ($M + H$)⁺, Rt 0.97 min.

Step 6: Preparation N-((S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide




To a solution of (R,E)-N-(4-(1,1-difluoroethyl)-2-fluorobenzylidene)-2-methylpropane-2-sulfonamide (497 mg, 1.706 mmol) in DCM (9.59 mL) was added methylmagnesium bromide (3M in diethylether; 1.20 mL) at 0 °C. The reaction mixture was allowed to stir for 1 hr at 0 °C, gradually allowed to warm to room temperature and stirred for 1 hr at room temperature. The mixture was cooled to 0 °C, additional methylmagnesium bromide (3M in diethylether; 0.5 mL) was added and stirring was continued for 30 min at 0 °C. The reaction mixture was carefully quenched with saturated aqueous ammonium chloride solution (6 mL) and diluted with water (20 mL). The separated aqueous phase was extracted with DCM (30 mL). The combined organic layers were washed with brine (50 mL), concentrated under reduced pressure. The residue was purified by column chromatography [SiO₂, 24 g, heptane/ethyl acetate] providing N-((S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (349 mg) as a white solid. LCMS m/z 308.2 ($M + H$)⁺, Rt 0.91 min.


Step 7: Preparation (S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethanamine




To N-((S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfonamide (349 mg, 1.135 mmol) was added 4M HCl in dioxane (3.01 mL) to give a purple solution. To the mixture was added diethylether (20 mL) and the mixture was stirred for 15 min at ~10 °C. The mixture was concentrated under reduced pressure to ~2 mL of volume and diethylether (20 mL) was added. The solids were filtered off, rinsed with diethylether (4x 10 mL) and dried under reduced pressure providing (S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethanamine (244 mg) as an off-white solid (HCl salt). LCMS m/z 204.1 ($M + H$)⁺, Rt 0.42 min.

Intermediate 311: (S)-tert-butyl 1-(3-hydroxyphenyl)ethylcarbamate

A slurry of (S)-3-(1-aminoethyl)phenol (1.188 g, 6.84 mmol) and Boc_2O (1.747 mL, 7.53 mmol) in DCM (17.10 mL) was stirred at room temperature under N_2 while slowly adding DIEA (1.434
5 mL, 8.21 mmol). The initially insoluble starting materials slowly dissolve. The solution was stirred at room temperature for 16 hours and then concentrated. The oily residue was re-dissolved in EtOAc and washed with Na_2CO_3 saturated, followed by brine. The original aqueous layer was re-extracted with EtOAc, which was then washed with brine and combined with the previous EtOAc batch. The combined organics were dried over Na_2SO_4 , filtered and
10 concentrated to 2.4g crude clear yellowish oil which was purified by silica gel column chromatography (EtOAc/Heptane 0 to 30%), yielding (S)-tert-butyl 1-(3-hydroxyphenyl)ethylcarbamate as a clear colourless oil, which solidifies upon sitting (1.79 g, 7.55 mmol, 110 % yield). ^1H NMR (400 MHz, CDCl_3) δ 1.44 (br. s., 12 H) 4.08 - 4.18 (m, 1 H) 4.76 (br. s., 1 H) 6.72 (dd, $J=7.46$, 1.83 Hz, 1 H) 6.78 (br. s., 1 H) 6.88 (br. s., 1 H) 7.16 - 7.24
15 (m, 1 H). LCMS m/z 223.0/182.0 (the parent not observed, just the Boc fragments) ($\text{M} + \text{H}$) $^+$, Rt 0.71 min.

Intermediate 312: (S)-tert-butyl 1-(4-hydroxy-3-methylphenyl)ethylcarbamate

Made as above Intermediate 195: (S)-tert-butyl 1-(4-hydroxy-3-methylphenyl)ethylcarbamate, clear colourless oil. (1.27 g, 5.05 mmol, 103 % yield). ^1H NMR (400 MHz, CDCl_3) δ 1.42 (s, 9 H) 1.54 (s, 3 H) 2.24 (s, 3 H) 4.70 (br. s., 1 H) 6.72 (d, $J=8.22$ Hz, 1 H) 7.01 (d, $J=9.00$ Hz, 1 H) 7.05 (s, 1 H). LCMS m/z 252.2 ($\text{M} + \text{H}$) $^+$, Rt 0.80 min.
20






Intermediate 313: (S)-1-(3-(cyclohexyloxy)phenyl)ethanamine hydrochloride**Step 1**

- 5 To a solution of (S)-tert-butyl 1-(3-hydroxyphenyl)ethylcarbamate (100 mg, 0.421 mmol), cyclohexanol (0.180 ml, 1.686 mmol) and PPh₃ (221 mg, 0.843 mmol) in THF (2 ml), was added DEAD (0.133 ml, 0.843 mmol) dropwise, under N₂, at room temperature. The resulting yellow solution was stirred for 3 hours, at which point another batch of cyclohexanol (0.180 ml, 1.686 mmol), PPh₃ (221 mg, 0.843 mmol), and 10min later DEAD (0.133 ml, 0.843 mmol), was
- 10 added at room temperature. The reaction mixture was stirred for 16 hours and then concentrated. The crude clear oil was re-dissolved in DMSO and purified by reverse phase HPLC. The combined product fractions were desalted by addition of equal amount of EtOAc and about 250mg Na₂CO₃ in a separatory funnel. The phases were separated and the organic washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to yield (S)-tert-butyl
- 15 1-(3-(cyclohexyloxy)phenyl)ethylcarbamate (74.1 mg, 0.232 mmol, 55.0 % yield) as a clear colourless film. LCMS *m/z* 305.0/264.0 (the parent not observed, just the Boc fragments) (M + H)⁺, Rt 1.12 min.


Step 2

- 20 (S)-tert-butyl 1-(3-(cyclohexyloxy)phenyl)ethylcarbamate (74.1 mg, 0.232 mmol) was dissolved in 4M HCl in dioxane (1 ml, 4.00 mmol) and the resulting mixture was allowed to sit for 1 hour, then concentrated to yield (S)-1-(3-(cyclohexyloxy)phenyl)ethanamine as an HCl salt (yield assumed quantitative). LCMS *m/z* 220.1 (M + H)⁺, Rt 0.66 min.
- 25 The Intermediates in **Table 19** were prepared using the method described for the preparation of **Intermediate 313**.

Table 19


Intermediate: Name	Structure	LCMS
314: (S)-1-(3-((S)-tetrahydrofuran-3-yloxy)phenyl)ethanamine		MS m/z 208.1 (M + H) ⁺ , Rt 0.41 min.
315: (S)-1-(3-isobutoxyphenyl)ethanamine		MS m/z 194.1 (M + H) ⁺ , Rt 0.61 min.
316: (S)-1-(4-isobutoxy-3-methylphenyl)ethanamine		MS m/z 191.1 (M + H) ⁺ , Rt 0.70 min.
317: (S)-1-(2-fluoro-4-isobutoxyphenyl)ethanamine		MS m/z 195.2 (M + H) ⁺ , Rt 0.64 min.
318: (S)-1-(4-(cyclopropylmethoxy)phenyl)ethanamine		MS m/z 175.1 (M + H) ⁺ , Rt 0.53 min.

5 Intermediate 319: (S)-1-(3-phenoxyphenyl)ethanamine



Into a 20ml microwave vial was weighted 1-(pyridin-2-yl)propan-2-one ligand (90 mg, 0.665 mmol), phenol (407 mg, 4.32 mmol), CuBr (47.7 mg, 0.332 mmol) and Cs₂CO₃ (2166 mg, 6.65 mmol). To the mixture was added DMSO (5 ml) and (S)-1-(3-bromophenyl)ethanamine (0.5 ml, 3.32 mmol). The tube was flushed with N₂, capped, and the black mixture heated in the oil bath at 90°C for 18 hours. The heterogenous mixture was diluted with EtOAc and filtered through a glass-fritted funnel, eluting with EtOAc and another 5mls of DMSO. The volatiles were then removed *in vacuo* and the crude brown liquid was filtered through 1um PTFE filter and purified by reverse phase HPLC. The combined product fractions were desalted by addition of equal amount of EtOAc and about 250mg Na₂CO₃ in a separatory funnel. The phases were separated and the organic washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to yield (S)-1-(3-phenoxyphenyl)ethanamine (361.5 mg, 1.678 mmol, 50.5 % yield) as an amber oil. LCMS *m/z* 214.1 (M + H)⁺, Rt 0.61 min.

15 Intermediate 320: (S)-1-(4-(trifluoromethoxy)phenyl)ethanamine



Step 1

To a cloudy solution of 4-(trifluoromethoxy)benzaldehyde (5 g, 26.3 mmol) and (R)-2-methylpropane-2-sulfinamide (3.51 g, 28.9 mmol) in DCE (52 mL), under N₂, was added copper (II) sulfate (6.30 g, 39.4 mmol), and the resulting mixture heated in a preheated oil bath at 55 °C for 22 hours. The reaction mixture was filtered through a pad of celite, eluting with DCM. The filtrate was concentrated to afford a viscous yellow oil of (R,E)-2-methyl-N-(4-(trifluoromethoxy)benzylidene)propane-2-sulfinamide (7.9 g, 26.9 mmol, 102 % yield). Material was taken onto next step without further purification. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.27 (s, 9 H) 7.32 (d, *J*=8.07 Hz, 2 H) 7.91 (d, *J*=8.75 Hz, 2 H) 8.59 (s, 1 H). LCMS *m/z* 294.1 (M + H)⁺, Rt 1.01 min.

Step 2

To a solution of (R,E)-2-methyl-N-(4-(trifluoromethoxy)benzylidene)propane-2-sulfonamide (7.7 g, 26.3 mmol) in CH₂Cl₂ (150 mL), cooled to 0°C (water/ice bath), under nitrogen, was added 3M methyl magnesium bromide (35 mL, 105 mmol) in Et₂O. The reaction mixture was stirred at 0°C for 30min, then allowed to warm up to room temperature and stirred additional 4 hrs.

- 5 The reaction mixture was cooled again to 0°C and quenched with the slow addition of a saturated NH₄Cl solution. The by-phasic mixture was diluted with DCM and Water and the aqueous extracted with DCM two times. The organic phases were combined, washed with brine, dried (Na₂SO₄), filtered and concentrated to 11.5g crude white solid. Silica gel column chromatography (EtOAc/Heptane 0 to 30%) afforded (R)-2-methyl-N-((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)propane-2-sulfonamide (5.08 g, 16.2 mmol, 62% yield) as a white crystalline solid. ¹H NMR (400 MHz, CDCl₃) δ 1.21 (s, 9 H) 1.53 (d, J=6.70 Hz, 3 H) 3.31 (d, J=2.74 Hz, 1 H) 4.59 (qd, J=6.67, 3.37 Hz, 1 H) 7.18 (d, J=8.02 Hz, 2 H) 7.36 (d, J=8.66 Hz, 2 H). LCMS *m/z* 310.2 (M + H)⁺, Rt 0.90 min.

15 Step 3

- (R)-2-methyl-N-((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)propane-2-sulfonamide (5.08 g, 16.4 mmol) was dissolved by swirling in 4M HCl in dioxane (16.4 ml, 65.6 mmol), at room temperature. The solution was allowed to sit for 1 hr with occasional swirling. To the clear solution was added 45ml ether and the resulting cloudy solution sonicated for 1 min, upon which time the white solid product precipitates out. The solid was filtered through a Buchner funnel, washed 5 times with ~20 ml ether and allowed to air dry. Obtained (S)-1-(4-(trifluoromethoxy)phenyl)ethanamine (3.2 g, 13.2 mmol, 80 % yield), ¹H NMR (400 MHz, CD₃OD) δ 1.64 (d, J=6.90 Hz, 3 H) 4.52 (q, J=6.88 Hz, 1 H) 7.38 (d, J=8.02 Hz, 2 H) 7.57 (d, J=8.71 Hz, 2 H). LCMS *m/z* 206.1 (M + H)⁺, Rt 0.52 min.







25


The Intermediates in **Table 20** were prepared using the method described for the preparation of **Intermediate 320**.

Table 20


30

Intermediate: Name	Structure	¹ H NMR (400 MHz, CD ₃ OD), LCMS
--------------------	-----------	--

321: (S)-1-(2-fluoro-4-(trifluoromethoxy)phenyl)ethanamine		δ ppm 1.66 (d, $J=6.94$ Hz, 3 H) 4.75 (q, $J=6.94$ Hz, 1 H) 7.23 - 7.31 (m, 2 H) 7.60 - 7.68 (m, 1 H). MS m/z 224.1 ($M + H$) ⁺ , Rt 0.54 min.
322: (S)-1-(4-(difluoromethoxy)phenyl)ethanamine		δ ppm 1.63 (d, $J=6.90$ Hz, 3 H) 4.48 (q, $J=6.88$ Hz, 1 H) 6.63 - 7.10 (m, 1 H) 7.24 (d, $J=8.71$ Hz, 2 H) 7.50 (d, $J=8.66$ Hz, 2 H). MS m/z 171.1 ($M + H$) ⁺ , Rt 0.43 min.
323: (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethanamine		δ ppm 1.64 (d, $J=6.90$ Hz, 3 H) 4.54 (q, $J=6.88$ Hz, 1 H) 7.39 (dt, $J=8.52, 1.56$ Hz, 1 H) 7.46 - 7.59 (m, 2 H). MS m/z 224.1 ($M + H$) ⁺ , Rt 0.55 min.
324: (S)-1-(4-(difluoromethoxy)-3-fluorophenyl)ethanamine		δ ppm 1.62 (d, $J=6.90$ Hz, 3 H) 4.49 (q, $J=6.83$ Hz, 1 H) 6.67 - 7.10 (m, 1 H) 7.27 - 7.33 (m, 1 H) 7.35 - 7.44 (m, 2 H). MS m/z 206.1 ($M + H$) ⁺ , Rt 0.46 min.
325: (S)-1-(4-(difluoromethoxy)-2-fluorophenyl)ethanamine		δ ppm 1.65 (d, $J=6.94$ Hz, 3 H) 4.71 (q, $J=6.94$ Hz, 1 H) 6.71 - 6.97 (m, 1 H) 7.05 - 7.14 (m, 2 H) 7.55 (t, $J=8.68$ Hz, 1 H). MS m/z 206.1 ($M + H$) ⁺ , Rt 0.46 min.
326: (S)-1-(3-(trifluoromethoxy)phenyl)ethanamine		δ ppm 1.63 (d, $J=6.90$ Hz, 3 H) 4.53 (q, $J=6.86$ Hz, 1 H) 7.35 (ddt, $J=8.21, 2.27, 1.09, 1.09$ Hz, 1 H) 7.41 (s, 1 H) 7.47 (d, $J=7.82$ Hz, 1 H) 7.54 - 7.61 (m, 1 H). MS m/z 206.1 ($M + H$) ⁺ , Rt 0.51 min.

327: (S)-1-(3-(difluoromethoxy)phenyl)ethanamine		δ ppm 1.63 (d, $J=6.90$ Hz, 3 H) 4.49 (q, $J=6.88$ Hz, 1 H) 6.64 - 7.08 (m, 1 H) 7.21 (dd, $J=8.19, 1.83$ Hz, 1 H) 7.26 (t, $J=2.03$ Hz, 1 H) 7.33 (d, $J=7.78$ Hz, 1 H) 7.45 - 7.53 (m, 1 H). MS m/z 188.1 ($M + H$) ⁺ , Rt 0.43 min.
--	---	--


Intermediate 328 (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



5

To a Parshaker flask were added benzyl 4-((S)-1-((4-((R)-4-((S)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)-5-fluoropyrimidin-2-yl)amino)ethyl)piperidine-1-carboxylate (850 mg, 1.56 mmole) and 20% Pd(OH)₂ in activated carbon (880 mg, 1.25 mmole), then was added MeOH (100 mL) under nitrogen gas. The reaction mixture was shaken under 50 psi hydrogen overnight. The reaction mixture was filtered through a celite. The celite cake was washed with MeOH and the filtrate was concentrate *in vacuo*. The resulting crude product was purified by flash column chromatography (basic alumina, 40 g) eluting w/ 0-20% MeOH/DCM to afford the title product as a white solid (230 mg). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.18 (d, $J = 2.87$ Hz, 1H), 5.15 (br s, 1H), 4.71 – 4.63 (m, 1H), 4.56 – 4.47 (m, 1H), 4.47 – 4.34 (m, 2H), 4.25 – 4.14 (m, 1H), 3.96 – 3.82 (m, 1H), 3.16 (d, $J = 12.34$ Hz, 2H), 2.67 – 2.54 (m, 2H), 1.85 – 1.66 (m, 2H), 1.64 – 1.52 (m, 1H), 1.40 – 1.26 (m, 2H), 1.20 (d, $J = 6.60$ Hz, 3H), 1.18 (s, 9H), 1.10 (d, $J = 6.46$ Hz, 3H). HRMS(C) $t_R = 2.36$ min; MS m/z 410.2571 ($M+H$)⁺



Intermediate 329 (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chloro-3-(trifluoromethoxy)phenyl)piperidin-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one



A cloudy solution of (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (32 mg, 0.078 mmol), 4-bromo-1-chloro-2-(trifluoromethoxy)benzene (26 mg, 0.094 mmol), Pd(OAc)₂ (2 mg, 8 μmol), BINAP (5 mg, 8 μmol), and Cs₂CO₃ (51 mg, 0.156 mmol) in 6 mL toluene was heated at 90°C for 3 days. The mixture was cooled to room temperature, and filtered through Celite. The celite cake was rinsed with 5 mL EtOAc. The filtrate was poured into 5 mL water. Organic layer was separated, and the aqueous was further extracted with EtOAc (5 mL). The organic extracts were combined and concentrated by rotary evaporation. The crude was dissolved in a mixture of MeOH (1 mL) and DMSO (1 mL) and purified by reverse phase HPLC. Selected fractions were collected and concentrated by rotary evaporation to afford the title product as a colorless oil (34 mg). (400 MHz, CD₂Cl₂) δ 8.19 (d, *J* = 2.95 Hz, 1H), 7.31 (d, *J* = 8.85 Hz, 1H), 6.87 – 6.80 (m, 2H), 5.05 (br s, 1H), 4.73 – 4.63 (m, 1H), 4.56 – 4.44 (m, 2H), 4.25 – 4.13 (m, 1H), 4.01 – 3.88 (m, 1H), 3.79 – 3.69 (m, 2H), 2.82 – 2.69 (m, 2H), 2.00 – 1.79 (m, 2H), 1.68 – 1.56 (m, 1H), 1.54 – 1.36 (m, 2H), 1.23 (d, *J* = 6.87 Hz, 3H), 1.15 (s, 9H), 1.09 (d, *J* = 6.44 Hz, 3H), HRMS(C) *t*R = 5.61 min; MS *m/z* 604.2328 (M+H)⁺



The intermediates in Table 21 were prepared with procedures similar to those used to prepare Intermediate 301

20 **Table 21.**

Intermediate: Name	Structure	LCMS
330: (R)-N-((S)-1-(5-chloro-6-(1,1-difluoroethyl)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfonamide		MS <i>m/z</i> 325.2 (M + H) ⁺ , Rt 0.85 min.
331: (R)-N-((S)-1-(5-chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfonamide		MS <i>m/z</i> 359.1 (M + H) ⁺ , Rt 0.95 min.







The intermediates in Table 22 were prepared with procedures similar to those used to prepare Intermediate 302


25 **Table 22.**

Intermediate: Name	Structure	LCMS
332: (S)-1-(5-chloro-6-(1,1-difluoroethyl)pyridin-3-yl)ethanamine		MS m/z 221.1 (M + H) ⁺ , Rt 0.50 min.
333: (S)-1-(5-chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)ethanamine		MS m/z 255.1 (M + H) ⁺ , Rt 0.62 min.

The intermediates in **Table 23a** were prepared using a method similar to that described for the
5 preparation of **Intermediate 306**

Table 23a.


Intermediate 334	Intermediate 335	Intermediate 336
		
Intermediate 337	Intermediate 338	Intermediate 339
		
Intermediate 340	Intermediate 341	

**Table 23b.** Chemical name and analytical data for each intermediate listed in **Table 23a**.

Intermediate: Name	Analytical data
334: (S)-1-(4-bromo-2,5-difluorophenyl)ethanamine	LCMS m/z (M + H) ⁺ 236.0, RT 0.5 min.
335: (S)-1-(4-bromo-2,3-difluorophenyl)ethanamine	LCMS m/z (M + H) ⁺ 238.1, RT 0.55 min.
336: (S)-1-(4-bromo-2-fluorophenyl)ethanamine	LCMS m/z (M + H) ⁺ 218.0, 220.1, RT 0.47 min.
337: (S)-1-(4-chloro-2-fluorophenyl)ethanamine	LCMS m/z (M + H) ⁺ 174.2, RT 0.47 min.
338: (S)-1-(4-bromo-3-fluorophenyl)ethanamine	LCMS m/z (M + H) ⁺ 218.1, 220.1, RT 0.52 min.
339: (S)-1-(3,4-dichlorophenyl)ethanamine	LCMS m/z (M + H) ⁺ 190.0, RT 0.57 min.
340: (S)-1-(6-chloro-5-fluoropyridin-3-yl)ethanamine	LCMS m/z (M + H) ⁺ 175.2, RT 0.37 min.
341: (S)-1-(5,6-dichloropyridin-3-yl)ethanamine	LCMS m/z (M + H) ⁺ 191.1, RT 0.42 min.

5

Intermediate 342: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (112 mg, 0.40 mmol), (S)-1-phenylethanamine (58 mg, 0.48 mmol, 1.2 equiv), and DIPEA (153 mg, 1.2

10


mmol, 3.0 equiv) in DMSO (4.0 mL) was heated at 100 °C for 90 min. The reaction mixture was

poured into 5 ml of water, extracted with EA (2x10ml), the solvent was removed to yield the crude product. Silica gel column chromatography (ethyl acetate in heptane 10 to 50%)
 5 provided the pure product (142 mg, white solid) in a 93% yield. HRMS m/z 385.2231 ($M + H$)⁺, RT=3.35 min.

The Following Intermediates were prepared using a method similar to that described for the preparation of **Intermediate 342 or Example 3**

10


Intermediate 343 : (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(2,3-dihydro-1H-inden-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



HRMS(B) t_R = 3.54 min; m/z 492.2485

15


Intermediate 344 (4R)-3-(2-((1-(3-(4-bromo-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one



HRMS(C) t_R = 1.76 min; MS m/z 561.43


20

Intermediate 345 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.94 min; m/z 480.2485

Intermediate 346 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.78 min; m/z 498.2391

Intermediate 347 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((1-(3-phenethyl-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.71 min; m/z 480.2485

Intermediate 348 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(isoquinolin-8-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 2.77 min; m/z 504.2337 (M+H)

Intermediate 349 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.96 min; m/z 554.1656

Intermediate 350 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(3-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 3.13 min; m/z 518.2089

Intermediate 351 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.97 min; m/z 536.1995

Intermediate 352 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.91 min; m/z 520.2046

Intermediate 353 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.87 min; m/z 520.2046

Intermediate 354 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(2-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.76 min; m/z 536.1995

Intermediate 355 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.76 min; m/z 550.2151

Intermediate 356 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 3.38 min; m/z 532.1882

Intermediate 357 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.63 min; m/z 480.2485

Intermediate 358 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(4-chlorophenyl)-4-methyloxazol-
5 2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 1.65 min; MS m/z 518.1 (M+H)

Intermediate 359 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-
10 2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 1.59 min; MS m/z 486.2

Intermediate 360 (4R)-3-(2-((1-(3-(4-bromo-3-methoxyphenyl)-1,2,4-oxadiazol-5-
15 yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one



HRMS(C) tR = 1.76 min; MS m/z 561.43


Intermediate 361 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



5

HRMS(C) tR = 1.94 min; m/z 480.2485


Intermediate 362 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-((1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



10


HRMS(C) tR = 1.96 min; m/z 512.2548

Intermediate 363 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.78 min; m/z 498.2391

Intermediate 364 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-phenethyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.71 min; m/z 480.2485

Intermediate 365 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(isoquinolin-8-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 2.77 min; m/z 504.2337 (M+H)

Intermediate 366 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.96 min; m/z 554.1656

Intermediate 367 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(3-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 3.13 min; m/z 518.2089

Intermediate 368 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.97 min; m/z 536.1995

Intermediate 369 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.91 min; m/z 520.2046

Intermediate 370 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.87 min; m/z 520.2046

Intermediate 371 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(2-(trifluoromethoxy)phenyl)-
5 1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.76 min; m/z 536.1995

Intermediate 372 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(3-(2,2,2-
10 trifluoroethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.76 min; m/z 550.2151

Intermediate 373 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(2,2-
15 difluorobenzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 3.38 min; m/z 532.1882

Intermediate 374 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(C) tR = 1.63 min; m/z 480.2485

Intermediate 375 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 1.65 min; MS m/z 518.1 (M+H)

Intermediate 376 (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




HRMS(B) tR = 1.59 min; MS m/z 486.2

Intermediate 377: (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-((1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




Anal. RP-HPLC tR = 1.69 min; MS m/z 611.1 (M + H)+.

Intermediate 378 benzyl 4-((S)-1-((4-((R)-4-((S)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)-5-fluoropyrimidin-2-yl)amino)ethyl)piperidine-1-carboxylate



¹H NMR (400 MHz, CD₂Cl₂) δ 8.18 (s, 1H), 7.41 – 7.30 (m, 5H), 5.15 (s, 2H), 5.03 (br s, 1H), 4.71 – 4.64 (m, 1H), 4.54 – 4.45 (m, 2H), 4.30 – 4.12 (m, 3H), 3.99 – 3.86 (m, 1H), 2.77 (br s, 2H), 1.87 – 1.57 (m, 3H), 1.36 – 1.24 (m, 2H), 1.20 (d, J = 6.44 Hz, 3H), 1.16 (s, 9H), 1.09 (d, J = 5.91 Hz, 3H). HRMS(C) tR = 4.46 min; MS m/z 544.2964 (M+H)+


Intermediate 379: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, *J* = 2.3 Hz, 1H), 8.21 (d, *J* = 5.7 Hz, 1H), 7.79 (dd, *J* = 8.1, 2.4 Hz, 1H), 7.47 (d, *J* = 5.8 Hz, 1H), 7.39 - 7.28 (m, 3H), 7.13 - 7.07 (m, 1H), 5.28 (p, *J* = 6.9 Hz, 1H), 4.75 (dt, *J* = 8.1, 3.5 Hz, 1H), 4.62 (dd, *J* = 9.4, 3.1 Hz, 1H), 4.49 - 4.40 (m, 1H),
 5 4.34 (t, *J* = 9.0 Hz, 1H), 2.35 (d, *J* = 1.9 Hz, 3H), 1.60 (d, *J* = 6.7 Hz, 3H), 1.25 (s, 12H), 1.01 (d, *J* = 6.5 Hz, 3H); MS *m/z* 492.6 (*M* - H).

Intermediate**380:**

(R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




10

LCMS *t*R = 1.86 min; MS *m/z* 528.5 (*M* - H)⁺.**Intermediate****381:**


(R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(6-(4-fluoro-3-methylphenyl)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one

15



LCMS tR = 1.69 min; MS m/z 494.0 (M + H)+.


Intermediate 382: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



5

LCMS tR = 1.74 min; MS m/z 530.0 (M + H)+.

Intermediate 383: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




10

¹H NMR (400 MHz, CDCl₃) δ 8.86 (d, *J* = 2.3 Hz, 1H), 8.83 (d, *J* = 5.1 Hz, 1H), 8.20 (d, *J* = 5.7 Hz, 1H), 7.93 (dd, *J* = 8.1, 2.4 Hz, 1H), 7.87 (s, 1H), 7.69 (dd, *J* = 5.2, 1.7 Hz, 1H), 7.48 (d, *J* = 5.8 Hz, 1H), 7.45 (d, *J* = 8.1 Hz, 1H), 6.37 - 5.79 (m, 1H), 5.33 (p, *J* = 6.9 Hz, 1H), 4.74 (ddd, *J* = 8.2, 4.6, 3.0 Hz, 1H), 4.62 (dd, *J* = 9.3, 3.0 Hz, 1H), 4.43 (qd, *J* = 6.4, 4.2 Hz, 1H), 4.34 (t, *J* = 9.0 Hz, 1H), 1.67 (br s, 1H), 1.62 (d, *J* = 6.8 Hz, 3H), 1.26 (s, 9H), 1.02 (d, *J* = 6.4 Hz, 3H); MS m/z 531.3 (M + H).

15


Intermediate 384: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(6'-(trifluoromethyl)-[2,3'-bipyridin]-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one

20




LCMS tR = 1.51 min; MS m/z 531.1 (M + H).

Intermediate 385: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(6'-(trifluoromethyl)-[3,3'-
5 bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.51 min; MS m/z 531.3 (M + H).

Intermediate 386: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(6-(trifluoromethyl)-[2,3'-
10 bipyridin]-6'-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.59 min; MS m/z 531.2 (M + H).

Intermediate 387: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-
15 [3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



LCMS tR = 1.60 min; MS m/z 545.2 (M + H).


Intermediate 388: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



5

LCMS tR = 1.65 min; MS m/z 545.2 (M + H).


Intermediate 389: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



10


LCMS tR = 1.65 min; MS m/z 549.2 (M + H).

Intermediate 390: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.65 min; MS m/z 545.6 (M + H).

- 5 **Intermediate 391:** (R)-4-((S)-1-tert-butoxyethyl)-3-(2-((S)-1-(3-fluoro-4-((3,3,4-trimethylpiperazin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.63 min; MS m/z 543.5 (M + H).

- 10 **Intermediate 392:** (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



LCMS tR = 0.94 min; MS m/z 486.0 (M - H).

- 15 **Intermediate 393:** (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorophenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.81 min; MS m/z 534.5 (M - H).

Intermediate**394:**

(R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(3-

5 (trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.74 min; MS m/z 531.0 (M + H).

Intermediate**395:**


(R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-fluoro-3-

methylphenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.71 min; MS m/z 495.0 (M + H).

Intermediate 396: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(2,4-dichlorophenyl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




LCMS tR = 1.84 min; MS m/z 536.0 (M + H).

- 5 **Intermediate 397:** (R)-3-(2-(((S)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one




LCMS tR = 1.77 min; MS m/z 548.0 (M + H).

- 10 **Intermediate 398:** 4-(2-(((S)-1-((4-((R)-4-((R)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)thiazol-4-yl)benzonitrile



LCMS tR = 1.55 min; MS m/z 493.1 (M + H).


- 15 **Intermediate 399:** (R)-3-(2-(((S)-1-(5-bromopyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one



¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, *J* = 2.2 Hz, 1H), 8.15 (d, *J* = 6.0 Hz, 1H), 7.78 (dd, *J* = 8.3, 2.3 Hz, 1H), 7.50 (d, *J* = 5.9 Hz, 1H), 7.21 (d, *J* = 8.3 Hz, 1H), 5.22 (p, *J* = 6.9 Hz, 1H), 4.72 (ddd, *J* = 8.3, 4.7, 3.0 Hz, 1H), 4.62 (dd, *J* = 9.3, 3.0 Hz, 1H), 4.41 - 4.31 (m, 2H), 1.56 (d, *J* = 6.8 Hz, 3H), 1.21 (s, 9H), 1.00 (d, *J* = 6.4 Hz, 3H). MS *m/z* 466.2 (M + H).

Intermediate**400:**

(4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-((1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




10

Anal. RP-HPLC *t*_R = 1.54, 1.56 min (Column = Acquity BEH C18 1.7μm 2.1x50mm. Column Temperature = 50°C. Eluents = A: Water (3.75 mM Ammonium formate, 2% ACN); B: ACN (3.75 mM Ammonium formate, 5% Water);. Flow Rate = 1 mL/min. Gradient = 2% to 98% B in 1.70 min.; MS *m/z* 549.3 (M + H)⁺.


15

Intermediate 401: (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one



Anal. RP-HPLC tR = 1.69 min; MS m/z 549.4 (M + H)⁺.

Intermediate 402: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)-6-(difluoromethyl)pyrimidin-4-yl)oxazolidin-2-one




5

A solution of (R)-4-((R)-1-tert-butoxyethyl)-3-(6-(difluoromethyl)-2-(methylsulfonyl)pyrimidin-4-yl)oxazolidin-2-one (0.146 g, 0.371 mmol), (S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethanamine (91 mg, 0.41 mmol, 1.1 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.097 mL, 0.56 mmol, 1.5 equiv) in DMSO (2.0 mL) was heated at 85 °C for 18 h. The reaction was cooled to room temperature and diluted with DCM (20 mL) and water (20 mL). The layers were separated and the aqueous layer was extracted with DCM (20 mL). The combined organic layers were washed with saturated aqueous NaCl (10 mL), dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 20% to 60%) provided (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)-6-(difluoromethyl)pyrimidin-4-yl)oxazolidin-2-one as a yellow oily solid in 37% yield. MS m/z 537.2 (M + H)⁺; Rt-1.22 min.

10

15

Intermediate 403: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



20
















A solution of (R)-4-((R)-1-tert-butoxyethyl)-3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one (70 mg, 0.209 mmol), (S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethanamine (60 mg, 0.23 mmol, 1.1
















equiv), and N-ethyl-N-isopropylpropan-2-amine (0.091 mL, 0.52 mmol, 2.5 equiv) in DMSO (1.0 mL) was heated at 85-110 °C for 3-5 h. The reaction was cooled to room temperature and diluted with ethyl acetate (30 mL) and dilute aqueous sodium chloride (30 mL). The layers were separated and the organic layer was dried over Na₂SO₄, filtered and concentrated to give crude (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one, which was used without further purification. MS *m/z* 520.2 (M + H)⁺; Rt-1.31 min.













The intermediates in **Table 24a** were prepared using a method similar to that described for the preparation of **Intermediate 403**.













Table 24a.

Intermediate 405	Intermediate 406	
Intermediate 407	Intermediate 408	Intermediate 409
Intermediate 410	Intermediate 411	Intermediate 412
Intermediate 413	Intermediate 414	Intermediate 415

		
Intermediate 416	Intermediate 417	Intermediate 418
		
Intermediate 419	Intermediate 420	Intermediate 421
		
Intermediate 422	Intermediate 423	Intermediate 424
		
Intermediate 425	Intermediate 426	Intermediate 427
		
Intermediate 428	Intermediate 429	Intermediate 430

		
Intermediate 431	Intermediate 432	Intermediate 433
		
Intermediate 434	Intermediate 435	Intermediate 436
		
Intermediate 437	Intermediate 438	Intermediate 439
		
Intermediate 440	Intermediate 441	Intermediate 442
		
Intermediate 443	Intermediate 444	Intermediate 445

Intermediate 443	Intermediate 444	Intermediate 445
		
Intermediate 446	Intermediate 447	Intermediate 448
		
Intermediate 449	Intermediate 450	Intermediate 451
		
Intermediate 452	Intermediate 453	Intermediate 454
		
Intermediate 455	Intermediate 456	Intermediate 457

		
Intermediate 458	Intermediate 459	Intermediate 460
		
Intermediate 461	Intermediate 462	Intermediate 463
		
Intermediate 464	Intermediate 465	Intermediate 466
		
Intermediate 467	Intermediate 468	Intermediate 469





		
Intermediate 470		
		

Table 24b. Chemical name and analytical data for each intermediate listed in **Table 24a**.

Intermediate: Name	Analytical data
405: (R)-4-((R)-1-tert-butoxyethyl)-3-(6-chloro-2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 521.1 (M + H) ⁺ ; Rt-1.29 min
406: (R)-4-((R)-1-tert-butoxyethyl)-3-(6-chloro-2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 505.3 (M + H) ⁺ ; Rt-1.29 min
407: (R)-4-((R)-1-tert-butoxyethyl)-3-(6-chloro-2-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 517.2 (M + H) ⁺ ; Rt-1.13 min
408: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 535.2 (M + H) ⁺ ; Rt-1.14 min
409: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(5-phenylisoxazol-3-	MS <i>m/z</i> 486.3 (M + H) ⁺ ; Rt-1.25 min

yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	
410: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 537.2 (M + H) ⁺ ; Rt-1.33 min
411: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS m/z 520.2 (M + H) ⁺ ; Rt-1.16 min
412: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS m/z 504.2 (M + H) ⁺ ; Rt-1.16 min
413: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 537.2 (M + H) ⁺ ; Rt-1.28 min
414: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 519.3 (M + H) ⁺ ; Rt-1.30 min
415: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS m/z 503.4 (M + H) ⁺ ; Rt-1.11 min
416: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-6-(fluoromethyl)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 518.2 (M + H) ⁺ ; Rt-1.18 min
417: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-(fluoromethyl)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 534.2 (M + H) ⁺ ; Rt-1.21 min
418: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 502.2 (M + H) ⁺ ; Rt-0.99 min
419: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 485.4 (M + H) ⁺ ; Rt-0.93 min
420: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 520.2 (M + H) ⁺ ; Rt-1.30 min
421: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)-5-	MS m/z 504.3 (M + H) ⁺ ; Rt-1.13 min

fluoropyrimidin-4-yl)oxazolidin-2-one	
422: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(5-(4-fluorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 504.3 (M + H) ⁺ ; Rt-1.22 min
423: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(5-(morpholinomethyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 509.4 (M + H) ⁺ ; Rt-0.80 min
424: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((R)-1-(5-(morpholinomethyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 509.4 (M + H) ⁺ ; Rt-0.83 min
425: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 499.3 (M + H) ⁺ ; Rt-0.98 min
426: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(2-(pyridin-2-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 503.2 (M + H) ⁺ ; Rt-1.19 min
427: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(2-(pyridin-3-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 503.3 (M + H) ⁺ ; Rt-0.92 min
428: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(2-(pyridin-4-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 503.3 (M + H) ⁺ ; Rt-0.89 min
429: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 500.4 (M + H) ⁺ ; Rt-1.02 min
430: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 516.3 (M + H) ⁺ ; Rt-1.04 min
431: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 499.3 (M + H) ⁺ ; Rt-0.76 min
432: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 501.3 (M + H) ⁺ ; Rt-1.04 min
433: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)amino)-6-	MS m/z 499.3 (M + H) ⁺ ; Rt-1.02 min


methy pyrimidin-4-yl)oxazolidin-2-one	
434: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 500.2 (M + H) ⁺ ; Rt-0.88 min
435: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 520.2 (M + H) ⁺ ; Rt-1.14 min
436: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 486.3 (M + H) ⁺ ; Rt-0.87 min
437: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 481.4 (M + H) ⁺ ; Rt-0.94 min
438: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)-6-methylpyrimidin-4-yl)oxazolidin-2-one	MS m/z 533.4 (M + H) ⁺ ; Rt-0.96 min
439: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-methyl-2-(((S)-1-(2-(6-methylpyridin-3-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 497.3 (M + H) ⁺ ; Rt-0.63 min
440: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(6-(trifluoromethyl)pyridin-3-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 537.3 (M + H) ⁺ ; Rt-0.95 min
441: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 537.3 (M + H) ⁺ ; Rt-0.80 min
442: methyl 6-((R)-4-((R)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)-2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidine-4-carboxylate	MS m/z 560.3 (M + H) ⁺ ; Rt-1.20 min
443: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 499.2 (M + H) ⁺ ; Rt-0.77 min
444: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-(difluoromethyl)phenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS m/z 518.3 (M + H) ⁺ ; Rt-0.89 min

445: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)-6-(trifluoromethyl)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 499.2 (M + H) ⁺ ; Rt-1.27 min.
446: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 471.3 (M + H) ⁺ ; Rt-1.01 min
447: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(4-(1-ethoxycyclopropyl)-2-fluorophenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 487.3 (M + H) ⁺ ; Rt-1.02 min
448: 4-((S)-1-(4-((R)-4-((R)-1-tert-butoxyethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)-2-chloro-N-cyclopentylbenzamide	MS <i>m/z</i> 530.3 (M + H) ⁺ ; Rt-0.91 min
449: 1-(4-((S)-1-(4-((R)-4-((R)-1-tert-butoxyethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)-3-fluorophenyl)cyclopropanecarbonitrile	MS <i>m/z</i> 468.3 (M + H) ⁺ ; Rt-0.91 min
450: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 483.3 (M + H) ⁺ ; Rt-0.86 min
451: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 465.3 (M + H) ⁺ ; Rt-0.83 min
452: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(2-fluoro-4-(1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 469.3 (M + H) ⁺ ; Rt-0.80 min
453: (R)-4-((R)-1-tert-butoxyethyl)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 489.3 (M + H) ⁺ ; Rt-1.15 min
454: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 457.4 (M + H) ⁺ ; Rt-1.06 min
455: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(2-fluoro-4-isopropylphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 445.3 (M + H) ⁺ ; Rt-1.05 min
456: (R)-4-((R)-1-tert-butoxyethyl)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-	MS <i>m/z</i> 501.3 (M + H) ⁺ ; Rt-0.98 min

yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	
457: (R)-4-((R)-1-tert-butoxyethyl)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 475.3 (M + H) ⁺ ; Rt-1.20 min
458: (R)-4-((R)-1-tert-butoxyethyl)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 487.2 (M + H) ⁺ ; Rt-0.90 min
459: (R)-4-((R)-1-tert-butoxyethyl)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-isopropylphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 463.3 (M + H) ⁺ ; Rt-1.20 min
460: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 461.3 (M + H) ⁺ ; Rt-1.14 min
461: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 519.3 (M + H) ⁺ ; Rt-0.98 min
462: (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 502.3 (M + H) ⁺ ; Rt-0.95 min
463: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 457.4 (M + H) ⁺ ; Rt 1.04 min
464: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-methoxyphenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 451.3 (M + H) ⁺ ; Rt 1.03 min
465: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2,3-difluorophenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 421.2 (M + H) ⁺ ; Rt = 0.91 min
466: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2,3-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 439.2 (M + H) ⁺ ; Rt = 1.05 min;

467: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3,4-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 439.2 (M + H) ⁺ ; Rt = 1.03 min;
468: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2,4-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 439.3 (M + H) ⁺ ; Rt = 1.04 min;
469: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3,5-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 439.2 (M + H) ⁺ ; Rt = 1.04 min;
470: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-chloro-2-(((S)-1-(5-(2-(trifluoromethyl)pyridin-4-yl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	MS <i>m/z</i> 565.4 (M + H) ⁺ ; Rt = 0.98 min;

Intermediate 473: (2R,3R)-3-(tert-butoxy)-2-((6-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)amino)butan-1-ol




5

A solution of (S)-4,6-difluoro-N-(1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)pyrimidin-2-amine (80 mg, 0.25 mmol), (2R,3R)-2-amino-3-(tert-butoxy)butan-1-ol (55 mg, 0.28 mmol, 1.1 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.11 mL, 0.63 mmol, 2.5 equiv) in DMSO (1.3 mL) was heated at 85 °C for 16 hours. The reaction was cooled to room temperature and diluted with ethyl acetate (30 mL) and dilute aqueous sodium chloride (30 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (20 mL). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane) provided (2R,3R)-3-(tert-butoxy)-2-((6-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)amino)butan-1-ol (0.058 g, white solid) in 50% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.66 (s, 1H), 7.61 (m, 2H), 7.13 (t, J = 8.6 Hz, 2H), 5.35 (s, 1H), 5.30 – 5.14 (m, 2H), 5.04 (m, 1H), 3.94 (m, 1H), 3.77 – 3.65


(m, 2H), 1.57 (d, J = 6.9 Hz, 3H), 1.21 (s, 9H), 1.15 (d, J = 6.0 Hz, 3H). MS m/z 461.3 (M + H)⁺; Rt-0.88 min.

Intermediate 474 (2R,3R)-3-(tert-butoxy)-2-((2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-6-fluoropyrimidin-4-yl)amino)butan-1-ol



(2R,3R)-3-(tert-butoxy)-2-((2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-6-fluoropyrimidin-4-yl)amino)butan-1-ol was prepared using a method similar to that described for the preparation of **Intermediate 473**. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.82 (s, 1H), 7.67 (s, 1H), 7.60 (d, J = 8.9 Hz, 2H), 7.41 (d, J = 8.8 Hz, 2H), 5.35 (s, 1H), 5.27 (m, 1H), 5.19 (m, 1H), 5.07 (m, 1H), 3.94 (m, 1H), 3.71 (m, 2H), 1.57 (d, J = 6.8 Hz, 3H), 1.21 (s, 9H), 1.14 (d, J = 5.9 Hz, 3H). MS m/z 477.3 (M + H)⁺; Rt-0.96 min


Intermediate 475: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



Triphosgene (18mg, 0.062 mmol, 0.5 equiv) was added to a solution of (2R,3R)-3-(tert-butoxy)-2-((6-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)amino)butan-1-ol (57 mg, 0.12 mmol) in DCM (1.2 mL) at -78 °C, followed by the dropwise addition of 2,6-lutidine (0.058 mL, 0.49 mmol, 4 equiv). The solution was allowed to warm to room temperature and was then heated at 35 °C for 30 min. The reaction was then cooled to room temperature and diluted with DCM (30 mL) and saturated aqueous sodium chloride (30 mL). The layers were separated and the organic layer was dried over Na₂SO₄, filtered and


concentrated to give crude (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one, which was used without further purification. MS m/z 487.4 ($M + H$)⁺; Rt-1.12 min.

Intermediate 476 : (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-6-fluoropyrimidin-4-yl)oxazolidin-2-one



(R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-6-fluoropyrimidin-4-yl)oxazolidin-2-one was prepared using a method similar to that described for the preparation of **Intermediate 475**. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.82 (s, 1H), 7.66 (s, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 7.17 (s, 1H), 5.31 (m, 1H), 4.70 (m, 1H), 4.62 (dd, J = 9.2, 3.0 Hz, 1H), 4.33 (m, 2H), 1.62 (d, J = 6.8 Hz, 3H), 1.13 (br s, 9H), 1.02 (d, J = 6.5 Hz, 3H). MS m/z 503.3 ($M + H$)⁺; Rt-1.21 min.

Intermediate 477







To a microwave vial with a stir bar was added (R)-4-((R)-1-tert-butoxyethyl)-3-(2-chloropyrimidin-4-yl)oxazolidin-2-one (43.6 mg, 0.145 mmol) and (S)-1-(3-((S)-tetrahydrofuran-3-yloxy)phenyl)ethanamine (25.1 mg, 0.121 mmol), followed by DMSO (605 μ L) and DIEA (63.5 μ L, 0.363 mmol). The vial was capped and the reaction mixture heated in a preheated oil bath at 110 °C for 21 hr. The mixture was diluted with water and extracted with EtOAc two times. The combined organic phases were washed with brine, dried over sodium sulfate, filtered, concentrated and dried on house vacuum to afford crude (R)-4-((R)-1-tert-





butoxyethyl)-3-(2-((S)-1-(3-((S)-tetrahydrofuran-3-yloxy)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one, as a brown solid film, (yield assumed quantitative). LCMS m/z 471.4 ($M + H$)⁺, Rt 0.85 min.


- 5 The compounds in **Table 25** were prepared using methods similar to those described for the preparation of **Intermediate 477**.

Table 25.


Intermediate: Name	Structure	LCMS
478: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(3-isobutoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 457.4 ($M + H$) ⁺ , Rt 1.04 min.
479: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(3-phenoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 477.3 ($M + H$) ⁺ , Rt 1.00 min.
480: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(4-isopropoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 443.4 ($M + H$) ⁺ , Rt 0.94 min.

<p>481: (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(4-isobutoxy-3-methylphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 471.4 (M + H)⁺, Rt 1.09 min.</p>
<p>482: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 487.3 (M + H)⁺, Rt 1.18 min.</p>
<p>483: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 505.4 (M + H)⁺, Rt 1.16 min.</p>
<p>484: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 469.3 (M + H)⁺, Rt 1.05 min.</p>

485: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 505.4 (M + H) ⁺ , Rt 1.14 min.
486: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(difluoromethoxy)-3-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one		MS m/z 487.3 (M + H) ⁺ , Rt 1.08 min.
487: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(difluoromethoxy)-2-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one		MS m/z 487.3 (M + H) ⁺ , Rt 1.04 min.
488: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 487.3 (M + H) ⁺ , Rt 1.10 min.

<p>489: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(difluoromethoxy)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 469.3 ($M + H$)⁺, R_t 1.03 min.</p>
---	--	---

Intermediate 490






- 5 To a microwave vial with a stir bar was added (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one (75.0 mg, 0.224 mmol) and (S)-1-(4-(trifluoromethoxy)phenyl)ethanamine (59.7 mg, 0.247 mmol), followed by DMSO (0.9 mL) and DIEA (118 μ L, 0.673 mmol). The vial was capped and the reaction mixture heated in a preheated oil bath at 85 °C for 2 hr. The mixture was diluted with brine and extracted with
- 10 EtOAc two times. The combined organic phases were dried over sodium sulfate, filtered, concentrated and dried on house vacuum to afford crude (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a brown solid film, (yield assumed quantitative). LCMS m/z 503.2 ($M + H$)⁺, R_t 1.24 min.

15


The compounds in **Table 26** were prepared using methods similar to those described for the preparation of **Intermediate 490**

Table 26.

Intermediate: Name	Structure	LCMS
--------------------	-----------	------

<p>491: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(2-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 521.3 (M + H)⁺, Rt 1.33 min.</p>
<p>492: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 485.2 (M + H)⁺, Rt 1.20 min.</p>
<p>493: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(6-chloro-2-(((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 521.3 (M + H)⁺, Rt 1.31 min.</p>

Intermediate 494











- To a suspension of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (30.0 mg, 0.106 mmol) and (S)-1-(4-(trifluoromethoxy)phenyl)ethanamine (38.4 mg, 0.159 mmol) in DMSO (0.53 mL), was added DIEA (64.7 μ L, 0.371 mmol) in a microwave vial. The vial was capped and the reaction mixture heated in a preheated oil bath at 100 °C for 3 hr.


The mixture was diluted with dilute brine and extracted with EtOAc two times. The combined organic phases were washed with brine, dried over magnesium sulfate, filtered, concentrated and dried on house vacuum to afford crude (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a clear colorless oil which was used without further purification (yield assumed quantitative). LCMS m/z 469.3 ($M + H$)⁺, Rt 0.98 min.

The compounds in Table 27 were prepared using methods similar to those described for the preparation of **Intermediate 494**.


10 **Table 27.**

Intermediate: Name	Structure	LCMS
495: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 487.3 ($M + H$) ⁺ , Rt 0.99 min.
496: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 487.3 ($M + H$) ⁺ , Rt 1.00 min.
497: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(difluoromethoxy)-3-fluorophenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one		MS m/z 469.4 ($M + H$) ⁺ , Rt 0.91 min.

<p>498: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(cyclopropylmethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 455.3 (M + H)⁺, Rt 0.96 min.</p>
<p>499: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 475.3 (M + H)⁺, Rt 1.07 min.</p>
<p>500: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 451.3 (M + H)⁺, Rt 0.90 min.</p>
<p>501: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(4-(difluoromethoxy)-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 469.3 (M + H)⁺, Rt 0.90 min.</p>
<p>502: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 469.3 (M + H)⁺, Rt 0.94 min.</p>

<p>503: (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(3-(difluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>		<p>MS m/z 451.3 (M + H)⁺, Rt 0.87 min.</p>
--	--	---


Intermediate 504 (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



- 5 To a Parshaker flask were added benzyl 4-((S)-1-((4-((R)-4-((S)-1-(tert-butoxy)ethyl)-2-oxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)piperidine-1-carboxylate (1g, 1.90 mmole) and 20% Pd(OH)₂ in activated carbon (1g, 1.42 mmole), then was added MeOH (100 mL) under nitrogen gas. The reaction mixture was shaken under 50 psi hydrogen overnight. The reaction mixture was filtered through a celite. The celite cake was washed with MeOH and the filtrate was
- 10 concentrate *in vacuo* to afford the title product as a white solid (630 mg). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.18 – 8.15 (m, 1H), 7.42 – 7.37 (m, 1H), 4.99 (br, s, 1H), 4.77 – 4.70 (m, 1H), 4.64 – 4.57 (m, 1H), 4.52 – 4.38 (m, 1H), 4.38 – 4.31 (m, 1H), 4.12 – 3.93 (m, 2H), 3.40 – 3.31 (m, 1H), 3.12 – 3.29 (m, 2H), 2.81 – 2.70 (m, 1H), 2.02 – 1.29 (m, 5H), 1.25 (s, 9H), 1.23 – 1.16 (m, 3H), 1.05 – 1.00 (m, 3H). HRMS(C) tR = 2.65 min; MS m/z 392.2655 (M+H)⁺

15


Intermediate 505 (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



- Intermediate 505 was prepared using a method similar to that described for the preparation of
- 20 Intermediate 329. ¹H NMR (400 MHz, CD₂Cl₂) δ 8.23 – 8.12 (m, 1H), 7.87 (d, J = 7.45 Hz, 1H), 7.69 (d, J = 6.22 Hz, 1H), 6.81 – 6.74 (m, 2H), 4.67 (m, 1H), 4.61 – 4.55 (m, 1H), 4.37 – 4.29 (m, 1H), 4.25 – 4.16 (m, 2H), 4.14 – 4.04 (m, 2H), 3.97 – 3.85 (m, 1H), 3.21 – 3.09 (m, 2H),


2.11 – 1.87 (m, 3H), 1.61 (s, 6H), 1.39 – 1.23 (m, 1H), 1.21 (d, $J = 7.45$ Hz, 3H), 1.15 – 1.07 (m, 1H), 1.06 (s, 9H), 0.96 (d, $J = 6.62$ Hz, 3H), HRMS(C) $t_R = 4.80$ min; MS m/z 579.3273 (M+H)+

- 5 **Intermediate 506** (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chloro-3-(trifluoromethoxy)phenyl)piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



Intermediate 506 was prepared using a method similar to that described for the preparation of Intermediate 329. ^1H NMR (400 MHz, CD_2Cl_2) δ 8.17 (br, s, 1H), 7.41 (d, $J = 6.14$ Hz, 1H), 7.31 (d, $J = 7.98$ Hz, 1H), 6.87 – 6.80 (m, 2H), 4.77 – 4.71 (m, 1H), 4.64 – 4.58 (m, 1H), 4.49 – 4.40 (m, 1H), 4.39 – 4.32 (m, 1H), 4.11 – 3.97 (m, 1H), 3.79 – 3.70 (m, 2H), 2.82 – 2.71 (m, 2H), 2.04 – 1.91 (m, 1H), 1.90 – 1.80 (m, 1H), 1.66 – 1.35 (m, 3H), 1.34 – 1.15 (m, 13H), 1.03 (d, $J = 7.36$ Hz, 3H), HRMS(C) $t_R = 5.68$ min; MS m/z 586.2419 (M+H)+

- 15 **Intermediate 507** benzyl 4-((S)-1-((R)-4-((S)-1-(tert-butoxy)ethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)piperidine-1-carboxylate









Intermediate 507 was prepared using a method similar to that described for the preparation of Intermediate 342. ^1H NMR (400 MHz, CD_2Cl_2) δ 8.16 (d, $J = 5.77$ Hz, 1H), 7.41 – 7.31 (m, 6H), 5.15 (s, 2H), 4.76 – 4.71 (m, 1H), 4.64 – 4.58 (m, 1H), 4.48 – 4.41 (m, 1H), 4.38 – 4.31 (m, 1H), 4.30 – 4.18 (m, 2H), 4.09 – 3.96 (m, 1H), 2.77 (br s, 2H), 1.94 – 1.54 (m, 3H), 1.37 – 1.25 (m, 3H), 1.23 (s, 9H), 1.20 (d, $J = 6.53$ Hz, 3H), 1.03 (d, $J = 5.91$ Hz, 3H). HRMS(C) $t_R = 4.64$ min; MS m/z 526.3012 (M+H)+

25

The intermediates in Table 27b were prepared using methods similar to those described for the preparation of Intermediate 303.


Table 27b.

Intermediate: Name	Structure	LCMS
508: (S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethanamine		LCMS(B) m/z (M + H) ⁺ 224.1, RT 0.39 min.
509: (S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethanamine		LCMS(B) m/z (M + H) ⁺ 240.0, RT 0.48 min.
510: (S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethanamine		LCMS(B) m/z (M + H) ⁺ 240.1, RT 0.46 min.
511: (S)-1-(1-(4-(difluoromethyl)phenyl)-1H-imidazol-4-yl)ethanamine		LCMS(B) m/z (M + H) ⁺ 238.1, RT 0.41 min.

512: (S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethanamine		LCMS(B) m/z (M + H) ⁺ 256.0, RT 0.47 min.
513: (S)-1-(1-(3,5-difluorophenyl)-1H-imidazol-4-yl)ethanamine		LCMS(B) m/z (M + H) ⁺ 224.1, RT 0.41 min.

Intermediate 514:

(R)-4-((R)-1-(tert-butoxy)ethyl)-3-(4-methoxybenzyl)oxazolidin-2-one




- 5 To a solution of benzyl ((2R,3R)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate (5.88 g, 19.9 mmol) in 100 mL DMF was added NaH (60% in mineral oil, 1.62 g, 40.6 mmol) at 0 °C. The reaction mixture was stirred for 30 min at 0 °C. To the reaction mixture were added 4-methoxybenzyl chloride (4.07 mL, 29.9 mmol) and tetrabutylammonium iodide (0.74 g, 1.99 mmol) and the resulting mixture was warmed to room temperature and stirred for
- 10 15.5 h. The reaction mixture was poured into ice water (200 mL) forming a white suspension. EtOAc (100 mL) was added and the resulting mixture was stirred for 5 min to form a clear two layer solution. After separation, the aqueous phase was extracted with EtOAc (100 mL x 3). The combined organic solution was washed with brine (80 mL), dried over Na₂SO₄, filtered and concentrated. Flash column chromatography (EtOAc/Heptane 0 to 70%) gave 5.90 g of the
- 15 desired product with minor impurities. Major product 1H NMR (400 MHz, MeOD) δ 7.38 - 7.29

(m, 2H), 6.99 - 6.93 (m, 2H), 4.68 - 4.58 (m, 1H), 4.33 (dd, $J = 9.3, 4.5$ Hz, 1H), 4.27 - 4.17 (m, 2H), 3.89 (dd, $J = 6.4, 4.8$ Hz, 1H), 3.81 (s, 3H), 3.65 (dd, $J = 9.0, 4.6$ Hz, 1H), 1.26 (s, 9H), 1.09 (s, 9H), 1.02 (d, $J = 6.3$ Hz, 3H). MS m/z 308.2 (M + H).

Intermediate 515:


5 (R)-4-((R)-1-hydroxyethyl)-3-(4-methoxybenzyl)oxazolidin-2-one



A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(4-methoxybenzyl)oxazolidin-2-one (5.90 g, 19.2 mmol) in CH_2Cl_2 (40 mL) was treated with TFA (40 mL) at room temperature for 20 min. The reaction mixture was concentrated in vacuo, then diluted with CH_2Cl_2 (~50 mL), and again concentrated. This procedure was repeated three times to remove TFA. Flash column chromatography (EtOAc/Heptane 30 ~ 100%) gave 3.81 g of the desired product. ^1H NMR (400 MHz, MeOD) δ 7.31 - 7.21 (m, 2H), 7.00 - 6.87 (m, 2H), 4.67 (d, $J = 15.0$ Hz, 1H), 4.34 - 4.18 (m, 3H), 3.95 (q, $J = 6.2$ Hz, 1H), 3.80 (s, 3H), 3.68 (dt, $J = 8.7, 5.5$ Hz, 1H), 1.09 (d, $J = 6.4$ Hz, 3H). MS m/z 252.2 (M + H).

15 **Intermediate 516:**

(R)-4-((S)-1-fluoroethyl)-3-(4-methoxybenzyl)oxazolidin-2-one




To a cooled (0 °C) solution of (R)-4-((R)-1-hydroxyethyl)-3-(4-methoxybenzyl)oxazolidin-2-one (2.27 g, 9.04 mmol) in 30 mL MeCN were added triethylamine (11.4 mL, 82 mmol) followed by perfluoro-1-butanefluoride (4.9 mL, 27.3 mmol) and $\text{NEt}_3(\text{HF})_3$ (4.5 mL, 27.6 mmol) and the resulting mixture was stirred at 0 °C for 70 min. The reaction mixture was diluted with water (60 mL) and extracted with EtOAc (3 x 60 mL). Combined organics were washed with water (70 mL), brine (70 mL), dried over Na_2SO_4 , filtered and concentrated. Flash column chromatography (EtOAc/heptane 5 to 70%) gave 2.19 g of the desired product. ^1H NMR (400

MHz, CDCl₃) δ 7.25 - 7.20 (m, 2H), 6.92 - 6.83 (m, 2H), 4.87 (d, J = 15.1 Hz, 1H), 4.75 (dq, J = 47.6, 6.6, 2.1 Hz, 1H), 4.26 (td, J = 9.2, 1.4 Hz, 1H), 4.17 - 4.05 (m, 2H), 3.81 (s, 3H), 3.71 (dddd, J = 19.8, 9.5, 5.8, 2.1 Hz, 1H), 1.29 (dd, J = 23.1, 6.2 Hz, 3H). MS m/z 254.5 (M + H).

Intermediate 517:

- 5 (R)-4-((S)-1-fluoroethyl)-3-(4-methoxybenzyl)oxazolidin-2-one




A solution of (R)-4-((S)-1-fluoroethyl)-3-(4-methoxybenzyl)oxazolidin-2-one (1.98 g 7.8 mmol) in 40 mL TFA was heated at 65 °C for 16 h. The reaction mixture was concentrated to remove TFA. Flash column chromatography (EtOAc/CH₂Cl₂, 0 to 100%) gave 0.91 g pale brown solid.

- 10 TLC (1:2 heptane:EtOAc) R_f = 0.25. ¹H NMR (400 MHz, CDCl₃) δ 5.60 (br s, 1H), 4.72 - 4.54 (m, 1H), 4.51 (td, J = 8.9, 0.9 Hz, 1H), 4.32 (dd, J = 9.2, 4.8 Hz, 1H), 4.02 - 3.88 (m, 1H), 1.38 (dd, J = 24.0, 6.3 Hz, 3H).

Intermediate 518:

(R)-3-(2,5-difluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one



15

Step 1: To a solution of (R)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one (6.35 g, 33.9 mmol) in DMF (170 mL) under a nitrogen atmosphere at 0 °C was added sodium hydride (2.14 g, 50.9 mmol, 60%) portion wise over 3 minutes. The reaction mixture was then stirred for 2 hr at 0 °C whereupon 2,4,5-Trifluoropyrimidine (5 g, 37.3 mmol) was added and the reaction mixture
20 allowed to stir 75 minutes at 0 °C then the mixture was allowed to warm to RT and stirred for 1 hr at RT. The reaction mixture was quenched with the slow addition of saturated solution of NH₄Cl and the aqueous mixture extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na₂SO₄), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 50%) provided a colorless oil of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,5-difluoropyrimidin-4-yl)oxazolidin-2-one (6.97 g, 23.1 mmol, 68 % yield)
25




which crystallizes upon standing. ^1H NMR (400 MHz, CDCl_3) 1.10 (d, $J=6.26$ Hz, 3 H) 1.18 (s, 9 H) 4.25 - 4.35 (m, 1 H) 4.49 - 4.62 (m, 2 H) 4.65 - 4.73 (m, 1 H) 8.45 (d, $J=1.57$ Hz, 1 H). LCMS m/z 246.1 (-t-butyl fragment) ($M + H$) $^+$, Rt 0.91 min.

Step 2: To a round bottom flask containing (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,5-difluoropyrimidin-4-yl)oxazolidin-2-one (6.97 g, 23.1 mmol) was added DCM (23 mL) and TFA (23 mL). The resulting reaction mixture stirred for 1 hr at room temperature. The volatiles were then removed and the residue neutralized with a saturated solution of NaHCO_3 . The aqueous mixture was then extracted with EtOAc. The organic phases were combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated to a colorless residue of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,5-difluoropyrimidin-4-yl)oxazolidin-2-one (5.08 g, 20.7 mmol, 90 % yield) which crystallizes upon standing. LCMS m/z 246.1 ($M + H$) $^+$, Rt 0.34 min.

Step 3: To a round bottom flask containing a solution of (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (4.64 g, 18.9 mmol) in Acetonitrile (63 mL) cooled to 0 °C was added perfluorobutanesulfonyl fluoride (10.2 mL, 56.8 mmol) followed by the addition of triethylamine trihydrofluoride (9.2 mL, 56.8 mmol) and triethylamine (23.7 mL, 170 mmol). The resulting reaction mixture allowed to stir at 0 °C for 4 hr. The reaction mixture was then diluted with water and the aqueous mixture was extracted with EtOAc. The organic phases combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided a white crystalline of (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one (2.24 g, 8.97 mmol, 47% yield). ^1H NMR (400 MHz, CDCl_3) 8.50 (s, 1 H), 5.00 - 5.25 (m, 1 H), 4.75 - 4.92 (m, 1 H), 4.54 - 4.68 (m, 2 H), 1.39 (dd, $J=23.1, 7.0$ Hz, 3 H). LCMS m/z 248.0 ($M + H$) $^+$, Rt 0.52 min.

The intermediates in **Table 27c** were prepared using a method similar to that described for the preparation of **Intermediate 247**.

25 **Table 27c.**

Intermediate 519	Intermediate 520	Intermediate 521
		

Intermediate 522





Table 27d. Chemical name, NMR chemical shifts and LCMS signal for each intermediate listed in **Table 27c**.

Intermediate: Name	¹ H NMR (400 MHz, CD ₃ OD) δ ppm	LCMS
519: (S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride		MS <i>m/z</i> 224.1 (M + H) ⁺ ; Rt-0.40 min
520: (S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride		MS <i>m/z</i> 240.1 (M + H) ⁺ ; Rt-0.46 min
521: (S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride		MS <i>m/z</i> 240.0 (M + H) ⁺ ; Rt-0.48 min
522: (S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride		MS <i>m/z</i> 256.0 (M – NH ₂) ⁺ ; Rt-0.47 min

5 EXAMPLES

Example 1


(4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




To a solution of 1-(3-(4-chlorophenyl)isoxazol-5-yl)ethanamine (610 mg, 2.74 mmol) and (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (774 mg, 2.74 mmol) in DMSO (5 ml) was added N-ethyl-N-isopropylpropan-2-amine (2 eq, 0.96 mL, 5.48 mmol) and
 5 heated in a microwave at 120°C for 2 hours. Dilute with EtOAc (50 ml), wash with water (50 ml), brine (50 ml), concentrate *in vacuo*. Flash column chromatography (silica, 40 g) eluting w/ 0-25% EtOAc/DCM afforded 500 mg of white solid : ¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 5.8, 1.6 Hz, 1H), 7.80 – 7.65 (m, 2H), 7.58 (dd, *J* = 5.8, 1.6 Hz, 1H), 7.49 – 7.37 (m, 2H), 6.48 – 6.35 (m, 1H), 5.66 – 5.44 (m, 1H), 4.71 (dddd, *J* = 9.8, 8.5, 4.6, 3.0 Hz, 1H), 4.63 (ddd, *J* =
 10 9.4, 3.1, 2.1 Hz, 1H), 4.50 – 4.26 (m, 2H), 1.71 (s, 1H), 1.25 (s, 5H), 1.15 (s, 5H), 1.03 (dd, *J* = 22.4, 6.4 Hz, 3H), 5.44 – 5.13 (m, 1H). HRMS(B) *t*R = 3.36 min; *m/z* 485.1830

Example 2

(4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-
 15 fluoropyrimidin-4-yl)oxazolidin-2-one



To a solution of (S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethanamine 75 mg, 0.337 mmol) and (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,5-difluoropyrimidin-4-yl)oxazolidin-2-one (101 mg, 0.337 mmol) in DMSO (1 ml) was added N-ethyl-N-isopropylpropan-2-amine (2 eq, 0.118 mL, 0.674 mmol)
 20 and heated in a microwave at 120°C for 2 hours. Dilute with EtOAc (25 ml), wash with water (25 ml), brine (25 ml), concentrate *in vacuo*. Flash column chromatography (silica, 40 g) eluting w/ 0-10% EtOAc/DCM afforded 124 mg yellow foam : ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, *J* = 2.8 Hz, 1H), 7.61 – 7.49 (m, 2H), 7.45 – 7.36 (m, 2H), 7.28 (d, *J* = 6.2 Hz, 1H), 5.65 (d, *J* = 8.9 Hz, 1H), 5.43 – 5.27 (m, 1H), 4.69 (qd, *J* = 5.6, 2.9 Hz, 1H), 4.62 – 4.35 (m,
 25 2H), 4.23 – 4.01 (m, 1H), 1.68 (d, *J* = 12.8 Hz, 2H), 1.26 – 1.16 (m, 2H), 1.12 (s, 8H), 1.05 (d, *J* = 6.4 Hz, 3H). HRMS(C) *t*R = 1.55 min; *m/z* 503.1736


Example 3

To a solution of (S)-1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethanamine
 5 (150 mg, 0.488 mmol) and (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-
 2-one (138 mg, 0.488 mmol) in DMSO (1 ml) was added N-ethyl-N-isopropylpropan-2-amine (2
 eq, 170 uL, 0.975 mmol) and heated in a microwave at 115°C for 2 hours. Dilute with EtOAc
 (25 ml), wash with water (25 ml), brine (25 ml), concentrate *in vacuo*. Flash column
 chromatography (silica, 40 g) eluting w/ 0-5% EtOAc/DCM afforded 140 mg. ¹H NMR (400
 10 MHz, CDCl₃) δ 8.30 – 8.19 (m, 4H), 8.01 (dd, *J* = 8.6, 2.1 Hz, 2H), 7.54 (d, *J* = 5.7 Hz, 2H),
 7.45 (dq, *J* = 8.4, 1.5 Hz, 2H), 4.53 (dd, *J* = 9.3, 2.4 Hz, 2H), 4.05 (p, *J* = 6.1 Hz, 1H), 3.51 (s,
 5H), 1.80 (s, 1H), 1.22 (t, *J* = 6.5 Hz, 12H). Anal. RP-HPLC *t*_R = 2.73 min (Gradient: 2 to 98%
 B in 4.4 min - flow 1 mL/min. Eluent A: Water + 3.75 mM NH₄Ac + 0.001% formic acid. Eluent
 B: ACN. Column: Acquity CSH 1.7µm 2.1x50mm - 50°C.) HRMS *m/z* 514.1039

15

The Following Examples were prepared using a method similar to that described for the
 preparation of **Intermediate 342** or **Example 3**


Example 4: (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-methylphenyl)-1,2,4-
 20 oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 5.6, 2.2 Hz, 3H), 7.96 (d, *J* = 2.0 Hz, 3H), 7.84 (dd,
J = 8.3, 2.1 Hz, 3H), 7.59 (dd, *J* = 5.8, 3.0 Hz, 3H), 7.46 (d, *J* = 8.3 Hz, 3H), 5.71 – 5.42 (m,
 25 3H), 5.32 (s, 1H), 4.75 (dtd, *J* = 10.3, 5.2, 2.9 Hz, 3H), 1.67 – 1.60 (m, 3H), 4.64 (ddd, *J* = 9.2,
 6.2, 2.9 Hz, 3H), 4.49 – 4.31 (m, 6H), 4.14 (q, *J* = 7.1 Hz, 1H), 2.46 (s, 9H), 2.07 (s, 1H), 1.77


(dd, $J = 6.8, 3.2$ Hz, 9H), 1.27 (d, $J = 23.6$ Hz, 29H), 1.05 (dd, $J = 11.3, 6.5$ Hz, 9H). HRMS(C) $t_R = 2.00$ min; MS m/z 500.98

Example 5 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-fluoro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, $J = 5.8, 2.4$ Hz, 3H), 8.02 – 7.83 (m, 6H), 7.59 (dd, $J = 5.8, 2.9$ Hz, 3H), 7.12 (t, $J = 8.9$ Hz, 3H), 5.72 – 5.47 (m, 5H), 5.32 (s, 1H), 4.75 (dtd, $J = 8.7, 4.8, 2.9$ Hz, 3H), 4.64 (ddd, $J = 9.3, 6.2, 2.9$ Hz, 3H), 4.49 – 4.28 (m, 6H), 3.52 (s, 2H), 2.36 (d, $J = 2.0$ Hz, 9H), 1.78 (s, 2H), 1.65 (s, 3H), 1.30 (s, 22H), 1.24 (d, $J = 2.4$ Hz, 6H), 1.05 (dd, $J = 11.3, 6.4$ Hz, 10H). HRMS(C) $t_R = 1.95$ min; m/z 484.2234

Example 6 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, $J = 5.8, 1.7$ Hz, 3H), 7.74 – 7.57 (m, 9H), 7.53 – 7.44 (m, 3H), 5.61 (qt, $J = 16.2, 9.7, 8.6$ Hz, 7H), 5.32 (s, 1H), 4.75 (ddd, $J = 8.6, 4.6, 2.9$ Hz, 3H), 4.64 (ddd, $J = 8.8, 5.8, 2.9$ Hz, 3H), 4.50 – 4.30 (m, 6H), 4.14 (q, $J = 7.2$ Hz, 2H), 4.01 (s, 9H), 2.07 (s, 2H), 1.85 – 1.73 (m, 9H), 1.62 (s, 2H), 1.36 – 1.18 (m, 30H), 1.05 (dd, $J = 10.8, 6.5$ Hz, 9H). HRMS(C) $t_R = 1.61$ min; m/z 516.1888

Example 7 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 5.8, 3.2 Hz, 1H), 8.11 – 7.93 (m, 2H), 7.70 – 7.54 (m, 2H), 5.80 – 5.40 (m, 2H), 4.75 (dtd, *J* = 8.6, 4.3, 2.2 Hz, 1H), 1.67 – 1.60 (m, 1H), 4.64 (ddd, *J* = 9.4, 4.2, 2.9 Hz, 1H), 4.50 – 4.30 (m, 2H), 1.77 (dd, *J* = 6.9, 3.4 Hz, 3H), 1.27 (d, *J* = 21.9 Hz, 9H), 1.06 (dd, *J* = 9.8, 6.5 Hz, 3H). HRMS(C) *t*R = 2.05 min; *m/z* 570.1605

Example 8 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 5.7 Hz, 3H), 8.10 (d, *J* = 1.3 Hz, 3H), 7.84 (dd, *J* = 8.3, 1.4 Hz, 3H), 7.71 (d, *J* = 8.3 Hz, 3H), 7.64 – 7.55 (m, 3H), 7.20 (d, *J* = 3.1 Hz, 3H), 6.55 (dd, *J* = 3.1, 0.8 Hz, 3H), 5.64 (p, *J* = 7.2 Hz, 5H), 5.32 (s, 1H), 1.69 – 1.61 (m, 4H), 4.77 (ddd, *J* = 8.7, 4.7, 2.9 Hz, 3H), 4.65 (td, *J* = 8.8, 8.4, 2.9 Hz, 3H), 4.52 – 4.27 (m, 6H), 3.90 (s, 9H), 3.51 (s, 2H), 1.89 – 1.75 (m, 9H), 1.28 (d, *J* = 23.5 Hz, 27H), 1.06 (dd, *J* = 10.9, 6.4 Hz, 10H). HRMS(C) *t*R = 1.77 min; *m/z* 505.2437


Example 9 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



^1H NMR (400 MHz, CDCl_3) δ 4.64 (ddd, $J = 9.9, 7.1, 2.9$ Hz, 1H), 4.47 – 4.30 (m, 2H), 1.06 (dd, $J = 9.3, 6.4$ Hz, 3H), 1.85 – 1.72 (m, 3H), 1.63 (s, 1H), 1.39 (s, 9H), 1.28 (d, $J = 21.1$ Hz, 9H), 4.84 – 4.71 (m, 1H), 8.25 (d, $J = 5.7$ Hz, 1H), 8.11 (q, $J = 2.0$ Hz, 1H), 7.89 (dt, $J = 7.7, 1.4$ Hz, 1H), 7.66 – 7.52 (m, 2H), 7.43 (t, $J = 7.8$ Hz, 1H), 5.63 (p, $J = 7.3$ Hz, 2H), 5.39 – 5.29 (m, 0H).

5 HRMS(C) $t_R = 2.02$ min; m/z 508.2798


Example 10 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



10 ^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, $J = 5.7, 2.9$ Hz, 1H), 8.04 (dq, $J = 7.8, 1.3$ Hz, 1H), 7.95 (dt, $J = 2.5, 1.2$ Hz, 1H), 7.67 – 7.49 (m, 2H), 7.39 (ddt, $J = 8.2, 2.5, 1.2$ Hz, 1H), 5.62 (h, $J = 6.7, 6.1$ Hz, 2H), 4.75 (dtd, $J = 9.1, 4.7, 2.9$ Hz, 1H), 4.64 (ddd, $J = 9.3, 4.9, 2.9$ Hz, 1H), 4.49 – 4.26 (m, 2H), 1.78 (dd, $J = 6.8, 3.6$ Hz, 3H), 1.61 (s, 1H), 1.27 (d, $J = 23.8$ Hz, 9H), 1.06 (dd, $J = 10.0, 6.5$ Hz, 3H). HRMS(C) $t_R = 1.82$ min; m/z 536.1995

15


Example 11 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-fluoro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



20 ^1H NMR (400 MHz, CDCl_3) δ 8.24 (dd, $J = 5.8, 3.3$ Hz, 1H), 8.13 – 7.99 (m, 2H), 7.60 (dd, $J = 5.8, 2.0$ Hz, 1H), 5.72 – 5.56 (m, 1H), 5.48 (s, 1H), 4.85 – 4.69 (m, 1H), 1.67 – 1.56 (m, 1H), 4.64 (ddd, $J = 9.5, 4.5, 2.9$ Hz, 1H), 4.53 – 4.28 (m, 2H), 1.77 (dd, $J = 7.0, 3.4$ Hz, 3H), 1.27 (d, $J = 22.0$ Hz, 9H), 1.06 (dd, $J = 9.8, 6.4$ Hz, 3H). HRMS(C) $t_R = 1.87$ min; m/z 554.1901


Example 12 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one

25



^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, J = 5.9, 1.9 Hz, 1H), 8.09 – 7.92 (m, 2H), 7.59 (dd, J = 5.7, 3.1 Hz, 1H), 7.43 – 7.32 (m, 2H), 5.60 (dt, J = 15.5, 7.8 Hz, 2H), 4.75 (dtd, J = 8.4, 5.0, 2.9 Hz, 1H), 4.64 (ddd, J = 9.5, 7.1, 2.9 Hz, 1H), 4.49 – 4.27 (m, 2H), 2.99 (hept, J = 6.9 Hz, 1H), 1.76 (dd, J = 7.0, 2.8 Hz, 3H), 1.60 (dd, J = 6.9, 2.8 Hz, 1H), 1.40 – 1.19 (m, 15H), 1.05 (dd, J = 11.0, 6.5 Hz, 3H). HRMS(C) t_R = 2.23 min; m/z 494.2642


Example 13 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(1,2-dimethyl-1H-indol-4-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, J = 5.8 Hz, 1H), 7.91 (dd, J = 7.5, 0.9 Hz, 1H), 7.60 (d, J = 5.8 Hz, 1H), 7.44 (dt, J = 8.2, 1.1 Hz, 1H), 7.33 – 7.20 (m, 1H), 6.99 – 6.89 (m, 1H), 5.66 (p, J = 7.3 Hz, 1H), 4.77 (ddd, J = 8.7, 4.7, 3.0 Hz, 1H), 1.66 – 1.60 (m, 1H), 4.66 (dd, J = 9.5, 3.0 Hz, 1H), 4.53 – 4.44 (m, 1H), 4.38 (q, J = 9.0, 8.3 Hz, 1H), 3.75 (s, 3H), 2.51 (d, J = 0.9 Hz, 3H), 1.84 – 1.76 (m, 3H), 1.28 (d, J = 26.5 Hz, 9H), 1.04 (d, J = 6.5 Hz, 3H). HRMS(C) t_R = 1.65 min; MS m/z 519.60

Example 14


(4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



135 mg orangish-red resin (solidified upon standing). ^1H NMR (400 MHz, CDCl_3) δ 8.25 (d, J = 5.7 Hz, 1H), 7.62 – 7.46 (m, 3H), 7.45 – 7.36 (m, 2H), 4.85 – 4.69 (m, 1H), 4.64 (ddd, J = 9.1, 5.6, 3.0 Hz, 1H), 4.44 (qd, J = 6.4, 4.6 Hz, 1H), 4.34 (dt, J = 15.4, 9.0 Hz, 1H), 2.40 (d, J = 1.3 Hz, 3H), 1.79 – 1.60 (m, 3H), 1.34 – 1.18 (m, 11H), 1.04 (dd, J = 14.8, 6.5 Hz, 3H). HRMS(C)

5 tR = 2.00 min; m/z 499.1986


Example 15 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



10 ^1H NMR (400 MHz, CDCl_3) δ 8.24 (dd, J = 5.6, 2.2 Hz, 3H), 7.96 (d, J = 2.0 Hz, 3H), 7.84 (dd, J = 8.3, 2.1 Hz, 3H), 7.59 (dd, J = 5.8, 3.0 Hz, 3H), 7.46 (d, J = 8.3 Hz, 3H), 5.71 – 5.42 (m, 3H), 5.32 (s, 1H), 4.75 (dtd, J = 10.3, 5.2, 2.9 Hz, 3H), 1.67 – 1.60 (m, 3H), 4.64 (ddd, J = 9.2, 6.2, 2.9 Hz, 3H), 4.49 – 4.31 (m, 6H), 4.14 (q, J = 7.1 Hz, 1H), 2.46 (s, 9H), 2.07 (s, 1H), 1.77 (dd, J = 6.8, 3.2 Hz, 9H), 1.27 (d, J = 23.6 Hz, 29H), 1.05 (dd, J = 11.3, 6.5 Hz, 9H). HRMS(C)

15 tR = 2.00 min; MS m/z 500.98


Example 16 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-fluoro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



20 ^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, J = 5.8, 2.4 Hz, 3H), 8.02 – 7.83 (m, 6H), 7.59 (dd, J = 5.8, 2.9 Hz, 3H), 7.12 (t, J = 8.9 Hz, 3H), 5.72 – 5.47 (m, 5H), 5.32 (s, 1H), 4.75 (dtd, J = 8.7, 4.8, 2.9 Hz, 3H), 4.64 (ddd, J = 9.3, 6.2, 2.9 Hz, 3H), 4.49 – 4.28 (m, 6H), 3.52 (s, 2H), 2.36 (d, J = 2.0 Hz, 9H), 1.78 (s, 2H), 1.65 (s, 3H), 1.30 (s, 22H), 1.24 (d, J = 2.4 Hz, 6H), 1.05 (dd, J = 11.3, 6.4 Hz, 10H). HRMS(C) tR = 1.95 min; m/z 484.2234


25

Example 17 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




¹H NMR (400 MHz, CDCl₃) δ 8.25 (dd, *J* = 5.8, 1.7 Hz, 3H), 7.74 – 7.57 (m, 9H), 7.53 – 7.44 (m, 3H), 5.61 (qt, *J* = 16.2, 9.7, 8.6 Hz, 7H), 5.32 (s, 1H), 4.75 (ddd, *J* = 8.6, 4.6, 2.9 Hz, 3H), 4.64 (ddd, *J* = 8.8, 5.8, 2.9 Hz, 3H), 4.50 – 4.30 (m, 6H), 4.14 (q, *J* = 7.2 Hz, 2H), 4.01 (s, 9H), 2.07 (s, 2H), 1.85 – 1.73 (m, 9H), 1.62 (s, 2H), 1.36 – 1.18 (m, 30H), 1.05 (dd, *J* = 10.8, 6.5 Hz, 9H). HRMS(C) *t*R = 1.61 min; *m/z* 516.1888

Example 18 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 5.8, 3.2 Hz, 1H), 8.11 – 7.93 (m, 2H), 7.70 – 7.54 (m, 2H), 5.80 – 5.40 (m, 2H), 4.75 (dtd, *J* = 8.6, 4.3, 2.2 Hz, 1H), 1.67 – 1.60 (m, 1H), 4.64 (ddd, *J* = 9.4, 4.2, 2.9 Hz, 1H), 4.50 – 4.30 (m, 2H), 1.77 (dd, *J* = 6.9, 3.4 Hz, 3H), 1.27 (d, *J* = 21.9 Hz, 9H), 1.06 (dd, *J* = 9.8, 6.5 Hz, 3H). HRMS(C) *t*R = 2.05 min; *m/z* 570.1605

Example 19 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 5.7 Hz, 3H), 8.10 (d, *J* = 1.3 Hz, 3H), 7.84 (dd, *J* = 8.3, 1.4 Hz, 3H), 7.71 (d, *J* = 8.3 Hz, 3H), 7.64 – 7.55 (m, 3H), 7.20 (d, *J* = 3.1 Hz, 3H), 6.55

(dd, $J = 3.1, 0.8$ Hz, 3H), 5.64 (p, $J = 7.2$ Hz, 5H), 5.32 (s, 1H), 1.69 – 1.61 (m, 4H), 4.77 (ddd, $J = 8.7, 4.7, 2.9$ Hz, 3H), 4.65 (td, $J = 8.8, 8.4, 2.9$ Hz, 3H), 4.52 – 4.27 (m, 6H), 3.90 (s, 9H), 3.51 (s, 2H), 1.89 – 1.75 (m, 9H), 1.28 (d, $J = 23.5$ Hz, 27H), 1.06 (dd, $J = 10.9, 6.4$ Hz, 10H). HRMS(C) $t_R = 1.77$ min; m/z 505.2437


5

Example 20 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




^1H NMR (400 MHz, CDCl_3) δ 4.64 (ddd, $J = 9.9, 7.1, 2.9$ Hz, 1H), 4.47 – 4.30 (m, 2H), 1.06 (dd, $J = 9.3, 6.4$ Hz, 3H), 1.85 – 1.72 (m, 3H), 1.63 (s, 1H), 1.39 (s, 9H), 1.28 (d, $J = 21.1$ Hz, 9H), 4.84 – 4.71 (m, 1H), 8.25 (d, $J = 5.7$ Hz, 1H), 8.11 (q, $J = 2.0$ Hz, 1H), 7.89 (dt, $J = 7.7, 1.4$ Hz, 1H), 7.66 – 7.52 (m, 2H), 7.43 (t, $J = 7.8$ Hz, 1H), 5.63 (p, $J = 7.3$ Hz, 2H), 5.39 – 5.29 (m, 0H). HRMS(C) $t_R = 2.02$ min; m/z 508.2798

15 **Example 21** (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, $J = 5.7, 2.9$ Hz, 1H), 8.04 (dq, $J = 7.8, 1.3$ Hz, 1H), 7.95 (dt, $J = 2.5, 1.2$ Hz, 1H), 7.67 – 7.49 (m, 2H), 7.39 (ddt, $J = 8.2, 2.5, 1.2$ Hz, 1H), 5.62 (h, $J = 6.7, 6.1$ Hz, 2H), 4.75 (dtd, $J = 9.1, 4.7, 2.9$ Hz, 1H), 4.64 (ddd, $J = 9.3, 4.9, 2.9$ Hz, 1H), 4.49 – 4.26 (m, 2H), 1.78 (dd, $J = 6.8, 3.6$ Hz, 3H), 1.61 (s, 1H), 1.27 (d, $J = 23.8$ Hz, 9H), 1.06 (dd, $J = 10.0, 6.5$ Hz, 3H). HRMS(C) $t_R = 1.82$ min; m/z 536.1995

25 **Example 22** (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-fluoro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



^1H NMR (400 MHz, CDCl_3) δ 8.24 (dd, J = 5.8, 3.3 Hz, 1H), 8.13 – 7.99 (m, 2H), 7.60 (dd, J = 5.8, 2.0 Hz, 1H), 5.72 – 5.56 (m, 1H), 5.48 (s, 1H), 4.85 – 4.69 (m, 1H), 1.67 – 1.56 (m, 1H), 4.64 (ddd, J = 9.5, 4.5, 2.9 Hz, 1H), 4.53 – 4.28 (m, 2H), 1.77 (dd, J = 7.0, 3.4 Hz, 3H), 1.27 (d, J = 22.0 Hz, 9H), 1.06 (dd, J = 9.8, 6.4 Hz, 3H). HRMS(C) t_R = 1.87 min; m/z 554.1901

Example 23 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




10

^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, J = 5.9, 1.9 Hz, 1H), 8.09 – 7.92 (m, 2H), 7.59 (dd, J = 5.7, 3.1 Hz, 1H), 7.43 – 7.32 (m, 2H), 5.60 (dt, J = 15.5, 7.8 Hz, 2H), 4.75 (dtd, J = 8.4, 5.0, 2.9 Hz, 1H), 4.64 (ddd, J = 9.5, 7.1, 2.9 Hz, 1H), 4.49 – 4.27 (m, 2H), 2.99 (hept, J = 6.9 Hz, 1H), 1.76 (dd, J = 7.0, 2.8 Hz, 3H), 1.60 (dd, J = 6.9, 2.8 Hz, 1H), 1.40 – 1.19 (m, 15H), 1.05 (dd, J = 11.0, 6.5 Hz, 3H). HRMS(C) t_R = 2.23 min; m/z 494.2642

15

Example 24 (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(1,2-dimethyl-1H-indol-4-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, J = 5.8 Hz, 1H), 7.91 (dd, J = 7.5, 0.9 Hz, 1H), 7.60 (d, J = 5.8 Hz, 1H), 7.44 (dt, J = 8.2, 1.1 Hz, 1H), 7.33 – 7.20 (m, 1H), 6.99 – 6.89 (m, 1H), 5.66 (p, J = 7.3 Hz, 1H), 4.77 (ddd, J = 8.7, 4.7, 3.0 Hz, 1H), 1.66 – 1.60 (m, 1H), 4.66 (dd, J = 9.5, 3.0

20


Hz, 1H), 4.53 – 4.44 (m, 1H), 4.38 (q, $J = 9.0, 8.3$ Hz, 1H), 3.75 (s, 3H), 2.51 (d, $J = 0.9$ Hz, 3H), 1.84 – 1.76 (m, 3H), 1.28 (d, $J = 26.5$ Hz, 9H), 1.04 (d, $J = 6.5$ Hz, 3H). HRMS(C) tR = 1.65 min; MS m/z 519.60

- 5 **Example 25** (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



- 135 mg orange-red resin (solidified upon standing). ^1H NMR (400 MHz, CDCl_3) δ 8.25 (d, $J = 5.7$ Hz, 1H), 7.62 – 7.46 (m, 3H), 7.45 – 7.36 (m, 2H), 4.85 – 4.69 (m, 1H), 4.64 (ddd, $J = 9.1, 5.6, 3.0$ Hz, 1H), 4.44 (qd, $J = 6.4, 4.6$ Hz, 1H), 4.34 (dt, $J = 15.4, 9.0$ Hz, 1H), 2.40 (d, $J = 1.3$ Hz, 3H), 1.79 – 1.60 (m, 3H), 1.34 – 1.18 (m, 11H), 1.04 (dd, $J = 14.8, 6.5$ Hz, 3H). HRMS(C) tR = 2.00 min; m/z 499.1986


- 15 **Example 26** (4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(4-(4-chlorophenyl)-5-methylthiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one



- 200 mg (white solid). ^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, $J = 2.9, 1.0$ Hz, 1H), 7.68 – 7.52 (m, 2H), 7.47 – 7.35 (m, 2H), 5.99 – 5.65 (m, 1H), 5.49 – 5.20 (m, 1H), 4.67 (ddt, $J = 21.5, 8.9, 5.4$ Hz, 1H), 4.58 – 4.40 (m, 2H), 4.22 – 4.05 (m, 1H), 2.53 (d, $J = 6.0$ Hz, 3H), 1.74 (s, 1H), 1.16 (s, 5H), 1.13 – 1.05 (m, 6H), 1.01 (d, $J = 6.4$ Hz, 3H). HRMS(B) tR = 5.16 min; m/z 534.1744

Example 27


- 25 (4R)-3-(2-((1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-(tert-butoxy)ethyl)oxazolidin-2-one



210 mg (white solid). ^1H NMR (400 MHz, CDCl_3) δ 8.25 (dd, $J = 2.9, 1.9$ Hz, 1H), 7.87 – 7.71 (m, 2H), 7.62 – 7.50 (m, 2H), 7.40 (d, $J = 8.7$ Hz, 1H), 5.85 (d, $J = 15.8$ Hz, 1H), 5.58 – 5.36 (m, 1H), 4.81 – 4.57 (m, 1H), 4.57 – 4.39 (m, 2H), 4.23 – 4.00 (m, 1H), 2.07 (s, 2H), 1.77 (s, 1H),
 5 1.16 (s, 5H), 1.11 (d, $J = 6.4$ Hz, 2H), 1.06 (s, 5H), 0.98 (d, $J = 6.4$ Hz, 2H). HRMS(B) tR = 5.15 min; m/z 566.1079 (M+H).


Example 28 (R)-3-(2-(((S)-1-(1-(4-chloro-3-(trifluoromethoxy)phenyl)piperidin-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one

10



(R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(1-(4-chloro-3-(trifluoromethoxy) phenyl)piperidin-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one (34 mg, 0.058 mmole) was dissolved in DCM (1 mL), TFA (1 mL) was added. The reaction solution was stirred for 2 hour at room
 15 temperature and was concentrated by rotary evaporation. The resulting residue was dissolved in DCM (2 mL) and water 2 mL) and the pH was adjusted to ~9 with NH_4OH . The DCM layer was separated and concentrated by rotary evaporation to afford 28 mg of the title product as a yellow oil (ratio of two peaks with same MS: 96/4% by LC-MS). (400 MHz, CD_2Cl_2) δ 8.22 (d, $J = 2.27$ Hz, 1H), 7.31 (d, $J = 8.85$ Hz, 1H), 6.88 – 6.79 (m, 2H), 5.12 (br s, 1H), 4.61 – 4.50 (m,
 20 2H), 4.46 – 4.37 (m, 1H), 4.26 – 4.15 (m, 1H), 3.93 (br s, 1H), 3.77 – 3.68 (m, 2H), 3.20 (br s, 1H), 2.79 – 2.67 (m, 2H), 1.96 – 1.78 (m, 2H), 1.70 – 1.58 (m, 1H), 1.55 – 1.28 (m, 2H), 1.23 (d, $J = 6.63$ Hz, 3H), 1.19 (d, $J = 7.19$ Hz, 3H), HRMS(C) tR = 4.47 min; MS m/z 548.1689 (M+H)+


25 **Example 29** (R)-3-(5-fluoro-2-(((S)-1-(1-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one



A cloudy solution of (R)-4-(((S)-1-(tert-butoxy)ethyl)-3-(5-fluoro-2-(((S)-1-(piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (21 mg, 0.051 mmol), 4-bromo-2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridine (14 mg, 0.051 mmol), Pd(OAc)₂ (1 mg, 5 μmol), BINAP (3 mg, 5 μmol), and Cs₂CO₃ (25 mg, 0.077 mmol) in 6 mL toluene was heated at 90°C overnight. The mixture was cooled to room temperature, and filtered through Celite. The celite cake was rinsed with 5 mL EtOAc. The filtrate was poured into 5 mL water. Organic layer was separated, and the aqueous was further extracted with EtOAc (5 mL). The organic extracts were combined and concentrated by rotary evaporation. The resulting crude was dissolved in DCM (1 mL), TFA (1 mL) was added. The reaction solution was stirred for 2 hour at room temperature and was concentrated by rotary evaporation. The resulting residue was dissolved in DCM (2 mL) and water (2 mL) and the pH was adjusted to ~9 with NH₄OH. The DCM layer was separated and concentrated by rotary evaporation. The crude was dissolved in a mixture of MeOH (1 mL) and DMSO (1 mL) and purified by reverse phase HPLC. Selected fractions were collected and concentrated by rotary evaporation to afford the title product as a colorless oil (5 mg) (ratio of two peaks with same MS: 93/7% by LC-MS). (400 MHz, CD₂Cl₂) δ 8.16 – 8.08 (m, 2H), 6.79 – 6.75 (m, 1H), 6.57 – 6.52 (m, 1H), 4.97 – 4.86 (m, 1H), 4.47 – 4.39 (m, 2H), 4.33 – 4.25 (m, 1H), 4.11 – 4.02 (m, 1H), 3.89 – 3.75 (m, 3H), 2.97 (br s, 1H), 2.80 – 2.67 (m, 2H), 1.84 – 1.67 (m, 2H), 1.67 – 1.55 (m, 1H), 1.48 (s, 6H), 1.38 – 1.15 (m, 2H), 1.11 (d, J = 5.91 Hz, 3H), 1.07 (d, J = 5.91 Hz, 3H), HRMS(C) tR = 3.59 min; MS m/z 541.2557 (M+H)⁺

Examples 30, 31, 32, and 33

3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one




To a solution of (S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethanamine 72 mg, 0.322 mmol) and 3-(2-fluoropyrimidin-4-yl)-4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one (90 mg, 0.322 mmol) in DMSO (1 mL) was added N-ethyl-N-isopropylpropan-2-amine (2 eq, 0.113 mL, 0.645 mmol) and heated in a microwave at 120°C for 2 hours. Dilute with EtOAc (25 mL), wash with water

(25 ml), brine (25 ml), concentrate *in vacuo*. Flash column (silica, 40 g, 50 μ) eluting w/ 0-5% EtOAc/DCM followed by Flash column (silica, 80 g, 15 μ) eluting w/ 0-5% EtOAc/heptane separated 2 major peaks which were further separated via chiral SFC chromatography on an ID column (75 g/min, 120 bar, 21 x 250 mm) eluting 35% IPA/CO₂ (v/v) to give:

- 5 Example 30, Peak 1 : 10 mg (white foam) : ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 5.8 Hz, 1H), 8.09 – 7.95 (m, 2H), 7.58 (d, *J* = 5.7 Hz, 1H), 7.54 – 7.41 (m, 2H), 5.83 (s, 1H), 5.28 (s, 1H), 4.72 (s, 1H), 4.54 (dd, *J* = 9.6, 2.5 Hz, 1H), 4.37 (d, *J* = 9.5 Hz, 1H), 3.44 – 3.15 (m, 1H), 1.78 (d, *J* = 7.0 Hz, 3H), 1.63 (s, 1H), 1.32 (d, *J* = 7.3 Hz, 3H), 1.23 (d, *J* = 6.1 Hz, 3H). HRMS *m/z* **482.1081**, RT= 2.90 min. Chiral RT = 2.15 min
- 10 Example 31, Peak 2 : 38 mg (white foam) : ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 5.7 Hz, 1H), 8.09 – 7.93 (m, 2H), 7.58 (d, *J* = 5.7 Hz, 1H), 7.53 – 7.41 (m, 2H), 5.84 (s, 1H), 5.33 (s, 1H), 4.72 (s, 1H), 4.55 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.35 (t, *J* = 8.8 Hz, 1H), 3.39 – 3.17 (m, 1H), 1.78 (d, *J* = 7.0 Hz, 3H), 1.62 (d, *J* = 6.9 Hz, 1H), 1.32 (d, *J* = 7.3 Hz, 3H), 1.23 (d, *J* = 6.2 Hz, 1H). HRMS *m/z* **482.1081**, RT= 2.89 min. Chiral RT = 2.43 min
- 15 Example 32, Peak 3 : 45 mg (white foam) ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 5.8 Hz, 1H), 8.09 – 7.91 (m, 2H), 7.59 (d, *J* = 5.7 Hz, 1H), 7.52 – 7.38 (m, 2H), 6.22 (s, 1H), 5.38 (d, *J* = 48.6 Hz, 1H), 4.86 (dd, *J* = 8.2, 4.2 Hz, 1H), 1.83 – 1.75 (m, 3H), 4.56 (dd, *J* = 9.3, 2.5 Hz, 1H), 4.43 (t, *J* = 9.2 Hz, 1H), 3.50 (s, 1H), 2.97 (d, *J* = 46.0 Hz, 1H), 1.23 (d, *J* = 6.2 Hz, 1H), 1.12 (d, *J* = 7.6 Hz, 3H). HRMS *m/z* **482.1081**, RT= 2.86 min. Chiral RT = 2.55 min
- 20 Example 33, Peak 4 : 12 mg (white foam) ¹H NMR (400 MHz, CDCl₃) δ 8.28 (d, *J* = 5.8 Hz, 1H), 8.11 – 7.92 (m, 2H), 7.60 (d, *J* = 5.6 Hz, 1H), 7.53 – 7.40 (m, 2H), 5.77 (s, 1H), 5.45 (s, 1H), 4.96 – 4.77 (m, 1H), 4.57 (dd, *J* = 9.5, 2.4 Hz, 1H), 4.44 (t, *J* = 9.1 Hz, 1H), 2.94 (s, 1H), 1.79 (d, *J* = 7.1 Hz, 3H), 1.63 (d, *J* = 7.1 Hz, 1H), 1.23 (d, *J* = 6.1 Hz, 2H), 1.20 – 1.08 (m, 3H). HRMS *m/z* 482.1081, RT= 2.86 min. Chiral RT = 2.66 min

25


Example 34 3-(5-fluoro-2-(((S)-1-(3-fluoro-4-(hydroxymethyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one



- To a solution of (S)-4-(1-aminoethyl)-2-fluorophenyl)methanol (62.6 mg, 0.37 mmol) and 3-(2-
 30 fluoropyrimidin-4-yl)-4-(1,1,1-trifluoropropan-2-yl)oxazolidin-2-one (110 mg, 0.37 mmol) in DMSO (1 ml) was added N-ethyl-N-isopropylpropan-2-amine (2 eq, 0.129 mL, 0.74 mmol) and heated in a microwave at 120°C for 2 hours. Dilute with EtOAc (25 ml), wash with water (25

ml), brine (25 ml), concentrate *in vacuo*. Flash column (silica, 40 g, 50 μ) eluting w/ 5-50% EtOAc/DCM afforded 155 mg (white foam) : ^1H NMR (400 MHz, CDCl_3) δ 8.22 (dd, J = 6.6, 2.6 Hz, 1H), 7.40 (td, J = 7.8, 5.2 Hz, 1H), 7.12 (ddd, J = 7.8, 4.6, 1.6 Hz, 1H), 7.03 (ddd, J = 10.9, 6.3, 1.7 Hz, 1H), 5.52 (d, J = 22.7 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.75 (d, J = 9.6 Hz, 3H),
 5 4.59 (dt, J = 15.7, 9.1 Hz, 1H), 4.41 (ddd, J = 12.4, 9.1, 6.2 Hz, 1H), 1.89 (d, J = 18.6 Hz, 1H), 1.16 (d, J = 7.2 Hz, 1H), 1.04 – 0.74 (m, 2H). HRMS m/z 446.1377, RT= 2.03 min.


Example 35



10 A solution of (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (18.6 mg, 0.082 mmol) and 1-(5-(2,3-dichlorophenyl)pyrimidin-2-yl)ethanamine (22 mg, 0.082 mmol) in DMSO (2 mL) was heated at 100 °C for 2 h. The reaction mixture was poured into water (20 mL), and extracted with EtOAc (2 x 20 mL). Combined organics were dried over Na_2SO_4 ,
 15 filtered and concentrated. Silica gel column chromatography ((25% MeOH in EtOAc)/Heptane 10 to 100%) provided (4R)-3-(2-(1-(5-(2,3-dichlorophenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (12 mg, approx 1:1 mixture of diastereomers) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.72 (s, 4H), 8.15 (d, J = 5.7 Hz, 2H), 7.51 (ddd, J = 8.1, 2.8, 1.6 Hz, 2H), 7.40 – 7.11 (m, 6H), 6.07 – 5.96 (m, 2H), 5.32 (t, J = 7.4 Hz, 1H), 5.09 (s, 1H), 4.81 (s, 1H), 4.68 (s, 1H), 4.43 (dd, J = 7.3, 4.8 Hz, 2H), 4.33 (dd, J = 9.4, 8.3 Hz, 1H),
 20 4.18 (d, J = 9.0 Hz, 2H), 3.62 (s, 1H), 3.23 (s, 1H), 1.62-1.58 (m, 6H), 1.07 – 0.97 (m, 3H), 0.87 – 0.77 (m, 3H). HRMS m/z 475.1039 and 475.1042 ($M + \text{H}$) $^+$.


Example 36

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (68 mg, 0.18 mmol) in 3 ml of DCM was cooled to 0°C, treated with 1 ml of TFA, it was stirred at same temperature for 4 hours, the solvent was removed to yield the product as a TFA salt form, it was dissolved in 2 ml of MeOH, the TFA was removed by using a PL-HCO₃ MP SPE(0.9 mmol) cartridge, the solvent was removed to yield the pure product (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a white solid (52 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 5.8 Hz, 1H), 7.43 (d, *J* = 5.8 Hz, 1H), 7.40 – 7.31 (m, 4H), 7.31 – 7.24 (m, 1H), 5.84 (s, 1H), 4.94 (s, 1H), 4.58 (q, *J* = 4.9, 3.2 Hz, 1H), 4.40 (dd, *J* = 9.3, 2.8 Hz, 1H), 4.31 (t, *J* = 8.9 Hz, 1H), 1.56 (d, *J* = 7.0 Hz, 3H), 0.98 – 0.74 (m, 3H). HRMS *m/z* 329.1619 (M + H)⁺, RT = 2.23 min.

Example 37 and 38












(4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (97 mg, 0.17 mmol) was treated with 90% TFA/water for 2 hours. Concentrate *in vacuo* and neutralized by passing through a column of MP-carbonate resin (2.0 g, 0.55 mmol/g eluting with MeOH/DCM/MeOH afforded 58 mg of (R)-3-(2-(((R)-1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one as a waxy off-white foam. Separated the diastereomers via chiral SFC chromatography on an AD-H column (75 g/min, 120 bar, 21 x 250 mm) eluting 25% IPA/CO₂ (v/v) to give (R)-3-(2-(((R)-1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(3-chloro-4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one
















Example 37 Peak 1: 23 mg (off-white foam). ¹H NMR (400 MHz, CDCl₃) δ 8.32 – 8.17 (m, 4H), 8.01 (dd, *J* = 8.6, 2.1 Hz, 2H), 7.54 (d, *J* = 5.7 Hz, 2H), 7.45 (dq, *J* = 8.4, 1.5 Hz, 2H), 6.16 (s, 2H), 5.32 (s, 3H), 4.82 – 4.60 (m, 2H), 4.53 (dd, *J* = 9.3, 2.4 Hz, 2H), 4.43 (s, 2H), 4.29 (q, *J* = 8.9 Hz, 2H), 4.05 (p, *J* = 6.1 Hz, 1H), 3.51 (s, 5H), 1.80 (s, 1H), 1.22 (t, *J* = 6.5 Hz, 12H). HRMS(B) *t*R = 2.75 min. MS *m/z* 514.0979 Chiral RT = 2.10 min













Example 38 Peak 2: 58 mg (off-white foam). ^1H NMR (400 MHz, CDCl_3) δ 8.23 (dd, $J = 12.4$, 3.9 Hz, 8H), 8.01 (dd, $J = 8.5$, 2.1 Hz, 4H), 7.71 – 7.36 (m, 8H), 6.29 (s, 4H), 5.37 (d, $J = 37.2$ Hz, 5H), 4.86 (ddd, $J = 7.7$, 4.9, 2.4 Hz, 4H), 4.55 (dd, $J = 9.5$, 2.6 Hz, 4H), 4.41 (t, $J = 8.9$ Hz, 4H), 4.19 – 3.77 (m, 5H), 3.51 (s, 3H), 1.83 (s, 1H), 1.23 (d, $J = 6.1$ Hz, 4H), 1.12 – 0.95 (m, 5 12H). HRMS(B) $t_R = 2.73$ min. MS m/z 514.0979 Chiral RT = 3.70 min

The compounds in **Table 28a** were prepared using methods similar to those described for the preparation of **Examples 35, 36, or 37/38**.

10 **Table 28a**

39	40	41
		
42	43	44
		
45	46	47
		
48	49	50

		
51	52	53
		
54	55	56
		
57	58	59
		
60	61	62
		
63	64	65

		
66	67	68
		
69	70	71
		
72	73	74
		
75	76	77






		
78	79	
		

Table 28b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 28a.

Example: Name	¹ H NMR (400 MHz) δ ppm	LCMS
39 : (4R)-3-(2-(1-(5-(5-fluoro-2-methylphenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) δ 8.71 (d, J = 1.8 Hz, 4H), 8.23 (dd, J = 5.8, 1.0 Hz, 2H), 7.44 (dd, J = 12.1, 5.7 Hz, 2H), 7.35 – 7.26 (m, 3H), 7.08 (tt, J = 8.4, 2.8 Hz, 2H), 6.95 (dt, J = 9.0, 2.7 Hz, 2H), 6.16 (t, J = 8.5 Hz, 2H), 5.41 (p, J = 7.0 Hz, 1H), 5.20 (s, 1H), 4.91 (s, 1H), 4.78 (s, 1H), 4.58 – 4.49 (m, 2H), 4.42 (dd, J = 9.4, 8.3 Hz, 2H), 4.29 (s, 2H), 3.84 (s, 1H), 3.48 (br s, 1H), 2.27 (s, 6H), 1.95 (br s, 2H), 1.71-1.67 (m, 3H), 1.38 – 1.18 (m, 6H), 1.12 (br s, 3H) (approx 1:1 mixture of diastereomers)	HRMS (B) m/z 439.1865 and 439.1865 (M + H) ⁺
40 : (4R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(5-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(CDCl ₃) δ 8.95 (s, 4H), 8.41 (d, J = 5.8, 1H), 8.21 (d, J = 5.8 Hz, 1H), 7.92 – 7.66 (m, 7H), 7.48 - 7.44 (m, 3H), 6.45 - 6.35 (m, 2H), 5.41 (p, J = 6.9 Hz, 1H), 5.22 (br s, 1H), 4.94 - 4.90	HRMS (B) m/z 475.1684 (M + H) ⁺

	(m, 2H), 4.78 (br s, 1H), 4.65 – 4.35 (m, 4H), 4.30 (br s, 1H), 3.49 (br s, 1H), 2.77 (br s, 1H), 1.70 - 1.66 (m, 6H), 1.25 - 1.21 (m, 3H), 1.09 (br s, 3H) (approx 1:1 mixture of diastereomers)	
41 : (4R)-3-(2-(1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) δ 8.85 – 8.75 (m, 4H), 8.16 – 8.08 (m, 2H), 7.38 – 7.20 (m, 6H), 7.09 - 7.05 (m, 2H), 6.08 - 6.04 (m, 2H), 5.34 – 5.25 (m, 1H), 5.14 – 5.10 (m, 1H), 4.86 – 4.78 (m, 1H), 4.57 (dd, <i>J</i> = 9.5, 2.8 Hz, 1H), 4.49 – 4.28 (m, 3H), 3.54 (br s, 1H), 2.29 (br s, 6H), 1.58 - 1.53 (m, 6H), 1.19 – 1.12 (m, 3H), 1.00 (br s, 3H) (approx 1:1 mixture of diastereomers)	HRMS (B) <i>m/z</i> 439.1875 (M + H) ⁺ .
42 : (4R)-3-(2-((1-(5-(tert-butyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) δ 8.74 - 8.72 (m, 4H), 8.20 (d, <i>J</i> = 5.8 Hz, 2H), 7.46 – 7.40 (m, 2H), 6.19 - 6.15 (m, 2H), 5.37 – 5.29 (m, 1H), 5.30 (s, 1H), 4.98 – 4.86 (m, 1H), 4.82 (s, 1H), 4.61 – 4.50 (m, 3H), 4.47 – 4.37 (m, 2H), 4.32 – 4.21 (m, 2H), 3.84 (s, 1H), 1.63 - 1.58 (m, 6H), 1.39 - 1.37 (m, 18H), 1.24 - 1.20 (m, 3H), 1.14 – 1.00 (m, 3H) (approx 1:1 mixture of diastereomers)	HRMS (B) <i>m/z</i> 387.2135 (M + H) ⁺
43 : (4R)-4-((R)-1-hydroxyethyl)-3-(2-(1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	(CDCl ₃) δ 8.94 (d, <i>J</i> = 4.4 Hz, 4H), 8.23 (dd, <i>J</i> = 5.8, 2.2 Hz, 2H), 7.86 – 7.63 (m, 8H), 7.44 (dd, <i>J</i> = 13.5, 5.7 Hz, 2H), 6.12 (dd, <i>J</i> = 15.1, 7.4 Hz, 2H), 5.41 (t, <i>J</i> = 7.4 Hz, 1H), 5.20 (br s, 1H), 4.89 (d, <i>J</i> = 6.7 Hz, 1H), 4.80 (s, 1H), 4.58 – 4.48 (m, 2H), 4.43 (dd, <i>J</i> = 9.3, 8.2 Hz, 2H), 4.30 (br s, 1H), 3.77 (br s, 1H), 3.36 (br s, 1H), 1.90 (br s, 3H), 1.69 (d, <i>J</i> = 2.2 Hz, 3H),	HRMS (B) <i>m/z</i> 475.1682 and 475.1689 (M + H) ⁺ .

	1.37 – 1.17 (m, 3H), 1.12 (br s, 3H) (approx 1:1 mixture of diastereomers)	
44 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-phenoxyphenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(CDCl ₃) δ 8.21 (d, <i>J</i> = 5.9 Hz, 1H), 7.45 (d, <i>J</i> = 5.7 Hz, 1H), 7.42 – 7.26 (m, 4H), 7.13 (dd, <i>J</i> = 8.1, 6.7 Hz, 1H), 7.07 – 6.88 (m, 4H), 5.66 (b, 1H), 4.97 (s, 1H), 4.67 (ddd, <i>J</i> = 8.2, 5.1, 2.5 Hz, 1H), 4.51 – 4.25 (m, 2H), 3.61 (b, 1H), 1.56 (d, <i>J</i> = 6.9 Hz, 3H), 0.95 (d, <i>J</i> = 22.9 Hz, 3H).	HRMS (B) <i>m/z</i> 421.1875, (M+H) ⁺ , RT=2.56 min.
45 : (4R)-3-(2-((1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one		HRMS (B) <i>m/z</i> 441.1676, (M+H) ⁺ , RT=2.13 min.
46 : (4R)-3-(2-((1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one.		HRMS (B) <i>m/z</i> 431.1219, (M+H) ⁺ , RT=2.16 min.
47 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 9.13 (d, <i>J</i> = 1.5 Hz, 1H), 8.73 (d, <i>J</i> = 1.4 Hz, 1H), 8.39 (s, 1H), 8.32 (d, <i>J</i> = 7.9 Hz, 1H), 8.16 (d, <i>J</i> = 5.9 Hz, 1H), 7.78 (d, <i>J</i> = 7.8 Hz, 1H), 7.72 (t, <i>J</i> = 7.8 Hz, 1H), 7.39 (d, <i>J</i> = 5.8 Hz, 1H), 5.28 (q, <i>J</i> = 7.0 Hz, 1H), 4.51 (dd, <i>J</i> = 9.2, 2.8 Hz, 1H), 4.39 (t, <i>J</i> = 8.9 Hz, 1H), 3.81 (br s, 0H), 1.65 (d, <i>J</i> = 7.1 Hz, 3H), 0.80 (br s, 3H);	HRMS <i>m/z</i> 475.1686 (M + H) ⁺ .
48 : (R)-3-(2-((S)-1-(3-fluoro-4-((3,3,4-trimethylpiperazin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-	¹ H NMR (400 MHz, MeOD) δ 8.11 (d, <i>J</i> = 5.8 Hz, 1H), 7.40 – 7.30 (m, 2H), 7.16 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.07 (dd, <i>J</i> = 11.2, 1.7 Hz, 1H), 5.08 (q, <i>J</i> =	HRMS <i>m/z</i> 487.2808 (M + H) ⁺ .

2-one	7.0 Hz, 1H), 4.80 (br s, 1H), 4.52 (dd, $J = 9.2, 2.8$ Hz, 1H), 4.38 (t, $J = 8.9$ Hz, 1H), 3.99 (br s, 1H), 3.48 (s, 2H), 2.55 (t, $J = 4.9$ Hz, 2H), 2.48 (br s, 2H), 2.20 – 2.18 (m, 5H), 1.50 (d, $J = 7.0$ Hz, 3H), 1.04 (s, 6H), 0.78 (br s, 3H) ;	
49 : (R)-3-(2-(((S)-1-(4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorophenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.11 (d, $J = 5.8$ Hz, 1H), 7.38 – 7.30 (m, 2H), 7.18 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.10 (d, $J = 11.3$ Hz, 1H), 5.08 (q, $J = 6.9$ Hz, 1H), 4.80 (br s, 1H), 4.52 (dd, $J = 9.1, 2.8$ Hz, 1H), 4.38 (t, $J = 8.9$ Hz, 1H), 4.01 (br s, 1H), 3.60 (s, 2H), 2.60 – 2.58 (m, 4H), 2.05 – 1.89 (m, 4H), 1.50 (d, $J = 7.0$ Hz, 3H), 0.77 (br s, 3H)	HRMS m/z 480.2204 (M + H) ⁺ .
50 : (R)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.70 (d, $J = 2.5$ Hz, 1H), 8.14 (s, 1H), 7.97 (dd, $J = 8.2, 2.3$ Hz, 1H), 7.55 - 7.43 (m, 3H), 7.36 (d, $J = 5.8$ Hz, 1H), 7.13 (dd, $J = 9.5, 8.5$ Hz, 1H), 5.16 (q, $J = 7.0$ Hz, 1H), 4.78 (br s, 1H), 4.51 (dd, $J = 9.3, 2.7$ Hz, 1H), 4.37 (t, $J = 8.9$ Hz, 1H), 3.67 (br s, 1H), 2.33 (d, $J = 1.9$ Hz, 3H), 1.59 (d, $J = 7.1$ Hz, 3H), 0.68 (br s, 3H);	HRMS m/z 438.1927 (M + H) ⁺ .
51 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.79 (d, $J = 2.5$ Hz, 1H), 8.14 (s, 1H), 8.06 (dd, $J = 8.3, 2.4$ Hz, 1H), 7.95 - 7.89 (m, 2H), 7.74 - 7.64 (m, 2H), 7.55 (d, $J = 8.2$ Hz, 1H), 7.36 (d, $J = 5.7$ Hz, 1H), 5.18 (q, $J = 7.0$ Hz, 1H), 4.79 (s, 1H), 4.51 (dd, $J = 9.1, 2.7$ Hz, 1H), 4.37 (t, $J = 8.9$ Hz, 1H), 3.63 (br s, 1H), 1.60 (d, $J = 7.0$ Hz, 3H), 0.68 (br s, 3H);	HRMS m/z 474.1739 (M + H) ⁺ .

52 : (R)-3-(2-(((S)-1-(6-(4-fluoro-3-methylphenyl)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.60 (d, <i>J</i> = 2.2 Hz, 1H), 8.13 (d, <i>J</i> = 6.0 Hz, 1H), 7.88 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.84 - 7.69 (m, 3H), 7.35 (d, <i>J</i> = 5.8 Hz, 1H), 7.12 (t, <i>J</i> = 9.0 Hz, 1H), 5.17 (q, <i>J</i> = 7.0 Hz, 1H), 4.83 (br s, 1H), 4.52 (dd, <i>J</i> = 9.3, 2.7 Hz, 1H), 4.39 (t, <i>J</i> = 8.9 Hz, 1H), 3.87 (br s, 1H), 2.33 (d, <i>J</i> = 1.9 Hz, 3H), 1.59 (d, <i>J</i> = 7.0 Hz, 3H), 0.76 (br s, 3H);	HRMS <i>m/z</i> 438.1985 (<i>M</i> + <i>H</i>) ⁺ .
53 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.68 (d, <i>J</i> = 2.1 Hz, 1H), 8.27 (s, 1H), 8.19 (d, <i>J</i> = 7.7 Hz, 1H), 8.14 (d, <i>J</i> = 5.8 Hz, 1H), 7.98 - 7.85 (m, 2H), 7.76 - 7.62 (m, 2H), 7.35 (d, <i>J</i> = 5.8 Hz, 1H), 5.19 (q, <i>J</i> = 7.0 Hz, 1H), 4.83 (s, 1H), 4.52 (dd, <i>J</i> = 9.1, 2.7 Hz, 1H), 4.39 (t, <i>J</i> = 8.9 Hz, 1H), 3.84 (br s, 1H), 1.60 (d, <i>J</i> = 7.1 Hz, 3H), 0.75 (br s, 3H);	HRMS <i>m/z</i> 474.1816 (<i>M</i> + <i>H</i>) ⁺ .
54 : (R)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 9.00 (d, <i>J</i> = 1.5 Hz, 1H), 8.65 (d, <i>J</i> = 1.5 Hz, 1H), 8.15 (d, <i>J</i> = 5.9 Hz, 1H), 7.94 (ddd, <i>J</i> = 7.3, 2.3, 0.9 Hz, 1H), 7.87 (ddd, <i>J</i> = 7.7, 4.9, 2.4 Hz, 1H), 7.38 (d, <i>J</i> = 5.8 Hz, 1H), 7.16 (dd, <i>J</i> = 9.5, 8.6 Hz, 1H), 5.25 (q, <i>J</i> = 7.0 Hz, 1H), 4.82 (br s, 1H), 4.51 (dd, <i>J</i> = 9.3, 2.8 Hz, 1H), 4.38 (t, <i>J</i> = 8.9 Hz, 1H), 3.84 (br s, 1H), 2.35 (d, <i>J</i> = 1.8 Hz, 3H), 1.63 (d, <i>J</i> = 7.1 Hz, 3H), 0.80 (br s, 3H);	HRMS <i>m/z</i> 439.1872 (<i>M</i> + <i>H</i>) ⁺ .
55 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.95 (d, <i>J</i> = 2.3 Hz, 1H), 8.79 (d, <i>J</i> = 5.1 Hz, 1H), 8.22 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 8.19 - 8.11 (m, 2H), 7.99 (dd, <i>J</i> = 5.1, 1.7 Hz, 1H), 7.61 (d, <i>J</i> = 8.3 Hz, 1H),	HRMS <i>m/z</i> 475.1685 (<i>M</i> + <i>H</i>) ⁺ .

	7.37 (d, $J = 5.8$ Hz, 1H), 5.19 (q, $J = 7.0$ Hz, 1H), 4.78 (s, 1H), 4.55 - 4.45 (m, 1H), 4.37 (t, $J = 8.9$ Hz, 1H), 3.73 - 3.44 (m, 1H), 1.60 (d, $J = 7.0$ Hz, 3H), 0.69 (br s, 3H);	
56 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(6'-(trifluoromethyl)-[2,3'-bipyridin]-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 9.30 (d, $J = 2.0$ Hz, 1H), 8.75 (s, 1H), 8.60 (dd, $J = 8.2, 2.1$ Hz, 1H), 8.14 (d, $J = 5.8$ Hz, 5H), 7.98 (t, $J = 1.4$ Hz, 2H), 7.93 (d, $J = 8.4$ Hz, 1H), 7.36 (d, $J = 5.8$ Hz, 1H), 5.20 (q, $J = 7.0$ Hz, 1H), 4.83 (br s, 1H), 4.52 (dd, $J = 9.2, 2.7$ Hz, 1H), 4.39 (t, $J = 8.9$ Hz, 1H), 3.80 (br s, 1H), 1.61 (d, $J = 7.0$ Hz, 3H), 0.75 (br s, 3H);	HRMS m/z 475.1689 (M + H) $^+$.
57 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(6'-(trifluoromethyl)-[3,3'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 9.03 (d, $J = 2.2$ Hz, 1H), 8.88 (d, $J = 1.8$ Hz, 1H), 8.34 (dd, $J = 8.3, 2.2$ Hz, 1H), 8.15 (dd, $J = 8.1, 2.5$ Hz, 2H), 7.93 (d, $J = 8.4$ Hz, 1H), 7.63 - 7.58 (m, 1H), 7.37 (d, $J = 5.8$ Hz, 1H), 5.19 (q, $J = 7.1$ Hz, 1H), 4.79 (br s, 1H), 4.51 (dd, $J = 9.1, 2.7$ Hz, 1H), 4.38 (t, $J = 8.9$ Hz, 1H), 3.71 - 3.47 (m, 1H), 1.61 (d, $J = 7.1$ Hz, 3H), 0.70 (br s, 3H);	HRMS m/z 475.1689 (M + H) $^+$.
58 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(6-(trifluoromethyl)-[2,3'-bipyridin]-6'-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 9.24 - 9.19 (m, 1H), 8.47 (dd, $J = 8.3, 2.3$ Hz, 1H), 8.24 - 8.07 (m, 3H), 7.79 (dd, $J = 7.7, 0.9$ Hz, 1H), 7.60 (d, $J = 8.2$ Hz, 2H), 7.39 (d, $J = 5.9$ Hz, 1H), 5.21 (q, $J = 7.0$ Hz, 1H), 4.80 (br s, 1H), 4.58 - 4.44 (m, 1H), 4.38 (t, $J = 8.8$ Hz, 1H), 3.69 (br s, 1H), 1.61 (d, $J = 7.1$ Hz, 3H), 0.69 (br s, 3H);	HRMS m/z 475.1721 (M + H) $^+$.
59 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-	^1H NMR (400 MHz, MeOD) δ 8.81 (d, $J = 5.0$ Hz, 1H), 8.38 (s, 1H), 8.15 (d,	HRMS m/z 489.1881 (M

[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	$J = 5.1$ Hz, 1H), 7.90 (s, 1H), 7.72 (dd, $J = 5.0$, 1.6 Hz, 1H), 7.45 (s, 1H), 7.37 (d, $J = 5.8$ Hz, 1H), 5.14 (q, $J = 7.0$ Hz, 1H), 4.79 (br s, 1H), 4.52 (dd, $J = 9.3$, 2.7 Hz, 1H), 4.38 (t, $J = 8.9$ Hz, 1H), 3.65 (br s, 1H), 2.32 (s, 3H), 1.58 (d, $J = 7.1$ Hz, 3H), 0.77 (br s, 3H);	+ H) ⁺ .
60 : (R)-3-(2-(((S)-1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.82 - 8.80 (m, 2H), 8.19 (d, $J = 1.5$ Hz, 1H), 8.14 (d, $J = 5.8$ Hz, 1H), 8.10 (dd, $J = 10.8$, 1.9 Hz, 1H), 8.00 (dd, $J = 5.2$, 1.7 Hz, 1H), 7.38 (d, $J = 5.8$ Hz, 1H), 5.54 (q, $J = 6.9$ Hz, 1H), 4.64 (s, 1H), 4.55 (dd, $J = 9.3$, 2.7 Hz, 1H), 4.41 (t, $J = 8.8$ Hz, 1H), 3.93 (br s, 1H), 1.60 (d, $J = 6.9$ Hz, 3H) 0.87 (br s, 3H);	HRMS m/z 493.1575 (M + H) ⁺ .
61 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.79 (s, 1H), 8.78 (d, $J = 4.6$ Hz, 1H), 8.15 (s, 1H), 8.14 (d, $J = 6.3$ Hz, 1H), 8.05 (s, 1H), 7.98 (d, $J = 5.0$ Hz, 1H), 7.37 (d, $J = 5.8$ Hz, 1H), 5.49 – 5.38 (m, 1H), 4.90 – 4.84 (m, 1H), 4.55 (dd, $J = 9.2$, 2.6 Hz, 1H), 4.41 (t, $J = 8.8$ Hz, 1H), 3.96 (br s, 1H), 2.57 (s, 3H), 1.53 (d, $J = 6.7$ Hz, 3H), 0.87 (br s, 3H);	HRMS m/z 489.1829 (M + H) ⁺ .
62 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(2-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.79 (d, $J = 5.0$ Hz, 1H), 8.15 (d, $J = 5.9$ Hz, 1H), 7.88 (s, 1H), 7.74 - 7.65 (m, 2H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.37 (d, $J = 5.8$ Hz, 1H), 5.14 (t, $J = 7.1$ Hz, 1H), 4.79 (br s, 1H), 4.52 (dd, $J = 9.3$, 2.7 Hz, 1H), 4.38 (t, $J = 8.9$ Hz, 1H), 3.61 (br s, 1H), 2.53 (s, 3H), 1.59 (d, $J = 7.0$ Hz, 3H), 0.76 (br s, 3H);	HRMS m/z 489.1840 (M+H) ⁺ .
63 : (R)-3-(2-(((S)-1-(2'-(tert-butyl)-[3,4'-bipyridin]-6-	¹ H NMR (400 MHz, MeOD) δ 8.85 (d, $J = 1.8$ Hz, 1H), 8.56 (dd, $J = 5.3$, 0.8	HRMS m/z 463.2439 (M

yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.16 - 8.08 (m, 1H), 7.73 (d, J = 0.7 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.54 (dd, J = 5.2, 1.7 Hz, 1H), 7.36 (d, J = 5.8 Hz, 1H), 5.18 (q, J = 7.0 Hz, 1H), 4.78 (br s, 1H), 4.56 - 4.46 (m, 1H), 4.37 (t, J = 8.8 Hz, 1H), 3.59 (br s, 1H), 1.60 (d, J = 7.1 Hz, 3H), 1.42 (s, 9H), 0.67 (br s, 3H);	+ H) ⁺ .
64 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(2'-(1,1,1-trifluoro-2-methylpropan-2-yl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.84 (d, J = 2.2 Hz, 1H), 8.64 (d, J = 5.1 Hz, 1H), 8.16 - 8.03 (m, 2H), 7.86 (s, 1H), 7.64 (dd, J = 5.1, 1.6 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.35 (d, J = 5.8 Hz, 1H), 5.18 (q, J = 7.0 Hz, 1H), 4.78 (br s, 1H), 4.50 (dd, J = 9.3, 2.7 Hz, 1H), 4.37 (t, J = 8.8 Hz, 1H), 3.57 (br s, 1H), 1.68 (s, 6H), 1.60 (d, J = 7.1 Hz, 3H), 0.67 (br s, 3H);	HRMS m/z 517.2167 (M + H) ⁺ .
65 : 4-(2-((S)-1-((4-((R)-4-((R)-1-hydroxyethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)thiazol-4-yl)benzonitrile	¹ H NMR (400 MHz, MeOD) δ 8.19 (d, J = 5.8 Hz, 1H), 8.15 - 8.09 (m, 2H), 7.90 (s, 1H), 7.80 - 7.74 (m, 2H), 7.43 (d, J = 5.8 Hz, 1H), 5.51 (q, J = 7.5 Hz, 1H), 4.82 (br s, 1H), 4.49 (dd, J = 9.0, 3.1 Hz, 1H), 4.38 (t, J = 8.9 Hz, 1H), 4.10 (br s, 1H), 1.73 (d, J = 7.1 Hz, 3H), 0.78 (br s, 3H);	HRMS m/z 437.1375 (M + H) ⁺ .
66 : (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.16 (d, J = 5.8 Hz, 1H), 7.82 - 7.76 (m, 2H), 7.53 - 7.47 (m, 2H), 7.40 (d, J = 5.8 Hz, 1H), 6.78 (s, 1H), 5.34 (q, J = 7.1 Hz, 1H), 4.87 (ddd, J = 8.4, 4.2, 2.7 Hz, 1H), 4.54 (dd, J = 9.2, 2.7 Hz, 1H), 4.41 (t, J = 8.9 Hz, 1H), 4.31 (br s, 1H), 1.63 (d, J = 7.0 Hz, 3H), 0.93 (br s, 3H);	HRMS m/z 430.1260 (M + H) ⁺ .
67 : (R)-3-(2-(((R)-1-(4-(2,4-	¹ H NMR (400 MHz, MeOD) δ 8.18 (d,	HRMS m/z

dichlorophenyl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	$J = 5.8$ Hz, 1H), 7.86 (d, $J = 8.4$ Hz, 1H), 7.78 (s, 1H), 7.58 (d, $J = 2.2$ Hz, 1H), 7.44 - 7.39 (m, 2H), 5.43 (q, $J = 7.0$ Hz, 1H), 4.64 (br s, 1H), 4.56 - 4.49 (m, 2H), 4.30 (br s, 1H), 1.71 (d, $J = 7.0$ Hz, 3H), 1.06 (d, $J = 6.5$ Hz, 3H);	480.0639 (M + H) ⁺ .
68 : (R)-3-(2-(((S)-1-(4-(2,4-dichlorophenyl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.19 (d, $J = 5.8$ Hz, 1H), 7.91 (d, $J = 8.5$ Hz, 1H), 7.81 (s, 1H), 7.58 (d, $J = 2.1$ Hz, 1H), 7.46 - 7.39 (m, 2H), 5.50 (q, $J = 7.0$ Hz, 1H), 4.82 (br s, 1H), 4.51 (dd, $J = 9.0, 2.7$ Hz, 1H), 4.38 (t, $J = 8.9$ Hz, 1H), 4.04 (br s, 1H), 1.72 (d, $J = 7.0$ Hz, 3H), 0.82 (br s, 3H);	HRMS m/z 480.0637 (M + H) ⁺ .
69 : (R)-3-(2-(((R)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.17 (d, $J = 5.8$ Hz, 1H), 7.86 - 7.81 (m, 2H), 7.69 (s, 1H), 7.59 - 7.54 (m, 2H), 7.42 (d, $J = 5.8$ Hz, 1H), 5.44 (q, $J = 7.0$ Hz, 1H), 4.69 (br s, 1H), 4.52 (ddt, $J = 19.3, 9.1, 4.6$ Hz, 2H), 4.26 (br s, 1H), 1.71 (d, $J = 7.0$ Hz, 3H), 1.08 (d, $J = 6.5$ Hz, 3H);	HRMS m/z 490.0533 (M + H) ⁺ .
70 : (R)-3-(2-(((S)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, MeOD) δ 8.21 (d, $J = 5.8$ Hz, 1H), 7.89 - 7.84 (m, 2H), 7.71 (s, 1H), 7.61 - 7.56 (m, 2H), 7.44 (d, $J = 5.8$ Hz, 1H), 5.52 (t, $J = 3.5$ Hz, 1H), 4.84 (br s, 1H), 4.52 (dd, $J = 9.4, 2.8$ Hz, 1H), 4.40 (t, $J = 8.9$ Hz, 1H), 4.13 (br s, 1H), 1.74 (d, $J = 7.0$ Hz, 3H), 0.81 (br s, 3H);	HRMS m/z 490.0533 (M + H) ⁺ .
71 : 4-(2-((R)-1-((4-((R)-4-((R)-1-hydroxyethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)thiazol-4-yl)benzonitrile	¹ H NMR (400 MHz, MeOD) δ 8.17 (d, $J = 5.8$ Hz, 1H), 8.14 - 8.09 (m, 2H), 7.91 (s, 1H), 7.80 - 7.74 (m, 2H), 7.42 (d, $J = 5.8$ Hz, 1H), 5.46 (q, $J = 7.0$ Hz, 1H), 4.70 (br s, 1H), 4.59 - 4.45	HRMS m/z 437.1382 (M + H) ⁺ .

	(m, 2H), 4.27 (br s, 1H), 1.73 (d, J = 7.0 Hz, 3H), 1.08 (d, J = 6.5 Hz, 3H);	
72 : (R)-4-((R)-1-hydroxyethyl)-3-2-((S)-1-(4-((4-methylpiperazin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.12 (d, J = 5.8 Hz, 1H), 7.41 – 7.22 (m, 5H), 5.09 (q, J = 7.0 Hz, 1H), 4.53 (dd, J = 9.3, 2.8 Hz, 1H), 4.39 (t, J = 8.9 Hz, 1H), 3.99 (s, 1H), 3.52 (d, J = 1.5 Hz, 2H), 2.56 (bs, 8H), 2.28 (s, 3H), 1.52 (d, J = 7.0 Hz, 3H), 0.78 (s, 3H).	HRMS m/z 441.2593 (M + H) ⁺ .
73 : (4R)-3-2-((1-(3-fluoro-4-(4-methyl-1H-pyrazol-1-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.14 (t, J = 5.7 Hz, 1H), 7.86 – 7.77 (m, 1H), 7.64 (td, J = 8.3, 2.2 Hz, 1H), 7.56 (d, J = 3.0 Hz, 1H), 7.42 – 7.28 (m, 3H), 5.20 – 4.99 (m, 1H), 4.75 – 4.47 (m, 2H), 4.37 (dt, J = 17.1, 8.9 Hz, 1H), 2.17 (s, 3H), 1.56 (d, J = 7.1 Hz, 3H), 1.10 (d, J = 6.5 Hz, 1.5H), 0.82 (br s, 1.5H).	HRMS m/z 427.1870 (M + H) ⁺ .
74 : (4R)-3-2-((1-(5-(3,4-dichlorophenyl)-1H-imidazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.27 (d, J = 3.1 Hz, 1H), 7.63 (d, J = 5.0 Hz, 1H), 7.50 (dd, J = 8.4, 1.6 Hz, 1H), 7.41 (s, 1H), 5.14 (q, J = 7.0 Hz, 1H), 4.72 (td, J = 7.1, 5.1 Hz, 1H), 4.56 – 4.42 (m, 2H), 4.16 (qd, J = 6.4, 5.1 Hz, 1H), 1.63 (dd, J = 10.1, 7.1 Hz, 3H), 1.11 (d, J = 6.5 Hz, 3H).	HRMS m/z 481.0930 (M + H) ⁺ .
75 : (4R)-3-2-((1-(5-(3,4-dichlorophenyl)-1H-imidazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.19 (d, J = 5.8 Hz, 1H), 7.91 (s, 1H), 7.63 (s, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 5.8 Hz, 1H), 5.27 – 5.12 (m, 1H), 4.67 (s, 1H), 4.62 – 4.47 (m, 2H), 4.26 (s, 1H), 1.65 (d, J = 7.1 Hz, 3H), 1.08 (d, J = 6.5 Hz, 3H).	HRMS m/z 463.1018 (M + H) ⁺ .
76 : (R)-3-2-(((S)-1-(5-((4,4-difluoropiperidin-1-yl)methyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-	^1H NMR (400 MHz, MeOD) δ 8.47 (d, J = 2.0 Hz, 1H), 8.15 (d, J = 5.9 Hz, 1H), 7.78 (dd, J = 8.0, 2.2 Hz, 1H),	HRMS m/z 463.2250 (M + H) ⁺ .










hydroxyethyl)oxazolidin-2-one	7.45 (d, $J = 8.1$ Hz, 1H), 7.37 (d, $J = 5.7$ Hz, 1H), 5.26 – 5.08 (m, 1H), 4.81 (d, $J = 6.4$ Hz, 1H), 4.53 (dd, $J = 9.1, 2.7$ Hz, 1H), 4.39 (t, $J = 8.9$ Hz, 1H), 3.95 – 3.64 (m, 1H), 3.61 (s, 2H), 2.59 (t, $J = 5.6$ Hz, 4H), 1.99 (tt, $J = 13.7, 5.6$ Hz, 4H), 1.56 (d, $J = 7.0$ Hz, 3H), 0.77 (s, 3H).	
77 : (R)-3-(2-(((S)-1-(6-((4,4-difluoropiperidin-1-yl)methyl)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.52 (d, $J = 2.3$ Hz, 1H), 8.14 (d, $J = 5.9$ Hz, 1H), 7.85 (dd, $J = 8.1, 2.3$ Hz, 1H), 7.51 (d, $J = 8.0$ Hz, 1H), 7.36 (d, $J = 5.8$ Hz, 1H), 5.16 (q, $J = 7.1$ Hz, 1H), 4.83 (d, $J = 4.5$ Hz, 1H), 4.54 (dd, $J = 9.3, 2.7$ Hz, 1H), 4.40 (t, $J = 8.9$ Hz, 1H), 4.16-3.76 (br s, 1H), 3.69 (s, 2H), 2.61 (t, $J = 5.7$ Hz, 4H), 1.99 (tt, $J = 13.5, 5.6$ Hz, 4H), 1.57 (d, $J = 7.0$ Hz, 3H), 0.83 (s, 3H).	HRMS m/z 463.2267 ($M + H$) $^+$.
78 : (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 9.13 (d, $J = 1.5$ Hz, 1H), 8.79 (d, $J = 1.5$ Hz, 1H), 8.40 (s, 1H), 8.33 (d, $J = 7.8$ Hz, 1H), 8.15 (d, $J = 5.8$ Hz, 1H), 7.78 (d, $J = 7.9$ Hz, 1H), 7.72 (t, $J = 7.8$ Hz, 1H), 7.38 (d, $J = 5.8$ Hz, 1H), 5.25 (q, $J = 7.0$ Hz, 1H), 4.59 - 4.51 (m, 2H), 4.33 (br s, 1H), 1.64 (d, $J = 7.0$ Hz, 3H), 1.09 (d, $J = 6.5$ Hz, 3H);	HRMS m/z 475.1685 ($M + H$) $^+$.
79 : (R)-3-(2-(((R)-1-(5-(4-fluoro-3-methylphenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	^1H NMR (400 MHz, MeOD) δ 8.99 (d, $J = 1.5$ Hz, 1H), 8.70 (d, $J = 1.6$ Hz, 1H), 8.14 (d, $J = 5.8$ Hz, 1H), 7.99 - 7.92 (m, 1H), 7.88 (ddd, $J = 8.4, 4.9, 2.4$ Hz, 1H), 7.37 (d, $J = 5.8$ Hz, 1H), 7.16 (dd, $J = 9.5, 8.6$ Hz, 1H), 5.22 (q, $J = 7.0$ Hz, 1H), 4.64 (br s, 1H), 4.60 - 4.51 (m, 2H), 4.32 (t, $J = 8.7$ Hz, 1H),	HRMS m/z 439.1869 ($M + H$) $^+$.













	2.35 (d, $J = 2.0$ Hz, 3H), 1.62 (d, $J = 7.0$ Hz, 3H), 1.08 (d, $J = 6.5$ Hz, 3H);	
--	---	--














The compounds in **Table 29a** were prepared using methods similar to those described for the preparation of **Examples 35, 36, or 37/38**.















5

Table 29a

80 and 81	82 and 83	84 and 85
		
86 and 87	88 and 89	90 and 91
		
92 and 93	94 and 95	96 and 97
		
98 and 99	100 and 101	102 and 103

		
104 and 105	106 and 107	108 and 109
		
110 and 111	112 and 113	114 and 115
		
116 and 117	118 and 119	120 and 121
		
122 and 123	124 and 125	126 and 127

		
128 and 129	130 and 131	132 and 133
		
134 and 135	136 and 137	138 and 139
		
140 and 141	142 and 143	144 and 145
		
146 and 147	148 and 149	
		

150 and 151	152 and 153	154 and 155
		
156 and 157	158 and 159	160 and 161
		
162 and 163	164 and 165	
		
166 and 167	168 and 169	170 and 171
		
172 and 173	174 and 175	176 and 177
		
178 and 179	180 and 181	182 and 183













		
184 and 185	186 and 187	188 and 189
		
190 and 191	192 and 193	194 and 195
		
196 and 197	198 and 199	200 and 201
		

Table 29b. Chemical name, NMR chemical shifts, chiral separation conditions and LCMS signal for compounds listed in Table 29a.

Example: Name	Chiral separation conditions, peak identification and analytical data
<p>80 and 81:</p> <p>(R)-3-(2-((1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 20x250mm 35% IPA 10mM NH₄OH in CO₂, flow 75 g/min, 232 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>80 : First eluted product (40 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 2H), 8.22 (d, <i>J</i> = 5.76 Hz, 1H), 7.83 – 7.70 (m, 2H), 7.49 – 7.35 (m, 2H), 6.12 (d, <i>J</i> = 8.09 Hz, 1H), 5.40 (p, <i>J</i> = 7.25 Hz, 1H), 4.89 (s, 1H), 4.51 (dd, <i>J</i> = 2.70, 9.45 Hz, 1H), 4.42 (dd, <i>J</i> = 8.23, 9.37 Hz, 1H), 3.30 (s, 1H), 1.68 (d, <i>J</i> = 7.25 Hz, 3H), 1.12 (br s, 3H). HRMS(B) <i>m/z</i> 493.1599 (M + H)⁺.</p> <p>81: Second eluted product (45 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.91 (s, 2H), 8.22 (d, <i>J</i> = 5.7 Hz, 1H), 7.84 – 7.71 (m, 2H), 7.40 (dd, <i>J</i> = 11.6, 7.2 Hz, 2H), 6.14 (d, <i>J</i> = 6.8 Hz, 1H), 5.21 (s, 1H), 4.79 (s, 1H), 4.58 – 4.48 (m, 1H), 4.30 (s, 1H), 3.81 (s, 1H), 1.66 (m, 3H), 1.24 (m, 3H). HRMS(B) <i>m/z</i> 493.1600 (M + H)⁺.</p>
<p>82 and 83:</p> <p>(R)-3-(2-((1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 20x250mm 30% IPA 10mM NH₄OH in CO₂, flow 75 g/min, 232 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>82: First eluted product (13 mg) ¹H NMR (400 MHz, CDCl₃)</p>

	<p>δ 8.91 (s, 2H), 8.22 (d, J = 5.8 Hz, 1H), 7.90 – 7.85 (m, 1H), 7.68 (d, J = 1.8 Hz, 2H), 7.45 (d, J = 5.7 Hz, 1H), 6.08 (d, J = 8.2 Hz, 1H), 5.40 (q, J = 7.5 Hz, 1H), 4.89 (s, 1H), 4.51 (dd, J = 9.4, 2.7 Hz, 1H), 4.42 (dd, J = 9.4, 8.3 Hz, 1H), 4.09 (s, 1H), 3.29 (s, 1H), 1.68 (d, J = 7.5 Hz, 3H), 1.12 (br s, 3H). HRMS(B) m/z 509.1306 ($M + H$)⁺.</p> <p>83: Second eluted product (12 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 2H), 8.23 (d, J = 5.7 Hz, 1H), 7.88 (d, J = 1.7 Hz, 1H), 7.69 (d, J = 1.4 Hz, 2H), 7.42 (d, J = 5.7 Hz, 1H), 6.09 (d, J = 6.8 Hz, 1H), 5.21 (s, 1H), 4.78 (s, 1H), 4.53 (d, J = 8.9 Hz, 1H), 4.31 (s, 1H), 3.70 (s, 1H), 1.66 (m, 3H), 1.24 (m, 3H). HRMS(B) m/z 509.1312 ($M + H$)⁺.</p>
<p>84 and 85:</p> <p>(R)-3-(2-((1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column C6 AD-H 20x250mm 35% IPA 5 mM NH₄OH in CO₂, flow 80mL/min, 232 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>84: First eluted product (28 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 2H), 8.22 (d, J = 5.7 Hz, 1H), 7.70 – 7.58 (m, 2H), 7.49 – 7.37 (m, 2H), 6.03 (d, J = 7.5 Hz, 1H), 5.39 (t, J = 7.4 Hz, 1H), 4.89 (s, 1H), 4.55 – 4.47 (m, 1H), 4.42 (dd, J = 9.4, 8.3 Hz, 1H), 3.25 (s, 1H), 1.67 (dd, J = 7.0, 4.3 Hz, 3H), 1.12 (br s, 3H). HRMS(B) m/z 475.1026 ($M + H$)⁺.</p> <p>85: Second eluted product (22 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 2H), 8.23 (d, J = 5.7 Hz, 1H), 7.71 – 7.57 (m, 2H), 7.46 – 7.38 (m, 2H), 6.01 (s, 1H), 5.18 (s, 1H), 4.78 (s, 1H), 4.53 (d, J = 9.0 Hz, 1H), 4.31 (s, 2H), 3.64 (s, 1H), 1.66 (d, J = 6.9 Hz, 3H), 1.26 – 1.21 (m, 3H). HRMS(B) m/z 475.1032 ($M + H$)⁺.</p>

<p>86 and 87:(R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 20x250mm 35% IPA 10mM NH₄OH in CO₂, flow 75 g/min, 232 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p> <p>86: : First eluted product (80 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.94 (s, 2H), 8.23 (d, <i>J</i> = 5.7 Hz, 1H), 7.85 – 7.63 (m, 4H), 7.46 (d, <i>J</i> = 5.7 Hz, 1H), 6.11 (d, <i>J</i> = 8.2 Hz, 1H), 5.41 (p, <i>J</i> = 7.2 Hz, 1H), 4.90 (s, 1H), 4.52 (dd, <i>J</i> = 9.5, 2.6 Hz, 1H), 4.43 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 3.34 (s, 1H), 1.67 (d, <i>J</i> = 7.2 Hz, 3H), 1.12 br (s, 3H). HRMS(B) <i>m/z</i> 475.1681 (M + H)⁺.</p> <p>87: Second eluted product (67 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 2H), 8.20 (d, <i>J</i> = 5.9 Hz, 1H), 7.86 – 7.64 (m, 4H), 7.46 (d, <i>J</i> = 5.9 Hz, 1H), 6.48 (br s, 1H), 5.20 (br s, 1H), 4.79 (br s, 1H), 4.55 (d, <i>J</i> = 8.6 Hz, 1H), 4.34-4.30 (m, 2H), 3.65 (br s, 1H), 1.67 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.5 Hz, 3H). HRMS(B) <i>m/z</i> 475.1677 (M + H)⁺.</p>
<p>88 and 89:</p> <p>(R)-3-(2-((1-(5-(4-chloro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column C6 AD-H 20x250mm 35% IPA 5 mM NH₄OH in CO₂, flow 80mL/min, 232 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(4-chloro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(4-chloro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>88: First eluted product (16 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.79 (s, 2H), 8.13 (d, <i>J</i> = 5.7, 1H), 7.44 – 7.17 (m, 4H), 6.07 – 5.96 (m, 1H), 5.29 (t, <i>J</i> = 7.7 Hz, 1H), 5.12 (s, 1H), 4.81 (d, <i>J</i> = 7.3 Hz, 1H), 4.55 (s, 1H), 4.43 (dd, <i>J</i> = 9.4, 2.6</p>

	<p>Hz, 1H), 3.38 (s, 1H), 2.39 (s, 3H), 1.57 (d, $J = 7.7$ Hz, 3H), 1.02 (br s, 3H). HRMS(B) m/z 455.1575 (M + H)⁺.</p> <p>89: Second eluted product (9 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 2H), 8.13 (d, $J = 5.7$ Hz, 1H), 7.41 (d, $J = 8.3$ Hz, 1H), 7.37 – 7.23 (m, 3H), 5.97 (br s, 1H), 5.08 (br s, 1H), 4.71 (br s, 1H), 4.45 (d, $J = 9.0$ Hz, 1H), 4.40 – 4.18 (m, 2H), 3.86 (br s, 1H), 2.39 (s, 3H), 1.57 (d, $J = 7.7$ Hz, 3H), 1.16 – 1.13 (m, 3H). HRMS(B) m/z 455.1578 (M + H)⁺.</p>
<p>90 and 91:</p> <p>(R)-3-(2-((1-(5-(3-chloro-5-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column Coated 1 P9: AD-H 4.6x100mm 5-55% IPA 5mM NH₃ in CO₂, flow 5 mL/min, 177 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(3-chloro-5-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(3-chloro-5-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>90: First eluted product (4 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.83 (s, 2H), 8.14 (d, $J = 5.8$ Hz, 1H), 7.69 – 7.57 (m, 3H), 7.37 (d, $J = 5.8$ Hz, 1H), 5.99 (d, $J = 7.7$ Hz, 1H), 5.32 (p, $J = 7.1$ Hz, 1H), 4.81 (d, $J = 7.5$ Hz, 1H), 4.42 (dd, $J = 9.4$, 2.4 Hz, 1H), 4.33 (dd, $J = 9.4$, 8.3 Hz, 1H), 3.18 (br s, 1H), 1.57 (d, $J = 9.5$ Hz, 3H), 1.03 (br s, 3H). HRMS(B) m/z 509.1299 (M + H)⁺.</p> <p>91: Second eluted product (4 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.83 (s, 2H), 8.13 (d, $J = 5.7$ Hz, 1H), 7.69 – 7.58 (m, 3H), 7.34 (d, $J = 5.7$ Hz, 1H), 5.97 (d, $J = 7.5$ Hz, 1H), 5.35-5.31 (m, 1H), 5.13 (br s, 1H), 4.45 (d, $J = 9.0$ Hz, 1H), 4.35 – 4.24 (m, 1H), 4.22 (s, 1H), 3.62 (br s, 1H), 1.57 (d, $J = 7.0$ Hz, 3H), 1.19 – 1.16 (m, 3H). HRMS(B) m/z 509.1298 (M + H)⁺.</p>
<p>92 and 93:</p> <p>(R)-3-(2-((1-(3-(4-chlorophenyl)-</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column, 74 ml/min, 60 bar, eluting 25% IPA with 5mM NH₄OH/CO₂ (v/v) to</p>

<p>1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>give (R)-3-(2-(((R)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>92: First eluted product (12.4 mg). HRMS(B) <i>m/z</i> 431.1225 (M + H)⁺. RT=2.39 min.</p> <p>93: Second eluted product (14.3 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, <i>J</i> = 6.0 Hz, 1H), 8.10 – 7.94 (m, 2H), 7.57 (d, <i>J</i> = 5.7 Hz, 1H), 7.53 – 7.43 (m, 2H), 5.96 (b, 1H), 5.38 (s, 1H), 4.84 (ddd, <i>J</i> = 8.3, 4.5, 2.5 Hz, 1H), 4.54 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.40 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 4.18 – 3.59 (b, 1H), 1.79 (d, <i>J</i> = 7.1 Hz, 3H), 1.01 (b, 3H). HRMS(B) <i>m/z</i> 431.1219 (M + H)⁺, RT=2.40min.</p>
<p>94 and 95:</p> <p>(R)-3-(2-((1-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography ID-H, 5UM, 20x250 MM column, 80 ml/min, 99 bar, eluting 30% IPA with 5mM NH₄OH/CO₂ (v/v) to give (R)-3-(2-(((R)-1-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>94: First eluted product (30.1 mg). HRMS (B) <i>m/z</i> 415.1519 (M + H)⁺. RT=1.80 min.</p> <p>95: Second eluted product (32.3 mg). HRMS(B) <i>m/z</i> 415.1521 (M + H)⁺, RT=1.79min.</p>
<p>96 and 97:</p> <p>(R)-4-((R)-1-hydroxyethyl)-3-(((1-(3-(2-phenoxyethyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column, 80 ml/min, 99 bar, eluting 20% IPA with 5mM NH₄OH/CO₂ (v/v) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-(2-phenoxyethyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(2-phenoxyethyl)-1,2,4-oxadiazol-5-</p>

	<p>yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p> <p>96: First eluted product (19.2 mg). HRMS(B) <i>m/z</i> 441.1867 (M + H)⁺. RT=1.90 min.</p> <p>97: Second eluted product (31.2 mg). HRMS(B) <i>m/z</i> 441.1864 (M + H)⁺, RT=1.94min.</p>
<p>98 and 99:</p> <p>(R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column, 80 ml/min, 100 bar, eluting 15% IPA with 0.5% NH₄OH/CO₂ (v/v) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p> <p>98: First eluted product (48mg). HRMS(B) <i>m/z</i> 411.1768 (M + H)⁺. RT=1.82 min.</p> <p>99: Second eluted product (50 mg). HRMS(B) <i>m/z</i> 411.1768 (M + H)⁺, RT=1.82min.</p>
<p>100 and 101:</p> <p>(R)-3-(2-((1-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column, 80 ml/min, 100 bar, eluting 15% IPA with 0.5% NH₄OH/CO₂ (v/v) to give (R)-3-(2-(((R)-1-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>100: First eluted product (40mg). HRMS(B) <i>m/z</i> 415.1516 (M + H)⁺. RT=1.96 min.</p> <p>101: Second eluted product (13 mg). HRMS(B) <i>m/z</i> 415.1518 (M + H)⁺. RT=1.97 min.</p>

<p>102 and 103:</p> <p>(R)-3-(2-((1-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column , 74 ml/min, 99 bar, eluting 35% IPA with 5mM NH₄OH/CO₂ (v/v) to give (R)-3-(2-((R)-1-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-((S)-1-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>102: First eluted product (44mg). HRMS(B) <i>m/z</i> 415.1514 (M + H)⁺. RT=1.58 min.</p> <p>103: Second eluted product (51mg). HRMS(B) <i>m/z</i> 415.1510 (M + H)⁺. RT=1.58 min.</p>
<p>104 and 105:</p> <p>(R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(5-(<i>m</i>-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column , 74 ml/min, 99 bar, eluting 35% IPA with 5mM NH₄OH/CO₂ (v/v) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-((R)-1-(5-(<i>m</i>-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(5-(<i>m</i>-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p> <p>104: First eluted product (42mg). HRMS(B) <i>m/z</i> 411.1762 (M + H)⁺. RT=1.78 min.</p> <p>105: Second eluted product (51mg). HRMS(B) <i>m/z</i> 411.1762 (M + H)⁺. RT=1.82 min.</p>
<p>106 and 107:</p> <p>(R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(5-(<i>o</i>-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column , 74 ml/min, 99 bar, eluting 35% IPA with 5mM NH₄OH/CO₂ (v/v) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-((R)-1-(5-(<i>o</i>-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(5-(<i>o</i>-tolyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p> <p>106: First eluted product (44mg). HRMS(B) <i>m/z</i> 411.1766</p>

	<p>(M + H)⁺. RT=1.80 min.</p> <p>107: Second eluted product (42mg). HRMS(B) <i>m/z</i> 411.1764 (M + H)⁺. RT=1.80 min.</p>
<p>108 and 109:</p> <p>(R)-3-(2-((1-(4-(4-chlorophenyl)-5-methylthiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography ID, 5UM, 20x250 MM column , 89 ml/min, 99 bar, eluting 22% MeOH/CO₂ (v/v) to give (R)-3-(2-(((R)-1-(4-(4-chlorophenyl)-5-methylthiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(4-(4-chlorophenyl)-5-methylthiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>108: First eluted product (44mg). HRMS(B) <i>m/z</i> 411.1766 (M + H)⁺. RT=1.80 min.</p> <p>109: Second eluted product (34mg). HRMS(B) <i>m/z</i> 460.1198 (M + H)⁺. RT=2.41 min.</p>
<p>110 and 111:</p> <p>(R)-3-(2-{1-[5-(3-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA, 5UM, 20x250 MM column , 80ml/min, eluting 20% IPA with 5mM NH₄OH/CO₂ (v/v) to give (R)-3-(2-{(R)-1-[5-(3-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-(2-{(S)-1-[5-(3-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>110: First eluted product (34.1 mg). HRMS(B) <i>m/z</i> 415.1510 (M + H)⁺. RT=1.70 min.</p> <p>111: Second eluted product (41.9 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.23 (s, 1H), 7.82 (dt, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.72 (ddd, <i>J</i> = 9.1, 2.6, 1.6 Hz, 1H), 7.64 – 7.42 (m, 2H), 7.35 – 7.17 (m, 1H), 6.21 (s, 1H), 5.57 – 5.35 (m, 1H), 4.93 (dt, <i>J</i> = 6.7, 2.9 Hz, 1H), 4.61 (dd, <i>J</i> = 9.5, 2.4 Hz, 2H), 4.42 (dd, <i>J</i> = 9.3, 8.3 Hz, 2H), 3.98 (s, 1H), 1.08 (d, <i>J</i> = 6.4 Hz, 3H), 0.92 – 0.77 (m, 3H). HRMS(B) <i>m/z</i> 415.1515 (M + H)⁺, RT=1.70min.</p>

<p>112 and 113:</p> <p>(R)-4-((R)-1-Hydroxy-ethyl)-3-{2-[1-(5-pyridin-3-yl-[1,3,4]oxadiazol-2-yl)-ethylamino]-pyrimidin-4-yl}-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography AD-H 20X250 mm, 20% MeOH in CO₂, 80g/min, UV220 nm to give (R)-4-((R)-1-Hydroxy-ethyl)-3-{2-[1-(5-pyridin-3-yl-[1,3,4]oxadiazol-2-yl)-ethylamino]-pyrimidin-4-yl}-oxazolidin-2-one and (R)-4-((R)-1-Hydroxy-ethyl)-3-{2-[1-(5-pyridin-3-yl-[1,3,4]oxadiazol-2-yl)-ethylamino]-pyrimidin-4-yl}-oxazolidin-2-one.</p> <p>112: First eluted product (39.9 mg). HRMS(B) <i>m/z</i> 398.1566 (M + H)⁺. RT=1.18 min.</p> <p>113: Second eluted product (40.2 mg). ¹H NMR (400 MHz, CDCl₃) δ 9.26 (s, 1H), 8.80 (s, 1H), 8.33 (d, <i>J</i> = 7.9 Hz, 1H), 8.23 (s, 1H), 7.54 (d, <i>J</i> = 5.3 Hz, 1H), 7.48 (dd, <i>J</i> = 8.2, 4.6 Hz, 1H), 6.17 (s, 1H), 5.46 (s, 1H), 4.99 – 4.84 (m, 1H), 4.60 (dd, <i>J</i> = 9.3, 2.3 Hz, 2H), 4.42 (dd, <i>J</i> = 9.3, 8.3 Hz, 2H), 4.01 (s, 1H), 1.09 (d, <i>J</i> = 6.5 Hz, 3H), 0.91 – 0.81 (m, 3H). HRMS(B) <i>m/z</i> 398.1660, (M + H)⁺. RT=1.17 min.</p>
<p>114 and 115:</p> <p>(R)-3-{2-[1-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-ethylamino]-pyrimidin-4-yl}-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography AD-H 21X250 mm, 25% MeOH in CO₂, 75g/min, UV224 nm to give (R)-3-{2-[1-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-ethylamino]-pyrimidin-4-yl}-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-{2-[1-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-ethylamino]-pyrimidin-4-yl}-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>114: First eluted product (48.9 mg). HRMS(B) <i>m/z</i> 411.1855 (M + H)⁺. RT=1.85 min.</p> <p>115: Second eluted product (52.2 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, <i>J</i> = 5.7 Hz, 1H), 7.38 (d, <i>J</i> = 5.8 Hz, 1H), 7.31 – 7.13 (m, 5H), 6.09 (s, 1H), 5.21 (dq, <i>J</i> = 14.4, 7.1 Hz, 1H), 4.90 – 4.69 (m, 1H), 4.42 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.33 – 4.20 (m, 1H), 4.12 (s, 2H), 3.99 (d, <i>J</i> = 24.4 Hz, 1H), 1.54 (d, <i>J</i> = 7.1 Hz, 3H), 0.96 (d, <i>J</i> = 6.6 Hz, 3H). HRMS(B) <i>m/z</i> 411.1864, (M + H)⁺. RT=1.86 min.</p>
<p>116 and 117:</p>	<p>Chiral separation was achieved by chiral SFC column</p>

<p>(R)-3-{2-[1-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-ethylamino]-5-fluoro-pyrimidin-4-yl}-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>chromatography AD-H 21X250 mm, 25% MeOH in CO₂, 75g/min, UV231 nm to give (R)-3-{2-[(R)-1-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-ethylamino]-5-fluoro-pyrimidin-4-yl}-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-{2-[(S)-1-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-ethylamino]-5-fluoro-pyrimidin-4-yl}-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>116: First eluted product (29.4 mg). HRMS(B) <i>m/z</i> 429.1667 (M + H)⁺. RT=1.84 min.</p> <p>117: Second eluted product (52.2 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, <i>J</i> = 2.8 Hz, 1H), 7.38 – 7.13 (m, 5H), 5.64 (d, <i>J</i> = 8.3 Hz, 1H), 5.25 – 5.08 (m, 1H), 4.66 (s, 1H), 4.44 (t, <i>J</i> = 9.0 Hz, 1H), 4.28 (dd, <i>J</i> = 9.1, 5.8 Hz, 1H), 4.12 (s, 2H), 3.84 (s, 1H), 1.58 – 1.50 (m, 3H), 0.99 (d, <i>J</i> = 6.4 Hz, 3H). HRMS(B) <i>m/z</i> 429.1671, (M + H)⁺. RT=1.84 min.</p>
<p>118 and 119:</p> <p>(4R)-3-{2-[1-(3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}-pyrimidin-4-yl}-4-((R)-1-hydroxyethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography AD-H 21X250 mm, 25% IPA in CO₂, 75g/min, UV240 nm to give (R)-3-{2-[(R)-1-(3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}-pyrimidin-4-yl}-4-((S)-1-hydroxyethyl)-oxazolidin-2-one and (R)-3-{2-[1-(3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}-pyrimidin-4-yl}-4-((R)-1-hydroxyethyl)-oxazolidin-2-one</p> <p>118: First eluted product (34.3 mg). HRMS(B) <i>m/z</i> 477.0856 (M + H)⁺. RT=2.31 min.</p> <p>119: Second eluted product (33.5 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 8.04 – 7.81 (m, 2H), 7.76 – 7.58 (m, 2H), 7.55 (d, <i>J</i> = 5.8 Hz, 1H), 5.38 (s, 1H), 4.84 (ddd, <i>J</i> = 8.3, 4.5, 2.5 Hz, 1H), 4.54 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.39 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 3.92 (s, 1H), 1.78 (d, <i>J</i> = 7.1 Hz, 3H), 1.01 (d, <i>J</i> = 7.2 Hz, 3H). HRMS(B) <i>m/z</i> 477.0856 (M + H)⁺. RT=2.32 min.</p>
<p>120 and 121:</p> <p>(4R)-3-{2-[(1-(3-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-</p>	<p>Chiral separation was achieved by chiral SFC column chromatography OJ-H 21X250 mm, 15% MeOH in CO₂, 80g/min, UV233 nm to give (R)-3-{2-[(R)-1-(3-(3-fluoro-4-</p>

<p>yl)-ethyl]amino}pyrimidin-4-yl}-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}pyrimidin-4-yl}-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-{2-[(1(S)-(3-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}pyrimidin-4-yl}-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>120: First eluted product (40.1 mg). HRMS(B) <i>m/z</i> 429.1785 (M + H)⁺. RT=2.23 min.</p> <p>121: Second eluted product (42.9 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 7.87 – 7.63 (m, 2H), 7.55 (d, <i>J</i> = 5.8 Hz, 1H), 7.39 – 7.13 (m, 1H), 6.13 (s, 1H), 5.34 (d, <i>J</i> = 20.8 Hz, 1H), 4.84 (ddd, <i>J</i> = 8.3, 4.5, 2.5 Hz, 1H), 4.54 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.39 (t, <i>J</i> = 8.9 Hz, 1H), 3.86 (d, <i>J</i> = 36.7 Hz, 1H), 2.34 (d, <i>J</i> = 1.9 Hz, 3H), 1.77 (d, <i>J</i> = 7.1 Hz, 3H), 1.01 (d, <i>J</i> = 6.8 Hz, 4H). HRMS(B) <i>m/z</i> 429.1783 (M + H)⁺. RT=2.24 min.</p>
<p>122 and 123:</p> <p>(R)-3-(5-Fluoro-2-{1-[3-(3-fluoro-4-methyl-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography OJ-H 21X250 mm, 15% MeOH in CO₂, 80g/min, UV233 nm to give (R)-3-(5-Fluoro-2-{(R)-1-[3-(3-fluoro-4-methyl-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-{2-[(S)-1-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-ethylamino]-5-fluoro-pyrimidin-4-yl}-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>122: First eluted product (58.7 mg). HRMS(B) <i>m/z</i> 447.1573 (M + H)⁺. RT=2.22 min.</p> <p>123: Second eluted product (36.4 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, <i>J</i> = 2.7 Hz, 1H), 7.63 (dddd, <i>J</i> = 17.6, 9.8, 8.0, 1.7 Hz, 2H), 7.32 – 7.14 (m, 1H), 5.96 – 5.72 (m, 1H), 5.22 (q, <i>J</i> = 6.9, 5.9 Hz, 1H), 4.69 – 4.57 (m, 1H), 4.45 (t, <i>J</i> = 9.0 Hz, 1H), 4.35 (dd, <i>J</i> = 9.2, 5.6 Hz, 1H), 4.14 – 3.96 (m, 1H), 2.25 (d, <i>J</i> = 1.9 Hz, 3H), 1.67 (dd, <i>J</i> = 11.7, 7.0 Hz, 3H), 0.95 (t, <i>J</i> = 7.8 Hz, 3H). HRMS(B) <i>m/z</i> 447.1573 (M + H)⁺. RT=2.22 min.</p>

<p>124 and 125:</p> <p>(R)-3-(2-{1-[3-(3,4-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography AD-H 21X250 mm, 25% IPA in CO₂, 75g/min, UV226 nm to give (R)-3-(2-{(R)-1-[3-(3,4-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-(2-{(S)-1-[3-(3,4-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>124: First eluted product (43.2 mg). HRMS(B) <i>m/z</i> 443.1112 (M + H)⁺. RT=2.09 min.</p> <p>125: Second eluted product (40.7 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, <i>J</i> = 5.8 Hz, 1H), 7.93 – 7.67 (m, 2H), 7.47 (d, <i>J</i> = 5.7 Hz, 1H), 7.30 – 7.10 (m, 1H), 6.07 (s, 1H), 5.30 (s, 1H), 4.76 (ddd, <i>J</i> = 8.3, 4.6, 2.5 Hz, 1H), 4.45 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.31 (dd, <i>J</i> = 9.4, 8.4 Hz, 1H), 4.02 – 3.52 (m, 1H), 1.69 (d, <i>J</i> = 7.1 Hz, 3H), 1.07 – 0.88 (m, 3H). HRMS(B) <i>m/z</i> 433.1109, (M + H)⁺. RT=2.18 min.</p>
<p>126 and 127:</p> <p>(R)-3-(2-{1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IA. 21X250 mm, 30% (70% MeOH:30%DCM) in CO₂, 70g/min, UV239 nm to give (R)-3-(2-{(R)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-(2-{(S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>126: First eluted product (37.4 mg). HRMS(B) <i>m/z</i> 464.0869 (M + H)⁺. RT=2.63 min.</p> <p>127: Second eluted product (27.3 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1H), 7.76 (d, <i>J</i> = 2.0 Hz, 1H), 7.53 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.3 Hz, 2H), 6.37 (s, 1H), 5.70 (s, 1H), 5.11 (s, 1H), 4.77 (ddd, <i>J</i> = 7.4, 4.6, 2.6 Hz, 1H), 4.46 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.31 (dd, <i>J</i> = 9.4, 8.4 Hz, 1H), 1.61 (d, <i>J</i> = 7.0 Hz, 3H), 0.86 (d, <i>J</i> = 7.5 Hz, 3H). HRMS(B) <i>m/z</i> 464.0855, (M + H)⁺. RT=2.56 min.</p>

<p>128 and 129:</p> <p>(R)-3-(2-{1-[3-(2,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography OJ-H. 21X250 mm, 15% MeOH in CO₂, 75g/min, UV231 nm to give (R)-3-(2-((R)-1-[3-(2,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-(2-((S)-1-[3-(2,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>128: First eluted product (72.9 mg). HRMS(B) <i>m/z</i> 464.0869 (M + H)⁺. RT=2.54 min.</p> <p>129: Second eluted product (36.5 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.39 – 8.11 (m, 1H), 7.65 (d, <i>J</i> = 8.4 Hz, 1H), 7.56 – 7.47 (m, 2H), 7.42 – 7.28 (m, 1H), 6.60 (s, 1H), 5.80 (s, 1H), 5.27 (d, <i>J</i> = 37.0 Hz, 1H), 4.72 – 4.45 (m, 3H), 4.31 (t, <i>J</i> = 8.7 Hz, 1H), 1.71 (d, <i>J</i> = 6.9 Hz, 3H), 1.19 (d, <i>J</i> = 6.4 Hz, 3H). HRMS(B) <i>m/z</i> 464.0876, (M + H)⁺. RT=2.55 min.</p>
<p>130 and 131:</p> <p>(R)-3-(2-{1-[3-(3,4-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography ID 21X250 mm, 30% iIPA in CO₂, 75g/min, UV233 nm to give and (R)-3-(2-((S)-1-[3-(3,4-Difluorophenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>130: First eluted product (63.9 mg). HRMS(B) <i>m/z</i> 451.1324 (M + H)⁺. RT=2.20 min.</p> <p>131: Second eluted product (58.1 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, <i>J</i> = 2.8 Hz, 1H), 7.97 – 7.72 (m, 2H), 7.27 (dt, <i>J</i> = 9.9, 8.4 Hz, 1H), 6.09 (s, 1H), 5.47 – 5.16 (m, 1H), 4.84 – 4.64 (m, 1H), 4.54 (t, <i>J</i> = 9.0 Hz, 1H), 4.43 (dd, <i>J</i> = 9.1, 5.4 Hz, 1H), 3.87 (s, 1H), 1.76 (d, <i>J</i> = 7.1 Hz, 3H), 1.04 (d, <i>J</i> = 6.5 Hz, 3H). HRMS(B) <i>m/z</i> 451.1324 (M + H)⁺. RT=2.20 min.</p>
<p>132 and 133:</p> <p>(R)-3-(2-{1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-</p>	<p>Chiral separation was achieved by chiral SFC column chromatography IC. 21X250 mm, 40% MeOH in CO₂, 80g/min, UV239 nm to give (R)-3-(2-((R)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-</p>

<p>yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-(2-((S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>132: First eluted product (107 mg). HRMS(B) <i>m/z</i> 482.0781 (M + H)⁺. RT=2.63 min.</p> <p>133: Second eluted product (61.1 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, <i>J</i> = 2.8 Hz, 1H), 7.86 (d, <i>J</i> = 1.9 Hz, 1H), 7.61 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.52 (d, <i>J</i> = 8.3 Hz, 1H), 6.45 (s, 1H), 5.72 (d, <i>J</i> = 7.6 Hz, 1H), 5.25 (t, <i>J</i> = 7.1 Hz, 1H), 4.66 – 4.42 (m, 2H), 4.26 (t, <i>J</i> = 6.2 Hz, 1H), 1.68 (d, <i>J</i> = 6.9 Hz, 3H), 1.19 (d, <i>J</i> = 6.4 Hz, 3H). HRMS(B) <i>m/z</i> 482.0777 (M + H)⁺. RT=2.63 min.</p>
<p>134 and 135:</p> <p>(R)-3-(2-{1-[3-(2,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography AD-H, 21X250 mm, 35% IPA in CO₂, 75g/min, UV237 nm to give (R)-3-(2-((R)-1-[3-(2,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-(2-((S)-1-[3-(2,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>134: First eluted product (53.4 mg). HRMS(B) <i>m/z</i> 482.0778 (M + H)⁺. RT=2.54 min.</p> <p>135: Second eluted product (107 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, <i>J</i> = 2.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (d, <i>J</i> = 2.0 Hz, 1H), 7.42 – 7.22 (m, 1H), 6.60 (s, 1H), 5.88 (s, 1H), 5.24 (t, <i>J</i> = 6.7 Hz, 1H), 4.98 – 4.71 (m, 1H), 4.63 – 4.40 (m, 2H), 3.83 (s, 1H), 1.70 (d, <i>J</i> = 7.1 Hz, 3H), 1.05 (d, <i>J</i> = 6.4 Hz, 3H). HRMS(B) <i>m/z</i> 482.0774 (M + H)⁺. RT=2.53 min.</p>
<p>136 and 137:</p> <p>(R)-3-(2-{1-[4-(3-Chloro-4-fluoro-phenyl)-thiazol-2-yl]-ethylamino}-</p>	<p>Chiral separation was achieved by chiral SFC column chromatography OD-H, 21X250 mm, 30% IPA in CO₂, 75g/min, UV220 nm to give (R)-3-(2-((R)-1-[4-(3-Chloro-4-</p>

<p>pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one</p>	<p>fluoro-phenyl)-thiazol-2-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one and (R)-3-(2-((S)-1-[4-(3-Chloro-4-fluoro-phenyl)-thiazol-2-yl]-ethylamino)-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one.</p> <p>136: First eluted product (76.9 mg). HRMS(B) <i>m/z</i> 464.0930 (M + H)⁺. RT=2.50 min.</p> <p>137: Second eluted product (88.6 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, <i>J</i> = 6.0 Hz, 1H), 7.95 (dd, <i>J</i> = 7.0, 2.2 Hz, 1H), 7.72 (ddd, <i>J</i> = 8.6, 4.5, 2.2 Hz, 1H), 7.50 (d, <i>J</i> = 5.7 Hz, 1H), 7.34 (s, 1H), 7.18 (t, <i>J</i> = 8.6 Hz, 1H), 5.61 – 5.35 (m, 1H), 4.75 (ddd, <i>J</i> = 8.1, 4.4, 2.4 Hz, 1H), 4.45 (dd, <i>J</i> = 9.3, 2.7 Hz, 1H), 4.34 (t, <i>J</i> = 8.9 Hz, 1H), 3.87 (s, 1H), 1.73 (d, <i>J</i> = 6.9 Hz, 3H), 0.90 (q, <i>J</i> = 6.9, 6.3 Hz, 3H). HRMS(B) <i>m/z</i> 464.0940 (M + H)⁺. RT=2.49 min.</p>
<p>138 and 139:</p> <p>(R)-3-(5-fluoro-2-((1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 20x250mm 45% IPA 10mM NH₄OH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(5-fluoro-2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(5-fluoro-2-(((R)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>138: First eluted product (6 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.84 (s, 2H), 8.15 (d, <i>J</i> = 2.8 Hz, 1H), 7.76 – 7.55 (m, 3H), 6.17 (br s, 1H), 5.24 (t, <i>J</i> = 7.1 Hz, 1H), 4.56 (d, <i>J</i> = 7.4 Hz, 1H), 4.47 (t, <i>J</i> = 8.8 Hz, 1H), 4.33 (dd, <i>J</i> = 9.0, 5.1 Hz, 1H), 4.00 (br s, 1H), 1.59 (d, <i>J</i> = 6.9 Hz, 3H), 1.06 (br d, <i>J</i> = 5.7 Hz, 3H). HRMS(B) <i>m/z</i> 493.1587 (M + H)⁺.</p> <p>139: Second eluted product (10 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.86 (s, 2H), 8.14 (d, <i>J</i> = 2.9 Hz, 1H), 7.77 – 7.55 (m, 4H), 6.32 (br s, 1H), 5.18 (br s, 1H), 4.49 – 4.29 (m, 3H), 3.96 (p, <i>J</i> = 6.1 Hz, 1H), 2.69 (br s, 1H), 1.58 (d, <i>J</i> = 7.0 Hz, 3H), 1.15 (d, <i>J</i> = 5.9 Hz, 3H). HRMS(B) <i>m/z</i></p>

	493.1591 (M + H) ⁺ .
140 and 141: (4R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(2-phenylthiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column OD 20x250mm 25% MeOH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-((R)-1-(2-phenylthiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(2-phenylthiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>140: First eluted product (48 mg) ¹H NMR (400 MHz, CDCl₃) δ 10.83 (s, 1H), 8.13 – 7.69 (m, 5H), 7.47 (d, <i>J</i> = 4.6 Hz, 4H), 5.31 – 5.14 (m, 1H), 4.82 (d, <i>J</i> = 7.7 Hz, 1H), 4.66 (dd, <i>J</i> = 9.6, 2.2 Hz, 1H), 4.46 (dd, <i>J</i> = 9.6, 8.0 Hz, 1H), 3.38 (d, <i>J</i> = 9.6 Hz, 1H), 1.84 (d, <i>J</i> = 6.8 Hz, 3H), 1.55 – 1.09 (m, 1H), 1.03 – 0.71 (m, 4H). HRMS(B) <i>m/z</i> 411.1365. Chiral RT = 2.90 min</p> <p>141: Second eluted product (46 mg) ¹H NMR (400 MHz, CDCl₃) δ 11.03 (s, 1H), 8.11 – 7.64 (m, 5H), 7.49 (d, <i>J</i> = 4.9 Hz, 3H), 5.52 – 5.10 (m, 1H), 4.70 (dd, <i>J</i> = 23.0, 8.0 Hz, 2H), 4.42 (t, <i>J</i> = 8.6 Hz, 2H), 1.86 (d, <i>J</i> = 6.8 Hz, 3H), 1.53 – 1.08 (m, 4H), 0.99 – 0.61 (m, 1H). HRMS(B) <i>m/z</i> 411.1365. Chiral RT = 4.00 min</p>
142 and 143: (4R)-3-(2-((1-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD 20x250mm 20% MeOH in CO₂, flow 90 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>142: First eluted product (15.5 mg) : ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, <i>J</i> = 5.8 Hz, 4H), 7.79 (dd, <i>J</i> = 7.6, 1.8 Hz, 4H), 7.56 – 7.26 (m, 15H), 5.83 (s, 4H), 5.17 (s, 4H), 4.57 (q, <i>J</i> = 6.1 Hz, 4H), 4.39 (dd, <i>J</i> = 9.3, 2.5 Hz, 4H), 4.29 – 4.04 (m, 9H), 3.96 (p, <i>J</i> = 6.2 Hz, 1H), 2.96 (s, 4H), 1.88 –</p>

	<p>1.56 (m, 5H), 1.49 – 1.01 (m, 28H), 0.93 – 0.59 (m, 4H). HRMS(B) m/z 430.1156. Chiral RT = 3.40 min</p> <p>143: Second eluted product (10 mg) ^1H NMR (400 MHz, CDCl_3) δ 8.25 (d, J = 5.8 Hz, 3H), 7.91 (dd, J = 7.7, 1.8 Hz, 3H), 7.62 – 7.52 (m, 6H), 7.43 (dtd, J = 25.2, 7.5, 1.6 Hz, 6H), 6.30 (s, 3H), 5.40 (s, 3H), 4.87 (ddd, J = 8.3, 4.3, 2.3 Hz, 3H), 4.55 (dd, J = 9.5, 2.5 Hz, 3H), 4.39 (t, J = 8.9 Hz, 3H), 4.10 – 3.75 (m, 4H), 3.50 (s, 3H), 3.18 – 2.93 (m, 3H), 1.72 (d, J = 6.8 Hz, 0H), 1.39 – 1.16 (m, 5H), 1.10 – 0.93 (m, 9H), 0.93 – 0.76 (m, 2H). HRMS(B) m/z 430.1156. Chiral RT = 4.80 min</p>
<p>144 and 145:</p> <p>(4R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column ID 21x250mm 25% MeOH in CO_2, flow 75 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-((R)-1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>144: First eluted product (36 mg) : (CDCl_3) δ 8.24 (d, J = 5.7 Hz, 1H), 8.06 – 7.88 (m, 2H), 7.50 (d, J = 5.8 Hz, 1H), 7.41 – 7.32 (m, 2H), 6.05 (s, 1H), 5.22 (s, 1H), 4.71 (s, 1H), 4.49 (dd, J = 9.3, 2.5 Hz, 1H), 4.43 – 4.14 (m, 2H), 4.12 – 3.99 (m, 0H), 3.51 (s, 1H), 3.37 (s, 1H), 2.98 (hept, J = 6.9 Hz, 1H), 2.04 – 1.73 (m, 1H), 1.44 – 1.17 (m, 11H). HRMS(B) m/z 438.2016. Chiral RT = 3.20 min</p> <p>145: Second eluted product (36 mg) : (CDCl_3) δ 8.25 (d, J = 5.7 Hz, 1H), 8.05 – 7.91 (m, 2H), 7.54 (d, J = 5.7 Hz, 1H), 7.42 – 7.31 (m, 2H), 6.23 (s, 1H), 5.33 (d, J = 10.8 Hz, 1H), 4.85 (ddd, J = 8.5, 4.5, 2.3 Hz, 1H), 4.56 (dd, J = 9.4, 2.5 Hz, 1H), 1.84 – 1.73 (m, 3H), 4.39 (t, J = 8.9 Hz, 1H), 3.86 (s, 1H), 3.51 (s, 1H), 3.15 (s, 1H), 2.97 (hept, J = 7.0 Hz, 1H), 1.94 (d, J = 7.1 Hz, 1H), 1.28 (d, J = 6.9 Hz, 6H), 0.99 (d, J = 6.9 Hz, 3H). HRMS(B) m/z 438.2016. Chiral RT =</p>

	4.60 min
146 and 147: (4R)-4-((R)-1-hydroxyethyl)-3-(2- ((1-(3-(2- (trifluoromethoxy)phenyl)-1,2,4- oxadiazol-5- yl)ethyl)amino)pyrimidin-4- yl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 25% MeOH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-(2-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(2-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>146: First eluted product (8.3 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.9 Hz, 1H), 8.07 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.69 – 7.39 (m, 4H), 5.73 (s, 1H), 5.26 (s, 1H), 4.78 – 4.57 (m, 1H), 4.48 (dd, <i>J</i> = 9.3, 2.3 Hz, 1H), 4.39 – 4.00 (m, 2H), 3.52 (s, 1H), 2.93 (s, 1H), 1.80 (d, <i>J</i> = 7.1 Hz, 3H), 1.62 (s, 3H), 1.21 (dd, <i>J</i> = 18.6, 6.3 Hz, 5H). HRMS(B) <i>m/z</i> 480.1369. Chiral RT = 2.10 min</p> <p>147: Second eluted product (38.5 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 8.10 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.67 – 7.52 (m, 2H), 7.51 – 7.40 (m, 2H), 5.88 (s, 1H), 5.39 (s, 1H), 4.86 (ddd, <i>J</i> = 8.5, 4.6, 2.5 Hz, 1H), 1.75 – 1.64 (m, 1H), 4.55 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.39 (t, <i>J</i> = 8.9 Hz, 1H), 4.14 – 3.58 (m, 1H), 2.86 (s, 1H), 1.80 (d, <i>J</i> = 7.1 Hz, 3H), 1.23 (d, <i>J</i> = 6.1 Hz, 1H), 1.00 (s, 3H). HRMS(B) <i>m/z</i> 480.1369. Chiral RT = 2.55 min</p>
148 and 149: (4R)-3-(2-((1-(3-(4-fluoro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 15% MeOH in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-fluoro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-fluoro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>

	<p>148: First eluted product (13 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 8.03 – 7.80 (m, 2H), 7.52 (d, <i>J</i> = 5.7 Hz, 1H), 7.13 (t, <i>J</i> = 8.9 Hz, 1H), 5.85 (s, 1H), 5.23 (s, 1H), 4.69 (d, <i>J</i> = 8.4 Hz, 1H), 4.50 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 4.41 – 4.04 (m, 2H), 3.51 (s, 2H), 3.11 (s, 1H), 2.36 (d, <i>J</i> = 2.0 Hz, 3H), 1.78 (d, <i>J</i> = 7.1 Hz, 3H), 1.21 (d, <i>J</i> = 6.4 Hz, 4H). HRMS(B) <i>m/z</i> 428.1608 Chiral RT = 4.25 min</p> <p>149: Second eluted product (49 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.7 Hz, 1H), 8.01 – 7.80 (m, 2H), 7.56 (d, <i>J</i> = 5.7 Hz, 1H), 7.12 (t, <i>J</i> = 8.9 Hz, 1H), 5.76 (s, 1H), 5.46 – 5.12 (m, 1H), 4.85 (ddd, <i>J</i> = 8.4, 4.6, 2.4 Hz, 1H), 4.55 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 4.40 (t, <i>J</i> = 8.9 Hz, 1H), 2.89 (s, 1H), 2.35 (d, <i>J</i> = 2.0 Hz, 3H), 1.79 (d, <i>J</i> = 7.1 Hz, 3H), 1.43 – 1.13 (m, 2H), 1.16 – 0.74 (m, 3H). HRMS(B) <i>m/z</i> 428.1608 Chiral RT = 6.15 min</p>
<p>150 and 151:</p> <p>(4R)-3-(2-((1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column ID 21x250mm 40% MeOH + 10mM NH₄OH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>150: First eluted product (106 mg) : (CDCl₃) δ 8.24 (d, <i>J</i> = 2.9 Hz, 1H), 7.99 – 7.87 (m, 2H), 7.38 – 7.22 (m, 2H), 5.96 (d, <i>J</i> = 7.1 Hz, 1H), 5.31 (d, <i>J</i> = 9.1 Hz, 1H), 4.56 – 4.25 (m, 4H), 3.49 (s, 4H), 3.30 (d, <i>J</i> = 13.4 Hz, 1H), 2.72 (q, <i>J</i> = 7.6 Hz, 2H), 1.68 (s, 0H), 1.66 – 1.38 (m, 2H), 1.35 – 1.08 (m, 7H). HRMS(B) <i>m/z</i> 442.1765 Chiral RT = 2.80 min</p> <p>151: Second eluted product (10.6 mg) : (CDCl₃) δ 8.27 (d, <i>J</i> = 2.7 Hz, 2H), 8.05 – 7.87 (m, 4H), 7.39 – 7.23 (m, 4H), 5.77 (d, <i>J</i> = 6.7 Hz, 2H), 5.30 – 5.17 (m, 2H), 4.73 (dt, <i>J</i> = 10.7, 5.1 Hz, 2H), 4.54 (t, <i>J</i> = 9.1 Hz, 2H), 1.85 – 1.73 (m, 6H), 4.44 (dd, <i>J</i> = 9.2, 5.6 Hz, 2H), 3.86 – 3.59 (m, 2H),</p>

	3.51 (s, 2H), 2.72 (q, J = 7.6 Hz, 6H), 1.37 – 1.19 (m, 8H), 1.01 (d, J = 6.9 Hz, 8H), 0.92 – 0.69 (m, 1H). HRMS(B) m/z 442.1765 Chiral RT = 4.05 min
152 and 153: (4R)-3-(2-((1-(5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IC 4.6x100mm 5-55% IPA + 20 mM NH₄OH/in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>152: First eluted product (25 mg) : (CDCl₃) δ 8.22 (d, J = 5.8 Hz, 1H), 7.84 – 7.79 (m, 1H), 7.75 (dd, J = 8.0, 1.8 Hz, 1H), 7.48 (d, J = 5.7 Hz, 1H), 7.34 – 7.20 (m, 1H), 5.90 (d, J = 4.6 Hz, 1H), 5.18 (s, 1H), 4.93 – 4.74 (m, 1H), 1.85 – 1.71 (m, 3H), 4.61 (dd, J = 9.3, 2.2 Hz, 1H), 4.50 – 4.38 (m, 1H), 4.33 (t, J = 8.8 Hz, 1H), 4.21 (s, 1H), 4.11 – 4.00 (m, 0H), 2.34 (s, 6H), 1.22 (dd, J = 10.3, 6.3 Hz, 5H). HRMS(B) m/z 425.1982. Chiral RT = 1.75 min</p> <p>153: Second eluted product (25 mg) : (CDCl₃) δ 8.23 (d, J = 5.7 Hz, 1H), 7.81 (d, J = 1.9 Hz, 1H), 7.75 (dd, J = 7.8, 1.9 Hz, 1H), 7.53 (d, J = 5.7 Hz, 1H), 7.28 (d, J = 3.6 Hz, 1H), 5.67 (d, J = 6.0 Hz, 1H), 5.48 – 5.30 (m, 1H), 5.02 – 4.91 (m, 1H), 4.62 (dd, J = 9.5, 2.3 Hz, 1H), 4.42 (dd, J = 9.4, 8.3 Hz, 1H), 3.88 (s, 2H), 2.34 (s, 6H), 1.79 (d, J = 7.2 Hz, 3H), 1.63 (s, 1H), 1.33 – 1.16 (m, 1H), 1.06 (d, J = 6.4 Hz, 3H). HRMS(B) m/z 425.1981. Chiral RT = 2.15 min</p>
154 and 155: (4R)-4-((R)-1-hydroxyethyl)-3-(2-(((1-(3-(isoquinolin-8-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column OJ-H 21x250mm 20% MeOH + 5 mM NH₄OH/CO₂/in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-(isoquinolin-8-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(isoquinolin-8-yl)-1,2,4-</p>

	<p>oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>154: First eluted product (10 mg) : (CDCl₃) δ 8.47 – 8.11 (m, 4H), 7.99 (d, <i>J</i> = 8.1 Hz, 2H), 7.83 (t, <i>J</i> = 7.9 Hz, 3H), 7.57 (s, 4H), 5.94 (s, 2H), 5.47 (s, 2H), 4.95 – 4.65 (m, 2H), 4.42 (d, <i>J</i> = 88.6 Hz, 6H), 3.52 (s, 5H), 2.09 – 1.51 (m, 1H), 1.47 – 0.99 (m, 7H), 0.96 – 0.68 (m, 1H). HRMS(B) <i>m/z</i> 447.1655. Chiral RT = 2.55 min</p> <p>155: Second eluted product (28.7 mg) : (CDCl₃) δ 10.26 (s, 2H), 8.63 (s, 2H), 8.28 (d, <i>J</i> = 7.3 Hz, 4H), 7.97 (d, <i>J</i> = 8.2 Hz, 2H), 7.77 (t, <i>J</i> = 7.8 Hz, 3H), 7.58 (d, <i>J</i> = 5.3 Hz, 2H), 6.08 (s, 2H), 5.62 (p, <i>J</i> = 7.1 Hz, 2H), 5.11 – 4.84 (m, 2H), 4.61 (dd, <i>J</i> = 8.8, 2.7 Hz, 2H), 4.41 (t, <i>J</i> = 8.9 Hz, 2H), 4.30 (s, 2H), 3.89 (s, 2H), 3.63 – 3.43 (m, 8H), 1.73 (d, <i>J</i> = 33.4 Hz, 0H), 1.32 (q, <i>J</i> = 5.2 Hz, 3H), 1.04 (d, <i>J</i> = 7.1 Hz, 6H). HRMS(B) <i>m/z</i> 447.1655. Chiral RT = 2.90 min</p>
<p>156 and 157:</p> <p>(4R)-3-(2-((1-(3-(4-chloro-2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IC 4.6x100mm 5-55% IPA + 20 mM NH₄OH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-chloro-2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-chloro-2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>156: First eluted product (50 mg) : (CDCl₃) δ 8.16 (d, <i>J</i> = 5.9 Hz, 1H), 7.81 – 7.64 (m, 1H), 7.57 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.48 (d, <i>J</i> = 5.8 Hz, 1H), 6.50 (s, 1H), 5.35 (s, 1H), 4.78 (ddd, <i>J</i> = 7.4, 4.6, 2.4 Hz, 1H), 4.45 (dd, <i>J</i> = 9.3, 2.5 Hz, 1H), 4.31 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 3.92 (d, <i>J</i> = 48.4 Hz, 1H), 3.41 (s, 1H), 3.18 – 2.11 (m, 1H), 1.70 (d, <i>J</i> = 7.1 Hz, 3H), 1.30 – 1.08 (m, 1H), 0.93 (d, <i>J</i> = 7.6 Hz, 3H). HRMS(B) <i>m/z</i> 498.1030. Chiral RT = 2.03 min</p> <p>157: Second eluted product (15 mg) : (CDCl₃) δ 8.15 (d, <i>J</i> =</p>

	6.2 Hz, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.59 (dd, J = 8.4, 2.1 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 5.96 (s, 1H), 5.17 (s, 1H), 4.73 – 4.47 (m, 1H), 4.40 (dd, J = 9.2, 2.4 Hz, 1H), 4.21 (d, J = 37.9 Hz, 1H), 3.42 (s, 3H), 1.60 (s, 3H), 1.33 – 0.99 (m, 1H), 0.92 – 0.64 (m, 1H). HRMS(B) m/z 498.1030. Chiral RT = 2.18 min
158 and 159: (4R)-3-(5-fluoro-2-((1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	Chiral separation was achieved by chiral SFC column chromatography (Column ID 21x250mm 40% MeOH + 10mM NH ₄ OH in CO ₂ , flow 75 g/min, 238 nm UV collection) to give (R)-3-(5-fluoro-2-(((R)-1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(5-fluoro-2-(((S)-1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one 158: First eluted product (51 mg) : (CDCl ₃) δ 8.17 (d, J = 2.7 Hz, 1H), 7.92 – 7.83 (m, 2H), 7.30 – 7.21 (m, 2H), 5.83 (d, J = 6.5 Hz, 1H), 5.21 (dd, J = 13.8, 6.9 Hz, 1H), 4.77 – 4.57 (m, 1H), 4.46 (t, J = 9.1 Hz, 1H), 4.36 (dd, J = 9.2, 5.6 Hz, 1H), 3.96 (p, J = 6.1 Hz, 1H), 3.63 (s, 1H), 2.88 (hept, J = 7.0 Hz, 1H), 1.76 – 1.60 (m, 3H), 1.19 (d, J = 7.0 Hz, 7H), 1.14 (d, J = 6.1 Hz, 4H), 0.93 (d, J = 7.0 Hz, 3H). HRMS(B) m/z 456.1921 Chiral RT = 2.60 min 159: Second eluted product (54 mg) : (CDCl ₃) δ 8.24 (d, J = 3.0 Hz, 1H), 8.02 – 7.89 (m, 2H), 7.39 – 7.30 (m, 2H), 5.98 (d, J = 7.2 Hz, 1H), 5.31 (d, J = 8.6 Hz, 1H), 4.52 – 4.27 (m, 4H), 1.83 – 1.67 (m, 3H), 3.49 (s, 1H), 2.97 (hept, J = 6.9 Hz, 1H), 1.28 (d, J = 6.9 Hz, 6H), 1.21 (dd, J = 11.1, 6.2 Hz, 5H). HRMS(B) m/z 456.1921. Chiral RT = 3.70 min
160 and 161: (4R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-	Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 25% IPA in CO ₂ , flow 75 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-

<p>yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-(((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>160: First eluted product (15 mg) : (CDCl₃) δ 8.27 (d, <i>J</i> = 2.0 Hz, 1H), 8.16 (t, <i>J</i> = 7.3 Hz, 2H), 7.71 (d, <i>J</i> = 7.9 Hz, 1H), 7.56 (t, <i>J</i> = 7.8 Hz, 1H), 1.74 – 1.56 (m, 3H), 7.50 – 7.37 (m, 1H), 6.06 (s, 1H), 5.26 (d, <i>J</i> = 47.9 Hz, 1H), 4.59 (d, <i>J</i> = 9.5 Hz, 1H), 4.52 – 4.23 (m, 2H), 1.14 (dd, <i>J</i> = 6.3, 4.8 Hz, 5H), 1.03 – 0.88 (m, 2H), 0.88 – 0.71 (m, 0H), 4.85 – 4.72 (m, 0H), 4.16 (s, 1H), 3.97 (p, <i>J</i> = 6.1 Hz, 0H), 2.88 (s, 1H), 2.34 – 1.77 (m, 1H). HRMS(B) <i>m/z</i> 464.1420. Chiral RT = 2.10 min</p> <p>161: Second eluted product (38.5 mg) : (CDCl₃) δ 8.36 (d, <i>J</i> = 1.8 Hz, 1H), 8.31 – 8.19 (m, 2H), 7.87 – 7.76 (m, 1H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.57 (d, <i>J</i> = 5.7 Hz, 1H), 6.04 (s, 1H), 5.42 (s, 1H), 4.87 (ddd, <i>J</i> = 8.4, 4.7, 2.5 Hz, 1H), 4.55 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 4.41 (dd, <i>J</i> = 9.5, 8.3 Hz, 1H), 4.11 – 3.72 (m, 1H), 2.83 (s, 1H), 2.13 – 1.57 (m, 1H), 1.23 (d, <i>J</i> = 6.1 Hz, 2H), 1.05 (d, <i>J</i> = 9.5 Hz, 3H). HRMS(B) <i>m/z</i> 464.1420 Chiral RT = 2.55 min</p>
<p>162 and 163:</p> <p>(4R)-3-(2-((1-(3-(4-fluoro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 10% MeOH in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-fluoro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-fluoro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>162: First eluted product (13 mg) : CDCl₃) δ 8.24 (d, <i>J</i> = 5.9 Hz, 1H), 8.04 (ddt, <i>J</i> = 13.4, 6.5, 1.9 Hz, 2H), 7.55 (d, <i>J</i> = 5.7 Hz, 1H), 7.35 (t, <i>J</i> = 9.0 Hz, 1H), 6.08 (s, 1H), 5.27 (s, 1H), 4.78 – 4.58 (m, 1H), 4.52 (dd, <i>J</i> = 9.3, 2.5 Hz, 1H),</p>

	<p>4.44 (d, $J = 15.7$ Hz, 1H), 4.25 (d, $J = 11.2$ Hz, 1H), 3.51 (s, 2H), 2.97 (s, 1H), 1.98 – 1.67 (m, 0H), 1.22 (d, $J = 6.5$ Hz, 4H). HRMS(B) m/z 498.1275 Chiral RT = 3.60 min</p> <p>163: Second eluted product (40 mg) : (CDCl₃) δ 8.25 (d, $J = 6.2$ Hz, 1H), 8.13 – 7.98 (m, 2H), 7.57 (d, $J = 5.6$ Hz, 1H), 7.35 (dd, $J = 9.4, 8.6$ Hz, 1H), 5.77 (s, 1H), 5.40 (s, 1H), 4.85 (ddd, $J = 8.2, 4.7, 2.5$ Hz, 1H), 4.54 (dd, $J = 9.4, 2.5$ Hz, 1H), 4.41 (dd, $J = 9.4, 8.3$ Hz, 1H), 3.87 (t, $J = 65.5$ Hz, 1H), 3.52 (s, 1H), 2.76 (s, 1H), 1.79 (d, $J = 7.1$ Hz, 3H), 1.34 – 1.25 (m, 1H), 1.05 (s, 3H).). HRMS(B) m/z 498.1275 Chiral RT = 4.80 min</p>
<p>164 and 165:</p> <p>(4R)-3-(2-((1-(3-(3-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 35% IPA in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(3-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(3-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>164: First eluted product (18 mg) : (CDCl₃) δ 8.25 (d, $J = 5.8$ Hz, 1H), 7.92 (dt, $J = 7.7, 1.4$ Hz, 1H), 7.83 (t, $J = 2.0$ Hz, 1H), 7.62 – 7.43 (m, 2H), 7.36 – 7.24 (m, 1H), 6.61 (t, $J = 73.3$ Hz, 1H), 6.25 (d, $J = 59.0$ Hz, 1H), 5.36 (d, $J = 30.2$ Hz, 1H), 4.86 (ddd, $J = 8.5, 4.8, 2.5$ Hz, 1H), 4.55 (dd, $J = 9.3, 2.5$ Hz, 1H), 4.40 (t, $J = 8.9$ Hz, 1H), 3.51 (s, 2H), 1.83 (s, 1H), 1.34 – 1.16 (m, 1H), 1.02 (s, 3H). HRMS(B) m/z 462.1463 Chiral RT = 1.65 min</p> <p>165: Second eluted product (63 mg) : (CDCl₃) δ 8.25 (d, $J = 5.8$ Hz, 1H), 7.92 (dt, $J = 7.7, 1.4$ Hz, 1H), 7.83 (t, $J = 2.0$ Hz, 1H), 7.62 – 7.43 (m, 2H), 7.36 – 7.24 (m, 1H), 6.61 (t, $J = 73.3$ Hz, 1H), 6.25 (d, $J = 59.0$ Hz, 1H), 5.36 (d, $J = 30.2$ Hz, 1H), 4.86 (ddd, $J = 8.5, 4.8, 2.5$ Hz, 1H), 4.55 (dd, $J = 9.3, 2.5$ Hz, 1H), 4.40 (t, $J = 8.9$ Hz, 1H), 3.51 (s, 2H), 1.83</p>

	(s, 1H), 1.34 – 1.16 (m, 1H), 1.02 (s, 3H). HRMS(B) m/z 462.1463 Chiral RT = 2.10 min
166 and 167: (4R)-3-(2-((1-(3-(4-chloro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 30% MeOH in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-chloro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-chloro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>166: First eluted product (10 mg) : (CDCl₃) δ 8.38 – 8.18 (m, 1H), 7.61 (hept, <i>J</i> = 2.3, 1.9 Hz, 2H), 7.57 – 7.45 (m, 2H), 5.89 (s, 1H), 5.33 (s, 2H), 4.70 (s, 1H), 4.50 (dd, <i>J</i> = 9.4, 2.4 Hz, 1H), 4.00 (s, 2H), 3.07 (s, 1H), 1.75 (s, 2H), 1.34 – 1.11 (m, 6H). HRMS(B) m/z 461.1464. RT = 2.24 min. Chiral RT = 2.85 min</p> <p>167: Second eluted product (120 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 7.63 (d, <i>J</i> = 7.5 Hz, 2H), 7.57 (d, <i>J</i> = 5.7 Hz, 1H), 7.52 – 7.46 (m, 1H), 5.74 (s, 1H), 5.35 (d, <i>J</i> = 20.7 Hz, 1H), 4.85 (ddd, <i>J</i> = 8.3, 4.7, 2.4 Hz, 1H), 4.54 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 4.40 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 4.01 (s, 3H), 3.52 (s, 3H), 2.85 (s, 1H), 1.88 – 1.76 (m, 2H), 1.67 (s, 1H), 1.23 (d, <i>J</i> = 6.1 Hz, 1H), 1.03 (s, 3H). HRMS(B) m/z 461.1464. RT = 2.23 min. Chiral RT = 3.55 min</p>
168 and 169: (4R)-3-(2-((1-(3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 35% IPA in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>

	<p>168: First eluted product (14 mg) : (CDCl₃) δ 8.23 (d, J = 6.2 Hz, 1H), 7.86 (dd, J = 8.2, 1.8 Hz, 1H), 7.78 (d, J = 1.7 Hz, 1H), 7.55 (d, J = 5.7 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 6.46 (s, 1H), 5.29 (d, J = 27.6 Hz, 1H), 4.90 – 4.58 (m, 1H), 4.52 (dd, J = 9.4, 2.5 Hz, 1H), 4.46 – 4.17 (m, 2H), 3.51 (s, 1H), 2.93 (s, 2H), 1.22 (dd, J = 8.8, 6.2 Hz, 4H). HRMS(B) m/z 476.1256. RT = 2.42 min. Chiral RT = 1.65 min</p> <p>169: Second eluted product (62 mg) : (CDCl₃) δ 8.15 (d, J = 5.8 Hz, 1H), 7.79 (dd, J = 8.3, 1.7 Hz, 1H), 7.69 (d, J = 1.7 Hz, 1H), 7.47 (d, J = 5.8 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.38 (s, 1H), 5.26 (d, J = 24.5 Hz, 1H), 4.76 (ddd, J = 8.5, 4.6, 2.4 Hz, 1H), 4.46 (dd, J = 9.3, 2.5 Hz, 1H), 4.32 (t, J = 8.9 Hz, 1H), 4.06 – 3.60 (m, 1H), 3.42 (s, 2H), 1.86 (d, J = 7.1 Hz, 3H), 1.14 (d, J = 6.1 Hz, 1H), 1.04 – 0.72 (m, 3H). HRMS(B) m/z 476.1256. RT = 2.43 min. Chiral RT = 1.95 min</p>
<p>170 and 171:</p> <p>(4R)-3-(2-((1-(3-(4-chloro-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 20% MeOH in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-chloro-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-chloro-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>170: First eluted product (23 mg) : (CDCl₃) δ 8.42 (d, J = 2.0 Hz, 1H), 8.25 (d, J = 5.9 Hz, 1H), 8.18 (dd, J = 8.4, 2.1 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 5.7 Hz, 1H), 5.81 (s, 1H), 5.33 (s, 2H), 4.66 (s, 1H), 4.52 (dd, J = 9.3, 2.5 Hz, 1H), 4.46 – 4.14 (m, 2H), 2.84 (s, 1H), 1.79 (d, J = 7.0 Hz, 3H), 1.23 (d, J = 6.5 Hz, 4H). HRMS(B) m/z 498.1030. RT = 2.57 min. Chiral RT = 2.70 min</p> <p>171: Second eluted product (83 mg) : (CDCl₃) δ 8.42 (d, J = 2.0 Hz, 1H), 8.31 – 8.12 (m, 2H), 7.62 (dd, J = 26.0, 7.1 Hz,</p>

	2H), 1.92 – 1.70 (m, 3H), 6.31 (s, 1H), 5.32 (s, 2H), 4.86 (ddd, $J = 8.3, 4.8, 2.4$ Hz, 1H), 4.54 (dd, $J = 9.3, 2.5$ Hz, 1H), 4.42 (dd, $J = 9.4, 8.3$ Hz, 1H), 4.13 – 3.77 (m, 1H), 2.71 (s, 2H), 1.44 – 0.84 (m, 4H). HRMS(B) m/z 498.1030. RT = 2.57 min. Chiral RT = 3.60 min
172 and 173: (4R)-3-(2-((1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	Chiral separation was achieved by chiral SFC column chromatography (Column IA 21x250mm 40% IPA + 10 mM NH ₄ OH in CO ₂ , flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one 172: First eluted product (73 mg) : (CDCl ₃) δ 8.24 (d, $J = 5.8$ Hz, 1H), 8.05 – 7.87 (m, 2H), 7.50 (d, $J = 5.8$ Hz, 1H), 7.41 – 7.30 (m, 2H), 5.98 (s, 1H), 1.57 – 1.47 (m, 0H), 5.22 (s, 1H), 4.71 (s, 1H), 4.13 – 4.00 (m, 0H), 4.48 (dd, $J = 9.5, 2.4$ Hz, 1H), 4.33 (s, 1H), 4.18 (s, 1H), 3.51 (d, $J = 5.3$ Hz, 0H), 3.30 (s, 1H), 2.73 (q, $J = 7.6$ Hz, 2H), 1.78 (d, $J = 7.1$ Hz, 3H), 1.39 – 1.08 (m, 7H). HRMS(B) m/z 424.1859. RT = 2.39 min. Chiral RT = 2.15 min 173: Second eluted product (17 mg) : (CDCl ₃) δ 8.25 (d, $J = 5.8$ Hz, 2H), 8.04 – 7.89 (m, 4H), 7.54 (d, $J = 5.8$ Hz, 2H), 7.39 – 7.29 (m, 4H), 5.97 (s, 2H), 5.53 – 5.22 (m, 2H), 4.85 (ddd, $J = 8.2, 4.4, 2.4$ Hz, 2H), 4.55 (dd, $J = 9.3, 2.5$ Hz, 2H), 4.39 (dd, $J = 9.4, 8.3$ Hz, 2H), 4.12 – 3.97 (m, 0H), 3.76 (d, $J = 62.5$ Hz, 2H), 3.51 (s, 2H), 3.03 (s, 2H), 2.72 (q, $J = 7.6$ Hz, 4H), 1.98 – 1.71 (m, 1H), 1.45 – 1.13 (m, 10H), 1.12 – 0.80 (m, 7H). HRMS(B) m/z 424.1859. RT = 2.40 min. Chiral RT = 3.25 min
174 and 175: (4R)-4-((R)-1-hydroxyethyl)-3-2-(((1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-	Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 25% IPA in CO ₂ , flow 75 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-2-(((R)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-

<p>yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>174: First eluted product (55 mg) : (CDCl₃) δ 8.30 – 8.14 (m, 3H), 7.76 (dd, <i>J</i> = 8.7, 2.5 Hz, 2H), 7.55 (dd, <i>J</i> = 12.4, 5.8 Hz, 1H), 6.61 (s, 1H), 5.32 (s, 1H), 4.77 – 4.62 (m, 1H), 4.62 – 4.46 (m, 1H), 4.40 (t, <i>J</i> = 8.8 Hz, 1H), 4.24 (t, <i>J</i> = 9.0 Hz, 1H), 3.51 (s, 1H), 1.81 (s, 2H), 1.22 (dd, <i>J</i> = 9.6, 6.3 Hz, 4H). HRMS(B) <i>m/z</i> 464.1420. RT = 2.43 min. Chiral RT = 2.55 min</p> <p>175: Second eluted product (51 mg) : (CDCl₃) δ 8.22 (dd, <i>J</i> = 21.0, 7.0 Hz, 3H), 7.75 (d, <i>J</i> = 8.1 Hz, 2H), 7.56 (d, <i>J</i> = 5.8 Hz, 1H), 6.47 (s, 1H), 5.37 (d, <i>J</i> = 39.2 Hz, 1H), 4.86 (ddd, <i>J</i> = 8.7, 4.7, 2.5 Hz, 1H), 4.55 (dd, <i>J</i> = 9.3, 2.5 Hz, 1H), 4.40 (t, <i>J</i> = 8.9 Hz, 1H), 4.19 – 3.70 (m, 1H), 3.50 (s, 1H), 2.01 – 1.70 (m, 0H), 1.23 (d, <i>J</i> = 6.1 Hz, 1H), 1.01 (s, 3H). HRMS(B) <i>m/z</i> 464.1420. RT = 2.44 min. Chiral RT = 3.25 min</p>
<p>176 and 177:</p> <p>(4R)-4-((R)-1-hydroxyethyl)-3-(2-(((1-(3-phenethyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 15% IPA in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-phenethyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-phenethyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>176: First eluted product (17 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 6.2 Hz, 1H), 7.54 (d, <i>J</i> = 5.5 Hz, 1H), 7.36 – 7.07 (m, 5H), 5.83 (s, 1H), 5.10 (s, 1H), 4.67 (d, <i>J</i> = 7.6 Hz, 1H), 4.57 – 4.41 (m, 1H), 4.10 (d, <i>J</i> = 38.8 Hz, 2H), 3.36 – 3.14 (m, 1H), 3.07 (d, <i>J</i> = 2.1 Hz, 4H), 1.94 – 1.67 (m, 1H), 1.28 (d, <i>J</i> = 3.8 Hz, 1H), 1.18 (d, <i>J</i> = 6.5 Hz, 3H). HRMS(B) <i>m/z</i> 424.1859. RT = 2.24 min. Chiral RT = 4.50 min</p>

	<p>177: Second eluted product (19 mg) : (CDCl₃) δ 8.25 (d, J = 5.9 Hz, 1H), 7.56 (d, J = 5.7 Hz, 1H), 7.38 – 7.08 (m, 5H), 6.03 (s, 1H), 5.31 (d, J = 11.3 Hz, 1H), 4.84 (ddd, J = 8.3, 4.5, 2.3 Hz, 1H), 4.56 (dd, J = 9.3, 2.5 Hz, 1H), 4.40 (dd, J = 9.3, 8.3 Hz, 1H), 3.91 – 3.62 (m, 1H), 3.51 (s, 2H), 3.36 – 3.10 (m, 1H), 3.06 (s, 4H), 1.72 (d, J = 7.0 Hz, 3H), 1.59 – 1.35 (m, 1H), 1.06 (d, J = 6.8 Hz, 3H).). HRMS(B) m/z 424.1859. RT = 2.30 min. Chiral RT = 5.90 min</p>
<p>178 and 179:</p> <p>(4R)-3-(2-((1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 20% IPA in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>178:First eluted product (49 mg) : (CDCl₃) δ 8.26 (d, J = 2.8 Hz, 1H), 8.05 (p, J = 1.4 Hz, 1H), 8.03 – 7.92 (m, 1H), 7.62 (d, J = 8.4 Hz, 1H), 5.73 (d, J = 7.6 Hz, 1H), 5.44 – 5.25 (m, 1H), 4.60 – 4.40 (m, 3H), 4.32 (p, J = 5.7, 5.3 Hz, 1H), 2.81 – 1.89 (m, 2H), 1.80 (s, 3H), 1.22 (d, J = 6.3 Hz, 3H).). HRMS(B) m/z 533.1171. RT = 2.64 min. Chiral RT = 3.05 min</p> <p>179:Second eluted product (81 mg) : (CDCl₃) δ 8.27 (d, J = 2.7 Hz, 1H), 8.04 (p, J = 1.4 Hz, 1H), 7.97 (dd, J = 8.4, 1.9 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 5.68 (t, J = 4.0 Hz, 1H), 5.33 (s, 1H), 4.68 (dt, J = 10.9, 4.6 Hz, 1H), 4.56 (t, J = 9.0 Hz, 1H), 4.44 (dd, J = 9.2, 5.3 Hz, 1H), 3.85 (s, 1H), 1.95 (d, J = 7.0 Hz, 2H), 1.84 – 1.73 (m, 3H), 1.36 – 1.19 (m, 1H), 1.08 (s, 3H). HRMS(B) m/z 533.1173. RT = 2.64 min. Chiral RT = 3.75 min</p>
<p>180 and 181:</p> <p>(4R)-4-((R)-1-hydroxyethyl)-3-(2-</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 25% IPA in CO₂, flow 80 g/min, 238 nm UV collection) to (R)-4-((R)-1-</p>

<p>((1-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>hydroxyethyl)-3-(2-(((R)-1-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>180: First eluted product (19 mg) : (CDCl₃) δ 8.24 (d, <i>J</i> = 5.8 Hz, 1H), 8.16 – 8.06 (m, 2H), 7.53 (d, <i>J</i> = 5.8 Hz, 1H), 7.34 (d, <i>J</i> = 8.3 Hz, 2H), 6.24 (s, 1H), 5.29 (d, <i>J</i> = 24.7 Hz, 1H), 4.81 – 4.61 (m, 1H), 1.85 – 1.74 (m, 3H), 4.51 (dd, <i>J</i> = 9.4, 2.4 Hz, 1H), 4.46 – 4.32 (m, 1H), 4.31 – 4.13 (m, 1H), 3.51 (s, 1H), 3.25 (d, <i>J</i> = 66.2 Hz, 1H), 1.22 (dd, <i>J</i> = 8.9, 6.3 Hz, 4H). HRMS(B) <i>m/z</i> 480.1369. RT = 2.50 min. Chiral RT = 2.20 min</p> <p>181: Second eluted product (44 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 8.17 – 8.05 (m, 2H), 7.55 (d, <i>J</i> = 5.7 Hz, 1H), 7.33 (d, <i>J</i> = 8.3 Hz, 2H), 6.41 (s, 1H), 5.35 (d, <i>J</i> = 27.1 Hz, 1H), 4.96 – 4.77 (m, 1H), 4.55 (dd, <i>J</i> = 9.3, 2.5 Hz, 1H), 4.40 (t, <i>J</i> = 8.9 Hz, 1H), 4.16 – 3.55 (m, 1H), 3.03 (s, 1H), 1.78 (d, <i>J</i> = 7.1 Hz, 3H), 1.23 (d, <i>J</i> = 6.1 Hz, 1H), 1.01 (s, 3H). HRMS(B) <i>m/z</i> 480.1369. RT = 2.51 min. Chiral RT = 2.45 min</p>
<p>182 and 183:</p> <p>(4R)-4-((R)-1-hydroxyethyl)-3-(2-(((1-(3-(3-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 30% IPA in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-(3-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(3-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>182: First eluted product (13.8 mg) : (CDCl₃) δ 8.14 (d, <i>J</i> = 5.9 Hz, 1H), 7.67 (t, <i>J</i> = 6.8 Hz, 1H), 7.60 – 7.52 (m, 1H), 7.46 (dd, <i>J</i> = 14.2, 5.8 Hz, 1H), 7.37 (td, <i>J</i> = 8.0, 2.8 Hz, 1H), 7.05 (dd, <i>J</i> = 8.2, 2.7 Hz, 1H), 4.71 – 4.51 (m, 1H),</p>

	<p>4.51 – 4.23 (m, 4H), 4.23 – 4.04 (m, 1H), 3.97 (hept, $J = 6.1$ Hz, 1H), 1.64 (d, $J = 1.5$ Hz, 3H), 1.13 (dd, $J = 10.4, 6.3$ Hz, 6H). HRMS(B) m/z 494.1526. RT = 2.38 min. Chiral RT = 1.95 min</p> <p>183: Second eluted product (65 mg) : (CDCl₃) δ 8.25 (d, $J = 5.8$ Hz, 1H), 7.77 (dt, $J = 7.7, 1.2$ Hz, 1H), 7.63 (dd, $J = 2.7, 1.4$ Hz, 1H), 7.56 (d, $J = 5.7$ Hz, 1H), 7.45 (t, $J = 8.0$ Hz, 1H), 7.14 (ddd, $J = 8.3, 2.7, 1.0$ Hz, 1H), 6.06 (s, 1H), 5.35 (d, $J = 24.3$ Hz, 1H), 4.85 (ddd, $J = 8.3, 4.5, 2.5$ Hz, 1H), 4.55 (dd, $J = 9.3, 2.5$ Hz, 1H), 4.51 – 4.34 (m, 4H), 4.05 (hept, $J = 6.1$ Hz, 1H), 3.89 (s, 1H), 2.96 (s, 1H), 1.84 – 1.75 (m, 3H), 1.23 (d, $J = 6.2$ Hz, 6H), 1.02 (s, 3H). HRMS(B) m/z 494.1526. RT = 2.39 min. Chiral RT = 2.45 min</p>
<p>184 and 185:</p> <p>(4R)-3-(2-((1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 20% MeOH in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>184: First eluted product (48 mg) : (CDCl₃) δ 8.21 (d, $J = 5.7$ Hz, 1H), 7.58 – 7.35 (m, 5H), 5.94 (s, 1H), 4.62 (dd, $J = 9.2, 2.5$ Hz, 1H), 4.55 – 4.42 (m, 1H), 1.74 – 1.65 (m, 3H), 4.32 (t, $J = 8.9$ Hz, 1H), 3.51 (s, 2H), 2.38 (s, 3H), 2.27 – 1.93 (m, 1H), 1.22 (d, $J = 6.6$ Hz, 3H). HRMS(B) m/z 443.1360. RT = 2.51 min. Chiral RT = 2.90 min</p> <p>185: Second eluted product (31 mg) : (CDCl₃) δ 7.61 – 7.47 (m, 3H), 7.45 – 7.35 (m, 2H), 5.84 (s, 1H), 5.31 (d, $J = 10.0$ Hz, 1H), 4.94 (s, 1H), 4.58 (d, $J = 9.8$ Hz, 2H), 1.78 – 1.66 (m, 3H), 4.44 (t, $J = 8.8$ Hz, 1H), 4.22 (s, 1H), 3.52 (s, 2H), 2.38 (s, 3H), 1.16 (d, $J = 6.4$ Hz, 3H). HRMS(B) m/z 443.1360. RT = 2.52 min. Chiral RT = 4.00 min</p>

<p>186 and 187:</p> <p>(4R)-3-(2-((1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 30% IPA in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>186: First eluted product (114 mg) : (MeOD) δ 8.14 (dd, J = 111.8, 3.1 Hz, 1H), 7.64 – 7.53 (m, 2H), 7.53 – 7.42 (m, 2H), 5.35 – 5.18 (m, 1H), 5.18 – 5.05 (m, 1H), 4.80 – 4.70 (m, 1H), 4.55 – 4.45 (m, 2H), 4.17 (td, J = 6.7, 3.9 Hz, 1H), 4.07 (dt, J = 8.9, 5.4 Hz, 1H), 2.38 (d, J = 1.9 Hz, 3H), 1.67 (dd, J = 7.1, 5.4 Hz, 3H), 1.14 (dd, J = 27.1, 6.3 Hz, 3H). HRMS(B) m/z 461.1266. RT = 2.29 min. Chiral RT = 3.60 min</p> <p>187: Second eluted product (14 mg) : (MeOD) δ 8.14 (dd, J = 115.3, 3.2 Hz, 1H), 7.59 (ddt, J = 6.7, 4.3, 2.1 Hz, 2H), 7.53 – 7.42 (m, 2H), 5.14 (dq, J = 30.9, 6.9 Hz, 1H), 4.71 (dt, J = 9.6, 4.6 Hz, 1H), 4.39 (q, J = 7.4, 5.0 Hz, 1H), 3.98 (ddt, J = 28.7, 12.3, 5.6 Hz, 2H), 2.37 (d, J = 2.3 Hz, 3H), 1.67 (dd, J = 7.1, 4.0 Hz, 3H), 1.32 (d, J = 6.5 Hz, 2H), 1.17 (d, J = 6.1 Hz, 2H), 1.08 – 0.76 (m, 2H). HRMS(B) m/z 461.1266. RT = 2.37 min. Chiral RT = 6.05 min</p>
<p>188 and 189:</p> <p>(4R)-3-(2-((1-(4-(4-chlorophenyl)-5-methylthiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column ID 21x250mm 25% MeOH 10 mM NH₄OH in CO₂, flow 75 g/min, 230 nm UV collection) to give (R)-3-(2-(((R)-1-(4-(4-chlorophenyl)-5-methylthiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(4-(4-chlorophenyl)-5-methylthiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>188: First eluted product (61.8 mg) : ¹H NMR (400 MHz, CDCl₃) δ 8.24 (d, J = 3.2 Hz, 1H), 7.64 – 7.53 (m, 2H), 7.49</p>

	<p>– 7.38 (m, 2H), 5.75 (d, $J = 6.1$ Hz, 1H), 5.22 (s, 1H), 4.54 – 4.24 (m, 4H), 3.49 (s, 2H), 2.52 (s, 3H), 1.17 (d, $J = 6.4$ Hz, 3H). HRMS(E) m/z 478.1114 (M+H). RT = 5.98 min. Chiral RT = 3.90 min.</p> <p>189: Second eluted product (82 mg) : ^1H NMR (400 MHz, CDCl_3) δ 8.32 – 7.93 (m, 1H), 7.68 – 7.52 (m, 2H), 7.43 (dd, $J = 8.6, 2.5$ Hz, 2H), 5.75 (d, $J = 6.8$ Hz, 1H), 5.35 – 5.21 (m, 1H), 4.58 (dt, $J = 8.6, 5.3$ Hz, 1H), 1.77 – 1.64 (m, 3H), 4.53 – 4.43 (m, 1H), 4.38 (dd, $J = 9.0, 5.0$ Hz, 1H), 3.96 (d, $J = 11.1$ Hz, 1H), 3.50 (s, 2H), 2.52 (d, $J = 6.1$ Hz, 3H), 1.04 (d, $J = 49.6$ Hz, 3H). HRMS(B) m/z 477.1038. RT = 2.48 min. Chiral RT = 5.80 min.</p>
<p>190 and 191:</p> <p>(4R)-3-(2-((1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column ID 21x250mm 30% MeOH 10 mM NH_4OH in CO_2, flow 75 g/min, 230 nm UV collection) to give (R)-3-(2-(((S)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>190: First eluted product (63.7 mg) : ^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, $J = 3.0$ Hz, 1H), 7.86 – 7.71 (m, 2H), 7.62 – 7.50 (m, 2H), 7.41 (s, 1H), 5.80 (d, $J = 6.7$ Hz, 1H), 1.83 – 1.68 (m, 3H), 5.33 (t, $J = 5.2$ Hz, 1H), 4.38 (t, $J = 13.2$ Hz, 4H), 3.51 (s, 1H), 1.20 (d, $J = 6.2$ Hz, 3H). HRMS(E) m/z 510.0447 (M+H). RT = 5.95 min. Chiral RT = 3.30 min.</p> <p>191: Second eluted product (77.1) : ^1H NMR (400 MHz, CDCl_3) δ 8.13 (dd, $J = 109.6, 2.8$ Hz, 1H), 7.78 (dd, $J = 8.6, 2.1$ Hz, 2H), 7.57 (dd, $J = 8.8, 2.3$ Hz, 2H), 7.40 (s, 1H), 5.78 (d, $J = 6.5$ Hz, 1H), 1.82 – 1.67 (m, 3H), 5.46 – 5.24 (m, 1H), 4.64 – 4.26 (m, 2H), 4.05 – 3.74 (m, 1H), 3.51 (s, 1H), 0.96 (s, 3H). HRMS(E) m/z 510.0445 (M+H). RT = 5.91 min. Chiral RT = 5.40 min.</p>

<p>192 and 193:</p> <p>(R)-3-(2-((1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IC 21x250mm, 45% MeOH in CO₂, flow 75 g/min, 220 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>192 : First eluted product (49 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 2H), 8.24 (d, <i>J</i> = 2.8 Hz, 1H), 7.76 – 7.51 (m, 2H), 7.48 – 7.35 (m, 1H), 6.17 (d, <i>J</i> = 7.9 Hz, 1H), 5.30 (tt, <i>J</i> = 12.5, 5.8 Hz, 1H), 4.69 – 4.47 (m, 2H), 4.41 (dd, <i>J</i> = 8.9, 5.1 Hz, 1H), 4.09 (br s, 1H), 1.69 - 1.65 (m, 3H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H). HRMS(B) <i>m/z</i> 493.0948 (M + H)⁺.</p> <p>193 : Second eluted product (40 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.89 (d, <i>J</i> = 1.6 Hz, 2H), 8.25 (d, <i>J</i> = 2.9 Hz, 1H), 7.76 – 7.53 (m, 2H), 7.43 (ddd, <i>J</i> = 8.3, 3.9, 2.2 Hz, 1H), 6.24 (d, <i>J</i> = 7.5 Hz, 1H), 5.26 (br s, 1H), 4.60 – 4.36 (m, 4H), 1.64 (d, <i>J</i> = 4.8 Hz, 2H), 1.29-1.25 (m, 3H). HRMS(B) <i>m/z</i> 493.0949 (M + H)⁺.</p>
<p>194 and 195:</p> <p>(R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(5-(3-methyl-4-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IA 21x250mm, 35% IPA 10mM NH₄OH in CO₂, flow 75 g/min, 235 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-methyl-4-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(5-(3-methyl-4-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p> <p>194: First eluted product (15 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 2H), 8.23 (d, <i>J</i> = 5.7 Hz, 1H), 7.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.54 – 7.42 (m, 4H), 6.07 (d, <i>J</i> = 8.2 Hz, 1H), 5.45 – 5.36 (m, 1H), 4.89 (s, 1H), 4.52 (dd, <i>J</i> = 9.5, 2.6 Hz, 1H), 4.42 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 3.36 (br s, 1H), 2.60 (dq, <i>J</i> = 3.7, 1.7 Hz, 3H), 1.71 – 1.60 (m, 3H), 1.11 (br s,</p>


	<p>3H). HRMS(D) m/z 489.1850 ($M + H$)⁺.</p> <p>195: Second eluted product (11 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.94 (s, 2H), 8.23 (d, J = 5.7 Hz, 1H), 7.81 – 7.74 (m, 1H), 7.49 (d, J = 6.9 Hz, 1H), 7.42 (d, J = 5.7 Hz, 1H), 6.02 (br s, 1H), 5.18 (br s, 1H), 4.80 (br s, 1H), 4.53 (d, J = 8.8 Hz, 1H), 4.30 (br s, 2H), 3.71 (br s, 1H), 2.60 (q, J = 1.8 Hz, 3H), 1.69 - 1.65 (m, 3H), 1.25 – 1.19 (m, 3H). HRMS(D) m/z 489.1862 ($M + H$)⁺.</p>
<p>196 and 197:</p> <p>(R)-4-((R)-1-hydroxyethyl)-3-(2-((1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IC 21x250mm, 30% IPA 10mM NH₄OH in CO₂, flow 75 g/min, 227 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.</p> <p>198: First eluted product (50 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.65 (dd, J = 5.1, 0.8 Hz, 1H), 8.26 (d, J = 5.8 Hz, 1H), 7.59 – 7.49 (m, 2H), 7.24 (dd, J = 5.2, 1.6 Hz, 1H), 5.63 (d, J = 6.4 Hz, 1H), 5.38 (s, 1H), 4.80 (ddd, J = 8.3, 4.5, 2.5 Hz, 1H), 4.51 (dd, J = 9.4, 2.5 Hz, 1H), 4.40 (dd, J = 9.4, 8.3 Hz, 1H), 3.93 (br s, 1H), 2.79 (br s, 1H), 2.54 (s, 3H), 1.73 (d, J = 7.0 Hz, 3H), 1.67 (s, 6H), 1.05 (d, J = 6.9 Hz, 3H). HRMS(D) m/z 537.1898 ($M + H$)⁺.</p> <p>199: Second eluted product (50 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.65 (dd, J = 5.2, 0.8 Hz, 1H), 8.25 (d, J = 5.8 Hz, 1H), 7.59 – 7.46 (m, 2H), 7.26 (dd, J = 5.1, 1.6 Hz, 1H), 5.69 (s, 1H), 5.13 (br s, 1H), 4.82 (br s, 1H), 4.58 (d, J = 6.7 Hz, 1H), 4.31 (t, J = 8.4 Hz, 2H), 4.15 (br s, 1H), 2.53 (s, 3H), 1.76 – 1.65 (m, 9H), 1.25 – 1.18 (m, 3H). HRMS(D) m/z 537.1900($M + H$)⁺.</p>

<p>198 and 199: (4R)-3-(5-fluoro-2-((1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column ID 21x250mm, 25% IPA 10mM NH₄OH in CO₂, flow 75 g/min, 230 nm UV collection) to give</p> <p>(4R)-3-(5-fluoro-2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (4R)-3-(5-fluoro-2-(((R)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>200: First eluted product (7 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.55 (td, <i>J</i> = 5.4, 0.8 Hz, 1H), 8.17 (dd, <i>J</i> = 4.5, 2.8 Hz, 1H), 7.46 – 7.40 (m, 1H), 7.16 (ddd, <i>J</i> = 8.1, 5.1, 1.6 Hz, 1H), 5.56 (dd, <i>J</i> = 14.8, 6.8 Hz, 1H), 5.20 – 5.13 (m, 1H), 4.49 – 4.37 (m, 2H), 4.30 (d, <i>J</i> = 6.8 Hz, 1H), 3.32 (d, <i>J</i> = 3.7 Hz, 1H), 2.46 (s, 3H), 1.67 – 1.50 (m, 9H), 1.18 – 1.12 (m, 3H). HRMS(D) <i>m/z</i> 555.1821 (M + H)⁺.</p> <p>201: Second eluted product (33 mg) ¹H NMR (400 MHz, CDCl₃) δ 8.60 – 8.52 (m, 1H), 8.17 (d, <i>J</i> = 2.8 Hz, 1H), 7.42 (dt, <i>J</i> = 1.7, 0.8 Hz, 1H), 7.21 – 7.12 (m, 1H), 5.56 (d, <i>J</i> = 6.9 Hz, 1H), 5.24 (p, <i>J</i> = 7.0 Hz, 1H), 4.55 (dt, <i>J</i> = 8.6, 5.5 Hz, 1H), 4.45 (t, <i>J</i> = 8.8 Hz, 1H), 4.31 (dd, <i>J</i> = 9.0, 5.2 Hz, 1H), 3.95 (td, <i>J</i> = 13.7, 13.0, 6.9 Hz, 1H), 2.45 (s, 3H), 1.64 (d, <i>J</i> = 6.9 Hz, 3H), 1.57 (s, 6H), 1.00 (d, <i>J</i> = 6.0 Hz, 3H). HRMS(D) <i>m/z</i> 555.1839 (M + H)⁺.</p>
<p>200 and 201: (R)-3-(2-((1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IA 21x250mm, 25% MeOH 10mM NH₄OH in CO₂, flow 75 g/min, 232 nm UV collection) to give (R)-3-(2-(((S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-</p>

	<p>hydroxyethyl)oxazolidin-2-one.</p> <p>192 : First eluted product (35 mg) ^1H NMR (400 MHz, CDCl_3) δ 8.85 – 8.79 (m, 2H), 8.12 (dd, J = 6.1, 4.0 Hz, 1H), 7.70 – 7.52 (m, 2H), 7.41 – 7.30 (m, 2H), 6.14 (s, 1H), 5.36 – 5.27 (m, 1H), 4.85 – 4.76 (m, 1H), 4.43 (dd, J = 9.4, 2.6 Hz, 1H), 4.38 – 4.24 (m, 1H), 4.13 – 3.93 (m, 1H), 3.15 (br s, 1H), 1.60 (d, J = 7.0 Hz, 3H), 1.02 (br s, 3H). HRMS(D) m/z 493.1605 ($M + H$)$^+$.</p> <p>193: Second eluted product (36 mg) ^1H NMR (400 MHz, CDCl_3) δ 8.83 (d, J = 1.4 Hz, 2H), 8.12 (d, J = 5.8 Hz, 1H), 7.71 – 7.53 (m, 2H), 7.42 – 7.31 (m, 2H), 6.19 (br s, 1H), 5.08 (br s, 1H), 4.68 (br s, 1H), 4.46 (d, J = 8.3 Hz, 1H), 4.21 (br s, 2H), 3.50 (br s, 1H), 1.60 (d, J = 7.0 Hz, 3H), 1.19 – 1.12 (m, 3H). HRMS(D) m/z 493.1630 ($M + H$)$^+$.</p>
--	---

Examples 202 and 203

(4R)-3-(2-((1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



5

(4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-((1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)oxazolidin-2-one (124 mg, 0.246 mmol) was treated with 90% TFA/water for 2 hours. Concentrated *in vacuo* and neutralized by passing through a column of MP-carbonate resin (2.0 g, 0.55 mmol/g eluting with MeOH/DCM/MeOH) afforded the diastereomeric mixture. Chiral SFC chromatography on an ID column (75 g/min, 120 bar, 21 x 250 mm) eluting 45% IPA/CO₂ (v/v) to give (R)-3-(2-(((R)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-

10


(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.

202: Peak 1: 15 mg (pale orange foam) : (CDCl₃) δ 8.22 (d, *J* = 3.2 Hz, 1H), 7.63 – 7.50 (m, 2H), 7.45 – 7.38 (m, 2H), 7.28 (s, 1H), 5.65 (d, *J* = 7.0 Hz, 1H), 5.16 (s, 1H), 4.80 – 4.25 (m, 3H), 3.51 (s, 1H), 1.71 (d, *J* = 7.0 Hz, 3H), 1.38 – 1.15 (m, 4H). HRMS(B) *m/z* 447.1110. RT = 2.20 min.

203 : Peak 2: 87 mg (pale orange foam) : (CDCl₃) δ 8.24 (d, *J* = 2.9 Hz, 1H), 7.59 – 7.49 (m, 2H), 7.46 – 7.37 (m, 2H), 7.24 – 7.18 (m, 1H), 5.66 (d, *J* = 8.1 Hz, 1H), 5.32 (dd, *J* = 8.3, 6.6 Hz, 1H), 4.79 (s, 1H), 4.56 (t, *J* = 8.9 Hz, 1H), 4.39 (dd, *J* = 9.1, 5.7 Hz, 1H), 4.04 (td, *J* = 11.0, 9.7, 4.8 Hz, 1H), 3.51 (s, 1H), 1.70 (s, 1H), 1.23 (d, *J* = 6.2 Hz, 2H), 1.16 (d, *J* = 6.4 Hz, 3H). HRMS(B) *m/z* 447.1110. RT = 2.20 min.

Examples 204 and 205

(4R)-3-(2-(((1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



(4R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (3.50 g, 2.88 mmol) was treated with 90% TFA/water for 2 hours. Concentrated *in vacuo* and neutralized by passing through a column of MP-carbonate resin (6.0 g, 0.55 mmol/g eluting with MeOH/DCM/MeOH afforded the diastereomeric mixture. Chiral SFC chromatography on an OJ-H column (75 g/min, 120 bar, 21 x 250 mm) eluting 30% IPA + 10 mM NH₄OH/CO₂ (v/v) to give (R)-3-(2-(((S)-1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((R)-1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.


204: Peak 1 : 1.40 g (white powder crystals) : ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 5.8 Hz, 1H), 7.76 – 7.63 (m, 2H), 7.54 (d, *J* = 5.7 Hz, 1H), 7.50 – 7.37 (m, 2H), 6.46 (s, 1H), 5.90 – 5.55 (m, 1H), 5.27 – 5.04 (m, 1H), 4.93 – 4.79 (m, 1H), 4.56 (dd, *J* = 9.3, 2.5 Hz, 1H), 4.40 (dd,

$J = 9.4, 8.4$ Hz, 1H), 3.51 (s, 2H), 3.25 (d, $J = 68.4$ Hz, 1H), 1.98 – 1.55 (m, 2H), 0.91 (s, 3H). HRMS(B) m/z 429.1204. RT = 2.45 min.

205: Peak 2 : 1.35 g (off-white foam) : ^1H NMR (400 MHz, CDCl_3) δ 8.22 (d, $J = 6.0$ Hz, 1H), 7.79 – 7.64 (m, 2H), 7.54 (d, $J = 5.8$ Hz, 1H), 7.49 – 7.37 (m, 2H), 6.47 (s, 1H), 5.77 (s, 1H), 1.80 – 1.61 (m, 4H), 5.16 (s, 1H), 4.71 – 4.45 (m, 2H), 4.46 – 4.22 (m, 2H), 3.51 (s, 2H), 2.87 (s, 1H), 1.20 (d, $J = 6.5$ Hz, 4H). HRMS(B) m/z 429.1204. RT = 2.45 min.


Example 206

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



(R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (360 mg, 0.741 mg) was treated with 90% TFA/water for 2 hours. Concentrated *in vacuo* and neutralized by passing through a column of MP-carbonate resin (2.0 g, 0.55 mmol/g eluting with MeOH/DCM/MeOH afforded the desired product (120 mg, pale yellow foam). ^1H NMR (400 MHz, CDCl_3) δ 8.15 (d, $J = 6.0$ Hz, 1H), 7.64 – 7.49 (m, 3H), 7.49 – 7.35 (m, 2H), 7.29 (s, 1H), 5.33 (dd, $J = 9.4, 5.1$ Hz, 1H), 5.04 – 4.81 (m, 1H), 1.80 – 1.69 (m, 3H), 4.71 – 4.53 (m, 1H), 4.45 (dd, $J = 9.4, 8.1$ Hz, 1H), 4.28 – 3.97 (m, 1H), 3.51 (s, 3H), 1.14 (d, $J = 6.4$ Hz, 3H). HRMS(B) m/z 429.1204. RT = 2.22 min.

Example 207: (R)-3-(6-chloro-2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



Trifluoroacetic acid (2 mL) was added to a solution of (R)-4-((R)-1-tert-butoxyethyl)-3-(6-chloro-2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one (25.0 mg, 0.039 mmol), in DCM (2 mL) and the solution was stirred at room temperature for 1 h.













- 5 The reaction mixture was then concentrated and purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(6-chloro-2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (10.0 mg, white solid) in 44% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 8.4 Hz, 2H), 7.63 (s, 1H), 7.48 (d, J = 8.4 Hz, 2H), 5.30 (br m, 1H), 4.80 – 4.77 (m, 1H), 4.55 – 4.52 (m, 1H), 4.41 – 4.36 (m, 1H), 3.77 – 3.62 (br m, 1H), 1.78 (d, J = 7.1 Hz, 3H), 0.95 (br m, 3H); HRMS *m/z* 465.0847 (M + H)⁺; Rt- 2.25 min.
- 10










The compounds in **Table 30a** were prepared using methods similar to those described for the preparation of **Examples 35, 36, 37/38, or 207**.










15










Table 30a.
















208	209	
210	211	212













		
213	214	215
		
216	217	218
		
219	220	221
		
222	223	224













		
225	226	227
		
228	229	230
		
231	232	233















		
234	235	236
		
237	238	239
		
240	241	242












		
243	244	245
		
246	247	248
		
249	250	251
















		
252	253	254
		
255	256	257
		
258	259	260
		
261	262	263
		

264	265	266
		
267	268	269
		
270	271	272
		
273	274	275
		
276	277	278

		
279	280	281
		
282	283	284
		
285	286	287
		
288	289	

		
290	291	292
		
293	294	295
		
296	297	298
		
299	300	301
		

302	303	304
		
305	306	
		
307	308	309
		
310	311	312
		
313	314	315

		
316	317	318
		
319	320	321
		
322	323	324
		
325	326	327
		
328	329	330







		
331	332	333
		

Table 30b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 30a.

Example: Name	¹ H NMR (400 MHz, CDCl ₃) δ ppm	LCMS
208: (R)-3-(6-chloro-2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.59 (s, 1H), 7.52 – 7.48 (m, 1H), 7.44 – 7.42 (m, 1H), 7.37 (d, J = 9.7 Hz, 1H), 5.31 (br m, 1H), 4.68 – 4.66 (m, 1H), 4.49 – 4.46 (m, 1H), 4.38 – 4.34 (m, 1H), 3.43 (br m, 1H), 1.59 (d, J = 7.0 Hz, 3H), 0.83 (br m, 3H)	HRMS <i>m/z</i> 449.1009 (M + H) ⁺ ; Rt-2.39 min
209: (R)-3-(6-chloro-2-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.77 (s, 1H), 7.61 (s, 1H), 7.55 (s, 1H), 7.36 – 7.30 (m, 1H), 7.25 – 7.21 (m, 1H), 7.17 (dd, J = 11.4, 1.5 Hz, 1H), 5.26 (br m, 1H), 4.70 (ddd, J = 8.1, 5.2, 2.5 Hz, 1H), 4.45 (dd, J = 9.4, 2.5 Hz, 1H), 4.39 – 4.31 (m, 1H), 3.98 (s, 3H), 3.67 – 3.55 (m, 1H), 1.57 (d, J = 6.9 Hz, 3H), 0.82 (br m, 3H)	HRMS <i>m/z</i> 461.1505 (M + H) ⁺ ; Rt-2.00
210: (R)-3-(2-((S)-1-(3-(4-chlorophenyl)-1,2,4-	8.00 (d, J = 8.6 Hz, 2H), 7.91 (s, 1H), 7.48 (d, J = 8.6 Hz, 2H), 6.45 (t, J = 56 Hz, 1H),	HRMS <i>m/z</i>

oxadiazol-5-yl)ethylamino)-6-(difluoromethyl)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	4.84 (m, 1H), 4.83 (dt, J = 5.3, 2.5 Hz, 1H), 4.57 (d, J = 9.0 Hz, 1H), 4.46–4.37 (m, 1H), 3.69 (m, 1H), 1.83 (d, J = 7.0 Hz, 3H), 0.96 (br m, 3H)	481.1206 (M + H) ⁺ ; Rt-2.32
211: (R)-3-(2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)-6-(trifluoromethyl)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	8.00 (d, J = 8.6 Hz, 2H), 7.93 (s, 1H), 7.48 (d, J = 8.6 Hz, 2H), 5.31 (br. s., 1 H), 4.90 – 4.80 (m, 1H), 4.57 (dd, J = 9.6, 1.8 Hz, 1H), 4.48 – 4.35 (m, 1H), 3.74 (br m, 1H), 1.81 (d, J = 7.1 Hz, 3H), 1.25 – 0.84 (br m, 3H)	HRMS <i>m/z</i> 499.1106 (M + H) ⁺ ; Rt-2.50
212: (R)-3-(6-chloro-2-(((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.90 (s, 1H), 7.80 (s, 1H), 7.59 (br s, 1H), 7.25 – 7.21 (m, 1H), 7.12 (dd, J = 11.0, 6.3 Hz, 1H), 5.25 (br m, 1H), 4.72 (m, 1H), 4.49 (d, J = 9.4 Hz, 1H), 4.43 – 4.33 (m, 1H), 4.02 (s, 3H), 3.72 (br m, 1H), 1.58 (d, J = 7.0 Hz, 3H), 0.88 (br s, 3H)	HRMS <i>m/z</i> 479.1415 (M + H) ⁺ ; Rt-2.04
213: (R)-3-(6-chloro-2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.70 (d, J = 8.6 Hz, 2H), 7.60 (s, 1H), 7.46 (d, J = 8.6 Hz, 2H), 6.54 (s, 1H), 5.23 (m, 1H), 4.87 (m, 1H), 4.58 (d, J = 9.5 Hz, 1H), 4.47 – 4.39 (m, 1H), 3.89 (m, 1H), 1.67 (d, J = 7.1 Hz, 3H), 1.05 (d, J = 5.7 Hz, 3H)	HRMS <i>m/z</i> 464.0894 (M + H) ⁺ ; Rt-2.38
214: (R)-3-(6-chloro-2-(((S)-1-(5-phenylisoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.78 – 7.73 (m, 2H), 7.59 (s, 1H), 7.50 – 7.44 (m, 3H), 6.54 (s, 1H), 5.23 (m, 1H), 4.87 (m, 1H), 4.58 (d, J = 9.5 Hz, 1H), 4.42 (d, J = 9.3, 8.4 Hz, 1H), 3.89 (m, 1H), 1.67 (d, J = 7.1 Hz, 3H), 1.05 (d, J = 5.7 Hz, 3H)	HRMS <i>m/z</i> 430.1278 (M + H) ⁺ ; Rt-2.19
215: (R)-3-(6-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-	7.80 (s, 1H), 7.73 (s, 1H), 7.63 – 7.55 (m, 2H), 7.19 – 7.10 (m, 3H), 5.04 (m, 1H),	HRMS <i>m/z</i>

1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	4.72 (m, 1H), 4.47 (m, 1H), 4.43 – 4.34 (m, 1H), 3.73 (m, 1H), 1.62 (d, J = 6.9 Hz, 3H), 0.97 (br m, 3H)	431.1644 (M + H) ⁺ ; Rt-2.06
216: (R)-3-(6-chloro-2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.95 (s, 1H), 7.80 (d, J = 8.7 Hz, 2H), 7.65 (s, 1H), 7.48 (d, J = 8.7 Hz, 2H), 5.35 (m, 1H), 4.80 (m, 1H), 4.59 (d, J = 8.5 Hz, 1H), 4.40 (m, 1H), 3.72 (m, 1H), 1.74 (d, J = 6.9 Hz, 3H), 0.97 (br s, 3H)	HRMS m/z 480.0666 (M + H) ⁺ ; Rt-2.46
217: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	8.14 (d, J = 3.4 Hz, 1H), 7.93 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 5.33 (m, 1H), 4.71 (m, 1H), 4.58 (t, J = 9.0 Hz, 1H), 4.48 (dd, J = 9.3, 5.3 Hz, 1H), 3.72 (m, 1H), 1.79 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 6.2 Hz, 3H)	HRMS m/z 464.0964 (M + H) ⁺ ; Rt-2.08
218: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	8.07 (d, J = 3.8 Hz, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 6.62 (s, 1H), 5.31 (m, 1H), 4.95 (m, 1H), 4.62 (t, J = 9.0 Hz, 1H), 4.43 (dd, J = 9.3, 5.4 Hz, 1H), 3.98 – 3.88 (m, 1H), 1.73 (d, J = 7.1 Hz, 3H), 1.18 (d, J = 6.5 Hz, 3H)	HRMS m/z 448.1186 (M + H) ⁺ ; Rt-2.03
219: (R)-3-(6-chloro-2-(((S)-1-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.85 (d, J = 8.4 Hz, 2H), 7.65 (s, 1H), 7.48 (d, J = 8.4 Hz, 2H), 5.44 (m, 1H), 4.86 (m, 1H), 4.59 (d, J = 9.5 Hz, 1H), 4.40 (t, J = 8.9 Hz, 1H), 3.33 (m, 1H), 1.80 (d, J = 7.0 Hz, 3H), 0.91 (br s, 3H)	HRMS m/z 481.0618 (M + H) ⁺ ; Rt-2.25
220: (R)-3-(6-chloro-2-(((S)-1-(1-(4-	7.86 (s, 1H), 7.79 (s, 1H), 7.60 (s, 1H), 7.56 (d, J = 9.0 Hz, 2H), 7.44 (d, J = 9.0	HRMS m/z

chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	Hz, 2H), 5.03 (m, 1H), 4.76 (m, 1H), 4.51 (m, 1H), 4.45 – 4.33 (m, 1H), 3.75 (m, 1H), 1.63 (d, J = 6.9 Hz, 3H), 0.96 (br m, 3H)	463.1055 (M + H) ⁺ ; Rt-2.31
221: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	8.24 (d, J = 2.7 Hz, 1H), 7.85 (s, 1H), 7.70 (s, 1H), 7.59 (d, J = 8.9 Hz, 2H), 7.41 (d, J = 8.9 Hz, 2H), 5.34 (m, 1H), 5.04 (m, 1H), 4.57 – 4.48 (m, 2H), 4.43 – 4.34 (m, 1H), 3.84 (m, 1H), 1.61 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.2 Hz, 3H)	HRMS <i>m/z</i> 447.1350 (M + H) ⁺ ; Rt-1.98
222: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-6-(fluoromethyl)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.82 (s, 1H), 7.71 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 6.65 (s, 1H), 5.46 (s, 1H), 5.36 – 5.29 (m, 2H), 4.96 (m, 1H), 4.62 (d, J = 9.0 Hz, 1H), 4.53 – 4.45 (m, 1H), 3.99 (m, 1H), 1.73 (d, J = 7.2 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H)	HRMS <i>m/z</i> 462.1347 (M + H) ⁺ ; Rt-2.22
223: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-(fluoromethyl)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.88 (s, 1H), 7.87 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 5.47 (s, 1H), 5.38 – 5.30 (m, 2H), 4.86 (ddd, J = 8.1, 4.3, 2.2 Hz, 1H), 4.69 – 4.62 (m, 1H), 4.45 (dd, J = 9.5, 8.2 Hz, 1H), 3.61 (m, 1H), 1.80 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 6.4 Hz, 3H)	HRMS <i>m/z</i> 478.1116 (M + H) ⁺ ; Rt-2.28
224: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.99 (d, J = 7.1 Hz, 1H), 7.93 (s, 1H), 7.85 – 7.78 (m, 3H), 7.47 (d, J = 8.7 Hz, 2H), 5.43 – 5.34 (m, 1H), 4.89 (ddd, J = 8.1, 4.1, 2.2 Hz, 1H), 4.69 (dd, J = 9.4, 8.2 Hz, 1H), 3.69 (dd, J = 6.3, 4.4 Hz, 1H), 1.83 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 446.1065 (M + H) ⁺ ; Rt-1.90
225: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-	10.64 (d, J = 5.9 Hz, 1H), 7.98 (s, 1H), 7.95 (d, J = 7.1 Hz, 1H), 7.78 – 7.74 (m, 2H), 7.59 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 9.0 Hz, 2H), 5.06 (quin, J = 6.7 Hz, 1H),	HRMS <i>m/z</i> 429.1441 (M + H) ⁺ ;

hydroxyethyl)oxazolidin-2-one	4.84 (ddd, J = 8.2, 4.4, 2.3 Hz, 1H), 4.62 (dd, J = 9.6 2.3 Hz, 1H), 4.45 (dd, J = 9.5, 8.2 Hz, 1H), 3.80 – 3.69 (m, 1H), 1.70 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H)	Rt-1.62
226: (R)-3-(6-chloro-2-(((S)-1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.70 (d, J = 8.6 Hz, 2H), 7.65 (s, 1H), 7.45 (d, J = 8.6 Hz, 2H), 6.50 (s, 1H), 5.09 (m, 1H), 4.87 (m, 1H), 4.59 (d, J = 9.1 Hz, 1H), 4.46 – 4.37 (m, 1H), 3.49 (m, 1H), 1.72 (d, J = 7.1 Hz, 3H), 0.89 (br s, 3H)	HRMS <i>m/z</i> 464.0898 (M + H) ⁺ ; Rt-2.37
227: (R)-3-(2-(((S)-1-(3-(4-chlorophenyl)isoxazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	8.13 (d, J = 3.5 Hz, 1H), 7.69 (d, J = 8.5 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 6.52 (s, 1H), 5.17 (m, 1H), 4.94 (m, 1H), 4.64 – 4.57 (m, 1H), 4.52 (dd, J = 9.4, 5.4 Hz, 1H), 3.66 (m, 1H), 1.76 (d, J = 7.1 Hz, 3H), 1.04 (d, J = 6.4 Hz, 3H)	HRMS <i>m/z</i> 448.1190 (M + H) ⁺ ; Rt-2.07
228: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-6-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.84 (br s, 1H), 7.76 (s, 1H), 7.57 (d, J = 8.9 Hz, 2H), 7.44 (d, J = 9.0 Hz, 2H), 7.13 (s, 1H), 5.05 (m, 1H), 4.72 (m, 1H), 4.47 (m, 1H), 4.43 – 4.35 (m, 1H), 1.62 (d, J = 6.9 Hz, 3H), 0.96 (br m, 3H)	HRMS <i>m/z</i> 447.1347 (M + H) ⁺ ; Rt-2.23
229: (R)-3-(6-chloro-2-(((S)-1-(5-(4-fluorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.82 – 7.69 (m, 2H), 7.62 (s, 1H), 7.17 (t, J = 8.6 Hz, 2H), 6.51 (s, 1H), 5.23 (d, J = 5.8 Hz, 1H), 4.89 (m, 1H), 4.59 (m, 1H), 4.47 – 4.40 (m, 1H), 3.91 (m, 1H), 1.68 (d, J = 7.1 Hz, 3H), 1.07 (d, J = 6.3 Hz, 3H)	HRMS <i>m/z</i> 448.1192 (M + H) ⁺ ; Rt-2.23
230: (R)-3-(6-chloro-2-(((S)-1-(5-(morpholinomethyl)isoxazol-3-	7.59 (s, 1H), 6.57 (s, 1H), 5.23 (m, 1H), 4.82 (m, 1H), 4.56 (m, 1H), 4.43 – 4.34 (m, 2H), 4.20 (m, 1H), 3.97 (m, 4H), 3.24 (m, 4H), 1.61 (d, J = 7.2 Hz, 3H), 1.04 (br s,	HRMS <i>m/z</i> 453.1662 (M + H) ⁺ ;

yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	3H)	Rt-1.26
231: (R)-3-(6-chloro-2-(((R)-1-(5-(morpholinomethyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.55 (s, 1H), 6.55 (s, 1H), 5.87 (m, 1H), 5.05 (m, 1H), 4.65 (m, 1H), 4.56 (m, 1H), 4.34 – 4.31 (m, 2H), 4.20 (m, 1H), 3.97 – 3.95 (m, 4H), 3.18 (m, 4H), 1.62 (d, J = 7.0 Hz, 3H), 1.18 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 453.1651 (M + H) ⁺ ; Rt-1.27
232: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	10.78 (d, J = 5.8 Hz, 1H), 7.98 (s, 1H), 7.73 (s, 1H), 7.59 (d, J = 8.7 Hz, 2H), 7.56 (s, 1H), 7.43 (d, J = 8.7 Hz, 2H), 5.00 (m, 1H), 4.89 – 4.74 (m, 1H), 4.60 (dd, J = 9.6, 2.2 Hz, 1H), 4.52 – 4.35 (m, 1H), 3.69 (dd, J = 6.5, 4.6 Hz, 1H), 2.52 (s, 3H), 1.69 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 443.1596 (M + H) ⁺ ; Rt-1.62
233: (R)-3-(6-chloro-2-(((S)-1-(2-(pyridin-2-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	8.63 (m, 1H), 8.14 (s, 1H), 7.95 – 7.89 (m, 2H), 7.61 (s, 1H), 7.42 (m, 1H), 5.28 (m, 1H), 4.52 (m, 1H), 4.47 – 4.35 (m, 3H), 1.77 (m, 3H), 0.96 (br s, 3H)	HRMS <i>m/z</i> 447.1011 (M + H) ⁺ ; Rt-1.99
234: (R)-3-(6-chloro-2-(((S)-1-(2-(pyridin-3-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	9.30 (m, 1H), 8.70 (m, 1H), 8.54 (m, 1H), 7.88 (s, 1H), 7.69 (m, 1H), 7.61 (s, 1H), 5.30 (m, 1H), 4.52 (m, 1H), 4.42 – 4.36 (m, 3H), 1.76 (d, J = 6.9 Hz, 3H), 1.03 (br s, 3H)	HRMS <i>m/z</i> 447.1011 (M + H) ⁺ ; Rt-1.72
235: (R)-3-(6-chloro-2-(((S)-1-(2-(pyridin-4-yl)thiazol-5-	8.83 (m, 2H), 8.12 (m, 2H), 7.98 (s, 1H), 7.63 (s, 1H), 5.40 (m, 1H), 4.73 (m, 1H), 4.52 (m, 1H), 4.39 (m, 1H), 1.77 (m, 3H),	HRMS <i>m/z</i> 447.1006

yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	1.00 (br s, 3H)	(M + H) ⁺ ; Rt-1.52
236: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	11.03 (d, J = 6.8 Hz, 1H), 7.71 (d, J = 8.7 Hz, 2H), 7.56 (s, 1H), 7.46 (d, J = 8.7 Hz, 2H), 6.70 (s, 1H), 5.32 (quin, J = 7.1 Hz, 1H), 4.95 (ddd, J = 7.9, 4.4, 1.9 Hz, 1H), 4.62 (dd, J = 9.5, 1.9 Hz, 1H), 4.53 – 4.43 (m, 1H), 4.06 – 3.94 (m, 1H), 2.51 (s, 3H), 1.74 (d, J = 7.2 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H)	HRMS <i>m/z</i> 444.1443 (M + H) ⁺ ; Rt-1.81
237: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	11.12 (d, J = 5.4 Hz, 1H), 7.88 (s, 1H), 7.81 (d, J = 8.7 Hz, 2H), 7.62 (s, 1H), 7.45 (d, J = 8.7 Hz, 2H), 5.37 – 5.27 (m, 1H), 4.84 (ddd, J = 8.2, 4.2, 2.2 Hz, 1H), 4.65 (dd, J = 9.6, 2.2 Hz, 1H), 4.44 (dd, J = 9.4, 8.3 Hz, 1H), 3.61 – 3.52 (m, 1H), 2.52 (s, 3H), 1.81 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 460.1213 (M + H) ⁺ ; Rt-1.88
238: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	11.13 (d, J = 8.3 Hz, 1H), 8.43 (s, 1H), 7.91 (s, 1H), 7.67 (s, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 5.97 (quin, J = 7.0 Hz, 1H), 4.98 (ddd, J = 8.1, 4.4, 2.4 Hz, 1H), 4.77 (dd, J = 9.6, 2.3 Hz, 1H), 4.53 – 4.46 (m, 1H), 4.44 – 4.36 (m, 1H), 2.55 (s, 3H), 1.70 (d, J = 6.8 Hz, 3H), 1.06 (d, J = 6.6 Hz, 3H)	HRMS <i>m/z</i> 443.1599 (M + H) ⁺ ; Rt-1.35
239: (R)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	11.42 (d, J = 5.0 Hz, 1H), 8.00 (d, J = 8.6 Hz, 2H), 7.64 (s, 1H), 7.48 (d, J = 8.6 Hz, 2H), 5.30 – 5.20 (m, 1H), 4.77 (ddd, J = 7.9, 4.5, 2.0 Hz, 1H), 4.57 (dd, J = 9.5, 1.9 Hz, 1H), 4.40 (dd, J = 9.4, 8.2 Hz, 1H), 3.65 – 3.55 (m, 1H), 2.56 (s, 3H), 1.90 (d, J = 7.2 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 445.1393 (M + H) ⁺ ; Rt-1.96

240: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	10.80 (d, J = 7.3 Hz, 1H), 7.79 (d, J = 2.5 Hz, 1H), 7.54 – 7.48 (m, 3H), 7.46 – 7.41 (m, 2H), 6.58 (d, J = 2.5 Hz, 1H), 5.40 – 5.30 (m, 1H), 4.85 (ddd, J = 7.7, 5.1, 2.3 Hz, 1H), 4.50 – 4.38 (m, 2H), 4.02 – 3.93 (m, 1H), 2.50 (s, 3H), 1.71 (d, J = 7.1 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 443.1601 (M + H) ⁺ ; Rt-1.66
241: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	11.00 (m, 1H), 8.15 (s, 1H), 7.69 (d, J = 8.5 Hz, 2H), 7.53 (s, 1H), 7.51 (d, J = 8.5 Hz, 2H), 5.51 (m, 1H), 4.70 (m, 1H), 4.58 (m, 1H), 4.51 (m, 1H), 3.96 (m, 1H), 2.50 (s, 3H), 1.78 (d, J = 6.5 Hz, 3H), 1.17 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 444.1548 (M + H) ⁺ ; Rt-1.54
242: (R)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.97 (s, 1H), 7.69 (m, 2H), 7.60 (s, 1H), 7.52 (d, J = 8.9 Hz, 2H), 5.41 (m, 1H), 4.97 (m, 1H), 4.54 (m, 1H), 4.43 (m, 1H), 3.77 (m, 1H), 1.71 (d, J = 7.0 Hz, 3H), 1.05 (br s, 3H)	HRMS <i>m/z</i> 464.1003 (M + H) ⁺ ; Rt-2.15
243: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	10.91 (d, J = 7.3 Hz, 1H), 8.15 (s, 1H), 7.89 (d, J = 7.0 Hz, 1H), 7.75 (d, J = 7.0 Hz, 1H), 7.70 (d, J = 8.5 Hz, 2H), 7.52 (d, J = 8.5 Hz, 2H), 5.53 (quin, J = 6.9 Hz, 1H), 5.04 (m, 1H), 4.60 – 4.50 (m, 2H), 3.99 (m, 1H), 1.79 (d, J = 7.2 Hz, 3H), 1.19 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 430.1398 (M + H) ⁺ ; Rt-1.56
244: (R)-3-(2-(((S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	11.05 (d, J = 5.9 Hz, 1H), 7.56 (s, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.31 (d, J = 8.7 Hz, 1H), 7.24 (s, 1H), 5.37 (quin, J = 6.7 Hz, 1H), 4.75 (m, 1H), 4.56 (dd, J = 9.6, 2.3 Hz, 1H), 4.40 (m, 1H), 3.47 (m, 1H), 2.53 (s, 3H), 1.92 (t, J = 18.2, Hz, 3H), 1.66 (d, J = 7.0 Hz, 3H), 0.84 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 425.1803 (M + H) ⁺ ; Rt-1.68

245: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-(((R)-1-hydroxyethyl)oxazolidin-2-one	11.1 (d, J = 6.6 Hz, 1H), 7.58 (s, 1H), 7.25 (m, 1H), 6.83 (dd, J = 10.5, 6.6 Hz, 1H), 5.33 (quin, J = 6.9 Hz, 1H), 4.83 (ddd, J = 8.1, 4.7, 2.3 Hz, 1H), 4.59 (dd, J = 9.6, 2.3 Hz, 1H), 4.48 – 4.37 (m, 3H), 3.83 (m, 1H), 2.53 (s, 3H), 1.61 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 477.1574 (M + H) ⁺ ; Rt-1.78
246: (R)-4-((R)-1-hydroxyethyl)-3-(6-methyl-2-(((S)-1-(2-(6-methylpyridin-3-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	11.16 (d, J = 6.9 Hz, 1H), 9.54 (d, J = 1.9 Hz, 1H), 8.76 (dd, J = 8.3, 2.1 Hz, 1H), 8.00 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.63 (s, 1H), 5.43 (quin, J = 6.9 Hz, 1H), 5.06 (ddd, J = 7.9, 4.2, 1.8 Hz, 1H), 4.74 (dd, J = 9.6, 1.9 Hz, 1H), 4.14 (m, 1H), 2.86 (s, 3H), 2.52 (s, 3H), 1.87 (d, J = 7.1 Hz, 3H), 1.13 (d, J = 6.4 Hz, 3H)	HRMS <i>m/z</i> 441.1710 (M + H) ⁺ ; Rt-1.16
247: (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(2-(6-(trifluoromethyl)pyridin-3-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	11.05 (br s, 1H), 9.21 (s, 1H), 8.34 (d, J = 8.8 Hz, 1H), 7.97 (d, J = 7.0 Hz, 1H), 7.92 (s, 1H), 7.82 (d, J = 7.0 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 5.35 (m, 1H), 4.85 (m, 1H), 4.64 (m, 1H), 4.46 (m, 1H), 3.58 (m, 1H), 1.85 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.4 Hz, 3H)	HRMS <i>m/z</i> 481.1272 (M + H) ⁺ ; Rt-1.77
248: (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	11.05 (br s, 1H), 8.84 (d, J = 5.1 Hz, 1H), 8.15 (s, 1H), 7.99 (d, J = 7.1 Hz, 1H), 7.95 (s, 1H), 7.92 (dd, J = 5.1, 1.3 Hz, 1H), 7.83 (d, J = 7.0 Hz, 1H), 5.36 (m, 1H), 4.85 (m, 1H), 4.65 (dd, J = 9.7, 2.0 Hz, 1H), 4.46 (m, 1H), 3.62 (m, 1H), 1.85 (d, J = 6.9 Hz, 3H), 0.97 (d, J = 6.5 Hz, 3H)	HRMS <i>m/z</i> 481.1268 (M + H) ⁺ ; Rt-1.72
249: methyl 2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-((R)-4-((R)-1-hydroxyethyl)-2-oxooxazolidin-3-yl)pyrimidine-4-	8.27 (s, 1H), 7.96 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H), 5.41 (m, 1H), 4.66 (m, 1H), 4.45 (m, 1H), 4.01 (s, 3H), 3.75 (m, 1H), 1.78 (d, J = 6.9 Hz, 3H), 0.98 (d, J = 6.1 Hz, 3H)	HRMS <i>m/z</i> 504.1111 (M + H) ⁺ ; Rt-2.17

carboxylate		
250: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	11.00 (d, J = 8.5 Hz, 1H), 7.95 (m, 1H), 7.87 (m, 1H), 7.61 (m, 2H), 7.43 (d, J = 1.8 Hz, 1H), 7.35 (m, 2H), 5.95 (m, 1H), 5.02 (m, 1H), 4.80 (dd, J = 9.6, 2.4 Hz, 1H), 4.50 (m, 1H), 4.40 (m, 1H), 2.60 (m, 3H), 1.70 (m, 3H), 1.07 (m, 3H)	LCMS <i>m/z</i> 443.2 (M + H) ⁺ ; Rt-0.60
251: (R)-3-(2-(((S)-1-(2-(4-(difluoromethyl)phenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	10.92 (br s, 1H), 7.95 (m, 3H), 7.84 (s, 1H), 7.80 (d, J = 7.0 Hz, 1H), 7.60 (d, J = 8.2 Hz, 2H), 6.69 (t, J = 56 Hz, 1H), 5.27 (m, 1H), 4.81 (ddd, J = 8.2, 4.3, 2.1 Hz, 1H), 4.64 (dd, J = 9.6, 2.1 Hz, 1H), 4.45 (m, 1H), 3.39 (br m, 1H), 1.84 (d, J = 7.0 Hz, 3H), 0.89 (d, J = 6.5 Hz, 3H)	LCMS <i>m/z</i> 462.2 (M + H) ⁺ ; Rt-0.70
252: (R)-3-(2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.77 (br. s., 3 H) 1.64 (d, J=6.99 Hz, 3 H) 4.40 - 4.47 (m, 1 H) 4.57 (dd, J=9.22, 2.52 Hz, 1 H) 5.43 - 5.51 (m, 1 H) 7.50 (d, J=9.15 Hz, 2 H) 7.62 (t, J=7.73 Hz, 1 H) 7.67 (d, J=6.85 Hz, 1 H) 8.15 (d, J=6.80 Hz, 1 H)	HRMS (B) <i>m/z</i> 415.1402 (M + H) ⁺ ; Rt-2.18 min
253: (R)-3-(2-((S)-1-(4-(1-ethoxycyclopropyl)-2-fluorophenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.80 (br. s., 3 H) 0.95 - 1.00 (m, 2 H) 1.15 (t, J=7.07 Hz, 3 H) 1.19 - 1.23 (m, 2 H) 1.61 (d, J=6.99 Hz, 3 H) 3.44 (qd, J=7.05, 1.34 Hz, 2 H) 4.41 - 4.49 (m, 1 H) 4.59 (dd, J=9.19, 2.49 Hz, 1 H) 5.40 (br. s., 1 H) 7.06 (d, J=2.15 Hz, 1 H) 7.09 (s, 1 H) 7.36 (t, J=7.92 Hz, 1 H) 7.66 (d, J=6.85 Hz, 1 H) 8.12 (d, J=7.14 Hz, 1 H)	HRMS (B) <i>m/z</i> 431.2090 (M + H) ⁺ ; Rt-1.72 min
254: 2-chloro-N-cyclopentyl-4-((S)-1-(4-((R)-4-((R)-1-hydroxyethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide	(CD ₃ OD) 0.86 (br. s., 3 H) 1.57 (d, J=6.99 Hz, 3 H) 1.59 - 1.69 (m, 3 H) 1.74 (d, J=4.99 Hz, 2 H) 1.95 - 2.06 (m, 2 H) 2.66 (s, 1 H) 4.29 (d, J=6.46 Hz, 1 H) 4.38 - 4.46 (m, 1 H) 4.57 (dd, J=9.24, 2.54 Hz, 1 H) 5.13 (br. s., 1 H) 7.39 (s, 2 H) 7.47 (s, 1 H) 7.61 (d, J=6.21 Hz, 1 H) 8.13 (br. s., 1	HRMS (B) <i>m/z</i> 474.1908 (M + H) ⁺ ; Rt-1.58 min

	H) 8.40 (br. s., 1 H)	
255: 1-(3-fluoro-4-((S)-1-(4-((R)-4-((R)-1-hydroxyethyl)-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)phenyl)cyclopropanecarbonitrile	(CD ₃ OD) 0.80 (br. s., 3 H) 1.47 - 1.51 (m, 2 H) 1.60 (d, <i>J</i> =6.94 Hz, 3 H) 1.72 - 1.76 (m, 2 H) 4.41 - 4.47 (m, 1 H) 4.58 (dd, <i>J</i> =9.22, 2.57 Hz, 1 H) 5.39 (br. s., 1 H) 7.12 (dd, <i>J</i> =11.64, 1.91 Hz, 1 H) 7.18 (dd, <i>J</i> =8.09, 1.79 Hz, 1 H) 7.41 (t, <i>J</i> =8.05 Hz, 1 H) 7.64 (d, <i>J</i> =6.65 Hz, 1 H) 8.13 (d, <i>J</i> =6.80 Hz, 1 H)	HRMS (B) <i>m/z</i> 412.1785 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.51 min
256: (R)-3-(2-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.82 (br. s., 3 H) 1.64 (d, <i>J</i> =6.94 Hz, 3 H) 3.92 (s, 3 H) 4.07 (d, <i>J</i> =16.09 Hz, 1 H) 4.43 - 4.50 (m, 1 H) 4.60 (dd, <i>J</i> =9.22, 2.47 Hz, 1 H) 4.91 (ddd, <i>J</i> =8.20, 3.97, 2.45 Hz, 2 H) 5.45 (br. s., 1 H) 7.31 - 7.44 (m, 3 H) 7.73 (d, <i>J</i> =7.09 Hz, 1 H) 7.82 (d, <i>J</i> =0.68 Hz, 1 H) 7.98 (s, 1 H) 8.13 (d, <i>J</i> =7.04 Hz, 1 H)	HRMS (B) <i>m/z</i> 427.1890 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.37 min
257: (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	(CD ₃ OD) 0.80 (br. s., 3 H) 1.62 (d, <i>J</i> =6.94 Hz, 3 H) 3.92 (s, 3 H) 3.99 (br. s., 1 H) 4.42 - 4.50 (m, 1 H) 4.60 (dd, <i>J</i> =9.24, 2.45 Hz, 1 H) 5.21 (br. s., 1 H) 7.38 (d, <i>J</i> =8.17 Hz, 2 H) 7.53 - 7.59 (m, 2 H) 7.73 (d, <i>J</i> =7.14 Hz, 1 H) 7.79 (d, <i>J</i> =0.68 Hz, 1 H) 7.93 (s, 1 H) 8.12 (d, <i>J</i> =6.11 Hz, 1 H)	HRMS (B) <i>m/z</i> 409.1982 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.27 min
258: (R)-3-(2-((S)-1-(2-fluoro-4-(1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.83 (br. s., 3 H) 1.65 (d, <i>J</i> =6.99 Hz, 3 H) 4.07 (br. s., 1 H) 4.43 - 4.52 (m, 1 H) 4.61 (dd, <i>J</i> =9.24, 2.45 Hz, 1 H) 4.90 - 4.94 (m, 2 H) 5.45 (br. s., 1 H) 7.36 - 7.42 (m, 3 H) 7.73 (d, <i>J</i> =7.04 Hz, 1 H) 7.98 (s, 2 H) 8.13 (d, <i>J</i> =6.90 Hz, 1 H)	HRMS (B) <i>m/z</i> 413.1732 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.26 min
259: (R)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.75 (br. s., 3 H) 1.54 (d, <i>J</i> =7.04 Hz, 3 H) 3.85 (br. s., 1 H) 4.42 - 4.55 (m, 2 H) 5.27 (q, <i>J</i> =6.99 Hz, 1 H) 7.42 (d, <i>J</i> =8.90 Hz, 2 H) 7.58 (t, <i>J</i> =7.92 Hz, 1 H) 8.21 (d, <i>J</i> =2.74 Hz, 1 H)	HRMS (B) <i>m/z</i> 433.1299 (<i>M</i> + <i>H</i>) ⁺ ; Rt-2.03 min

260: (R)-3-(2-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.73 - 0.87 (m, 7 H) 1.39 (s, 3 H) 1.60 (d, <i>J</i> =6.94 Hz, 3 H) 3.99 (br. s., 1 H) 4.40 - 4.49 (m, 1 H) 4.59 (dd, <i>J</i> =9.19, 2.54 Hz, 1 H) 5.39 (br. s., 1 H) 7.01 (dd, <i>J</i> =12.40, 1.74 Hz, 1 H) 7.05 (dd, <i>J</i> =8.00, 1.79 Hz, 1 H) 7.29 (t, <i>J</i> =8.09 Hz, 1 H) 7.69 (d, <i>J</i> =6.99 Hz, 1 H) 8.12 (d, <i>J</i> =6.94 Hz, 1 H)	HRMS (B) <i>m/z</i> 401.1992 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.87 min
261: (R)-3-(2-((S)-1-(2-fluoro-4-isopropylphenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.12 (d, <i>J</i> =6.7 Hz, 1 H), 7.69 (d, <i>J</i> =7.0 Hz, 1 H), 7.31 (t, <i>J</i> =8.0 Hz, 1 H), 6.98 - 7.09 (m, 2 H), 5.42 (d, <i>J</i> =12.9 Hz, 1 H), 4.59 (dd, <i>J</i> =9.2, 2.5 Hz, 1 H), 4.40 - 4.49 (m, 1 H), 2.91 (spt, <i>J</i> =6.8 Hz, 1 H), 1.61 (d, <i>J</i> =6.7 Hz, 3 H), 1.23 (d, <i>J</i> =7.0 Hz, 6 H), 0.80 (br. s., 3 H)	HRMS (B) <i>m/z</i> 389.1987 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.83 min
262: (R)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.75 (br. s., 3 H) 1.53 (d, <i>J</i> =6.94 Hz, 3 H) 3.91 (s, 3 H) 4.42 - 4.56 (m, 2 H) 4.65 (br. s., 1 H) 5.22 (m, <i>J</i> =7.04 Hz, 1 H) 7.22 - 7.31 (m, 2 H) 7.31 - 7.40 (m, 1 H) 7.79 (s, 1 H) 7.94 (s, 1 H) 8.21 (br. s., 1 H)	HRMS (B) <i>m/z</i> 445.1800 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.64 min
263: (R)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.52 - 0.78 (m, 5 H) 0.82 (br. s., 2 H) 1.36 (s, 3 H) 1.49 (d, <i>J</i> =6.99 Hz, 3 H) 3.86 (br. s., 1 H) 4.42 - 4.56 (m, 2 H) 4.62 (br. s., 1 H) 5.18 (m, <i>J</i> =6.31 Hz, 1 H) 6.90 - 7.00 (m, 2 H) 7.24 (t, <i>J</i> =8.17 Hz, 1 H) 8.20 (d, <i>J</i> =2.93 Hz, 1 H)	HRMS (B) <i>m/z</i> 419.1895 (<i>M</i> + <i>H</i>) ⁺ ; Rt-2.21 min
264: (R)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.76 (br. s., 3 H) 1.53 (d, <i>J</i> =6.90 Hz, 3 H) 3.91 (br. s., 1 H) 4.42 - 4.57 (m, 2 H) 4.66 (br. s., 1 H) 5.23 (d, <i>J</i> =6.41 Hz, 1 H) 7.28 - 7.40 (m, 3 H) 7.97 (s, 2 H) 8.21 (br. s., 1 H)	HRMS (B) <i>m/z</i> 431.1640 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.55 min

265: (R)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-isopropylphenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.71 (br. s., 3 H) 1.21 (d, <i>J</i> =6.94 Hz, 6 H) 1.50 (d, <i>J</i> =6.99 Hz, 3 H) 2.87 (dt, <i>J</i> =13.72, 6.83 Hz, 1 H) 3.89 (br.s., 1 H) 4.43 - 4.56 (m, 2 H) 4.63 (br. s., 1 H) 5.20 (q, <i>J</i> =6.52 Hz, 1 H) 6.90 - 7.00 (m, 2 H) 7.26 (t, <i>J</i> =7.90 Hz, 1 H) 8.21 (d, <i>J</i> =2.84 Hz, 1 H)	HRMS (B) <i>m/z</i> 407.1890 (M + H) ⁺ ; Rt-2.18 min
266: (R)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.73 (br. s., 3 H) 1.47 - 1.52 (m, 9 H) 4.43 - 4.55 (m, 3 H) 4.59 - 4.67 (m, 1 H) 5.15 - 5.27 (m, 1 H) 7.15 - 7.23 (m, 2 H) 7.30 (t, <i>J</i> =8.09 Hz, 1 H) 8.20 (d, <i>J</i> =3.08 Hz, 1 H)	HRMS (B) <i>m/z</i> 423.1838 (M + H) ⁺ ; Rt-1.59 min
267: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 0.79 (br. s., 3 H) 1.52 (d, <i>J</i> =6.99 Hz, 3 H) 3.92 (s, 3 H) 4.43 - 4.56 (m, 2 H) 4.64 (d, <i>J</i> =3.42 Hz, 1 H) 5.21 (q, <i>J</i> =6.83 Hz, 1 H) 7.14 (dd, <i>J</i> =11.40, 6.31 Hz, 1 H) 7.39 (dd, <i>J</i> =10.93, 6.14 Hz, 1 H) 7.86 (d, <i>J</i> =0.59 Hz, 1 H) 8.00 (d, <i>J</i> =1.86 Hz, 1 H) 8.23 (d, <i>J</i> =3.03 Hz, 1 H)	HRMS (B) <i>m/z</i> 463.1708 (M + H) ⁺ ; Rt-1.72 min
268: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ CN) 0.98 (d, <i>J</i> =6.65 Hz, 3 H) 1.72 (d, <i>J</i> =7.04 Hz, 3 H) 4.00 (br. s., 1 H) 4.26 - 4.42 (m, 1 H) 4.51 (dd, <i>J</i> =8.80, 2.93 Hz, 1 H) 4.62 (dd, <i>J</i> =7.24, 1.37 Hz, 1 H) 5.49 (quin, <i>J</i> =6.85 Hz, 1 H) 7.49 (d, <i>J</i> =8.61 Hz, 2 H) 7.66 - 7.78 (m, 2 H) 7.91 (d, <i>J</i> =8.61 Hz, 2 H) 8.05 (d, <i>J</i> =7.04 Hz, 1 H) 10.52 (br. s., 1 H)	HRMS (B) <i>m/z</i> 446.1060 (M + H) ⁺ ; Rt-1.81 min
269: (R)-3-(6-chloro-2-(((S)-1-(2-fluoro-4-(2-fluoropropan-2-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 0.80 (br. s., 3 H) 1.26 (s, 3 H) 1.63 - 1.73 (m, 9 H) 4.28 - 4.36 (m, 1 H) 4.44 (dd, <i>J</i> =9.39, 2.54 Hz, 1 H) 4.64 (br. s., 1 H) 5.21 (br. s., 1 H) 7.07 - 7.18 (m, 2 H) 7.28 - 7.33 (m, 1 H) 7.51 (s, 1 H)	HRMS (B) <i>m/z</i> 441.1501 (M + H) ⁺ ; Rt-2.35 min

270: (R)-3-(5-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) δ 8.20 (s, 1 H), 8.03 (d, J =1.2 Hz, 1 H), 7.30 - 7.52 (m, 6 H), 5.06 (d, J =6.7 Hz, 1 H), 4.67 (dt, J =8.6, 6.1 Hz, 1 H), 4.45 (t, J =8.8 Hz, 1 H), 4.31 (dd, J =9.0, 6.3 Hz, 1 H), 3.81 (br. s., 1 H), 1.49 (d, J =6.7 Hz, 3 H), 0.91 (br. s., 3 H)	HRMS (B) m/z 399.1029 (M + H) ⁺ RT=1.95 min.
271: (R)-3-(2-((S)-1-(2,5-difluoro-4-isopropylphenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.14 (br. s., 1 H), 7.64 (d, J =6.7 Hz, 1 H), 7.07 (dd, J =10.2, 6.3 Hz, 2 H), 5.37 (d, J =5.1 Hz, 1 H), 4.85 (s, 1H), 4.57 (dd, J =9.4, 2.3 Hz, 1 H), 4.38 - 4.49 (m, 1 H), 3.96 (br. s., 1 H), 3.11 - 3.25 (m, 1 H), 1.57 (d, J =7.0 Hz, 3 H), 1.23 (dd, J =7.0, 2.0 Hz, 6 H), 0.80 (br. s., 3 H)	HRMS (B) m/z 407.1895, (M+H) ⁺ , RT=1.95 min.
272: (R)-3-(2-(((S)-1-(4-bromo-2,5-difluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.14 (d, J =5.9 Hz, 1 H), 7.51 (d, J =6.3 Hz, 1 H), 7.44 (dd, J =9.4, 5.5 Hz, 1 H), 7.24 (dd, J =9.0, 6.3 Hz, 1 H), 5.33 (q, J =6.7 Hz, 1 H), 4.85 (s, 8 H), 4.54 (dd, J =9.2, 2.5 Hz, 2 H), 4.34 - 4.47 (m, 1 H), 1.54 (d, J =6.7 Hz, 3 H), 0.83 (br. s., 3 H)	HRMS (B) m/z 443.0527, (M+H) ⁺ , RT=1.74 min.
273: (R)-3-(2-((S)-1-(5-chloro-6-(1,1-difluoroethyl)pyridin-3-yl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.55 (d, J =1.2 Hz, 1 H), 8.16 (d, J =5.9 Hz, 1 H), 7.99 (s, 1 H), 7.64 (d, J =5.9 Hz, 1 H), 5.27 (br. s., 1 H), 4.85(s, 2 H), 4.56 (dd, J =9.0, 2.3 Hz, 1 H), 4.39 - 4.47 (m, 1 H), 2.04 (t, J =19.0 Hz, 3 H), 1.63 (d, J =7.0 Hz, 3 H), 0.82 (br. s., 3 H)	HRMS (B) m/z 428.1299, (M+H) ⁺ , RT=1.65 min.
274: (R)-3-(2-((S)-1-(5-chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.15 (d, J =2.0 Hz, 2 H), 7.92 (d, J =2.3 Hz, 1 H), 7.71 (d, J =7.0 Hz, 1 H), 5.25 (br. s., 1 H), 4.89 - 4.99 (m, 3H), 4.59 (dd, J =9.4, 2.3 Hz, 1 H), 4.41 - 4.50 (m, 1 H), 4.00 (br. s., 1 H), 1.62 (d, J =7.0 Hz, 6 H)	HRMS (B) m/z 462.1149, (M+H) ⁺ , RT=1.87 min.

275: (R)-3-(2-((S)-1-(4-bromo-2,3-difluorophenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.16 (br. s., 1 H), 7.71 (d, <i>J</i> =6.7 Hz, 1 H), 7.36 - 7.48 (m, 1 H), 7.09 - 7.22 (m, 1 H), 5.42 (br. s., 1 H), 4.87 (s, 1 H), 4.57 (dd, <i>J</i> =9.0, 2.3 Hz, 1 H), 4.39 - 4.50 (m, 1 H), 3.82 (br. s., 1 H), 1.62 (d, <i>J</i> =7.0 Hz, 6 H)	HRMS (B) <i>m/z</i> 443.0532, (M+H) ⁺ , RT=1.81 min.
276: (R)-3-(2-(((S)-1-(4-bromo-2,5-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.22 (d, <i>J</i> =2.3 Hz, 1 H), 7.41 (dd, <i>J</i> =9.0, 5.5 Hz, 1 H), 7.21 (dd, <i>J</i> =9.2, 6.5 Hz, 1 H), 5.13 - 5.23 (m, 1 H), 4.86 (s, 1 H), 4.38 - 4.55 (m, 2 H), 3.99 - 4.16 (m, 1 H), 1.49 (d, <i>J</i> =7.0 Hz, 6 H)	HRMS (B) <i>m/z</i> 461.0432, (M+H) ⁺ , RT=2.01 min.
277: (R)-3-(2-(((S)-1-(4-bromo-2-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.20 (d, <i>J</i> =2.3 Hz, 1 H), 7.18 - 7.38 (m, 3 H), 5.18 (q, <i>J</i> =7.0 Hz, 1 H), 4.61 (t, <i>J</i> =9.0 Hz, 1 H), 4.42 - 4.55 (m, 2 H), 3.89 (br. s., 1 H), 1.49 (d, <i>J</i> =7.0 Hz, 6 H)	HRMS (B) <i>m/z</i> 443.0534, (M+H) ⁺ , RT=1.99 min.
278: (R)-3-(2-(((S)-1-(4-chloro-2-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.21 (d, <i>J</i> =2.7 Hz, 1 H), 7.36 (t, <i>J</i> =8.4 Hz, 1 H), 7.05 - 7.21 (m, 2 H), 5.20 (q, <i>J</i> =7.0 Hz, 1 H), 4.62 (d, <i>J</i> =8.6 Hz, 1 H), 4.42 - 4.56 (m, 2 H), 3.90 (br. s., 1 H), 1.50 (d, <i>J</i> =7.0 Hz, 6 H)	HRMS (B) <i>m/z</i> 399.1029, (M+H) ⁺ , RT=1.95 min.
279: (R)-3-(2-((S)-1-(5-bromo-3-fluoropyridin-2-yl)ethylamino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.45 (s, 1 H), 8.21 (d, <i>J</i> =2.7 Hz, 1 H), 7.86 (dd, <i>J</i> =9.4, 2.0 Hz, 1 H), 5.35 (q, <i>J</i> =6.7 Hz, 1 H), 4.67 - 4.77 (m, 1 H), 4.43 - 4.58 (m, 2 H), 4.08 - 4.20 (m, 1 H), 1.51 (d, <i>J</i> =6.7 Hz, 3 H), 1.09 (d, <i>J</i> =6.7 Hz, 3 H)	HRMS (B) <i>m/z</i> 444.0483, (M+H) ⁺ , RT=1.75 min.
280: (R)-3-(2-((R)-1-(5-bromo-3-fluoropyridin-2-	(CD ₃ OD) 8.44 (s, 1 H), 8.22 (d, <i>J</i> =2.7 Hz, 1 H), 7.86 (dd, <i>J</i> =9.4, 1.6 Hz, 1 H), 5.30 -	HRMS (B) <i>m/z</i>

yl)ethylamino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	5.38 (m, 1 H), 4.61 - 4.71 (m, 1H), 4.50 - 4.58 (m, 1 H), 4.43 - 4.49 (m, 1 H), 3.92 (br. s., 1 H), 1.52 (d, $J=7.0$ Hz, 6 H)	444.0478, (M+H) ⁺ , RT=1.75 min.
281: (R)-3-(2-((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.27 (br. s., 1 H), 8.01 (dd, $J=8.6, 2.3$ Hz, 2 H), 7.47 - 7.56 (m, 2 H), 5.30 - 5.43 (m, 1 H), 4.68 (d, $J=13.7$ Hz, 1 H), 4.40 - 4.57 (m, 2 H), 4.00 (br. s., 1 H), 1.72 (d, $J=7.0$ Hz, 6 H)	HRMS (B) m/z 449.1140, (M+H) ⁺ , RT=2.04 min.
282: (R)-3-(2-((S)-1-(5-bromopyridin-2-yl)ethylamino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.65 (d, $J=2.0$ Hz, 1 H), 8.22 (d, $J=2.3$ Hz, 1 H), 8.07 (dd, $J=8.6, 2.3$ Hz, 1 H), 7.51 (d, $J=8.2$ Hz, 1 H), 5.00 - 5.08 (m, 1 H), 4.61 (br. s., 1 H), 4.42 - 4.55 (m, 2 H), 4.06 - 4.17 (m, 1 H), 1.55 (d, $J=7.0$ Hz, 3 H), 1.08 (d, $J=6.7$ Hz, 3 H)	HRMS (B) m/z 426.0574, (M+H) ⁺ , RT=1.61 min.
283: (R)-3-(2-(((S)-1-(4-bromo-3-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.21 (d, $J=2.7$ Hz, 1 H), 7.52 (t, $J=7.6$ Hz, 1 H), 7.21 (dd, $J=9.8, 2.0$ Hz, 1 H), 7.12 (dd, $J=8.2, 2.0$ Hz, 1 H), 4.88 - 4.97 (m, 1 H), 4.59 (d, $J=8.2$ Hz, 1 H), 4.42 - 4.55 (m, 2 H), 3.88 (br. s., 1 H), 1.49 (d, $J=7.0$ Hz, 3 H), 0.80 (br. s., 3 H)	HRMS (B) m/z 443.0526, (M+H) ⁺ , RT=1.96 min.
284: (R)-3-(2-(((S)-1-(5-chloro-6-(1,1-difluoroethyl)pyridin-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.51(s, 1H), 8.24(s, 1H), 7.76 (s, 1H), 5.13 (m, 1 H), 4.91 (m, 1H), 4.42 - 4.55 (m, 2H), 4.41 (br. s., 1 H), 2.12 (t, $J=7.0$ Hz, 3H), 1.22 (m, 6H)	HRMS (B) m/z 446.1208, (M+H) ⁺ , RT=1.85 min.
285: (R)-3-(2-(((S)-1-(5-	(CD ₃ OD) 8.22 (d, $J=2.7$ Hz, 1 H), 8.11 (d,	HRMS (B)

chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	$J=2.0$ Hz, 1 H), 7.84 (d, $J=2.0$ Hz, 1 H), 4.89 - 5.02 (m, 3 H), 4.62 (d, $J=3.5$ Hz, 1 H), 4.42 - 4.57 (m, 2 H), 3.90 (br. s., 1 H), 1.52 (d, $J=7.0$ Hz, 3 H), 0.85 (br. s., 3 H)	m/z 480.1065, ($M+H$) ⁺ , RT=2.10 min.
286: (R)-3-(2-(((S)-1-(2,4-dichlorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.21 (d, $J=2.3$ Hz, 1 H), 7.36 - 7.46 (m, 2 H), 7.24 (dd, $J=8.2, 2.0$ Hz, 1 H), 5.25 (q, $J=6.7$ Hz, 1 H), 4.59 (br.s., 1 H), 4.40 - 4.54 (m, 2 H), 3.81 (br. s., 1 H), 1.47 (d, $J=7.0$ Hz, 6 H)	HRMS (B) m/z 415.0741, ($M+H$) ⁺ , RT=2.07 min.
287: (R)-3-(2-(((S)-1-(6-bromopyridin-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.40 (d, $J=2.3$ Hz, 1 H), 8.12 (br. s., 1 H), 7.75 (dd, $J=8.4, 2.5$ Hz, 1 H), 7.59 (d, $J=8.2$ Hz, 1 H), 5.17 (br. s., 1 H), 5.05 (q, $J=7.0$ Hz, 1 H), 4.43 (t, $J=8.6$ Hz, 1 H), 4.00 - 4.14 (m, 2 H), 1.59 (d, $J=7.0$ Hz, 3 H), 1.40 (d, $J=6.7$ Hz, 3 H)	HRMS (B) m/z 426.0570, ($M+H$) ⁺ , RT=1.51 min.
288: (R)-3-(2-(((S)-1-(4-chloro-3-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.21 (d, $J=3.1$ Hz, 1 H), 7.38 (t, $J=8.0$ Hz, 1 H), 7.12 - 7.28 (m, 2 H), 4.88 - 5.00 (m, 1 H), 4.59 (br. s., 1 H), 4.42 - 4.55 (m, 2 H), 3.89 (br. s., 1 H), 1.49 (d, $J=7.0$ Hz, 3 H), 0.81 (br. s., 3 H)	HRMS (B) m/z 399.1031, ($M+H$) ⁺ , RT=1.91 min.
289: (R)-3-(2-(((R)-1-(5-bromopyridin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.57 (d, $J=2.3$ Hz, 1 H), 7.88 - 7.97 (m, 2 H), 7.37 (d, $J=8.6$ Hz, 1 H), 5.09 (br. s., 1 H), 4.94 (d, $J=7.0$ Hz, 1 H), 4.38 (t, $J=8.8$ Hz, 1 H), 3.93 - 4.12 (m, 2 H), 1.51 (d, $J=7.0$ Hz, 3 H), 1.31 (d, $J=6.3$ Hz, 3 H)	HRMS (B) m/z 426.0574, ($M+H$) ⁺ , RT=1.55 min.
290: (R)-3-(2-(((S)-1-(3,4-dichlorophenyl)ethyl)amin	(CD ₃ OD) 8.20 (d, $J=2.7$ Hz, 1 H), 7.51 (d, $J=2.0$ Hz, 1 H), 7.43 (d, $J=8.2$ Hz, 1 H),	HRMS (B) m/z

o)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	7.29 (dd, $J=8.4, 1.8$ Hz, 1 H), 4.87 -4.97 (m, 1 H), 4.59 (br. s., 1 H), 4.40 - 4.55 (m, 2 H), 3.89 (br. s., 1 H), 1.49 (d, $J=7.0$ Hz, 6 H)	415.0738, (M+H) ⁺ , RT=2.02 min.
291: (R)-3-(2-(((S)-1-(6-chloro-5-fluoropyridin-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.25 (s, 1H), 8.22 (m, 1H), 7.51 (m, 1H), 5.51 (s, 1H), 4.91 (m, 1 H), 4.51 (m, 2H), 4.41 (m, 1 H), 3.62 (m, 1H), 1.45 (d, $J=7.0$ Hz, 3 H), 1.01 (br. s., 3H)	HRMS (B) m/z 400.0981, (M+H) ⁺ , RT=1.61 min.
292: (R)-3-(2-(((S)-1-(5,6-dichloropyridin-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.37 (s, 1H), 8.15 (m, 1H), 7.76 (m, 1H), 5.68 (s, 1H), 4.94 (m, 1 H), 4.51 (m, 2H), 4.45 (m, 1 H), 3.68 (m, 1H), 1.58 (d, $J=7.0$ Hz, 3 H), 1.01 (br. s., 3H)	HRMS (B) m/z 416.0690, (M+H) ⁺ , RT=1.73 min.
293: (R)-3-(2-(((R)-1-(3,5-dichloropyridin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(cdcl ₃) 8.43 (d, $J=2.0$ Hz, 1 H), 8.23 (d, $J=2.3$ Hz, 1 H), 7.72 (d, $J=2.0$ Hz, 1 H), 6.29 (d, $J=7.8$ Hz, 1 H), 5.50 (br. s., 1 H), 4.48 - 4.59 (m, 2 H), 4.37 - 4.47 (m, 1 H), 4.24 (br. s., 1 H), 1.48 (d, $J=6.7$ Hz, 3 H), 1.22 (d, $J=6.7$ Hz, 3 H)	HRMS (B) m/z 416.0685, (M+H) ⁺ , RT=1.83 min.
294: (R)-3-(2-(((S)-1-(3,5-dichloropyridin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.42 (d, $J=2.0$ Hz, 1 H), 8.22 (d, $J=2.7$ Hz, 1 H), 7.72 (d, $J=2.0$ Hz, 1 H), 6.22 (d, $J=8.2$ Hz, 1 H), 5.51 (br. s., 1 H), 4.47 - 4.67 (m, 2 H), 4.34 - 4.45 (m, 1 H), 1.49 (d, $J=7.0$ Hz, 3 H), 1.14 (br. s., 3 H)	HRMS (B) m/z 416.0687, (M+H) ⁺ , RT=1.82 min.
295: (R)-3-(6-chloro-2-(((S)-1-(3,5-dichloropyridin-2-yl)ethyl)amino)pyrimidin-4-	(CDCl ₃) 8.43 (d, $J=2.0$ Hz, 1 H), 7.73 (d, $J=2.0$ Hz, 1 H), 7.50 (s, 1 H), 6.39 (d, $J=7.4$ Hz, 1 H), 5.52 (br. s., 1 H), 4.72 - 4.93 (m, 1 H), 4.32 - 4.62 (m, 2 H), 4.13	HRMS (B) m/z 432.0391, (M+H) ⁺ ,

yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(br. s., 1 H), 1.50 (d, $J=6.7$ Hz, 3 H), 1.07 (br. s., 3 H)	RT=2.27 min.
296: (R)-3-(6-chloro-2-(((S)-1-(3-fluoro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.13 (br. s., 1 H), 7.49 (s, 1 H), 7.07 (dd, $J=10.8$, 2.2 Hz, 1 H), 6.17 (br. s., 1 H), 5.40 (br. s., 1 H), 4.70 - 5.04(m, 1 H), 4.52 (br. s., 1 H), 4.41 (q, $J=7.8$ Hz, 3 H), 4.18 (br. s., 1 H), 1.53 (br. s., 3 H), 1.01 - 1.18 (m, 3 H)	HRMS (B) m/z 480.1066, (M+H) ⁺ , RT=2.21 min.
297: (R)-3-(2-(((R)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.19 (d, $J=2.7$ Hz, 1 H), 7.81 (d, $J=2.3$ Hz, 1 H), 7.59 (d, $J=9.0$ Hz, 2 H), 7.41 (d, $J=9.0$ Hz, 2 H), 6.39 (d, $J=2.3$ Hz, 1 H), 5.12 (br. s., 1 H), 4.25 - 4.58 (m, 4 H), 3.03 (br. s., 1 H), 1.61 (d, $J=7.0$ Hz, 3 H), 1.20 (d, $J=6.3$ Hz, 3 H)	HRMS (B) m/z 447.1348, (M+H) ⁺ , RT=2.00 min.
298: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.19 (d, $J=2.0$ Hz, 1 H), 7.80 (d, $J=2.0$ Hz, 1 H), 7.58 (d, $J=9.0$ Hz, 2 H), 7.41 (d, $J=9.0$ Hz, 2 H), 6.39 (d, $J=2.3$ Hz, 1 H), 5.18 (br. s., 1 H), 4.60 (t, $J=5.5$ Hz, 1 H), 4.51 (t, $J=8.6$ Hz, 1 H), 4.34 (dd, $J=8.8$, 5.3 Hz, 1 H), 4.00 (br. s., 1 H), 1.62 (d, $J=7.0$ Hz, 3 H), 1.03 (br. s., 3 H)	HRMS (B) m/z 447.1345, (M+H) ⁺ , RT=1.98 min.
299: (R)-3-(2-(((R)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.20 (d, $J=2.7$ Hz, 1 H), 7.76 (s, 1 H), 7.45 (d, $J=8.6$ Hz, 2 H), 7.31 (d, $J=8.6$ Hz, 2 H), 7.14 (s, 1 H), 5.61 (d, $J=7.4$ Hz, 1 H), 5.07 (d, $J=5.9$ Hz, 1 H), 4.32 - 4.57 (m, 4 H), 1.59 (d, $J=6.7$ Hz, 3 H), 1.21 (d, $J=6.3$ Hz, 3 H)	HRMS (B) m/z 447.1346, (M+H) ⁺ , RT=1.32 min.
300: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-	(CDCl ₃) 8.19 (d, $J=2.7$ Hz, 1 H), 7.71 (s, 1 H), 7.45 (d, $J=8.6$ Hz, 2 H), 7.30 (d, $J=8.6$ Hz, 2 H), 7.12 (s, 1 H), 5.42 (d, $J=7.8$ Hz, 1 H), 5.20 (quin, $J=7.1$ Hz, 1 H), 4.74 (br. s., 1 H), 4.54 (t, $J=8.8$ Hz, 1 H), 4.29 (dd,	HRMS (B) m/z 447.1350, (M+H) ⁺ , RT=1.34

hydroxyethyl)oxazolidin-2-one	$J=8.6, 5.9$ Hz, 1 H), 3.99 (br. s., 1 H), 1.62 (d, $J=7.0$ Hz, 3 H), 1.15 (d, $J=6.3$ Hz, 3 H)	min.
301: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.20 (d, $J=2.7$ Hz, 1 H), 7.09 (dd, $J=11.3, 7.0$ Hz, 1 H), 6.79 (dd, $J=10.4, 6.8$ Hz, 1 H), 5.52 (br. s., 1 H), 5.11 (quin, $J=6.7$ Hz, 1 H), 4.45 - 4.59 (m, 2 H), 4.31 - 4.44 (m, 3 H), 3.87 (br. s., 1 H), 1.53 (d, $J=7.0$ Hz, 3 H), 1.03 (d, $J=4.3$ Hz, 3 H)	HRMS (B) m/z 481.1315, (M+H) ⁺ , RT=2.04 min.
302: (R)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.19 (d, $J=2.3$ Hz, 1 H), 6.62 - 6.75 (m, 3 H), 5.48 (br. s., 1 H), 5.14 (t, $J=6.8$ Hz, 1 H), 4.43 - 4.54 (m, 2 H), 4.24 - 4.40 (m, 3 H), 3.82 (br. s., 1 H), 1.53 (d, $J=6.7$ Hz, 3 H), 0.99 (br. s., 3 H)	HRMS (B) m/z 463.1403, (M+H) ⁺ , RT=2.03 min.
303: (R)-3-(5-fluoro-2-(((S)-1-(3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.20 (d, $J=2.3$ Hz, 1 H), 7.12 (dd, $J=11.7, 2.0$ Hz, 1 H), 7.04 - 7.09 (m, 1 H), 6.93 - 7.03 (m, 1 H), 5.44 (br. s., 1 H), 4.86 (d, $J=6.3$ Hz, 1 H), 4.45 - 4.55 (m, 1 H), 4.27 - 4.45 (m, 3 H), 3.76 (br. s., 1 H), 1.51 (d, $J=7.0$ Hz, 3 H), 1.01 (br. s., 3 H)	HRMS (B) m/z 463.1403, (M+H) ⁺ , RT=1.99 min.
304: (R)-3-(5-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.22 (d, $J=2.7$ Hz, 1 H), 7.77 (d, $J=2.3$ Hz, 1 H), 7.54 - 7.67 (m, 2 H), 7.14 (t, $J=8.4$ Hz, 2 H), 6.36 (d, $J=2.3$ Hz, 1 H), 5.66 (d, $J=7.8$ Hz, 1 H), 5.10 - 5.25 (m, 1 H), 4.55 - 4.64 (m, 1 H), 4.47 - 4.54 (m, 1 H), 4.34 (dd, $J=8.6, 5.1$ Hz, 1 H), 4.02 (br. s., 1 H), 1.61 (d, $J=7.0$ Hz, 6 H)	HRMS (B) m/z 431.1643, (M+H) ⁺ , RT=1.80 min.
305: (R)-3-(5-fluoro-2-(((S)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-	(CDCl ₃) 8.30 (d, $J=2.7$ Hz, 1 H), 8.20 (d, $J=2.7$ Hz, 1 H), 7.23 - 7.37 (m, 2 H), 5.96 - 6.10 (m, 1 H), 4.97 - 5.14 (m, 1 H), 4.44 - 4.57 (m, 2 H), 4.28 - 4.44 (m, 3 H), 3.96 (br. s., 1 H), 1.54 (d, $J=6.7$ Hz, 6 H)	HRMS (B) m/z 446.1449, (M+H) ⁺ , RT=1.58

hydroxyethyl)oxazolidin-2-one		min.
306: (R)-3-(5-fluoro-2-(((R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 8.28 (d, <i>J</i> =2.3 Hz, 1 H), 8.20 (d, <i>J</i> =3.1 Hz, 1 H), 7.21 - 7.36 (m, 2 H), 6.02 (d, <i>J</i> =6.7 Hz, 1 H), 5.00 (br. s., 1H), 4.25 - 4.57 (m, 5 H), 1.52 (d, <i>J</i> =6.7 Hz, 3 H), 1.20 (d, <i>J</i> =6.3 Hz, 3 H)	HRMS (B) <i>m/z</i> 446.1447, (M+H) ⁺ , RT=1.59 min.
307: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 9.02 (br. s., 1 H), 8.20 (d, <i>J</i> =6.7 Hz, 1 H), 7.89 (s, 1 H), 7.64 - 7.72 (m, 3 H), 7.56 - 7.64 (m, 2 H), 5.37 (d, <i>J</i> =6.3 Hz, 1 H), 4.75 - 5.01 (m, 2 H), 4.56 (dd, <i>J</i> =9.4, 2.3 Hz, 1 H), 4.40 - 4.50 (m, 1 H), 1.72 (d, <i>J</i> =7.0 Hz, 3 H), 1.02 (d, <i>J</i> =6.3 Hz, 3 H)	HRMS (B) <i>m/z</i> 429.1438, (M+H) ⁺ , RT=1.30 min.
308: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.19 (d, <i>J</i> =2.3 Hz, 1 H), 8.15 (d, <i>J</i> =7.0 Hz, 1 H), 7.74 (dd, <i>J</i> =7.8, 6.7 Hz, 3 H), 7.45 (d, <i>J</i> =9.0 Hz, 2 H), 6.53 (d, <i>J</i> =2.3 Hz, 1 H), 5.46 (br. s., 1 H), 4.81 - 4.97 (m, 2 H), 4.60 (dd, <i>J</i> =9.4, 2.3 Hz, 1 H), 4.42 - 4.53 (m, 1 H), 4.32 (br. s., 1 H), 1.69 (d, <i>J</i> =7.0 Hz, 3H), 0.91 (br. s., 3 H)	HRMS (B) <i>m/z</i> 429.1441, (M+H) ⁺ , RT=1.65 min.
309: (R)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 9.34 (s, 1 H), 7.95 (s, 1 H), 7.67 - 7.75 (m, 2 H), 7.60 - 7.67 (m, 2 H), 7.44 (s, 1 H), 5.34 (br. s., 1 H), 4.75 - 4.88 (m, 2 H), 4.52 (d, <i>J</i> =9.8 Hz, 1 H), 4.36 - 4.45 (m, 1 H), 1.68 (d, <i>J</i> =7.0 Hz, 3 H), 0.99 (br. s., 3 H)	HRMS (B) <i>m/z</i> 463.1056, (M+H) ⁺ , RT=1.68 min.
310: (R)-3-(6-chloro-2-(((S)-1-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-	(cd3od) 8.04 (d, <i>J</i> =2.3 Hz, 1 H), 7.71 (dd, <i>J</i> =9.0, 4.7 Hz, 2 H), 7.35 (s, 1 H), 7.19 (t, <i>J</i> =8.8 Hz, 2 H), 6.43 (d, <i>J</i> =2.7Hz, 1 H), 5.29 (q, <i>J</i> =7.0 Hz, 1 H), 4.79 - 4.87 (m, 2 H), 4.52 (dd, <i>J</i> =9.2, 2.5 Hz, 1 H), 4.35 -	HRMS (B) <i>m/z</i> 447.1346, (M+H) ⁺ , RT=2.18

hydroxyethyl)oxazolidin-2-one	4.44 (m, 1 H), 1.59 (d, $J=7.0$ Hz, 3 H), 0.85 (br. s., 3 H)	min.
311: (R)-3-(2-(((S)-1-(2,4-dichlorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.15 (d, $J=6.7$ Hz, 1 H), 7.70 (d, $J=7.0$ Hz, 1 H), 7.51 (d, $J=2.0$ Hz, 1 H), 7.46 (d, $J=8.6$ Hz, 1 H), 7.34 (dd, $J=8.6, 2.0$ Hz, 1 H), 5.47 (d, $J=5.1$ Hz, 1 H), 4.57 (dd, $J=9.0, 2.3$ Hz, 2 H), 4.33 - 4.50 (m, 2 H), 3.80 (br. s., 2 H), 1.58 (d, $J=7.0$ Hz, 6 H)	HRMS (B) m/z 397.0834, (M+H) ⁺ , RT=1.77 min.
312: (R)-3-(2-(((S)-1-(3,4-dichlorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.13 (d, $J=6.7$ Hz, 1 H), 7.70 (d, $J=7.0$ Hz, 1 H), 7.57 (d, $J=2.0$ Hz, 1 H), 7.51 (d, $J=8.2$ Hz, 1 H), 7.33 (dd, $J=8.4, 2.2$ Hz, 1 H), 5.19 (br. s., 1 H), 4.75 - 5.00 (m, 2 H), 4.58 (dd, $J=9.4, 2.3$ Hz, 1 H), 4.34 - 4.51 (m, 1 H), 3.92 (br. s., 1 H), 1.59 (d, $J=6.7$ Hz, 6 H)	HRMS (B) m/z 397.0831, (M+H) ⁺ , RT=1.72 min.
313: (R)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 7.80 (d, $J=2.3$ Hz, 1 H), 7.56 (d, $J=8.6$ Hz, 2 H), 7.51 (s, 1 H), 7.42 (d, $J=8.6$ Hz, 3 H), 6.39 (d, $J=2.3$ Hz, 1 H), 6.08 (br. s., 1 H), 5.22 (br. s., 1 H), 4.76 (ddd, $J=7.9, 5.0, 2.3$ Hz, 1 H), 4.40 - 4.49 (m, 1 H), 4.31 - 4.39 (m, 1 H), 3.99 (br. s., 1 H), 1.61 (d, $J=7.0$ Hz, 6 H)	HRMS (B) m/z 463.1056, (M+H) ⁺ , RT=2.34 min.
314: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 10.88 (br. s., 1 H), 7.93 (d, $J=7.0$ Hz, 1 H), 7.75 (d, $J=7.0$ Hz, 1 H), 7.20 - 7.30 (m, 1 H), 6.83 (dd, $J=10.6, 6.7$ Hz, 1 H), 5.34 (t, $J=6.8$ Hz, 1 H), 4.85 (ddd, $J=7.4, 4.7, 2.0$ Hz, 1 H), 4.61 (dd, $J=9.4, 2.0$ Hz, 1 H), 4.34 - 4.52 (m, 3 H), 3.78 - 3.96 (m, 1 H), 1.61 (d, $J=7.0$ Hz, 3 H), 0.96 (d, $J=6.3$ Hz, 3 H)	HRMS (B) m/z 463.1410, (M+H) ⁺ , RT=1.79 min.


315: (R)-3-(2-(((S)-1-(2-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 10.61 (d, <i>J</i> =4.7 Hz, 1 H), 7.98 (d, <i>J</i> =5.5 Hz, 1 H), 7.75 (d, <i>J</i> =5.9 Hz, 1 H), 7.41 (t, <i>J</i> =8.8 Hz, 1 H), 6.64 - 6.85(m, 2 H), 5.39 (t, <i>J</i> =6.5 Hz, 1 H), 4.85 (ddd, <i>J</i> =7.6, 4.9, 2.0 Hz, 1 H), 4.60 (dd, <i>J</i> =9.8, 2.0 Hz, 1 H), 4.40 - 4.50 (m, 1 H), 4.35 (q, <i>J</i> =8.2 Hz, 2 H), 3.79 - 3.96 (m, 1 H), 1.61 (d, <i>J</i> =7.0 Hz, 3 H), 0.94 (d, <i>J</i> =6.3 Hz, 3 H)	HRMS (B) <i>m/z</i> 445.1492, (M+H) ⁺ , RT=1.74 min.
316: (R)-3-(2-(((S)-1-(3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(cdcl ₃) 10.84 (d, <i>J</i> =3.9 Hz, 1 H), 7.92 (d, <i>J</i> =7.0 Hz, 1 H), 7.73 (d, <i>J</i> =7.0 Hz, 1 H), 7.09 - 7.20 (m, 2 H), 6.97 - 7.10 (m, 1 H), 4.93 (t, <i>J</i> =6.7 Hz, 1 H), 4.78 (td, <i>J</i> =5.1, 2.3 Hz, 1 H), 4.56 (dd, <i>J</i> =9.4, 2.0 Hz, 1 H), 4.35 - 4.47 (m, 3 H), 3.64 - 3.75 (m, 1 H), 1.62 (d, <i>J</i> =7.0 Hz, 3 H), 0.94 (d, <i>J</i> =6.3 Hz, 3 H)	HRMS (B) <i>m/z</i> 445.1491, (M+H) ⁺ , RT=1.69 min.
317: (R)-3-(2-(((S)-1-(5-bromopyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 11.02 (d, <i>J</i> =6.7 Hz, 1 H), 8.59 (d, <i>J</i> =1.6 Hz, 1 H), 8.03 (dd, <i>J</i> =8.4, 1.8 Hz, 1 H), 7.94 (d, <i>J</i> =6.7 Hz, 1 H), 7.76(d, <i>J</i> =6.7 Hz, 1 H), 7.58 (d, <i>J</i> =8.6 Hz, 1 H), 5.40 (t, <i>J</i> =7.0 Hz, 1 H), 4.83 - 4.95 (m, 1 H), 4.62 (dd, <i>J</i> =9.4, 1.6 Hz, 1 H), 4.40 - 4.51 (m, 1 H), 3.70 - 3.84 (m, 1 H), 1.70 (d, <i>J</i> =7.0 Hz, 3 H), 1.02 (d, <i>J</i> =6.3 Hz, 3 H)	HRMS (B) <i>m/z</i> 408.0668, (M+H) ⁺ , RT=1.29 min.
318: (R)-3-(2-(((R)-1-(5-bromopyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CDCl ₃) 10.97 (d, <i>J</i> =4.3 Hz, 1 H), 8.62 (d, <i>J</i> =1.6 Hz, 1 H), 8.09 (dd, <i>J</i> =8.2, 1.6 Hz, 1 H), 7.99 (d, <i>J</i> =6.7 Hz, 1 H), 7.77(d, <i>J</i> =6.7 Hz, 1 H), 7.63 (d, <i>J</i> =8.2 Hz, 1 H), 5.37 (t, <i>J</i> =6.5 Hz, 1 H), 4.59 - 4.74 (m, 2 H), 4.29 - 4.46 (m, 2 H), 1.70 (d, <i>J</i> =6.7 Hz, 3 H), 1.17 (d, <i>J</i> =6.3 Hz, 3 H)	HRMS (B) <i>m/z</i> 408.0670, (M+H) ⁺ , RT=1.33 min.
319: (R)-3-(2-(((S)-1-(4,5-dichloro-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.15 (d, <i>J</i> =7.0 Hz, 1 H), 7.70 (d, <i>J</i> =6.3 Hz, 1 H), 7.58 (d, <i>J</i> =7.0 Hz, 1 H), 7.41 (d, <i>J</i> =9.8 Hz, 1 H), 5.42 (d, <i>J</i> =3.5 Hz, 1 H), 4.87 (d, <i>J</i> =5.5 Hz, 2 H), 4.58 (dd, <i>J</i> =9.0, 2.3 Hz, 1 H), 4.38 - 4.50 (m, 1 H),	HRMS (B) <i>m/z</i> 415.0733, (M+H) ⁺ , RT=1.84

one	3.91 (br. s., 1 H), 1.60 (d, $J=7.0$ Hz, 3 H), 0.84 (br. s., 3H)	min.
320: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 9.26 (s, 1 H), 8.19 (d, $J=7.0$ Hz, 1 H), 7.77 (d, $J=6.7$ Hz, 1 H), 7.54 - 7.71 (m, 3 H), 5.51 (d, $J=5.9$ Hz, 1 H), 4.81 - 4.90 (m, 1 H), 4.58 (dd, $J=9.2, 2.2$ Hz, 1 H), 4.41 - 4.51 (m, 1 H), 3.75 (br. s., 1 H), 2.44 (s, 3 H), 1.66 (d, $J=6.7$ Hz, 3 H), 0.87 (br. s., 3 H)	HRMS (B) m/z 445.1794, (M+H) ⁺ , RT=1.02 min.
321: (R)-3-(5-chloro-2-(((S)-1-(4,5-dichloro-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.20 (s, 1 H), 7.43 (d, $J=7.0$ Hz, 1 H), 7.26 (d, $J=9.4$ Hz, 1 H), 5.11 (br. s., 1 H), 4.68 - 4.90 (m, 1 H), 4.43 (t, $J=8.2$ Hz, 1 H), 4.25 - 4.37 (m, 1 H), 3.44 - 3.86 (m, 1 H), 1.42 (d, $J=7.0$ Hz, 3 H), 0.73 (br. s., 3 H)	HRMS (B) m/z 449.0347, (M+H) ⁺ , RT=2.14 min.
322: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.74 (d, $J=6.3$ Hz, 1 H), 8.11 - 8.22 (m, 2 H), 8.07 (d, $J=6.3$ Hz, 1 H), 7.59 - 7.77 (m, 2 H), 7.40 - 7.53 (m, 1H), 5.48 (d, $J=5.5$ Hz, 1 H), 4.77 - 5.01 (m, 2 H), 4.57 (dd, $J=9.0, 2.3$ Hz, 1 H), 4.38 - 4.51 (m, 1 H), 2.83 (s, 3 H), 1.66 (d, $J=7.0$ Hz, 2 H), 0.82 (br.s., 3 H)	HRMS (B) m/z 456.1840, (M+H) ⁺ , RT=1.10 min.
323: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(6-methylpyridin-3-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.91 (s, 1 H), 8.60 (d, $J=8.2$ Hz, 1 H), 8.18 (d, $J=6.3$ Hz, 1 H), 7.95 (d, $J=8.2$ Hz, 1 H), 7.73 (d, $J=6.3$ Hz, 1H), 7.54 (dd, $J=10.2, 6.7$ Hz, 1 H), 7.42 (dd, $J=10.8, 6.1$ Hz, 1 H), 5.49 (d, $J=4.7$ Hz, 1 H), 4.88 (s, 1 H), 4.58 (dd, $J=9.2, 2.2$ Hz, 1 H), 4.39 - 4.51(m, 1 H), 3.83 (br. s., 1 H), 2.82 (s, 3 H), 1.66 (d, $J=7.0$ Hz, 3 H), 0.83 (br. s., 3 H)	HRMS (B) m/z 456.1847, (M+H) ⁺ , RT=1.18 min.
324: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-	(CD ₃ OD) 8.80 (d, $J=5.1$ Hz, 1 H), 8.18 (d, $J=6.7$ Hz, 1 H), 7.97 - 8.07 (m, 1 H), 7.77 - 7.90 (m, 2 H), 7.54 (dd, $J=10.6, 6.3$ Hz, 1 H), 7.40 (dd, $J=11.0, 6.3$ Hz, 1 H), 5.49 (br. s., 1 H), 4.79 - 5.02 (m, 1 H), 4.53 - 4.68	HRMS (B) m/z 510.1560, (M+H) ⁺ , RT=1.94

hydroxyethyl)oxazolidin-2-one	(m, 1 H), 4.39 - 4.52 (m, 1 H), 3.80 (br. s., 1 H), 1.61 - 1.73 (m, 6 H)	min.
325: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.90 (s, 1 H), 8.12 - 8.29 (m, 2 H), 7.92 (d, <i>J</i> =8.2 Hz, 1 H), 7.75 (d, <i>J</i> =6.7 Hz, 1 H), 7.43 - 7.55 (m, 1 H), 7.37 (dd, <i>J</i> =10.8, 6.1 Hz, 1 H), 5.47 (br. s., 1 H), 4.81 - 4.97 (m, 1 H), 4.58 (dd, <i>J</i> =9.0, 2.3 Hz, 1 H), 4.39 - 4.51 (m, 1 H), 3.82 (br. s., 1 H), 1.66 (d, <i>J</i> =7.0 Hz, 3 H), 0.82 (br. s., 3 H)	HRMS (B) <i>m/z</i> 510.1565, (M+H) ⁺ , RT=1.98 min.
326: (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one		HRMS (B) <i>m/z</i> 401.2188 (M + H) ⁺ ; Rt 1.80 min
327: (R)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-methoxyphenyl)-ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(CD ₃ OD) 8.22 (d, <i>J</i> = 3.13 Hz, 1H), 7.14 - 7.41 (m, 1H), 6.55 - 6.79 (m, 2H), 5.19 (q, <i>J</i> = 7.04 Hz, 1H), 4.68 (d, <i>J</i> = 3.91 Hz, 1H), 4.43 - 4.60 (m, 2H), 3.92 (d, <i>J</i> = 17.22 Hz, 1H), 3.78 (s, 3H), 1.50 (d, <i>J</i> = 6.65 Hz, 3H)	HRMS (B) <i>m/z</i> 395.1525 (M + H) ⁺ ; Rt 1.78 min
328: (R)-3-(2-(((S)-1-(2,3-difluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, <cd3od>) 0.83 (br. s., 3 H) 1.60 (d, <i>J</i> =6.65 Hz, 3 H) 4.40 - 4.45 (m, 1 H) 4.56 (d, <i>J</i> =7.43 Hz, 1 H) 4.85 (m, 2H) 5.39 - 5.47 (m, 1 H) 7.11 - 7.21 (m, 3 H) 7.61 - 7.68 (m, 1 H) 8.12 (d, <i>J</i> =6.65 Hz, 1 H)	HRMS (B) <i>m/z</i> 365.1414, (M+H) ⁺ , RT=1.49 min.
329: (R)-3-(2-(((S)-1-(2,3-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, <cd3od>) 0.81 (br. s., 3 H) 1.52 (d, <i>J</i> =7.04 Hz, 3 H) 3.81 - 3.96 (m, 1 H) 4.44 - 4.56 (m, 2 H) 4.57 - 4.68 (m, 1 H) 5.21 - 5.32 (m, 1 H) 7.01 - 7.22 (m, 3H) 8.21 (d, <i>J</i> =3.08 Hz, 1 H)	HRMS (B) <i>m/z</i> 383.1327, (M+H) ⁺ , RT=1.81 min.

330: (R)-3-(2-(((S)-1-(3,4-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, <cd3od>) 0.83 (br. s., 3 H) 1.48 (d, <i>J</i> =7.04 Hz, 3 H) 3.81 - 3.97 (m, 1 H) 4.39 - 4.57 (m, 2 H) 4.59 - 4.68 (m, 1 H) 4.89 - 5.01 (m, 2 H) 7.11 - 7.32 (m, 3 H) 8.21 (d, <i>J</i> =3.13 Hz, 1 H)	HRMS (B) <i>m/z</i> 383.1328, (M+H) ⁺ , RT=1.81 min.
331: (R)-3-(2-(((S)-1-(2,4-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, <cd3od>) 0.73 (br. s., 3 H) 1.41 (d, <i>J</i> =6.99 Hz, 3 H) 3.81 (br. s., 1 H) 4.32 - 4.47 (m, 2 H) 4.54 (d, <i>J</i> =3.03 Hz, 1 H) 5.11 (d, <i>J</i> =6.94 Hz, 1 H) 6.73 - 6.89 (m, 2 H) 7.29 (td, <i>J</i> =8.57, 6.53 Hz, 1 H) 8.11 (d, <i>J</i> =2.98 Hz, 1 H)	HRMS (B) <i>m/z</i> 383.1323, (M+H) ⁺ , RT=1.80 min.
332: (R)-3-(2-(((S)-1-(3,5-difluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one		HRMS (B) <i>m/z</i> 383.1328, (M+H) ⁺ , RT=1.81 min.
333: (R)-3-(5-chloro-2-(((S)-1-(5-(2-(trifluoromethyl)pyridin-4-yl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	¹ H NMR (400 MHz, <cd3od>) 1.26 - 1.39 (m, 3 H) 1.61 (d, <i>J</i> =7.04 Hz, 3 H) 4.74 - 4.79 (m, 3 H) 4.96 (br. s., 1 H) 5.13 (d, <i>J</i> =7.04 Hz, 1 H) 7.69 (d, <i>J</i> =7.83 Hz, 1 H) 7.99 (d, <i>J</i> =4.30 Hz, 1 H) 8.17 (s, 1 H) 8.29 (d, <i>J</i> =8.22 Hz, 1 H) 8.80 (d, <i>J</i> =5.09 Hz, 1 H) 8.96 (s, 1 H)	LCMS <i>m/z</i> 509.2, (M+H) ⁺ , RT=0.69 min.


Example 334 (R)-3-(5-fluoro-2-(((S)-1-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



To (R)-3-(2-(((S)-1-(5-chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (20 mg, 0.042 mmol) in MeOH (10 mL) was added Pd(OH)₂ (10 mg, 0.014 mmol). The reaction was purged with N₂ and H₂ three times each. A hydrogen balloon was applied to the reaction. The reaction mixture was stirred for one hour and concentrated. The residue was applied directly to HPLC separation to give product (15 mg) as a trifluoroacetic acid salt. ¹HNMR (CD₃OD) δppm 8.21 (d, *J*=3.1 Hz, 1 H), 7.38 (t, *J*=8.0 Hz, 1 H), 7.12 - 7.28 (m, 2 H), 4.88 - 5.00 (m, 1 H), 4.59 (br. s., 1 H), 4.42 - 4.55 (m, 2 H), 3.89 (br. s., 1 H), 1.49 (d, *J*=7.0 Hz, 3 H), 0.81 (br. s., 3 H). HRMS (B) *m/z* 446.1448 (M+H)⁺, RT=1.90 min.

Example 335

(R)-3-(2-((S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethylamino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



A mixture of (R)-4-((R)-1-tert-butoxyethyl)-3-(2-chloro-5-fluoropyrimidin-4-yl)oxazolidin-2-one (40 mg, 0.126 mmol), (S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethanamine (36.9 mg, 0.164 mmol) and Huenig's base (0.11 mL, 0.629 mmol) in DMSO (0.25 mL) under argon atmosphere was heated at ~120 °C for ~16 hr in a sealed vial. The mixture was allowed to cool to room temperature and diluted with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (2x), the combined organic layers were washed with brine and dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was dissolved in DCM (0.8 mL) and cooled to 0 °C. To the mixture was added trifluoroacetic acid (0.3 mL), the ice-bath was removed and the mixture was stirred for ~1 hr at room temperature. The mixture was diluted with methanol (2 mL) and concentrated under reduced pressure. The residue was

dissolved in DMSO/water (~9/1), filtered through a syringe filter, and purified by reverse phase HPLC. Selected fractions were collected and lyophilized providing (R)-3-(2-((S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethylamino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one as its trifluoroacetic acid salt (19 mg) as a white solid.


- 5 ¹H NMR (400 Mhz, CD₃OD) δ ppm 9.77 (d, J=2.7 Hz, 1 H), 9.06 (t, J=7.8 Hz, 1 H), 8.80 - 8.87 (m, 2 H), 8.12 - 8.44 (m, 1 H), 6.82 (q, J=6.7 Hz, 1 H), 6.12 - 6.21 (m, 1 H), 5.99 - 6.11 (m, 2 H), 5.30 - 5.52 (m, 1 H), 3.09 (d, J=7.0 Hz, 3 H), 2.14 - 2.51 (m, 3 H). HRMS *m/z* 415.1390 (M + H)⁺; Rt-1.84 min.

- 10 The following Example was prepared using a method similar to that described for the preparation of **Example 335**

Example 336

(R)-3-(2-(((S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-


- 15 1-hydroxyethyl)oxazolidin-2-one



- ¹H NMR (400 Mhz, CCl₃D) δ ppm 8.19 (d, J=2.7 Hz, 1 H), 7.33 - 7.44 (m, 1 H), 7.18 - 7.30 (m, 2 H), 5.49 (m, J=5.9 Hz, 1 H), 5.19 (m, J=6.7, 6.7 Hz, 1 H), 4.41 - 4.52 (m, 2 H), 4.34 (m, J=7.2, 3.7 Hz, 1 H), 1.90 (t, J=18.2 Hz, 3 H), 1.51 - 1.60 (m, 3 H), 0.80 - 1.00 (m, 3 H). HRMS *m/z* 429.1553 (M + H)⁺; Rt-1.98 min.
- 20

Example 337

(R)-3-(6-chloro-2-(((S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one




A mixture of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one (55 mg, 0.165 mmol), (S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethanamine hydrochloride (35 mg, 0.155 mmol) and Huenig's base (0.072 mL, 0.411 mmol) in DMSO (0.6 mL) under argon atmosphere was heated at ~85 °C for ~3 hr in a sealed vial. The mixture was allowed to cool to room temperature and diluted with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (2x), the combined organic layers were washed with brine and dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was dissolved in DCM (0.8 mL) and cooled to 0 °C. To the mixture was added trifluoroacetic acid (0.4 mL), the ice-bath was removed and the mixture was stirred for ~1 hr at room temperature. The mixture was diluted with methanol (2 mL) and concentrated under reduced pressure. The residue was dissolved in DMSO/water (~9/1), filtered through a syringe filter, and purified by reverse phase HPLC. Selected fractions were collected and lyophilized providing (R)-3-(6-chloro-2-(((S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one as its trifluoroacetic acid salt (8.2 mg) as a white solid.

¹H NMR (400 Mhz, CD₃OD) δ ppm 7.50 (m, J=7.60, 7.6 Hz, 1 H), 7.25 - 7.38 (m, 3 H), 6.76 (t, J=1.0 Hz, 1 H), 5.31 - 5.43 (m, 1 H), 4.72 - 4.81 (m, 1 H), 4.52 (m, J=7.0 Hz, 1 H), 4.34 - 4.44 (m, 1 H), 1.55 (d, J=7.0 Hz, 3 H), 0.54 - 0.75 (m, CH₃). HRMS *m/z* 431.1097 (M + H)⁺; Rt-2.21 min.

The following Example was prepared using a method similar to that described for the preparation of **Example 337**


25 **Example 338**

(R)-3-(6-chloro-2-(((S)-1-(4-(1,1-difluoroethyl)-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



^1H NMR (400 Mhz, CD_3OD) δ ppm 7.45 (m, $J=7.6$, 7.6 Hz, 1 H), 7.21 - 7.36 (m, 3 H), 5.34 (m, $J=7.0$ Hz, 1 H), 4.71 - 4.79 (m, 1 H), 4.45 - 4.55 (m, 1 H), 4.32 - 4.41 (m, 1 H), 1.89 (t, $J=18.2$ Hz, 3 H), 1.52 (d, $J=7.0$ Hz, 3 H), 0.55 - 0.71 (m, CH_3). HRMS m/z 445.1257 ($\text{M} + \text{H}$) $^+$; Rt-2.32 min.


Example 339 (R)-3-(6-chloro-2-(((S)-1-(5-phenylthiophen-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



- 10 A solution of (R)-3-(2,6-dichloropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (0.040 g, 0.144 mmol), (S)-1-(5-(pyridin-2-yl)thiophen-2-yl)ethanamine hydrochloride (0.083 g, 0.346 mmol, 2.4 equiv) and N-ethyl-N-isopropylpropan-2-amine (0.075 mL, 0.432 mmol, 3.0 equiv) in DMSO (0.72 mL) was heated at 100 °C for 1 h. Purification by reverse phase HPLC separated the regioisomeric products and provided the trifluoroacetate salt of (R)-3-(6-chloro-2-(((S)-1-(5-phenylthiophen-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one (7.0 mg, white solid) in 8% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.59 (s, 1H), 7.56 – 7.52 (m, 2H), 7.40 – 7.34 (m, 2H), 7.29 (d, $J = 7.4$ Hz, 1H), 7.15 (d, $J = 3.6$ Hz, 1H), 6.93 (br s, 1H), 5.21 (m, 1H), 4.78 – 4.68 (m, 1H), 4.50 – 4.31 (m, 2H), 3.85 (m, 1H), 1.69 (d, $J = 6.9$ Hz, 3H), 0.93 (br s, 3H); HRMS m/z 445.1109 ($\text{M} + \text{H}$) $^+$; Rt-2.49 min.
- 20 The following Example was prepared using a method similar to that described for the preparation of **Example 339**


Example 340

(R)-3-(6-chloro-2-(((S)-1-(5-(pyridin-2-yl)thiophen-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



¹H NMR (400 MHz, CDCl₃) δ ppm 8.84 (d, J = 5.0 Hz, 1H), 8.05 (t, J = 7.8 Hz, 1H), 7.77 – 7.70 (m, 2H), 7.60 (s, 1H), 7.47 (t, J = 6.5 Hz, 1H), 7.13 (d, J = 3.9 Hz, 1H), 5.19 (m, 1H), 4.87 (m, 1H), 4.62 (m, 1H), 4.37 (t, J = 9.0 Hz, 1H), 3.61 (m, 1H), 1.70 (d, J = 7.0 Hz, 3H), 0.89 (br s, 3H). HRMS *m/z* 446.1054 (M + H)⁺; Rt-2.04

Example 341 (1:1 TFA:DCM)















10

A solution of (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(3-((S)-tetrahydrofuran-3-yloxy)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one (56.5 mg, 0.12 mmol) in DCM (0.6 ml) was treated with TFA (0.6ml) at room temperature. The resulting solution was let sit for 2 hours, then concentrated. The crude material was purified by reverse phase HPLC. Product fractions were combined and lyophilized to afford (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(3-((S)-tetrahydrofuran-3-yloxy)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one (15.2 mg, 0.036 mmol, 30 % yield) as a TFA salt. ¹H NMR (400 MHz, DMSO-d₆) δ 0.65 (br. s., 3 H) 1.41 (d, J=6.99 Hz, 3 H) 1.84 - 1.94 (m, 1 H) 2.10 - 2.22 (m, 1 H) 3.67 - 3.89 (m, 4 H) 4.33 - 4.47 (m, 2 H) 4.70 - 4.77 (m, 1 H) 4.96 (dd, J=6.06, 4.60 Hz, 1 H) 5.01 - 5.11 (m, 1 H) 6.73 (dd, J=8.07, 2.05 Hz, 1 H) 6.89 - 6.97 (m, 2 H) 7.19 (t, J=7.85 Hz, 1 H) 7.24 (d, J=6.06 Hz, 1 H) 8.14 (br. s., 1 H). LCMS *m/z* 415.3 (M + H)⁺, Rt 0.55 min. HRMS(A) *m/z* 415.1981 (M + H)⁺, Rt 1.33 min.

20

The compounds in Table 31a were prepared using methods similar to those described for the preparation of Example 341.

Table 31a.

342	343	344
		
345	346	347
		
348	349	350
		
351	352	353
		
354	355	




Table 31b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 31a.


5

Example: Name	¹ H NMR (400 MHz) δ ppm	LCMS
342: (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(3-isobutoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	(DMSO-d ₆) δ 0.93 (s, 3 H) 0.95 (s, 3 H) 1.41 (d, <i>J</i> =6.99 Hz, 3 H) 1.96 (dq, <i>J</i> =13.30, 6.64, 6.64, 6.64 Hz, 1 H) 3.55 - 3.89 (m, 4 H) 4.34 - 4.41 (m, 1 H) 4.42 - 4.48 (m, 1 H) 4.71 - 4.78 (m, 1 H) 5.06 (br. s., 1 H) 6.73 (dd, <i>J</i> =8.14, 1.93 Hz, 1 H) 6.87 - 6.99 (m, 2 H) 7.17 (t, <i>J</i> =7.87 Hz, 1 H) 7.23 (d, <i>J</i> =6.02 Hz, 1 H) 8.13 (br. s., 1 H)	HRMS <i>m/z</i> 401.2189 (<i>M</i> + <i>H</i>) ⁺ ; Rt-1.86 min
343: (R)-3-(6-chloro-2-(((S)-1-(4-(isobutylsulfonyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.55 (d, <i>J</i> =6.31 Hz, 3 H) 0.94 (dd, <i>J</i> =6.70, 1.91 Hz, 6 H) 1.43 (d, <i>J</i> =6.85 Hz, 3 H) 1.97 (dt, <i>J</i> =13.11, 6.70 Hz, 1 H) 3.14 (d, <i>J</i> =6.36 Hz, 2 H) 4.31 - 4.49 (m, 3 H) 4.71 (br. s., 1 H) 5.09 (t, <i>J</i> =7.19 Hz, 1 H) 7.17 (s, 1 H) 7.61 (d, <i>J</i> =8.22 Hz, 2 H) 7.83 (d, <i>J</i> =8.31 Hz, 2 H) 8.49 (d, <i>J</i> =7.78 Hz, 1 H)	HRMS <i>m/z</i> 483.1472 (<i>M</i> + <i>H</i>) ⁺ ; Rt-2.10 min

344: (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(DMSO-d ₆) δ 0.59 (br. s., 3 H) 1.44 (d, J =6.99 Hz, 3 H) 3.83 (br. s., 1 H) 4.34 - 4.41 (m, 1 H) 4.41 - 4.47 (m, 1 H) 4.70 - 4.76 (m, 2 H) 5.09 (quin, J =7.24 Hz, 1 H) 7.24 (d, J =6.02 Hz, 1 H) 7.28 (d, J =7.97 Hz, 2 H) 7.49 (d, J =8.61 Hz, 2 H) 8.16 (br. s., 1 H) 8.24 (br. s., 1 H)	HRMS m/z 413.1435 (M + H) ⁺ ; Rt-1.72 min
345: (R)-3-(2-(((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.57 (br. s., 3 H) 1.43 (d, J =7.04 Hz, 3 H) 4.31 - 4.47 (m, 3 H) 4.71 (br. s., 1 H) 5.08 (t, J =7.16 Hz, 1 H) 7.23 (d, J =5.87 Hz, 1 H) 7.29 (d, J =8.66 Hz, 1 H) 7.42 - 7.52 (m, 2 H) 8.09 (br. s., 1 H) 8.16 (br. s., 1 H)	HRMS m/z 431.1345 (M + H) ⁺ ; Rt-1.83 min
346: (R)-3-(2-(((S)-1-(2-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.37 - 0.66 (m, 3 H) 1.43 (d, J =7.04 Hz, 3 H) 4.32 - 4.46 (m, 2 H) 4.71 (br. s., 1 H) 5.26 (br. s., 1 H) 7.18 (d, J =8.51 Hz, 1 H) 7.22 (d, J =5.82 Hz, 1 H) 7.29 (d, J =10.86 Hz, 1 H) 7.49 (t, J =8.49 Hz, 1 H) 8.03 (br. s., 1 H) 8.16 (br. s., 1 H)	HRMS m/z 431.1341 (M + H) ⁺ ; Rt-1.85 min
347: (R)-3-(2-(((S)-1-(4-(difluoromethoxy)-3-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.64 (br. s., 3 H) 1.42 (d, J =6.99 Hz, 3 H) 4.34 - 4.47 (m, 3 H) 4.67 - 4.78 (m, 1 H) 5.06 (quin, J =7.27 Hz, 1 H) 6.93 - 7.18 (m, 1 H) 7.19 - 7.32 (m, 3 H) 7.38 (d, J =11.84 Hz, 1 H) 8.03 - 8.11 (m, 1 H) 8.15 (br. s., 1 H)	HRMS m/z 413.1436 (M + H) ⁺ ; Rt-1.60 min
348: (R)-3-(2-(((S)-1-(4-(difluoromethoxy)-3-	(DMSO-d ₆) δ 0.60 (br. s., 3 H)	HRMS m/z

fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	1.41 (d, $J=7.04$ Hz, 3 H) 4.35 - 4.43 (m, 1 H) 4.45 - 4.57 (m, 2 H) 4.89 (br. s., 1 H) 6.91 - 7.17 (m, 1 H) 7.17 - 7.31 (m, 2 H) 7.31 - 7.41 (m, 1 H) 7.82 - 8.03 (m, 1 H) 8.34 (br. s., 1 H)	431.1333 (M + H) ⁺ ; Rt-1.89 min
349: (R)-3-(2-(((S)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.61 (br. s., 3 H) 1.37 (d, $J=7.04$ Hz, 3 H) 4.29 - 4.42 (m, 3 H) 4.65 - 4.73 (m, 1 H) 5.01 (quin, $J=7.20$ Hz, 1 H) 7.04 (d, $J=8.51$ Hz, 2 H) 7.09 (s, 1 H) 7.17 (d, $J=5.92$ Hz, 1 H) 7.37 (d, $J=8.51$ Hz, 2 H) 8.08 (br. s., 1 H)	HRMS m/z 395.1523 (M + H) ⁺ ; Rt-1.49 min
350: (R)-3-(2-(((S)-1-(4-(difluoromethoxy)-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.61 (br. s., 3 H) 0.93 (br. s., 1 H) 1.44 (d, $J=6.94$ Hz, 3 H) 3.76 (br. s., 1 H) 4.34 - 4.47 (m, 2 H) 4.73 (d, $J=3.57$ Hz, 1 H) 5.26 (quin, $J=6.90$ Hz, 1 H) 6.98 (dd, $J=8.46$, 2.20 Hz, 1 H) 7.06 (dd, $J=11.20$, 2.30 Hz, 1 H) 7.26 (d, $J=5.77$ Hz, 1 H) 7.43 (t, $J=8.66$ Hz, 1 H) 8.17 (br. s., 1 H)	HRMS m/z 413.1431 (M + H) ⁺ ; Rt-1.60 min
351: (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(DMSO-d ₆) δ 0.60 (br. s., 3 H) 1.44 (d, $J=7.04$ Hz, 3 H) 3.87 (br. s., 1 H) 4.34 - 4.47 (m, 2 H) 4.71 - 4.76 (m, 2 H) 5.14 (quin, $J=7.23$ Hz, 1 H) 7.13 - 7.21 (m, 1 H) 7.25 (d, $J=5.97$ Hz, 1 H) 7.34 (s, 1 H) 7.38 - 7.46 (m, 2 H) 8.16 (br. s., 1 H)	HRMS m/z 413.1432 (M + H) ⁺ ; Rt-1.73 min
352: (R)-3-(2-(((S)-1-(3-(difluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.63 (br. s., 3 H) 1.43 (d, $J=7.04$ Hz, 3 H) 3.85 (br. s., 4 H) 4.35 - 4.47 (m, 2 H) 4.71 - 4.76 (m, 1 H) 5.09	HRMS m/z 395.1534 (M + H) ⁺ ; Rt-1.52 min

	(quin, $J=7.30$ Hz, 1 H) 6.96 - 7.02 (m, 1 H) 7.17 (d, $J=7.48$ Hz, 1 H) 7.21 - 7.27 (m, 2 H) 7.31 - 7.37 (m, 1 H) 8.15 (br. s., 1 H)	
353: (R)-3-(2-(((S)-1-(4-(difluoromethoxy)-2-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO- d_6) δ 0.33 - 1.02 (m, 3 H) 1.40 (d, $J=6.99$ Hz, 3 H) 4.32 - 4.55 (m, 3 H) 5.13 (br. s., 1 H) 6.96 (dd, $J=8.53$, 2.37 Hz, 1 H) 7.04 (dd, $J=11.10$, 2.40 Hz, 1 H) 7.17 - 7.38 (m, 1 H) 7.41 (t, $J=8.58$ Hz, 1 H) 7.97 (br. s., 1 H) 8.34 (br. s., 1 H)	HRMS m/z 431.1334 (M + H) ⁺ ; Rt-1.92 min
354: (R)-3-(5-fluoro-2-(((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO- d_6) δ 0.15 - 0.91 (m, 3 H) 1.41 (d, $J=7.04$ Hz, 3 H) 4.27 - 4.56 (m, 3 H) 4.94 (br. s., 2 H) 7.15 (d, $J=7.34$ Hz, 1 H) 7.30 (s, 1 H) 7.34 - 7.45 (m, 2 H) 7.97 (br. s., 1 H) 8.33 (br. s., 1 H)	HRMS m/z 431.1337 (M + H) ⁺ ; Rt-2.04 min
355: (R)-3-(2-(((S)-1-(3-(difluoromethoxy)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO- d_6) δ 0.58 (br. s., 3 H) 1.41 (d, $J=7.04$ Hz, 3 H) 3.89 (br. s., 2 H) 4.33 - 4.57 (m, 3 H) 4.90 (br. s., 1 H) 6.93 - 7.00 (m, 1 H) 7.11 - 7.18 (m, 1 H) 7.21 (d, $J=7.78$ Hz, 1 H) 7.32 (t, $J=8.00$ Hz, 1 H) 7.93 (br. s., 1 H) 8.32 (br. s., 1 H)	HRMS m/z 413.1435 (M + H) ⁺ ; Rt-1.83 min

Example 356 (1:3 TFA:DCM)

A solution of (R)-4-((R)-1-tert-butoxyethyl)-3-(2-((S)-1-(3-phenoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one (70.1 mg, 0.147 mmol) in DCM (1.1 ml) was treated with TFA (368 μ l) at room temperature. The resulting solution was let sit for 30min, then concentrated. The crude material was purified by reverse phase HPLC. Product fractions were combined and lyophilized to afford (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(3-phenoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one (41.3 mg, 0.097 mmol, 66 % yield) as a TFA salt. ^1H NMR (400 MHz, DMSO- d_6) δ 0.64 (br. s., 3 H) 1.42 (d, $J=6.90$ Hz, 3 H) 3.70 (br. s., 1 H) 4.32 - 4.48 (m, 3 H) 4.67 - 4.75 (m, 1 H) 5.08 (br. s., 1 H) 6.78 (d, $J=7.87$ Hz, 1 H) 6.91 (d, $J=7.87$ Hz, 2 H) 7.00 - 7.18 (m, 3 H) 7.22 - 7.37 (m, 4 H) 8.14 (br. s., 1 H). LCMS m/z 421.3 ($M + H$) $^+$, Rt 0.72 min. HRMS(A) m/z 421.1873 ($M + H$) $^+$, Rt 1.84 min.

The compounds in Table 32a were prepared using methods similar to those described for the preparation of **Example 356**

Table 32a.

357	358	359
360	361	362

363	364	365
366	367	368
369	370	371
372		

Table 32b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 32a.

Example: Name	¹ H NMR (400 MHz) δ ppm	LCMS
357: (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(4-isopropoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	(DMSO-d ₆) δ 0.69 (br. s., 3 H) 1.20 (d, J =6.02 Hz, 6 H) 1.39 (d, J =6.90 Hz, 3 H) 4.33 - 4.46 (m, 2 H) 4.51 (dt, J =11.93, 5.87 Hz, 1 H) 4.74 (br. s., 1 H) 4.94 - 5.05 (m, 1 H) 6.80 (d, J =8.41 Hz, 2 H) 7.17 - 7.29 (m, 3 H) 8.12 (d, J =5.67 Hz, 1 H)	HRMS m/z 387.2032 (M + H) ⁺ ; Rt-1.54 min
358: (R)-4-((R)-1-hydroxyethyl)-3-(2-((S)-1-(4-isobutoxy-3-methylphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one	The NMR not taken (not enough material made).	HRMS m/z 415.2340 (M + H) ⁺ ; Rt-1.98 min
359: (R)-3-(6-chloro-2-(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.56 (d, J =6.11 Hz, 3 H) 0.78 - 1.00 (m, 1 H) 1.41 (d, J =6.85 Hz, 3 H) 3.78 (br. s., 1 H) 4.66 - 4.74 (m, 1 H) 4.97 - 5.10 (m, 1 H) 7.16 (s, 1 H) 7.28 (d, J =8.22 Hz, 2 H) 7.47 (d, J =8.66 Hz, 2 H) 8.40 (d, J =7.63 Hz, 1 H)	HRMS m/z 477.1054 (M + H) ⁺ ; Rt-2.39 min
360: (R)-3-(5-fluoro-2-(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.49 (br. s., 3 H) 1.43 (d, J =7.04 Hz, 3 H) 4.39 (dd, J =8.31, 4.30 Hz, 1 H) 4.46 - 4.60 (m, 2 H) 4.92 (br. s., 2 H) 7.23 - 7.31 (m, 2 H) 7.47 (d, J =8.61 Hz, 2 H) 7.98 (br. s., 1 H) 8.34 (d, J =2.20 Hz, 1 H)	HRMS m/z 431.1345 (M + H) ⁺ ; Rt-2.05 min
361: (R)-3-(6-chloro-2-(((S)-1-(2-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.50 (d, J =6.02 Hz, 3 H) 0.93 (dd, J =12.30, 6.33 Hz, 1 H) 1.42	HRMS m/z 465.0958 (M + H) ⁺


	(d, $J=6.99$ Hz, 3 H) 4.25 - 4.57 (m, 3 H) 4.66 (br. s., 1 H) 5.14 - 5.27 (m, 1 H) 7.13 - 7.25 (m, 2 H) 7.29 (d, $J=10.07$ Hz, 1 H) 7.40 - 7.59 (m, 1 H) 8.36 - 8.49 (m, 1 H)	Rt-2.45 min
362:(R)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.48 (br. s., 3 H) 0.91 - 1.34 (m, 1 H) 1.45 (d, $J=7.04$ Hz, 3 H) 4.34 - 4.59 (m, 3 H) 5.16 (br. s., 1 H) 7.20 (d, $J=8.51$ Hz, 1 H) 7.32 (d, $J=10.51$ Hz, 1 H) 7.52 (t, $J=8.56$ Hz, 1 H) 8.06 (br. s., 1 H) 8.37 (br. s., 1 H)	HRMS m/z 449.1243 (M + H) ⁺ ; Rt-2.09 min
363:(R)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.40 - 0.82 (m, 3 H) 0.95 (d, $J=6.65$ Hz, 6 H) 1.40 (d, $J=6.99$ Hz, 3 H) 1.98 (dquin, $J=13.29, 6.64, 6.64, 6.64$ Hz, 1 H) 3.71 (d, $J=6.50$ Hz, 2 H) 4.38 - 4.70 (m, 4 H) 5.12 (br. s., 1 H) 6.65 - 6.78 (m, 2 H) 7.29 (t, $J=9.00$ Hz, 1 H) 7.89 (br. s., 1 H) 8.35 (br. s., 1 H)	HRMS m/z 437.2005 (M + H) ⁺ ; Rt-2.28 min
364:(R)-3-(2-(((S)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.62 (br. s., 3 H) 1.42 (d, $J=6.99$ Hz, 3 H) 4.35 - 4.44 (m, 1 H) 4.47 - 4.54 (m, 1 H) 4.56 (br. s., 1 H) 4.91 (br. s., 1 H) 7.10 (d, $J=8.51$ Hz, 2 H) 6.95 - 7.35 (m, 1 H) 7.41 (d, $J=8.61$ Hz, 2 H) 7.94 (br. s., 1 H) 8.34 (d, $J=2.64$ Hz, 1 H)	HRMS m/z 413.1433 (M + H) ⁺ ; Rt-1.83 min

365:(R)-3-(5-fluoro-2-(((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d6) δ 0.26 - 1.06 (m, 3 H) 1.44 (d, J =6.99 Hz, 3 H) 4.35 - 4.61 (m, 2 H) 5.21 (br. s., 3 H) 7.25 - 7.38 (m, 1 H) 7.42 - 7.55 (m, 2 H) 8.00 (br. s., 1 H) 8.37 (br. s., 1 H)	HRMS m/z 449.1244 (M + H) ⁺ ; Rt-2.09 min
366:(R)-3-(6-chloro-2-(((S)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d6) δ 0.65 (d, J =6.06 Hz, 3 H) 0.87 - 1.02 (m, 1 H) 1.42 (d, J =6.70 Hz, 3 H) 4.36 - 4.54 (m, 2 H) 4.69 - 4.79 (m, 1 H) 4.99 - 5.11 (m, 1 H) 6.96 - 7.39 (m, 1 H) 7.12 (d, J =8.51 Hz, 2 H) 7.17 (d, J =7.24 Hz, 1 H) 7.43 (d, J =8.51 Hz, 2 H) 8.39 (d, J =8.02 Hz, 1 H)	HRMS m/z 429.1139 (M + H) ⁺ ; Rt-2.20 min
367:(R)-3-(6-chloro-2-(((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d6) δ 0.57 (d, J =6.21 Hz, 3 H) 1.43 (d, J =6.75 Hz, 3 H) 4.31 - 4.55 (m, 3 H) 4.71 (br. s., 1 H) 4.99 - 5.13 (m, 1 H) 7.20 (s, 1 H) 7.30 (d, J =8.56 Hz, 1 H) 7.40 - 7.58 (m, 2 H) 8.41 (d, J =7.19 Hz, 1 H)	HRMS m/z 465.0959 (M + H) ⁺ ; Rt-2.43 min
368:(R)-3-(5-fluoro-2-(((S)-1-(4-(isobutylsulfonyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d6) δ 0.48 (br. s., 3 H) 0.96 (dd, J =6.70, 1.12 Hz, 6 H) 1.46 (d, J =7.04 Hz, 3 H) 2.00 (dquin, J =13.27, 6.60, 6.60, 6.60, 6.60 Hz, 1 H) 3.15 (d, J =6.46 Hz, 2 H) 4.34 - 4.61 (m, 4 H) 4.98 (br. s., 1 H) 7.62 (d, J =8.31 Hz, 2 H) 7.83 (d, J =8.31 Hz, 2 H)	HRMS m/z 467.1758 (M + H) ⁺ ; Rt-1.78 min

	8.07 (br. s., 1 H) 8.35 (br. s., 1 H)	
369:(R)-3-(5-fluoro-2-(((S)-1-(4-(isopropylsulfonyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.45 (br. s., 3 H) 1.11 (d, <i>J</i> =6.80 Hz, 6 H) 1.43 (d, <i>J</i> =7.04 Hz, 3 H) 3.33 (dt, <i>J</i> =13.58, 6.78 Hz, 1 H) 4.37 (dd, <i>J</i> =8.05, 4.13 Hz, 1 H) 4.43 - 4.58 (m, 2 H) 4.97 (br. s., 1 H) 7.61 (d, <i>J</i> =8.36 Hz, 2 H) 7.76 (d, <i>J</i> =8.36 Hz, 2 H) 8.06 (br. s., 1 H) 8.33 (br. s., 1 H)	HRMS <i>m/z</i> 453.1604 (M + H) ⁺ ; Rt-1.57 min
370:(R)-3-(6-chloro-2-(((S)-1-(4-(isopropylsulfonyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.53 (d, <i>J</i> =6.21 Hz, 3 H) 1.11 (dd, <i>J</i> =6.77, 3.74 Hz, 6 H) 1.43 (d, <i>J</i> =6.75 Hz, 3 H) 3.34 (dt, <i>J</i> =13.17, 6.50 Hz, 1 H) 3.68 (br. s., 1 H) 4.38 (dd, <i>J</i> =16.43, 7.97 Hz, 2 H) 4.64 - 4.76 (m, 1 H) 4.98 - 5.17 (m, 1 H) 7.18 (s, 1 H) 7.62 (d, <i>J</i> =8.31 Hz, 2 H) 7.78 (d, <i>J</i> =8.27 Hz, 2 H) 8.50 (d, <i>J</i> =7.34 Hz, 1 H)	HRMS <i>m/z</i> 469.1314 (M + H) ⁺ ; Rt-1.92 min
371:(R)-3-(2-(((S)-1-(4-(cyclopropylmethoxy)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(DMSO-d ₆) δ 0.24 - 0.35 (m, 2 H) 0.54 (dd, <i>J</i> =8.09, 1.74 Hz, 2 H) 0.74 (br. s., 3 H) 1.12 - 1.24 (m, 1 H) 1.42 (d, <i>J</i> =6.99 Hz, 3 H) 3.76 (d, <i>J</i> =6.99 Hz, 2 H) 4.36 - 4.50 (m, 3 H) 4.78 (d, <i>J</i> =2.89 Hz, 1 H) 4.98 - 5.10 (m, 1 H) 6.84 (d, <i>J</i> =8.61 Hz, 2 H) 7.18 - 7.36 (m, 3 H) 8.15 (d, <i>J</i> =5.62 Hz, 1 H)	HRMS <i>m/z</i> 399.2034 (M + H) ⁺ ; Rt-1.59 min
372:(R)-3-(2-(((S)-1-(2-fluoro-4-	(DMSO-d ₆) δ 0.51 - 0.82	HRMS <i>m/z</i>

isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one	(m, 3 H) 0.94 (d, $J=6.70$ Hz, 6 H) 1.42 (d, $J=6.85$ Hz, 3 H) 1.97 (dquin, $J=13.32, 6.70, 6.70, 6.70, 6.70$ Hz, 1 H) 3.70 (d, $J=6.55$ Hz, 2 H) 4.35 - 4.48 (m, 2 H) 4.71 - 4.79 (m, 1 H) 5.24 (quin, $J=7.10$ Hz, 1 H) 6.65 - 6.79 (m, 2 H) 7.19 - 7.34 (m, 2 H) 8.15 (br. s., 1 H)	419.2102 (M + H) ⁺ ; Rt-1.95 min
--	--	---

Example 373: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one



5

To a microwave vial with stir bar was added (R)-3-(2-fluoropyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one (28 mg, 0.12 mmol) and DMSO (1 mL). To this reaction mixture was added (S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethanamine (48 mg, 0.17 mmol) and DIEA (61 μ L, 0.35 mmol). Vial was capped and the reaction mixture was heated in a preheated sand bath at 80°C for 18 hr. Reaction mixture was purified by reverse phase HPLC. Product fractions combined, frozen and lyophilized to afford a TFA salt of (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one (28 mg, 0.04 mmol, 38% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.01 (d, $J=6.65$ Hz, 3 H) 1.82 (d, $J=7.04$ Hz, 3 H) 3.24 (s, 3 H) 3.72 - 3.86 (m, 1 H) 4.36 - 4.47 (m, 1 H) 4.60 (dd, $J=9.39, 2.35$ Hz, 1 H) 4.92 - 5.01 (m, 1 H) 5.48 (t, $J=7.04$ Hz, 1 H) 7.43 (d, $J=8.61$ Hz, 2 H) 7.72 (s, 1 H) 7.77 - 7.85 (m, 4 H) 8.02 (d, $J=7.04$ Hz, 1 H) 10.95 (d, $J=6.65$ Hz, 1 H). LCMS m/z 460.2 (M + H)⁺, Rt 0.82 min. HRMS (B) m/z 460.1213 (M + H)⁺, Rt 2.28 min.

The compounds in Table 33a were prepared using methods similar to those described for the preparation of Example 373.

Table 33a.

374*	375*	376
377	378	379

*Examples 374 and 375 were obtained in free form


5 Table 33b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 33a.

Example: Name	¹ H NMR (400 MHz, CDCl ₃) δ ppm	HRMS
374: (R)-3-(6-chloro-2-(((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one	0.89 (br. s., 3 H) 1.56 (br. s., 3 H) 3.20 (br. s., 3 H) 3.96 (s, 3 H) 4.28 - 4.37 (m, 1 H) 4.50 (dd, J=9.39, 2.89 Hz, 1 H) 4.88 (ddd, J=8.50, 4.32, 2.98 Hz, 1 H) 5.30 (quin, J=6.97 Hz, 1 H) 5.50 (br. s., 1 H) 7.07 (dd, J=10.91, 6.36 Hz, 1 H) 7.21 (dd, J=10.88, 6.04 Hz, 1 H) 7.55 (s, 1 H) 7.76 (d, J=2.45 Hz, 1 H) 7.79 (s, 1 H)	HRMS (B) <i>m/z</i> 493.1567 (M + H) ⁺ ; Rt-2.35 min
375: (R)-3-(6-chloro-2-(((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)amino)pyrimi	0.69 - 0.95 (m, 3 H) 1.57 - 1.61 (m, 3 H) 3.16 (br. s., 3 H) 4.26 - 4.37 (m, 1 H) 4.49 (dd, J=9.39, 2.74 Hz, 1 H) 4.78 - 4.90 (m, 1 H) 5.37 (quin, J=6.93 Hz, 1 H) 5.51 (br. s.,	HRMS (B) <i>m/z</i> 463.1170 (M + H) ⁺ ;

din-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one	1 H) 7.33 (d, $J=9.44$ Hz, 1 H) 7.38 - 7.43 (m, 1 H) 7.44 - 7.51 (m, 1 H) 7.56 (s, 1 H)	Rt-2.74 min
376: (R)-3-(6-chloro-2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one	1.01 (d, $J=4.21$ Hz, 3 H) 1.72 - 1.77 (m, 3 H) 3.21 (br. s., 3 H) 4.31 - 4.42 (m, 1 H) 4.53 (dd, $J=9.46$, 2.76 Hz, 1 H) 4.89 (ddd, $J=8.36$, 4.21, 2.79 Hz, 1 H) 5.46 (br. s., 1 H) 7.42 - 7.48 (m, 2 H) 7.65 (s, 1 H) 7.80 (d, $J=8.56$ Hz, 3 H)	HRMS (B) m/z 494.0823 (M + H) ⁺ ; Rt-2.80 min
377: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl) isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one	1.00 (d, $J=6.26$ Hz, 3 H) 1.74 (d, $J=7.04$ Hz, 3 H) 3.46 (s, 3 H) 4.03 - 4.19 (m, 1 H) 4.43 (t, $J=8.80$ Hz, 1 H) 4.65 (dd, $J=9.59$, 2.54 Hz, 1 H) 5.03 (ddd, $J=7.92$, 4.60, 2.74 Hz, 1 H) 5.44 (quin, $J=7.14$ Hz, 1 H) 6.69 (s, 1 H) 7.45 (d, $J=8.61$ Hz, 2 H) 7.71 (d, $J=8.61$ Hz, 2 H) 7.80 (d, $J=7.04$ Hz, 1 H) 7.94 (d, $J=7.04$ Hz, 1 H) 10.98 (d, $J=7.43$ Hz, 1 H)	HRMS (B) m/z 444.1433 (M + H) ⁺ ; Rt-2.21 min
378: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one	1.04 (d, $J=5.87$ Hz, 3 H) 1.75 (d, $J=6.26$ Hz, 3 H) 3.31 (s, 3 H) 3.95 (br. s., 1 H) 4.46 (t, $J=8.61$ Hz, 1 H) 4.60 (dd, $J=9.39$, 2.35 Hz, 1 H) 5.07 (d, $J=3.13$ Hz, 1 H) 5.57 (br. s., 1 H) 7.44 (d, $J=8.61$ Hz, 2 H) 7.57 (d, $J=8.22$ Hz, 2 H) 7.61 (br. s., 1 H) 7.85 (d, $J=7.04$ Hz, 1 H) 7.96 (d, $J=6.65$ Hz, 1 H) 8.53 (br. s., 1 H) 10.90 (d, $J=6.65$ Hz, 1 H)	HRMS (B) m/z 443.1598 (M + H) ⁺ ; Rt-1.57 min
379: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(6-methylpyridin-3-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-	0.97 (d, $J=6.65$ Hz, 3 H) 1.67 (d, $J=7.04$ Hz, 3 H) 2.88 (s, 3 H) 3.30 (s, 3 H) 3.67 - 3.89 (m, 1 H) 4.37 - 4.49 (m, 1 H) 4.61 (dd, $J=9.39$, 2.35 Hz, 1 H) 4.94 - 5.07 (m, 1 H) 5.62 (quin, $J=6.95$ Hz, 1 H) 7.22 - 7.26 (m, 1 H) 7.48 (dd, $J=10.37$, 6.06 Hz, 1 H) 7.66	HRMS (B) m/z 470.2007 (M + H) ⁺ ; Rt-1.53 min

2-one	(d, $J=8.22$ Hz, 1 H) 7.82 (d, $J=7.04$ Hz, 1 H) 7.97 (d, $J=7.04$ Hz, 1 H) 8.34 (d, $J=8.22$ Hz, 1 H) 9.00 (s, 1 H) 11.04 (d, $J=7.83$ Hz, 1 H)	
-------	--	--

Example 380 : (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



5 Step 1

To a microwave vial with stir bar was added (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-chloropyrimidin-4-yl)oxazolidin-2-one (147 mg, 0.49 mmol) and DMSO (4 mL). To this reaction mixture was added (S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethanamine HCl (148 mg, 0.54 mmol) and DIEA (0.26 mL, 1.47 mmol). Vial capped and the reaction mixture was heated in a preheated sand bath at 110 °C for 42 hr. The reaction mixture was diluted with water and extracted with EtOAc. Organic phases combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated onto silica gel. Silica gel column chromatography (EtOAc/Heptane 0 to 100%) provided (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (82 mg, 0.16 mmol, 33% yield). ^1H NMR (400 MHz, CDCl_3) δ 0.82 (br. s., 9 H) 0.90 - 0.98 (m, 3 H) 1.71 (d, $J=6.90$ Hz, 3 H) 4.13 (q, $J=7.16$ Hz, 1 H) 4.21 - 4.32 (m, 1 H) 4.42 - 4.51 (m, 1 H) 4.56 (dd, $J=8.31, 2.79$ Hz, 1 H) 5.39 (br. s., 1 H) 7.34 - 7.45 (m, 2 H) 7.57 (d, $J=5.77$ Hz, 1 H) 7.64 (s, 1 H) 7.76 - 7.86 (m, 2 H) 8.22 (d, $J=5.82$ Hz, 1 H). LCMS m/z 502.3 ($\text{M} + \text{H}$) $^+$, Rt 0.92 min.

20 Step 2

To a round bottom flask containing a stir bar and (R)-4-((S)-1-(tert-butoxy)ethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (82 mg, 0.16 mmol) was added DCM (1 mL) followed by the addition of TFA (1 mL). Resulting reaction mixture allowed to stir 30 min at RT. The volatiles were then removed and the residue neutralized by the addition of a saturated solution of NaHCO_3 . The aqueous mixture was then extracted with DCM. Organic phases combined, washed with water, brine, dried (Na_2SO_4), filtered and concentrated to a brown foam of (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-

yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one (61 mg, 0.14 mmol, 84 % yield) which was used without further purification. LCMS m/z 446.2 ($M + H$)⁺, Rt 0.71 min.

Step 3

5 To a round bottom flask with stir bar was added (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one (19 mg, 0.04 mmol) followed by the addition of DCM (1 mL) under nitrogen. Mixture was cooled to 0 °C in a ice/water bath. To this cold solution was added DIEA (0.03 mL, 0.17 mmol) followed by the addition of methanesulfonyl chloride (10 µL, 0.13 mmol). Reaction mixture stirred for 1 hr at
10 0 °C. The reaction mixture was then quenched with water and diluted with DCM. Phases partitioned and the aqueous phase extracted with DCM. Organic layers combined and washed with brine, dried (Na₂SO₄), filtered and concentrated to afford a orange residue of (S)-1-((R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-2-oxooxazolidin-4-yl)ethyl methanesulfonate (21 mg, 0.04 mmol, 94 % yield). LCMS m/z 524.2 ($M + H$)⁺, Rt
15 0.75 min.

Step 4

To a microwave vial containing (S)-1-((R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-2-oxooxazolidin-4-yl)ethyl methanesulfonate (21 mg, 0.04 mmol)
20 in DMF (1 mL) was added sodium azide (13 mg, 0.20 mmol). Resulting reaction mixture heated to 50 °C for 1 hr in a sand bath then to 80 °C for 42 hr. Reaction mixture was diluted with water and extracted with EtOAc. Organic phases combined, washed with brine, dried (Na₂SO₄), filtered and concentrated to a yellow residue of (S)-4-((R)-1-azidoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (14 mg, 0.030 mmol,
25 74.2 % yield). LCMS m/z 471.2 ($M + H$)⁺, Rt 0.92 min.

Step 5




To a round bottom flask containing (S)-4-((R)-1-azidoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (14 mg, 0.03 mmol) and
30 stir bar was added THF (1 mL) and trimethylphosphine (0.06 mL, 0.06 mmol, 1.0 M in THF). The resulting reaction mixture allowed to stir 2 hr at RT. A second addition of trimethylphosphine (0.06 mL, 0.06 mmol) occurred and the mixture allowed to stir 1.5 hr at RT. Reaction was quenched by the addition of a saturated solution of NH₄Cl and EtOAc. The phases were partitioned and aqueous phase extracted with EtOAc. Organic phases combined
35 and washed with brine, dried (Na₂SO₄), filtered and concentrated to a yellow residue. Residue dissolved in DMSO and purified by reverse phase HPLC. Product fractions combined, frozen and lyophilized to afford (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-

yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (2.6 mg, 4.60 μ mol, 15% yield) as a TFA salt.
 ^1H NMR (400 MHz, CD_3CN) δ 1.26 - 1.44 (m, 3 H) 1.68 (d, $J=6.65$ Hz, 3 H) 3.83 (quin, $J=6.26$ Hz, 1 H) 4.43 - 4.53 (m, 1 H) 7.46 (d, $J=8.61$ Hz, 2 H) 7.76 (s, 1 H) 7.89 (d, $J=8.61$ Hz, 2 H) 8.20 (br. s., 1 H). LCMS m/z 445.2 ($\text{M} + \text{H}$) $^+$, Rt 0.65 min. HRMS (B) m/z 445.1211 ($\text{M} + \text{H}$) $^+$,

5 Rt 1.58 min.

The compounds in Table 34a were prepared using methods similar to those described for the preparation of Example 380

Table 34a.

381	382	383
		


10

Table 34b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 34a.

Example: Name	^1H NMR (400 MHz) δ ppm	HRMS
381: (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(DMSO) 1.03 - 1.32 (m, 3 H) 1.55 (d, $J=6.65$ Hz, 3 H) 3.86 (br. s., 1 H) 4.51 (d, $J=7.04$ Hz, 1 H) 5.23 (br. s., 1 H) 7.28 (d, $J=5.87$ Hz, 1 H) 7.60 - 7.68 (m, 2 H) 7.73 (d, $J=8.61$ Hz, 2 H) 7.83 (br. s., 1 H) 8.25 (d, $J=5.87$ Hz, 1 H)	HRMS (B) m/z 428.1598 ($\text{M} + \text{H}$) $^+$; Rt-1.12 min
382: (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(DMSO) 1.09 (br. s., 3 H) 1.56 (d, $J=7.04$ Hz, 3 H) 4.45 - 4.54 (m, 1 H) 5.37 (br. s., 1 H) 7.00 (s, 1 H) 7.26 (d, $J=5.87$ Hz, 1 H) 7.60 (d, $J=8.61$ Hz, 2 H) 7.87 (d, $J=8.61$ Hz, 2 H) 8.07 (br. s., 1 H) 8.24 (d, $J=5.87$ Hz, 1 H)	HRMS (B) m/z 429.1438 ($\text{M} + \text{H}$) $^+$; Rt-1.49 min
383: (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2,4-difluoro-5-(4-methylpyridin-2-yl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(CDCl_3) 1.24 (br. s., 1 H) 1.53 (d, $J=5.87$ Hz, 3 H) 2.64 (br. s., 3 H) 3.31 (br. s., 3 H)	HRMS (B) m/z

(2,5-difluoro-4-(6-methylpyridin-3-yl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	4.42 (br. s., 1 H) 7.23 - 7.26 (m, 3 H) 7.40 (br. s., 1 H) 7.95 - 8.12 (m, 2 H) 8.67 (br. s., 1 H)	455.2005 (M + H) ⁺ ; Rt-1.06 min
--	--	---


Example 384: (S)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-(methylamino)ethyl)oxazolidin-2-one



- 5 To a microwave vial containing (S)-1-((R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-2-oxooxazolidin-4-yl)ethyl methanesulfonate (20 mg, 0.04 mmol) in DMF (1 mL) was added methyl amine (30 mg, 0.38 mmol, 40% wt in H₂O). Resulting reaction mixture allowed to stir at 80 °C for 18 hr whereupon a second addition of methylamine (0.1 mL, 40% wt in H₂O) occurred. The reaction mixture was stirred at 80 °C for 18 hr. The
- 10 reaction mixture was then diluted with water and extracted with EtOAc. Organic phases combined and washed with brine, dried (Na₂SO₄), filtered and concentrated. Residue dissolved in DMSO and purified by reverse phase HPLC. Product fractions combined, frozen and lyophilized to afford a TFA salt of (S)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-(methylamino)ethyl)oxazolidin-2-one (3.4 mg, 5.87 μmol,
- 15 15% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (d, J=5.87 Hz, 3 H) 1.78 (d, J=7.04 Hz, 3 H) 2.70 (s, 3 H) 4.02 (br. s., 1 H) 4.14 (br. s., 2 H) 5.33 (br. s., 1 H) 5.73 (d, J=6.26 Hz, 1 H) 6.23 (d, J=5.48 Hz, 1 H) 7.41 (d, J=8.61 Hz, 2 H) 7.78 (s, 1 H) 7.83 (d, J=8.22 Hz, 2 H) 8.05 (d, J=5.48 Hz, 1 H). LCMS *m/z* 459.2 (M + H)⁺, Rt 0.73 min. HRMS (B) *m/z* 459.1373 (M + H)⁺, Rt 1.68 min.

20

Example 385: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one



To a microwave vial with stir bar was added (R)-4-((R)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (20 mg, 0.09 mmol) and DMSO (1 mL). To this reaction mixture was added (S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethanamine (34 mg, 0.13 mmol) and DIEA (46 μ L, 0.26 mmol). Vial was then capped and heated in a preheated sand bath at 80°C for 2 hr. Reaction mixture was then purified by reverse phase HPLC. Product fractions combined, frozen and lyophilized to afford a TFA salt of (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one (4.2 mg, 7.63 μ mol, 8.74 % yield). ^1H NMR (400 MHz, CDCl_3) δ 1.21 (dd, $J=24.26, 6.26$ Hz, 3 H) 1.74 (d, $J=6.65$ Hz, 3 H) 4.52 - 4.58 (m, 2 H) 4.79 - 5.06 (m, 1 H) 5.29 (br. s., 1 H) 5.65 (t, $J=6.85$ Hz, 1 H) 7.41 (d, $J=8.61$ Hz, 2 H) 7.52 (s, 1 H) 7.57 (d, $J=9.00$ Hz, 2 H) 7.82 (d, $J=6.65$ Hz, 1 H) 7.98 (d, $J=7.04$ Hz, 1 H) 8.48 (s, 1 H) 10.97 (d, $J=6.65$ Hz, 1 H). LCMS m/z 431.1 ($M + H$) $^+$, Rt 0.61 min. HRMS (B) m/z 431.1392 ($M + H$) $^+$, Rt 1.54 min.

The compounds in Table 35a were prepared using methods similar to those described for the preparation of Example 385.

Table 35a.

386	387	388
389	390	391












392	393	394
		
395	396	397
		
398	399	400
		
401	402	
		

Table 35b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 35a.

Example: Name	¹ H NMR (400 MHz, CDCl ₃) δ ppm	HRMS
386: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl) isoxazol-	10.84 (d, J=6.7 Hz, 1 H), 8.02 (d, J=7.0 Hz, 1 H), 7.79 (d, J=7.0 Hz, 1 H), 7.71 (d,	HRMS (B) m/z


3-yl)ethyl)amino) pyrimidin-4-yl)-4-((R)-1- fluoroethyl)oxazolidin-2- one	J=8.6 Hz, 2 H), 7.46 (d, J=8.2 Hz, 2 H), 6.63 (s, 1 H), 5.33 (quin, J=6.9 Hz, 1 H), 4.95 - 5.21 (m, 2 H), 4.58 - 4.71 (m, 1 H), 4.43 - 4.56 (m, 1 H), 1.75 (d, J=7.0 Hz, 3 H), 1.17 (dd, J=23.9, 5.9 Hz, 3 H)	432.1242 (M + H) ⁺ ; Rt-2.18 min
387: (R)-3-(2-(((S)-1-(2- (4-chlorophenyl) thiazol-5- yl)ethyl)amino) pyrimidin- 4-yl)-4-((R)-1- fluoroethyl)oxazolidin-2- one	1.18 (dd, J=24.26, 6.65 Hz, 3 H) 1.82 (d, J=7.04 Hz, 3 H) 4.44 - 4.55 (m, 1 H) 4.57 - 4.66 (m, 1 H) 4.69 - 4.94 (m, 1 H) 5.00 - 5.13 (m, 1 H) 5.40 (quin, J=6.65 Hz, 1 H) 7.43 (d, J=8.22 Hz, 2 H) 7.75 (s, 1 H) 7.77 - 7.88 (m, 3 H) 8.04 (d, J=6.65 Hz, 1 H) 11.00 (d, J=5.48 Hz, 1 H)	HRMS (B) <i>m/z</i> 448.1014 (M + H) ⁺ ; Rt-2.27 min
388: (R)-3-(2-(((S)-1-(1- (4-chlorophenyl)-1H- imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)-4- ((S)-1-fluoroethyl) oxazolidin-2-one	1.36 (dd, J=23.87, 6.26 Hz, 3 H) 1.71 (d, J=6.26 Hz, 3 H) 4.46 - 4.58 (m, 1 H) 4.59 - 4.69 (m, 1 H) 4.86 - 5.12 (m, 2 H) 5.59 (br. s., 1 H) 7.42 (d, J=8.61 Hz, 2 H) 7.57 (d, J=9.00 Hz, 3 H) 7.90 (d, J=6.65 Hz, 1 H) 7.99 (d, J=7.04 Hz, 1 H) 8.41 (br. s., 1 H) 11.02 (d, J=7.04 Hz, 1 H)	HRMS (B) <i>m/z</i> 431.1400 (M + H) ⁺ ; Rt-1.55 min
389: (R)-3-(2-(((S)-1-(2- (4-chlorophenyl) thiazol-5- yl)ethyl)amino) pyrimidin- 4-yl)-4-((S)-1- fluoroethyl)oxazolidin-2- one	1.26 (dd, J=21.91, 6.65 Hz, 3 H) 1.81 (d, J=7.04 Hz, 3 H) 4.43 - 4.55 (m, 1 H) 4.57 - 4.65 (m, 1 H) 4.65 - 4.93 (m, 2 H) 5.33 (quin, J=6.65 Hz, 1 H) 7.45 (d, J=8.22 Hz, 2 H) 7.71 (s, 1 H) 7.81 (d, J=8.61 Hz, 2 H) 7.91 (d, J=7.04 Hz, 1 H) 8.08 (d, J=7.04 Hz, 1 H) 10.94 (d, J=5.87 Hz, 1 H)	HRMS (B) <i>m/z</i> 448.1007 (M + H) ⁺ ; Rt-2.22 min
390: (R)-3-(2-(((S)-1-(5- (4-chlorophenyl) isoxazol- 3-yl)ethyl)amino) pyrimidin-4-yl)-4-((S)-1- fluoroethyl)oxazolidin-2- one	1.48 (dd, J=23.48, 6.26 Hz, 3 H) 1.73 (d, J=7.04 Hz, 3 H) 4.41 - 4.56 (m, 1 H) 4.67 (dd, J=9.20, 2.54 Hz, 1 H) 4.74 - 5.05 (m, 2 H) 5.22 (t, J=6.65 Hz, 1 H) 6.62 (s, 1 H) 7.46 (d, J=8.22 Hz, 2 H) 7.70 (d, J=8.22 Hz, 2 H) 7.86 (d, J=7.04 Hz, 1 H) 7.99 (d, J=7.04 Hz, 1 H) 10.88 (d, J=6.26 Hz, 1 H)	HRMS (B) <i>m/z</i> 432.1233 (M + H) ⁺ ; Rt-2.16 min
391: (R)-3-(2-(((S)-1-(3- (4-chlorophenyl)-1,2,4- oxadiazol-5-	1.11 (dd, J=24.26, 7.04 Hz, 3 H) 1.90 (d, J=7.04 Hz, 3 H) 4.40 - 4.48 (m, 1 H) 4.50 - 4.57 (m, 1 H) 4.66 - 4.89 (m, 1 H) 4.93 -	HRMS (B) <i>m/z</i> 433.1190

yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	5.02 (m, 1 H) 5.30 - 5.41 (m, 1 H) 7.47 (d, $J=8.61$ Hz, 2 H) 7.84 (d, $J=7.04$ Hz, 1 H) 8.00 (d, $J=8.61$ Hz, 2 H) 8.10 (d, $J=6.65$ Hz, 1 H) 11.06 (d, $J=4.30$ Hz, 1 H)	(M + H) ⁺ ; Rt-2.30 min
392: (R)-4-((R)-1-fluoroethyl)-3-(2-(((S)-1-(2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	1.20 (dd, $J=23.87$, 6.26 Hz, 3 H) 1.84 (d, $J=7.04$ Hz, 3 H) 4.46 - 4.55 (m, 1 H) 4.57 - 4.65 (m, 1 H) 4.68 - 4.93 (m, 1 H) 5.07 (d, $J=5.87$ Hz, 1 H) 5.46 (t, $J=6.85$ Hz, 1 H) 7.80 (d, $J=7.04$ Hz, 1 H) 7.86 (s, 1 H) 7.94 (d, $J=5.09$ Hz, 1 H) 8.04 (d, $J=7.04$ Hz, 1 H) 8.17 (s, 1 H) 8.83 (d, $J=5.09$ Hz, 1 H) 11.14 (br. s., 1 H)	HRMS (B) m/z 483.1232 (M + H) ⁺ ; Rt-2.06 min
393: (R)-4-((R)-1-fluoroethyl)-3-(2-(((S)-1-(2-(6-(trifluoromethyl)pyridin-3-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	1.20 (dd, $J=23.87$, 6.26 Hz, 3 H) 1.84 (d, $J=7.04$ Hz, 3 H) 4.44 - 4.56 (m, 1 H) 4.57 - 4.65 (m, 1 H) 4.68 - 4.94 (m, 1 H) 5.07 (d, $J=5.48$ Hz, 1 H) 5.45 (t, $J=6.65$ Hz, 1 H) 7.72 - 7.88 (m, 3 H) 8.03 (d, $J=7.04$ Hz, 1 H) 8.36 (d, $J=7.83$ Hz, 1 H) 9.21 (s, 1 H) 11.12 (br. s., 1 H)	HRMS (B) m/z 483.1233 (M + H) ⁺ ; Rt-2.07 min
394: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	1.21 (dd, $J=23.48$, 6.65 Hz, 3 H) 1.69 (d, $J=6.65$ Hz, 3 H) 4.48 - 4.56 (m, 1 H) 4.59 - 4.64 (m, 1 H) 4.87 - 5.25 (m, 3 H) 7.43 (d, $J=8.61$ Hz, 2 H) 7.62 (d, $J=8.61$ Hz, 2 H) 7.67 (s, 1 H) 7.74 (d, $J=6.65$ Hz, 1 H) 7.95 - 8.02 (m, 2 H) 10.74 (d, $J=5.48$ Hz, 1 H)	HRMS (B) m/z 431.1407 (M + H) ⁺ ; Rt-1.95 min
395: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	1.17 (dd, $J=23.48$, 4.70 Hz, 3 H) 1.76 (d, $J=6.65$ Hz, 3 H) 4.39 (dd, $J=9.39$, 4.30 Hz, 1 H) 4.60 (t, $J=9.00$ Hz, 1 H) 4.68 - 4.90 (m, 2 H) 5.32 (d, $J=5.09$ Hz, 1 H) 7.44 (d, $J=8.61$ Hz, 2 H) 7.79 (d, $J=8.61$ Hz, 2 H) 7.85 (s, 1 H) 8.19 (d, $J=3.13$ Hz, 1 H)	HRMS (B) m/z 466.0916 (M + H) ⁺ ; Rt-2.32 min
396: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)	1.28 (dd, $J=23.09$, 6.65 Hz, 3 H) 1.68 (d, $J=6.65$ Hz, 3 H) 4.44 - 4.55 (m, 1 H) 4.57 - 4.65 (m, 1 H) 4.67 - 4.78 (m, 1 H) 4.81 -	HRMS (B) m/z 431.1407

pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	5.04 (m, 1 H) 5.09 (t, $J=6.65$ Hz, 1 H) 7.43 (d, $J=8.61$ Hz, 2 H) 7.56 - 7.67 (m, 3 H) 7.84 (d, $J=6.65$ Hz, 1 H) 7.93 (s, 1 H) 8.00 (d, $J=7.04$ Hz, 1 H) 10.73 (d, $J=5.87$ Hz, 1 H)	(M + H) ⁺ ; Rt-1.88 min
397: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	1.24 (dd, $J=23.87, 5.87$ Hz, 3 H) 1.68 (d, $J=6.65$ Hz, 3 H) 4.39 (dd, $J=9.39, 3.91$ Hz, 1 H) 4.62 (t, $J=9.00$ Hz, 1 H) 4.76 - 4.99 (m, 2 H) 5.14 (q, $J=7.04$ Hz, 1 H) 7.43 (d, $J=8.61$ Hz, 2 H) 7.57 (d, $J=8.61$ Hz, 2 H) 7.76 (s, 1 H) 7.96 (s, 1 H) 8.15 (d, $J=3.91$ Hz, 1 H)	HRMS (B) m/z 449.1303 (M + H) ⁺ ; Rt-2.20 min
398: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl) isoxazol-3-yl)ethyl)amino) -5-fluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	1.15 (dd, $J=24.26, 6.26$ Hz, 3 H) 1.72 (d, $J=7.04$ Hz, 3 H) 4.42 (dd, $J=9.39, 4.30$ Hz, 1 H) 4.62 (t, $J=9.00$ Hz, 1 H) 4.73 - 5.07 (m, 2 H) 5.17 - 5.23 (m, 1 H) 6.54 (s, 1 H) 7.45 (d, $J=8.61$ Hz, 2 H) 7.68 (d, $J=8.22$ Hz, 2 H) 8.15 (d, $J=3.52$ Hz, 1 H)	HRMS (B) m/z 450.1145 (M + H) ⁺ ; Rt-2.26 min
399: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	1.29 (dd, $J=23.87, 5.09$ Hz, 3 H) 1.75 (d, $J=6.65$ Hz, 3 H) 4.38 (d, $J=6.26$ Hz, 1 H) 4.58 (t, $J=8.80$ Hz, 1 H) 4.93 (br. s., 1 H) 5.32 (br. s., 1 H) 7.42 (d, $J=7.83$ Hz, 3 H) 7.56 (d, $J=7.83$ Hz, 2 H) 8.19 (br. s., 1 H) 8.62 (br. s., 1 H)	HRMS (B) m/z 449.1313 (M + H) ⁺ ; Rt-1.52 min
400: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	1.33 - 1.53 (m, 3 H) 1.71 (br. s., 3 H) 2.60 (s, 3 H) 4.54 (br. s., 1 H) 4.62 (d, $J=7.04$ Hz, 1 H) 4.94 - 5.20 (m, 1 H) 5.69 (br. s., 1 H) 7.30 (d, $J=8.22$ Hz, 2 H) 7.59 (d, $J=8.61$ Hz, 2 H) 7.82 - 8.02 (m, 1 H)	HRMS (B) m/z 445.1556 (M + H) ⁺ ; Rt-1.42 min
401: (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-	1.36 (dd, $J=24.26, 5.87$ Hz, 3 H) 1.72 (d, $J=5.87$ Hz, 3 H) 4.44 - 4.58 (m, 1 H) 4.63 (dd, $J=9.19, 2.93$ Hz, 1 H) 4.87 - 5.18 (m, 2	HRMS (B) m/z 415.1695

imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)oxazolidin-2-one	H) 5.54 (br. s., 1 H) 7.39 - 7.58 (m, 3 H) 7.87 (d, $J=6.65$ Hz, 1 H) 7.97 (d, $J=5.87$ Hz, 1 H) 8.26 (br. s., 1 H) 10.95 (br. s., 1 H)	(M + H) ⁺ ; Rt-1.34 min
402: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	1.32 (dd, $J=23.09$, 6.26 Hz, 3 H) 1.66 (d, $J=7.04$ Hz, 3 H) 2.45 (s, 3 H) 4.45 - 4.56 (m, 1 H) 4.63 (dd, $J=9.00$, 2.74 Hz, 1 H) 4.70 - 4.97 (m, 2 H) 5.48 (quin, $J=6.95$ Hz, 1 H) 7.11 (s, 1 H) 7.56 (dd, $J=10.17$, 6.65 Hz, 1 H) 7.86 (d, $J=7.04$ Hz, 1 H) 8.00 (d, $J=7.04$ Hz, 1 H) 8.59 (s, 1 H) 11.07 (br. s., 1 H)	HRMS (B) m/z 447.1761 (M + H) ⁺ ; Rt-1.20 min

Example 403: (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



- 5 A solution of (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (10 mg, 0.044 mmol), (S)-1-(1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)ethanamine (19 mg, 0.065 mmol, 1.5 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.031 mL, 0.175 mmol, 4 equiv) in DMSO (0.5 mL) was heated at 90 °C for 3 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (14 mg, white solid) in 55% yield. ¹H NMR (400 MHz, CDCl₃) δ 10.83 (d, $J=7.1$ Hz, 1 H), 9.06 (d, $J=2.3$ Hz, 1 H), 8.15 (dd, $J=8.5$, 2.4 Hz, 1 H), 7.93 - 8.04 (m, 2 H), 7.81 (dd, $J=7.7$, 6.3 Hz, 2 H), 6.61 (d, $J=2.6$ Hz, 1 H), 5.28 (quin, $J=7.1$ Hz, 1 H), 4.96 - 5.17 (m, 1 H), 4.68 - 4.81 (m, 1 H), 4.62 (dd, $J=9.1$, 3.2 Hz, 1 H), 4.45 - 4.54 (m, 1 H), 1.72 (d, $J=7.1$ Hz, 3 H), 1.14 - 1.29 (m, 3 H); HRMS m/z 466.1625 (M + H)⁺; Rt-1.83 min.

The compounds in **Table 36a** were prepared using methods similar to those described for the preparation of Example 403.

Table 36a.


404	405	406

Table 36b. Chemical name, NMR chemical shifts and LCMS signal for each compound listed in Table 36a.

Example: Name	¹ H NMR (400 MHz, CDCl ₃) δ ppm	LCMS
404: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	8.22 (d, J = 5.5 Hz, 1H), 7.77 (s, 1H), 7.45 (m, 3H), 7.30 (d, J = 8.7 Hz, 2H), 7.11 (s, 1H), 5.14 (m, 1H), 4.93 (m, 1H), 4.48 (m, 4H), 1.63 (d, J = 6.8 Hz, 3H)	LCMS <i>m/z</i> 417.1 (M + H) ⁺ ; Rt-0.59 min.
405: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	8.25 (m, 1H), 7.68 (m, 2H), 7.53 (m, 1H), 7.44 (m, 2H), 6.48 (s, 1H), 5.47 (m, 1H), 4.95 (m, 1H), 4.50 (m, 4H), 1.66 (d, J = 6.8 Hz, 3H)	LCMS <i>m/z</i> 418.2 (M + H) ⁺ ; Rt-0.82 min.
406: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	7.96 (m, 1H), 7.82 (m, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.22 (s, 1H), 5.73 (m, 1H), 5.42 (m, 1H), 5.05 – 4.90 (m, 1H), 4.54 (m, 2H), 2.60 (s, 3H), 1.72 (d, J = 6.7 Hz, 3H), 1.34 – 1.20 (m, 3H)	LCMS <i>m/z</i> 445.2 (M + H) ⁺ ; Rt-0.67 min.


5

Example 407 (R)-4-((S)-1-hydroxyethyl)-3-(2-(((S)-1-(1-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



Example 407 was prepared using a method similar to that described for the preparation of Example 28. Product was purified by reverse phase HPLC. ^1H NMR (400 MHz, CD_2Cl_2) δ 8.23 (d, $J = 4.18$ Hz, 1H), 8.19 (d, $J = 4.88$ Hz, 1H), 7.37 (d, $J = 4.88$ Hz, 1H), 6.68 (br, s, 1H), 6.68 – 6.63 (m, 1H), 5.03 (br, s, 1H), 4.80 (br, s, 1H), 4.50 – 4.36 (m, 3H), 4.09 – 3.91 (m, 3H), 2.90 – 2.79 (m, 2H), 1.99 – 1.79 (m, 2H), 1.78 – 1.65 (m, 2H), 1.59 (s, 6H), 1.52 – 1.32 (m, 2H), 1.23 (d, $J = 6.97$ Hz, 3H), 1.18 (d, $J = 6.27$ Hz, 3H), HRMS(C) $t_R = 3.62$ min; MS m/z 523.2649 (M+H)+


- 10 **Example 408** (R)-3-(2-(((S)-1-(1-(4-chloro-3-(trifluoromethoxy)phenyl)piperidin-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-hydroxyethyl)oxazolidin-2-one



Example 408 was prepared using a method similar to that described for the preparation of Example 28. TFA salt form of product was converted to free base form by using a PL-HCO₃ MP SPE cartridge, eluting with MeOH. ^1H NMR (400 MHz, CD_2Cl_2) δ 8.07 (d, $J = 5.33$ Hz, 1H), 7.25 (d, $J = 4.33$ Hz, 1H), 7.19 (d, $J = 9.48$ Hz, 1H), 6.76 – 6.68 (m, 2H), 4.98 (br, s, 1H), 4.69 (br, s, 1H), 4.39 – 4.25 (m, 3H), 3.90 (br, s, 1H), 3.65 – 3.56 (m, 2H), 2.68 – 2.56 (m, 2H), 1.86 – 1.15 (m, 6H), 1.12 (d, $J = 6.52$ Hz, 3H), 1.07 (d, $J = 4.74$ Hz, 3H), HRMS(C) $t_R = 4.44$ min; MS m/z 530.1782 (M+H)+

20

Example 409 (S)-3-(2-(((S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one




A mixture of (S)-3-(2-chloro-5-fluoropyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (40 mg, 0.135 mmol), (S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethanamine hydrochloride (61.1 mg, 0.271 mmol), Huenig's base (0.095 mL, 0.541 mmol) in DMSO (0.7 mL) under argon atmosphere was heated at 107 °C for ~16 hr. The mixture was diluted with DMSO and water, filtered through a syringe filter and purified by reverse phase HPLC. Selected fractions were collected and lyophilized providing (S)-3-(2-(((S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one as its trifluoroacetic acid salt (35.4 mg).

¹H NMR (400 Mhz, CD₃OD) δ ppm 8.26 (br. s., 1 H), 7.42 - 7.54 (m, 1 H), 7.23 - 7.33 (m, 2 H), 6.55 - 6.91 (m, 1 H), 5.26 (q, J=6.9 Hz, 1 H), 4.52 (t, J=9.0 Hz, 1 H), 4.36 - 4.45 (m, 1 H), 1.53 (d, J=7.0 Hz, 4 H), 0.78 (br. s., 3 H). HRMS *m/z* 449.1412 (M + H)⁺; Rt-2.27 min.

Examples 410 and 411 (S)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-

yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one / (S)-3-(2-(((R)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one



A mixture of (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (40 mg, 0.153 mmol), (S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethanamine/(R)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethanamine (mixture of diastereomers ~3/1, 37.7 mg, 0.168 mmol) and Huenig's base (0.059 mL, 0.337 mmol) in DMSO (0.7 mmol) under argon atmosphere was heated/radiated in the microwave at 140 °C for 15 min. The mixture was

diluted with DMSO and water, filtered through a syringe filter and purified by reverse phase HPLC. Selected fractions were collected and lyophilized providing (S)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (31.8 mg; first eluted product) and (S)-3-(2-(((R)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one (11.5 mg; second eluted product) as their trifluoroacetic acid salts.


410: First eluted product: ^1H NMR (500 Mhz, CD_3OD) δ ppm 8.22 (s, 1H), 8.03 - 7.93 (m, 2H), 7.54 - 7.46 (m, 3H), 5.84 (m, 1H), 5.49 (q, $J = 7.2$ Hz, 1H), 5.13 (dt, $J = 8.4, 3.1$ Hz, 1H), 4.60 - 4.21 (m, 2H), 2.74 (m, 1H), 1.75 (d, $J = 7.2$ Hz, 3H), 0.90 (br. s, 3H). HRMS m/z 465.1260 ($M + H$) $^+$; Rt-2.41 min.

411: Second eluted product: ^1H NMR (500 Mhz, CD_3OD) δ ppm 8.19 (dd, $J = 7.5, 6.0$ Hz, 1H), 8.10 - 7.91 (m, 2H), 7.55 - 7.50 (m, 2H), 7.47 (d, $J = 5.8$ Hz, 1H), 6.08 (td, $J = 55.6, 3.5$ Hz, 1H), 5.40 (t, $J = 7.1$ Hz, 1H), 4.59 - 4.42 (m, 1H), 4.39 (s, 1H), 3.03 (s, 1H), 1.72 (d, $J = 7.2$ Hz, 3H), 1.03 (d, $J = 7.2$ Hz, 3H). HRMS m/z 465.1250 ($M + H$) $^+$; Rt-2.42 min.

The following Examples were prepared using a method similar to that described for the preparation of **Examples 410/411**

20 Example 412

(S)-3-(2-(((S)-1-(4-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one




^1H NMR (400 Mhz, CD_3OD) δ ppm 8.19 (d, $J=6.7$ Hz, 1 H), 7.70 (d, $J=6.7$ Hz, 1 H), 7.47 - 7.56 (m, 1 H), 7.28 - 7.40 (m, 2 H), 6.60 - 6.95 (m, 1 H), 5.57 - 5.95 (m, 1 H), 5.47 (m, $J=5.1$ Hz, 1 H), 5.12 (dt, $J=7.8, 3.13$ Hz, 1 H), 4.46 - 4.60 (m, 2 H), 1.63 (d, $J=7.0$ Hz, 3 H), 0.77 - 0.95 (m, 3 H). HRMS m/z 431.1506 ($M + H$) $^+$; Rt-2.09 min.

Example 413 and 414 (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-(((S)-1-(5-(4-fluoro-3-

methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one / (S)-4-((R)-1,1-

difluoropropan-2-yl)-3-(2-(((R)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



A mixture of (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one 30 mg, 0.115 mmol), 1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethanamine (53.1 mg, 0.230 mmol), Huenig's Base 0.05 mL, 0.287 mmol) in DMSO (0.7 mL) under argon atmosphere was heated at 120 °C for ~16 hr. Additional amine (2 eq) was added and heating was continued for 3 hrs. More amine (2 eq) was added and heating was continued for 3 hr. The mixture was diluted with DMSO and water, filtered through a syringe filter and purified by reverse phase HPLC. Selected fractions were collected and lyophilized providing (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one / (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-(((R)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as their trifluoroacetic acid salts as off-white solids.

413: First eluted product (2.8 mg): ¹H NMR (500 Mhz, CD₃OD) δ ppm 8.98 (s, 2H), 8.16 (s, 1H), 7.59 (dd, J = 7.3, 2.3 Hz, 1H), 7.56 – 7.45 (m, 2H), 7.18 (t, J = 9.0 Hz, 1H), 6.40 – 5.96 (m, 1H), 5.25 (q, J = 6.9 Hz, 1H), 4.52 (dd, J = 9.4, 2.8 Hz, 1H), 4.42 (t, J = 8.4 Hz, 1H), 3.08 (s, 1H), 2.34 (d, J = 2.0 Hz, 3H), 1.62 (d, J = 7.0 Hz, 3H), 1.05 (d, J = 7.2 Hz, 3H). HRMS *m/z* 473.1916 (M + H)⁺; Rt-2.12 min.

414: Second eluted product (2.9 mg): ¹H NMR (500 Mhz, CD₃OD) δ ppm 8.96 (s, 2H), 8.16 (s, 1H), 7.57 (dd, J = 7.5, 2.4 Hz, 1H), 7.53 – 7.43 (m, 2H), 7.17 (t, J = 9.0 Hz, 1H), 5.92 (t, J = 56.9 Hz, 1H), 5.30 (q, J = 7.0 Hz, 1H), 5.13 (dt, J = 6.9, 3.3 Hz, 1H), 4.57 – 4.40 (m, 2H), 2.53 (s, 1H), 2.34 (d, J = 2.0 Hz, 3H), 1.64 (d, J = 7.0 Hz, 3H), 0.87 (s, 3H). HRMS *m/z* 473.1919 (M + H)⁺; Rt-2.17 min.

The compounds in **Table 37a** were prepared using methods similar to those described for the preparation of **Examples 35, 36, or 37/38**.

Table 37a









415	416	417
		
418	419	420
		
421	422 and 423	
		

Table 37b. Chemical name, NMR chemical shifts, chiral separation conditions and LCMS signal for compounds listed in Table 37a.

5

Example: Name	Chiral separation conditions, peak identification and analytical data
415: (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	Chiral separation was achieved by chiral SFC column chromatography (Column OD-H 21x250mm 30% MeOH + 20 mM NH ₄ OH in CO ₂ , flow 80 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-

	<p>((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(1-methyl-1H-indol-6-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>415: Peak 2: (11 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.7 Hz, 1H), 8.08 (d, <i>J</i> = 1.1 Hz, 1H), 7.80 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.70 (d, <i>J</i> = 8.3 Hz, 1H), 7.54 (d, <i>J</i> = 5.7 Hz, 1H), 7.19 (d, <i>J</i> = 3.1 Hz, 1H), 6.54 (dd, <i>J</i> = 3.0, 0.9 Hz, 1H), 5.96 (s, 1H), 5.35 (s, 1H), 4.96 – 4.81 (m, 1H), 4.55 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 4.38 (dd, <i>J</i> = 9.3, 8.4 Hz, 1H), 3.88 (s, 4H), 3.19 (s, 1H), 2.63 (s, 8H), 1.80 (d, <i>J</i> = 6.7 Hz, 1H), 0.96 (d, <i>J</i> = 6.4 Hz, 3H). HRMS(B) <i>m/z</i> 449.1812 RT = 2.18 min.</p>
<p>416: (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IA-H 21x250mm 15% MeOH in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-4-((R)-1-hydroxyethyl)-3-(2-(((R)-1-(3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one and (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one</p> <p>416: Peak 2 (62 mg) : (CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 8.02 (dt, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.95 (dt, <i>J</i> = 2.3, 1.3 Hz, 1H), 7.67 – 7.46 (m, 2H), 7.40 (ddt, <i>J</i> = 8.3, 2.5, 1.1 Hz, 1H), 5.90 (s, 1H), 5.40 (s, 1H), 4.86 (ddd, <i>J</i> = 8.4, 4.7, 2.5 Hz, 1H), 4.55 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 4.41 (t, <i>J</i> = 8.9 Hz, 1H), 3.90 (s, 1H), 3.52 (s, 1H), 2.77 (s, 1H), 1.86 – 1.77 (m, 3H), 1.34 – 1.19 (m, 1H), 1.03 (s, 3H). HRMS(B) <i>m/z</i> 480.1369. RT = 2.67 min. Chiral RT = 4.80 min</p>
<p>417: (R)-3-(2-(((S)-1-(3-(1,2-dimethyl-1H-indol-4-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IA 21x250mm 40% MeOH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(1,2-dimethyl-1H-indol-4-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(1,2-dimethyl-1H-indol-4-yl)-1,2,4-oxadiazol-5-</p>

	<p>yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one.</p> <p>417: Peak 2 (120 mg) : (CDCl₃) δ 8.16 (d, <i>J</i> = 6.2 Hz, 1H), 7.89 (dd, <i>J</i> = 7.5, 0.9 Hz, 1H), 7.63 (d, <i>J</i> = 6.2 Hz, 1H), 7.45 (dt, <i>J</i> = 8.1, 1.0 Hz, 1H), 7.34 – 7.21 (m, 1H), 6.95 – 6.85 (m, 1H), 5.47 – 5.19 (m, 1H), 1.91 – 1.79 (m, 3H), 4.81 (ddd, <i>J</i> = 8.3, 4.3, 2.4 Hz, 1H), 4.52 (dd, <i>J</i> = 9.5, 2.4 Hz, 1H), 4.35 (dd, <i>J</i> = 9.5, 8.3 Hz, 1H), 3.75 (s, 4H), 3.52 (s, 2H), 2.51 (d, <i>J</i> = 1.0 Hz, 3H), 0.86 (d, <i>J</i> = 5.5 Hz, 3H). HRMS(B) <i>m/z</i> 463.1968. RT= 2.23 min. Chiral RT = 3.35 min</p>
<p>418: (R)-3-(2-(((S)-1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column AD-H 21x250mm 15% MeOH + 10 mM NH₄OH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-chloro-3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>418: Peak 2 (120 mg) : CDCl₃) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 8.05 (p, <i>J</i> = 1.4 Hz, 1H), 7.98 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.70 – 7.49 (m, 2H), 5.74 (s, 1H), 5.51 – 5.35 (m, 1H), 4.85 (ddd, <i>J</i> = 8.3, 4.8, 2.5 Hz, 1H), 4.54 (dd, <i>J</i> = 9.3, 2.5 Hz, 1H), 4.41 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 2.72 (s, 1H), 1.79 (d, <i>J</i> = 7.1 Hz, 3H), 1.63 (d, <i>J</i> = 7.1 Hz, 2H), 1.05 (s, 3H). HRMS(B) <i>m/z</i> 515.1243. Chiral RT = 4.20 min</p>
<p>419: (R)-3-(2-(((S)-1-(3-(4-chloro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IA 21x250mm 30% MeOH in CO₂, flow 75 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-chloro-3-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-chloro-3-methylphenyl)-1,2,4-oxadiazol-5-</p>


	<p>yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>419: Peak 2 (92 mg) (CDCl₃) δ 8.20 (d, <i>J</i> = 6.0 Hz, 1H), 7.95 (d, <i>J</i> = 2.1 Hz, 1H), 7.83 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.61 (d, <i>J</i> = 6.0 Hz, 1H), 7.47 (d, <i>J</i> = 8.3 Hz, 1H), 5.33 (d, <i>J</i> = 7.1 Hz, 1H), 4.84 (ddd, <i>J</i> = 8.4, 4.7, 2.4 Hz, 1H), 1.89 – 1.74 (m, 3H), 4.56 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.41 (dd, <i>J</i> = 9.4, 8.3 Hz, 1H), 3.74 (d, <i>J</i> = 41.0 Hz, 1H), 3.52 (s, 1H), 2.46 (s, 3H), 1.12 – 0.85 (m, 3H). HRMS(B) <i>m/z</i> 411.1365. Chiral RT = 2.85 min</p>
<p>420: (R)-3-(2-(((S)-1-(3-(4-bromo-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IA 21x250mm 30% MeOH in CO₂, flow 90 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(4-bromo-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(4-bromo-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>420: Peak 2 (96 mg) (CDCl₃) δ 8.22 (d, <i>J</i> = 6.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.1 Hz, 1H), 7.63 – 7.52 (m, 3H), 5.37 (s, 1H), 4.84 (ddd, <i>J</i> = 8.3, 4.7, 2.4 Hz, 1H), 1.91 – 1.72 (m, 3H), 4.55 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 4.41 (t, <i>J</i> = 8.9 Hz, 1H), 4.00 (s, 3H), 3.52 (s, 1H), 1.02 (s, 3H). HRMS(B) <i>m/z</i> 504.0757. Chiral RT = 3.50 min</p>
<p>421: (R)-3-(2-(((S)-1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column IA-H 21x250mm 15% MeOH in CO₂, flow 80 g/min, 238 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>

	<p>421: Peak 2 (62 mg) : (CDCl₃) δ 8.25 (d, J = 5.7 Hz, 1H), 8.08 (t, J = 1.8 Hz, 1H), 7.87 (dt, J = 7.6, 1.4 Hz, 1H), 7.66 – 7.51 (m, 1H), 7.43 (t, J = 7.8 Hz, 1H), 5.92 – 5.68 (m, 1H), 5.35 (d, J = 9.3 Hz, 1H), 4.86 (ddd, J = 8.4, 4.4, 2.4 Hz, 1H), 1.74 – 1.64 (m, 1H), 4.55 (dd, J = 9.5, 2.5 Hz, 1H), 4.39 (dd, J = 9.4, 8.3 Hz, 1H), 3.51 (d, J = 5.3 Hz, 3H), 3.00 (d, J = 4.9 Hz, 1H), 1.79 (d, J = 7.2 Hz, 3H), 1.38 (s, 9H), 1.08 (q, J = 5.5 Hz, 1H), 1.00 (s, 3H). HRMS(B) m/z 452.2172. RT = 2.88 min. Chiral RT = 5.20 min</p>
<p>422 and 423: (R)-3-(2-(((R)-1-(3-(2,3-dihydro-1H-inden-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p>	<p>Chiral separation was achieved by chiral SFC column chromatography (Column ID 21x250mm 40% IPA + 10 mM NH₄OH in CO₂, flow 75 g/min, 222 nm UV collection) to give (R)-3-(2-(((R)-1-(3-(2,3-dihydro-1H-inden-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(3-(2,3-dihydro-1H-inden-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one</p> <p>422: First eluted product (15 mg) : ¹H NMR (400 MHz, CDCl₃) δ 8.24 (d, J = 5.8 Hz, 1H), 7.89 (d, J = 1.7 Hz, 1H), 7.81 (dd, J = 7.8, 1.7 Hz, 1H), 7.50 (d, J = 5.7 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 5.81 (s, 1H), 5.27 (d, J = 43.6 Hz, 1H), 4.70 (d, J = 7.9 Hz, 1H), 4.49 (dd, J = 9.3, 2.4 Hz, 1H), 4.42 – 4.09 (m, 2H), 3.51 (d, J = 3.1 Hz, 3H), 3.23 (s, 1H), 2.98 (t, J = 7.4 Hz, 4H), 2.14 (p, J = 7.5 Hz, 2H), 1.78 (d, J = 7.0 Hz, 3H), 1.75 – 1.62 (m, 0H), 1.21 (dd, J = 14.9, 6.3 Hz, 4H), 1.14 (d, J = 5.5 Hz, 1H). HRMS(D) m/z 437.1944 (M+H). RT = 3.57 min. Chiral RT = 2.35 min.</p> <p>423: Second eluted product (63 mg) : ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, J = 5.7 Hz, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.83 (dd, J = 7.8, 1.6 Hz, 1H), 7.54 (d, J = 5.7 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 5.79 (s, 1H), 5.32 (s, 1H), 4.85 (ddd, J = 8.4, 4.5, 2.5 Hz, 1H), 4.55 (dd, J = 9.5, 2.5 Hz, 1H), 4.39 (t, J = 8.9 Hz, 1H), 3.75 (d, J = 49.5 Hz, 1H), 3.51 (s, 1H), 2.97 (t, J = 7.4 Hz, 5H), 2.13 (p, J = 7.5 Hz, 2H), 1.78 (d, J = 7.2</p>

	Hz, 3H), 1.63 (s, 1H), 1.23 (d, $J = 6.1$ Hz, 1H), 0.98 (d, $J = 7.1$ Hz, 4H). HRMS(D) m/z 437.1942 (M+H). RT = 3.58 min. Chiral RT = 3.50 min.
--	---

Example 424 and 425

(4R)-3-(2-((1-(5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one



5

A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (150 mg, 0.529 mmol), 1-[3-(4-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamine (118 mg, 0.529 mmol, 1.0 equiv), and DIEA (0.185 mL, 1.059 mmol, 2.0 equiv) in DMSO (2 mL) was heated at 110 °C for 120 min. The reaction mixture was diluted with EtOAc (20 mL) and washed with water (10 mL), 4% brine (10 mL), concentrated *in vacuo*. The crude material, (R)-5-((R)-1-tert-Butoxy-ethyl)-1-(2-{1-[3-(4-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-pyrimidin-4-yl)-imidazolidin-2-one, was carried to the next step without further purification.

(R)-5-((R)-1-tert-Butoxy-ethyl)-1-(2-{1-[3-(4-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-ethylamino}-pyrimidin-4-yl)-imidazolidin-2-one (200 mg, 0.411 mmol) was treated with 10:1 TFA/water (10 ml) for 2 hours. The reaction was conc. *in vacuo* and neutralized by passing through a column of MP-carbonate eluting with MeOH/DCM/MeOH and Flash column (silica, 15 μ , 40 g) eluting w/ 5-60% EtOAc/heptane over 2.5 hours to give (R)-3-(2-(((R)-1-(5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one and (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one

424: first eluted product (45 mg, 50.8%). HRMS m/z 430.1156.


425: Second eluted product (46 mg, 52.0%). ^1H NMR (400 MHz, CDCl_3) δ 8.67 (s, 1H), 8.09

(dq, $J = 8.4, 2.0, 1.6$ Hz, 3H), 7.64 (d, $J = 6.4$ Hz, 1H), 7.58 – 7.48 (m, 2H), 5.48 – 5.27 (m, 1H), 4.94 (t, $J = 6.6$ Hz, 1H), 4.63 – 4.40 (m, 2H), 1.13 (d, $J = 6.5$ Hz, 3H), 0.89 (d, $J = 7.1$ Hz, 0H), 1.83 – 1.72 (m, 3H). HRMS m/z 430.1156.

25

Example 426

(S)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one



- 5 A mixture of (S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (23.35 mg, 0.089 mmol), (S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (30 mg, 0.116 mmol) and Huenig's base (0.047 mL, 0.268 mmol) in DMSO (0.6 mL) under argon atmosphere was heated at 80 °C for ~16 hr. The mixture was diluted with DMSO and water, filtered through a syringe filter and purified by reverse phase HPLC. Selected fractions
10 were collected and lyophilized providing (S)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one as its trifluoroacetic acid salt (30.2 mg) as a white solid.


¹H NMR (400 Mhz, CD₃OD) δ ppm 9.07 (br. s., 1 H), 8.24 (d, J=6.3 Hz, 1 H), 7.85 (s, 1 H), 7.53 - 7.72 (m, 5 H), 5.64 - 6.06 (m, 1 H), 5.36 (q, J=6.9 Hz, 1 H), 5.07 - 5.23 (m, 1 H), 4.41 - 4.62
15 (m, 2 H), 2.62 - 2.90 (m, 1 H), 1.71 (d, J=6.7 Hz, 3 H), 0.97 (d, J=7.0 Hz, 3 H);
LCMS *m/z* 463.2 (M + H)⁺, Rt 0.64 min.

The following Example was prepared using a method similar to that described for the preparation of **Example 426**.

20

Example 427

(S)-4-((R)-1,1-difluoropropan-2-yl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



- 25 ¹H NMR (400 Mhz, CD₃OD) δ ppm 9.13 (s, 1 H), 8.25 (d, J=6.7 Hz, 1 H), 7.86 (s, 1 H), 7.61 - 7.73 (m, 3 H), 7.36 (m, J=8.6, 8.6 Hz, 2 H), 5.69 - 6.06 (m, 1 H), 5.37 (q, J=6.7 Hz, 1 H), 5.10 -
















5.18 (m, 1 H), 4.46 - 4.59 (m, 2 H), 2.67 - 2.82 (m, 1 H), 1.72 (d, J=7.0 Hz, 3 H), 0.98 (d, J=7.4 Hz, 3 H)

LCMS m/z 447.2 (M + H)⁺, Rt 0.57 min.

- 5 The Examples in **Table 38a** were prepared using methods similar to those described for the preparation of **Examples 385 and 403**.

Table 38a.

428	429	430
431	432	433
434	435	436
437	438	439
440	441	442

		
443	444	445
		
446	447	448
		
449	450	451
		
452	453	454
		
455	456	457












		
458	459	460
		
461	462	463
		
464	465	
		

Table 38b. Chemical name, NMR chemical shifts, chiral separation conditions and LCMS signal for compounds listed in Table 38a.

Example: Name	¹ H NMR (400 MHz) δ ppm	LCMS
428: (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one	(CDCl ₃) 11.13 (d, J=5.9 Hz, 1 H), 8.84 (d, J=5.0 Hz, 1 H), 8.17 (s, 1 H), 8.06 (d, J=7.0 Hz, 1 H), 7.89 - 7.96 (m, 2 H), 7.80 (s, 1 H), 5.34 - 5.44 (m, 1 H), 4.81 - 4.90 (m, 1 H),	LCMS (B) <i>m/z</i> 483.1; Rt = 0.79 min.

	4.66 - 4.78 (m, 2 H), 4.59 - 4.65 (m, 1 H), 4.47 - 4.55 (m, 1 H), 1.83 (d, J=7.0 Hz, 3 H), 1.21 - 1.32 (m, 3 H)	
429: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.22 (d, J=2.9 Hz, 1 H), 7.75 (d, J=1.2 Hz, 1 H), 7.44 (d, J=8.9 Hz, 2 H), 7.30 (d, J=8.9 Hz, 2 H), 7.11 (s, 1H), 5.57 (d, J=7.7 Hz, 1 H), 5.02 - 5.14 (m, 1 H), 4.75 - 4.89 (m, 1 H), 4.56 - 4.64 (m, 2 H), 4.43 - 4.53 (m, 2 H), 1.61 (d, J=6.8 Hz, 3 H)	LCMS (B) <i>m/z</i> 435.1; Rt = 0.62 min.
430: (R)-3-(5-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.62 (d, J=3.9 Hz, 1 H), 8.14 - 8.21 (m, 1 H), 7.48 (dd, J=8.9, 4.4 Hz, 3 H), 7.24 - 7.34 (m, 2 H), 5.38 (br. s., 1 H), 4.88 - 5.03 (m, 1 H), 4.42 - 4.73 (m, 4 H), 1.75 (t, J=6.3 Hz, 3 H)	LCMS (B) <i>m/z</i> 419.2; Rt = 0.57 min.
431: (R)-3-(2-(((S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.63 (br. s., 1 H), 8.17 (d, J=3.3 Hz, 1 H), 7.36 - 7.52 (m, 4 H), 5.36 (br. s., 1 H), 4.94 (d, J=18.7 Hz, 1 H), 4.43 - 4.74 (m, 4 H), 1.74 (d, J=7.1 Hz, 3 H)	LCMS (B) <i>m/z</i> 437.2; Rt = 0.59 min.
432: (R)-3-(2-(((S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.57 (s, 1 H), 8.18 (d, J=1.9 Hz, 1 H), 7.63 (t, J=7.6 Hz, 1 H), 7.48 (br. s., 1 H), 7.35 (d, J=8.5 Hz, 1 H), 7.24 - 7.29 (m, 1 H), 5.33 (d, J=5.3 Hz, 1 H), 4.84 - 4.98 (m, 1 H), 4.54 - 4.74 (m, 3 H), 4.48 (t, J=7.5 Hz, 1 H), 1.73 (d, J=6.5 Hz, 3 H)	LCMS (B) <i>m/z</i> 453.1; Rt = 0.64 min.
433: (R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.56 (s, 1 H), 8.18 (d, J=1.9 Hz, 1H), 7.57 - 7.63 (m, 1 H), 7.33 - 7.48 (m, 3 H), 5.34 (br.	LCMS (B) <i>m/z</i> 453.1; Rt = 0.64

(fluoromethyl)oxazolidin-2-one	s., 1 H), 4.85 - 5.00 (m, 1 H), 4.41 - 4.75 (m, 4 H), 1.73 (d, J=7.0 Hz, 3 H)	min.
434: (R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)phenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.67 (s, 1 H), 8.17 (d, J=3.3 Hz, 1 H), 7.76 (d, J=8.3 Hz, 2 H), 7.60 (d, J=8.4 Hz, 2 H), 7.51 - 7.57 (m, 1 H), 6.58 - 6.90 (m, 1 H), 5.38 (d, J=6.5 Hz, 1 H), 4.86 - 5.01 (m, 1 H), 4.41 - 4.75 (m, 4 H), 1.75 (d, J=7.1 Hz, 3 H)	LCMS (B) <i>m/z</i> 451.2; Rt = 0.61 min.
435: (R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.60 (d, J=1.1 Hz, 1 H), 8.17 (d, J=3.3 Hz, 1 H), 7.84 (t, J=7.8 Hz, 1 H), 7.53 (d, J=4.0 Hz, 1 H), 7.41 (d, J=8.3 Hz, 1 H), 7.35 (d, J=9.7 Hz, 1 H), 6.78 - 7.10 (m, 1 H), 5.33 (d, J=6.4 Hz, 1 H), 4.85 - 4.99 (m, 1 H), 4.42 - 4.73 (m, 4 H), 1.73 (d, J=7.1 Hz, 3 H)	LCMS (B) <i>m/z</i> 469.2; Rt = 0.63 min.
436: (R)-3-(2-(((S)-1-(1-(3,5-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.63 (s, 1 H), 8.16 (dd, J=3.3, 2.0 Hz, 1 H), 7.51 (br. s., 1 H), 7.09 (d, J=6.6 Hz, 2 H), 6.97 - 7.05 (m, 1 H), 5.35 (d, J=6.4 Hz, 1 H), 4.40 - 4.93 (m, 5 H), 1.73 (d, J=7.0 Hz, 3 H)	LCMS (B) <i>m/z</i> 437.1; Rt = 0.59 min.
437: (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.13 (d, J=3.9 Hz, 1 H), 7.69 (d, J=8.4 Hz, 2 H), 7.46 (d, J=8.4 Hz, 2 H), 6.57 (s, 1 H), 5.18 (d, J=7.1 Hz, 1 H), 4.93 - 5.08 (m, 1 H), 4.64 - 4.72 (m, 1 H), 4.55 (dd, J=8.7, 7.2 Hz, 1 H), 4.27 - 4.52 (m, 2 H), 1.71 (d, J=7.1 Hz, 3 H)	LCMS (B) <i>m/z</i> 436.1; Rt = 0.91 min.
438: (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-5-	(CDCl ₃) 8.18 (d, J=3.5 Hz, 1 H), 7.89 (s, 1 H), 7.75 - 7.80 (m, 2 H),	LCMS (B) <i>m/z</i> 452.1;

fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	7.44 - 7.50 (m, 2 H), 5.28 (d, J=6.6 Hz, 1 H), 4.80 - 4.93 (m, 1 H), 4.68 (t, J=8.9 Hz, 1 H), 4.42 - 4.49 (m, 1 H), 4.16 - 4.41 (m, 2 H), 1.77 (d, J=7.0 Hz, 3 H)	Rt = 0.93 min.
439: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.13 (d, J=3.1 Hz, 1 H), 7.58 - 7.63 (m, 2 H), 7.31 - 7.37 (m, 2 H), 7.14 - 7.18 (m, 1 H), 5.41 (br. s., 1 H), 4.77 - 4.96 (m, 1 H), 4.46 - 4.72 (m, 4 H), 2.60 (s, 3 H), 1.70 (d, J=6.9 Hz, 3 H)	LCMS (B) <i>m/z</i> 449.2; Rt = 0.65 min.
440: (R)-3-(5-fluoro-2-(((S)-1-(2-(2-(trifluoromethyl)pyridin-4-yl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.85 (d, J=5.1 Hz, 1 H), 8.20 (d, J=3.5 Hz, 1 H), 8.16 (s, 1 H), 7.92 - 7.96 (m, 1 H), 7.90 (s, 1 H), 5.36 (d, J=7.0 Hz, 1 H), 4.78 - 4.91 (m, 1 H), 4.24 - 4.72 (m, 4 H), 1.79 (d, J=6.9 Hz, 3 H)	LCMS (B) <i>m/z</i> 487.1; Rt = 0.86 min.
441: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.88 (d, J=6.0 Hz, 1 H), 8.19 (d, J=3.0 Hz, 1 H), 7.76 (d, J=6.2 Hz, 1 H), 7.72 (s, 1 H), 7.21 - 7.33 (m, 2 H), 5.19 - 5.30 (m, 1 H), 4.78 (br. s., 1 H), 4.64 (t, J=8.8 Hz, 1 H), 4.41 - 4.49 (m, 1 H), 4.09 - 4.37 (m, 2 H), 2.90 (s, 3 H), 1.63 (d, J=6.9 Hz, 3 H)	LCMS (B) <i>m/z</i> 462.2; Rt = 0.60 min.
442: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(6-methylpyridin-3-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 9.01 (s, 1 H), 8.33 (d, J=8.2 Hz, 1 H), 8.17 (d, J=3.2 Hz, 1 H), 7.67 (d, J=8.3 Hz, 1 H), 7.21 - 7.29 (m, 2 H), 5.18 - 5.29 (m, 1 H), 4.06 - 4.83 (m, 5 H), 2.89 (s, 3 H), 1.62 (d, J=7.0 Hz, 3 H)	LCMS (B) <i>m/z</i> 462.1; Rt = 0.61 min.
443: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.89 (s, 1 H), 8.15 (dd, J=3.7, 1.2 Hz, 1 H), 8.06 (d, J=8.2 Hz, 1 H), 7.82 (d, J=8.2 Hz, 1 H), 7.17 - 7.30 (m, 2 H), 5.28 (d, J=5.7	LCMS (B) <i>m/z</i> 516.1; Rt = 0.97 min.

	Hz, 1 H), 4.77 - 4.90 (m, 1 H), 4.67 (t, J=8.8 Hz, 1 H), 4.49 (t, J=7.8 Hz, 1 H), 4.07 - 4.29 (m, 2 H), 1.66 (d, J=6.7 Hz, 3 H)	
444: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.85 (d, J=5.0 Hz, 1 H), 8.15 (dd, J=3.4, 2.4 Hz, 1 H), 7.84 (s, 1 H), 7.67 (d, J=4.9 Hz, 1 H), 7.21 - 7.33 (m, 2 H), 5.28 (br. s., 1 H), 4.81 (d, J=14.6 Hz, 1 H), 4.67 (t, J=8.8 Hz, 1 H), 4.45 - 4.53 (m, 1 H), 4.07 - 4.33 (m, 2 H), 1.63 - 1.68 (m, 3 H)	LCMS (B) <i>m/z</i> 516.0; Rt = 0.96 min.
445: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one	(CDCl ₃) 8.82 (s, 1 H), 8.18 (d, J=3.1 Hz, 1 H), 7.39 (dd, J=10.3, 6.0 Hz, 1 H), 7.27 - 7.30 (m, 1 H), 7.11 (s, 1 H), 5.19 - 5.28 (m, 1 H), 4.74 (br. s., 1 H), 4.64 (t, J=8.6 Hz, 1 H), 4.39 - 4.47 (m, 1 H), 4.13 - 4.32 (m, 2 H), 2.49 (s, 3 H), 1.63 (d, J=7.0 Hz, 3 H)	LCMS (B) <i>m/z</i> 451.1; Rt = 0.58 min.
446: (R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 8.72 (s, 1 H), 8.18 (d, J=3.1 Hz, 1 H), 7.79 - 7.91 (m, 1 H), 7.61 (br. s., 1 H), 7.33 - 7.48 (m, 2 H), 6.94 (t, J=54.0 Hz, 1 H), 5.34 (d, J=6.7 Hz, 1 H), 4.71 - 5.05 (m, 2 H), 4.55 - 4.65 (m, 1 H), 4.50 (dd, J=8.4, 6.5 Hz, 1 H), 1.74 (d, J=7.0 Hz, 3 H), 1.33 (dd, J=23.5, 6.7 Hz, 3 H)	LCMS <i>m/z</i> 483.0 (M + H) ⁺ , Rt 0.68 min; HPLC 2.801 min.
447: (R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)phenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 8.81 (s, 1 H), 8.18 (d, J=3.1 Hz, 1 H), 7.76 (d, J=8.2 Hz, 2 H), 7.62 (d, J=8.2 Hz, 2 H), 6.74 (t, J=56.0 Hz, 1 H), 5.38 (q, J=6.7 Hz, 1 H), 4.73 - 5.06 (m, 2 H), 4.59 (t, J=8.8 Hz, 1 H), 4.45 - 4.53 (m, 1 H), 1.76 (d, J=7.0 Hz, 3 H), 1.34	LCMS <i>m/z</i> 465.0 (M + H) ⁺ , Rt 0.65 min; HPLC 2.624 min.

	(dd, $J=23.5$, 6.3 Hz, 3 H).	
448: (R)-3-(2-(((S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 8.73 (s, 1 H), 8.18 (d, $J=3.1$ Hz, 1 H), 7.64 (t, $J=8.0$ Hz, 1 H), 7.57 (br. s., 1 H), 7.29 - 7.44 (m, 2 H), 5.34 (d, $J=6.7$ Hz, 1 H), 4.73 - 4.87 (m, 1 H), 4.59 (t, $J=8.8$ Hz, 1 H), 4.45 - 4.53 (m, 1 H), 1.74 (d, $J=7.0$ Hz, 3 H), 1.33 (dd, $J=23.1$, 6.3 Hz, 3 H)	LCMS m/z 467.0 (M + H) ⁺ , Rt 0.69 min; HPLC 2.847 min.
449: (R)-3-(2-(((S)-1-(1-(3,5-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 8.58 (s, 1 H), 8.18 (d, $J=2.7$ Hz, 1 H), 7.53 (br. s., 1 H), 7.09 (d, $J=5.1$ Hz, 2 H), 7.00 (t, $J=8.4$ Hz, 1 H), 5.29 - 5.36 (m, 1 H), 5.00 (br. s., 1 H), 4.87 (br. s., 1 H), 4.70 - 4.83 (m, 1 H), 4.54 - 4.64 (m, 1 H), 4.46 - 4.53 (m, 1 H), 1.73 (d, $J=7.0$ Hz, 3 H), 1.33 (dd, $J=23.1$, 6.3 Hz, 3 H).	LCMS m/z 451.1 (M + H) ⁺ , Rt 0.64 min; HPLC 2.132 min.
450: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 8.64 (s, 1 H), 8.18 (d, $J=3.1$ Hz, 1 H), 7.57 (d, $J=8.6$ Hz, 2 H), 7.51 (br. s., 1 H), 7.44 (d, $J=8.6$ Hz, 2 H), 5.35 (d, $J=6.7$ Hz, 1 H), 5.01 (br. s., 1 H), 4.89 (br. s., 1 H), 4.71 - 4.86 (m, 1 H), 4.54 - 4.64 (m, 1 H), 4.44 - 4.53 (m, 1 H), 1.74 (d, $J=7.0$ Hz, 3 H), 1.33 (dd, $J=23.5$, 6.7 Hz, 3 H).	LCMS m/z 449.0 (M + H) ⁺ , Rt 0.67 min; HPLC 2.354 min.
451: (R)-3-(5-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 8.61 (s, 1 H), 8.18 (d, $J=2.7$ Hz, 1 H), 7.48 (dd, $J=8.4$, 4.1 Hz, 3 H), 7.28 - 7.34 (m, 2 H), 5.35 (d, $J=6.7$ Hz, 1 H), 4.70 - 4.85 (m, 1 H), 4.54 - 4.62 (m, 1 H), 4.45 - 4.53 (m, 1 H), 1.75 (d, $J=7.0$ Hz, 3 H), 1.33 (dd, $J=23.1$, 6.3 Hz, 3 H).	LCMS m/z 433.1 (M + H) ⁺ , Rt 0.61 min; HPLC 1.997 min.
452: (R)-3-(2-(((S)-1-(5-(4-	(CDCl ₃) 8.11 (d, $J=3.5$ Hz, 1 H),	LCMS m/z

chlorophenyl)isoxazol-3-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	7.69 (d, $J=8.6$ Hz, 2 H), 7.46 (d, $J=8.6$ Hz, 2 H), 6.54 (s, 1 H), 5.17 (d, $J=5.1$ Hz, 1 H), 4.69 - 4.92 (m, 2 H), 4.51 - 4.65 (m, 2 H), 1.70 (d, $J=7.0$ Hz, 3 H), 1.30 (dd, $J=23.1, 6.3$ Hz, 3 H).	450.0 (M + H) ⁺ , Rt 0.96 min; HPLC 4.131 min.
453: (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 8.14 (d, $J=3.5$ Hz, 1 H), 7.94 (s, 1 H), 7.68 (s, 1 H), 7.59 (d, $J=8.6$ Hz, 2 H), 7.43 (d, $J=8.6$ Hz, 2 H), 5.08 (q, $J=6.7$ Hz, 1 H), 4.65 - 4.87 (m, 2 H), 4.59 (t, $J=8.8$ Hz, 1 H), 4.47 - 4.55 (m, 1 H), 1.66 (d, $J=7.0$ Hz, 3 H), 1.22 (dd, $J=23.5, 6.7$ Hz, 3 H).	LCMS m/z 449.0 (M + H) ⁺ , Rt 0.92 min; HPLC 3.864 min.
454: (R)-3-(2-(((S)-1-(1-(3,5-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 10.92 (d, $J=6.7$ Hz, 1 H), 8.30 (br. s., 1 H), 7.99 (d, $J=6.7$ Hz, 1 H), 7.88 (d, $J=7.0$ Hz, 1 H), 7.57 (br. s., 1 H), 6.92 - 7.11 (m, 3 H), 5.48 (d, $J=6.3$ Hz, 1 H), 4.84 - 5.14 (m, 2 H), 4.59 - 4.70 (m, 1 H), 4.48 - 4.57 (m, 1 H), 1.69 (d, $J=6.7$ Hz, 3 H), 1.34 (dd, $J=23.5, 5.9$ Hz, 3 H).	LCMS m/z 433.2 (M + H) ⁺ , Rt 0.59 min; HPLC 1.946 min.
455: (R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 10.91 (d, $J=7.0$ Hz, 1 H), 8.24 (br. s., 1 H), 7.98 (d, $J=6.7$ Hz, 1 H), 7.88 (d, $J=7.0$ Hz, 1 H), 7.82 (t, $J=7.4$ Hz, 1 H), 7.58 (br. s., 1 H), 7.30 - 7.43 (m, 2 H), 6.94 (dt, $J=55.6, 1.0$ Hz, 1 H), 5.44 (br. s., 1 H), 4.80 - 5.22 (m, 2 H), 4.64 (d, $J=9.0$ Hz, 1 H), 4.54 (t, $J=8.8$ Hz, 1 H), 1.71 (d, $J=6.3$ Hz, 3 H), 1.36 (dd, $J=23.5, 6.3$ Hz, 3 H).	LCMS m/z 465.2 (M + H) ⁺ , Rt 0.63 min; HPLC 2.191 min.
456: (R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)phenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-	(CDCl ₃) 11.00 (d, $J=7.0$ Hz, 1 H), 8.46 (s, 1 H), 7.99 (d, $J=7.0$ Hz, 1 H), 7.90 (d, $J=7.0$ Hz, 1 H), 7.75	LCMS m/z 447.3 (M + H) ⁺ , Rt 0.58


fluoroethyl)oxazolidin-2-one	(d, $J=8.2$ Hz, 2 H), 7.66 (s, 1 H), 7.59 (d, $J=8.2$ Hz, 2 H), 6.74 (t, $J=55.6$ Hz, 1 H), 5.58 (t, $J=6.8$ Hz, 1 H), 4.91 - 5.14 (m, 2 H), 4.60 - 4.68 (m, 1 H), 4.49 - 4.59 (m, 1 H), 1.72 (d, $J=6.7$ Hz, 3 H), 1.36 (dd, $J=23.5, 6.3$ Hz, 3 H).	min; HPLC 1.898 min.
457: (R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 10.97 (d, $J=7.4$ Hz, 1 H), 8.33 (s, 1 H), 7.99 (d, $J=6.7$ Hz, 1 H), 7.90 (d, $J=7.0$ Hz, 1 H), 7.50 - 7.65 (m, 2 H), 7.37 (d, $J=5.9$ Hz, 2 H), 5.53 (t, $J=6.7$ Hz, 1 H), 4.87 - 5.19 (m, 2 H), 4.60 - 4.70 (m, 1 H), 4.44 - 4.59 (m, 1 H), 1.71 (d, $J=6.7$ Hz, 3 H), 1.36 (dd, $J=23.5, 5.9$ Hz, 3 H).	LCMS m/z 449.1 (M + H) ⁺ , Rt 0.63 min; HPLC 2.193 min.
458: (R)-3-(2-(((S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 10.94 (d, $J=7.0$ Hz, 1 H), 8.27 (s, 1 H), 7.98 (d, $J=7.0$ Hz, 1 H), 7.88 (d, $J=6.7$ Hz, 1 H), 7.62 (t, $J=8.0$ Hz, 1 H), 7.55 (s, 1 H), 7.31 (dd, $J=9.0, 2.3$ Hz, 1 H), 7.23 (br. s., 1 H), 5.48 (t, $J=6.8$ Hz, 1 H), 4.83 - 5.19 (m, 2 H), 4.60 - 4.69 (m, 1 H), 4.46 - 4.58 (m, 1 H), 1.70 (d, $J=6.7$ Hz, 3 H), 1.35 (dd, $J=23.5, 6.3$ Hz, 3 H).	LCMS m/z 449.2 (M + H) ⁺ , Rt 0.64 min; HPLC 2.279 min.
459: (R)-3-(2-(((S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CDCl ₃) 10.96 (d, $J=7.0$ Hz, 1 H), 8.27 (s, 1 H), 7.98 (d, $J=7.0$ Hz, 1 H), 7.89 (d, $J=7.0$ Hz, 1 H), 7.53 (s, 1 H), 7.31 - 7.45 (m, 2 H), 5.51 (t, $J=6.7$ Hz, 1 H), 4.84 - 5.19 (m, 2 H), 4.60 - 4.72 (m, 1 H), 4.43 - 4.58 (m, 1 H), 1.70 (d, $J=6.7$ Hz, 3 H), 1.36 (dd, $J=23.5, 6.3$ Hz, 3 H).	LCMS m/z 433.2 (M + H) ⁺ , Rt 0.59 min; HPLC 1.870 min.
460: (R)-3-(2-(((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-	(CDCl ₃) 10.96 (d, $J=6.7$ Hz, 1 H), 7.99 (d, $J=7.0$ Hz, 1 H), 7.71 - 7.89	LCMS m/z 447.3 (M +

yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(m, 3 H), 7.20 (ddd, $J=14.6, 10.7, 6.1$ Hz, 2 H), 5.33 (quin, $J=6.7$ Hz, 1 H), 4.64 - 4.77 (m, 2 H), 4.52 - 4.64 (m, 2 H), 4.45 - 4.51 (m, 1 H), 3.99 (s, 3 H), 1.64 (d, $J=7.0$ Hz, 3 H), 1.23 (dd, $J=23.5, 6.7$ Hz, 3 H).	H) ⁺ , Rt 0.68 min; HPLC 2.612 min.
461: (R)-3-(5-fluoro-2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	(CD3OD) 9.32 (s, 1 H), 8.33 (d, $J=2.7$ Hz, 1 H), 7.94 (s, 1 H), 7.72 (dd, $J=9.0, 4.3$ Hz, 2 H), 7.37 (t, $J=8.4$ Hz, 2 H), 5.21 (q, $J=6.4$ Hz, 1 H), 4.78 - 4.95 (m, 2 H), 4.63 (t, $J=9.2$ Hz, 1 H), 4.41 (dd, $J=9.2, 4.5$ Hz, 1 H), 1.70 (d, $J=7.0$ Hz, 3 H), 1.12 - 1.29 (m, 3 H)	LCMS (B) m/z 433.1; Rt = 0.60 min.
462: (R)-3-(5-fluoro-2-(((S)-1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	(CD3OD) 8.74 - 8.84 (m, 2 H), 8.24 (br. s., 1 H), 8.14 (s, 1 H), 8.09 (dd, $J=10.8, 1.4$ Hz, 1 H), 7.97 (d, $J=4.7$ Hz, 1 H), 5.41 (d, $J=6.3$ Hz, 1 H), 4.75 - 4.94 (m, 2 H), 4.60 (t, $J=9.2$ Hz, 1 H), 4.41 (dd, $J=9.2, 4.9$ Hz, 1 H), 1.59 (d, $J=7.0$ Hz, 3 H), 1.04 (br. s., 3 H)	LCMS (B) m/z 513.2; Rt = 0.87 min
463: (R)-3-(2-(((S)-1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CD3OD) 8.87 (s, 1 H), 8.82 (d, $J=5.1$ Hz, 1 H), 8.15 - 8.27 (m, 3 H), 8.00 (d, $J=4.7$ Hz, 1 H), 7.81 (d, $J=6.7$ Hz, 1 H), 5.63 (d, $J=5.5$ Hz, 1 H), 4.75 - 5.02 (m, 2 H), 4.64 (dd, $J=9.0, 2.7$ Hz, 1 H), 4.48 - 4.58 (m, 1 H), 1.68 (d, $J=7.0$ Hz, 3 H), 1.21 - 1.46 (m, 3 H)	LCMS (B) m/z 495.2; Rt = 0.75 min
464: (R)-3-(2-(((S)-1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one	(CD3OD) 8.76 - 8.88 (m, 2 H), 8.11 - 8.25 (m, 3 H), 7.99 (d, $J=5.1$ Hz, 1 H), 7.67 (d, $J=4.7$ Hz, 1 H), 5.57 (d, $J=6.7$ Hz, 1 H), 5.10 (br. s., 1 H), 4.76 - 4.96 (m, 2 H), 4.47 - 4.62 (m, 2 H), 1.67 (d, $J=6.7$ Hz, 3	LCMS (B) m/z 495.2; Rt = 0.75 min

	H), 0.92 - 1.21 (m, 3 H)	
465: (R)-3-(5-fluoro-2-(((S)-1-(5-fluoro-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one	(CD ₃ OD) 8.73 - 8.86 (m, 2 H), 8.24 (br. s., 1 H), 8.16 (s, 1 H), 8.11 (d, <i>J</i> =11.0 Hz, 1 H), 7.98 (d, <i>J</i> =5.1 Hz, 1 H), 5.43(d, <i>J</i> =6.7 Hz, 1 H), 4.85 (s, 2 H), 4.61 (t, <i>J</i> =9.0 Hz, 1 H), 4.42 - 4.52 (m, 1 H), 1.58 (d, <i>J</i> =7.0 Hz, 3 H), 1.17 (d, <i>J</i> =19.2 Hz, 3 H)	LCMS (B) <i>m/z</i> 513.2; Rt = 0.95 min

Example 466

(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



5

Example 466 was prepared by a convergent route. Steps 1a - 1c give (S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine. Steps 2a - 2f give (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one. These intermediates were combined in Step 3 to give (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one.

10

Step 1a: To a solution of (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride (750 mg, 2.98 mmol) in DCM (30 mL) was added di-tert-butyl dicarbonate (0.761 mL, 3.28 mmol) and triethylamine (1.25 mL, 8.94 mmol). The resulting solution was stirred at r.t. overnight. Mixture was concentrated under reduced pressure and diluted with 40 mL EtOAc, washed with water, brine, dried over Na₂SO₄ and concentrated to give 940 mg of (S)-tert-butyl (1-(5-bromo-4-methylpyridin-2-yl)ethyl)carbamate as a light brown oil. MS *m/z* 317.2 (M + H). ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1H), 7.14 (s, 1H), 5.57 – 5.50 (m, 1H), 4.79 (p, *J* = 7.0 Hz, 1H), 2.40 (s, 3H), 1.47-1.43 (m, 12H).

15

Step 1b: N₂ was bubbled through a solution of (S)-tert-butyl (1-(5-bromo-4-methylpyridin-2-yl)ethyl)carbamate (200 mg, 0.635 mmol), (2-(trifluoromethyl)pyridin-4-yl)boronic acid (145 mg,

20

0.761 mmol) and Na_2CO_3 (2.0 M, 635 μl , 1.269 mmol) in dioxane for 5 min. $\text{Cl}_2\text{Pd}(\text{dppf})$ (CH_2Cl_2 adduct) (51.8 mg, 0.063 mmol) was added. The reaction mixture was stirred at 90 °C for 16 hr. The mixture was diluted with EtOAc, washed with water, brine, dried over Na_2SO_4 , filtered, concentrated and purified through flash column chromatography (0-100% EtOAc/Heptane) to give 200 mg (S)-tert-butyl (1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)carbamate as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.83 (d, J = 4.9 Hz, 1H), 8.36 (s, 1H), 7.66 (s, 1H), 7.51 - 7.42 (m, 1H), 7.21 (s, 1H), 5.60 (d, J = 7.7 Hz, 1H), 4.87 (p, J = 6.9 Hz, 1H), 2.30 (s, 3H), 1.48 (d, J = 6.9 Hz, 3H), 1.45 (s, 9H). MS m/z 382.3 (M + H).

Step 1c: To a solution of (S)-tert-butyl (1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)carbamate (200 mg, 0.524 mmol) in DCM (2 ml) at -78 °C was added trifluoroacetic acid (2 mL, 12.98 mmol). The solution was stirred at r.t. for 1 hr. The mixture was concentrated, diluted with 10 mL DCM and stirred with solid MP-carbonate to remove TFA. Filtered and concentrated to give 147 mg (S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine as a light brown sticky oil. MS m/z 282.1 (M + H). R_t = 0.85 min. (Column: XBridge C18 3.5 μm 2.1x50mm. Solvent A: 2% Acetonitrile, 3.75mM Ammonium Acetate, Water. Solvent B: Acetonitrile. Gradient: 5-95% B over 1.70 min. Flow rate: 2 mL/min.) The crude product was used to next step without further purification.

Step 2a: A solution of (2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-(tert-butoxy)butanoic acid dicyclohexylammonium salt (500 mg, 1.0 mmol) in 10 ml of THF and isobutyl chloroformate (167 mg, 1.2 mmol, 1.2 equiv) at -25°C was added N-methylmorpholine (124 mg, 1.2 mmol, 1.2 equiv), the mixture was stirred at same temperature for 10 min and filtered. The filtrate was cooled to -20°C and to it was added NaBH_4 , followed by 2 ml of water immediately afterwards. The reaction mixture was stirred at same temperature for 5 min. then gradually warmed to room temperature for 25 min, poured into water(10ml) and extracted with ethyl acetate (2x20ml). The combined organic phases were washed with water, brine and dried over Na_2SO_4 . The solvent was removed to yield benzyl ((2R)-(3R)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate as a clear oil. No further purification was required for next step. ^1H NMR (400 MHz, CDCl_3) δ 7.37 – 7.16 (m, 5H), 5.25 (d, J = 8.0 Hz, 1H), 5.02 (s, 1H), 4.04 (ddd, J = 12.0, 8.9, 2.8 Hz, 1H), 3.92 – 3.75 (m, 1H), 3.59 (dddd, J = 32.3, 14.6, 8.2, 4.3 Hz, 2H), 1.10 (s, 9H), 1.09 – 1.06 (m, 3H).

Step 2b: To a solution of benzyl ((2R,3R)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate (5.88 g, 19.9 mmol) in 100 mL DMF was added NaH (60% in mineral oil, 1.62 g, 40.6 mmol) at 0 °C. The reaction mixture was stirred for 30 min at 0 °C. To the reaction mixture were added 4-methoxybenzyl chloride (4.07 mL, 29.9 mmol) and tetrabutylammonium iodide (0.74 g, 1.99 mmol) and the resulting mixture was warmed to room temperature and stirred for 15.5 h. The

reaction mixture was poured into ice water (200 mL) forming a white suspension. EtOAc (100 mL) was added and the resulting mixture was stirred for 5 min to form a clear two layer solution. After separation, the aqueous phase was extracted with EtOAc (100 mL x 3). The combined organic solution was washed with brine (80 mL), dried over Na₂SO₄, filtered and concentrated.

5 Flash column chromatography (EtOAc/Heptane 0 to 70%) gave 5.90 g of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(4-methoxybenzyl)oxazolidin-2-one with minor impurities. Major product ¹H NMR (400 MHz, MeOD) δ 7.38 - 7.29 (m, 2H), 6.99 - 6.93 (m, 2H), 4.68 - 4.58 (m, 1H), 4.33 (dd, J = 9.3, 4.5 Hz, 1H), 4.27 - 4.17 (m, 2H), 3.89 (dd, J = 6.4, 4.8 Hz, 1H), 3.81 (s, 3H), 3.65 (dd, J = 9.0, 4.6 Hz, 1H), 1.09 (s, 9H), 1.02 (d, J = 6.3 Hz, 3H). MS m/z 308.2 (M + H).

10 Step 2c: A solution of (R)-4-((R)-1-(tert-butoxy)ethyl)-3-(4-methoxybenzyl)oxazolidin-2-one (5.90 g, 19.2 mmol) in CH₂Cl₂ (40 mL) was treated with TFA (40 mL) at room temperature for 20 min. The reaction mixture was concentrated in vacuo, then diluted with CH₂Cl₂ (~50 mL), and again concentrated. This procedure was repeated three times to remove TFA. Flash column chromatography (EtOAc/Heptane 30 ~ 100%) gave 3.81 g (R)-4-((R)-1-hydroxyethyl)-
15 3-(4-methoxybenzyl)oxazolidin-2-one. ¹H NMR (400 MHz, MeOD) δ 7.31 - 7.21 (m, 2H), 7.00 - 6.87 (m, 2H), 4.67 (d, J = 15.0 Hz, 1H), 4.34 - 4.18 (m, 3H), 3.95 (q, J = 6.2 Hz, 1H), 3.80 (s, 3H), 3.68 (dt, J = 8.7, 5.5 Hz, 1H), 1.09 (d, J = 6.4 Hz, 3H). MS m/z 252.2 (M + H).

Step 2d: To a cooled (0 °C) solution of (R)-4-((R)-1-hydroxyethyl)-3-(4-methoxybenzyl)oxazolidin-2-one (2.27 g, 9.04 mmol) in 30 mL MeCN were added triethylamine
20 (11.4 mL, 82 mmol) followed by perfluoro-1-butanefluoride (4.9 mL, 27.3 mmol) and NEt₃(HF)₃ (4.5 mL, 27.6 mmol) and the resulting mixture was stirred at 0 °C for 70 min. The reaction mixture was diluted with water (60 mL) and extracted with EtOAc (3 x 60 mL). Combined organics were washed with water (70 mL), brine (70 mL), dried over Na₂SO₄, filtered and concentrated. Flash column chromatography (EtOAc/heptane 5 to 70%) gave 2.19
25 g (R)-4-((S)-1-fluoroethyl)-3-(4-methoxybenzyl)oxazolidin-2-one. ¹H NMR (400 MHz, CDCl₃) δ 7.25 - 7.20 (m, 2H), 6.92 - 6.83 (m, 2H), 4.87 (d, J = 15.1 Hz, 1H), 4.75 (dq, J = 47.6, 6.6, 2.1 Hz, 1H), 4.26 (td, J = 9.2, 1.4 Hz, 1H), 4.17 - 4.05 (m, 2H), 3.81 (s, 3H), 3.71 (dddd, J = 19.8, 9.5, 5.8, 2.1 Hz, 1H), 1.29 (dd, J = 23.1, 6.2 Hz, 3H). MS m/z 254.5 (M + H).

Step 2e: A solution of (R)-4-((S)-1-fluoroethyl)-3-(4-methoxybenzyl)oxazolidin-2-one (1.98 g
30 7.8 mmol) in 40 mL TFA was heated at 65 °C for 16 h. The reaction mixture was concentrated to remove TFA. Flash column chromatography (EtOAc/CH₂Cl₂, 0 to 100%) gave 0.91 g (R)-4-((S)-1-fluoroethyl)-oxazolidin-2-one as a pale brown solid. TLC (1:2 heptane:EtOAc) R_f = 0.25. ¹H NMR (400 MHz, CDCl₃) δ 5.60 (br s, 1H), 4.72 - 4.54 (m, 1H), 4.51 (td, J = 8.9, 0.9 Hz, 1H), 4.32 (dd, J = 9.2, 4.8 Hz, 1H), 4.02 - 3.88 (m, 1H), 1.38 (dd, J = 24.0, 6.3 Hz, 3H).


Step 2f: To a cooled (0 °C) solution of 2,4-difluoropyrimidine (160 mg, 1.375 mmol) and (R)-4-((S)-1-fluoroethyl)oxazolidin-2-one (183 mg, 1.375 mmol) in DMF (Volume: 4.6 mL) was added NaH (60% in mineral oil, 66.0 mg, 1.650 mmol). The resulting mixture was stirred at 0 °C for 30 min and at room temperature for 2 hr. Desired product was observed from LC-MS.

- 5 The mixture was quenched with brine (1 ml). Diluted w/ EtOAc (20 ml) and water (10 ml), and separated layers. The organic was extracted with an additional 20 mL EtOAc. The combined organics were washed with brine, dried, and concentrated. Crude was purified through flash column chromatography (10-100% EtOAc/Heptane) to give 210 mg (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dd, J = 5.8, 2.1 Hz, 1H), 8.20 (dd, J = 5.7, 3.7 Hz, 1H), 5.33 (dq, J = 49.5, 6.6, 1.3 Hz, 1H), 4.77 (dddd, J = 26.5, 9.1, 3.4, 1.4 Hz, 1H), 4.65 (dd, J = 9.0, 3.4 Hz, 1H), 4.50 (td, J = 9.0, 1.3 Hz, 1H), 1.43 (dd, J = 23.1, 6.6 Hz, 3H). MS m/z 230.1 (M + H).
- 10

- Step 3: A solution of (S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine (28.1 mg, 0.1 mmol), (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (22.9 mg, 0.100 mmol) and DIPEA (52.4 µl, 0.300 mmol) in DMSO (Volume: 500 µl) was heated at 110 °C for 1 hr. The solution was then cooled to rt, and RP-HPLC (acetonitrile:water) purification provided a white solid. This material was purified again with flash column chromatography (0-10% MeOH/EtOAc) to give 14 mg (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a
- 15 white solid. ¹H NMR (400 MHz, MeOD) δ 8.81 (d, J = 5.0 Hz, 1H), 8.41 (s, 1H), 8.18 (s, 1H), 7.86 (s, 1H), 7.69 (dd, J = 5.0, 1.6 Hz, 1H), 7.44 (s, 1H), 7.41 (d, J = 5.8 Hz, 1H), 5.08 (br s, 1H), 4.73 (br d, J = 26.0 Hz, 1H), 4.56 - 4.27 (m, 3H), 2.32 (s, 3H), 1.58 (d, J = 7.1 Hz, 3H), 1.12 (br s, 3H); HRMS (B) m/z 491.1782 (M + H)⁺. Anal. RP-HPLC *t_R* = 3.42 min. Purity 100%/100%.
- 20

25 Example 467


(R)-3-(2-(((S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one.



(R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (50 mg, 0.218 mmol) and (S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethanamine (75 mg, 0.262 mmol) were taken up in 3 mL DMSO. Hunig's base (57 μ L, 0.327 mmol) was added. The mixture was heated to 110 $^{\circ}$ C for 1.5 h. The reaction mixture was poured into 30 mL water, and extracted with EtOAc (2 x 30 mL). Organics were washed with 20 mL each water, and brine. Combined organics were dried over Na_2SO_4 , filtered and concentrated on silica gel. Column chromatography (25-100% EtOAc/heptane) gave 82 mg white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.91 (d, J = 1.4 Hz, 2H), 8.25 (d, J = 5.7 Hz, 1H), 7.79 – 7.61 (m, 2H), 7.52 (d, J = 5.7 Hz, 1H), 7.44 (tt, J = 7.7, 0.8 Hz, 1H), 6.12 (s, 1H), 5.32 (s, 1H), 5.08 (br s, 1H), 4.80 (dddd, J = 26.5, 9.1, 3.4, 1.5 Hz, 1H), 4.58 (dd, J = 8.8, 3.4 Hz, 1H), 4.44 (td, J = 9.0, 1.3 Hz, 1H), 1.68 (d, J = 8.8 Hz, 3H), 1.43 – 1.24 (m, 3H). HRMS (A) m/z 495.1611 ($M + \text{H}$) $^+$. Anal. RP-HPLC t_R = 3.68 min. Purity 96%/100%.

Example 468

(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one




A solution of (S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine (27 mg, 0.10 mmol), (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (23 mg, 0.10 mmol) and DIPEA (52.4 μ L, 0.30 mmol) in DMSO (500 μ L) was heated at 110 $^{\circ}$ C for 1 hr. The solution was then cooled to rt and RP-HPLC purification (acetonitrile:water) provided the 32 mg of the major product as a white solid. ^1H NMR (400 MHz, MeOD) δ 8.98 (s, 1H), 8.79 (d, J = 5.1 Hz, 1H), 8.23 (dd, J = 8.2, 2.4 Hz, 1H), 8.17 (br s, 1H), 8.17 - 8.12 (m, 1H), 7.98 (dd, J = 5.1, 1.7 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 5.8 Hz, 1H), 5.11 (br s, 1H), 4.69 (br d, J = 27.2 Hz,

1H), 4.55 - 4.12 (m, 3H), 1.60 (d, $J = 7.1$ Hz, 3H), 1.03 (br s, 3H); HRMS (B) m/z 477.1699 ($M + H$)⁺.

Example 469


(R)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one



(R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (50 mg, 0.218 mmol), (S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethanamine (60.5 mg, 0.262 mmol), and DIPEA (57 ul, 0.327 mmol) were taken up in 3 mL DMSO. Heated to 110 C for 1 h. The reaction mixture was poured into 30 mL water and extracted with EtOAc (2 x 30 mL). Organics were washed with 20 mL each water, brine, and dried over Na₂SO₄, and filtered and concentrated on silica gel. Column chromatography (25-100% EtOAc/hept) gave the desired product (92 mg) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 2H), 8.25 (d, $J = 5.7$ Hz, 1H), 7.51 (d, $J = 5.7$ Hz, 1H), 7.42 – 7.31 (m, 2H), 7.21 – 7.12 (m, 1H), 6.15 (s, 1H), 5.28 (s, 2H), 4.80 (dddd, $J = 26.6, 9.0, 3.5, 1.6$ Hz, 1H), 4.57 (dd, $J = 8.8, 3.4$ Hz, 1H), 4.44 (td, $J = 9.0, 1.3$ Hz, 1H), 2.39 (d, $J = 1.9$ Hz, 3H), 1.66 (d, $J = 6.9$ Hz, 3H), 1.35 – 1.24 (m, 3H). HRMS (A) m/z 441.1849 ($M + H$)⁺. Anal. RP-HPLC $t_R = 3.10$ min. Purity 100%/100%.

Example 470


(R)-3-(5-fluoro-2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one



A solution of (S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine (50 mg, 0.178 mmol), (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one, (46.1 mg, 0.187 mmol) and DIPEA (93 μ l, 0.533 mmol) in DMSO (889 μ l) was heated at 110 °C for 1 hr. The the solution was then cooled to rt diluted with 10 mL EtOAc, washed with water, brine, dried over Na₂SO₄, concentrated and purified through RP-HPLC (acetonitrile:water) to provide 37 mg white solid. ¹H NMR (400 MHz, MeOD) δ 8.81 (d, J = 5.0 Hz, 1H), 8.39 (s, 1H), 8.26 (s, 1H), 7.85 (s, 1H), 7.69 (dd, J = 5.1, 1.6 Hz, 1H), 7.46 (s, 1H), 5.00 br (s, 1H), 4.66 - 4.37 (m, 4H), 2.32 (s, 3H), 1.57 (d, J = 7.1 Hz, 3H), 1.04 (br s, 3H); HRMS (B) m/z 509.1701 (M + H)⁺.

Example 471


10 (R)-4-(fluoromethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one



A solution of (R)-4-(fluoromethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (15 mg, 0.070 mmol), (S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (20 mg, 0.084 mmol, 1.2 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.043 mL, 0.24 mmol, 3.5 equiv) in DMSO (1.0 mL) was heated at 85 °C for 14 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-4-(fluoromethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (6 mg, white solid) in 17% yield. ¹H NMR (400 MHz, CDCl₃) δ 11.11 (d, J=6.9 Hz, 1 H), 8.40 (s, 1 H), 7.97 (d, J=7.0 Hz, 1 H), 7.88 (d, J=6.9 Hz, 1 H), 7.62 (s, 1 H), 7.47 (dd, J=8.7, 4.3 Hz, 2 H), 7.28 - 7.34 (m, 2 H), 5.75 (t, J=7.1 Hz, 1 H), 5.20 - 5.33 (m, 1 H), 4.45 - 4.75 (m, 4 H), 1.71 (d, J=6.8 Hz, 3 H); HRMS (A) m/z 401.1537 (M + H)⁺; Rt-1.22 min.

Example 472


25 (R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one



A solution of (R)-3-(2,5-difluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one (15 mg, 0.064 mmol), (S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (21 mg, 0.077 mmol, 1.2 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.039 mL, 0.23 mmol, 3.5 equiv) in DMSO (1.0 mL) was heated at 85 °C for 14 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one (11 mg, white solid) in 30% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1 H), 8.18 (d, J=1.9 Hz, 1 H), 7.57 - 7.63 (m, 1 H), 7.33 - 7.48 (m, 3 H), 5.34 (br. s., 1 H), 4.85 - 5.00 (m, 1 H), 4.41 - 4.75 (m, 4 H), 1.73 (d, J=7.0 Hz, 3 H); HRMS(A) *m/z* 453.1058 (M + H)⁺; Rt-1.51 min.

Example 473


(R)-3-(2-(((S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one



A solution of (R)-4-(fluoromethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (15 mg, 0.070 mmol), (S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (22 mg, 0.084 mmol, 1.2 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.043 mL, 0.24 mmol, 3.5 equiv) in DMSO (1.0 mL) was heated at 85 °C for 14 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one (14 mg, white solid) in 35% yield. ¹H NMR (400 MHz, CDCl₃) δ 11.04 (d, J=7.0 Hz, 1 H), 8.29 (s, 1 H), 7.97 (d, J=7.1 Hz, 1 H), 7.86 (d, J=6.9 Hz, 1 H), 7.57 - 7.67 (m, 2 H), 7.32 (dd, J=8.7, 2.5 Hz, 1 H), 7.24 (d, J=1.0 Hz, 1 H), 5.64 (t, J=7.1 Hz, 1 H), 5.12 - 5.27 (m, 1 H), 4.43 - 4.75 (m, 4 H), 1.70 (d, J=6.8 Hz, 3 H); HRMS(A) *m/z* 435.1151 (M + H)⁺; Rt-1.51 min.

Example 474


(R)-3-(2-(((S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one



A solution of (R)-4-(fluoromethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (15 mg, 0.070 mmol), (S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (22 mg, 0.084 mmol, 1.2 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.043 mL, 0.24 mmol, 3.5 equiv) in DMSO (1.0 mL) was heated at 85 °C for 14 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one (10 mg, white solid) in 26% yield. ¹H NMR (400 MHz, CDCl₃) δ 11.05 (d, J=8.2 Hz, 1 H), 8.30 (s, 1 H), 7.98 (d, J=7.2 Hz, 1 H), 7.87 (d, J=7.0 Hz, 1 H), 7.59 (s, 1 H), 7.31 - 7.46 (m, 2 H), 7.24 (br. s., 1 H), 5.61 - 5.71 (m, 1 H), 5.14 - 5.28 (m, 1 H), 4.44 - 4.76 (m, 4 H), 1.70 (d, J=6.8 Hz, 3 H); HRMS(A) *m/z* 419.1444 (M + H)⁺; Rt-1.35 min.

Example 475

(R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one




15

A solution of (R)-4-(fluoromethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (15 mg, 0.070 mmol), (S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (24 mg, 0.084 mmol, 1.2 equiv), and N-ethyl-N-isopropylpropan-2-amine (0.043 mL, 0.24 mmol, 3.5 equiv) in DMSO (1.0 mL) was heated at 85 °C for 14 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one (15 mg, white solid) in 37% yield. ¹H NMR (400 MHz, CDCl₃) δ 10.99 (d, J=7.2 Hz, 1 H), 8.24 (s, 1 H), 7.97 (d, J=6.8 Hz, 1 H), 7.78 - 7.87 (m, 2 H), 7.61 (s, 1 H), 7.38 (d, J=8.8 Hz, 1 H), 7.31 (d, J=1.0 Hz, 1 H), 6.79 - 7.09 (m, 1 H), 5.57 (t, J=7.0 Hz, 1 H), 5.09 - 5.23 (m, 1 H), 4.44 - 4.77 (m, 4 H), 1.70 (d, J=6.9 Hz, 3H); HRMS(A) *m/z* 451.1512 (M + H)⁺; Rt-1.48 min.

25

Example 476

(R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one



5 Step1 : Preparation of (S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride

To 1H-imidazole-4-carbaldehyde (2.56 g, 26.6 mmol), 4-chloro-2-fluoro-1-iodobenzene (0.739 g, 2.88 mmol) and Cs₂CO₃ (1.564 g, 4.80 mmol) in DMF (50mL) was added copper(I) iodide (0.023 g, 0.120 mmol) and (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (0.068 g, 0.480 mmol). The reaction was heated to 110 °C for 18 hours. The reaction mixture was then cooled to room temperature and filtered, and washed with EtOAc (100mL). The organic was washed with water (2x30mL) and brine (30mL), dried (Na₂SO₄) and concentrated. The residue was purified by silica gel chromatography to give 1-(4-chloro-2-fluorophenyl)-1H-imidazole-4-carbaldehyde (451 mg), to which was added (S)-2-methylpropane-2-sulfinamide (0.29 g, 2.4 mmol), CuSO₄ (0.638 g, 4 mmol) and DCE (10mL). The reaction was heated to 65 °C for 18 hours. The reaction was cooled to rt, filtered and concentrated to give (S,E)-N-((1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfinamide, to which was added DCM (20mL). The reaction mixture was cooled to -70 °C and methylmagnesium bromide (1.33 ml, 4 mmol) was added dropwise to the solution. The reaction was stirred for two hours and the cold bath was then removed, and the reaction was allowed to warm to rt and stir for 30 minutes. The reaction was cooled to 0 °C and HCl (1M) was added cautiously to quench until aqueous pH=8. The phases were separated and the aqueous layer was extracted with DCM (2x30mL). Combined organic was dried (Na₂SO₄) and concentrated to give (S)-N-((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)-2-methylpropane-2-sulfinamide (130mg), which was then dissolved in MeOH (5mL) and HCl (0.5 mL, 4M) was added. The reaction was stirred for one hour and concentrated to give product (100mg). LCMS *m/z* 240.1 (M + H)⁺; Rt-0.50 min.


Step 2: Preparation of (R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one

A solution of (S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (20 mg, 0.072 mmol), (S)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (15 mg, 0.065 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.040 mL, 0.23 mmol) in DMSO (0.5 mL) was heated at 90 °C for 8 hours. The reaction was then cooled to room temperature.

- 5 Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one (12 mg). ¹H NMR (400 MHz, CD₃OD) δ 8.68 (br. s., 1H), 8.22 (d, J=6.7 Hz, 1H), 7.76 (d, J=4.7 Hz, 1H), 7.70 - 7.55 (m, 3H), 7.45 (d, J=8.6 Hz, 1H), 5.36- 5.24 (m, 1H), 4.9-4.75 (m, 2H), 4.62 (dd, J=2.7, 9.4 Hz, 1H), 4.56 - 4.47 (m, 1H), 1.71 (d, J=6.7 Hz, 10 3H), 1.35 - 1.17 (m, 3H); HRMS(A) *m/z* 449.1306 (M + H)⁺; Rt-1.57 min.

Example 477


(R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one



- 15 A solution of (S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (20 mg, 0.072 mmol), (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one (15 mg, 0.061 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.040 mL, 0.23 mmol) in DMSO (0.5 mL) was heated at 90 °C for 8 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one (10 mg). ¹H NMR (400 MHz, CD₃OD) δ 8.25 (d, J=3.1 Hz, 1H), 7.96 (s, 1H), 7.58 - 7.45 (m, 2H), 7.36 (d, J=8.6 Hz, 1H), 7.26 (s, 1H), 5.06 (d, J=6.7 Hz, 1H), 4.9-4.75 (m, 2H), 4.67 - 4.55 (m, 2H), 4.53 - 4.43 (m, 1H), 1.57 (d, J=7.0 Hz, 3H), 1.26 - 1.06 (m, 3H); HRMS(A) *m/z* 467.1217 (M + H)⁺; Rt-1.66 min.

25 Example 478

(R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one



Step1 : Preparation of (S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride

To 1H-imidazole-4-carbaldehyde (3.01 g, 31.3 mmol), 2,4-difluoro-1-iodobenzene (1.008 g, 4.20 mmol), Cs₂CO₃ (2.281 g, 7.00 mmol) in DMF (50mL) was added copper(I) iodide (0.033 g, 0.175 mmol) and (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (0.100 g, 0.700 mmol). The reaction was heated to 110 °C for 18 hours. The reaction mixture was then cooled to room temperature and filtered, and washed with EtOAc (100mL). The organic was washed with water (2x30mL) and brine (30mL), dried (Na₂SO₄) and concentrated. The residue was purified by silica gel chromatography to give 1-(2,4-difluorophenyl)-1H-imidazole-4-carbaldehyde (651 mg), to which was added (S)-2-methylpropane-2-sulfinamide (0.424 g, 3.5 mmol), CuSO₄ (0.798 g, 5 mmol) and DCE (10mL). The reaction was heated to 65 °C for 18 hours. The reaction was cooled to rt, filtered and concentrated to give (S,E)-N-((1-(2,4-difluorophenyl)-1H-imidazol-4-yl)methylene)-2-methylpropane-2-sulfinamide, to which was added DCM (20mL). The reaction mixture was cooled to -70 °C and methylmagnesium bromide (1.667 ml, 5 mmol) was added dropwise to the solution. The reaction was stirred for two hours and the cold bath was then removed, and the reaction was allowed to warm to rt and stir for 30 minutes. The reaction was cooled to 0 °C and HCl (1M) was added cautiously to quench until aqueous pH=8. The phases were separated and the aqueous layer was extracted with DCM (2x30mL). Combined organic was dried (Na₂SO₄) and concentrated to give (S)-N-((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)-2-methylpropane-2-sulfinamide (230mg), which was then dissolved in MeOH (5mL) and HCl (0.5 mL, 4M) was added. The reaction was stirred for one hour and concentrated to give product (212mg). LCMS *m/z* 224.1 (M + H)⁺; Rt-0.39 min.


Step 2: Preparation of (R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one

A solution of (S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (18 mg, 0.069 mmol), (S)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one (13 mg, 0.057 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.040 mL, 0.23 mmol) in DMSO (0.5 mL) was heated at 90 °C for 8 hours. The reaction was then cooled to room temperature. Purification by

reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one (10 mg). ¹H NMR (400 MHz, CD₃OD) δ 8.22 (d, *J*=6.7 Hz, 1H), 7.88 (q, *J*=8.7 Hz, 6H), 7.71 (d, *J*=5.5 Hz, 1H), 5.27 (d, *J*=7.0 Hz, 1H), 4.86 (s, 2H), 4.68- 4.44 (m, 2H), 1.71 (d, *J*=7.0 Hz, 3H), 1.34 - 1.15 (m, 3H); HRMS(A) *m/z* 433.1603 (M + H)⁺; Rt-1.40 min.

Example 479


(R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one



- 10 A solution of (S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethanamine hydrochloride (18 mg, 0.069 mmol), (R)-3-(2,5-difluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one (15 mg, 0.061 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.040 mL, 0.23 mmol) in DMSO (0.5 mL) was heated at 90 °C for 8 hours. The reaction was then cooled to room temperature. Purification by reverse phase HPLC provided the trifluoroacetate salt of (R)-3-(2-(((S)-1-(1-
- 15 (2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one (18 mg). ¹H NMR (400 MHz, CD₃OD) δ 9.18 (s, 1H), 8.33 (d, *J*=3.1 Hz, 1H), 7.82 (s, 1H), 7.74 (dt, *J*=5.7, 8.7 Hz, 1H), 7.39 (ddd, *J*=2.5, 8.5, 10.9 Hz, 1H), 7.24 (t, *J*=8.4 Hz, 1H), 5.21 (d, *J*=6.7 Hz, 1H), 5.06 - 4.77 (m, 2H), 4.63 (t, *J*=9.0 Hz, 1H), 4.50 (dd, *J*=5.9, 8.6 Hz, 1H), 1.69 (d, *J*=6.7 Hz, 3H), 1.35 - 1.22 (m, 3H); HRMS(A) *m/z* 451.1514 (M +
- 20 H)⁺; Rt-1.47 min.

Example 480

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one



(R)-3-(2,5-difluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one (105 mg, 0.449 mmol), (S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethanamine (100 mg, 0.449 mmol), and DIPEA (157 μ L, 0.898 mmol) were dissolved in DMSO (1 mL) and the reaction mixture was heated at 120°C for 2 h.






- 5 The reaction mixture was cooled, diluted with EtOAc, washed with water and brine, and concentrated in vacuo. Column chromatography (5-50% EtOAc/DCM) gave the desired product (169 mg) as a white foam. ^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, J = 2.8 Hz, 1H), 7.59 – 7.50 (m, 2H), 7.45 – 7.36 (m, 2H), 7.25 (s, 1H), 5.66 (d, J = 7.6 Hz, 1H), 5.21 (br s, 1H), 4.86 (dddd, J = 20.0, 8.6, 7.0, 4.3, 2.8 Hz, 1H), 4.66 – 4.44 (m, 3H), 4.41 (br s, 1H), 1.71 (d, J = 7.0 Hz, 3H). HRMS-Acidic. LC-UV/ESI-MS data was recorded on an Acquity LCTp ToF - Rs(FWHM) > 12000 Accuracy < 5 ppm. Column: Acquity BEHC18 1.7 μ m 2.1x50mm - 50°C. Eluent A: Water + 0.1% formic acid. Eluent B: Acetonitrile + 0.1% formic acid. Gradient: from 0.2 to 98% B in 8.05 min - flow 0.9 mL/min. m/z 436.0996 ($M + H$) $^+$. Anal. RP-HPLC t_R = 3.46 min. Purity 100%/100%.





15






The compounds listed in Table 39 are made using methods similar to those described for Examples 1-465 and as outlined in the general synthetic procedures.





Table 39. The compounds in Table 39 are prepared following chemistry similar to that described for Examples 1-465 or as outlined in the Schemes given above.





Example	Name
	(R)-4-(fluoromethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one





	(R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(3,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-(difluoromethyl)-3-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-2,5-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one





	2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-2,5-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-2,5-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-2,5-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one





	(R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(4-chloro-2-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one





	(R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(1-(2,4-difluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
	(R)-3-(5-fluoro-2-(((S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one





	(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(5-(2-(trifluoromethyl)pyridin-4-yl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
	(R)-3-(5-fluoro-2-(((S)-1-(5-(2-(trifluoromethyl)pyridin-4-yl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
	(R)-3-(5-fluoro-2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one





	(R)-3-(5-fluoro-2-(((S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
	(R)-3-(5-fluoro-2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(5-(4-(trifluoromethyl)phenyl)pyr

	<p>imidin-2- yl)ethyl)amino)pyrimidin- 4-yl)oxazolidin-2-one</p>
	<p>(R)-3-(5-fluoro-2-(((S)-1- (5-(4- (trifluoromethyl)phenyl)pyr imidin-2- yl)ethyl)amino)pyrimidin- 4-yl)-4-((S)-1- fluoroethyl)oxazolidin-2- one</p>
	<p>(R)-3-(2-(((S)-1-(5-(4- chloro-3- (trifluoromethyl)phenyl)pyr imidin-2- yl)ethyl)amino)pyrimidin- 4-yl)-4-((S)-1- fluoroethyl)oxazolidin-2- one</p>
	<p>(R)-3-(2-(((S)-1-(5-(4- fluoro-3- methylphenyl)pyrimidin-2- yl)ethyl)amino)pyrimidin- 4-yl)-4-((S)-1- fluoroethyl)oxazolidin-2- one</p>

	(R)-3-(2-(((S)-1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(5-fluoro-2-(((S)-1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(5-fluoro-2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one

	(R)-3-(2-(((S)-1-(5-(4-chloro-3-fluorophenyl)-4-methylpyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(5-(4-chloro-3-fluorophenyl)-4-methylpyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(5-(3-chlorophenyl)-4-methylpyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(5-(3-chlorophenyl)-4-methylpyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one

	(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
	(R)-3-(5-fluoro-2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(2,5-difluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one

	(R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one
	(R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one

Biological Assays and Data

Mutant IDH1 biochemical assay: LC-MS detection of 2-HG.

Mutant IDH1 R132H catalytic activity was monitored using the quantitative liquid chromatography/mass spectrometry (LC-MS) detection of 2-HG, a product of the NADPH-dependent alpha-KG reduction reaction.

More specifically, the biochemical reactions were performed at room temperature in 384-well Greiner flat-bottom plates (Costar, Cat. No. 781201) using a final reaction volume of 30 μ L and the following assay buffer conditions: 50 mM HEPES pH 7.4, 10 mM $MgCl_2$, 50 mM KCl, 1 mM DTT, 0.02% BSA, 5 μ M NADPH and 100 μ M alpha-KG.

The final reaction mixture contained 3.3% DMSO and inhibitors with concentrations ranging 0.02 – 50 μ M. The IDH1 enzyme was used at a final concentration of 0.25 nM. Following 45 minutes incubation, the reaction mixtures were quenched by the addition of 10 μ L of 16% formic acid containing 800 nM of 5-carbon labeled ^{13}C -2-HG). The protein was then precipitated by the addition of 2.5 volumes of acetonitrile followed by centrifugation (3000 x g, 20 minutes). The concentration of 2-HG in the resulting supernatants was measured by LC-MS (see below).

LC-MS method. Reaction mixture supernatants were submitted to chromatographic separation on a BiobasicAX column (2.1 mm x 20 mm, 5 μ m particle, Thermo Scientific Inc.). The chromatographic mobile phases were A) 25 mM ammonium biocarbonate and B) acetonitrile (0.1% ammonium hydroxide). Nicotinamide was eluted at 1 ml/min using a 85-5% B gradient over 0.9 minutes (Agilent 1200SL LC system, Thermofisher LX-4 autosampler) and analyzed by multiple reaction monitoring (MRM) on a API4000 QTrap mass spectrometer (ABSciex, Framingham, MA) in the positive electrospray ionization (ESI+) mode. The mass transition for 2-HG and ^{13}C -2-HG were 147 $\rightarrow$ 129 and 152 $\rightarrow$ 134, respectively. The relative responses (2-HG/ ^{13}C -2-HG) were measured at varied inhibitor concentrations and used to calculate inhibitory IC50 values (normalized IC50 regression curves).

R132 protein expression and purification.

IDH1 R132H was cloned into the pET47b vector using the restriction sites XmaI/XhoI which yields an in frame, N-terminal His₆ site cleavable with Prescission protease. This plasmid was transformed into RosettaTM 2(DE3) (Novagen) cells. In shake flasks, 8L of cells were grown in Terrific Broth (Teknova) (plus kanamycin 50 μ g/mL and chloramphenicol 34 μ g/mL) at 37°C to an OD₆₀₀ of 0.8 and protein expression was induced by addition of IPTG to a concentration of 0.20mM. The cells were subsequently grown for 18 hours at 18°C.

His₆-IDH1 (R132H) Uncut protein

MAHHHHHSAALEVLFQGPMSKKISGGSVVEMQGDDEMTRIIWELIKEKLIFPYVELDLHSYD
 LGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVVEEFKLKQMWKSPNGTIRNILGGTV
 FREAIICKNIPRLVSGWVKPIIIGHHAYGDQYRATDFVVPGPVKVEITYTPSDGTQKVITYLVHNF
 EEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQ
 5 YKSQFEAQKIWYEHRLIDDMVAQAMKSEGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVL
 VCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRALDNNKELAFFAN
 ALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL (stop)
 (SEQ ID NO: 1)

10 **IDH1 (R132H) Prescission Cut Protein** (N-term gpg is cloning artifact)

GPGMSKKISGGSVVEMQGDDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAA
 EAIKKHNVGVKCATITPDEKRVVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVK
 PIIIGHHAYGDQYRATDFVVPGPVKVEITYTPSDGTQKVITYLVHNFEEGGGVAMGMYNQDKSI
 EDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLID
 15 MVAQAMKSEGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVT
 RHYRMYQKGQETSTNPIASIFAWTRGLAHRALDNNKELAFFANALEEVSIETIEAGFMTKDLA
 ACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL (stop) (SEQ ID NO: 2)

Purification

20 The cells were homogenized in Lysis Buffer with protease inhibitors (cOmplete EDTA-free protease inhibitor tablets (Roche), 1 tablet per 50mL of buffer), DNase, and to 200 μ M PMSF and lysed in a Microfluidizer. After lysis, Triton X-100 was added to 0.1% and stirred at 4°C for 30 minutes.

The cleared lysate was loaded onto 2 x 5mL HisTrap FF crude columns (GE), washed
 25 extensively with Lysis Buffer until the A_{280} stabilized and eluted with Ni Elution Buffer. Peak eluted fractions were concentrated to 30mL, EDTA was added to 1mM and GST-Prescission protease was added to 3U/100 μ g of protein. The sample was dialyzed against 2L Dialysis Buffer I (MWCO 50kDa) for 6 hours at 4°C then dialyzed against 2L of Dialysis Buffer II for at least 6 more hours. GST-Prescission cleaved sample was rocked with Glutathione Agarose
 30 Beads, spun down and then the supernatant was loaded through a 5mL HisTrap HP column and the flow through was collected.

Flow through was then diluted with ice cold 20mM Tris pH 7.4 and 1mM TCEP until the conductivity dropped to less than 5 mS/cm (a roughly three fold dilution). This sample was then flowed through a HiTrap Q column and the flow through was concentrated to 10mL and
 35 loaded onto an equilibrated 26/60 Superdex 200 column using SEC Buffer as the mobile phase. Peak fractions were collected, concentrated and aliquoted.

Lysis Buffer: 50mM Tris pH=7.4, 500mM NaCl, 20mM Imidazole, and 1mM TCEP

Ni Elution Buffer: 50mM Tris pH=7.4, 150mM NaCl, 200mM Imidazole, and 1mM TCEP

Dialysis Buffer I: 20mM Tris pH=7.4, 150mM NaCl, 1mM TCEP, and 50mM Imidazole

Dialysis Buffer II: 20mM Tris pH=7.4, 150mM NaCl, and 1mM TCEP

SEC Buffer: 20mM Tris pH=7.4, 150mM NaCl, and 1mM TCEP

The results of the mutant IDH1 biochemical assay (mIDH R132H) are given in Table 40. Some of the examples were run in the assay multiple times and therefore the IC₅₀ values are expressed as a range of activity.

Fluorescence biochemical assay

The IDH1 (R132H) mutant catalyzes the reduced form of NADP⁺ (NADPH) and α-ketoglutarate (α-KG) to form nicotinamide adenine dinucleotide phosphate (NADP⁺) and R (-)-2-hydroxyglutarate (2HG). The reaction can be monitored kinetically by following the oxidation of NADPH to NADP⁺ which is measured using fluorescence, excitation at 355 nm and emission at 530 nm. Reactions were monitored using the Perkin-Elmer Envision, Model 2101.

More specifically, the biochemical reactions were performed at room temperature in 384-well Greiner flat-bottom plates (Cat. No. 781076) using a final reaction volume of 20 μL and the following assay buffer conditions: 50 mM HEPES pH 7.5, 10 mM MgCl₂, 1 mM DTT, 0.02% BSA, 0.02% Tween-20, 10 μM NADPH and 100 μM α-KG. The final reaction mixture contained 2.5% DMSO and test compounds with concentrations ranging 0.0000008 – 25 μM. The IDH1 (R132H) enzyme was used at a final concentration of 10 nM. Curve fitting for dose response IC₅₀ determinations was done using a 4-parameter logistic model: $y = \min + ((\max - \min) / 1 + (x / IC_{50})^{\text{slope}})$.

The results of the fluorescence biochemical assay (mIDH R132H) are given in Table 40. Some of the examples were run in the assay multiple times and therefore the IC₅₀ values are expressed as a range of activity.

Table 40. Results of the LC-MS and fluorescence biochemical assays.

Example Number	Fluorescence biochemical assay IC ₅₀ (μM)	LC-MS biochemical assay IC ₅₀ (μM)
1	1.410	Not determined
2	0.406 to 0.412	Not determined
3	Not determined	Not determined

4	1.420	2.010
5	17.800	3.684
6	1.270	1.185
7	2.950	1.609 to 4.527
8	2.040	0.314 to 2.79
9	2.200	3.019
10	11.700	1.710
11	3.050	2.453
12	3.270	0.892
13	2.190	> 5
14	0.405	0.813
15	Not determined	Not determined
16	Not determined	Not determined
17	Not determined	Not determined
18	Not determined	Not determined
19	Not determined	Not determined
20	Not determined	Not determined
21	Not determined	Not determined
22	Not determined	Not determined
23	Not determined	Not determined
24	Not determined	Not determined
25	Not determined	Not determined
26	3.350	Not determined
27	2.800	Not determined
28	Not determined	0.005
29	Not determined	0.027
30	1.090	0.472
31	0.627	0.757
32	0.016	0.010
33	3.660	2.085
34	0.889 to 0.893	0.590
35	0.033	0.055
36	1.410	3.497
37	2.690	3.745
38	0.055	0.056
39	0.202	0.211
40	0.175	0.370
41	0.253	0.179
42	> 25	1.557
43	Not determined	0.045
44	0.029	0.033 to 0.034
45	1.000	1.237
46	2.530	1.930
47	0.033	0.036
48	0.463	0.775
49	Not determined	0.094
50	0.037	0.043

51	0.013	0.016
52	0.131 to 0.289	0.194
53	0.042 to 0.051	0.059
54	0.116	0.119
55	0.267 to 0.291	0.323
56	2.920	1.549
57	1.270	1.131
58	0.027	0.029
59	0.079 to 0.085	0.033
60	1.100	0.201
61	0.313	0.156
62	0.53 to 0.599	0.087
63	< 0.0159	0.005
64	< 0.0159	0.008
65	0.797	0.582
66	0.061 to 0.082	0.066
67	1.010	1.437
68	0.050	0.112
69	0.639	> 5
70	0.073	0.080
71	> 25	> 5
72	Not determined	12.152
73	0.181	0.571
74	Not determined	> 5
75	Not determined	Not determined
76	Not determined	0.546 to 0.568
77	Not determined	0.911
78	1.630	2.560
79	5.310	> 5
80	0.037	0.031
81	Not determined	1.089
82	0.019	0.022
83	0.662 to 0.683	0.489
84	0.012 to 0.083	0.013
85	1.930	0.524
86	0.032 to 0.049	0.019
87	6.690	> 5
88	0.048 to 0.058	0.034
89	1.360	1.776
90	0.034	0.013
91	0.274	Not determined
92	2.74 to 8.91	2.301 to 3.074
93	0.043 to 0.383	0.029 to 0.134
94	14.900	25.642
95	1.530	1.113
96	Not determined	> 50
97	0.972	0.984

98	0.351	0.487
99	9.790	3.057
100	Not determined	18.066
101	Not determined	0.572
102	Not determined	> 50
103	Not determined	6.354
104	> 25	> 50
105	2.430	1.720
106	> 25	32.926
107	1.220	1.416
108	11.700	5.902
109	0.0486 to 0.193	0.136 to 0.167
110	> 25	23.402
111	2.780	3.511
112	> 25	> 50
113	> 25	42.325
114	> 25	> 50
115	7.890	3.760
116	> 25	> 50
117	1.410	2.010
118	3.560	1.539
119	0.045	0.029 to 0.042
120	Not determined	2.668
121	0.182	0.045 to 0.081
122	0.370	0.268
123	0.017 to 0.044	0.024 to 0.029
124	18.8	>25
125	0.158	0.206
126	0.274	0.216
127	0.032	0.025 to 0.033
128	0.050	0.071
129	1.800	2.814
130	1.510	2.999
131	0.056	0.153 to 0.171
132	0.956	1.421
133	0.007	0.004 to 0.008
134	1.460	2.360
135	0.011	0.016
136	11.300	> 5
137	1.190	0.294
138	0.012	0.024
139	0.260	0.146
140	10.600	4.032
141	0.660	0.116
142	> 25	3.977
143	0.756	0.572
144	1.670	1.685

145	0.020	0.036
146	Not determined	> 5
147	Not determined	0.368
148	9.590	> 5
149	0.194	0.168 to 0.216
150	Not determined	> 5
151	0.043 to 0.044	0.012
152	5.990	> 5
153	0.329	0.288
154	1.790	3.839
155	0.756	0.857
156	2.700	1.145
157	0.033	0.032
158	Not determined	4.374
159	< 0.0159	0.006
160	1.230	1.115
161	0.158	0.305
162	3.620	> 5
163	0.079	0.152
164	4.680	> 5
165	0.152	0.304
166	0.871	0.243
167	0.131	0.067 to 0.076
168	3.200	> 5
169	0.038	0.044 to 0.086
170	3.690	1.884
171	0.056	0.031 to 0.052
172	Not determined	3.407
173	0.051 to 0.078	0.040
174	0.230	0.238
175	0.298 to 0.538	0.049
176	12.400	4.591
177	1.230	1.587
178	0.364	0.077
179	0.007	0.005 to 0.006
180	> 25	2.728
181	0.138	0.122
182	1.920	1.378
183	0.128	0.243
184	0.502	0.757
185	0.023	0.021
186	2.32 to 2.58	2.583
187	0.022	0.010
188	8.380	
189	0.064	0.156
190	0.037	0.014
191	> 50	

192	Not determined	0.010
193	Not determined	0.358
194	0.051	Not determined
195	2.930	Not determined
196	< 0.0159	0.005
197	2.010	Not determined
198	0.020	Not determined
199	1.200	Not determined
200	0.043	0.005
201	0.344	Not determined
202	1.680	1.093
203	0.016	0.008
204	0.026 to 0.059	0.02 to 0.05
205	2.700	2.052
206	0.03 to 0.051	0.022
207 as TFA salt	0.011	< 0.0228624
208 as TFA salt	0.101	Not determined
209 as TFA salt	0.087	0.164
210 as TFA salt	0.153	0.374
211 as TFA salt	0.496	2.628
212 as TFA salt	0.035	0.057
213 as TFA salt	0.011	<0.0228624
213	0.019	0.018
214 as TFA salt	0.046	0.107
215 as TFA salt	0.055	0.106 to 0.138
216 as TFA salt	0.004	0.011
217 as TFA salt	0.012 to 0.033	0.019 to 0.025
218 as TFA salt	0.019	0.018 to 0.044
219 as TFA salt	0.014	0.015
220 as TFA salt	0.014	0.017
221	0.061	0.046
222 as TFA salt	0.047	0.053
223 as TFA salt	0.023 to 0.046	0.014
224 as TFA salt	0.029	0.027
224	< 0.016	<0.022
225 as TFA salt	0.037	0.063
225	0.028 to 0.042	0.038 to 0.043
226 as TFA salt	0.009	Not determined
227 as TFA salt	0.015	0.22 to 0.023
228 as TFA salt	0.019	0.045
228	0.018	0.014 to 0.035
229 as TFA salt	0.054	0.081
230 as TFA salt	> 25	Not determined
231 as TFA salt	> 25	Not determined
232 as TFA salt	0.024	0.026
233 as TFA salt	0.377	Not determined
234 as TFA salt	0.213	Not determined

235 as TFA salt	0.964	Not determined
236 as TFA salt	0.024 to 0.042	0.023
237 as TFA salt	0.02 to 0.025	0.013
238 as TFA salt	0.017 to 0.024	0.012
239 as TFA salt	0.049 to 0.058	0.020
240 as TFA salt	0.142	0.067
241 as TFA salt	0.114	0.157
242 as TFA salt	0.042	0.053
243 as TFA salt	0.141	0.172
244 as TFA salt	0.300	Not determined
245 as TFA salt	0.115	Not determined
246 as TFA salt	0.273	Not determined
247 as TFA salt	0.079	Not determined
248 as TFA salt	0.172	Not determined
249 as TFA salt	0.635	Not determined
250 as TFA salt	0.025 to 0.047	Not determined
251 as TFA salt	0.020	Not determined
252 as TFA salt	0.309	0.353 to 0.482
253 as TFA salt	0.109	0.121
254 as TFA salt	0.234	Not determined
255 as TFA salt	0.450	Not determined
256 as TFA salt	0.570	0.489
257 as TFA salt	1.200	Not determined
258 as TFA salt	0.737	0.435
259 as TFA salt	0.105	0.103
259	0.049	Not determined
260 as TFA salt	0.040	0.039
261 as TFA salt	0.064	0.089
262 as TFA salt	0.088	0.167
263 as TFA salt	0.014	Not determined
264 as TFA salt	0.152	0.249
265 as TFA salt	Not determined	0.036
266 as TFA salt	0.453	Not determined
267 as TFA salt	0.048	0.095
268 as TFA salt	0.338	Not determined
269	0.251	Not determined
270 as TFA salt	0.174	0.163
271 as TFA salt	0.339	Not determined
272 as TFA salt	0.117	Not determined
273 as TFA salt	Not determined	0.585
274 as TFA salt	Not determined	0.265
275 as TFA salt	Not determined	0.311
276 as TFA salt	Not determined	0.051
277 as TFA salt	Not determined	0.086
278 as TFA salt	0.174	0.163
279 as TFA salt	12.700	Not determined
280 as TFA salt	3.640	Not determined

281 as TFA salt	0.026	0.064
282 as TFA salt	4.270	Not determined
283 as TFA salt	0.068	0.248
284 as TFA salt	0.266	Not determined
285 as TFA salt	0.053	0.146
286 as TFA salt	0.036	0.145
287 as TFA salt	2.250	46.301
288 as TFA salt	0.055	0.178
289 as TFA salt	2.110	Not determined
290 as TFA salt	0.034	0.053
291	> 25	Not determined
292	1.850	Not determined
293	> 7.91	Not determined
294	0.466	0.563
295	> 25	Not determined
296	0.251	0.277
297	2.960	Not determined
298	0.020	0.038
299	0.457	Not determined
300	0.010	0.017
301	0.021	0.033
302	0.045	Not determined
303	0.009	0.097
304	0.304	Not determined
305	0.968	0.772 to 1.781
306	2.570	Not determined
307 as TFA salt	0.029 to 0.049	0.038
308 as TFA salt	0.049 to 0.097	0.073
309 as TFA salt	0.003	0.004
309	0.003	0.004 to 0.005
310 as TFA salt	0.072	0.128
311 as TFA salt	0.518	0.445
312 as TFA salt	0.066	0.144
313 as TFA salt	0.020	0.019
314 as TFA salt	0.106 to 0.121	0.157 to 0.182
315 as TFA salt	0.161 to 0.514	0.35 to 0.463
316 as TFA salt	0.123 to 0.29	0.261
317 as TFA salt	3.7 to 5.63	Not determined
318 as TFA salt	> 25	Not determined
319 as TFA salt	0.035	0.086
320 as TFA salt	0.426	0.381
321 as TFA salt	0.013	0.087
322 as TFA salt	0.055 to 0.088	0.042
323 as TFA salt	0.071 to 0.122	0.072
324 as TFA salt	0.030	Not determined
325 as TFA salt	0.041	0.181
326 as TFA salt	0.063	Not determined

327 as TFA salt	0.236	0.562
328 as TFA salt	1.800	Not determined
329 as TFA salt	0.863	0.435
330 as TFA salt	0.268	0.850
331 as TFA salt	0.190	0.780
332 as TFA salt	1.020	0.704
333 as TFA salt	0.944	0.640
334 as TFA salt	0.341	0.943
335 as TFA salt	0.257	0.166 to 0.167
336 as TFA salt	0.035	0.049
336	0.027	0.048
337 as TFA salt	0.313	0.119
338 as TFA salt	0.091	0.093
339 as TFA salt	0.017	0.024 to 0.027
340 as TFA salt	0.061	0.120
341 as TFA salt	7.050	Not determined
342 as TFA salt	0.465	4.001
343 as TFA salt	0.073	0.225
344 as TFA salt	0.190	0.300
345 as TFA salt	0.201	0.378
346 as TFA salt	0.189	0.290
347 as TFA salt	0.395	0.564
348 as TFA salt	0.177	0.128
349 as TFA salt	0.681	Not determined
350 as TFA salt	0.413	Not determined
351 as TFA salt	0.168	Not determined
352 as TFA salt	0.770	Not determined
353 as TFA salt	0.103	0.117
354 as TFA salt	0.051	0.286
355 as TFA salt	0.152	0.381
356 as TFA salt	0.120	0.132
357 as TFA salt	0.358	0.439
358 as TFA salt	0.123	Not determined
359 as TFA salt	0.171	0.193
360 as TFA salt	0.056	0.119
361 as TFA salt	0.107	0.170
362 as TFA salt	0.072	0.142
363 as TFA salt	0.007	0.009
364 as TFA salt	0.124	0.286 to 0.472
365 as TFA salt	0.033	0.137
366 as TFA salt	0.151	0.345
367 as TFA salt	0.127	0.209
368 as TFA salt	0.091	0.127
369 as TFA salt	0.397	1.277
370 as TFA salt	0.441	1.303
371 as TFA salt	0.125	0.110
372 as TFA salt	0.014 to 0.044	0.029

373 as TFA salt	0.051	Not determined
374	0.032	0.021
375	0.093	0.241
376 as TFA salt	0.023	0.027
377 as TFA salt	0.052	Not determined
378 as TFA salt	0.025 to 0.028	Not determined
379 as TFA salt	0.053	Not determined
380 as TFA salt	0.036 to 0.037	0.050
380	0.036 to 0.055	Not determined
381 as TFA salt	0.139	0.059
382 as TFA salt	0.219	0.098
383 as TFA salt	0.164	Not determined
384 as TFA salt	10.5 to >25	Not determined
385 as TFA salt	0.017	<0.023
385	< 0.016 to 0.027	0.007
386 as TFA salt	0.059	Not determined
387 as TFA salt	0.032 to 0.036	Not determined
388 as TFA salt	< 0.0159	0.006
389 as TFA salt	0.020	Not determined
390 as TFA salt	0.022 to 0.037	0.022
391 as TFA salt	0.038 to 0.067	Not determined
392 as TFA salt	0.101 to 0.142	Not determined
393 as TFA salt	0.057 to 0.081	Not determined
394 as TFA salt	0.037 to 0.046	Not determined
395 as TFA salt	0.034 to 0.045	Not determined
396 as TFA salt	0.024 to 0.041	Not determined
397 as TFA salt	0.064 to 0.067	Not determined
398 as TFA salt	0.038 to 0.04	Not determined
399 as TFA salt	0.018	Not determined
400 as TFA salt	0.018 to 0.033	Not determined
401 as TFA salt	0.023 to 0.03	Not determined
401	0.018	Not determined
402 as TFA salt	0.044 to 0.05	Not determined
403 as TFA salt	0.137	Not determined
404	0.021 to 0.025	Not determined
405	0.027 to 0.037	Not determined
406 as TFA salt	0.028 to 0.03	Not determined
407	0.071	Not determined
408	0.043	Not determined
409 as TFA salt	0.209	0.501 to 0.515
410 as TFA salt	0.020	0.034
411 as TFA salt	0.756	1.601
412 as TFA salt	0.108	0.223 to 0.347
413 as TFA salt	0.023	Not determined
414 as TFA salt	2.210	Not determined
415	0.483 to 0.859	0.204
416	0.097	0.110

417	0.207	0.078 to 0.147
418	0.015 to 0.044	0.016 to 0.075
419	0.096	0.039 to 0.06
420	0.089	0.047 to 0.078
421	0.023	0.021
422	1.76 to 2.03	Not determined
423	0.036 to 0.042	Not determined
424	7.710	6.429
425	0.303	0.202 to 0.214
426 as TFA salt	< 0.0159	Not determined
427 as TFA salt	0.039 to 0.55	Not determined
428 as TFA salt	0.0678	Not determined
429	<0.016	Not determined
430 as TFA salt	0.050	Not determined
431 as TFA salt	0.047	Not determined
432 as TFA salt	0.016	Not determined
433 as TFA salt	0.032	Not determined
434 as TFA salt	0.017	Not determined
435 as TFA salt	0.017	Not determined
436 as TFA salt	0.06	Not determined
437 as TFA salt	0.036	Not determined
438 as TFA salt	0.045	Not determined
439 as TFA salt	0.392	Not determined
440 as TFA salt	0.172	Not determined
441 as TFA salt	<0.016	Not determined
442 as TFA salt	0.038	Not determined
443 as TFA salt	0.029	Not determined
444 as TFA salt	<0.016	Not determined
445 as TFA salt	0.112	Not determined
446 as TFA salt	0.0268	Not determined
447 as TFA salt	0.028	Not determined
448 as TFA salt	<0.016	Not determined
449 as TFA salt	0.0297	Not determined
450 as TFA salt	<0.016	Not determined
451 as TFA salt	0.0435	Not determined
452 as TFA salt	0.0293	Not determined
453 as TFA salt	0.0357	Not determined
454 as TFA salt	0.0234	Not determined
455 as TFA salt	<0.016	Not determined
456 as TFA salt	<0.016	Not determined
456	0.0010	Not determined
457 as TFA salt	0.017	Not determined
458 as TFA salt	<0.016	Not determined
459 as TFA salt	0.0246	Not determined
460 as TFA salt	0.024 to 0.043	Not determined
461 as TFA salt	0.045 to 0.064	Not determined

462 as TFA salt	0.0738	Not determined
463 as TFA salt	0.038	0.010
463	0.035 to 0.040	0.039
464 as TFA salt	0.0937	Not determined
465 as TFA salt	0.0681	Not determined
466	0.024 to 0.027	0.011
467	0.008 to 0.010	<0.00229
468	0.128	0.023
469	0.020	Not determined
470	Not determined	0.0128
471 as TFA salt	0.049	Not determined
472 as TFA salt	0.032	Not determined
473 as TFA salt	0.019	Not determined
474 as TFA salt	0.077	Not determined
475 as TFA salt	0.022	Not determined
476 as TFA salt	0.012	Not determined
477	0.017	Not determined
478 as TFA salt	0.051	Not determined
479 as TFA salt.	0.087	Not determined
480	0.014-0.020	0.005

IDH Cellular Assay

The IDH cellular assay consisted of two side-by-side comparator assays: 1) 2HG oncometabolite detection assay using LC-MS (See Mutant IDH1 biochemical assay for LC-MS detection details) and 2) Cell proliferation assay to monitor off-target killing of cells and to normalize 2HG level change.

IDH1 cellular screens were run with the HCT-116 cell line (express endogenous level of IDH1mut R132H, available from Horizon Discoveries X-Man isogenic human cell lines, catalog # HD104-013). The cells were grown in DMEM (LONZA Cat# 12-540F) with 10% Fetal bovine serum (Gibco cat# 10099) and 1X non-essential amino acids (NEAA LONZA cat# 13-114E). Panel assays were run periodically to test compound activity in cell lines with different endogenous mutations – HT1080 (IDH1mut R132C, EMEM + 10% FBS), SNU-1079 (IDH1mut R132C, RPMI + 10%FBS + 1% sodium pyruvate), and SW1353 (IDH2mut R172S, RPMI + 10%FBS + 1% sodium pyruvate).

The assay process was as follows:

Day 1: cells were seeded in 384-well plates (Corning Cat# 3707) in triplicates for both the cell proliferation and 2HG assay, and incubated at 37C, 95% Rh, 5% CO2 overnight.

Day 2: compounds were serially diluted 1:3 (10 point dilution from 10mM solutions in DMSO) and delivered to the cell assay plates via acoustic dispenser, with final concentration

ranging from 30uM to 1.5nM. The plates were returned to the incubator after treatment and incubated for 48 hours.

Day 4 Proliferation assay: CTG (cell titer-glo, Promega part # G755B) was added to the assay plates and luminescence signal was read on the plate reader.

- 5 Day 4 2HG assay : Extraction sample preparation consisted of aspirating all media from the assay plates, adding 70 ul of 90% methanol in water, dry ice incubation for 15 minutes, centrifuging at 2000 rpm for 30 min to ensure all particulates have settled, and transferring 30 ul of the supernatant into LC-MS ready plates. LC-MS analysis followed.

Certain compounds of the invention were tested in the IDH Cellular Assay.

10

Determination of Metabolic Stability in Liver Microsomes – Method I

The *in vitro* metabolic stability assay was performed in a 96-well glass plate with shaking incubation at 37 °C. A 10 mM DMSO stock solution of the test compound was sequentially diluted 1:1000 to yield a final reaction concentration of 1 µM in 50 mM KPi.

- 15 Immediately prior to the start of the experiment, respective animal or human liver microsomes (male Sprague-dawley rat, male CD-1 mouse, or pooled human liver microsomes) were diluted in 50 mM KPi to 1.25 mg/mL liver microsomal protein. 30 µL of the 10µM solution containing the test compound was added to 120 µL of microsomal protein for 150 µL enzyme-compound mixture. The reaction was initiated by
- 20 adding 150 µL of cofactor solution (2 mM NADPH, 4 mM MgCl in 50 mM KPi) to the enzyme-compound mixture, and the final reaction concentrations are listed in the table below.

25 Final Reaction Concentrations

Reaction component	Final reaction concentration
Potassium phosphate (KPi) buffer, pH 7.4	50 mM
MgCl ₂	2.0 mM
NADPH	1.0 mM
Liver microsomes	0.5 mg/mL
Test compound	1.0 µM
DMSO (test compound solvent)	0.01% (v/v)

30

At 0, 5, 10 and 30 minute time points in the reaction, reaction aliquots (50 µL) were removed and the reactions were terminated by the addition of acetonitrile (150 µL) containing a mass spectrometry internal standard (1 µM glyburide). The samples were centrifuged and the supernatants analyzed by LC-MS/MS for quantization of remaining compound. The percentage of compound remaining, relative to 0 minutes, was

used to estimate *in vitro* elimination-rate constant (k_{mic}) which was used to calculate *in vitro* metabolic clearance rates.

Analysis of the samples was performed on a high performance liquid chromatography-tandem mass spectrometry (LC/MS) system consisting of a Thermo TSQ Quantum Ultra mass spectrometer, an H-ESI ion source, a CTC-HTS Pal autosampler, and an Agilent LC Pump. Samples were separated on an XTerra C18 column, 2.1X20 mm, 3.5 μ m using the fast mobile phase gradient outlined below.

Time (min)	%B
0.0	5
0.2	5
0.85	95
1.02	95
1.05	5

Mobile phase A consisted of purified water containing 0.01% formic acid. Mobile phase B consisted of acetonitrile containing 0.01% formic acid. The flow rate was 1 mL/min. The injection volume was 10 μ L. Compounds were detected using the Thermo QuikQuan software which collects intensity data for all fragments related to the molecular weight of the test compound. After collection of the raw data, the software identifies and integrates the peak of the strongest intensity.

Each microsomal elimination rate, k_{mic} , was based on a 4-point elimination curve tested in singlet. LC-MS/MS raw data for a reaction plate was returned as integrated analyte peak areas for the test compound and internal standard used in the quench solution for the reaction to enable use of analyte:internal standard peak area ratios (PARs) for all data comparisons. The reaction time point (e.g. 0, 5, 20 or 30 minutes) was plotted versus the natural logarithm of percent test compound remaining relative to 0 minutes (based on relative PAR). The slope of this clearance plot, k_{mic} , was used to calculate the *in vitro* half-life, $t_{1/2}$. In order to focus on linear reaction kinetics, whenever possible, data points representing <10% test compound remaining were generally omitted from the definition of the clearance plot slope.

Determination of Metabolic Stability in Liver Microsomes – Method II

The *in vitro* metabolic stability assay was performed in a 96- deep-well plate with incubation at 37 °C. 10 mM DMSO stock solution of the test compound was diluted 1:20 in acetonitrile, followed by an additional 1:10 dilution in 100 mM potassium phosphate buffer (KPi) to yield a final reaction concentration of 1 µM. Immediately prior to the start of the experiment, 5 respective animal or human liver microsomes (male Sprague-dawley rat, male CD-1 mouse, or pooled human liver microsomes) were diluted in 100 mM KPi to 1.25 mg/mL liver microsomal protein. 290 µL of cofactor solution (1.7 mM NADPH, 1.7 mM UDPGA, 3.4 mM MgCl in 100 mM KPi) was added to 200 µL of microsomal protein for a final volume of 490 µL. The reaction was initiated by adding 10 µL of the 50µM test solution to 490 µL of microsomal protein for a 10 final volume 500 µL enzyme-compound mixture.

The final reaction concentrations are listed in the table below:

Final Reaction Concentrations

Reaction component	Final reaction concentration
Potassium phosphate (KPi) buffer, pH 7.4	50 mM
MgCl ₂	2.0 mM
NADPH	1.0 mM
UDPGA	1.0 mM
Liver microsomes	0.5 mg/mL
Test compound	1.0 µM
DMSO (test compound solvent)	0.01% (v/v)

At 0, 5, 15 and 30 minute time points in the reaction, reaction aliquots (75 µL) were 15 removed and the reactions were terminated by the addition of 50:50 acetonitrile/methanol solution (75 µL) containing a mass spectrometry internal standard (0.5 µM glyburide). The samples were centrifuged at 4000 RPM for 10 minutes. Supernatants (15 µL aliquots) were transferred to a new plate where each well contains 90 µL of deionized water. The supernatants solution were analyzed by UPLC/MS/MS for quantitation of parent remaining 20 compound under multiple reactions monitoring mode (MRM) in positive mode. The percentage of compound remaining, relative to 0 minutes, was used to estimate *in vitro* elimination-rate constant (k) which was used to calculate *in vitro* metabolic clearance rates.

Analysis of the samples was performed on an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) system consisting of an AB Sciex 25 Qtrap 5500 mass spectrometer, AB Sciex Turbo V ion source, Waters Acquity Sample Organizer, Waters Acquity Column manager, Waters Acquity Sample manager, and a Waters

Acquity Binary Solvent Manager. Chromatographic separation of analyte and internal standard was achieved using a reverse phase C-18 column (50 x 2.1 mm, 1.7 µm, Acquity UPLC BEH C-18) with the following UPLC mobile phases and elution gradient:

- 5 UPLC mobile phase A: 0.25% formic acid in 5% methanol; mobile phase B: 0.25% formic acid in 95% water.

LC gradient and flow rate are listed below:

	0-.01 min	10%B	700 µL/min
	0.01-1.0 min	10–95 %B	700 µL/min
10	1.0 – 1.1 min	95%B	700 µL/min
	1.1 – 1.2 min	95 – 10% B	700 µL/min
	1.2 – 1.5 min	10% B	700 µL/min

The injection volume was 5 µL. Compounds were detected using Analyst 1.5.1 software which collects intensity data for all fragments related to the molecular weight of the test compound.

- 15 After collection of the raw data, the software identifies and integrates the peak of the strongest intensity.

Each microsomal elimination rate, *k*, was based on a 4-point elimination curve tested in duplicates. LC-MS/MS raw data for a reaction plate was returned as integrated analyte peak areas for the test compound and internal standard used in the quench solution for the reaction
 20 to enable use of analyte:internal standard peak area ratios (PARs) for all data comparisons. The reaction time point (e.g. 0, 5, 15 and 30 minutes) was plotted versus the natural logarithm of percent test compound remaining relative to 0 minutes (based on relative PAR). The slope of this clearance plot, *k*, was used to calculate the *in vitro* half-life.

25 Half life ($t_{1/2}$) (min) = $\frac{-0.693}{k}$

The intrinsic clearance value, CL_{int} (expressed as µL/min/mg microsomal protein) calculation is shown below:

$$CL_{int} = \frac{0.693}{t_{1/2}} \cdot \frac{V}{M}$$

Where V = the incubation volume (mL) and M = the microsomal protein content in the incubation (mg)


Table 41. Results of the metabolic stability assays

Example Number	Rat microsomal stability CL _{int} [μ l min ⁻¹ mg ⁻¹]	Mouse microsomal stability CL _{int} [μ l min ⁻¹ mg ⁻¹]	Human microsomal stability CL _{int} [μ l min ⁻¹ mg ⁻¹]	Method
48	49.09	173.08	120.53	I
55	58.41	63.12	Not determined	I
61	34.65	67.65	66.43	I
122	69.39	Not determined	Not determined	I
169	68.78 60.93	Not determined	Not determined	I
174	48.53	Not determined	Not determined	I
175	50.51	56.29	39.77	I
181	56.58	Not determined	Not determined	I
380	42.93 30.16	51.00	31.15	I II
401	30.38 92.37	33.13	<7.70	I II
404	44.6 75.44	18.72	<7.70	I II
434 as TFA salt	40.97 10.81	10.68	<7.70	I II
456 as TFA salt	44.66 72.50	63.03	16.79	I II
463	50.8 49.78	35.45	28.27	I II
466	44.90	57.89	55.93	I
467	75.56 85.38	274.97	53.27	I II
468	30.46	28.95	70.11	I
469	131.74	Not determined	Not determined	I
470	52.76	47.31	83.59	I
471 as TFA salt	<7.70	14.75	<7.70	II
472 as TFA salt	12.03	45.59	<7.70	II
473 as TFA	72.47			I

salt	33.29	17.66	<7.70	II
474 as TFA salt	24.78	<7.70	<7.70	II
475 as TFA salt	53.95 16.24	15.72	<7.70	I II
476 as TFA salt	344.08	110.74	41.35	II
477	437.89	167.04	30.44	II
478 as TFA salt	219.31	55.30	10.94	II
479 as TFA salt	172.65	116.32	11.86	II
480	65.24	51.46	35.57	I

Enumerated Embodiments

Embodiment 1. A compound according to formula (I)



5 wherein:

R¹ is hydrogen, methyl or ethyl;


R^{2a} is hydrogen, methyl or C₁₋₃ haloalkyl;

R^{2b} is OH, halo, C₁₋₆ alkoxy, C₁₋₃ haloalkyl, NH₂, NH(CH₃) or N(CH₃)₂;

10 R³ and R⁴ are each independently hydrogen, methyl or ethyl or R³ and R⁴ are joined together forming cyclopropyl, cyclobutyl or oxetanyl;

R⁵ and R⁶ are each independently hydrogen, deuterium, halo, -C(O)OCH₃, C₁₋₃ alkyl or C₁₋₃ haloalkyl;

R⁷ is



wherein:

ring A is a 6 membered heteroaryl ring having one to three nitrogen atoms;

- 5 ring B is a 5 membered heteroaryl ring having one to four heteroatoms each independently selected from the group consisting of N, O and S;

X is N or CH;

each R^8 is independently hydrogen, halo, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy or C_{1-3} haloalkoxy;

- 10 n is 1 or 2;

R^9 is hydrogen, halo, C_{1-3} haloalkyl, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted 5 or 6 membered heterocyclic, optionally substituted heteroaryl, $-OR^{9a}$, $-SO_2R^{9a}$, $-C(O)NHR^{9a}$, CH_2R^{9b} or $CHCH_3R^{9b}$, provided that when X is N, R^9 is hydrogen, C_{1-3} haloalkyl, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, $-SO_2R^{9a}$ or $-C(O)NHR^{9a}$,
 15 wherein:

said C_{1-6} alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of: OH, phenyl and phenoxy, and

said C₃₋₆ cycloalkyl, 5 or 6 membered heterocyclic, aryl and heteroaryl are each optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, -NRR, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;

5 R^{9a} is optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted phenyl, or optionally substituted heterocyclic,

wherein:

said C₁₋₆ alkyl is optionally substituted with one C₃₋₆ cycloalkyl,

10 said C₃₋₆ cycloalkyl and heterocyclic are each optionally substituted with one to three substituents each independently selected from the group consisting of: hydroxyl, CH₂OH, -NRR, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and C₁₋₃ alkoxy, and

15 said phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, -NRR, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;

R^{9b} is optionally substituted C₃₋₆ cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclic,

20 said C₃₋₆ cycloalkyl and heterocyclic are each optionally substituted with one to four substituents each independently selected from the group consisting of: hydroxyl, CH₂OH, -NRR, -NRC(O)CH₃, 4 to 6 membered heterocyclic, cyano, halo, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and C₁₋₃ alkoxy, and


said phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy; and

25 each R is independently selected from the group consisting of H, C₁₋₃ alkyl and C₃₋₆ cycloalkyl; or a pharmaceutically acceptable salt thereof.

Embodiment 2. The compound according to embodiment 1 wherein R³ and R⁴ are both hydrogen; or a pharmaceutically acceptable salt thereof.

Embodiment 3. The compound according to embodiment 1 or 2 wherein R¹ is hydrogen; or a pharmaceutically acceptable salt thereof.

Embodiment 4. The compound according to any one of embodiments 1-3 according to formula (II):



5 (II); or a pharmaceutically acceptable salt thereof.

Embodiment 5. The compound according to any one of embodiments 1-4 wherein:

R⁵ is hydrogen or halo; and

R⁶ is hydrogen, halo, methyl, CH₂F, CHF₂, or CF₃; or a pharmaceutically acceptable salt thereof.

10 Embodiment 6. The compound according to embodiment 5 wherein R⁵ is hydrogen; or a pharmaceutically acceptable salt thereof.


Embodiment 7. The compound according embodiment 5 wherein R⁶ is hydrogen; or a pharmaceutically acceptable salt thereof.

15 Embodiment 8. The compound according to embodiment 5 wherein R⁵ and R⁶ are both hydrogen; or a pharmaceutically acceptable salt thereof.

Embodiment 9. The compound according to any one of embodiments 1-8 wherein R^{2a} is methyl; or a pharmaceutically acceptable salt thereof.

20 Embodiment 10. The compound according to any one of embodiments 1-9 wherein R^{2b} is OH, fluoro, methoxy, t-butoxy, CHF₂, CF₃, NH₂ or NH(CH₃); or a pharmaceutically acceptable salt thereof.


Embodiment 11. The compound according to any one of embodiments 1-10 having the following formula:



(III)

wherein R^{2b} is OH, NH₂ or fluoro; or a pharmaceutically acceptable salt thereof.

Embodiment 12. The compound according to any one of embodiments 1-11 according to
5 formula (IV):




(IV)

wherein R^{2b} is OH or NH₂; or a pharmaceutically acceptable salt thereof.

Embodiment 13. The compound according to embodiment 12 wherein R^{2b} is OH; or a pharmaceutically acceptable salt thereof.

10 Embodiment 14. The compound according to embodiment 12 wherein R^{2b} is NH₂; or a pharmaceutically acceptable salt thereof.

















Embodiment 15. The compound according to any one of embodiments 1-11 according to formula (V):









(V); or a pharmaceutically acceptable salt thereof.

Embodiment 16. The compound according to embodiment 15 wherein R^{2a} is methyl; or a pharmaceutically acceptable salt thereof.

Embodiment 17. The compound according to any one of embodiments 1-16 wherein R^7 is:





or

; or a pharmaceutically acceptable salt thereof.


Embodiment 18. The compound according to any one of embodiments 1-17 wherein R⁹ is
 5 hydrogen, halo, C₁₋₃ haloalkyl, optionally substituted C₁₋₆ alkyl or optionally substituted C₃₋₆ cycloalkyl; or a pharmaceutically acceptable salt thereof.

Embodiment 19. The compound according to any one of embodiments 1-17 wherein R⁹ is
 phenyl optionally substituted with one or two substituents each independently selected from
 the group consisting of: fluoro, chloro, bromo, cyano, methoxy, CH₂OH, C₁₋₄ alkyl, C₁₋₄
 10 haloalkyl and C₁₋₃ haloalkoxy; or a pharmaceutically acceptable salt thereof.

Embodiment 20. The compound according to any one of embodiments 1-17 wherein R⁹ is
 pyrazolyl, pyridinyl, indolyl or isoquinolinyl each of which is optionally substituted; or a
 pharmaceutically acceptable salt thereof.

Embodiment 21. The compound according to any one of embodiments 1-17 wherein R⁹ is
 15 CH₂R^{9b} wherein R^{9b} is piperidinyl, piperazinyl or morpholinyl each of which is optionally
 substituted with one to three substituents each independently selected from the group
 consisting of: hydroxyl, halo, CH₂OH, -NRR, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and C₁₋₃
 alkoxy.

Embodiment 22. The compound according to embodiment 1 according to formula (IV)



(IV)















wherein:

R^{2b} is OH;

R⁵ is hydrogen or fluoro;

5 R⁶ is hydrogen, chloro, methyl or CH₂F;

R⁷ is



10

or

;

R⁸ is hydrogen, methyl or fluoro;

n is 1 or 2; and

R⁹ is methylcyclopropyl, isobutoxy, phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, bromo, C₁₋₄ alkyl, CF₂H and CF₃ or pyridinyl optionally substituted with one or two substituents each independently selected from the group consisting of: methyl, CF₃ and C(CH₃)₂CF₃; or a
 5 pharmaceutically acceptable salt thereof.

Embodiment 23. The compound according to embodiment 22 wherein:


R⁵ is hydrogen and R⁶ is chloro, methyl or CH₂F

or

10 R⁶ is hydrogen and R⁵ is fluoro; or a pharmaceutically acceptable salt thereof.

Embodiment 24. The compound according to embodiment 22 wherein R⁵ and R⁶ are both hydrogen; or a pharmaceutically acceptable salt thereof.

15 Embodiment 25. The compound according to embodiment 1 according to formula (VI)




wherein:

R^{2b} is fluoro;

R⁵ is hydrogen or fluoro;

20 R⁶ is hydrogen;



R⁸ is hydrogen or methyl;

n is 1; and

R⁹ is phenyl optionally substituted with one chloro; or a pharmaceutically acceptable salt thereof.

5 Embodiment 26. The compound according to embodiment 1 selected from the group consisting of:

(R)-4-((R)-1-hydroxy(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-onethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

10 (R)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(6-(trifluoromethyl)-[2,3'-bipyridin]-6'-

15 yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

20 (R)-3-(2-(((S)-1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-

25 yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chloro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(3-chloro-5-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

30 (R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(4R)-3-(5-fluoro-2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-

35 yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; and

(R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

Embodiment 27. The compound according to embodiment 1 selected from the group

5 consisting of:

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

10 (R)-3-{2-[(R)-1-(3-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-[(S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one;

(R)-3-(2-[(S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-

15 ((R)-1-hydroxy-ethyl)-oxazolidin-2-one;

(R)-3-(5-fluoro-2-(((S)-1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

20 (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-

25 hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

30 (R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-(fluoromethyl)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-

35 hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

5 (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-(difluoromethyl)phenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

10 (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; and

(R)-3-(2-(((S)-1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

15

Embodiment 28. The compound according to embodiment 1 selected from the group consisting of:

(R)-3-(2-(((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

20 (R)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; and

(R)-3-(2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

25 Embodiment 29. The compound according to embodiment 1 selected from the group consisting of:

(R)-3-(6-chloro-2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one;

30 (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one; and

(S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

35 Embodiment 30. The compound according to embodiment 1 selected from the group consisting of:

(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one;

- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl) oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(2-(4-chlorophenyl) thiazol-5-yl)ethyl)amino) pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;
- 5 (R)-3-(2-(((S)-1-(5-(4-chlorophenyl) isoxazol-3-yl)ethyl)amino) pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl) amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl) oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl) oxazolidin-2-one;
- 10 (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)oxazolidin-2-one;
- (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one; and
- 15 (S)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

Embodiment 31. The compound according to embodiment 1 which is (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

20

Embodiment 32. The compound according to embodiment 1 which is (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

Embodiment 33. The compound according to embodiment 1 which is (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl) amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt.

25

Embodiment 34. The compound according to embodiment 1 which is (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

Embodiment 35. The compound according to embodiment 1 which is (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

30

Embodiment 36. The compound according to embodiment 1 which is (R)-3-(5-fluoro-2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

- 5 Embodiment 37. The compound according to embodiment 1 which is (R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

- Embodiment 38. A pharmaceutical composition comprising a compound according to any one
10 of embodiments 1-37, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

- Embodiment 39. A method for the treatment of a disease or disorder associated with a mutant IDH protein having a neomorphic activity comprising administration of a therapeutically
15 effective amount of a compound according to any one of embodiments 1-37, or a pharmaceutically acceptable salt thereof, to subject in need of treatment thereof.

- Embodiment 40. A method for the treatment of a disease or disorder associated with a mutant IDH protein having a neomorphic activity comprising administration of a therapeutically
20 effective amount of a compound according to any one of embodiments 1-37, or a pharmaceutically acceptable salt thereof, and another therapeutic agent to a subject in need of treatment thereof.

- Embodiment 41. A method for the treatment of brain cancer, leukemia, skin cancer, prostate
25 cancer, thyroid cancer, colon cancer, lung cancer or sarcoma comprising administration of a compound according to any one of previous embodiments 1-37, or a pharmaceutically acceptable salt thereof, to a subject in need of treatment thereof.

- Embodiment 42. A method for the treatment of glioma, glioblastoma multiforme,
30 paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, prostate, thyroid, colon, lung, central chondrosarcoma, central or periosteal chondroma tumors, fibrosarcoma, or cholangiocarcinoma comprising administration of a compound according to any one of previous embodiments 1-37, or a pharmaceutically acceptable salt thereof, to a subject in need
35 of treatment thereof.

Embodiment 43. A compound according to any one of previous embodiments 1-37, or a pharmaceutically acceptable salt thereof, for use in the treatment of brain cancer, leukemia, skin cancer, prostate cancer, thyroid cancer, colon cancer, lung cancer or sarcoma.


- 5 Embodiment 44. A compound according to any one of previous embodiments 1-37, or a pharmaceutically acceptable salt thereof, for use in the treatment of glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, prostate, thyroid, colon, lung, central chondrosarcoma, central or periosteal chondroma tumors,
10 fibrosarcoma, or cholangiocarcinoma.

Embodiment 45. A compound according to embodiment 1 which is (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

CLAIMS

What is claimed is:

1. A compound according to formula (I)



wherein:

R¹ is hydrogen, methyl or ethyl;


R^{2a} is hydrogen, methyl or C₁₋₃ haloalkyl;

R^{2b} is OH, halo, C₁₋₆ alkoxy, C₁₋₃ haloalkyl, NH₂, NH(CH₃) or N(CH₃)₂;

R³ and R⁴ are each independently hydrogen, methyl or ethyl or R³ and R⁴ are joined together forming cyclopropyl, cyclobutyl or oxetanyl;

R⁵ and R⁶ are each independently hydrogen, deuterium, halo, -C(O)OCH₃, C₁₋₃ alkyl or C₁₋₃ haloalkyl;

R⁷ is



wherein:

ring A is a 6 membered heteroaryl ring having one to three nitrogen atoms;

ring B is a 5 membered heteroaryl ring having one to four heteroatoms each independently selected from the group consisting of N, O and S;

X is N or CH;

each R⁸ is independently hydrogen, halo, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy or C₁₋₃ haloalkoxy;

n is 1 or 2;

R⁹ is hydrogen, halo, C₁₋₃ haloalkyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl, optionally substituted 5 or 6 membered heterocyclic, optionally substituted heteroaryl, -OR^{9a}, -SO₂R^{9a}, -C(O)NHR^{9a}, CH₂R^{9b} or CHCH₃R^{9b}, provided that when X is N, R⁹ is hydrogen, C₁₋₃ haloalkyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -SO₂R^{9a} or -C(O)NHR^{9a}, wherein:

said C₁₋₆ alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of: OH, phenyl and phenoxy, and

said C₃₋₆ cycloalkyl, 5 or 6 membered heterocyclic, aryl and heteroaryl are each optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, -NRR, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;

R^{9a} is optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted phenyl, or optionally substituted heterocyclic,

wherein:

said C₁₋₆ alkyl is optionally substituted with one C₃₋₆ cycloalkyl,

said C₃₋₆ cycloalkyl and heterocyclic are each optionally substituted with one to three substituents each independently selected from the group consisting of: hydroxyl, CH₂OH, -NRR, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and C₁₋₃ alkoxy, and

said phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, -NRR, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;

R^{9b} is optionally substituted C₃₋₆ cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclic,


said C₃₋₆ cycloalkyl and heterocyclic are each optionally substituted with one to four substituents each independently selected from the group consisting of: hydroxyl, CH₂OH, -NRR, -NRC(O)CH₃, 4 to 6 membered heterocyclic, cyano, halo, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and C₁₋₃ alkoxy, and

said phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy; and

each R is independently selected from the group consisting of H, C₁₋₃ alkyl and C₃₋₆ cycloalkyl; or a pharmaceutically acceptable salt thereof.


2. The compound according to claim 1 wherein R³ and R⁴ are both hydrogen; or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or 2 wherein R^1 is hydrogen; or a pharmaceutically acceptable salt thereof.
4. The compound according to any one of claims 1-3 according to formula (II):



(II); or a pharmaceutically acceptable salt thereof.


5. The compound according to any one of claims 1-4 wherein:
- R^5 is hydrogen or halo; and
 - R^6 is hydrogen, halo, methyl, CH_2F , CHF_2 , or CF_3 ; or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 5 wherein R^5 is hydrogen; or a pharmaceutically acceptable salt thereof.
7. The compound according claim 5 wherein R^6 is hydrogen; or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 5 wherein R^5 and R^6 are both hydrogen; or a pharmaceutically acceptable salt thereof.
9. The compound according to any one of claims 1-8 wherein R^{2a} is methyl; or a pharmaceutically acceptable salt thereof.
10. The compound according to any one of claims 1-9 wherein R^{2b} is OH, fluoro, methoxy, t-butoxy, CHF_2 , CF_3 , NH_2 or $NH(CH_3)$; or a pharmaceutically acceptable salt thereof.
11. The compound according to any one of claims 1-10 having the following formula:



(III)

wherein R^{2b} is OH, NH₂ or fluoro; or a pharmaceutically acceptable salt thereof.

12. The compound according to any one of claims 1-11 according to formula (IV):




(IV)

wherein R^{2b} is OH or NH₂; or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 12 wherein R^{2b} is OH; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 12 wherein R^{2b} is NH₂; or a pharmaceutically acceptable salt thereof.

















15. The compound according to any one of claims 1-11 according to formula (V):









(V); or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 15 wherein R^{2a} is methyl; or a pharmaceutically acceptable salt thereof.

17. The compound according to any one of claims 1-16 wherein R^7 is:





or

; or a pharmaceutically acceptable salt thereof.


18. The compound according to any one of claims 1-17 wherein R^9 is hydrogen, halo, C_{1-3} haloalkyl, optionally substituted C_{1-6} alkyl or optionally substituted C_{3-6} cycloalkyl; or a pharmaceutically acceptable salt thereof.

19. The compound according to any one of claims 1-17 wherein R^9 is phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, bromo, cyano, methoxy, CH_2OH , C_{1-4} alkyl, C_{1-4} haloalkyl and C_{1-3} haloalkoxy; or a pharmaceutically acceptable salt thereof.

20. The compound according to any one of claims 1-17 wherein R^9 is pyrazolyl, pyridinyl, indolyl or isoquinolinyl each of which is optionally substituted; or a pharmaceutically acceptable salt thereof.

21. The compound according to any one of claims 1-17 wherein R^9 is CH_2R^{9b} wherein R^{9b} is piperidinyl, piperazinyl or morpholinyl each of which is optionally substituted with one to three substituents each independently selected from the group consisting of: hydroxyl, halo, CH_2OH , -NRR, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, and C_{1-3} alkoxy.

22. The compound according to claim 1 according to formula (IV)



(IV)















wherein:

R^{2b} is OH;

R⁵ is hydrogen or fluoro;

R⁶ is hydrogen, chloro, methyl or CH₂F;

R⁷ is



or

;

R⁸ is hydrogen, methyl or fluoro;

n is 1 or 2; and

R^9 is methylcyclopropyl, isobutoxy, phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, bromo, C_{1-4} alkyl, CF_2H and CF_3 or pyridinyl optionally substituted with one or two substituents each independently selected from the group consisting of: methyl, CF_3 and $C(CH_3)_2CF_3$; or a pharmaceutically acceptable salt thereof.

23. The compound according to claim 22 wherein:


R^5 is hydrogen and R^6 is chloro, methyl or CH_2F

or

R^6 is hydrogen and R^5 is fluoro; or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 22 wherein R^5 and R^6 are both hydrogen; or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 1 according to formula (VI)




wherein:

R^{2b} is fluoro;

R^5 is hydrogen or fluoro;

R^6 is hydrogen;



R^8 is hydrogen or methyl;

n is 1; and

R⁹ is phenyl optionally substituted with one chloro; or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 1 selected from the group consisting of:

(R)-4-((R)-1-hydroxy(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-onethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(6-(trifluoromethyl)-[2,3'-bipyridin]-6'-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chloro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chloro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(3-chloro-5-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(3,4-dichlorophenyl)pyrimidin-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(4R)-3-(5-fluoro-2-(((S)-1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(2-fluoro-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; and

(R)-3-(2-(((S)-1-(2,5-difluoro-4-(2-methylpyridin-4-yl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

27. The compound according to claim 1 selected from the group consisting of:

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-{2-[(R)-1-(3-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-yl)ethyl]amino}pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-{(S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one;

(R)-3-(2-{(S)-1-[3-(3,4-Dichloro-phenyl)-isoxazol-5-yl]-ethylamino}-5-fluoro-pyrimidin-4-yl)-4-((R)-1-hydroxy-ethyl)-oxazolidin-2-one;

(R)-3-(5-fluoro-2-(((S)-1-(3-(4-isopropylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)-4-methyloxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(4-(4-bromophenyl)thiazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-(fluoromethyl)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-6-methylpyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(2-(4-(difluoromethyl)phenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
(R)-3-(6-chloro-2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; and
(R)-3-(2-(((S)-1-(3-(3-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

28. The compound according to claim 1 selected from the group consisting of:

(R)-3-(2-(((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one;
(R)-3-(5-fluoro-2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; and
(R)-3-(2-(((S)-1-(2-fluoro-4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-hydroxyethyl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

29. The compound according to claim 1 selected from the group consisting of:

(R)-3-(6-chloro-2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-methoxyethyl)oxazolidin-2-one; and
(S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

30. The compound according to claim 1 selected from the group consisting of:

(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;

(R)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(5-(4-chlorophenyl)isoxazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-((R)-1-fluoroethyl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one;
(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
(R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one; and
(S)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-((R)-1,1-difluoropropan-2-yl)oxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

31. The compound according to claim 1 which is (R)-4-((R)-1-hydroxyethyl)-3-(2-(((S)-1-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

32. The compound according to claim 1 which is (S)-4-((R)-1-aminoethyl)-3-(2-(((S)-1-(2-(4-chlorophenyl)thiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

33. The compound according to claim 1 which is (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(1-(4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt.

34. The compound according to claim 1 which is (R)-3-(2-(((S)-1-(1-(4-chlorophenyl)-1H-imidazol-4-yl)ethyl)amino)pyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

35. The compound according to claim 1 which is (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

36. The compound according to claim 1 which is (R)-3-(5-fluoro-2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)-4-((S)-1-fluoroethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

37. The compound according to claim 1 which is (R)-3-(2-(((S)-1-(1-(3-chloro-4-fluorophenyl)-1H-imidazol-4-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

38. A compound according to claim 1 which is (R)-3-(2-(((S)-1-(5-(4-chlorophenyl)oxazol-2-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

39. A pharmaceutical composition comprising a compound according to any one of claims 1-38, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

40. A method for the treatment of a disease or disorder associated with a mutant IDH protein having a neomorphic activity comprising administration of a therapeutically effective amount of a compound according to any one of claims 1-38, or a pharmaceutically acceptable salt thereof, to subject in need of thereof.

41. A method for the treatment of a disease or disorder associated with a mutant IDH protein having a neomorphic activity comprising administration of a therapeutically effective amount of a compound according to any one of claims 1-38, or a pharmaceutically acceptable salt thereof, and another therapeutic agent to subject in need of thereof.